LncRNA | |||||||||
---|---|---|---|---|---|---|---|---|---|
ID | Name | Alias | Species | NCBI accession | Ensembl | ||||
EL0001 | 116HG | N/A | Homo sapiens | N/A | N/A | ||||
EL0002 | 1700007L15Rik | linc-Iqcg; linc1609 | Mus musculus | NR_045709 | ENSMUSG00000097318 | ||||
EL0003 | 1B FGF-antisense transcripts | N/A | Homo sapiens | N/A | N/A | ||||
EL0004 | 4930503E24Rik | 4930503E24Rik; NR_028310.1 | Mus musculus | NR_028310 | N/A | ||||
EL0005 | 4930570G19Rik | C630015G22 | Mus musculus | NR_040399, NR_040398, NR_040400 | ENSMUSG00000085084 | ||||
EL0006 | 51A | antisense to intron 1 of the SORL1 gene | Homo sapiens | N/A | N/A | ||||
EL0007 | 5430416N02Rik | 100041797; Adapt33; Gm3514 | Mus musculus | NR_034038 | ENSMUSG00000097772 | ||||
EL0008 | 5730458M16Rik | N/A | Mus musculus | AK017674 | N/A | ||||
EL0009 | 6430411K18Rik | PEG11as | Mus musculus | NR_002848 | N/A | ||||
EL0010 | 9130001E16Rik | N/A | Mus musculus | XR_386048 | N/A | ||||
EL0011 | 9530018H14Rik | lncRNA-HIT | Mus musculus | AK020562 | N/A | ||||
EL0012 | A130040M12Rik | CA782090; H3053C11; VL30 | Mus musculus | N/A | N/A | ||||
EL0013 | AA174084 | N/A | Homo sapiens | N/A | N/A | ||||
EL0014 | AATBC | N/A | Homo sapiens | NR_026961 | ENSG00000215458 | ||||
EL0015 | AB019562 | N/A | Homo sapiens | N/A | N/A | ||||
EL0016 | AB073614 | N/A | Homo sapiens | N/A | N/A | ||||
EL0017 | AB074278 | N/A | Homo sapiens | N/A | N/A | ||||
EL0018 | AB209630 | N/A | Homo sapiens | N/A | N/A | ||||
EL0019 | ABHD11-AS1 | LINC00035; NCRNA00035; WBSCR26 | Homo sapiens | NR_026690 | ENSG00000225969 | ||||
EL0020 | Abhd11os | 2010001M06Rik; AI462243; Wbscr26; Wnscr26 | Mus musculus | NR_026688 | ENSMUSG00000085042 | ||||
EL0021 | Abhd11os | Wbscr26 | Rattus norvegicus | NR_026689 | N/A | ||||
EL0022 | STAG3L2 | AC004166.7; STAG3L2; MGC131759; STAG3L2P | Homo sapiens | NR_040584 | ENSG00000277072 | ||||
EL0023 | AC006050.3-003 | N/A | Homo sapiens | N/A | N/A | ||||
EL0024 | LOC101927596 | AC013264.2 | Homo sapiens | NR_135584 | ENSG00000231621 | ||||
EL0025 | MTCO1P5 | MTCO1P5; AC026166.2-001 | Homo sapiens | N/A | ENSG00000233026 | ||||
EL0026 | AC058791.1 | LOC646329 | Homo sapiens | NR_034120 | ENSG00000226380 | ||||
EL0027 | PLAC9P1 | AC079776.2 | Homo sapiens | NR_026740 | ENSG00000214100 | ||||
EL0028 | AC100865.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0029 | AC104699.1 | N/A | Homo sapiens | N/A | ENSG00000224220 | ||||
EL0030 | AC104699.1.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0031 | ACTA2-AS1 | ZXF1; uc001kfo.1 | Homo sapiens | NR_125373 | ENSG00000180139 | ||||
EL0032 | ADAMTS9-AS2 | N/A | Homo sapiens | NR_038264 | ENSG00000241684 | ||||
EL0033 | Adapt15 | Gadd7 | Cricetulus griseus | NR_045124 | N/A | ||||
EL0034 | AF070632 | N/A | Homo sapiens | N/A | N/A | ||||
EL0035 | AF075041 | N/A | Homo sapiens | N/A | N/A | ||||
EL0036 | AF086415 | N/A | Homo sapiens | N/A | N/A | ||||
EL0037 | AF116616 | ASLNC13387; AF116616 | Homo sapiens | N/A | N/A | ||||
EL0038 | AF118081 | N/A | Homo sapiens | N/A | N/A | ||||
EL0039 | AF339813 | N/A | Homo sapiens | N/A | N/A | ||||
EL0040 | AFAP1-AS1 | AFAP1-AS; AFAP1AS | Homo sapiens | NR_026892 | ENSG00000272620 | ||||
EL0041 | AGAP2-AS1 | PUNISHER | Homo sapiens | NR_027032 | ENSG00000255737 | ||||
EL0042 | AI364715 | N/A | Homo sapiens | N/A | N/A | ||||
EL0043 | AIRN | AIR; IGF2R-AS; IGF2R-AS1; IGF2RAS; NCRNA00088 | Homo sapiens | NR_047511, NR_047514 | ENSG00000268257 | ||||
EL0044 | Airn | 2810051F02Rik; 2810434M15Rik; AI256653; AI597500; AW049873; Air; B930018I07Rik; D17Ertd663e; IGF2RAS | Mus musculus | NR_027773, NR_027772, NR_027784, NR_002853 | ENSMUSG00000078247 | ||||
EL0045 | AK022029 | N/A | Homo sapiens | N/A | N/A | ||||
EL0046 | AK022159 | N/A | Homo sapiens | N/A | N/A | ||||
EL0047 | AK028007 | N/A | Mus musculus | N/A | N/A | ||||
EL0048 | AK038798 | N/A | Mus musculus | N/A | N/A | ||||
EL0049 | AK042766 | N/A | Mus musculus | N/A | N/A | ||||
EL0050 | AK044955 | N/A | Mus musculus | N/A | N/A | ||||
EL0051 | AK056988 | N/A | Homo sapiens | N/A | N/A | ||||
EL0052 | AK057054 | N/A | Homo sapiens | N/A | N/A | ||||
EL0053 | AK081227 | N/A | Mus musculus | N/A | N/A | ||||
EL0054 | AK093543 | N/A | Homo sapiens | N/A | N/A | ||||
EL0055 | AK094838 | ASLNC18814; AK094838 | Homo sapiens | N/A | N/A | ||||
EL0056 | AK095147 | N/A | Homo sapiens | N/A | N/A | ||||
EL0057 | AK123657 | N/A | Homo sapiens | N/A | N/A | ||||
EL0058 | AK123790 | N/A | Homo sapiens | N/A | N/A | ||||
EL0059 | AK130977 | N/A | Homo sapiens | N/A | N/A | ||||
EL0060 | AK133540 | N/A | Mus musculus | N/A | N/A | ||||
EL0061 | AK133808 | N/A | Mus musculus | N/A | N/A | ||||
EL0062 | AK139328 | N/A | Mus musculus | N/A | N/A | ||||
EL0063 | AK143294 | N/A | Mus musculus | N/A | N/A | ||||
EL0064 | AK143693 | N/A | Mus musculus | N/A | N/A | ||||
EL0065 | AK153778 | N/A | Mus musculus | N/A | N/A | ||||
EL0066 | AKR7L | AFAR3; AFB1-AR3; AKR7A4 | Homo sapiens | NR_040289, NR_040288 | ENSG00000211454 | ||||
EL0067 | AL389956 | N/A | Homo sapiens | N/A | N/A | ||||
EL0068 | Alg2 | 1110018A23Rik; 1300013N08Rik; ALPG2; CDGIi; MNCb-5081 | Mus musculus | AK209601.1 | ENSMUSG00000039740 | ||||
EL0069 | alncRNA-EC7 | N/A | Mus musculus | N/A | N/A | ||||
EL0070 | alpha-250 and alpha-280 | N/A | Homo sapiens | N/A | N/A | ||||
EL0071 | alpha-280/250 | N/A | Homo sapiens | N/A | N/A | ||||
EL0072 | alpha-MHC antisense transcripts | N/A | Mus musculus | N/A | N/A | ||||
EL0073 | Alu lncRNAs | N/A | Homo sapiens | N/A | N/A | ||||
EL0074 | Ancr-1 | N/A | Apis mellifera | NR_003566 | N/A | ||||
EL0075 | antisense TGF beta 3 | N/A | Gallus gallus | N/A | N/A | ||||
EL0076 | AOC4P | AOC4; UPAT | Homo sapiens | NR_002773 | ENSG00000260105 | ||||
EL0077 | AP000688.29 | N/A | Homo sapiens | N/A | N/A | ||||
EL0078 | AP001439.1 | AP001439.2 | Homo sapiens | N/A | ENSG00000224541 | ||||
EL0079 | AP5M1 | C14orf108; MUDENG; Mu5; MuD | Homo sapiens | NR_026895 | ENSG00000053770 | ||||
EL0080 | APOA1-AS | N/A | Homo sapiens | NR_126362 | ENSG00000235910 | ||||
EL0081 | APOLO | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0082 | APTR | RSBN1L-AS1 | Homo sapiens | NR_134251, NR_134254, NR_134253, NR_038361 | ENSG00000214293 | ||||
EL0083 | ARA | N/A | Homo sapiens | N/A | N/A | ||||
EL0084 | Arid2-IR | N/A | Homo sapiens | N/A | N/A | ||||
EL0085 | AS Uchl1 | N/A | Mus musculus | N/A | N/A | ||||
EL0086 | ASAR6 | N/A | Mus musculus | N/A | N/A | ||||
EL0087 | ASAR6 | N/A | Homo sapiens | N/A | N/A | ||||
EL0088 | ASCO-RNA | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0089 | asHSFB2a | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0090 | ASK00420 | N/A | Homo sapiens | N/A | N/A | ||||
EL0091 | ASL | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0092 | ASLNC00339 | ASLNC00339; uc.341- | Homo sapiens | N/A | N/A | ||||
EL0093 | ASncmtRNAs | N/A | Homo sapiens | N/A | N/A | ||||
EL0094 | asOct4-pg5 | N/A | Homo sapiens | N/A | N/A | ||||
EL0095 | AT102202 | N/A | Homo sapiens | N/A | N/A | ||||
EL0096 | AT1G04425 | AT1G04425 | Arabidopsis thaliana | NR_143387 | N/A | ||||
EL0097 | AT1G10682 | AT1G10682 | Arabidopsis thaliana | NR_139737 | N/A | ||||
EL0098 | AT1G11175 | AT1G11175 | Arabidopsis thaliana | NR_143555 | N/A | ||||
EL0099 | AT1G11185 | AT1G11185 | Arabidopsis thaliana | NR_143556 | N/A | ||||
EL0100 | AT1G13448 | AT1G13448 | Arabidopsis thaliana | NR_139742 | N/A | ||||
EL0101 | AT1G15002 | AT1G15002 | Arabidopsis thaliana | N/A | N/A | ||||
EL0102 | AT1G15175 | AT1G15175 | Arabidopsis thaliana | NR_139747, NR_139745, NR_139746 | N/A | ||||
EL0103 | AT1G15405 | AT1G15405 | Arabidopsis thaliana | NR_143560 | N/A | ||||
EL0104 | AT1G16635 | AT1G16635 | Arabidopsis thaliana | NR_143561 | N/A | ||||
EL0105 | AT1G18745 | AT1G18745 | Arabidopsis thaliana | NR_143562 | N/A | ||||
EL0106 | AT1G21529 | AT1G21529 | Arabidopsis thaliana | NR_143564 | N/A | ||||
EL0107 | AT1G26208 | AT1G26208 | Arabidopsis thaliana | NR_139783, NR_139785, NR_139784, NR_139787, NR_139786, NR_139788 | N/A | ||||
EL0108 | AT1G26558 | AT1G26558 | Arabidopsis thaliana | NR_143570, NR_143571 | N/A | ||||
EL0109 | AT1G31935 | AT1G31935 | Arabidopsis thaliana | NR_143573 | N/A | ||||
EL0110 | AT1G34418 | AT1G34418 | Arabidopsis thaliana | NR_143576 | N/A | ||||
EL0111 | AT1G43765 | AT1G43765 | Arabidopsis thaliana | NR_143577 | N/A | ||||
EL0112 | AT1G46554 | AT1G46554 | Arabidopsis thaliana | NR_143578 | N/A | ||||
EL0113 | AT1G57835 | AT1G57835 | Arabidopsis thaliana | NR_143584 | N/A | ||||
EL0114 | AT1G58590 | AT1G58590 | Arabidopsis thaliana | NR_143585, NR_143586 | N/A | ||||
EL0115 | AT1G64618 | AT1G64618 | Arabidopsis thaliana | NR_143590 | N/A | ||||
EL0116 | AT1G67105 | AT1G67105 | Arabidopsis thaliana | NR_143592 | N/A | ||||
EL0117 | AT1G67365 | AT1G67365 | Arabidopsis thaliana | NR_139904 | N/A | ||||
EL0118 | AT1G69252 | AT1G69252 | Arabidopsis thaliana | NR_143594, NR_143595 | N/A | ||||
EL0119 | AT1G70518 | AT1G70518 | Arabidopsis thaliana | NR_143597 | N/A | ||||
EL0120 | AT1G74205 | AT1G74205 | Arabidopsis thaliana | N/A | N/A | ||||
EL0121 | At1NC018710 | N/A | Arabidopsis thaliana | KJ935038 | N/A | ||||
EL0122 | AT1TU075330 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0123 | AT1TU099900 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0124 | AT2G01422 | AT2G01422 | Arabidopsis thaliana | NR_143713, NR_143714 | N/A | ||||
EL0125 | AT2G06002 | AT2G06002 | Arabidopsis thaliana | NR_143731 | N/A | ||||
EL0126 | AT2G09795 | AT2G09795 | Arabidopsis thaliana | NR_140605, NR_140604, NR_140603 | N/A | ||||
EL0127 | AT2G14878 | AT2G14878 | Arabidopsis thaliana | NR_143748 | N/A | ||||
EL0128 | AT2G15292 | AT2G15292 | Arabidopsis thaliana | NR_143750 | N/A | ||||
EL0129 | AT2G15555 | AT2G15555 | Arabidopsis thaliana | NR_143751 | N/A | ||||
EL0130 | AT2G18735 | AT2G18735 | Arabidopsis thaliana | NR_143754 | N/A | ||||
EL0131 | AT2G26355 | AT2G26355 | Arabidopsis thaliana | NR_140673 | N/A | ||||
EL0132 | AT2G31585 | AT2G31585 | Arabidopsis thaliana | NR_143761, NR_143762 | N/A | ||||
EL0133 | AT2G32315 | AT2G32315 | Arabidopsis thaliana | NR_140697 | N/A | ||||
EL0134 | AT2G32795 | AT2G32795 | Arabidopsis thaliana | NR_143763 | N/A | ||||
EL0135 | AT2G41178 | AT2G41178 | Arabidopsis thaliana | NR_140743, NR_140744 | N/A | ||||
EL0136 | AT2G41312 | AT2G41312 | Arabidopsis thaliana | NR_143767, NR_143768 | N/A | ||||
EL0137 | AT2G42388 | AT2G42388 | Arabidopsis thaliana | NR_143769 | N/A | ||||
EL0138 | AT2G42485 | AT2G42485 | Arabidopsis thaliana | NR_143771 | N/A | ||||
EL0139 | AT2G43375 | AT2G43375 | Arabidopsis thaliana | NR_143772 | N/A | ||||
EL0140 | AT2G44798 | AT2G44798 | Arabidopsis thaliana | NR_140771, NR_140770, NR_140768, NR_140769, NR_140773, NR_140772, NR_140774, NR_140777, NR_140775, N | N/A | ||||
EL0141 | AT2G44995 | AT2G44995 | Arabidopsis thaliana | NR_143773 | N/A | ||||
EL0142 | AT2G45023 | AT2G45023 | Arabidopsis thaliana | NR_143774, NR_143775 | N/A | ||||
EL0143 | AT2G45245 | AT2G45245 | Arabidopsis thaliana | NR_143779, NR_143777, NR_143778, NR_143776 | N/A | ||||
EL0144 | AT2G46192 | AT2G46192 | Arabidopsis thaliana | NR_143781 | N/A | ||||
EL0145 | At2NC044550 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0146 | AT2TU076050 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0147 | AT2TU077810 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0148 | AT3G04485 | AT3G04485 | Arabidopsis thaliana | NR_143900 | N/A | ||||
EL0149 | AT3G06125 | AT3G06125 | Arabidopsis thaliana | NR_143908, NR_143909, NR_143910 | N/A | ||||
EL0150 | AT3G07215 | AT3G07215 | Arabidopsis thaliana | NR_143920, NR_143921, NR_143919, NR_143922 | N/A | ||||
EL0151 | AT3G13277 | AT3G13277 | Arabidopsis thaliana | NR_143938 | N/A | ||||
EL0152 | AT3G27884 | AT3G27884 | Arabidopsis thaliana | NR_141631, NR_141632, NR_141630 | N/A | ||||
EL0153 | AT3G27990 | AT3G27990 | Arabidopsis thaliana | NR_141633, NR_141634, NR_141635, NR_141636 | N/A | ||||
EL0154 | AT3G29644 | AT3G29644 | Arabidopsis thaliana | NR_141640, NR_141637, NR_141639, NR_141638, NR_141641 | N/A | ||||
EL0155 | AT3G44798 | AT3G44798 | Arabidopsis thaliana | NR_143947 | N/A | ||||
EL0156 | AT3G45638 | AT3G45638 | Arabidopsis thaliana | NR_143948, NR_143949 | N/A | ||||
EL0157 | AT3G48115 | AT3G48115 | Arabidopsis thaliana | NR_143950, NR_143951 | N/A | ||||
EL0158 | AT3G52072 | AT3G52072 | Arabidopsis thaliana | NR_141677, NR_141673, NR_141675, NR_141676, NR_141672, NR_141674, NR_141678 | N/A | ||||
EL0159 | AT3G52742 | AT3G52742 | Arabidopsis thaliana | NR_143952 | N/A | ||||
EL0160 | AT3G52748 | AT3G52748 | Arabidopsis thaliana | NR_143953 | N/A | ||||
EL0161 | AT3G54366 | AT3G54366 | Arabidopsis thaliana | NR_143955 | N/A | ||||
EL0162 | AT3G57157 | AT3G57157 | Arabidopsis thaliana | NR_143957 | N/A | ||||
EL0163 | AT3G59765 | AT3G59765 | Arabidopsis thaliana | NR_141706, NR_141705, NR_141704 | N/A | ||||
EL0164 | AT3G60972 | AT3G60972 | Arabidopsis thaliana | NR_143960 | N/A | ||||
EL0165 | AT3G61198 | AT3G61198 | Arabidopsis thaliana | NR_143962 | N/A | ||||
EL0166 | AT3TU028510 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0167 | AT3TU075200 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0168 | At4 | N/A | Arabidopsis thaliana | AF055372 | N/A | ||||
EL0169 | At4-1 | N/A | Arabidopsis thaliana | AY536062 | N/A | ||||
EL0170 | At4-2 | N/A | Arabidopsis thaliana | AY334555 | N/A | ||||
EL0171 | At4-3 | N/A | Arabidopsis thaliana | AI995459 | N/A | ||||
EL0172 | AT4G01533 | AT4G01533 | Arabidopsis thaliana | NR_143963 | N/A | ||||
EL0173 | AT4G01593 | AT4G01593 | Arabidopsis thaliana | NR_141720, NR_141721, NR_141722 | N/A | ||||
EL0174 | AT4G02005 | AT4G02005 | Arabidopsis thaliana | NR_141725, NR_141727, NR_141728, NR_141724, NR_141726, NR_141723 | N/A | ||||
EL0175 | AT4G03811 | AT4G03811 | Arabidopsis thaliana | NR_144062 | N/A | ||||
EL0176 | AT4G06701 | AT4G06701 | Arabidopsis thaliana | NR_144088, NR_144089, NR_144090, NR_144092, NR_144091 | N/A | ||||
EL0177 | AT4G08035 | AT4G08035 | Arabidopsis thaliana | NR_144096, NR_144097 | N/A | ||||
EL0178 | AT4G13495 | AT4G13495 | Arabidopsis thaliana | NR_144107, NR_144108 | N/A | ||||
EL0179 | AT4G14548 | AT4G14548 | Arabidopsis thaliana | NR_144109 | N/A | ||||
EL0180 | AT4G15242 | AT4G15242 | Arabidopsis thaliana | NR_144110 | N/A | ||||
EL0181 | AT4G20362 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0182 | AT4G30975 | AT4G30975 | Arabidopsis thaliana | NR_142380, NR_142378, NR_142379 | N/A | ||||
EL0183 | AT4G36648 | AT4G36648 | Arabidopsis thaliana | NR_144117 | N/A | ||||
EL0184 | AT4G38932 | AT4G38932 | Arabidopsis thaliana | NR_142410 | N/A | ||||
EL0185 | AT4G40065 | AT4G40065 | Arabidopsis thaliana | NR_144119 | N/A | ||||
EL0186 | At4NC047210 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0187 | AT4TU030900 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0188 | AT4TU034830 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0189 | AT5G01175 | AT5G01175 | Arabidopsis thaliana | NR_142485, NR_142484 | N/A | ||||
EL0190 | AT5G03285 | AT5G03285 | Arabidopsis thaliana | NR_144233 | N/A | ||||
EL0191 | AT5G06165 | AT5G06165 | Arabidopsis thaliana | NR_144254 | N/A | ||||
EL0192 | AT5G07322 | AT5G07322 | Arabidopsis thaliana | NR_144258 | N/A | ||||
EL0193 | AT5G15022 | AT5G15022 | Arabidopsis thaliana | NR_143266 | N/A | ||||
EL0194 | AT5G23410 | AT5G23410; K19M13.3; K19M13_3 | Arabidopsis thaliana | NR_144271 | N/A | ||||
EL0195 | AT5G24735 | AT5G24735 | Arabidopsis thaliana | NR_144274 | N/A | ||||
EL0196 | AT5G40316 | AT5G40316 | Arabidopsis thaliana | NR_144283 | N/A | ||||
EL0197 | AT5G43403 | AT5G43403 | Arabidopsis thaliana | NR_144284 | N/A | ||||
EL0198 | AT5G43725 | AT5G43725 | Arabidopsis thaliana | NR_144285, NR_144286 | N/A | ||||
EL0199 | AT5G44569 | AT5G44569 | Arabidopsis thaliana | NR_144287 | N/A | ||||
EL0200 | AT5G48412 | AT5G48412 | Arabidopsis thaliana | NR_144289 | N/A | ||||
EL0201 | AT5G50190 | AT5G50190; K6A12.5; K6A12_5 | Arabidopsis thaliana | NR_144291 | N/A | ||||
EL0202 | At5NC025190 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0203 | At5NC029980 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0204 | At5NC055270 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0205 | At5NC056820 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0206 | AT5TU062110 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0207 | AtCR20-1 | N/A | Arabidopsis thaliana | D79218 | N/A | ||||
EL0208 | AtGUT15 | N/A | Arabidopsis thaliana | U84973 | N/A | ||||
EL0209 | Atp2a2 | 9530097L16Rik; D5Wsu150e; SERCA2; SERCA2B; Serca2a; mKIAA4195 | Mus musculus | NR_027838 | ENSMUSG00000029467 | ||||
EL0210 | ATP6V1G2-DDX39B | N/A | Homo sapiens | NR_037853 | ENSG00000254870 | ||||
EL0211 | AtR18 | N/A | Arabidopsis thaliana | AB646771 | N/A | ||||
EL0212 | AtR18 | N/A | Nicotiana tabacum | N/A | N/A | ||||
EL0213 | AtR8 | N/A | Arabidopsis thaliana | AB646770 | N/A | ||||
EL0214 | AtR8 | N/A | Nicotiana tabacum | N/A | N/A | ||||
EL0215 | ATXN7L3B | lnc-SCA7 | Homo sapiens | N/A | ENSG00000253719 | ||||
EL0216 | ATXN8OS | KLHL1AS; NCRNA00003; SCA8 | Homo sapiens | NR_002717 | N/A | ||||
EL0217 | AX746718 | N/A | Homo sapiens | N/A | N/A | ||||
EL0218 | AX800134 | N/A | Homo sapiens | N/A | N/A | ||||
EL0219 | B1 SINE RNA | N/A | Meriones unguiculatus | N/A | N/A | ||||
EL0220 | B1 SINE RNA | N/A | Mus musculus | N/A | N/A | ||||
EL0221 | B130024G19Rik | N/A | Mus musculus | NR_045850 | ENSMUSG00000100005 | ||||
EL0222 | B2 SINE RNA | N/A | Mus musculus | N/A | N/A | ||||
EL0223 | B4GALT1-AS1 | N/A | Homo sapiens | NR_108109, NR_108110, NR_108108 | ENSG00000233554 | ||||
EL0224 | BACE1-AS | BACE1-AS1; BACE1AS; NCRNA00177 | Homo sapiens | NR_037803 | ENSG00000278768 | ||||
EL0225 | BALR-2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0226 | BALR-6 | N/A | Homo sapiens | N/A | N/A | ||||
EL0227 | BANCR | LINC00586 | Homo sapiens | NR_047671 | ENSG00000278910 | ||||
EL0228 | BC002350 | ASLNC22124; BC002350 | Homo sapiens | N/A | N/A | ||||
EL0229 | BC011663 | N/A | Homo sapiens | N/A | N/A | ||||
EL0230 | BC014579 | N/A | Homo sapiens | N/A | N/A | ||||
EL0231 | BC017743 | N/A | Homo sapiens | N/A | N/A | ||||
EL0232 | BC023629 | N/A | Homo sapiens | N/A | N/A | ||||
EL0233 | BC091525 | ASLNC23844; BC091525 | Homo sapiens | N/A | N/A | ||||
EL0234 | Bc1 | Gm24367 | Mus musculus | NR_038088 | N/A | ||||
EL0235 | BCAR4 | N/A | Homo sapiens | NR_131216, NR_131222, NR_024050, NR_131217, NR_024049 | ENSG00000262117 | ||||
EL0236 | BcMF11 | N/A | Brassica campestris | DQ925484 | N/A | ||||
EL0237 | BCYRN1 | BC200; BC200a; LINC00004; NCRNA00004 | Homo sapiens | NR_001568 | ENSG00000236824 | ||||
EL0238 | BCYRN1P2 | BC200g | Homo sapiens | N/A | N/A | ||||
EL0239 | BDNF-AS | ANTI-BDNF; BDNF1; BDNFOS; NCRNA00049; BDNF-AS | Homo sapiens | NR_033312, NR_033315, NR_033313, NR_002832, NR_033314 | ENSG00000245573 | ||||
EL0240 | BE503655 | N/A | Homo sapiens | N/A | N/A | ||||
EL0241 | bft | Dmel_CR42938; 263a; CR31863; CR33580; CR42938; DmelCR42938; Dmel_CR31863; Dmel_CR33580; dme-miR-263a; dme-mir-263a; miR-263; miR-263a; mir-263a | Drosophila melanogaster | N/A | N/A | ||||
EL0242 | BGLT3 | BGL3; LINC01083; lncRNA-BGL3 | Homo sapiens | NR_121648 | ENSG00000260629 | ||||
EL0243 | BISPR | lncBST2 | Homo sapiens | NR_130765, NR_130766 | ENSG00000282851 | ||||
EL0244 | BLACAT1 | LINC00912; linc-UBC1; onco-lncRNA-30 | Homo sapiens | NR_103783 | ENSG00000281406 | ||||
EL0245 | BM742401 | N/A | Homo sapiens | N/A | N/A | ||||
EL0246 | BOK-AS1 | BOK-AS; BOKAS; NAToB; NCRNA00151 | Homo sapiens | NR_033346 | ENSG00000234235 | ||||
EL0247 | Borg | N/A | Mus musculus | NR_131206 | N/A | ||||
EL0248 | BPESC1 | BPESC1; NCRNA00187 | Homo sapiens | NR_026783 | ENSG00000232416 | ||||
EL0249 | BRCA1 | BRCAI; BRCC1; BROVCA1; FANCS; IRIS; PNCA4; PPP1R53; PSCP; RNF53 | Homo sapiens | NR_027676 | ENSG00000012048 | ||||
EL0250 | Bvht | Braveheart; Gm20748 | Mus musculus | NR_045420 | ENSMUSG00000098098 | ||||
EL0251 | BX647187 | N/A | Homo sapiens | N/A | N/A | ||||
EL0252 | BX648207 | N/A | Homo sapiens | N/A | N/A | ||||
EL0253 | bxd | Dmel_CR31273; CR31273; CR31277; DmelCR31273 | Drosophila melanogaster | NR_002035, NR_002034, NR_002033, NR_002032 | N/A | ||||
EL0254 | C1401f132 | N/A | Homo sapiens | N/A | N/A | ||||
EL0255 | C14orf132 | C14orf88 | Homo sapiens | N/A | ENSG00000227051 | ||||
EL0256 | C1orf74 | URLC4 | Homo sapiens | N/A | ENSG00000162757 | ||||
EL0257 | PCOTH | C1QTNF9B-AS1 | Homo sapiens | N/A | ENSG00000205861 | ||||
EL0258 | C2dat1 | CAMK2D | Mus musculus | N/A | N/A | ||||
EL0259 | C530045E16Rik | N/A | Mus musculus | AK049728 | N/A | ||||
EL0260 | C5orf66-AS1 | CTC-276P9.1; Epist | Homo sapiens | NR_105050, NR_105049 | ENSG00000249082 | ||||
EL0261 | C5T1lncRNA | N/A | Homo sapiens | N/A | N/A | ||||
EL0262 | C730029A08Rik | AK038898 | Mus musculus | AK050225 | N/A | ||||
EL0263 | C730036E19Rik | lncLSTR | Mus musculus | NR_038011 | ENSMUSG00000102095 | ||||
EL0264 | CACNAICAS3 | N/A | Homo sapiens | N/A | N/A | ||||
EL0265 | CADM1 | BL2; IGSF4; IGSF4A; NECL2; Necl-2; RA175; ST17; SYNCAM; TSLC1; sTSLC-1; sgIGSF; synCAM1 | Homo sapiens | N/A | ENSG00000182985 | ||||
EL0266 | CADM3-AS1 | CTA-134P22.2; CADM3-AS1 | Homo sapiens | NR_037870 | ENSG00000225670 | ||||
EL0267 | CAHM | LINC00468 | Homo sapiens | NR_037593 | ENSG00000270419 | ||||
EL0268 | CAI2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0269 | CAR Intergenic 10 | N/A | Homo sapiens | N/A | N/A | ||||
EL0270 | CARs | N/A | Homo sapiens | N/A | N/A | ||||
EL0271 | CASC15 | LINC00340 | Homo sapiens | NR_015410 | ENSG00000272168 | ||||
EL0272 | CASC2 | C10orf5 | Homo sapiens | NR_026939, NR_026940, NR_026941 | ENSG00000177640 | ||||
EL0273 | CASC9 | ESCCAL-1; ESSCAL1; LINC00981 | Homo sapiens | NR_103849, NR_103850, NR_103848 | ENSG00000249395 | ||||
EL0274 | CBR3-AS1 | PlncRNA-1; PlncRNA1 | Homo sapiens | NR_038893, NR_038892, NR_038894 | ENSG00000236830 | ||||
EL0275 | CCAL | N/A | Homo sapiens | N/A | N/A | ||||
EL0276 | CCAT1 | CARLo-5; onco-lncRNA-40 | Homo sapiens | NR_108049 | ENSG00000247844 | ||||
EL0277 | CCAT1-L | N/A | Homo sapiens | N/A | N/A | ||||
EL0278 | CCAT2 | LINC00873; NCCP1 | Homo sapiens | NR_109834 | ENSG00000280997 | ||||
EL0279 | CCAT3 | N/A | Homo sapiens | N/A | N/A | ||||
EL0280 | CCAT7 | N/A | Homo sapiens | N/A | N/A | ||||
EL0281 | CCAT8 | N/A | Homo sapiens | N/A | ENST00000377549 | ||||
EL0282 | CCDC26 | RAM | Homo sapiens | NR_130917, NR_130918, NR_130919, NR_130920 | ENSG00000229140 | ||||
EL0283 | CCEPR | CCHE1; lncRNA-CCHE1 | Homo sapiens | NR_131782 | N/A | ||||
EL0284 | CCLS96.1 | N/A | Silene latifolia | AB094078 | N/A | ||||
EL0285 | CCND1 | BCL1; D11S287E; PRAD1; U21B31 | Homo sapiens | N/A | ENSG00000110092 | ||||
EL0286 | CCND1 promoter-derived lncRNAs | N/A | Homo sapiens | N/A | N/A | ||||
EL0287 | CD99P1 | CD99L1; CXYorf12; MIC2R; NCRNA00103 | Homo sapiens | NR_033380, NR_033381 | ENSG00000223773 | ||||
EL0288 | Cdc28 lncRNA | N/A | Saccharomyces cerevisiae | N/A | N/A | ||||
EL0289 | CDKN2B-AS1 | ANRIL; CDKN2B-AS; CDKN2BAS; NCRNA00089; PCAT12; p15AS | Homo sapiens | NR_003529, NR_047532, NR_047543, NR_047535, NR_047537, NR_047534, NR_047536, NR_047538, NR_120536, N | ENSG00000240498 | ||||
EL0290 | CDR1-AS | CDR1NAT; CDR1as; ciRS-7 | Homo sapiens | AK094540 | N/A | ||||
EL0291 | CECR3 | N/A | Homo sapiens | NR_038398 | ENSG00000241832 | ||||
EL0292 | CECR9 | N/A | Homo sapiens | N/A | N/A | ||||
EL0293 | ceruloplasmin | NRCP | Mus musculus | N/A | N/A | ||||
EL0294 | CES1P1 | CES1A2; CES1A3; CES4; CESR; PCE-3 | Homo sapiens | NR_003276 | ENSG00000228695 | ||||
EL0295 | CHL1-AS2 | N/A | Homo sapiens | NR_144486, NR_144487 | ENSG00000224318 | ||||
EL0296 | CHRF | N/A | Homo sapiens | N/A | N/A | ||||
EL0297 | cis-NATPHO1;2 | N/A | Oryza sativa | AK071338 | N/A | ||||
EL0298 | COL3A1 | EDS4A | Homo sapiens | N/A | ENSG00000168542 | ||||
EL0299 | COLDAIR | N/A | Arabidopsis thaliana | HG975388 | N/A | ||||
EL0300 | COOLAIR | N/A | Arabidopsis thaliana | GQ352646 | N/A | ||||
EL0301 | CPS1-IT1 | CPS1-IT; CPS1IT; CPS1IT1; PRO0132 | Homo sapiens | NR_002763 | ENSG00000280837 | ||||
EL0302 | CR613944 | N/A | Homo sapiens | N/A | N/A | ||||
EL0303 | CR619813 | CR619813; uc010meg.2 | Homo sapiens | N/A | N/A | ||||
EL0304 | CRG | Dmel_CR44887; CR44887; DmelCR44887 | Drosophila melanogaster | NR_125225 | N/A | ||||
EL0305 | CRNDE | CRNDEP; LINC00180; NCRNA00180; PNAS-108; lincIRX5 | Homo sapiens | NR_034105, NR_110453, NR_110454, NR_034106 | ENSG00000245694 | ||||
EL0306 | Crxos | AA606869; AY5908911; Egam1; Crxos | Mus musculus | NR_038092 | ENSMUSG00000074365 | ||||
EL0307 | AC130456.2 | CTA-363E6.2 | Homo sapiens | N/A | ENSG00000259925 | ||||
EL0308 | CTB-167B5.2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0309 | AC021078.1 | CTB-89H12.4 | Homo sapiens | N/A | ENSG00000230551 | ||||
EL0310 | CTBP1-AS | PCAT10 | Homo sapiens | NR_104331 | ENSG00000280927 | ||||
EL0311 | CTD-3080P12.3 | N/A | Homo sapiens | NR_109911 | ENSG00000249201 | ||||
EL0312 | CTD903 | N/A | Homo sapiens | N/A | N/A | ||||
EL0313 | CU1NC165 | N/A | Cucumis sativus | N/A | N/A | ||||
EL0314 | CU1NC272 | N/A | Cucumis sativus | N/A | N/A | ||||
EL0315 | CU1NC333 | N/A | Cucumis sativus | N/A | N/A | ||||
EL0316 | CU1NC355 | N/A | Cucumis sativus | N/A | N/A | ||||
EL0317 | CU2NC636 | N/A | Cucumis sativus | N/A | N/A | ||||
EL0318 | CU3NC1105 | N/A | Cucumis sativus | N/A | N/A | ||||
EL0319 | CX3CL1 | ABCD-3; C3Xkine; CXC3; CXC3C; NTN; NTT; SCYD1; fractalkine; neurotactin | Homo sapiens | N/A | ENSG00000006210 | ||||
EL0320 | CYP2C91 | N/A | Sus scrofa | NR_132429 | N/A | ||||
EL0321 | CYP4A22-AS1 | ncRNA-a3 | Homo sapiens | N/A | N/A | ||||
EL0322 | Cyp4b1-ps2 | Gm12839; OTTMUSG00000008630 | Mus musculus | NR_033575 | N/A | ||||
EL0323 | CYP51A1-AS1 | LRRD1-AS1 | Homo sapiens | NR_122109, NR_122110 | ENSG00000188693 | ||||
EL0324 | CYP707A1 | N/A | Arabidopsis thaliana | AB428731 | N/A | ||||
EL0325 | CYTOR | C2orf59; LINC00152; NCRNA00152 | Homo sapiens | NR_024205, NR_024206, NR_024204 | ENSG00000222041 | ||||
EL0326 | Dab2 | 5730435J12Rik; AA960054; AI957090; D15Wsu122e; D630005B22Rik; Doc-2; Doc2; p96 | Mus musculus | N/A | ENSMUSG00000022150 | ||||
EL0327 | DACOR1 | LP2570; TCONS_00023265 | Homo sapiens | N/A | N/A | ||||
EL0328 | Dalir | Dali; Gm28525 | Mus musculus | NR_130904 | ENSMUSG00000099784 | ||||
EL0329 | DANCR | AGU2; ANCR; KIAA0114; SNHG13; lncRNA-ANCR | Homo sapiens | NR_024031 | ENSG00000226950 | ||||
EL0330 | DAOA-AS1 | DAOA-AS; DAOAAS; G30 | Homo sapiens | NR_040247 | ENSG00000232307 | ||||
EL0331 | DAPK1 | DAPK | Homo sapiens | N/A | ENSG00000196730 | ||||
EL0332 | DBET | DBE-T; DUX4L30 | Homo sapiens | NR_121644 | ENSG00000281591 | ||||
EL0333 | DBH-AS1 | NCRNA00118 | Homo sapiens | NR_102735 | ENSG00000225756 | ||||
EL0334 | DDR2 | MIG20a; NTRKR3; TKT; TYRO10 | Homo sapiens | N/A | ENSG00000162733 | ||||
EL0335 | DDX6P1 | DDX6-Lp; DDX6P; bA150A6.3 | Homo sapiens | N/A | ENSG00000230056 | ||||
EL0336 | DGCR5 | LINC00037; NCRNA00037 | Homo sapiens | NR_110533, NR_002733, NR_045121 | ENSG00000283406 | ||||
EL0337 | DHFR upstream transcripts | DHFR minor transcript 5'-UTR; ENSG00000228716 | Homo sapiens | N/A | N/A | ||||
EL0338 | DHRS4-AS1 | AS1DHRS4; C14orf167; DHRS4AS1; PRO1488 | Homo sapiens | NR_023922, NR_023923, NR_023924, NR_023921 | ENSG00000215256 | ||||
EL0339 | DIO3OS | C14orf134; DIO3-AS1; DIO3-OS; NCRNA00041 | Homo sapiens | NR_002770 | N/A | ||||
EL0340 | Dio3os | AW556460; Dio3as | Mus musculus | NR_002866 | N/A | ||||
EL0341 | DISC2 | DISC1-AS1; DISC1OS; NCRNA00015 | Homo sapiens | NR_002227 | N/A | ||||
EL0342 | DKFZP434K028 | DKFZP434K028; LOC26070 | Homo sapiens | NR_026882 | ENSG00000124915 | ||||
EL0343 | DLEU1 | BCMS; BCMS1; DLB1; DLEU2; LEU1; LEU2; LINC00021; NCRNA00021; XTP6 | Homo sapiens | NR_109974, NR_109973, NR_002605 | ENSG00000176124 | ||||
EL0344 | DLEU2 | 1B4; BCMSUN; DLB2; LEU2; LINC00022; MIR15AHG; NCRNA00022; RFP2OS; TRIM13OS | Homo sapiens | NR_002612 | ENSG00000231607 | ||||
EL0345 | Dleu2 | 1810047A16Rik; 4932411A06Rik; 7730401J12Rik; AI197277; AI788824; Alt1; Gm9069; Leu2 | Mus musculus | NR_028264 | ENSMUSG00000097589 | ||||
EL0346 | DLG2-AS1 | DLG2-AS; DLG2AS; PSZA11q14; SZ-1 | Homo sapiens | N/A | N/A | ||||
EL0347 | Dlx1as | Dix1as; Dlx1os | Mus musculus | NR_002854 | ENSMUSG00000084946 | ||||
EL0348 | Dlx4os | A730090H04Rik; Dlx4as | Mus musculus | NR_040279 | ENSMUSG00000086552 | ||||
EL0349 | DLX6-AS1 | DLX6-AS; DLX6AS; Evf-2; NCRNA00212 | Homo sapiens | NR_015448 | ENSG00000231764 | ||||
EL0350 | Dlx6os1 | A230055N17Rik; Dlx6as1; Evf-1; Evf-2; Evf1; Evf1/2; Evf2; Shhrs; mEvf-1 | Mus musculus | NR_015388 | ENSMUSG00000090063 | ||||
EL0351 | DMRT2 | N/A | Homo sapiens | N/A | ENSG00000173253 | ||||
EL0352 | Dmrt2 | Terra | Mus musculus | N/A | ENSMUSG00000048138 | ||||
EL0353 | DMTF1 | DMP1; DMTF; MRUL; hDMP1 | Homo sapiens | NR_024549, NR_024550 | ENSG00000135164 | ||||
EL0354 | DNM3OS | DNM3-AS1; MIR199A2HG | Homo sapiens | NR_103486, NR_038397 | ENSG00000230630 | ||||
EL0355 | DQ786243 | DQ786243 | Homo sapiens | N/A | N/A | ||||
EL0356 | DRAIC | N/A | Homo sapiens | NR_026979 | ENSG00000245750 | ||||
EL0357 | Dreh | N/A | Mus musculus | NR_105051 | N/A | ||||
EL0358 | DSCAM-AS1 | M41 | Homo sapiens | NR_038898, NR_038896, NR_038900, NR_038899 | ENSG00000235123 | ||||
EL0359 | dutA | DDB_G0294515 | Dictyostelium discoideum AX4 | N/A | N/A | ||||
EL0360 | E130102H24Rik | N/A | Mus musculus | NR_040708 | ENSMUSG00000086782 | ||||
EL0361 | EBER | N/A | Epstein-Barr virus | N/A | N/A | ||||
EL0362 | EEF1A1P9 | EEF1AL7 | Homo sapiens | N/A | N/A | ||||
EL0363 | EFNA3 | EFL2; EPLG3; Ehk1-L; LERK3 | Homo sapiens | N/A | ENSG00000143590 | ||||
EL0364 | EGFLAM-AS1 | lncRNA-LOWEG; lncRNA-CTD-2108O9.1; EGFLAM-AS1 | Homo sapiens | N/A | ENSG00000249491 | ||||
EL0365 | EGFR-AS1 | N/A | Homo sapiens | NR_047551 | ENSG00000224057 | ||||
EL0366 | EGOT | EGO; NCRNA00190 | Homo sapiens | NR_004428 | ENSG00000235947 | ||||
EL0367 | EHHADH-AS1 | N/A | Homo sapiens | NR_038990 | ENSG00000223358 | ||||
EL0368 | ELFN1-AS1 | MYCLo-2 | Homo sapiens | NR_120510, NR_120509, NR_120508 | ENSG00000236081 | ||||
EL0369 | EMX2OS | EMX2-AS1; NCRNA00045 | Homo sapiens | NR_002791 | ENSG00000229847 | ||||
EL0370 | Emx2os | N/A | Mus musculus | NR_002863 | ENSMUSG00000087095 | ||||
EL0371 | ENO1 | ENO1L1; HEL-S-17; MPB1; NNE; PPH | Homo sapiens | N/A | ENSG00000074800 | ||||
EL0372 | enod40 | N/A | Arabidopsis thaliana | AK220907 | N/A | ||||
EL0373 | enod40 | N/A | Brassica napus | CX190651 | N/A | ||||
EL0374 | enod40 | N/A | Daucus carota | BI452209 | N/A | ||||
EL0375 | ENOD40 | N/A | Glycine soja | N/A | N/A | ||||
EL0376 | ENOD40 | N/A | Medicago truncatula | N/A | N/A | ||||
EL0377 | ENOD40 | N/A | Phaseolus vulgaris | X86441 | N/A | ||||
EL0378 | ENOD40 | N/A | Sesbania rostrata | Y12714 | N/A | ||||
EL0379 | enod40 | N/A | Thlaspi caerulescens | DN923678 | N/A | ||||
EL0380 | ENOD40 | N/A | Vicia faba | N/A | N/A | ||||
EL0381 | ENOD40 | N/A | Vigna radiata | AF061818 | N/A | ||||
EL0382 | ENOD40 | N/A | Zea mays | N/A | N/A | ||||
EL0383 | enod40 | ENOD40; LjENOD40 | Lotus japonicus | N/A | N/A | ||||
EL0384 | enod40 | Enod40; MsENOD40 | Medicago sativa | X80263 | N/A | ||||
EL0385 | enod40 | Ntenod40 | Nicotiana tabacum | X98716 | N/A | ||||
EL0386 | enod40 | OsENOD40 | Oryza sativa | AB024054 | N/A | ||||
EL0387 | enod40 | ENOD40; Mtenod40; MtENOD40 | Medicago truncatula | X80264 | N/A | ||||
EL0388 | ENOD40-1 | GmENOD40 ENOD40 | Glycine max | X69154 | N/A | ||||
EL0389 | enod40-1 | LjENOD40-1 | Lotus japonicus | AJ271787 | N/A | ||||
EL0390 | enod40-2 | LjENOD40-2 | Lotus japonicus | AJ271788 | N/A | ||||
EL0391 | KCP | CRIM21; NET67; KCP | Homo sapiens | N/A | ENSG00000135253 | ||||
EL0392 | TTTY7 | CLONE795723; LINC00129; NCRNA00129A; TTTY7B; TTY7; TTTY7 | Homo sapiens | NR_001534 | ENSG00000147753 | ||||
EL0393 | AC079610.1 | N/A | Homo sapiens | N/A | ENSG00000196096 | ||||
EL0394 | LINC00336 | C6orf227; NCRNA00336 | Homo sapiens | NR_027908 | ENSG00000197251 | ||||
EL0395 | AL445248.1 | N/A | Homo sapiens | N/A | ENSG00000203325 | ||||
EL0396 | AC006305.1 | N/A | Homo sapiens | N/A | ENSG00000206129 | ||||
EL0397 | LINC01020 | N/A | Homo sapiens | NR_026994 | ENSG00000215231 | ||||
EL0398 | FAM66B | FAM66E | Homo sapiens | NR_027423 | ENSG00000215374 | ||||
EL0399 | LINC01139 | LINK-A; LINKA | Homo sapiens | NR_015407 | ENSG00000215808 | ||||
EL0400 | LINC00323 | C21orf130; NCRNA00323; PRED42 | Homo sapiens | NR_024100 | ENSG00000226496 | ||||
EL0401 | LINC01204 | N/A | Homo sapiens | NR_104644, NR_104645 | ENSG00000229563 | ||||
EL0402 | LINC01721 | N/A | Homo sapiens | NR_040102 | ENSG00000230133 | ||||
EL0403 | ENSG00000230544.1 | N/A | Homo sapiens | N/A | ENSG00000230544 | ||||
EL0404 | ENSG00000231133.1 | N/A | Homo sapiens | N/A | ENSG00000231133 | ||||
EL0405 | SPRY4-AS1 | THCAT68 | Homo sapiens | NR_120664 | ENSG00000231185 | ||||
EL0406 | LEF1-AS1 | LEF1NAT | Homo sapiens | NR_029374, NR_029373 | ENSG00000232021 | ||||
EL0407 | LINC01798 | N/A | Homo sapiens | NR_110156 | ENSG00000232046 | ||||
EL0408 | ENSG00000232956.3 | N/A | Homo sapiens | N/A | ENSG00000232956 | ||||
EL0409 | LINC01762 | N/A | Homo sapiens | NR_125972, NR_125973 | ENSG00000233154 | ||||
EL0410 | LOC100129434 | N/A | Homo sapiens | NR_125368 | ENSG00000233251 | ||||
EL0411 | SMIM2-IT1 | C13orf44-IT1 | Homo sapiens | NR_046843 | ENSG00000235285 | ||||
EL0412 | ENSG00000237036.3 | N/A | Homo sapiens | N/A | ENSG00000237036 | ||||
EL0413 | TTLL11-IT1 | N/A | Homo sapiens | N/A | ENSG00000237548 | ||||
EL0414 | ENSG00000240453.1 | N/A | Homo sapiens | N/A | ENSG00000240453 | ||||
EL0415 | AC093620.1 | N/A | Homo sapiens | N/A | ENSG00000241269 | ||||
EL0416 | ENSG00000245910.3 | N/A | Homo sapiens | N/A | ENSG00000245910 | ||||
EL0417 | AC109349.1 | N/A | Homo sapiens | N/A | ENSG00000248176 | ||||
EL0418 | LOC101928858 | N/A | Homo sapiens | NR_130779 | ENSG00000249364 | ||||
EL0419 | AC026427.1 | N/A | Homo sapiens | N/A | ENSG00000249772 | ||||
EL0420 | LOC105377448 | N/A | Homo sapiens | NR_133945 | ENSG00000250195 | ||||
EL0421 | LOC339874 | N/A | Homo sapiens | NR_038976 | ENSG00000250608 | ||||
EL0422 | AL359075.2 | N/A | Homo sapiens | N/A | ENSG00000254154 | ||||
EL0423 | AP001528.2 | N/A | Homo sapiens | N/A | ENSG00000255471 | ||||
EL0424 | AC007848.2 | N/A | Homo sapiens | N/A | ENSG00000256218 | ||||
EL0425 | LINC00929 | N/A | Homo sapiens | NR_038852, NR_038851 | ENSG00000259150 | ||||
EL0426 | LINC00596 | N/A | Homo sapiens | N/A | ENSG00000259334 | ||||
EL0427 | ENSG00000259484.1 | N/A | Homo sapiens | N/A | ENSG00000259484 | ||||
EL0428 | ENSG00000259758.1 | N/A | Homo sapiens | N/A | ENSG00000259758 | ||||
EL0429 | LINC00667 | N/A | Homo sapiens | NR_015389 | ENSG00000263753 | ||||
EL0430 | AC016876.2 | N/A | Homo sapiens | N/A | ENSG00000264772 | ||||
EL0431 | LINC01538 | N/A | Homo sapiens | NR_033983 | ENSG00000266952 | ||||
EL0432 | Gm6768 | N/A | Mus musculus | N/A | ENSMUSG00000021908 | ||||
EL0433 | ENSMUST00000041159 | N/A | Mus musculus | N/A | ENSMUST00000041159 | ||||
EL0434 | Tdpx-ps1 | N/A | Mus musculus | N/A | ENSMUSG00000082431 | ||||
EL0435 | Gm15054 | N/A | Mus musculus | N/A | ENSMUSG00000084282 | ||||
EL0436 | Gm12919 | N/A | Mus musculus | N/A | ENSMUSG00000083220 | ||||
EL0437 | Gm7327 | N/A | Mus musculus | N/A | ENSMUSG00000050900 | ||||
EL0438 | Gm14155 | N/A | Mus musculus | N/A | ENSMUSG00000087033 | ||||
EL0439 | Gm14089 | N/A | Mus musculus | N/A | ENSMUSG00000084802 | ||||
EL0440 | ENSMUST00000142855 | N/A | Mus musculus | N/A | ENSMUST00000142855 | ||||
EL0441 | Gm13133 | N/A | Mus musculus | N/A | ENSMUSG00000086565 | ||||
EL0442 | Gm11827 | N/A | Mus musculus | N/A | ENSMUSG00000086765 | ||||
EL0443 | Gm15834 | N/A | Mus musculus | N/A | ENSMUSG00000085054 | ||||
EL0444 | ENSMUST00000167632 | N/A | Mus musculus | N/A | ENSMUST00000167632 | ||||
EL0445 | ENST00000318333 | ASHG19A3A043106; ENST00000318333; SRP9P1-201 | Homo sapiens | N/A | ENST00000318333 | ||||
EL0446 | RPL12P1 | ASHG19A3A029791; ENST00000374520; RPL12P1-001 | Homo sapiens | N/A | ENSG00000204194 | ||||
EL0447 | ENST00000395084 | N/A | Homo sapiens | N/A | ENST00000395084 | ||||
EL0448 | AL353608.3 | ENST00000414223; RP11-561O23.5-002 | Homo sapiens | NR_015361 | ENSG00000234394 | ||||
EL0449 | ENST00000414355 | N/A | Homo sapiens | N/A | ENST00000414355 | ||||
EL0450 | AL355581.1 | RP11-73O6.3 | Homo sapiens | N/A | ENSG00000227678 | ||||
EL0451 | POM121L13P | ASHG19A3A050006; ENST00000422362; POM121L13P-001 | Homo sapiens | N/A | ENSG00000236339 | ||||
EL0452 | LINC01384 | LINC01384-001; ENST00000422494.1 | Homo sapiens | NR_109883 | ENSG00000237396 | ||||
EL0453 | LINC01852 | RP11-1008C21.2-001; ENST00000434223 | Homo sapiens | N/A | ENSG00000236914 | ||||
EL0454 | ENST00000435885.1 | N/A | Homo sapiens | N/A | ENST00000435885 | ||||
EL0455 | ENST00000442037 | H19-015; ENST00000442037 | Homo sapiens | N/A | ENSG00000130600 | ||||
EL0456 | TDGF1P1 | TDGF1P1-001; ENST00000445734 | Homo sapiens | N/A | ENSG00000227988 | ||||
EL0457 | ZNRD1ASP | C6orf12; HCG8; HCGVIII; HCGVIII-1; HTEX4; NCRNA00171; TCTEX4; ZNRD1-AS; ZNRD1-AS1; ZNRD1AS; ZNRD1AS1 | Homo sapiens | NR_026751 | ENSG00000204623 | ||||
EL0458 | MTCO3P10 | ASHG19A3A034382; ENST00000455912; RP11-1217F2.3-001 | Homo sapiens | N/A | ENSG00000231537 | ||||
EL0459 | AL133244.1 | ASHG19A3A013479; ENST00000456007; AL133244.1-001 | Homo sapiens | N/A | ENSG00000223951 | ||||
EL0460 | AC096915.1 | ASHG19A3A022744; ENST00000456185; RP11-24H1.1-001 | Homo sapiens | N/A | ENSG00000226082 | ||||
EL0461 | LINC00887 | LINC00887-004; ENST00000456816 | Homo sapiens | N/A | ENSG00000214145 | ||||
EL0462 | ENST00000460164 | RP11-731F5.2-002; ENST00000460164 | Homo sapiens | N/A | ENST00000460164 | ||||
EL0463 | AC004893.2 | AC004893.11-002; ENST00000468960 | Homo sapiens | NR_110102 | ENSG00000242687 | ||||
EL0464 | ENST00000501583 | N/A | Homo sapiens | N/A | ENST00000501583 | ||||
EL0465 | HAND2-AS1 | DEIN; NBLA00301; UPH | Homo sapiens | NR_136197, NR_136196, NR_136195, NR_136201, NR_136194, NR_136199, NR_136200, NR_136192, NR_136193, N | ENSG00000237125 | ||||
EL0466 | AC012312.1 | CTC-558O19.1-001; ENST00000503710 | Homo sapiens | N/A | ENSG00000249545 | ||||
EL0467 | LINC01096 | LINC01096-002; ENST00000503938 | Homo sapiens | N/A | ENSG00000246095 | ||||
EL0468 | ENST00000537266 | N/A | Homo sapiens | N/A | ENST00000537266 | ||||
EL0469 | AC022075.3 | RP11-277P12.10-001; ENST00000539009 | Homo sapiens | N/A | ENSG00000256288 | ||||
EL0470 | AC026369.2 | RP11-598F7.5-001; ENST00000540136 | Homo sapiens | N/A | ENSG00000256694 | ||||
EL0471 | LINC02446 | RP11-291B21.2-001; ENST00000544591 | Homo sapiens | N/A | ENSG00000256039 | ||||
EL0472 | ENST00000545440 | N/A | Homo sapiens | N/A | ENSG00000255717 | ||||
EL0473 | LINC01234 | LCAL84; onco-lncRNA-32 | Homo sapiens | NR_110025, NR_110026 | ENSG00000249550 | ||||
EL0474 | LINC02086 | CTD-2377D24.6-003; ENST00000575202 | Homo sapiens | N/A | ENSG00000244649 | ||||
EL0475 | EPB41L4A-AS1 | C5orf26; NCRNA00219; TIGA1 | Homo sapiens | NR_015370 | N/A | ||||
EL0476 | EPB41L4A-AS2 | EPB41L4A Antisense RNA 2 | Homo sapiens | NR_027706 | ENSG00000278921 | ||||
EL0477 | EPOR | EPO-R | Homo sapiens | NR_033663 | ENSG00000187266 | ||||
EL0478 | ERCC1 | COFS4; RAD10; UV20 | Homo sapiens | XR_001753632, XR_001753631 | ENSG00000012061 | ||||
EL0479 | ERICD | ERIC; LINC01130; TCONS_00014875 | Homo sapiens | N/A | N/A | ||||
EL0480 | DLGAP2 | DAP2; SAPAP2; C8orf68; ERICH1-AS1 | Homo sapiens | NR_073397 | ENSG00000198010 | ||||
EL0481 | ESCCAL-5 | N/A | Homo sapiens | N/A | N/A | ||||
EL0482 | ESRG | HESRG | Homo sapiens | NR_027122 | ENSG00000265992 | ||||
EL0483 | EVADR | N/A | Homo sapiens | NR_125857 | N/A | ||||
EL0484 | EWSAT1 | LINC00277; NCRNA00277; TMEM84 | Homo sapiens | NR_026949 | ENSG00000212766 | ||||
EL0485 | FADS1 | D5D; FADS6; FADSD5; LLCDL1; TU12 | Homo sapiens | N/A | ENSG00000149485 | ||||
EL0486 | FALEC | FAL1; LINC00568; ncRNA-a1 | Homo sapiens | NR_051960 | ENSG00000228126 | ||||
EL0487 | FAM30A | C14orf110; HSPC053; KIAA0125 | Homo sapiens | NR_026800 | ENSG00000226777 | ||||
EL0488 | FAM3D-AS1 | lnc-KCTD6-3 | Homo sapiens | NR_134853 | ENSG00000244383 | ||||
EL0489 | FAM83A-AS1 | HCCC11; HCCC11_v1; HCCC11_v2 | Homo sapiens | NR_024479 | ENSG00000204949 | ||||
EL0490 | FAR2P1 | HEL-182 | Homo sapiens | NR_026758 | ENSG00000180178 | ||||
EL0491 | FAS-AS1 | FAS-AS; FASAS; SAF | Homo sapiens | NR_028371 | N/A | ||||
EL0492 | FENDRR | FOXF1-AS1; TCONS_00024240; lincFOXF1; onco-lncRNA-21 | Homo sapiens | NR_033925, NR_036444 | ENSG00000268388 | ||||
EL0493 | Fendrr | 1110050K14Rik; LL66; linc-Foxf1a; lincFoxf1 | Mus musculus | NR_045471, NR_130109 | ENSMUSG00000097336 | ||||
EL0494 | FER1L4 | C20orf124 | Homo sapiens | NR_119376 | ENSG00000088340 | ||||
EL0495 | FEZF1-AS1 | N/A | Homo sapiens | NR_036484 | ENSG00000230316 | ||||
EL0496 | FFAR2 | FFA2R; GPR43 | Homo sapiens | AC002511.1 | ENSG00000126262 | ||||
EL0497 | FGF10-AS1 | FGF10-AS1; RP11-473L15.2 | Homo sapiens | NR_108034 | ENSG00000248464 | ||||
EL0498 | FGF14-AS2 | FGF14 antisense RNA 2 | Homo sapiens | NR_036487 | ENSG00000272143 | ||||
EL0499 | FGFR3-AS1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0500 | FH | FMRD; HLRCC; LRCC; MCL; MCUL1 | Homo sapiens | N/A | ENSG00000091483 | ||||
EL0501 | Firre | 5830467J12Rik; 6720401G13Rik; AW048145 | Mus musculus | NR_015505 | ENSMUSG00000085396 | ||||
EL0502 | FKBP10 | BRKS1; FKBP65; OI11; OI6; PPIASE; hFKBP65 | Homo sapiens | N/A | ENSG00000141756 | ||||
EL0503 | FLC | AT5G10140; AGAMOUS-like 25; AGL25; FLF; FLOWERING LOCUS C; FLOWERING LOCUS F; MADS BOX PROTEIN FLOWERING LOCUS F; REDUCED STEM BRANCHING 6; RSB6; T31P16.130; T31P16_130 | Arabidopsis thaliana | N/A | N/A | ||||
EL0504 | FMR1-AS1 | ASFMR1; FMR1-AS; FMR1AS; FMR4 | Homo sapiens | NR_024503, NR_024502, NR_024501, NR_024499 | ENSG00000268066 | ||||
EL0505 | FMR5 | N/A | Homo sapiens | N/A | N/A | ||||
EL0506 | FMR6 | N/A | Homo sapiens | N/A | N/A | ||||
EL0507 | FOSB | AP-1; G0S3; GOS3; GOSB | Homo sapiens | N/A | ENSG00000125740 | ||||
EL0508 | FOXC2-AS1 | ODRUL | Homo sapiens | NR_125795 | ENSG00000260944 | ||||
EL0509 | FOXCUT | LINC01379; TCONS_00011636 | Homo sapiens | NR_125804 | ENSG00000280916 | ||||
EL0510 | FR0257520 | N/A | Homo sapiens | N/A | N/A | ||||
EL0511 | FR0348383 | N/A | Homo sapiens | N/A | N/A | ||||
EL0512 | FRLnc1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0513 | frq antisense RNAs | N/A | Neurospora crassa | N/A | N/A | ||||
EL0514 | FTX | LINC00182; MIR374AHG; NCRNA00182 | Homo sapiens | NR_028379 | ENSG00000230590 | ||||
EL0515 | Ftx | B230206F22Rik; BB219131; NCRNA00182; Thcytx | Mus musculus | NR_028381, NR_028380 | ENSMUSG00000086370 | ||||
EL0516 | G22 | N/A | Lorisoidea | N/A | N/A | ||||
EL0517 | G730013B05Rik | linc-Cblb; linc1610 | Mus musculus | NR_040380, NR_040379 | ENSMUSG00000097694 | ||||
EL0518 | GACAT1 | LINC00876 | Homo sapiens | NR_126370, NR_126369 | ENSG00000232991 | ||||
EL0519 | GACAT2 | MTCL1-AS1; MTCL1AS1 | Homo sapiens | NR_120598 | ENSG00000265962 | ||||
EL0520 | GACAT3 | LINC01458; lncRNA-AC130710 | Homo sapiens | NR_126559 | ENSG00000236289 | ||||
EL0521 | GADD45G | CR6; DDIT2; GADD45gamma; GRP17 | Homo sapiens | N/A | ENSG00000130222 | ||||
EL0522 | GAL10 | YBR019C | Saccharomyces cerevisiae S288c | N/A | N/A | ||||
EL0523 | GAPLINC | LINC01540 | Homo sapiens | NR_110429, NR_110428 | ENSG00000266835 | ||||
EL0524 | GAS1RR | LncRNA-Hh | Homo sapiens | NR_049794 | ENSG00000226237 | ||||
EL0525 | GAS2L3 | G2L3 | Homo sapiens | N/A | ENSG00000139354 | ||||
EL0526 | GAS5 | NCRNA00030; SNHG2 | Homo sapiens | NR_002578 | ENSG00000234741 | ||||
EL0527 | Gas5 | Gas-5; Mir5117; Snhg2 | Mus musculus | NR_002840 | ENSMUSG00000053332 | ||||
EL0528 | GAS6-AS1 | N/A | Homo sapiens | NR_044995 | ENSG00000233695 | ||||
EL0529 | GAS8-AS1 | C16orf3 | Homo sapiens | NR_122031 | ENSG00000221819 | ||||
EL0530 | GATA3-AS1 | N/A | Homo sapiens | NR_024256, NR_104328, NR_104330, NR_104329, NR_104327, NR_104336 | ENSG00000197308 | ||||
EL0531 | GDNF-AS1 | GDNFOS | Homo sapiens | NR_103441 | ENSG00000248587 | ||||
EL0532 | Gfra1 | AU042498 | Mus musculus | NR_104342 | ENSMUSG00000025089 | ||||
EL0533 | GHET1 | lncRNA-GHET1 | Homo sapiens | NR_130107 | ENSG00000281189 | ||||
EL0534 | GHSR | GHDP | Homo sapiens | N/A | ENSG00000121853 | ||||
EL0535 | Gli3 | AI854843; AU023367; Bph; GLI3-190; GLI3FL; Pdn; Xt; add | Mus musculus | N/A | ENSMUSG00000021318 | ||||
EL0536 | Gm10371 | ENSMUSG00000072589 | Mus musculus | NR_126579 | ENSMUSG00000072589 | ||||
EL0537 | Gm15050 | OTTMUSG00000018865 | Mus musculus | XR_001785250 | ENSMUSG00000087626 | ||||
EL0538 | Gm15577 | OTTMUSG00000024006 | Mus musculus | N/A | ENSMUSG00000086708 | ||||
EL0539 | Gm16845 | N/A | Mus musculus | NR_040406, NR_040407 | ENSMUSG00000096981 | ||||
EL0540 | Gm2694 | C230036H16Rik; linc1582 | Mus musculus | NR_033430, NR_125722 | ENSMUSG00000097248 | ||||
EL0541 | Gm30731 | Pnky; lnc-pou3f2 | Mus musculus | NR_131335 | ENSMUSG00000107859 | ||||
EL0542 | Gm32592 | N/A | Mus musculus | XR_377901 | ENSMUSG00000107902 | ||||
EL0543 | Gm6644 | Akr1b3p; EG626009 | Mus musculus | NR_037965 | N/A | ||||
EL0544 | GNAS-AS1 | GNAS-AS; GNAS1AS; GNASAS; NCRNA00075; NESP-AS; NESPAS; SANG | Homo sapiens | NR_002785 | ENSG00000235590 | ||||
EL0545 | GNG12-AS1 | N/A | Homo sapiens | NR_040077 | ENSG00000232284 | ||||
EL0546 | GRMZM2G010274_T01 | N/A | Zea mays | N/A | N/A | ||||
EL0547 | GRMZM2G088590_T04 | N/A | Zea mays | KJ682620 | N/A | ||||
EL0548 | GRMZM2G420571_T01 | N/A | Zea mays | KJ682541 | N/A | ||||
EL0549 | GRMZM2G518002_T01 | N/A | Zea mays | N/A | N/A | ||||
EL0550 | GRMZM2G580571_T01 | N/A | Zea mays | N/A | N/A | ||||
EL0551 | AF181450.1 | GS1-5L10.1 | Homo sapiens | N/A | ENSG00000253576 | ||||
EL0552 | GSTT1-AS1 | N/A | Homo sapiens | NR_132348 | N/A | ||||
EL0553 | GUCY1B2 | GC-SB2 | Homo sapiens | NR_003923 | ENSG00000123201 | ||||
EL0554 | GUT15 | AT2G18440; GENE WITH UNSTABLE TRANSCRIPT 15; T30D6.5; T30D6_5 | Arabidopsis thaliana | NR_143753, NR_143752 | N/A | ||||
EL0555 | H19 | AI747191 | Mus musculus | NR_130974, NR_130973 | ENSMUSG00000000031 | ||||
EL0556 | H19 | ASM; ASM1; BWS; D11S813E; LINC00008; NCRNA00008; WT2 | Homo sapiens | NR_131224, NR_131223, NR_002196 | ENSG00000130600 | ||||
EL0557 | HA117 | N/A | Homo sapiens | N/A | N/A | ||||
EL0558 | HAGLR | HOXD-AS1; Mdgt | Homo sapiens | NR_033979, NR_110466, NR_110465, NR_110460, NR_110459, NR_110461, NR_110468, NR_110464, NR_110467, N | ENSG00000224189 | ||||
EL0559 | HAGLROS | N/A | Homo sapiens | NR_110457 | N/A | ||||
EL0560 | Halr1 | Gm15055; Haunt; Linchoxa1; OTTMUSG00000018881; linc-Evx1; linc-Hoxa1; linc1547 | Mus musculus | NR_110440 | ENSMUSG00000085412 | ||||
EL0561 | HAR1A | HAR1F; LINC00064; NCRNA00064 | Homo sapiens | NR_003244 | N/A | ||||
EL0562 | HAR1B | HAR1R; LINC00065; NCRNA00065 | Homo sapiens | NR_003245 | ENSG00000231133 | ||||
EL0563 | HBB | CD113t-C; beta-globin | Homo sapiens | N/A | ENSG00000244734 | ||||
EL0564 | HCP5 | 6S2650E; D6S2650E; P5-1 | Homo sapiens | NR_040662 | ENSG00000206337 | ||||
EL0565 | HEIH | HCCAT2; LINC-HEIH; LINC00848; lncRNA-HEIH | Homo sapiens | NR_045680 | ENSG00000278970 | ||||
EL0566 | HELLPAR | LINC-HELLP; lncHELLP | Homo sapiens | JX088243.1 | N/A | ||||
EL0567 | HELLS | ICF4; LSH; Nbla10143; PASG; SMARCA6 | Homo sapiens | XR_001747095 | ENSG00000119969 | ||||
EL0568 | HID1 | N/A | Arabidopsis thaliana | KM044009 | N/A | ||||
EL0569 | HIF1A-AS1 | 5'aHIF-1A; 5'aHIF1alpha | Homo sapiens | NR_047116 | ENSG00000258777 | ||||
EL0570 | HIF1A-AS2 | 3'aHIF-1A; aHIF | Homo sapiens | NR_045406 | ENSG00000258667 | ||||
EL0571 | HIF2PUT | N/A | Homo sapiens | N/A | N/A | ||||
EL0572 | HIV1230 | N/A | Homo sapiens | N/A | N/A | ||||
EL0573 | HLA-AS1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0574 | Hm629797 | Mrhl | Mus musculus | HM629797 | ENSMUSG00000098439 | ||||
EL0575 | HNF1A-AS1 | C12orf27; NCRNA00262 | Homo sapiens | NR_024345 | ENSG00000241388 | ||||
EL0576 | Hog | Hotdog | Mus musculus, Atelerix albiventris | BK008787 | N/A | ||||
EL0577 | HOST2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0578 | HOTAIR | HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 | Homo sapiens | NR_047517, NR_047518, NR_003716 | ENSG00000228630 | ||||
EL0579 | Hotair | Gm16258; OTTMUSG00000032781 | Mus musculus | NR_047528 | ENSMUSG00000086903 | ||||
EL0580 | HOTAIRM1 | HOXA-AS1; HOXA1-AS1; NCRNA00179 | Homo sapiens | NR_038366, NR_038367 | ENSG00000233429 | ||||
EL0581 | Hotairm1 | Gm15051; Hoxaas1 | Mus musculus | NR_131181 | ENSMUSG00000087658 | ||||
EL0582 | HOTTIP | HOXA-AS6; HOXA13-AS1; NCRNA00213 | Homo sapiens | NR_037843 | ENSG00000243766 | ||||
EL0583 | Hottip | Gm15053 | Mus musculus | NR_110441, NR_110442 | ENSMUSG00000055408 | ||||
EL0584 | HOXA11-AS | HOXA-AS51; HOXA11AS; HOXA11S; NCRNA00076; HOXA11-AS | Homo sapiens | NR_002795 | ENSG00000240990 | ||||
EL0585 | Hoxa11os | Hoxa11as; Hoxa11s | Mus musculus | NR_015348 | ENSMUSG00000086427 | ||||
EL0586 | HOXA13 | HOX1; HOX1J | Homo sapiens | N/A | ENSG00000106031 | ||||
EL0587 | HOXA-AS | CG7895; DmelCG7895; DmNK-4; DROHOXHK4; DROHOXNK4; HOX; msh-2; msh2; NK-4; NK-4/msh-2; NK4; NK4/msh-2; NKX2.5; Tin; TIN; tin/NK4 | Homo sapiens | N/A | N/A | ||||
EL0588 | HOXA-AS2 | HOXA3as | Homo sapiens | NR_122069 | ENSG00000253552 | ||||
EL0589 | Hoxaas3 | 2700086A05Rik | Mus musculus | NR_015611 | ENSMUSG00000085696 | ||||
EL0590 | HOXA-AS3 | HOXA6as | Homo sapiens | NR_038832, NR_038831 | ENSG00000254369 | ||||
EL0591 | Hoxd3as | Dxoh-3; Hoxd3os | Mus musculus | N/A | N/A | ||||
EL0592 | HSR1 | N/A | Candida albicans SC5314 | N/A | N/A | ||||
EL0593 | Hsromega | Dmel_CR31400; CR31400; DmelCR31400; HSRomega; Hsr-omega; Hsr93D-n; er3; hrsomega; hsr omega; hsr-omega; hsromega; hsrw; l(3)05241; l(3)93De; l(3)er3; n(3)05241; Hsromega | Drosophila melanogaster | NR_048444, NR_074035, NR_002068, NR_074036, NR_133429, NR_002067, NR_002069 | N/A | ||||
EL0594 | HSUR1 | Herpesvirus saimiri U RNAs | Herpesvirus saimiri | N/A | N/A | ||||
EL0595 | HSUR2 | Herpesvirus saimiri U RNAs | Herpesvirus saimiri | N/A | N/A | ||||
EL0596 | HTT-AS | HTT-AS1; HTTAS | Homo sapiens | NR_045414 | N/A | ||||
EL0597 | HTTAS_v1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0598 | Huc1 | H19 upstream conserved regions 1 & 2 | Mus musculus | N/A | N/A | ||||
EL0599 | Huc2 | H19 upstream conserved regions 1 & 2 | Mus musculus | N/A | N/A | ||||
EL0600 | HULC | HCCAT1; LINC00078; NCRNA00078 | Homo sapiens | NR_004855 | ENSG00000251164 | ||||
EL0601 | human immunodeficiency virus-encoded antisense RNAtranscript | N/A | Human Immunodeficiency Virus | N/A | N/A | ||||
EL0602 | HvCesA6 | N/A | Hordeum vulgare | N/A | N/A | ||||
EL0603 | HvISP1 | N/A | Hordeum vulgare | AV911716 | N/A | ||||
EL0604 | HYMAI | NCRNA00020 | Homo sapiens | NR_002768 | ENSG00000283122 | ||||
EL0605 | ICR | N/A | Homo sapiens | N/A | N/A | ||||
EL0606 | ICR1 | ICR1 | Saccharomyces cerevisiae S288c | NR_132191 | N/A | ||||
EL0607 | IFNG-AS1 | GS1-410F4.2; NEST; Tmevpg1 | Homo sapiens | NR_104124, NR_104125 | ENSG00000255733 | ||||
EL0608 | IGF2-AS | IGF2-AS1; IGF2AS; PEG8 | Homo sapiens | NR_028043, NR_133657 | ENSG00000099869 | ||||
EL0609 | IL7R | CD127; CDW127; IL-7R-alphaA; ILRA; IL7R | Homo sapiens | NR_120485 | ENSG00000168685 | ||||
EL0610 | ILF3 | CBTF; DRBF; DRBP76; MMP4; MPHOSPH4; MPP4; NF-AT-90; NF110; NF110b; NF90; NF90a; NF90b; NFAR; NFAR-1; NFAR2; TCP110; TCP80 | Homo sapiens | N/A | ENSG00000129351 | ||||
EL0611 | INTS7 | C1orf73; INT7 | Homo sapiens | NR_037667 | ENSG00000143493 | ||||
EL0612 | IPO5P1 | RP11-15H20.6 | Homo sapiens | NR_103742, NR_103741 | ENSG00000213971 | ||||
EL0613 | IPS1 | AT3G09922; A. THALIANA INDUCED BY PHOSPHATE STARVATION1; ATIPS1; INDUCED BY PHOSPHATE STARVATION1 | Arabidopsis thaliana | AF236376 | N/A | ||||
EL0614 | IPS1 | N/A | Brassica rapa | JN575635 | N/A | ||||
EL0615 | IPS1 | N/A | Nicotiana benthamiana | N/A | N/A | ||||
EL0616 | IPS1 | N/A | Populus tremula | N/A | N/A | ||||
EL0617 | IPS1 | N/A | Vitis vinifera | N/A | N/A | ||||
EL0618 | IPW | NCRNA00002 | Homo sapiens | NR_023915 | N/A | ||||
EL0619 | IRAIN | IGF1R-AS | Homo sapiens | NR_126453 | ENSG00000259424 | ||||
EL0620 | JADRR | lncRNA-JADE | Homo sapiens | N/A | N/A | ||||
EL0621 | JPX | DCBALD06; ENOX; LINC00183; NCRNA00183 | Homo sapiens | NR_024582 | ENSG00000225470 | ||||
EL0622 | Jpx | 2010000I03Rik; 2510040I06Rik; Enox | Mus musculus | NR_015508 | ENSMUSG00000097571 | ||||
EL0623 | Kcna2-AS | Kcna2 antisense RNA | Homo sapiens | N/A | N/A | ||||
EL0624 | KCNE2 | ATFB4; LQT5; LQT6; MIRP1 | Homo sapiens | N/A | ENSG00000159197 | ||||
EL0625 | KCNIP4-IT1 | NCRNA00099; UM9(5); UM9-5 | Homo sapiens | NR_002813 | ENSG00000280650 | ||||
EL0626 | KCNIP4-IT1 | UM9-5; NCRNA00099; KCNIP4-IT1 | Sus scrofa | N/A | N/A | ||||
EL0627 | KCNQ1DN | BWRT; HSA404617 | Homo sapiens | NR_024627 | ENSG00000237941 | ||||
EL0628 | KCNQ1OT1 | KCNQ1-AS2; KCNQ10T1; Kncq1; KvDMR1; KvLQT1-AS; LIT1; NCRNA00012 | Homo sapiens | NR_002728 | ENSG00000269821 | ||||
EL0629 | Kcnq1ot1 | Kvlqt1-as; Lit1; Tssc8 | Mus musculus | NR_001461 | ENSMUSG00000101609 | ||||
EL0630 | Khps1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0631 | Khps1a | Khps1 | Rattus norvegicus | NR_133650 | N/A | ||||
EL0632 | KIR antisense lncRNA | N/A | Homo sapiens | N/A | N/A | ||||
EL0633 | KRAS1P | KRAS1P; c-Kras1 | Homo sapiens | N/A | N/A | ||||
EL0634 | KRT18P55 | N/A | Homo sapiens | NR_028334 | ENSG00000265480 | ||||
EL0635 | KRT19P3 | N/A | Homo sapiens | N/A | ENSG00000249681 | ||||
EL0636 | Ks-1 | N/A | Apis mellifera | NR_003567 | N/A | ||||
EL0637 | LA16c-313D11.11 | N/A | Homo sapiens | N/A | N/A | ||||
EL0638 | LALR | N/A | Homo sapiens | N/A | N/A | ||||
EL0639 | LBX2-AS1 | N/A | Homo sapiens | NR_024606 | ENSG00000257702 | ||||
EL0640 | LCAL1 | onco-lncRNA-27 | Homo sapiens | NR_130915 | N/A | ||||
EL0641 | LDMAR | N/A | Hybrid rice | JQ317784 | N/A | ||||
EL0642 | LDMAR | N/A | Oryza sativa | N/A | N/A | ||||
EL0643 | LeENOD40 | N/A | Solanum lycopersicum | AY388519 | N/A | ||||
EL0644 | LEIGC | N/A | Homo sapiens | N/A | N/A | ||||
EL0645 | LGALS3 | CBP35; GAL3; GALBP; GALIG; L31; LGALS2; MAC2 | Homo sapiens | NR_003225 | ENSG00000131981 | ||||
EL0646 | LINC00032 | C9orf14; NCRNA00032 | Homo sapiens | NR_026679 | ENSG00000283945 | ||||
EL0647 | LINC00160 | C21orf52; NCRNA00160 | Homo sapiens | NR_024351 | ENSG00000230978 | ||||
EL0648 | LINC00173 | NCRNA00173 | Homo sapiens | NR_027345, NR_027346 | ENSG00000196668 | ||||
EL0649 | LINC00210 | NCRNA00210 | Homo sapiens | NR_048550 | ENSG00000231814 | ||||
EL0650 | LINC00237 | NCRNA00237 | Homo sapiens | N/A | N/A | ||||
EL0651 | LINC00261 | ALIEN; C20orf56; DEANR1; HCCDR1; NCRNA00261; onco-lncRNA-17 | Homo sapiens | NR_001558 | ENSG00000259974 | ||||
EL0652 | LINC00271 | C6orf217; NCRNA00271 | Homo sapiens | NR_026805 | ENSG00000231028 | ||||
EL0653 | LINC00299 | C2orf46; NCRNA00299 | Homo sapiens | NR_034135 | ENSG00000236790 | ||||
EL0654 | LINC00312 | ERR-10; ERR10; LMCD1DN; LOH3CR2A; NAG-7; NAG7; NCRNA00312 | Homo sapiens | NR_024065 | N/A | ||||
EL0655 | LINC00313 | C21orf84; CH507-42P11.5; NCRNA00313 | Homo sapiens | NR_026863 | ENSG00000185186 | ||||
EL0656 | LINC00461 | EyeLinc1; VISC; Visc-1a; Visc-1b; Visc-2 | Homo sapiens | NR_015436, NR_024383, NR_024384 | ENSG00000245526 | ||||
EL0657 | LINC00467 | C1orf97 | Homo sapiens | NR_026761 | ENSG00000153363 | ||||
EL0658 | LINC00473 | C6orf176; bA142J11.1 | Homo sapiens | NR_026861, NR_026860 | ENSG00000223414 | ||||
EL0659 | LINC00491 | BC008363; LINC00491 | Homo sapiens | NR_103756, NR_103755, NR_103754, NR_103753 | ENSG00000250682 | ||||
EL0660 | LINC00538 | PROX1UT; Yiya | Homo sapiens | NR_046189 | ENSG00000281664 | ||||
EL0661 | LINC00570 | ncRNA-a5 | Homo sapiens | NR_047499 | ENSG00000224177 | ||||
EL0662 | LINC00581 | linc-MBOAT1-4 | Homo sapiens | NR_103790 | ENSG00000280989 | ||||
EL0663 | LINC00635 | LINC00635-001 | Homo sapiens | NR_024276, NR_015414 | ENSG00000241469 | ||||
EL0664 | LINC00659 | CCAT4; LINC00659-001 | Homo sapiens | NR_046225, NR_046224 | ENSG00000228705 | ||||
EL0665 | LINC00663 | Long Intergenic Non-Protein Coding RNA 663; CTC-559E9.1 | Homo sapiens | NR_026956 | N/A | ||||
EL0666 | LINC00668 | Long Intergenic Non-Protein Coding RNA 668 | Homo sapiens | NR_034100 | ENSG00000265933 | ||||
EL0667 | LINC00673 | HI-LNC75; HILNC75; LUCAIR1; SLNCR; SLNCR1 | Homo sapiens | NR_036488 | N/A | ||||
EL0668 | LINC00850 | KUCG1 | Homo sapiens | NR_109813 | ENSG00000280752 | ||||
EL0669 | LINC00853 | PDZK1IP1-AS1; ncRNA-a4 | Homo sapiens | NR_047498 | ENSG00000224805 | ||||
EL0670 | LINC00901 | LSAMP-AS4; TCONS_00005428 | Homo sapiens | NR_121607 | ENSG00000242385 | ||||
EL0671 | LINC00942 | LOC100292680; LINC00942 | Homo sapiens | NR_028415 | ENSG00000249628 | ||||
EL0672 | LINC00951 | N/A | Homo sapiens | NR_038887 | N/A | ||||
EL0673 | LINC00963 | N/A | Homo sapiens | NR_038955 | ENSG00000204054 | ||||
EL0674 | LINC00964 | N/A | Homo sapiens | NR_027321 | ENSG00000249816 | ||||
EL0675 | LINC00970 | AK126698 | Homo sapiens | NR_104091 | ENSG00000203601 | ||||
EL0676 | LINC00974 | N/A | Homo sapiens | NR_038442 | ENSG00000226629 | ||||
EL0677 | LINC00982 | LINC00982; FLJ42875 | Homo sapiens | NR_015440, NR_024371 | ENSG00000177133 | ||||
EL0678 | LINC00987 | LOC100499405; LINC00987 | Homo sapiens | NR_036466 | ENSG00000237248 | ||||
EL0679 | LINC01016 | Long Intergenic Non-Protein Coding RNA 1016 | Homo sapiens | NR_038989 | ENSG00000249346 | ||||
EL0680 | LINC01018 | SRHC | Homo sapiens | NR_024423, NR_024424 | ENSG00000250056 | ||||
EL0681 | LINC01021 | N/A | Homo sapiens | NR_038848 | ENSG00000250337 | ||||
EL0682 | LINC01024 | MA-linc1 | Homo sapiens | NR_102741, NR_102740, NR_102739 | ENSG00000245146 | ||||
EL0683 | SLC44A3-AS1 | LINC01057 | Homo sapiens | NR_104131 | ENSG00000224081 | ||||
EL0684 | LINC01105 | LOC150622; LINC01105; FLJ30594 | Homo sapiens | NR_026832 | ENSG00000232044 | ||||
EL0685 | LINC01125 | LINC01125 | Homo sapiens | NR_038386 | ENSG00000228486 | ||||
EL0686 | LINC01133 | N/A | Homo sapiens | NR_038849 | ENSG00000224259 | ||||
EL0687 | LINC01158 | PANTR1; linc-Brn1a; linc-POU3F3 | Homo sapiens | NR_037883, NR_131233, NR_131234, NR_131235 | ENSG00000233639 | ||||
EL0688 | LINC01207 | N/A | Homo sapiens | NR_038834 | ENSG00000248771 | ||||
EL0689 | LINC01225 | LOC149086; LINC01225 | Homo sapiens | NR_034112 | ENSG00000260386 | ||||
EL0690 | LINC01233 | XLOC_013014 | Homo sapiens | NR_110663, NR_110664 | ENSG00000269364 | ||||
EL0691 | LINC01262 | LINC01262; RP11-462G22.1 | Homo sapiens | NR_121679 | ENSG00000250739 | ||||
EL0692 | LINC01315 | lnc-C22orf32-1 | Homo sapiens | NR_120597, NR_120596, NR_120595 | ENSG00000229891 | ||||
EL0693 | LINC01370 | HI-LNC25; HILNC25 | Homo sapiens | NR_109936, NR_109937 | ENSG00000237767 | ||||
EL0694 | LINC01419 | LVCAT7; TCONS_00014497 | Homo sapiens | NR_122034 | ENSG00000253898 | ||||
EL0695 | LINC01426 | lincRNA-uc002yug.2 | Homo sapiens | NR_038885, NR_038886 | ENSG00000234380 | ||||
EL0696 | LINC01433 | LOC728228; LINC01433 | Homo sapiens | NR_033917 | ENSG00000230176 | ||||
EL0697 | LINC01451 | HCCAT4 | Homo sapiens | NR_135288 | ENSG00000279141 | ||||
EL0698 | LINC01468 | lnc-MBL2-4 | Homo sapiens | NR_120641, NR_120642 | ENSG00000231131 | ||||
EL0699 | LINC01503 | lnc-PPP2R4-5; LINC01503 | Homo sapiens | NR_120685, NR_120686 | ENSG00000233901 | ||||
EL0700 | LINC01511 | LINC01511; RP11-325I22.2 | Homo sapiens | NR_125810 | ENSG00000250584 | ||||
EL0701 | LINC01512 | HI-LNC77 | Homo sapiens | NR_024478 | N/A | ||||
EL0702 | LINC01527 | lnc-SPRR2D-1 | Homo sapiens | XR_241125 | ENSG00000224308 | ||||
EL0703 | LINC01550 | C14orf64 | Homo sapiens | NR_015430 | ENSG00000246223 | ||||
EL0704 | LINC01564 | TCONS_00011314; XLOC_005327 | Homo sapiens | NR_125841 | ENSG00000235899 | ||||
EL0705 | LINC01613 | n341773 | Homo sapiens | NR_132393 | ENSG00000261432 | ||||
EL0706 | LINC01616 | n341006 | Homo sapiens | NR_132652 | ENSG00000261340 | ||||
EL0707 | LINC01617 | C8orf23; NCRNA00249; XLOC_006844 | Homo sapiens | NR_147034 | N/A | ||||
EL0708 | LINC01618 | LOC152578; RP11-752D24.3 | Homo sapiens | NR_040106 | ENSG00000250302 | ||||
EL0709 | LINC01628 | N/A | Homo sapiens | NR_110600 | ENSG00000232688 | ||||
EL0710 | LINC01630 | Uncharacterized LOC100287225 | Homo sapiens | NR_040074, NR_040075 | ENSG00000227115 | ||||
EL0711 | LINC02 | N/A | Gossypium barbadense | N/A | N/A | ||||
EL0712 | linc1242 | linc-Enah | Mus musculus | N/A | N/A | ||||
EL0713 | linc1257 | Linc-Myo1g; Ak160548 | Mus musculus | N/A | N/A | ||||
EL0714 | linc1368 | linc-Adamts9 | Mus musculus | N/A | N/A | ||||
EL0715 | linc-CBR1-2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0716 | lincDR1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0717 | lincGARS | N/A | Homo sapiens | N/A | N/A | ||||
EL0718 | linc-ITGB1 | linc-ITGB1 | Homo sapiens | N/A | ENSG00000150093 | ||||
EL0719 | LINCMD1 | LINC-MD1; MIR133BHG | Homo sapiens | NR_131248 | N/A | ||||
EL0720 | lincMLKN1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0721 | LINC-PINT | LincRNA-Pint; MKLN1-AS1; PINT | Homo sapiens | NR_110473, NR_110472, NR_034120, NR_109855, NR_109854, NR_109853, NR_015431, NR_109852, NR_109851, N | ENSG00000231721 | ||||
EL0722 | Linc-rbe | N/A | Rattus norvegicus | N/A | N/A | ||||
EL0723 | LincR-Ccr2-5'AS | N/A | Mus musculus | N/A | N/A | ||||
EL0724 | lincRNA1039 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0725 | lincRNA1085 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0726 | lincRNA1128 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0727 | lincRNA1310 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0728 | lincRNA1534 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0729 | lincRNA1828 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0730 | lincRNA20 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0731 | lincRNA2085 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0732 | lincRNA2131 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0733 | lincRNA2198 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0734 | lincRNA262 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0735 | lincRNA2623 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0736 | lincRNA2752 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0737 | lincRNA2962 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0738 | lincRNA3241 | N/A | Populus trichocarpa | N/A | N/A | ||||
EL0739 | lincRNA-BC2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0740 | lincRNA-BC4 | N/A | Homo sapiens | N/A | N/A | ||||
EL0741 | lincRNA-BC5 | N/A | Homo sapiens | N/A | N/A | ||||
EL0742 | lincRNA-BC8 | N/A | Homo sapiens | N/A | N/A | ||||
EL0743 | lincRNA-CALCA | N/A | Homo sapiens | N/A | N/A | ||||
EL0744 | lincRNA-LALR1 | LncRNA-LALR1 | Homo sapiens | N/A | N/A | ||||
EL0745 | lincRNA-TSPAN8 | N/A | Homo sapiens | N/A | N/A | ||||
EL0746 | lincRNA-ZNF532 | N/A | Homo sapiens | N/A | N/A | ||||
EL0747 | LINC-ROR | ROR; lincRNA-RoR | Homo sapiens | NR_048536 | ENSG00000258609 | ||||
EL0748 | LINC-RSAS | repeat-rich sense-antisense transcript | Rattus norvegicus | N/A | N/A | ||||
EL0749 | lincSFPQ | N/A | Homo sapiens | N/A | N/A | ||||
EL0750 | LINK-A | N/A | Homo sapiens | N/A | N/A | ||||
EL0751 | LL34 | N/A | Homo sapiens | N/A | N/A | ||||
EL0752 | Llme23 | N/A | Homo sapiens | N/A | N/A | ||||
EL0753 | lnc13 | N/A | Homo sapiens | N/A | N/A | ||||
EL0754 | lnc-168 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0755 | lnc-173 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0756 | lnc-225 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0757 | lnc-31 | N/A | Mus musculus | N/A | N/A | ||||
EL0758 | Lnc34a | N/A | Homo sapiens | N/A | N/A | ||||
EL0759 | lnc-508 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0760 | lnc-ACACA-1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0761 | lnc-AF085935 | N/A | Homo sapiens | N/A | N/A | ||||
EL0762 | lnc-AL355149.1-1 | N/A | Homo sapiens | N/A | ENSG00000266584 | ||||
EL0763 | lncARSR | N/A | Homo sapiens | N/A | N/A | ||||
EL0764 | lnc-bc060912 | N/A | Homo sapiens | N/A | N/A | ||||
EL0765 | lnc-BMP2-2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0766 | lnc-CPN2-1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0767 | lnc-CYP4A22-2/3 | N/A | Homo sapiens | N/A | N/A | ||||
EL0768 | lnc-DILC | N/A | Homo sapiens | N/A | N/A | ||||
EL0769 | lnc-FOXG1-2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0770 | lnc-FZD1-2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0771 | lnc-ITPR2-3 | N/A | Homo sapiens | N/A | N/A | ||||
EL0772 | lnc-KCMF1-2:1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0773 | lnc-LCE5A-1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0774 | lnc-LCP2-2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0775 | lncLGR | N/A | Mus musculus | AK028540 | N/A | ||||
EL0776 | lnc-LLPH-2:1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0777 | lnc-MX1-1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0778 | lnc-PLA2R1-1:1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0779 | lnc-PSD4-1:14 | N/A | Homo sapiens | N/A | N/A | ||||
EL0780 | lncRNA1329 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0781 | lncRNA1459 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0782 | lncRNA1471 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0783 | lncRNA1785 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0784 | lncRNA1840 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0785 | lncRNA2.7 | HHV5gp156 | Human herpesvirus 5 | N/A | N/A | ||||
EL0786 | lncRNA246 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0787 | lncRNA2943 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0788 | LncRNA-314 | N/A | Solanum lycopersicum and S. pimpinellifolium | N/A | N/A | ||||
EL0789 | lncRNA3294 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0790 | lncRNA3613 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0791 | lncRNA-422 | N/A | Homo sapiens | N/A | N/A | ||||
EL0792 | lncRNA496 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0793 | lncRNA504 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0794 | lncRNA506 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0795 | lncRNA864 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0796 | lncRNA950 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL0797 | lncRNA-AK058803 | N/A | Homo sapiens | N/A | N/A | ||||
EL0798 | LncRNA-AP001631.9 | N/A | Homo sapiens | N/A | ENSG00000236663 | ||||
EL0799 | lncRNA-ATB | N/A | Homo sapiens | N/A | N/A | ||||
EL0800 | lncRNA-DQ786227 | N/A | Homo sapiens | N/A | N/A | ||||
EL0801 | lncRNA-HSVIII | N/A | Mus musculus | N/A | N/A | ||||
EL0802 | lncRNA-n336928 | N/A | Homo sapiens | N/A | N/A | ||||
EL0803 | lncRNA-Rel | N/A | Mus musculus | N/A | N/A | ||||
EL0804 | lncRNA-αGT | N/A | Gallus gallus | N/A | N/A | ||||
EL0805 | lnc-RP3-368B9 | N/A | Homo sapiens | N/A | N/A | ||||
EL0806 | lnc-SLC30A4-1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0807 | lnc-SPAM1-6 | N/A | Homo sapiens | N/A | N/A | ||||
EL0808 | lnc-TTC34-3 | N/A | Homo sapiens | N/A | N/A | ||||
EL0809 | lnc-uc003wbd | N/A | Homo sapiens | N/A | N/A | ||||
EL0810 | lnc-ZNF180-2 | lnc-ZNF180-2 | Homo sapiens | N/A | ENSG00000167384 | ||||
EL0811 | lnc-ZNF674-1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0812 | LOC100129973 | RP11-430B1.2 | Homo sapiens | NR_102751 | ENSG00000259577 | ||||
EL0813 | LOC100131831 | N/A | Homo sapiens | N/A | N/A | ||||
EL0814 | LOC100287482 | LOC100287482; SMKR1 | Homo sapiens | N/A | ENSG00000240204 | ||||
EL0815 | LOC100288798 | N/A | Homo sapiens | NR_125378, NR_125379, NR_125377, NR_125380, NR_125381 | N/A | ||||
EL0816 | LOC100506974 | N/A | Homo sapiens | XR_001752796, XR_001752794, XR_001752797, XR_001752795 | N/A | ||||
EL0817 | LOC101211037 | CR20 | Cucumis sativus | XR_969194, XR_969192, XR_969189, XR_969193, XR_969191, XR_969190, XR_969187, XR_969188, XR_969185, X | N/A | ||||
EL0818 | LINC01844 | Uncharacterized LOC101926975 | Homo sapiens | NR_110558 | ENSG00000236714 | ||||
EL0819 | LOC101927497 | LOC101927497 | Homo sapiens | NR_110086, NR_110087, NR_110088 | ENSG00000237819 | ||||
EL0820 | LOC103643717 | TCONS_00011169 | Zea mays | XR_561214 | N/A | ||||
EL0821 | LOC103692984 | N/A | Rattus norvegicus | NR_132098 | ENSRNOG00000060019 | ||||
EL0822 | LOC105246506 | N/A | Mus musculus | NR_131039 | N/A | ||||
EL0823 | LOC105372753 | N/A | Homo sapiens | XR_001754985, XR_001754984, XR_001754986, XR_001754987, XR_001754983 | ENSG00000229962 | ||||
EL0824 | LOC105374631 | CTD-2247C11.5-001; ENST00000507950 | Homo sapiens | NR_134266 | ENSG00000250529 | ||||
EL0825 | LOC105377769 | CTC-338M12.5; ENST00000514487 | Homo sapiens | XR_941333, XR_941334 | ENSG00000250222 | ||||
EL0826 | LOC105435934 | CsM10 | Cucumis sativus | XR_969890, XR_969892, XR_969891, XR_969893, XR_969894 | N/A | ||||
EL0827 | LOC389023 | N/A | Homo sapiens | N/A | N/A | ||||
EL0828 | LOC389332 | NR_024418; AC009014.3-001 | Homo sapiens | NR_024418 | ENSG00000271824 | ||||
EL0829 | AC100861.1 | RP11-1149O23.3 | Homo sapiens | NR_033928 | ENSG00000246582 | ||||
EL0830 | LOC400891 | N/A | Homo sapiens | N/A | N/A | ||||
EL0831 | LOC401317 | N/A | Homo sapiens | N/A | N/A | ||||
EL0832 | LOC548136 | enod40 | Hordeum vulgare | AF542513 | N/A | ||||
EL0833 | LOC652276 | NR_015441; AC141586.5-002 | Homo sapiens | NR_015441 | ENSG00000215154 | ||||
EL0834 | LpENOD40 | N/A | Lolium perenne | AF538350 | N/A | ||||
EL0835 | Lrrc9 | 4921529O18Rik; 4930432K16Rik | Mus musculus | AK144081.1 | ENSMUSG00000021090 | ||||
EL0836 | LSINCT1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0837 | LSINCT10 | N/A | Homo sapiens | N/A | N/A | ||||
EL0838 | LSINCT11 | N/A | Homo sapiens | N/A | N/A | ||||
EL0839 | LSINCT12 | N/A | Homo sapiens | N/A | N/A | ||||
EL0840 | LSINCT2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0841 | LSINCT3 | N/A | Homo sapiens | N/A | N/A | ||||
EL0842 | LSINCT4 | N/A | Homo sapiens | N/A | N/A | ||||
EL0843 | LSINCT5 | N/A | Homo sapiens | NR_145480 | ENSG00000281560 | ||||
EL0844 | LSINCT6 | N/A | Homo sapiens | N/A | N/A | ||||
EL0845 | LSINCT7 | N/A | Homo sapiens | N/A | N/A | ||||
EL0846 | LSINCT8 | N/A | Homo sapiens | N/A | N/A | ||||
EL0847 | LSINCT9 | N/A | Homo sapiens | N/A | N/A | ||||
EL0848 | LUADT1 | N/A | Homo sapiens | NR_132442 | ENSG00000196634 | ||||
EL0849 | LUCAT1 | SCAL1 | Homo sapiens | NR_103548, NR_103549 | ENSG00000248323 | ||||
EL0850 | LUNAR1 | Leukemia-Associated Non-Coding IGF1R Activator RNA 1; RP11-6O2.2 | Homo sapiens | NR_126487 | ENSG00000278090 | ||||
EL0851 | M14574 | N/A | Homo sapiens | N/A | N/A | ||||
EL0852 | MAFA-AS1 | TCONS_00014882 | Homo sapiens | NR_126358 | ENSG00000254338 | ||||
EL0853 | MALAT1 | HCN; LINC00047; NCRNA00047; NEAT2; PRO2853; mascRNA | Homo sapiens | NR_002819 | ENSG00000251562 | ||||
EL0854 | Malat1 | 2210401K01Rik; 9430072K23Rik; AI647968; Neat2 | Mus musculus | NR_002847 | ENSMUSG00000092341 | ||||
EL0855 | MALAT2 | N/A | Homo sapiens | N/A | N/A | ||||
EL0856 | MAP3K14 | FTDCR1B; HS; HSNIK; NIK | Homo sapiens | XR_934591 | ENSG00000006062 | ||||
EL0857 | MAR | N/A | Panax ginseng | AF485333 | N/A | ||||
EL0858 | Maternal somatic nucleus RNAs | Paramecium tetraurelia maternal macronucleus noncoding RNAs | Paramecium tetraurelia | N/A | N/A | ||||
EL0859 | MDC1-AS1 | MDC1-AS | Homo sapiens | NR_133647 | ENSG00000224328 | ||||
EL0860 | Mdrl | 2310010G23Rik | Mus musculus | NR_131979 | ENSMUSG00000097468 | ||||
EL0861 | MEG3 | FP504; GTL2; LINC00023; NCRNA00023; PRO0518; PRO2160; onco-lncRNA-83; prebp1 | Homo sapiens | NR_046467, NR_046465, NR_046472, NR_046471, NR_033359, NR_003530, NR_033358, NR_002766, NR_046470, N | ENSG00000214548 | ||||
EL0862 | Meg3 | 2900016C05Rik; 3110050O07Rik; 6330408G06Rik; AI425946; AW108224; D12Bwg1266e; Gtl2; R74756; R75394 | Mus musculus | NR_027652, NR_027651, NR_003633 | ENSMUSG00000021268 | ||||
EL0863 | MEG8 | Bsr; Rian | Rattus norvegicus | N/A | N/A | ||||
EL0864 | MESTIT1 | MEST-AS1; MEST-IT; MEST-IT1; NCRNA00040; PEG1-AS | Homo sapiens | NR_004382 | N/A | ||||
EL0865 | MHM | N/A | Gallus gallus | N/A | N/A | ||||
EL0866 | MHM-lncRNA | N/A | Gallus gallus | N/A | N/A | ||||
EL0867 | MHRT | Myheart | Homo sapiens | NR_126491 | ENSG00000258444 | ||||
EL0868 | Mhrt | D830015G02Rik; ENSMUSG00000053118; Myheart | Mus musculus | NR_033497 | ENSMUSG00000097652 | ||||
EL0869 | MIAT | C22orf35; GOMAFU; LINC00066; NCRNA00066; RNCR2; lncRNA-MIAT | Homo sapiens | NR_003491, NR_033319, NR_033320, NR_033321 | ENSG00000225783 | ||||
EL0870 | Miat | 3632434I06; A230057G18Rik; Rncr2; gomafu | Mus musculus | NR_003718, NR_033657 | ENSMUSG00000097767 | ||||
EL0871 | MIAT | RNCR2/MIAT | Gallus gallus | N/A | N/A | ||||
EL0872 | MINA | MDIG53; NO52; ROX; MINA | Homo sapiens | XR_001740332, XR_241516, XR_001740331 | ENSG00000170854 | ||||
EL0873 | MINCR | LINC01604 | Homo sapiens | NR_120682, NR_120683 | ENSG00000253716 | ||||
EL0874 | MIR100HG | AGD1; linc-NeD125; lncRNA-N2 | Homo sapiens | NR_024430 | ENSG00000255248 | ||||
EL0875 | Mir124a-1hg | A930011O12Rik; Rncr3; mir-124-1; mir-3078 | Mus musculus | NR_040709 | ENSMUSG00000097545 | ||||
EL0876 | Mir142hg | A430104N18Rik; AW909330 | Mus musculus | BE136127 | ENSMUSG00000084796 | ||||
EL0877 | MIR155HG | BIC; MIRHG2; NCRNA00172 | Homo sapiens | NR_001458 | ENSG00000234883 | ||||
EL0878 | MIR17HG | C13orf25; FGLDS2; LINC00048; MIHG1; MIRH1; MIRHG1; NCRNA00048; miR-17-92 | Homo sapiens | NR_027350, NR_027349 | ENSG00000215417 | ||||
EL0879 | MIR21 | MIRN21; hsa-mir-21; miR-21; miRNA21 | Homo sapiens | NR_029493 | N/A | ||||
EL0880 | MIR31HG | LOC554202; MIR31HG | Homo sapiens | NR_027054 | ENSG00000171889 | ||||
EL0881 | MIR4435-2HG | AGD2; AK001796; LINC00978; MIR4435-1HG | Homo sapiens | NR_136164, NR_136163, NR_136162, NR_136165, NR_136161, NR_136166, NR_015395, NR_024373 | ENSG00000172965 | ||||
EL0882 | MIR7-3HG | C19orf30; Huh7; LINC00306; NCRNA00306; PGSF1; uc002mbe.2 | Homo sapiens | NR_027148 | ENSG00000176840 | ||||
EL0883 | MIR99AHG | C21orf34; C21orf35; LINC00478; MONC | Homo sapiens | NR_136541, NR_136542, NR_027790, NR_111005, NR_111004, NR_136552, NR_136551, NR_027791, NR_136543, N | ENSG00000215386 | ||||
EL0884 | Mira | Mira | Mus musculus | NR_045199 | N/A | ||||
EL0885 | MKRN3-AS1 | FNZ127; MKRN3-AS; MKRN3AS; NCRNA00009; ZNF127-AS; ZNF127AS | Homo sapiens | N/A | N/A | ||||
EL0886 | mlncR1 | N/A | Digitalis purpurea | JO460015 | N/A | ||||
EL0887 | mlncR1 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0888 | mlncR10 | N/A | Digitalis purpurea | JO460027 | N/A | ||||
EL0889 | mlncR10 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0890 | mlncR11 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0891 | mlncR12 | N/A | Digitalis purpurea | JO464553 | N/A | ||||
EL0892 | mlncR13 | N/A | Digitalis purpurea | JO461863 | N/A | ||||
EL0893 | mlncR13 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0894 | mlncR14 | N/A | Digitalis purpurea | JO460868 | N/A | ||||
EL0895 | mlncR14 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0896 | mlncR15 | N/A | Digitalis purpurea | JO460756 | N/A | ||||
EL0897 | mlncR15 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0898 | mlncR16 | N/A | Digitalis purpurea | JO461597 | N/A | ||||
EL0899 | mlncR16 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0900 | mlncR17 | N/A | Digitalis purpurea | JO464502 | N/A | ||||
EL0901 | mlncR17 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0902 | mlncR18 | N/A | Digitalis purpurea | JO460757 | N/A | ||||
EL0903 | mlncR18 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0904 | mlncR19 | N/A | Digitalis purpurea | JO461384 | N/A | ||||
EL0905 | mlncR2 | N/A | Digitalis purpurea | JO460538 | N/A | ||||
EL0906 | mlncR2 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0907 | mlncR20 | N/A | Digitalis purpurea | JO462548 | N/A | ||||
EL0908 | mlncR21 | N/A | Digitalis purpurea | JO460109 | N/A | ||||
EL0909 | mlncR22 | N/A | Digitalis purpurea | JO463958 | N/A | ||||
EL0910 | mlncR23 | N/A | Digitalis purpurea | JO460543 | N/A | ||||
EL0911 | mlncR24 | N/A | Digitalis purpurea | JO460800 | N/A | ||||
EL0912 | mlncR25 | N/A | Digitalis purpurea | JO463091 | N/A | ||||
EL0913 | mlncR26 | N/A | Digitalis purpurea | JO467391 | N/A | ||||
EL0914 | mlncR27 | N/A | Digitalis purpurea | JO463416 | N/A | ||||
EL0915 | mlncR28 | N/A | Digitalis purpurea | JO460815 | N/A | ||||
EL0916 | mlncR29 | N/A | Digitalis purpurea | JO460003 | N/A | ||||
EL0917 | mlncR3 | N/A | Digitalis purpurea | JO467387 | N/A | ||||
EL0918 | mlncR3 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0919 | mlncR30 | N/A | Digitalis purpurea | JO462174 | N/A | ||||
EL0920 | mlncR31 | N/A | Digitalis purpurea | JO463507 | N/A | ||||
EL0921 | mlncR4 | N/A | Digitalis purpurea | JO460228 | N/A | ||||
EL0922 | mlncR4 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0923 | mlncR5 | N/A | Digitalis purpurea | JO460314 | N/A | ||||
EL0924 | mlncR5 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0925 | mlncR6 | N/A | Digitalis purpurea | JO460006 | N/A | ||||
EL0926 | mlncR6 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0927 | mlncR7 | N/A | Digitalis purpurea | JO460072 | N/A | ||||
EL0928 | mlncR7 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0929 | mlncR8 | N/A | Digitalis purpurea | JO463019 | N/A | ||||
EL0930 | mlncR8 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0931 | mlncR9 | N/A | Salvia miltiorrhiza | N/A | N/A | ||||
EL0932 | MNX1-AS1 | CCAT5 | Homo sapiens | NR_038835 | ENSG00000243479 | ||||
EL0933 | MR1 | HLALS | Homo sapiens | N/A | ENSG00000153029 | ||||
EL0934 | MRAK052686 | N/A | Homo sapiens | N/A | N/A | ||||
EL0935 | MsENOD40-1 | N/A | Medicago sativa | AF035556 | N/A | ||||
EL0936 | MsENOD40-2 | N/A | Medicago sativa | AF035557 | N/A | ||||
EL0937 | MSUR1 | N/A | Mus musculus | N/A | N/A | ||||
EL0938 | Msx1 | AA675338; AI324650; Hox-7; Hox7; Hox7.1; msh | Mus musculus | N/A | ENSMUSG00000048450 | ||||
EL0939 | Msx1os | Msx1as | Mus musculus | NR_027920 | N/A | ||||
EL0940 | MT1DP | MTM | Homo sapiens | NR_027781, NR_003658 | ENSG00000205361 | ||||
EL0941 | MT1JP | MT1; MT1J; MT1NP; MTB | Homo sapiens | NR_036677 | ENSG00000255986 | ||||
EL0942 | Mt4 | N/A | Barrel clover | N/A | N/A | ||||
EL0943 | Mt4 | N/A | Medicago sativa | N/A | N/A | ||||
EL0944 | Mt4 | N/A | Medicago truncatula | U76742 | N/A | ||||
EL0945 | MtENOD40-1 | N/A | Medicago truncatula | N/A | N/A | ||||
EL0946 | MtENOD40-2 | N/A | Medicago truncatula | X80262 | N/A | ||||
EL0947 | MT-ND5 | MTND5; ND5 | Homo sapiens | N/A | N/A | ||||
EL0948 | MT-ND6 | MTND6; ND6 | Homo sapiens | N/A | N/A | ||||
EL0949 | Munc | DRReRNA | Mus musculus | NR_131190 | N/A | ||||
EL0950 | MVIH | N/A | Homo sapiens | N/A | N/A | ||||
EL0951 | MYCNOS | MYCN-AS1; N-CYM; NCYM; NYCM | Homo sapiens | NR_110230 | ENSG00000233718 | ||||
EL0952 | MYCNUT | MYCNUN; lncUSMycN | Homo sapiens | NR_125783 | ENSG00000223850 | ||||
EL0953 | Myh8 | 4832426G23Rik; AI327267; MHCp; MyHC-pn; Myhs-p; Myhsp | Mus musculus | N/A | ENSMUSG00000055775 | ||||
EL0954 | MYHAS | ASLNC11435; AK097500 | Homo sapiens | NR_125367 | N/A | ||||
EL0955 | MYLK-AS1 | N/A | Homo sapiens | NR_038266, NR_121654 | ENSG00000239523 | ||||
EL0956 | n335550 | N/A | Homo sapiens | N/A | N/A | ||||
EL0957 | n340790 | N/A | Homo sapiens | N/A | N/A | ||||
EL0958 | n386477 | N/A | Homo sapiens | N/A | N/A | ||||
EL0959 | NALT1 | LINC01573; MIR4674HG; NALT | Homo sapiens | NR_121577 | ENSG00000237886 | ||||
EL0960 | NAMA | N/A | Homo sapiens | NR_102271, NR_102270 | ENSG00000271086 | ||||
EL0961 | NBAT1 | CASC14; NBAT-1 | Homo sapiens | NR_034143 | ENSG00000260455 | ||||
EL0962 | NBR2 | NCRNA00192 | Homo sapiens | NR_003108 | ENSG00000198496 | ||||
EL0963 | ncC11orf49 | N/A | Homo sapiens | N/A | N/A | ||||
EL0964 | ncHDAC5 | N/A | Homo sapiens | N/A | N/A | ||||
EL0965 | ncNRFR | N/A | Homo sapiens | N/A | N/A | ||||
EL0966 | ncRAB31 | N/A | Homo sapiens | N/A | N/A | ||||
EL0967 | ncRNA-a6 | N/A | Homo sapiens | N/A | N/A | ||||
EL0968 | ncRNACCND1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0969 | NCRUPAR | NCRNA00193; ncR-uPAR | Homo sapiens | NR_028375 | N/A | ||||
EL0970 | ncSRPK1 | N/A | Homo sapiens | N/A | N/A | ||||
EL0971 | Nctc1 | 9530074L01; Rhit1 | Mus musculus | NR_002452 | ENSMUSG00000087090 | ||||
EL0972 | NDM29 | N/A | Homo sapiens | N/A | N/A | ||||
EL0973 | NEAT1 | LINC00084; NCRNA00084; TncRNA; VINC | Homo sapiens | NR_131012, NR_028272 | ENSG00000245532 | ||||
EL0974 | Neat1 | 2310043N10Rik; VINC | Mus musculus | NR_131212, NR_003513 | ENSMUSG00000092274 | ||||
EL0975 | Nespas | Gnas-as; Nespos | Mus musculus | NR_002846 | ENSMUSG00000086537 | ||||
EL0976 | Nfkb2 | NF-kappaB2; lyt; p49; p49/p100; p50B; p52 | Mus musculus | N/A | ENSMUSG00000025225 | ||||
EL0977 | NKILA | N/A | Homo sapiens | NR_131157 | ENSG00000278709 | ||||
EL0978 | Nkx2-2os | Gm14112; Nkx2-2as; Nkx2.2AS | Mus musculus | NR_030769 | ENSMUSG00000086509 | ||||
EL0979 | NONHSAT012762 | N/A | Homo sapiens | N/A | N/A | ||||
EL0980 | NONHSAT037832 | N/A | Homo sapiens | N/A | N/A | ||||
EL0981 | NONHSAT073641 | N/A | Homo sapiens | N/A | N/A | ||||
EL0982 | NONHSAT123350 | N/A | Homo sapiens | N/A | N/A | ||||
EL0983 | NONHSAT125629 | N/A | Homo sapiens | N/A | N/A | ||||
EL0984 | NONRATT021972 | N/A | Rattus norvegicus | N/A | N/A | ||||
EL0985 | NORAD | LINC00657 | Homo sapiens | NR_027451 | ENSG00000260032 | ||||
EL0986 | NOS2 | HEP-NOS; INOS; NOSA; NOS2 | Homo sapiens | N/A | ENSG00000007171 | ||||
EL0987 | np_17856 | N/A | Mus musculus | N/A | N/A | ||||
EL0988 | np_5318 | N/A | Mus musculus | N/A | N/A | ||||
EL0989 | NPAP1 | C15orf2 | Homo sapiens | N/A | ENSG00000185823 | ||||
EL0990 | npc15 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0991 | npc156 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0992 | npc311 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0993 | npc33 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0994 | npc34 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0995 | npc351 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0996 | npc375 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0997 | npc43 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL0998 | npc48 | N/A | Arabidopsis thaliana | HG975424 | N/A | ||||
EL0999 | npc523 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1000 | npc531 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1001 | npc536 | N/A | Arabidopsis thaliana | HG975425 | N/A | ||||
EL1002 | npc60 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1003 | npc78 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1004 | npc82 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1005 | npc83 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1006 | NPPA-AS1 | NPPA-AS; NPPAAS | Homo sapiens | NR_037806 | N/A | ||||
EL1007 | NPTN-IT1 | lncRNA-LET | Homo sapiens | NR_103844 | ENSG00000281183 | ||||
EL1008 | NR_038125 | N/A | Homo sapiens | N/A | N/A | ||||
EL1009 | NR024118 | N/A | Rattus norvegicus | N/A | N/A | ||||
EL1010 | NRAV | DYNLL1-AS1; DYNLL1AS1 | Homo sapiens | NR_038854 | ENSG00000248008 | ||||
EL1011 | NRG1 | ARIA; GGF; GGF2; HGL; HRG; HRG1; HRGA; MST131; MSTP131; NDF-IT2; SMDF; NRG1 | Homo sapiens | N/A | ENSG00000157168 | ||||
EL1012 | NRIR | lncRNA-CMPK2 | Homo sapiens | NR_126359 | ENSG00000225964 | ||||
EL1013 | NRON | NCRNA00194 | Homo sapiens | NR_045006 | N/A | ||||
EL1014 | NRSE | N/A | Hippocampus comes | N/A | N/A | ||||
EL1015 | nta-eTMX27 | N/A | Nicotiana tabacum | N/A | N/A | ||||
EL1016 | NtENOD40-1 | N/A | Nicotiana tabacum | N/A | N/A | ||||
EL1017 | NUTF2P3 | NUTF2P3-001 | Homo sapiens | N/A | ENSG00000228248 | ||||
EL1018 | ObENOD40 | N/A | Oryza brachyantha | AB024055 | N/A | ||||
EL1019 | OGT | HINCUT-1; HRNT1; O-GLCNAC | Homo sapiens | N/A | ENSG00000147162 | ||||
EL1020 | OIP5-AS1 | cyrano | Homo sapiens | NR_026757 | ENSG00000247556 | ||||
EL1021 | OR3A4P | OLFRA05; OLFRA06; OR17-13; OR17-16; OR17-24; OR17-25; OR24; OR25; OR3A4; OR3A5P | Homo sapiens | NR_024128 | ENSG00000279517 | ||||
EL1022 | ORAOV1 | TAOS1 | Homo sapiens | N/A | ENSG00000149716 | ||||
EL1023 | OS9 | ERLEC2; OS-9 | Homo sapiens | N/A | ENSG00000135506 | ||||
EL1024 | OsIPS1 | N/A | Oryza sativa | AY568759 | N/A | ||||
EL1025 | osk | Dmel_CG10901; CG10901; Dm-osk; DmelCG10901; OSK; Osk; Oskar; norka | Drosophila melanogaster | N/A | N/A | ||||
EL1026 | OsPI1 | N/A | Oryza sativa | N/A | N/A | ||||
EL1027 | OVAAL | LINC01131; OVAL | Homo sapiens | NR_125716 | ENSG00000236719 | ||||
EL1028 | P14695 | N/A | Homo sapiens | N/A | N/A | ||||
EL1029 | P16984 | N/A | Homo sapiens | N/A | N/A | ||||
EL1030 | P19780 | N/A | Homo sapiens | N/A | N/A | ||||
EL1031 | P23099 | N/A | Homo sapiens | N/A | N/A | ||||
EL1032 | P24363 | N/A | Homo sapiens | N/A | N/A | ||||
EL1033 | P28210 | N/A | Homo sapiens | N/A | N/A | ||||
EL1034 | P2rx3 | N/A | Rattus norvegicus | NR_073054 | ENSRNOG00000008552 | ||||
EL1035 | P33863 | N/A | Homo sapiens | N/A | N/A | ||||
EL1036 | P4091 | N/A | Homo sapiens | N/A | N/A | ||||
EL1037 | P6391 | N/A | Homo sapiens | N/A | N/A | ||||
EL1038 | P6488 | N/A | Homo sapiens | N/A | N/A | ||||
EL1039 | P700 | N/A | Homo sapiens | N/A | N/A | ||||
EL1040 | P8611 | N/A | Homo sapiens | N/A | N/A | ||||
EL1041 | P8725 | N/A | Homo sapiens | N/A | N/A | ||||
EL1042 | P8860 | N/A | Homo sapiens | N/A | N/A | ||||
EL1043 | P9745 | N/A | Homo sapiens | N/A | N/A | ||||
EL1044 | PACERR | PACER; PTGS2-AS1 | Homo sapiens | NR_125801 | ENSG00000273129 | ||||
EL1045 | PAN | CG17964; CG32005; CG34403; cTCF; d-TCF; Dm Pan; DmelCG34403; dTcf; dTCF; DTcf; DTCF; IA5; l(4)102ABb; l(4)13; Lef; LEF-1; LEF/TCF; LEF/TCF-1; lef1; Lef1; LEF1; LEF1/TCF; Pan; PAN; pan.dTCF; tcf; Tcf; TCF; Tcf-1; Tcf/LEF; TCF/LEF; TCF/LEF1 | Homo sapiens | N/A | N/A | ||||
EL1046 | PANDAR | PANDA | Homo sapiens | NR_109836 | ENSG00000281450 | ||||
EL1047 | PARTICL | PARTICLE | Homo sapiens | NR_038942 | N/A | ||||
EL1048 | Paupar | N/A | Mus musculus | NR_117095 | ENSMUSG00000102424 | ||||
EL1049 | PAWR | PAR4; Par-4 | Homo sapiens | XR_944561, XR_944560 | ENSG00000177425 | ||||
EL1050 | PAX8-AS1 | N/A | Homo sapiens | NR_047570, NR_015377 | ENSG00000189223 | ||||
EL1051 | PCA3 | DD3; NCRNA00019; PCAT3 | Homo sapiens | NR_132312, NR_015342, NR_132313 | ENSG00000225937 | ||||
EL1052 | PCAT1 | PCA1; PCAT-1 | Homo sapiens | NR_045262 | ENSG00000253438 | ||||
EL1053 | PCAT18 | LINC01092 | Homo sapiens | NR_024259 | ENSG00000265369 | ||||
EL1054 | PCAT29 | N/A | Homo sapiens | NR_126437, NR_126438 | ENSG00000259641 | ||||
EL1055 | PCAT5 | LINC01452; TPCAT-10-36067 | Homo sapiens | NR_110138 | ENSG00000280719 | ||||
EL1056 | PCAT6 | KDM5B-AS1; KDM5BAS1; PCAN-R1; ncRNA-a2; onco-lncRNA-96 | Homo sapiens | NR_046325, NR_046326 | ENSG00000228288 | ||||
EL1057 | PCAT7 | PCAN-R2 | Homo sapiens | NR_121566, NR_121567, NR_121569, NR_121568 | ENSG00000231806 | ||||
EL1058 | PCGEM1 | LINC00071; NCRNA00071; PCAT9 | Homo sapiens | NR_002769 | ENSG00000227418 | ||||
EL1059 | PCNA-AS1 | PCNA-AS; PCNAAS | Homo sapiens | NR_028370 | N/A | ||||
EL1060 | PCNCR1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1061 | PDLIM3 | ALP | Homo sapiens | NR_047562 | ENSG00000154553 | ||||
EL1062 | PDZRN3-AS1 | PDZRN3-AS1; | Homo sapiens | NR_046681 | N/A | ||||
EL1063 | PEG10 | EDR; HB-1; MEF3L; Mar2; Mart2; RGAG3 | Homo sapiens | N/A | ENSG00000242265 | ||||
EL1064 | pGmENOD40 | N/A | Pisum sativum | X81064 | N/A | ||||
EL1065 | PHO84 | YML123C | Saccharomyces cerevisiae S288c | N/A | N/A | ||||
EL1066 | PHO84 antisense transcripts | antisense transcripts | Saccharomyces cerevisiae S288c | N/A | N/A | ||||
EL1067 | PICSAR | C21orf113; LINC00162; NCRNA00162; NLC1-C; NLC1C; PRED74 | Homo sapiens | NR_024089 | ENSG00000275874 | ||||
EL1068 | Pinc | N/A | Mus musculus | NR_003202 | ENSMUSG00000099877 | ||||
EL1069 | Pinci1-1 | N/A | Phytophthora infestans | N/A | N/A | ||||
EL1070 | PINK1-AS | NAPINK11; PINK1AS; PINK1-AS | Homo sapiens | NR_046507 | ENSG00000117242 | ||||
EL1071 | PISRT1 | NCRNA00195 | Homo sapiens | NR_027070 | ENSG00000281473 | ||||
EL1072 | Platr14 | 4930500J02Rik | Mus musculus | NR_040322, NR_040323 | ENSMUSG00000086454 | ||||
EL1073 | PLEC | EBS1; EBSMD; EBSND; EBSO; EBSOG; EBSPA; HD1; LGMD2Q; PCN1; PLEC1b; PLTN; PLEC | Homo sapiens | N/A | ENSG00000178209 | ||||
EL1074 | PMS2P5 | PMS2L5; PMS7 | Homo sapiens | NR_027777, NR_027775, NR_027776 | N/A | ||||
EL1075 | pncRNA-D | promoter-associated ncRNA-D | Homo sapiens | N/A | N/A | ||||
EL1076 | POT1-AS1 | N/A | Homo sapiens | NR_125718, NR_125719 | ENSG00000224897 | ||||
EL1077 | linc-POU3F3 | PANTR1; linc-Brn1a; linc-POU3F3 | Homo sapiens | NR_037883, NR_131233, NR_131234, NR_131235 | ENSG00000233639 | ||||
EL1078 | POU5F1P4 | Oct4-pg4; POU5FLC1 | Homo sapiens | NR_034180 | ENSG00000237872 | ||||
EL1079 | POU6F2-AS2 | POU6F2 Antisense RNA 2 | Homo sapiens | XR_001745172, XR_001745173 | ENSG00000233854 | ||||
EL1080 | pouBW1 | N/A | Gushi chickens and Anka broilers | N/A | N/A | ||||
EL1081 | PPP3CB | CALNA2; CALNB; CNA2; PP2Bbeta | Homo sapiens | N/A | ENSG00000107758 | ||||
EL1082 | PRAL | N/A | Homo sapiens | N/A | N/A | ||||
EL1083 | PRAS | N/A | Homo sapiens | N/A | N/A | ||||
EL1084 | Prep | AI047692; AI450383; D10Wsu136e; PEP; Pop | Mus musculus | N/A | ENSMUSG00000019849 | ||||
EL1085 | PRINS | NCRNA00074 | Homo sapiens | N/A | ENSG00000277563 | ||||
EL1086 | Prion-associated RNAs | highly structured (shs)RNA | Homo sapiens | N/A | N/A | ||||
EL1087 | pRNA | DDB_G0295593 | Dictyostelium discoideum AX4 | N/A | N/A | ||||
EL1088 | PRNCR1 | CARLo-3; PCAT8 | Homo sapiens | NR_109833 | ENSG00000282961 | ||||
EL1089 | PRR26 | C10orf108 | Homo sapiens | NR_027151, NR_027152 | ENSG00000180525 | ||||
EL1090 | PRSS21 | ESP-1; ESP1; TEST1; TESTISIN | Homo sapiens | NR_073012 | ENSG00000007038 | ||||
EL1091 | PsiLNCRNA00268512 | N/A | Populus sp. | N/A | N/A | ||||
EL1092 | PSORS1C3 | NCRNA00196 | Homo sapiens | NR_026816 | ENSG00000204528 | ||||
EL1093 | psvA antisense RNA | EB4 gene locus | Dictyostelium discoideum AX4 | N/A | N/A | ||||
EL1094 | PTCSC1 | NCRNA00197; PTCSC | Homo sapiens | N/A | N/A | ||||
EL1095 | PTCSC2 | N/A | Homo sapiens | N/A | ENSG00000236130 | ||||
EL1096 | PTCSC3 | N/A | Homo sapiens | NR_049735 | ENSG00000259104 | ||||
EL1097 | PTENP1 | PTEN-rs; PTEN2; PTENpg1; PTH2; psiPTEN | Homo sapiens | NR_023917 | ENSG00000237984 | ||||
EL1098 | PTENP1-AS | PTENP1as; PTENpg1-asRNA | Homo sapiens | NR_103745 | ENSG00000281128 | ||||
EL1099 | Ptgs2os2 | Gm26687; Linc-cox2; Lincrna-cox2 | Mus musculus | NR_110420 | ENSMUSG00000097754 | ||||
EL1100 | PTHLH | BDE2; HHM; PLP; PTHR; PTHRP | Homo sapiens | N/A | ENSG00000087494 | ||||
EL1101 | PU.1 AS | N/A | Sus scrofa | N/A | N/A | ||||
EL1102 | PVT1 | LINC00079; MYC; NCRNA00079; onco-lncRNA-100 | Homo sapiens | NR_003367 | ENSG00000249859 | ||||
EL1103 | PWR1 | PWR1 | Saccharomyces cerevisiae S288c | NR_132192 | N/A | ||||
EL1104 | R05532 | N/A | Homo sapiens | N/A | N/A | ||||
EL1105 | RAB4B-EGLN2 | RERT-lncRNA | Homo sapiens | NR_037791 | N/A | ||||
EL1106 | RAD1 | HRAD1; REC1 | Homo sapiens | NR_026591 | ENSG00000113456 | ||||
EL1107 | RAD51-AS1 | TODRA | Homo sapiens | NR_040058 | ENSG00000245849 | ||||
EL1108 | RBM4 | LARKA; ZCCHC21; ZCRB3A; RBM4 | Homo sapiens | AF087999 | ENSG00000173933 | ||||
EL1109 | RBM5-AS1 | LUST | Homo sapiens | NR_045388 | ENSG00000281691 | ||||
EL1110 | RCCRT1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1111 | RD29A | N/A | Arabidopsis thaliana | AB428729 | N/A | ||||
EL1112 | RepA | N/A | Mus musculus | N/A | N/A | ||||
EL1113 | REST/CoREST-regulated lncRNAs | N/A | Homo sapiens | N/A | N/A | ||||
EL1114 | RGMB-AS1 | RGMB Antisense RNA | Homo sapiens | NR_033932 | ENSG00000246763 | ||||
EL1115 | RHOXF1P1 | TCONS_00017086; lncRHOXF1 | Homo sapiens | NR_131250 | ENSG00000234493 | ||||
EL1116 | Rian | 5530401N18Rik; C130089L09Rik; Meg8 | Mus musculus | NR_028261 | ENSMUSG00000097451 | ||||
EL1117 | Rmrp | 1110032O22Rikr; Rmrp | Mus musculus | NR_001460 | ENSMUSG00000088088 | ||||
EL1118 | Rmst | 100041799; AI853140; C230053E11Rik; D930049J19Rik; Dmt2; Gm3515; M2; Ncrms | Mus musculus | NR_028262 | N/A | ||||
EL1119 | RMST | LINC00054; NCRMS; NCRNA00054 | Homo sapiens | NR_024037 | ENSG00000255794 | ||||
EL1120 | RN7SK | 7SK | Homo sapiens | NR_001445 | ENSG00000202198 | ||||
EL1121 | RN7SL1 | 7L1a; 7SL; RN7SL; RNSRP1 | Homo sapiens | NR_002715 | ENSG00000276168 | ||||
EL1122 | RNA polymerase III-dependent lncRNAs | N/A | Homo sapiens | N/A | N/A | ||||
EL1123 | RNA44121|UCSC-2000-3182 | N/A | Homo sapiens | N/A | N/A | ||||
EL1124 | RNA50010|UCSC-9199-1005 | N/A | Homo sapiens | N/A | N/A | ||||
EL1125 | RNA58351|CombinedLit_316_550 | N/A | Homo sapiens | N/A | N/A | ||||
EL1126 | RNA-a | N/A | Homo sapiens | N/A | N/A | ||||
EL1127 | RNase MRP | N/A | Homo sapiens | N/A | N/A | ||||
EL1128 | rncs-1 | CELE_F55A4.9 | Caenorhabditis elegans | NR_000961 | N/A | ||||
EL1129 | RNY1 | HY1; Y1 | Homo sapiens | NR_004391 | ENSG00000201098 | ||||
EL1130 | roX1 | Dmel_CR32777; BcDNA:GH10432; CR32777; DmelCR32777; EG:EG0002.2; RoX1; chrX:3706836..3706970; roX; rox1 | Drosophila melanogaster | NR_123784, NR_073631, NR_073632, NR_002097, NR_002098 | N/A | ||||
EL1131 | roX2 | Dmel_CR32665; CR32665; DmelCR32665; RoX2; roX; rox2 | Drosophila melanogaster | NR_002104, NR_002105, NR_047796, NR_047795, NR_123871, NR_123872 | N/A | ||||
EL1132 | RP11-1008C21.2 | N/A | Homo sapiens | N/A | ENST00000434223 | ||||
EL1133 | RP11-119F7.4 | N/A | Homo sapiens | N/A | N/A | ||||
EL1134 | LOC102724601 | RP11-160H22.5 | Homo sapiens | NR_121197 | ENSG00000227373 | ||||
EL1135 | LINC01537 | RP11-169D4.1-001 | Homo sapiens | NR_126364 | ENSG00000227467 | ||||
EL1136 | LINC01513 | RP11-1C1.7 | Homo sapiens | N/A | ENSG00000246016 | ||||
EL1137 | RP11-284N8.3.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1138 | AL353732.1 | RP11-354P17.15-001 | Homo sapiens | N/A | ENSG00000261696 | ||||
EL1139 | KCNMB2-AS1 | RP11-385J1.2 | Homo sapiens | NR_126560 | ENSG00000237978 | ||||
EL1140 | AC027031.2 | RP11-395G23.3 | Homo sapiens | N/A | ENSG00000254615 | ||||
EL1141 | RP11-395P13.3-001 | N/A | Homo sapiens | N/A | N/A | ||||
EL1142 | LINC01627 | RP11-397D12.4 | Homo sapiens | N/A | ENSG00000224648 | ||||
EL1143 | RP11-401P9.4 | N/A | Homo sapiens | N/A | ENSG00000261685 | ||||
EL1144 | KCNK15-AS1 | RP11-445H22.4 | Homo sapiens | NR_132377 | ENSG00000244558 | ||||
EL1145 | AL355870.1 | RP11-445K13.2 | Homo sapiens | N/A | ENSG00000233256 | ||||
EL1146 | RP11-457M11.2 | N/A | Homo sapiens | N/A | N/A | ||||
EL1147 | AC108134.4 | RP11-473M20.11 | Homo sapiens | N/A | ENSG00000263011 | ||||
EL1148 | LINC00383 | RP11-501G6.1 | Homo sapiens | N/A | ENSG00000237534 | ||||
EL1149 | AL138930.1 | RP11-528G1.2 | Homo sapiens | N/A | ENSG00000234425 | ||||
EL1150 | ZBTB20-AS4 | RP11-58D2.1 | Homo sapiens | NR_046877 | ENSG00000242767 | ||||
EL1151 | AC104590.1 | RP11-643M14.1 | Homo sapiens | NR_135690 | ENSG00000259251 | ||||
EL1152 | AL133217.1 | RP11-672F9.1 | Homo sapiens | N/A | ENSG00000226113 | ||||
EL1153 | RP11-766N7.3 | N/A | Homo sapiens | N/A | N/A | ||||
EL1154 | LINC01612 | RP11-789C1.1 | Homo sapiens | N/A | ENSG00000250266 | ||||
EL1155 | Z95152.1 | RP1-179N16.3 | Homo sapiens | N/A | ENSG00000237719 | ||||
EL1156 | LINC01969 | RP11-893F2.6 | Homo sapiens | NR_110806 | ENSG00000251085 | ||||
EL1157 | AL020996.1 | RP1-317E23.3 | Homo sapiens | N/A | ENSG00000228172 | ||||
EL1158 | RP13-514E23.1 | N/A | Homo sapiens | N/A | ENSG00000261496 | ||||
EL1159 | RP1-90D4.3 | N/A | Homo sapiens | N/A | N/A | ||||
EL1160 | AL021707.1 | RP3-508I15.14 | Homo sapiens | N/A | ENSG00000225450 | ||||
EL1161 | AL109741.3 | RP4-575N6.5 | Homo sapiens | N/A | ENSG00000260940 | ||||
EL1162 | AL121845.1 | RP4-583P15.10 | Homo sapiens | N/A | ENSG00000229299 | ||||
EL1163 | RP4-620F22.3 | N/A | Homo sapiens | N/A | N/A | ||||
EL1164 | AC244098.1 | RP5-1014O16.1 | Homo sapiens | N/A | ENSG00000223377 | ||||
EL1165 | AL445307.1 | RP5-826L7.1 | Homo sapiens | N/A | ENSG00000228692 | ||||
EL1166 | RP5-833A20.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1167 | RP5-843L14.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1168 | RPL34-AS1 | RP11-462C24.1; FLJ37673; RPL34-AS1 | Homo sapiens | NR_026968 | ENSG00000234492 | ||||
EL1169 | RPLP0P2 | RPLP0L2; RPLP0_3_1146 | Homo sapiens | NR_002775 | ENSG00000243742 | ||||
EL1170 | Rr18 | Xca; Xce; Xite | Mus musculus | N/A | N/A | ||||
EL1171 | RRP1B | KIAA0179; NNP1L; Nnp1; PPP1R136; RRP1 | Homo sapiens | N/A | ENSG00000160208 | ||||
EL1172 | Rubie | N/A | Mus musculus | NR_046459 | ENSMUSG00000085123 | ||||
EL1173 | RUNX1 | AML1; AML1-EVI-1; AMLCR1; CBF2alpha; CBFA2; EVI-1; PEBP2aB; PEBP2alpha | Homo sapiens | N/A | ENSG00000159216 | ||||
EL1174 | RUNX1-IT1 | C21orf96 | Homo sapiens | NR_026812 | N/A | ||||
EL1175 | RZE1 | N/A | Cryptococcus neoformans | N/A | N/A | ||||
EL1176 | SALRNA1 | SAL-RNA1; XLOC_023166 | Homo sapiens | NR_126480 | N/A | ||||
EL1177 | SAMMSON | LINC01212 | Homo sapiens | NR_110000 | ENSG00000240405 | ||||
EL1178 | SARCC | N/A | Homo sapiens | N/A | N/A | ||||
EL1179 | Scarb2 | 9330185J12Rik; Cd36l2; LGP85; LIMP II; LIMP-2; MLGP85 | Mus musculus | AK036863.1 | ENSMUSG00000029426 | ||||
EL1180 | SCHLAP1 | LINC00913; PCAT11; PCAT114 | Homo sapiens | NR_104322, NR_104325, NR_104324, NR_104323, NR_104319, NR_104320, NR_104321 | ENSG00000281131 | ||||
EL1181 | Sema3g | AK129018 | Mus musculus | AK087277.1 | ENSMUSG00000021904 | ||||
EL1182 | SENCR | FLI1-AS1; lncRNA9 | Homo sapiens | NR_038908 | ENSG00000254703 | ||||
EL1183 | sfRNA | N/A | Japanese encephalitis virus | EF116943.1 | N/A | ||||
EL1184 | SFTA3 | NANCI; SFTPH; SP-H | Homo sapiens | NR_138595, NR_138596, NR_138597, NR_138598, NR_138599, NR_138600, NR_138601 | ENSG00000229415 | ||||
EL1185 | SGO1-AS1 | SGOL1-AS1 | Homo sapiens | NR_132785 | ENSG00000231304 | ||||
EL1186 | Sho | N/A | Petunia hybrida | AF346892 | N/A | ||||
EL1187 | Si lincRNA113 | N/A | Setaria italica | N/A | N/A | ||||
EL1188 | Si lincRNA121 | N/A | Setaria italica | N/A | N/A | ||||
EL1189 | Si lincRNA150 | N/A | Setaria italica | N/A | N/A | ||||
EL1190 | Si lincRNA18 | N/A | Setaria italica | N/A | N/A | ||||
EL1191 | Si lincRNA180 | N/A | Setaria italica | N/A | N/A | ||||
EL1192 | Si lincRNA212 | N/A | Setaria italica | N/A | N/A | ||||
EL1193 | Si lincRNA248 | N/A | Setaria italica | N/A | N/A | ||||
EL1194 | Si lincRNA288 | N/A | Setaria italica | N/A | N/A | ||||
EL1195 | Si lincRNA32 | N/A | Setaria italica | N/A | N/A | ||||
EL1196 | Si lincRNA373 | N/A | Setaria italica | N/A | N/A | ||||
EL1197 | Si lincRNA396 | N/A | Setaria italica | N/A | N/A | ||||
EL1198 | Si lincRNA403 | N/A | Setaria italica | N/A | N/A | ||||
EL1199 | Si lincRNA416 | N/A | Setaria italica | N/A | N/A | ||||
EL1200 | Si lincRNA438 | N/A | Setaria italica | N/A | N/A | ||||
EL1201 | Si lincRNA446 | N/A | Setaria italica | N/A | N/A | ||||
EL1202 | Si lincRNA489 | N/A | Setaria italica | N/A | N/A | ||||
EL1203 | Si lincRNA69 | N/A | Setaria italica | N/A | N/A | ||||
EL1204 | Si NAT52 | N/A | Setaria italica | N/A | N/A | ||||
EL1205 | Si NAT80 | N/A | Setaria italica | N/A | N/A | ||||
EL1206 | SIRT1-AS | N/A | Homo sapiens | N/A | N/A | ||||
EL1207 | SIRT1-AS 622C mutation | N/A | Homo sapiens | N/A | N/A | ||||
EL1208 | Six3os1 | D17Mgi26; E130112H22Rik; Rncr1; Six3os | Mus musculus | NR_038085, NR_015387, NR_015386, NR_038086, NR_038083, NR_038082, NR_038084, NR_015385 | ENSMUSG00000093460 | ||||
EL1209 | SKP2 | FBL1; FBXL1; FLB1; p45 | Homo sapiens | XR_001742203 | ENSG00000145604 | ||||
EL1210 | SLC25A25-AS1 | N/A | Homo sapiens | NR_033374 | N/A | ||||
EL1211 | Slc44a1 | 2210409B22Rik; 4833416H08Rik; AW547365; CHTL1; CTL1; Cdw92 | Mus musculus | XR_390309 | ENSMUSG00000028412 | ||||
EL1212 | SLC6A6 | TAUT | Homo sapiens | NR_103507, XR_427286, XR_940495 | ENSG00000131389 | ||||
EL1213 | SLC7A2-IT1A/B | N/A | Homo sapiens | N/A | N/A | ||||
EL1214 | SLCO5A1 | OATP-J; OATP-RP4; OATP5A1; OATPJ; OATPRP4; SLC21A15 | Homo sapiens | XR_928814, XR_428341 | ENSG00000137571 | ||||
EL1215 | SMAD1-AS1 | N/A | Homo sapiens | NR_126371 | ENSG00000250902 | ||||
EL1216 | Smad7 | Madh7 | Mus musculus | N/A | ENSMUSG00000025880 | ||||
EL1217 | sme2 | SPNCRNA.103; SPNCRNA.1341 | Schizosaccharomyces pombe 972h- | N/A | N/A | ||||
EL1218 | SNAR-A1 | SNAR-A53113498 | Homo sapiens | NR_004435 | N/A | ||||
EL1219 | SNCG | BCSG1; SR | Homo sapiens | N/A | ENSG00000173267 | ||||
EL1220 | SNED1 | SST3; Snep | Homo sapiens | XR_001738694, XR_001738695 | ENSG00000162804 | ||||
EL1221 | SNHG1 | LINC00057; NCRNA00057; U22HG; UHG | Homo sapiens | NR_003098 | ENSG00000255717 | ||||
EL1222 | SNHG11 | C20orf198; LINC00101; NCRNA00101 | Homo sapiens | NR_003239 | ENSG00000174365 | ||||
EL1223 | SNHG12 | ASLNC04080; C1orf79; LINC00100; NCRNA00100 | Homo sapiens | NR_024127 | ENSG00000197989 | ||||
EL1224 | SNHG14 | 115HG; LNCAT; NCRNA00214; UBE3A-AS; UBE3A-AS1; UBE3AATS | Homo sapiens | N/A | N/A | ||||
EL1225 | SNHG15 | C7orf40; Linc-Myo1g; MYO1GUT | Homo sapiens | NR_003697 | ENSG00000232956 | ||||
EL1226 | SNHG16 | ncRAN | Homo sapiens | NR_038108, NR_038109, NR_038110, NR_038111 | ENSG00000163597 | ||||
EL1227 | SNHG19 | SNORD60HG | Homo sapiens | NR_132114 | ENSG00000260260 | ||||
EL1228 | SNHG3 | NCRNA00014; RNU17C; RNU17D; U17HG; U17HG-A; U17HG-AB | Homo sapiens | NR_036473, NR_002909 | ENSG00000242125 | ||||
EL1229 | Snhg3 | Rnu17d; U17HG | Mus musculus | NR_003270 | ENSMUSG00000085241 | ||||
EL1230 | SNHG4 | NCRNA00059; U19H | Homo sapiens | NR_036536, NR_003141 | N/A | ||||
EL1231 | SNHG5 | C6orf160; LINC00044; NCRNA00044; U50HG; bA33E24.2 | Homo sapiens | NR_003038 | ENSG00000203875 | ||||
EL1232 | SNHG6 | HBII-276HG; NCRNA00058; U87HG | Homo sapiens | NR_002599 | N/A | ||||
EL1233 | SNHG8 | LINC00060; NCRNA00060 | Homo sapiens | NR_003584, NR_034010, NR_034011 | ENSG00000269893 | ||||
EL1234 | SNORA17B | ACA43; SNORA43 | Homo sapiens | NR_002975 | ENSG00000276161 | ||||
EL1235 | Sox2ot | B230215L15Rik | Mus musculus | NR_015580 | ENSMUSG00000105265 | ||||
EL1236 | SOX2-OT | NCRNA00043; SOX2OT | Homo sapiens | NR_075091, NR_075092, NR_075093, NR_004053, NR_075089, NR_075090 | ENSG00000242808 | ||||
EL1237 | SOX2OT-S1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1238 | SOX2OT-S2 | N/A | Homo sapiens | N/A | N/A | ||||
EL1239 | Sox4 | AA682046; Sox-4 | Mus musculus | AK054386.1 | ENSMUSG00000076431 | ||||
EL1240 | SPRY4-IT1 | SPRIGHTLY | Homo sapiens | NR_131221 | ENSG00000281881 | ||||
EL1241 | SRA1 | SRA; SRAP; STRAA1; pp7684 | Homo sapiens | NR_045586, NR_045587 | ENSG00000213523 | ||||
EL1242 | SrENOD40-1 | N/A | Sesbania rostrata | Y12714 | N/A | ||||
EL1243 | SRG1 | SRG1 | Saccharomyces cerevisiae S288c | NR_132168 | N/A | ||||
EL1244 | SRP RNA | 7S RNA; SRP RNA; 4.5S SRP RNA; 4.5S RNA; RN7SL1 RNA; ENSG00000258486 | Archaeoglobus fulgidus, Methanococcus jannaschii | N/A | N/A | ||||
EL1245 | Srsf9 | 25kDa; 2610029M16Rik; SRp30c; Sfrs9 | Mus musculus | NR_036616 | ENSMUSG00000029538 | ||||
EL1246 | ST7-AS1 | ST7AS1; ST7OT1 | Homo sapiens | NR_002330 | ENSG00000227199 | ||||
EL1247 | ST7-AS2 | ST7AS2; ST7OT2 | Homo sapiens | NR_109980, NR_109981, NR_002331 | ENSG00000226367 | ||||
EL1248 | ST7-OT3 | NCRNA00026; ST7; ST7OT3 | Homo sapiens | NR_002332 | N/A | ||||
EL1249 | ST7-OT4 | NCRNA00042; ST7OT4 | Homo sapiens | NR_002329 | ENSG00000214188 | ||||
EL1250 | SUMO1P3 | Small ubiquitin-like modifier (SUMO) 1 pseudogene 3 | Homo sapiens | NR_002190 | ENSG00000235082 | ||||
EL1251 | TalIPS1 | N/A | Triticum aestivum | BQ744479 | N/A | ||||
EL1252 | TalncRNA106 | N/A | Triticum aestivum | KC549677 | N/A | ||||
EL1253 | TalncRNA108 | N/A | Triticum aestivum | KC549678 | N/A | ||||
EL1254 | TalncRNA18 | N/A | Triticum aestivum | KC549675 | N/A | ||||
EL1255 | TalncRNA73 | N/A | Triticum aestivum | KC549676 | N/A | ||||
EL1256 | TapmlnRNA19 | N/A | Triticum aestivum | N/A | N/A | ||||
EL1257 | TapmlnRNA27 | N/A | Triticum aestivum | N/A | N/A | ||||
EL1258 | TapmlnRNA30 | N/A | Triticum aestivum | N/A | N/A | ||||
EL1259 | TapmlnRNA5 | N/A | Triticum aestivum | N/A | N/A | ||||
EL1260 | TapmlnRNA9 | N/A | Triticum aestivum | N/A | N/A | ||||
EL1261 | TAR-191 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1262 | TAR-224 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1263 | TARID | EYA4-AS1 | Homo sapiens | NR_109982 | ENSG00000227954 | ||||
EL1264 | TaS1 | N/A | Triticum aestivum | BQ168479 | N/A | ||||
EL1265 | TaS2 | N/A | Triticum aestivum | CA648596 | N/A | ||||
EL1266 | TC0100223 | N/A | Homo sapiens | N/A | N/A | ||||
EL1267 | TC0101441 | N/A | Homo sapiens | N/A | N/A | ||||
EL1268 | TC0101686 | N/A | Homo sapiens | N/A | N/A | ||||
EL1269 | TC1500845 | N/A | Homo sapiens | N/A | N/A | ||||
EL1270 | TCF7 | TCF-1 | Homo sapiens | NR_033449 | ENSG00000081059 | ||||
EL1271 | TCL6 | TNG1; TNG2 | Homo sapiens | NR_028288 | ENSG00000187621 | ||||
EL1272 | TCONS_00000649 | N/A | Zea mays | KJ731892 | N/A | ||||
EL1273 | TCONS_00000966 | N/A | Brassica napus | N/A | N/A | ||||
EL1274 | TCONS_00007700 | N/A | Zea mays | KJ731849 | N/A | ||||
EL1275 | TCONS_00010027 | N/A | Zea mays | N/A | N/A | ||||
EL1276 | TCONS_00012273 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1277 | TCONS_00012662 | N/A | Zea mays | KJ731890 | N/A | ||||
EL1278 | TCONS_00012690 | N/A | Zea mays | KJ731898 | N/A | ||||
EL1279 | TCONS_00012703 | N/A | Zea mays | KJ731903 | N/A | ||||
EL1280 | TCONS_00012768 | N/A | Zea mays | KJ731916 | N/A | ||||
EL1281 | TCONS_00014512 | N/A | Homo sapiens | N/A | N/A | ||||
EL1282 | AC069120.3 | TCONS_00014978; RP11-675F6.4-001 | Homo sapiens | N/A | ENSG00000254100 | ||||
EL1283 | TCONS_00018278 | N/A | Homo sapiens | N/A | N/A | ||||
EL1284 | TCONS_00022311 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1285 | TCONS_00023843 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1286 | TCONS_00024309 | N/A | Zea mays | KJ731978 | N/A | ||||
EL1287 | TCONS_00024310 | N/A | Zea mays | KJ731979 | N/A | ||||
EL1288 | TCONS_00024647 | N/A | Homo sapiens | N/A | N/A | ||||
EL1289 | TCONS_00026506 | N/A | Homo sapiens | N/A | N/A | ||||
EL1290 | TCONS_00026694 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1291 | TCONS_00028236 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1292 | TCONS_00032782 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1293 | TCONS_00037470 | N/A | Zea mays | KJ732037 | N/A | ||||
EL1294 | TCONS_00039944 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1295 | TCONS_00042984 | N/A | Zea mays | KJ732080 | N/A | ||||
EL1296 | TCONS_00044116 | N/A | Zea mays | KJ732097 | N/A | ||||
EL1297 | TCONS_00044376 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1298 | TCONS_00048079 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1299 | TCONS_00049512 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1300 | TCONS_00053930 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1301 | TCONS_00054544 | N/A | Zea mays | KJ731879 | N/A | ||||
EL1302 | TCONS_00055243 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1303 | TCONS_00056386 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1304 | TCONS_00056395 | N/A | Zea mays | KJ732143 | N/A | ||||
EL1305 | TCONS_00060049 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1306 | TCONS_00061773 | N/A | Populus tomentosa | N/A | N/A | ||||
EL1307 | TCONS_00082174 | N/A | Zea mays | KJ732289 | N/A | ||||
EL1308 | TCONS_00089485 | N/A | Zea mays | N/A | N/A | ||||
EL1309 | TCONS_00090092_MEG3 | N/A | Homo sapiens | N/A | N/A | ||||
EL1310 | TCONS_l2_00000179 | N/A | Homo sapiens | N/A | N/A | ||||
EL1311 | TCONS_l2_00003938 | N/A | Homo sapiens | N/A | N/A | ||||
EL1312 | TCONS_l2_00004424 | N/A | Homo sapiens | N/A | N/A | ||||
EL1313 | TCONS_l2_00006843 | N/A | Homo sapiens | N/A | N/A | ||||
EL1314 | TCONS_l2_00010365 | N/A | Homo sapiens | N/A | N/A | ||||
EL1315 | TCONS_l2_00014091 | N/A | Homo sapiens | N/A | N/A | ||||
EL1316 | TCONS_l2_00018070 | N/A | Homo sapiens | N/A | N/A | ||||
EL1317 | TCONS_l2_00018071 | N/A | Homo sapiens | N/A | N/A | ||||
EL1318 | TCONS_l2_00020565 | N/A | Homo sapiens | N/A | N/A | ||||
EL1319 | TCONS_l2_00021262 | N/A | Homo sapiens | N/A | N/A | ||||
EL1320 | TCONS_l2_00030560 | N/A | Homo sapiens | N/A | N/A | ||||
EL1321 | TDRG1 | LINC00532 | Homo sapiens | NR_024015 | ENSG00000204091 | ||||
EL1322 | TER | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1323 | TER1 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1324 | TER2 | N/A | Arabidopsis thaliana | N/A | N/A | ||||
EL1325 | TERC | DKCA1; PFBMFT2; SCARNA19; TR; TRC3; hTR | Homo sapiens | NR_001566 | ENSG00000270141 | ||||
EL1326 | TGFB2-OT1 | N/A | Homo sapiens | NR_125715 | ENSG00000281453 | ||||
EL1327 | TH2LCRR | TH2-LCR | Homo sapiens | NR_132124, NR_132125, NR_132126 | ENSG00000223442 | ||||
EL1328 | THRIL | BRI3BP-AS1; BRI3BPAS1; Linc1992; TCONS_00020260 | Homo sapiens | NR_110375 | ENSG00000280634 | ||||
EL1329 | TI09485 | N/A | Homo sapiens | N/A | N/A | ||||
EL1330 | TI10124 | N/A | Homo sapiens | N/A | N/A | ||||
EL1331 | TI13831 | N/A | Homo sapiens | N/A | N/A | ||||
EL1332 | TI18318 | N/A | Homo sapiens | N/A | N/A | ||||
EL1333 | TI21327 | N/A | Homo sapiens | N/A | N/A | ||||
EL1334 | TI22687 | N/A | Homo sapiens | N/A | N/A | ||||
EL1335 | tie-1as | N/A | Danio rerio | NR_036574 | N/A | ||||
EL1336 | TINCR | LINC00036; NCRNA00036; PLAC2; onco-lncRNA-16 | Homo sapiens | NR_027064 | ENSG00000223573 | ||||
EL1337 | TIP ncRNA | N/A | Mus musculus | N/A | N/A | ||||
EL1338 | TK105282 | N/A | Mus musculus | N/A | N/A | ||||
EL1339 | TK111271 | N/A | Mus musculus | N/A | N/A | ||||
EL1340 | TK99129 | N/A | Mus musculus | N/A | N/A | ||||
EL1341 | Tmcc3 | AW488095; C630016B22Rik; C88213; Tmcc1 | Mus musculus | N/A | ENSMUSG00000020023 | ||||
EL1342 | TMEM179 | C14orf90A; TMEM179 | Homo sapiens | XR_943436, XR_943435, XR_943433 | ENSG00000258986 | ||||
EL1343 | TMEM72 | C10orf127; KSP37 | Homo sapiens | N/A | ENSG00000187783 | ||||
EL1344 | Tmevp3 | NeST | Mus musculus | N/A | N/A | ||||
EL1345 | Tmevpg1 | AI447422 | Mus musculus | NR_104123 | N/A | ||||
EL1346 | TMPOP2 | lncRNA-EBIC | Homo sapiens | N/A | ENSG00000262904 | ||||
EL1347 | TNXA | D6S103E; HXBL; TNX; XA | Homo sapiens | NR_001284 | ENSG00000248290 | ||||
EL1348 | Tog | Twin of Hotdog | Mus musculus, Atelerix albiventris | BK008788 | N/A | ||||
EL1349 | TP53COR1 | TRP53COR1; linc-p21; lincRNA-p21 | Homo sapiens | CD515754.1 | N/A | ||||
EL1350 | TP53TG1 | LINC00096; NCRNA00096; P53TG1; P53TG1-D; TP53AP1 | Homo sapiens | NR_015381 | ENSG00000182165 | ||||
EL1351 | TP73-AS1 | KIAA0495; PDAM | Homo sapiens | NR_033709, NR_033710, NR_033711, NR_033708, NR_033712 | ENSG00000227372 | ||||
EL1352 | TPS1 | SlTPS1 | Solanum lycopersicum | N/A | N/A | ||||
EL1353 | TPS11 | N/A | Solanum lycopersicum | N/A | N/A | ||||
EL1354 | TPSI1 | N/A | Solanum lycopersicum | NR_131747 | N/A | ||||
EL1355 | TRAF3IP2-AS1 | C6UAS; C6orf3; NCRNA00248; TRAF3IP2-AS2 | Homo sapiens | NR_034108, NR_034109, NR_034110, NR_034111 | ENSG00000231889 | ||||
EL1356 | TRE1 | N/A | Mus musculus | N/A | N/A | ||||
EL1357 | TRE2 | N/A | Mus musculus | N/A | N/A | ||||
EL1358 | TRE3 | N/A | Mus musculus | N/A | N/A | ||||
EL1359 | Trenod40 | N/A | Trifolium repens | AJ000268 | N/A | ||||
EL1360 | Trenod40-1 | N/A | Trifolium repens | AF426838 | N/A | ||||
EL1361 | Trenod40-2 | N/A | Trifolium repens | AF426839 | N/A | ||||
EL1362 | Trenod40-3 | N/A | Trifolium repens | AF426840 | N/A | ||||
EL1363 | TRERNA1 | LINC00651; treRNA | Homo sapiens | NR_051976 | ENSG00000231265 | ||||
EL1364 | TRIM52-AS1 | RIM52 Antisense RNA 1 | Homo sapiens | NR_102762, NR_102759, NR_102760, NR_102761 | ENSG00000248275 | ||||
EL1365 | Trp53cor1 | Gm16197; OTTMUSG00000031656; linc-p21; lincRNA-p21 | Mus musculus | NR_036469 | ENSMUSG00000085912 | ||||
EL1366 | TRPM2-AS | TRPM2-AS1 | Homo sapiens | NR_109964 | ENSG00000230061 | ||||
EL1367 | Trpm3 | 6330504P12Rik; 9330180E14; AU018608; B930001P07Rik; LTRPC3; MLSN2 | Mus musculus | XR_386462, XR_386463 | ENSMUSG00000052387 | ||||
EL1368 | TSIX | LINC00013; NCRNA00013; XIST-AS; XIST-AS1; XISTAS | Homo sapiens | NR_003255 | ENSG00000270641 | ||||
EL1369 | Tsix | N/A | Mus musculus | NR_002844 | ENSMUSG00000085715 | ||||
EL1370 | TSNAX-DISC1 | N/A | Homo sapiens | NR_028393, NR_028394, NR_028395, NR_028397, NR_028396, NR_028398, NR_028400, NR_028399 | ENSG00000270106 | ||||
EL1371 | TSPAN8 | CO-029; TM4SF3 | Homo sapiens | N/A | ENSG00000127324 | ||||
EL1372 | Ttc39aos1 | Gm12750; lincRNA-EPS | Mus musculus | NR_131195 | N/A | ||||
EL1373 | tts-1 | CELE_F09E10.11 | Caenorhabditis elegans | NR_001528, NR_001529 | N/A | ||||
EL1374 | TU1273 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1375 | TU1378 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1376 | TU1403 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1377 | TU1555 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1378 | TU1567 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1379 | TU1970 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1380 | TU3327 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1381 | TU3423 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1382 | TU4313 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1383 | TU4314 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1384 | TU4508 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1385 | TU4652 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1386 | TU4684 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1387 | TU4779 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1388 | TU5007 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1389 | TU506 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1390 | TU51 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1391 | TU5846 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1392 | TU6607 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1393 | TU6608 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1394 | TU718 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1395 | TU781 | N/A | Ganoderma lucidum | N/A | N/A | ||||
EL1396 | TUBA4B | TUBA4 | Homo sapiens | NR_003063 | ENSG00000243910 | ||||
EL1397 | TUC339 | N/A | Homo sapiens | N/A | N/A | ||||
EL1398 | T-UCRs | N/A | Homo sapiens | N/A | N/A | ||||
EL1399 | TUG1 | LINC00080; NCRNA00080; TI-227H | Homo sapiens | NR_110492, NR_002323, NR_110493 | ENSG00000253352 | ||||
EL1400 | Tug1 | AI316828 | Mus musculus | NR_002321, NR_110490, NR_002322 | ENSMUSG00000056579 | ||||
EL1401 | TUNAR | HI-LNC78; LINC00617; TUNA | Homo sapiens | NR_132399, NR_132398, NR_038861 | ENSG00000250366 | ||||
EL1402 | TUSC7 | LINC00902; LSAMP-AS1; LSAMP-AS3; LSAMPAS3; NCRNA00295 | Homo sapiens | NR_015391 | ENSG00000243197 | ||||
EL1403 | TUSC8 | LINC01071; XLOC_010588 | Homo sapiens | NR_104174 | ENSG00000237361 | ||||
EL1404 | U1 spliceosomal lncRNA | N/A | Homo sapiens | N/A | N/A | ||||
EL1405 | Ube3a-ATS | N/A | Homo sapiens | N/A | N/A | ||||
EL1406 | uc.115- | N/A | Mus musculus | N/A | N/A | ||||
EL1407 | uc.173 | N/A | Mus musculus | N/A | N/A | ||||
EL1408 | uc.184+ | N/A | Mus musculus | N/A | N/A | ||||
EL1409 | uc.283-plus | N/A | Homo sapiens | N/A | N/A | ||||
EL1410 | uc.341 | N/A | Homo sapiens | N/A | N/A | ||||
EL1411 | uc.388 | N/A | Homo sapiens | N/A | N/A | ||||
EL1412 | uc.73 | N/A | Homo sapiens | N/A | N/A | ||||
EL1413 | uc001aka.2 | N/A | Homo sapiens | N/A | N/A | ||||
EL1414 | uc001gch.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1415 | uc001gzl.3 | N/A | Homo sapiens | N/A | N/A | ||||
EL1416 | uc001lsz | N/A | Homo sapiens | N/A | N/A | ||||
EL1417 | uc001ncr | N/A | Homo sapiens | N/A | N/A | ||||
EL1418 | LOC100288208 | uc001vjj.1 | Homo sapiens | NR_144452 | ENSG00000177596 | ||||
EL1419 | uc002nbr.3 | N/A | Homo sapiens | N/A | N/A | ||||
EL1420 | LINC01589 | uc003bgl.1; TCONS_00029353 | Homo sapiens | NR_131244 | ENSG00000238120 | ||||
EL1421 | uc003erl.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1422 | uc003iqu | LINC01207 | Homo sapiens | NR_038834 | ENSG00000248771 | ||||
EL1423 | uc003jfz.2 | ASHG19A3A028003; uc003jfz.2 | Homo sapiens | N/A | N/A | ||||
EL1424 | uc003tfx | N/A | Homo sapiens | N/A | N/A | ||||
EL1425 | AC091173.1 | uc003xut. | Homo sapiens | N/A | ENSG00000251127 | ||||
EL1426 | uc004bbl.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1427 | uc004bdv.3 | N/A | Homo sapiens | N/A | N/A | ||||
EL1428 | uc009wkz.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1429 | uc021re1.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1430 | uc022axw.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1431 | UCA1 | CUDR; LINC00178; NCRNA00178; UCAT1; onco-lncRNA-36 | Homo sapiens | NR_015379 | ENSG00000214049 | ||||
EL1432 | UCA1 | N/A | Rattus norvegicus | N/A | N/A | ||||
EL1433 | UCH1LAS | UCH1LAS; RP11-124A7.2 | Homo sapiens | N/A | N/A | ||||
EL1434 | UCHL1-AS1 | N/A | Homo sapiens | NR_102709 | ENSG00000251173 | ||||
EL1435 | UFC1 | HSPC155 | Homo sapiens | N/A | ENSG00000143222 | ||||
EL1436 | Uhg1 | Dmel_CR32886; BEST:GM03135; CG14486; CR32886; DmelCR32886; Dros-UHG1; FBgn0040741; dUHG1; dUhg1 | Drosophila melanogaster | NR_001754, NR_073887 | N/A | ||||
EL1437 | Uhg2 | Dmel_CR32873; CR32873; DmelCR32873; Dros-UHG2; dUHG2; dUhg2 | Drosophila melanogaster | NR_001637, NR_073751 | N/A | ||||
EL1438 | ULK4P2 | D-X; FAM7A2 | Homo sapiens | NR_027470 | ENSG00000260128 | ||||
EL1439 | URHC | N/A | Homo sapiens | N/A | N/A | ||||
EL1440 | VAI | VA RNA I;VA RNA II. | Human adenovirus | N/A | N/A | ||||
EL1441 | VAII | N/A | Human adenovirus | N/A | N/A | ||||
EL1442 | Vax2os | Vas2os1; Vax2os2; Vax2os | Mus musculus | NR_002871, NR_002873, NR_075094, NR_075095 | ENSMUSG00000085794 | ||||
EL1443 | VIM2P | VIM2; VIMP1; lncRNA-CIR | Homo sapiens | N/A | ENSG00000220548 | ||||
EL1444 | VL30 LTRs | N/A | Mus musculus | N/A | N/A | ||||
EL1445 | VL30 RNAs | N/A | Mus musculus | N/A | N/A | ||||
EL1446 | VLDLR-AS1 | linc-VLDLR; lincRNA-VLDLR | Homo sapiens | NR_015375 | ENSG00000236404 | ||||
EL1447 | VNN2 | FOAP-4; GPI-80 | Homo sapiens | NR_110146, NR_034174, NR_034173, NR_110144, NR_110143, NR_110145 | ENSG00000112303 | ||||
EL1448 | VPS9D1-AS1 | MYU | Homo sapiens | NR_036480 | ENSG00000261373 | ||||
EL1449 | VsENOD40 | N/A | Vicia sativa | X83683 | N/A | ||||
EL1450 | VTRNA2-1 | CBL-3; CBL3; MIR886; MIRN886; VTRNA2; hsa-mir-886; hvg-5; nc886; svtRNA2-1a | Homo sapiens | NR_030583 | ENSG00000270123 | ||||
EL1451 | Wbp1l | Opal1; RGD1305793 | Rattus norvegicus | N/A | ENSRNOG00000020020 | ||||
EL1452 | WFDC21P | LNCDC; linc-DC; lnc-DC | Homo sapiens | NR_030732 | ENSG00000261040 | ||||
EL1453 | WISP1 | CCN4c; WISP1i; WISP1tc; WISP1 | Homo sapiens | NR_037944 | ENSG00000104415 | ||||
EL1454 | WRAP53 | DKCB3; TCAB1; WDR79 | Homo sapiens | XR_001752551 | ENSG00000141499 | ||||
EL1455 | WSPAR | LncTCF7; TCONS_00009511 | Homo sapiens | NR_131252 | ENSG00000249073 | ||||
EL1456 | WT1-AS | WIT-1; WIT11; WT1AS; WT1-AS | Homo sapiens | NR_120548, NR_120547, NR_023920, NR_120549, NR_120546 | ENSG00000183242 | ||||
EL1457 | Wt1os | 6030498F17; AI314831; Wt1-as | Mus musculus | NR_015462 | ENSMUSG00000074987 | ||||
EL1458 | XACT | N/A | Homo sapiens | NR_131204 | ENSG00000241743 | ||||
EL1459 | XIST | DXS1089; DXS399E; LINC00001; NCRNA00001; SXI1; swd66 | Homo sapiens | NR_001564 | ENSG00000229807 | ||||
EL1460 | Xist | A430022B11; AI314753 | Mus musculus | NR_001570, NR_001463 | ENSMUSG00000086503 | ||||
EL1461 | XLOC_000078 | N/A | Oryza sativa | N/A | N/A | ||||
EL1462 | XLOC_000371 | N/A | Homo sapiens | N/A | N/A | ||||
EL1463 | XLOC_000495 | N/A | Oryza sativa | N/A | N/A | ||||
EL1464 | XLOC_000620 | N/A | Homo sapiens | N/A | N/A | ||||
EL1465 | XLOC_000629 | N/A | Oryza sativa | N/A | N/A | ||||
EL1466 | XLOC_000775 | N/A | Oryza sativa | N/A | N/A | ||||
EL1467 | XLOC_000829 | N/A | Oryza sativa | N/A | N/A | ||||
EL1468 | XLOC_000869 | N/A | Oryza sativa | N/A | N/A | ||||
EL1469 | XLOC_000909 | N/A | Oryza sativa | N/A | N/A | ||||
EL1470 | XLOC_000999 | N/A | Oryza sativa | N/A | N/A | ||||
EL1471 | XLOC_001095 | N/A | Oryza sativa | N/A | N/A | ||||
EL1472 | XLOC_001234 | N/A | Oryza sativa | N/A | N/A | ||||
EL1473 | XLOC_001235 | N/A | Oryza sativa | N/A | N/A | ||||
EL1474 | XLOC_003286 | N/A | Homo sapiens | N/A | N/A | ||||
EL1475 | XLOC_003405 | N/A | Homo sapiens | N/A | N/A | ||||
EL1476 | XLOC_004026 | N/A | Oryza sativa | N/A | N/A | ||||
EL1477 | XLOC_004031 | N/A | Oryza sativa | N/A | N/A | ||||
EL1478 | XLOC_004122 | N/A | Homo sapiens | N/A | N/A | ||||
EL1479 | XLOC_004186 | N/A | Oryza sativa | N/A | N/A | ||||
EL1480 | XLOC_004275 | N/A | Oryza sativa | N/A | N/A | ||||
EL1481 | XLOC_004478 | N/A | Oryza sativa | N/A | N/A | ||||
EL1482 | XLOC_004507 | N/A | Oryza sativa | N/A | N/A | ||||
EL1483 | XLOC_004531 | N/A | Oryza sativa | N/A | N/A | ||||
EL1484 | XLOC_004562 | N/A | Homo sapiens | N/A | N/A | ||||
EL1485 | XLOC_004689 | N/A | Oryza sativa | N/A | N/A | ||||
EL1486 | XLOC_004714 | N/A | Oryza sativa | N/A | N/A | ||||
EL1487 | XLOC_004798 | N/A | Oryza sativa | N/A | N/A | ||||
EL1488 | XLOC_004876 | N/A | Oryza sativa | N/A | N/A | ||||
EL1489 | XLOC_004881 | N/A | Oryza sativa | N/A | N/A | ||||
EL1490 | XLOC_004932 | N/A | Oryza sativa | N/A | N/A | ||||
EL1491 | XLOC_004933 | N/A | Oryza sativa | N/A | N/A | ||||
EL1492 | XLOC_004944 | N/A | Oryza sativa | N/A | N/A | ||||
EL1493 | XLOC_005031 | N/A | Oryza sativa | N/A | N/A | ||||
EL1494 | XLOC_005912 | N/A | Homo sapiens | N/A | N/A | ||||
EL1495 | XLOC_007072 | N/A | Oryza sativa | N/A | N/A | ||||
EL1496 | XLOC_007697 | XLOC_007697; LOC105500239 | Homo sapiens | NR_131213 | N/A | ||||
EL1497 | XLOC_008559 | XLOC_008559; LOC105378427 | Homo sapiens | NR_131214 | N/A | ||||
EL1498 | XLOC_009232 | N/A | Oryza sativa | N/A | N/A | ||||
EL1499 | XLOC_009911 | XLOC_009911; LOC105500240 | Homo sapiens | NR_131215 | N/A | ||||
EL1500 | XLOC_010235 | N/A | Homo sapiens | N/A | N/A | ||||
EL1501 | XLOC_012255 | N/A | Homo sapiens | N/A | N/A | ||||
EL1502 | XLOC_014172 | N/A | Homo sapiens | N/A | N/A | ||||
EL1503 | XLOC_014388 | N/A | Homo sapiens | N/A | N/A | ||||
EL1504 | XLOC_016182 | N/A | Oryza sativa | N/A | N/A | ||||
EL1505 | XLOC_018316 | N/A | Oryza sativa | N/A | N/A | ||||
EL1506 | XLOC_037529 | N/A | Oryza sativa | N/A | N/A | ||||
EL1507 | XLOC_040350 | N/A | Oryza sativa | N/A | N/A | ||||
EL1508 | XLOC_057324 | N/A | Oryza sativa | N/A | N/A | ||||
EL1509 | XLOC_057981 | N/A | Oryza sativa | N/A | N/A | ||||
EL1510 | Xlsirts | N/A | Xenopus laevis | N/A | N/A | ||||
EL1511 | XR_250621.1 | N/A | Homo sapiens | N/A | N/A | ||||
EL1512 | XRN1 | YGL173C; DST2; KEM1; RAR5; SEP1; SKI1 | Saccharomyces cerevisiae S288c | N/A | N/A | ||||
EL1513 | Yam-1 | N/A | Mus musculus | N/A | N/A | ||||
EL1514 | LOC105373051 | Z82214.3 | Homo sapiens | NR_134632 | ENSG00000236272 | ||||
EL1515 | ZEB1-AS1 | N/A | Homo sapiens | NR_024284 | N/A | ||||
EL1516 | ZEB2-AS1 | ZEB2-AS; ZEB2AS; ZEB2NAT | Homo sapiens | NR_040248 | ENSG00000238057 | ||||
EL1517 | ZFAS1 | C20orf199; HSUP1; HSUP2; NCRNA00275; ZNFX1-AS1 | Homo sapiens | NR_003604, NR_036658, NR_003606, NR_003605, NR_036659 | ENSG00000177410 | ||||
EL1518 | ZFAT-AS1 | NCRNA00070; SAS-ZFAT; ZFAT-AS; ZFATAS | Homo sapiens | NR_002438 | ENSG00000248492 | ||||
EL1519 | Zfhx2os | Zfhx2as | Mus musculus | NR_004444 | ENSMUSG00000093452 | ||||
EL1520 | Zim3 | 1700128I23Rik | Mus musculus | NR_036631 | ENSMUSG00000108043 | ||||
EL1521 | Zm401 | N/A | Nicotiana tabacum | N/A | N/A | ||||
EL1522 | Zm401 | N/A | Zea mays | AY800268 | N/A | ||||
EL1523 | Zm401p10 | N/A | Zea mays | AY911609 | N/A | ||||
EL1524 | ZMAT1 | ZMAT1; KIAA1789 | Homo sapiens | N/A | ENSG00000166432 | ||||
EL1525 | ZmIPS1 | N/A | Zea mays | BM379264 | N/A | ||||
EL1526 | ZNF295-AS1 | C21orf121; NCRNA00318; PRED87 | Homo sapiens | NR_119384, NR_119385, NR_027273 | ENSG00000237232 | ||||
EL1527 | ZNF350-AS1 | HCCAT3; uc002pyc | Homo sapiens | NR_103847 | ENSG00000269235 | ||||
EL1528 | ZNF667-AS1 | MORT | Homo sapiens | NR_036521, NR_036522 | ENSG00000166770 | ||||
EL1529 | ZNF674-AS1 | NR_015378; ZNF674-AS1 | Homo sapiens | NR_015378 | ENSG00000230844 | ||||
EL1530 | ZPR4 | AT2G36307; LITTLE ZIPPER 4 | Arabidopsis thaliana | NR_143764 | N/A | ||||
EL1533 | apela | ELABELA, ela, si:ch211-42i9.4, tdl | Danio rerio | NM_001297547 | ENSDARG00000094729 | ||||
EL1536 | MRLN | LINC00948, Linc-RAM, M1, MLN, MUSER1 | Homo sapiens | NM_001304731, NM_001304732 | ENSG00000227877 | ||||
EL1535 | DWORF | N/A | Homo sapiens | NR_037902 | ENSG00000240045 | ||||
EL1532 | APELA | ELA, Ende, tdl | Homo sapiens | NM_001297550, XM_017007623 | ENSG00000248329 | ||||
EL1537 | Mrln | 2310015B20Rik, Mln | Mus musculus | NM_001304739, XM_017314076 | ENSMUSG00000019933 | ||||
EL1531 | Apela | Ela, Ende, Gm10664 | Mus musculus | NM_001297554, XM_011242247 | ENSMUSG00000079042 | ||||
EL1534 | Gm34302 | N/A | Mus musculus | XR_375707, XR_375708 | ENSMUSG00000103476 | ||||
EL0388 | ENOD40-1 | N/A | Glycine max | X69154 | N/A | ||||
EL1538 | SclA | Dmel_CG45090, BEST:LP06756, BcDNA:RE28911, CG45090, CR31696, DmelCG45090, ORF-A, mel1, pncr003, pncr003:2L, pncr003:2L ORFA, pncr:003:2L, scl, sclA | Drosophila melanogaster | NM_001299066, NM_001299065, NM_001299067 | N/A | ||||
EL1539 | SclB | Dmel_CG45091, BEST:LP06756, BcDNA:RE28911, CG45091, CR31696, DmelCG45091, ORF-B, mel2, pncr003, pncr003:2L, pncr003:2L ORFB, pncr:003:2L, scl | Drosophila melanogaster | NM_001299063, NM_001299062, NM_001299064, NM_001299061 | N/A | ||||
EL1540 | tal-1A | Dmel_CG42384, CG42384, Dm1, DmelCG42384, ORF 1A, ORF1, Pep1, Tal1A, pri, tal | Drosophila melanogaster | NM_001144578 | N/A | ||||
EL1541 | tal-2A | Dmel_CG42385, CG42385, Dm2, DmelCG42385, ORF 2A, ORF2, Pep2, pri, tal | Drosophila melanogaster | NM_001144579 | N/A | ||||
EL1542 | tal-3A | Dmel_CG42386, CG42386, Dm3, DmelCG42386, ORF 3A, ORF3, Pep3, pri, tal | Drosophila melanogaster | NM_001144580 | N/A | ||||
EL1543 | tal-AA | Dmel_CG42387, CG42387, Dm4, Dm_3R:52381, DmelCG42387, ORF AA, ORF4, Pep4, pri, tal | Drosophila melanogaster | NM_001144577 | N/A |
DISEASES | |||||||||
---|---|---|---|---|---|---|---|---|---|
ID | lncRNA Name |
Disease | Method | Sample | Expression pattern |
Function type |
Description | PMID | Source |
EL0001 | 116HG | Prader-Willi syndrome | N/A | N/A | N/A | regulation | Long ncRNA 116HG has been shown to play a role in the development of Prader–Willi syndrome (PWS) (Powell et al., 2013). | 24624135 | LncRNADisease |
EL0003 | 1B FGF-antisense transcripts | endometriosis | N/A | N/A | N/A | expression | Mihalich et al, reported patients with endometriosis show low expression of 1B FGF-antisense transcripts, which correlates with endometrial cell proliferation | 23781896 | LncRNADisease |
EL0004 | 4930503E24Rik | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL0006 | 51A | Alzheimer's disease | N/A | N/A | N/A | regulation | 51A expression drives a splicing shift of SORL1 from the synthesis of the canonical long protein variant 1 to an alternatively spliced protein form. This process, resulting in a decreased synthesis of SORL1 variant 1, is associated with an impaired processing of APP, leading to increase of A formation. | 22996644 | LncRNADisease |
EL0008 | 5730458M16Rik | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 22 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0011 | 9530018H14Rik | breast cancer | qPCR, Luciferase reporter assay etc. | breast cancer tissue, cell lines(NMuMG, 4T1) | up-regulated | expression | The level of expression of lncRNA-HIT in normal breast tissue was low and gradually increased to invasive carcinoma suggesting lncRNA-HIT may play a role in tumor progression in humans. These data further support the findings demonstrating the involvement of lncRNA-HIT in EMT and invasion as observed in NMuMG and 4T1 cells, and suggest that conserved human lncRNA-HIT could play a pivotal role in breast cancer metastasis. | 25605728 | Lnc2Cancer |
EL0012 | A130040M12Rik | cancer | N/A | N/A | N/A | expression | These results indicate that PSF is a major tumor-suppressor protein and VL30-1 RNA is a major tumor-promoter RNA in mice. | 19805375 | LncRNADisease |
EL0013 | AA174084 | gastric cancer | qPCR, RIP etc. | gastric cancer tissue | down-regulated | N/A | Expression levels of AA174084 were down-regulated significantly in 95 of 134 GC tissues (71%) compared with the levels in paired, adjacent, normal tissues. AA174084 levels had significant, negative correlations with age, Borrmann type, and perineural invasion. Plasma AA174084 levels in patients with GC dropped markedly on day 15 after surgery compared with preoperative levels and were associated with invasion and lymphatic metastasis. AA174084 levels in gastric juice from patients with GC were significantly higher than the levels in normal mucosa or in patients with minimal gastritis, gastric ulcers, and atrophic gastritis. The area under ROC was up to 0.848. | 24986041 | Lnc2Cancer |
EL0014 | AATBC | bladder cancer | microarray, qPCR, in vitro knockdown etc. | bladder cancer tissue | up-regulated | interaction | We found that AATBC was overexpressed in bladder cancer patient tissues and positively correlated with tumor grade and pT stage. We also found that inhibition of AATBC resulted in cell proliferation arrest through G1 cell cycle mediated by cyclin D1, CDK4, p18 and phosphorylated Rb. In addition, inhibition of AATBC induced cell apoptosis through the intrinsic apoptosis signaling pathway, as evidenced by the activation of caspase-9 and caspase-3. The investigation for the signaling pathway revealed that the apoptosis following AATBC knockdown was mediated by activation of phosphorylated JNK and suppression of NRF2. | 25473900 | Lnc2Cancer |
EL0015 | AB019562 | hypopharyngeal squamous cell carcinoma | microarray, qPCR etc. | primary HSCC tissue | up-regulated | expression | AB209630 expression was significantly lower in carcinomas than in adjacent nontumor tissues. AB019562 expression was significantly higher in carcinomas than in adjacent nontumor tissues. | 26131061 | Lnc2Cancer |
EL0016 | AB073614 | ovarian cancer | microarray, qPCR, Western blot, knockdown, FCA etc. | ovarain cancer tissue, cell lines (A2780, Caov3, HO-8910, OVCAR3, SKOV3 etc.) | up-regulated | interaction | Results showed that AB073614 expression was significantly up-regulated in 85.3% (64/75) cancerous tissues compared with normal counterparts. Knockdown of AB073614 expression significantly inhibited cell proliferation and invasion, resulted in cell arrest in G1 phase of cell cycle and a dramatic increase of apoptosis. Finally, western blot assays indicated that lncRNA AB073614 may exert its function by targeting ERK1/2 and AKT-mediated signaling pathway. In conclusion, our study suggests that lncRNA AB073614 acts as a functional oncogene in OC development. | 26299803 | Lnc2Cancer |
EL0016 | AB073614 | glioma | qRT-PCR | N/A | up-regulated | N/A | AB073614 expression was significantly up-regulated in cancerous tissues compared with normal brain tissues | 27104549 | |
EL0017 | AB074278 | urothelial carcinoma of the bladder | microarray, qPCR, in vitro knockdown etc. | urothelial carcinoma of the bladder tissue | up-regulated | N/A | We implicate upregulation of AB074278 in apoptosis avoidance and the maintenance of a proproliferative state in cancer through a potential interaction with EMP1, a tumor suppressor and a negative regulator of cell proliferation. | 25165097 | LncRNADisease Lnc2Cancer |
EL0018 | AB209630 | hypopharyngeal squamous cell carcinoma | microarray, qPCR etc. | primary HSCC tissue | down-regulated | expression | AB209630 expression was significantly lower in carcinomas than in adjacent nontumor tissues. AB019562 expression was significantly higher in carcinomas than in adjacent nontumor tissues. | 26131061 | Lnc2Cancer |
EL0018 | AB209630 | hypopharyngeal squamous cell carcinoma | qRT-PCR | tissues/cell lines and adjacent normal tissues/cell lines | down-regulated | N/A | increased expression of AB209630 might either stimulate or inhibit biological activities involved in HSCC development | 26895099 | |
EL0019 | ABHD11-AS1 | gastric cancer | qPCR etc. | gastric cancer tissue | up-regulated | N/A | Results show that compared with adjacent nontumor tissues the expression level of ABHD11-AS1 in gastric cancer tissues was significantly increased. | 24984296 | Lnc2Cancer |
EL0019 | ABHD11-AS1 | gastric cancer | qPCR etc. | gastric cancer tissue, gastric juice | up-regulated | expression | The results showed that ABHD11-AS1 levels in gastric cancer tissues were significantly higher than those in other tissues. Its levels in gastric juice from gastric cancer patients were not only significantly higher than those from cases of normal mucosa or minimal gastritis, atrophic gastritis, and gastric ulcers but also associated with gender, tumor size, tumor stage, Lauren type, and blood carcinoembryonic antigen (CEA) levels. | 26280398 | Lnc2Cancer |
EL0020 | Abhd11os | neurodegenerative diseases | N/A | N/A | N/A | N/A | The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo. Abhd11os overexpression produces neuroprotection against an N-terminal fragment of mutant huntingtin, whereas Abhd11os knockdown is protoxic. | 25619660 | LncRNADisease |
EL0021 | Abhd11os | NNK-induced rat lung cancer | qRT-PCR | lung tissue | up-regulated | N/A | level of NR_026689 was determined and significantly increased in rat whole blood at the 10th and 20th | 26908441 | |
EL0022 | STAG3L2 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | up-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL0023 | AC006050.3-003 | lung squamous cell carcinoma | N/A | N/A | N/A | N/A | The expression of lncRNA AC006050.3-003 was significantly lower in PR samples compared to the PD samples in another 60 lung squamous cell carcinoma patients. Receiver operating characteristic curve analysis revealed that lncRNA AC006050.3-003 was a valuable biomarker for differentiating PR patients from PD patients with an area under the curve of 0.887 (95% confidence interval 0.779, 0.954). | 25250788 | LncRNADisease |
EL0024 | LOC101927596 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL0025 | MTCO1P5 | laryngeal squamous cell carcinoma | microarray, qPCR etc. | LSCC tissue | down-regulated | expression | AC026166.2-001 and RP11-169D4.1-001 were distinctly dysregulated, with AC026166.2-001 exhibiting lower expression in cancer tissues and RP11-169D4.1-001 higher expression. We verified that both AC026166.2-001 and RP11-169D4.1-001 were expressed at a lower level in cervical lymph nodes compared with paired laryngeal cancer tissues and paired normal tissues. RP11-169D4.1-001 levels were positively correlated with lymph node metastasis. | 25243407 | Lnc2Cancer |
EL0027 | PLAC9P1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL0028 | AC100865.1 | coronary artery disease | microarray, qPCR | plasma from coronary artery disease (CAD) patients | up-regulated | expression | The present study screened lncRNAs by microarray analysis in the plasma from CAD patients and control individuals and found that 265 lncRNAs were differentially expressed. Receiver operating characteristic (ROC) curve analysis showed that lncRNA AC100865.1(referred to as CoroMarker) was the best of these lncRNAs. | 26201019 | |
EL0029 | AC104699.1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | up-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL0030 | AC104699.1.1 | ovarian cancer | high-throughput molecular profiles | 399 Ovarian cancer (OV) patients | N/A | expression | Two protective lncRNAs, RP11-284N8.3.1 and AC104699.1.1, were not only differentially expressed throughout the progression of malignant OV but were also independently predictive of the survival of patients with different OV stages. A functional analysis of the two lncRNAs predicted their roles in immune system activation and other anti-tumor processes in the OV microenvironment. | 26629053 | |
EL0031 | ACTA2-AS1 | lung adenocarcinoma | microarray, qPCR, knockdown etc. | lung adenocarcinoma tissue, cell lines (A549) | up-regulated | expression | Enhanced expression of long non-coding RNA ZXF1 promoted the invasion and metastasis in lung adenocarcinoma. | 24721325 | LncRNADisease Lnc2Cancer |
EL0032 | ADAMTS9-AS2 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
EL0032 | ADAMTS9-AS2 | glioma | qPCR, Western blot, knockdown etc. | glioma tumor tissue, cell lines (T98G, A172, SNB-19 etc.) | down-regulated | regulation | A new tumor suppressor?LncRNA?ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells. | 24833086 | LncRNADisease Lnc2Cancer |
EL0033 | Adapt15 | obesity | knockdown | mutant Chinese hamster ovary cell line | N/A | mutation | Here we report that gadd7 is induced by lipotoxic stress in a reactive oxygen species (ROS)-dependent fashion and is necessary for both lipid- and general oxidative stress-mediated cell death. Depletion of gadd7 by mutagenesis or short hairpin RNA knockdown significantly reduces lipid and non-lipid induced ROS | 19150982 | |
EL0033 | Adapt15 | diabetes | knockdown | mutant Chinese hamster ovary cell line | N/A | mutation | Here we report that gadd7 is induced by lipotoxic stress in a reactive oxygen species (ROS)-dependent fashion and is necessary for both lipid- and general oxidative stress-mediated cell death. Depletion of gadd7 by mutagenesis or short hairpin RNA knockdown significantly reduces lipid and non-lipid induced ROS | 19150982 | |
EL0034 | AF070632 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | expression | We noted that LINC01419 was characterized by a significant increase in transcript expression from dysplasia to early HCC. The lncRNA AK021443 was also up-regulated in advanced HCC samples when compared with early HCC. Moreover, expression of LINC01419 and AK021443 was up-regulated in HCC tissues when compared with non-tumor liver tissue. AF070632 expression was down-regulated in HCC and was decreased in advanced HCC when compared with early HCC. These results suggest that LINC01419 may be related to the initiation of HCC, whereas AK021443 and AF070632 may be associated with the progression of HCC. | 26540467 | Lnc2Cancer |
EL0035 | AF075041 | pancreatic cancer | qPCR etc. | pancreatic cancer tissue, cell lines (Sw1990, PANC-1, BXPC-3 etc.) | up-regulated | expression | We further confirmed the selected 6 up-regulation of LncRNAs in PC tissues and PC cell lines through qPCR. Comparing to 293T cells, the expression of LncRNA AF339813 was significantly increased about 10-fold in PANC-1 cells, 8-fold in SW1990 cells and 8.9-fold in BxCP-3 cells. The other 5 LncRNAs have a certain degree of up-regulation in PC cell lines. | 26045769 | Lnc2Cancer |
EL0036 | AF086415 | nasopharyngeal carcinoma | microarray, qPCR, knockdown etc. | nasopharyngeal carcinoma tissue, cell lines (CNE-2 etc.) | down-regulated | expression | Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294004) were confirmed by qPCR. | 24379026 | LncRNADisease Lnc2Cancer |
EL0037 | AF116616 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0038 | AF118081 | lung cancer | qPCR, knockdown etc. | lung cancer tissue, cell lines (16HBE) | up-regulated | regulation | LncRNA AF118081 was identified as the most significantly overexpressed lncRNA in 16HBE-T cells, lung cancer cells, and patient samples. Cell proliferation, colony formation, apoptosis, migration, and invasion were assayed in 16HBE-T cells following the knockdown of lncRNA AF118081 with small interfering RNA. AF118081 knockdown inhibited cell growth and tumor invasion. An in vivo (nude mouse) model was then used to assay tumor growth, and the downregulation of AF118081 clearly suppressed tumor growth, consistent with the results of the in vitro assays. | 25050996 | Lnc2Cancer |
EL0039 | AF339813 | pancreatic cancer | qPCR, Western blot, knockdown etc. | pancreatic cancer tissue, cell lines (Sw1990, PANC-1, BXPC-4 etc.) | up-regulated | interaction | We found LncRNA AF339813 was positively regulated by NUF2. We further demonstrated that knockdown of AF339813 by siRNA in PC cells significantly reduced cell proliferation and promoted apoptosis.We further demonstrated that knockdown of AF339813 by siRNA in PC cells significantly reduced cell proliferation and promoted apoptosis. Thus, we conclude that NUF2 is consistently overexpressed in human PC and NUF2 is closely linked with human PC progression through the meditator LncRNA AF339813. | 26045769 | Lnc2Cancer |
EL0040 | AFAP1-AS1 | nasopharyngeal carcinoma | microarray, qPCR, Western blot, knockdown, ISH etc. | NPC tissue, cell lines (5-8F, HNE2, HK-1) | up-regulated | interaction | AFAP1-AS1 expression was upregulated in NPC and associated with NPC metastasis and poor prognosis. In vitro experiments demonstrated that AFAP1-AS1 knockdown significantly inhibited the NPC cell migration and invasive capability. AFAP1-AS1 knockdown also increased AFAP1 protein expression. Proteomic and bioinformatics analyses suggested that AFAP1-AS1 affected the expression of several small GTPase family members and molecules in the actin cytokeratin signaling pathway. AFAP1-AS1 promoted cancer cell metastasis via regulation of actin filament integrity. | 26246469 | Lnc2Cancer |
EL0040 | AFAP1-AS1 | Barrett's esophagus | N/A | N/A | N/A | expression | Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma. | 23333711 | LncRNADisease Lnc2Cancer |
EL0040 | AFAP1-AS1 | esophageal squamous cell carcinoma | overexpression, Kaplan-Meier survival analysis | cisplatin-resistant and parental ESCC cell lines | up-regulated | expression | High expression of AFAP1-AS1 could serve as a potential biomarker to predict tumor response and survival. Determination of this lncRNA expression might be useful for selection ESCC patients for dCRT. | 26756568 | |
EL0040 | AFAP1-AS1 | esophageal adenocarcinoma | qPCR etc. | EAC tissue, cell lines (OE-33, SK-GT-4, FLO-1, HEEpiC etc.) | up-regulated | expression | Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma. | 23333711 | LncRNADisease Lnc2Cancer |
EL0040 | AFAP1-AS1 | pancreatic ductal adenocarcinoma | qPCR etc. | blood, cell lines (Panc1, MIAPaCa-2, Capan2, SW1990 etc.) | up-regulated | expression | Microarray analysis revealed that up-regulation of AFAP1-AS1 expression in PDAC tissues compared with normal adjacent tissues, which was confirmed by RT-qPCR in 69/90 cases (76.7%). Its overexpression was associated with lymph node metastasis, perineural invasion, and poor survival. AFAP1-AS1 is a potential novel prognostic marker to predict the clinical outcome of PDAC patients after surgery and may be a rational target for therapy. | 25925763 | Lnc2Cancer |
EL0040 | AFAP1-AS1 | non-small cell lung cancer | qPCR etc. | non-small-cell lung cancer tissue | up-regulated | expression | Results showed that patients with high LncRNA AFAP1-AS1 expression lived shorter than those with low LncRNA AFAP1-AS1 expression (Log rank test, P<0.001). Besides, the prognostic value of LncRNA AFAP1-AS1 as well as the clinical features was assessed by Cox regression analysis. The outcome revealed that LncRNA AFAP1-AS1 was closely related to the prognosis of NSCLC | 26463625 | Lnc2Cancer |
EL0040 | AFAP1-AS1 | hepatocelluar carcinoma | real-time PCR; MTT assay | 78 HCC tissues | up-regulated | N/A | AFAP1-AS1 was significantly correlated with pathological staging | 26892468 | |
EL0040 | AFAP1-AS1 | lung cancer | RNA-seq, qPCR, Western blot etc. | cell line (A549 ) | up-regulated | interaction | AFAP1-AS1 was the most significantly upregulated in lung cancer and associated with poor prognosis. AFAP1-AS1 knockdown significantly inhibited the cell invasive and migration capability in lung cancer cells. AFAP1-AS1 knockdown also increased the expression of its antisense protein coding gene, actin filament associated protein 1 (AFAP1), and affected the expression levels of several small GTPase family members and molecules in the actin cytokeratin signaling pathway, which suggested that AFAP1-AS1 promoted cancer cell metastasis via regulation of actin filament integrity. | 26245991 | Lnc2Cancer |
EL0042 | AI364715 | gastric cancer | qPCR etc. | gastric cancer tissue | down-regulated | expression | The expression level of AI364715 in gastric cancer tissues was downregulated. Meanwhile, its expression level was closely associated with tumor size and differentiation. | 25971582 | Lnc2Cancer |
EL0044 | Airn | alcoholic liver disease | N/A | N/A | N/A | expression | Up regulation in liver by DDC (Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate ). | 19362547 | LncRNADisease |
EL0044 | Airn | chronic nonalcoholic liver disease | N/A | N/A | N/A | expression | Up regulation in liver by DDC (Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate ). | 19362547 | LncRNADisease |
EL0044 | Airn | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Up regulation in liver by DDC (Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate ). Furthermore, over expression of H19 and AIR was demonstrated in tumors formed in mice withdrawn for 9 months. | 19362547 | LncRNADisease |
EL0045 | AK022029 | pancreatic cancer | qPCR etc. | pancreatic cancer tissue, cell lines (Sw1990, PANC-1, BXPC-5 etc.) | up-regulated | expression | We further confirmed the selected 6 up-regulation of LncRNAs in PC tissues and PC cell lines through qPCR. Comparing to 293T cells, the expression of LncRNA AF339813 was significantly increased about 10-fold in PANC-1 cells, 8-fold in SW1990 cells and 8.9-fold in BxCP-3 cells. The other 5 LncRNAs have a certain degree of up-regulation in PC cell lines. | 26045769 | Lnc2Cancer |
EL0046 | AK022159 | pancreatic cancer | qPCR etc. | pancreatic cancer tissue, cell lines (Sw1990, PANC-1, BXPC-6 etc.) | up-regulated | expression | We further confirmed the selected 6 up-regulation of LncRNAs in PC tissues and PC cell lines through qPCR. Comparing to 293T cells, the expression of LncRNA AF339813 was significantly increased about 10-fold in PANC-1 cells, 8-fold in SW1990 cells and 8.9-fold in BxCP-3 cells. The other 5 LncRNAs have a certain degree of up-regulation in PC cell lines. | 26045769 | Lnc2Cancer |
EL0047 | AK028007 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL0048 | AK038798 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 16 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0049 | AK042766 | Restless legs syndrome | N/A | N/A | N/A | expression | A recent study suggested that the predisposition to RLS results from reduced expression of Meis1 mediated by intronic cis-regulatory elements. Intriguingly, in the developing mouse brain, Meis1 is co-expressed in the developing cerebellar granule cell layer along with a genomically-associated lncRNA AK042766 | 19696892 | LncRNADisease |
EL0050 | AK044955 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 7 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0051 | AK056988 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
EL0052 | AK057054 | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | down-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL0053 | AK081227 | Rett syndrome | microarray, qRT-PCR | mice brain | up-regulated | N/A | transcriptional dysregulation of lncRNAs upon Mecp2 loss contributes to the neurological phenotype of Rett syndrome and highlights the complex interaction between ncRNAs and coding-RNAs. | 23611944 | |
EL0054 | AK093543 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | N/A | To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. | 24876753 | Lnc2Cancer |
EL0055 | AK094838 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0056 | AK095147 | nasopharyngeal carcinoma | microarray, qPCR, knockdown etc. | nasopharyngeal carcinoma tissue, cell lines (CNE-2 etc.) | down-regulated | expression | Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294005) were confirmed by qPCR. | 24379026 | LncRNADisease Lnc2Cancer |
EL0057 | AK123657 | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116 ,SW1116) | down-regulated | N/A | Functional experiments demonstrated three dysregulated lncRNAs, AK123657, BX648207 and BX649059 were required for efficient invasion and proliferation suppression in CRC cell lines. | 24809982 | Lnc2Cancer |
EL0058 | AK123790 | hepatocelluar carcinoma | microarray, qPCR, RIP, RNA pulldown assay etc. | HCC tissue | down-regulated | N/A | AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. | 21769904 | Lnc2Cancer |
EL0059 | AK130977 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL0062 | AK139328 | liver ischemia/reperfusion injury | microarray, qRT-PCR | mouse plasma after liver ischemia/reperfusion injury (IRI) | up-regulated | expression | LncRNA AK139328 had been previously reported to be upregulated in the liver after IRI, and silencing of hepatic AK139328 ameliorated liver IRI. microarray and RT-PCR analyses failed to detect the presence of AK139328 in mouse plasma. | 26221732 | |
EL0062 | AK139328 | ischemia/reperfusion | N/A | N/A | N/A | regulation | Silencing of Long Noncoding RNA AK139328 Attenuates Ischemia/Reperfusion Injury in Mouse Livers. | 24312245 | LncRNADisease |
EL0062 | AK139328 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL0063 | AK143294 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL0064 | AK143693 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL0065 | AK153778 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 26 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0066 | AKR7L | gastric cancer | microarray, qPCR, knockdown etc. | gastric cancer tissue | down-regulated | N/A | TUSC7 was downregulated in GC samples and was an independent prognostic indicator of disease-free survival (DFS) and disease-specific survival (DSS) in GC patients; TUSC7 was a direct transcriptional target of p53 via interaction of p53 with the putative p53-response element in the upstream region of TUSC7 | 25765901 | LncRNADisease Lnc2Cancer |
EL0067 | AL389956 | pancreatic cancer | qPCR etc. | pancreatic cancer tissue, cell lines (Sw1990, PANC-1, BXPC-7 etc.) | up-regulated | expression | We further confirmed the selected 6 up-regulation of LncRNAs in PC tissues and PC cell lines through qPCR. Comparing to 293T cells, the expression of LncRNA AF339813 was significantly increased about 10-fold in PANC-1 cells, 8-fold in SW1990 cells and 8.9-fold in BxCP-3 cells. The other 5 LncRNAs have a certain degree of up-regulation in PC cell lines. | 26045769 | Lnc2Cancer |
EL0068 | Alg2 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL0073 | Alu lncRNAs | macular degeneration | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease |
EL0076 | AOC4P | colorectal cancer | N/A | colorectal cancer cells | N/A | interaction | UPAT interacts with and stabilizes the epigenetic factor UHRF1 by interfering with its β-transducin repeat-containing protein (TrCP)-mediated ubiquitination. UHRF1 up-regulates Stearoyl-CoA desaturase 1 and Sprouty 4, which are required for the survival of colon tumor cells. | 26768845 | |
EL0076 | AOC4P | hepatocelluar carcinoma | qPCR, Western blot, RNA pulldown assay, knockdown, | HCC tissue, cell lines (J7 and SK-Hep1) | down-regulated | interaction | we identified a differentially expressed novel tumor suppressive lncRNA termed amine oxidase, copper containing 4, pseudogene (AOC4P). The level of AOC4P expression was significantly downregulated in 68% of HCC samples and negatively correlated with advanced clinical stage, capsule invasion and vessel invasion. Low AOC4P expression correlated with poor prognostic outcomes, serving as an independent prognostic factor for HCC. In vitro functional assays indicated that AOC4P overexpression significantly reduced cell proliferation, migration and invasion by inhibiting the epithelial-mesenchymal transition (EMT) | 26160837 | Lnc2Cancer |
EL0077 | AP000688.29 | enterovirus 71 infection | N/A | N/A | N/A | expression | A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation (2.25-fold in microarray analysis) was observed in AP000688.29, 3.33-fold up-regulation (2.77-fold in microarray analysis) in AC002511.1, 2.29-fold up-regulation (2.40-fold in microarray analysis) in RP5-843L14.1, and 2.99-fold up-regulation (2.22-fold in microarray analysis) in RP4-620F22.3 | 23220233 | LncRNADisease |
EL0078 | AP001439.1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | down-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL0079 | AP5M1 | nasopharyngeal carcinoma | microarray, qPCR, knockdown etc. | nasopharyngeal carcinoma tissue, cell lines (CNE-2 etc.) | up-regulated | expression | Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294007) were confirmed by qPCR. | 24379026 | LncRNADisease Lnc2Cancer |
EL0082 | APTR | glioblastoma | qPCR, Northern blot, Luciferase reporter assays, knockdown etc. | primary glioblastoma tissue, cell lines (A172, HCT116) | up-regulated | N/A | We identified a novel lncRNA, APTR, that acts in trans to repress the CDKN1A/p21 promoter independent of p53 to promote cell proliferation. | 24748121 | Lnc2Cancer |
EL0083 | ARA | Cancer | microarray, qRT-PCR | MCF-7/ADR and HepG2/ADR cells | N/A | N/A | The functions of ARA were assessed by silencing this lncRNA in vitro, and ARA knockdown reduced the proliferation, induced cell death, G2/M arrest and migration defects. modulate multiple signalling pathways, including MAPK signalling pathway, metabolism pathways, cell cycle and cell adhesion-related biological pathways, and regulate cellular processes, including transcriptional processes and protein binding function. | 24184505 | |
EL0084 | Arid2-IR | renal inflammation | N/A | N/A | N/A | N/A | Arid2-IR is a novel lncRNA that functions to promote NF-KB-dependent renal inflammation. Overexpression of Arid2-IR promoted interleukin-1ǂ-induced NF-NJB signaling and inflammatory cytokine expression without alteration of TGF-beta1-induced fibrotic response. | 25743111 | LncRNADisease |
EL0085 | AS Uchl1 | Parkinson's disease | N/A | N/A | N/A | N/A | Uch1 RNA levels are strongly down-regulated in neurochemical models of PD in vitro and in vivo | 25883552 | LncRNADisease |
EL0090 | ASK00420 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | down-regulated | N/A | LncRNA expression was then analyzed in CC cells and normal, primary cervical epithelial cells in the same manner. The levels of TI17313, TI13831, TI10124, and TI18318 were increased in 3 cancer cell lines (HeLa, SiHa, and CaSki) when compared with normal, primary cervical epithelial cells. Expression of the 5 other lncRNAs was below the level of detection in cultured cells. | 25007342 | Lnc2Cancer |
EL0092 | ASLNC00339 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0093 | ASncmtRNAs | cancer | N/A | several tumor cell lines | down-regulated | N/A | the ASncmtRNAs are down-regulated in tumor cells regardless of tissue of origin. down-regulation of the ASncmtRNAs constitutes a vulnerability or Achilles' heel of cancer cells, suggesting that the ASncmtRNAs are promising targets for cancer therapy. | 25100722 | |
EL0093 | ASncmtRNAs | cancer | N/A | several tumor cell lines | down-regulated | N/A | the ASncmtRNAs are down-regulated in tumor cells regardless of tissue of origin. down-regulation of the ASncmtRNAs constitutes a vulnerability or Achilles' heel of cancer cells, suggesting that the ASncmtRNAs are promising targets for cancer therapy. | 25100722 | |
EL0209 | Atp2a2 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 4 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0210 | ATP6V1G2-DDX39B | dilated cardiomyopathy | N/A | N/A | N/A | mutation | The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. | 16101831 | LncRNADisease |
EL0210 | ATP6V1G2-DDX39B | hepatitis C virus-associated dilated cardiomyopathy | N/A | N/A | N/A | mutation | The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. | 16101831 | LncRNADisease |
EL0215 | ATXN7L3B | spinocerebellar ataxia type 7 | N/A | N/A | N/A | N/A | STAGA is required for the transcription initiation of miR-124, which in turn mediates the post-transcriptional cross-talk between lnc-SCA7, a conserved long noncoding RNA,and ATXN7 mRNA. In SCA7, mutations in ATXN7 disrupt these regulatory interactions and result in a neuron-specific increase in ATXN7 expression. Strikingly, in mice this increase is most prominent in the SCA7 disease-relevant tissues, namely the retina and cerebellum. | 25306109 | LncRNADisease |
EL0216 | ATXN8OS | spinocerebellar ataxia type 8 | N/A | N/A | N/A | locus | Patients show a trinucleotide (CUG) expansion in a noncoding RNA termed ataxin 8 opposite strand (ATXN8OS), an antisense transcript to the KLHL1 gene. | 16804541 | LncRNADisease |
EL0216 | ATXN8OS | spinocerebellar ataxia type 8 | N/A | N/A | N/A | mutation | The low prevalence of SCA8 seems to be correlated with the low frequency of large (CTA/CTG)n copy number alleles in Chinese population. | 18841561 | LncRNADisease |
EL0216 | ATXN8OS | spinocerebellar ataxia type 8 | N/A | N/A | N/A | expression | Spinocerebellar ataxia type 8 (SCA8) involves bidirectional expression of CUG (ATXN8OS) and CAG (ATXN8) expansion transcripts. | 19229559 | LncRNADisease |
EL0216 | ATXN8OS | spinocerebellar ataxia type 8 | N/A | N/A | N/A | expression | RNA gain-of-function plays a significant role in SCA8: 1) CUG(exp) transcripts accumulate as ribonuclear inclusions that co-localize with MBNL1 in selected neurons in the brain. | 19680539 | LncRNADisease |
EL0216 | ATXN8OS | spinocerebellar ataxia type 8 | N/A | N/A | N/A | mutation | The ATXN8OS (CTA)n(CTG)n composite repeat expansion is transmitted in an autosomal dominant manner with reduced penetrance. | 20301445 | LncRNADisease |
EL0216 | ATXN8OS | Spinocerebellar ataxia type 8 | N/A | N/A | N/A | Interaction | ATXN8OS transcript contributes to SCA8 pathogenesis by altering the activity of MBNL/CELF alternative splicing proteins. | 20380817 | LncRNADisease |
EL0216 | ATXN8OS | Spinocerebellar ataxia type 8 | N/A | N/A | N/A | mutation | Expansion repeats in the ATXN8OS lncRNA gene are partly responsible for the pathology of spinocerebellar ataxia type 8 through a toxic RNA gain-of-function mechanism that includes formation of ribonuclear inclusions in the cerebellum and deregulation of muscleblind-like splicing regulator 1-mediated alternative splicing | 22814587 | LncRNADisease |
EL0216 | ATXN8OS | Spinocerebellar ataxia type 8 | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0217 | AX746718 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL0218 | AX800134 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | expression | We determined that a panel based on the expression of uc001ncr and AX800134 accurately diagnosed HBV-positive HCC (AUC values of 0.9494 and 0.9491 for the training and validation cohorts, respectively). The diagnostic performance of the panel remained high in patients with AFP>=400 ng/ml (AUC values of 0.9371 and 0.9527 for the training and validation cohorts, respectively). The panel also diagnosed early HCC (AUC values of 0.9450 and 0.9564 for the training and validation cohorts, respectively) | 26674525 | Lnc2Cancer |
EL0219 | B1 SINE RNA | brain ischemia | N/A | N/A | N/A | expression | SINE B2 was induced by global ischemia after 1 day in Mongolian gerbils. | 15016078 | LncRNADisease |
EL0220 | B1 SINE RNA | infection of mouse minute virus | N/A | N/A | N/A | expression | Increased levels of B1 and B2 SINE transcripts in mouse fibroblast cells due to minute virus of mice infection. | 15351211 | LncRNADisease |
EL0222 | B2 SINE RNA | infection of chicken embryo lethal orphan adenovirus | N/A | N/A | N/A | Interaction | CELO protein Gam1 was able to mediate transcriptional activation of these B2 SINE-containing RNAs. Upregulation of B2-SINE-containing RNAs could be a novel contribution of Gam1 to CELO host cell infection. | 12729754 | LncRNADisease |
EL0222 | B2 SINE RNA | heat shock | N/A | heat shocked cells | N/A | interaction | B2 rna potently inhibits transcription by binding to core pol ii with high affinity and specificity. | 15300239 | |
EL0222 | B2 SINE RNA | heat shock | N/A | N/A | N/A | interaction | A small noncoding rna polymerase iii transcript, b2 rna, associates with rna polymerase ii and represses transcription of specific mrna genes. | 15300240 | |
EL0222 | B2 SINE RNA | infection of mouse minute virus | N/A | N/A | N/A | expression | Increased levels of B1 and B2 SINE transcripts in mouse fibroblast cells due to minute virus of mice infection. | 15351211 | LncRNADisease |
EL0222 | B2 SINE RNA | pain | N/A | N/A | N/A | expression | Comt1 is differentially expressed among the strains, and this differential expression is cis-regulated. A B2 short interspersed nuclear element (SINE) was inserted in the 3'-untranslated region (3'-UTR) of Comt1 in 14 strains generating a common haplotype that correlates with gene expression. A haplotype, defined by a 3'-UTR B2 SINE element, regulates Comt1 expression and some mouse behaviors. | 20659173 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | Interaction | The BACE1-antisense transcript (BACE1-AS) regulates BACE1 mRNA and subsequently BACE1 protein expression in vitro and in vivo. BACE1 mRNA expression is under the control of a regulatory noncoding RNA that may drive Alzheimer's disease-associated pathophysiology. | 18587408 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | brain samples from Alzheimer's disease patients | up-regulated | interaction | BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p | 20507594 | |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | expression | The BACE1-antisense transcript (BACE1-AS) is markedly upregulated in brain samples from AD patients and promotes the stability of the (sense) BACE1 transcript. | 21785702 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | regulation | It has been shown that misexpression of lncRNAs contributes to numerous diseases. For example, an lncRNA may influence the pathogenesis of Alzheimer's disease. The BACE1-AS can regulate BACE1 mRNA expression. BACE1 mRNA expression is under the control of a regulatory non-coding RNA that may drive Alzheimer's disease-associated pathophysiology | 22535282 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | expression | BACE1 is one of two peptidases that carry out the initial proteolytic cleavage of APP, allowing it to accumulate in the brain. BACE1AS levels were found to be higher in human subjects with AD, and also in BACE1 transgenic mouse models of AD | 22817756 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | expression | he accumulation of this protein has been implicated in many neurological disorders and elevated levels of both BACE1 and BACE1-AS have been detected in subjects with Alzheimer's disease | 22928560 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | expression | BACE1-AS is elevated in brains of patients with AD, suggesting that the lncRNA is the driving force behind BACE1 dysregulation in AD | 23562612 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0224 | BACE1-AS | Inclusion body myositis | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | expression | The expression of BACE1 antisense transcript (BACE1-AS) was linked to increased amyloid-β 1–42 in patients with Alzheimer’s disease and gave rise for a stabilizing function of the lncRNA. | 24531795 | LncRNADisease |
EL0224 | BACE1-AS | Alzheimer's disease | N/A | N/A | N/A | regulation | In Alzheimer disease, the protein-coding gene BACE-1 (β-site amyloid precursor protein-cleaving enzyme) cleaves amyloid precursor protein (APP) to β-amyloid peptide (Aβ), the accumulation of which (amyloid plaques) is associated with disease. LncRNA BACE1-AS, located on the antisense strand to BACE1, binds complementarily to BACE1 mRNA, increases its stability, regulates BACE1 translation, and thereby the production of Aβ. | 24667321 | LncRNADisease |
EL0224 | BACE1-AS | colon cancer | qPCR etc. | cell lines (SNU-C4R, SNU-C5R etc.) | down-regulated | regulation | We selected three lncRNAs, snaR, BACE1AS, and PRAS, and we detected their expression by RT-qPCR using specific primer sets. SnaR and BACE1AS were significantly down-regulated in both resistant cell lines (SNU-C4R and SNU-C5R), whereas PRAS was down-regulated in SNU-C4R cells but not in SNU-C5R cells. Down-regulation of snaR decreased cell death after 5-FU treatment, which indicates that snaR loss decreases in vitro sensitivity to 5-FU. | 25078450 | Lnc2Cancer |
EL0224 | BACE1-AS | ovarian cancer | siRNA | human anisomycin-treated ovarian cancer stem cells (OCSCs) | up-regulated | interaction | lncRNA BACE1-AS as a novel target for anisomycin. Elevation of lncRNA BACE1-AS expression is a potential mechanism for suppressing human OCSC proliferation and invasion. | 26783004 | |
EL0225 | BALR-2 | B cell acute lymphoblastic leukemia | microarray, qPCR etc. | blood (mononuclear cells) | up-regulated | expression | Importantly, high expression of BALR-2 correlated with poor overall survival and diminished response to prednisone treatment. BALR-2 plays a functional role in the pathogenesis and/or clinical responsiveness of B-ALL and that altering the levels of particular lncRNAs may provide a future diretcion for therapeutic development. | 25681502 | Lnc2Cancer |
EL0226 | BALR-6 | B-lymphoblastic leukemia | qPCR, Northern blot, knockdown etc. | cell lines(MV, Reh, 697, Nalm-6, 70Z/3, HEK 293) | up-regulated | interaction | Overexpression of BALR-6 in murine bone marrow transplantation experiments caused a significant increase in early hematopoietic progenitor populations, suggesting that its dysregulation may cause developmental changes. Notably, the knockdown of BALR-6 resulted in global dysregulation of gene expression. The gene set was enriched for leukemia-associated genes, as well as for the transcriptome regulated by Specificity Protein 1 (SP1). We confirmed changes in the expression of SP1, as well as its known interactor and downstream target CREB1. Luciferase reporter assays demonstrated an enhancement of SP1-mediated transcription in the presence of BALR-6. These data provide a putative mechanism for regulation by BALR-6 in B-ALL | 26694754 | Lnc2Cancer |
EL0227 | BANCR | colorectal cancer | chromatin immunoprecipitation; luciferase assays; RT-PCR | fentanyl-treated colorectal cancer (CRC) cells | up-regulated | expression | Fentanyl induced BANCR upregulation and Ets-1 downregulation in CRC cells. Further studies showed that Ets-1 negatively regulated BANCR expression via the deacetylation of histones H3 within BANCR promoter. Ets-1 overexpression inhibited fentanyl-induced effects that could be reversed by BANCR co-overexpression | 26296467 | |
EL0227 | BANCR | melanoma | microarray, RNA-seq, qPCR etc. | cell lines (293T, sk-mel-5, Colo-829 etc.) | up-regulated | N/A | BRAF-regulated lncRNA 1 (BANCR) was identified as a recurrently overexpressed, previously unannotated 693-bp transcript on chromosome 9 with a potential functional role in melanoma cell migration. | 22581800 | LncRNADisease Lnc2Cancer |
EL0227 | BANCR | melanoma | N/A | N/A | N/A | regulation | This screen revealed a 693 bp novel lncRNA transcript, named BRAF-activated non-coding RNA (BANCR).Depletion of BANCR in melanoma cells resulted in profound migration defects, indicating a significant role of BANCR in regulation of melanoma cell motility. | 24115003 | LncRNADisease |
EL0227 | BANCR | gastric cancer | qPCR etc. | gastric cancer tissue | up-regulated | interaction | In our results, the expression of BANCR was increased in gastric cancer tissues compared with paired adjacent normal tissues. Moreover, high expression of BANCR was positively associated with clinical stage, tumor depth, lymph node metastasis and distant metastasis in gastric cancer patients. BANCR overexpression was an independent unfavorable prognostic biomarker for gastric cancer patients. | 26054683 | Lnc2Cancer |
EL0227 | BANCR | retinoblastoma | qPCR, knockdown etc. | retinoblastoma tissue, cell lines (Weri-Rb1, Y79) | up-regulated | expression | In our results, lncRNA BANCR is overexpressed in retinoblastoma tissues and cell lines and is associated with tumor size, choroidal invasion, and optic nerve invasion. lncRNA BANCR plays a significant role in retinoblastoma aggressiveness and prognosis and may act as a promising target for therapeutic strategy and prognostic prediction. | 25894373 | Lnc2Cancer |
EL0227 | BANCR | papillary thyroid carcinoma | qPCR, knockdown, RIP, FCA etc. | PTC tissue, cell line (IHH-4) | up-regulated | interaction | The expression of BANCR was significantly up-regulated while PTCSC3 and NAMA were significantly down-regulated in papillary thyroid carcinoma (PTC) compared to that in normal tissue. BANCR-knockdown in a PTC-derived cell line (IHH-4) resulted in significant suppression of thyroid stimulating hormone receptor (TSHR). BANCR-knockdown also led to inhibition of cell growth and cell cycle arrest at G0/G1 phase through down-regulation of cyclin D1. In addition, BANCR was enriched by polycomb enhancer of zeste homolog 2 (EZH2), and silencing BANCR led to decreased chromatin recruitment of EZH2, which resulted significantly reduced expression of TSHR. | 26323637 | Lnc2Cancer |
EL0227 | BANCR | colorectal cancer | qPCR, Western blot etc. | colorectal cancer tissue | up-regulated | N/A | The quantitative polymerase chain reaction results showed that BANCR was frequently overexpressed in cancer tissues and this overexpression was found to significantly correlate with lymph node metastasis and tumour stage. The ectopic expression of BANCR contributed to the migration of human CRC Caco-2 cells, whereas knockdown of BANCR inhibited the migration of the HCT116 cells in vitro. Further investigation into the underlying mechanisms responsible for the migratory effects revealed that BANCR induced the epithelial-mesenchymal transition (EMT) through an MEK/extracellular signal-regulated kinase-dependent mechanism as treatment with the MEK inhibitor, U0126 decreased migration and reversed the EMT in the BANCR-overexpressed HCT116 cells. | 25013510 | Lnc2Cancer |
EL0227 | BANCR | lung cancer | qPCR, Western blot etc. | lung cancer tissue, cell lines (NCI-H1688, NCI-H446) | down-regulated | expression | The results showed that BANCR levels were downregulated in LC cells. When BANCR expression was improved by tranfetcion with pcDNA-BANCR vetcor, tumor growth was suppressed.Vise versa, when BANCR was knockdown by si-BANCR, cell proliferation and migration of LC were remarkably promoted. We further found that MAPK pathways were involved in the BANCR-mediated cell proliferation and migration of LC. | 25661343 | Lnc2Cancer |
EL0227 | BANCR | papillary thyroid carcinoma | qPCR, Western blot, FCA etc. | PTC tissue, cells line (IHH-4) | up-regulated | expression | The results revealed that BANCR levels were significantly higher in the PTC tissues and PTC IHH-4 cells compared with the normal controls. Knockdown of BANCR in the IHH-4 cells inhibited proliferation and increased apoptosis of the cells in vitro. Further investigation of the underlying mechanisms revealed that BANCR markedly activated autophagy. Overexpression of BANCR inhibited apoptosis in the IHH-4 cells, whereas inhibition of autophagy stimulated apoptosis in the BANCR-overexpressed cells. BANCR overexpression also increased cell proliferation and the inhibition of autophagy abrogated BANCR overexpression-induced cell proliferation. | 25289082 | Lnc2Cancer |
EL0227 | BANCR | malignant melanoma | qPCR, Western blot, in vitro knockdown etc. | malignant melanoma tissue, cell lines (A-375, 1205Lu, UACC903, CHL-1 and sk-mel-5 etc.) | up-regulated | N/A | BANCR was abnormally overexpressed in human malignant melanoma cell lines and tissues, and increased with tumor stages.The linkage between BANCR and MAPK pathway may provide a novel interpretation for the mechanism of proliferation regulation in malignant melanoma | 24967732 | Lnc2Cancer |
EL0227 | BANCR | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1, NCI-H1975, SK-MES-1 etc.) | down-regulated | expression | Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. | 24655544 | LncRNADisease Lnc2Cancer |
EL0227 | BANCR | colorectal cancer | qPCR, Western blot, knockdown etc. | colorectal cancer tissue, cell lines (SW480, HCT116, RQO, HT-29 etc.) | down-regulated | interaction | In this study, we show that BANCR expression was significantly down-regulated in colorectal cancer tissues compared with normal tissues, and overexpression of BANCR suppressed colorectal cancer cell growth in vitro and in vivo.Down_regulation of BANCR contributes to theproliferation of colorectal cancer cells,at least in part,through the regulation of p21 protein. | 25928067 | Lnc2Cancer |
EL0227 | BANCR | gastric adenocarcinoma | qPCR, Western blot, knockdown, MTT assay etc. | gastric adenocarcinoma tissue, cell lines (BGC823, SGC7901) | up-regulated | interaction | BANCR expression was significantly up-regulated in gastric tumor tissues and gastric cell lines. Down-regulation of BANCR inhibited gastric cancer cell growth and promoted cell apoptosis, and it also contributed to a significant decrease of NF-B1 (P50/105) expression and 3'UTR of NF-B1 activity. Overexpression of NF-B1 reversed the effect of BANCR on cancer cell growth and apoptosis. MiroRNA-9 (miR-9) targeted NF-B1, and miR-9 inhibitor also reversed the effects of BANCR on gastric cancer cell growth and apoptosis. | 26248136 | Lnc2Cancer |
EL0227 | BANCR | hepatocellular carcinoma | quantitative real-time PCR (qRT-PCR), overexpression, downregulation, flow cytometry, and transwell invasion and migration assays | human hepatocellular carcinoma tissues | up-regulated | expression | BANCR may contribute to HCC initiation and progression and would be used as not only a novel prognostic marker but also a potential therapeutic target for this disease. | 26758762 | |
EL0227 | BANCR | osteosarcoma | real-time PCR | osteosarcoma cell lines and clinical specimens | down-regulated | N/A | BANCR expression was significantly associated with large tumor size; MG-63 cell proliferation | 27051014 | |
EL0227 | BANCR | Eosinophilic esophagitis | RNA sequencing | healthy controls and patients with active EoE | up-regulated | expression | Repression of BANCR significantly altered the expression of IL-13-induced proinflammatory genes. | 24920534 | |
EL0227 | BANCR | osteosarcoma | RT-PCR, Western blotting and CCK-8 assay | MG-63 cells | up-regulated | expression | After the construct pcDNA3.1-BANCR (BRAF-regulated lncRNA 1) was transfected into MG-63 cells, RT-PCR, Western blotting and CCK-8 assay showed that BANCR was positively correlated with baicalein. | 25893737 | |
EL0228 | BC002350 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0229 | BC011663 | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | down-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL0230 | BC014579 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. | 26540467 | Lnc2Cancer |
EL0231 | BC017743 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
EL0232 | BC023629 | pancreatic cancer | qPCR etc. | pancreatic cancer tissue, cell lines (Sw1990, PANC-1, BXPC-8 etc.) | up-regulated | expression | We further confirmed the selected 6 up-regulation of LncRNAs in PC tissues and PC cell lines through qPCR. Comparing to 293T cells, the expression of LncRNA AF339813 was significantly increased about 10-fold in PANC-1 cells, 8-fold in SW1990 cells and 8.9-fold in BxCP-3 cells. The other 5 LncRNAs have a certain degree of up-regulation in PC cell lines. | 26045769 | Lnc2Cancer |
EL0233 | BC091525 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0235 | BCAR4 | breast cancer | microarray, qPCR, knockdown etc. | cell lines (ZR-75-1, MCF7, BCAR4 etc.) | differential expression | expression | BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. | 22892392 | LncRNADisease Lnc2Cancer |
EL0235 | BCAR4 | breast cancer | N/A | N/A | N/A | N/A | BCAR4 binding of SNIP1 and PNUTS in response to CCL21 releases the SNIP1's inhibition of p300-dependent histone acetylation, which in turn enables the BCAR4-recruited PNUTS to bind H3K18ac and relieve inhibition of RNA Pol II via activation of the PP1 phosphatase. | 25416949 | LncRNADisease |
EL0235 | BCAR4 | breast cancer | qPCR etc. | cell line (ZR-75-1) | up-regulated | N/A | Breast cancer anti-estrogen resistance 4 (BCAR4), caused OH-TAM resistance and anchorage-independent cell growth in ZR-75-1 cells. | 16778085 | LncRNADisease Lnc2Cancer |
EL0235 | BCAR4 | breast cancer | qPCR etc. | cell line (ZR-75-1) | up-regulated | expression | BCAR4 is expressed in 27% of primary breast tumors. Forced expression of BCAR4 in human ZR-75-1 and MCF7 breast cancer cells resulted in cell proliferation in the absence of estrogen and in the presence of various antiestrogens.BCAR4 may be a good target for treating antiestrogen-resistant breast cancer. | 21506106 | LncRNADisease Lnc2Cancer |
EL0235 | BCAR4 | breast cancer | qPCR, Western blot etc. | cell lines (ZR-75-1, BCAR3, EGFR etc.) | up-regulated | expression | High BCAR4 mRNA levels were associated with poor MFS and overall survival, reflecting tumour aggressiveness. | 20859285 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | esophageal cancer | ISH, Northern hybridization etc. | esophageal cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | cervical cancer | ISH, Northern hybridization etc. | cervical cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | ovarian cancer | ISH, Northern hybridization etc. | ovarian cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | parotid cancer | ISH, Northern hybridization etc. | parotid cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | breast cancer | ISH, Northern hybridization etc. | breast cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | tongue cancer | ISH, Northern hybridization etc. | tongue cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | lung cancer | ISH, Northern hybridization etc. | lung cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | breast cancer | microarray, ISH etc. | breast cancer tissue | up-regulated | expression | In ductal carcinomas in situ, furthermore, significant BC200 (BCYRN1) expression was associated with high nuclear grade, suggesting that the presence of BC200 RNA in such tumors may be used as a prognostic indicator of tumor progression. | 15240511 | LncRNADisease Lnc2Cancer |
EL0237 | BCYRN1 | Alzheimer's disease | N/A | N/A | N/A | expression | In normal aging, BC200 levels in cortical areas were reduced by >60% between the ages of 49 and 86. In contrast, BC200 RNA was significantly up-regulated in AD brains, in comparison with age-matched normal brains. | 17553964 | LncRNADisease |
EL0237 | BCYRN1 | Alzheimer's disease | N/A | N/A | N/A | expression | Increased levels of BC200 were found in brain regions that are preferentially affected in AD. Further, in advanced stages of AD, BC200 was mis-localized and clustered in the perikaryon. These observations suggest that deregulation of these synaptic lncRNAs is involved in the synaptic and neural network dysfunction that is found in both early and later stages of AD. | 20380817 | LncRNADisease |
EL0237 | BCYRN1 | Alzheimer's disease | N/A | N/A | N/A | expression | BC200 levels in Brodmann's area 9 (the area of brain affected in AD) were found to be higher in age-matched AD brains compared with normal brains, and the relative levels of BC200 RNA in affected areas increased with the severity of AD. | 23562612 | LncRNADisease |
EL0237 | BCYRN1 | ovarian cancer | ovarian cancer tissue and normal ovarian tissue samples | ovarian cancer tissue and normal ovarian tissue samples | up-regulated | N/A | tumor suppressive function in ovarian cancer by affecting cell proliferation | 26893717 | |
EL0237 | BCYRN1 | glioma | qPCR etc. | cell lines(U251, U87) | down-regulated | expression | MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. | 25645334 | Lnc2Cancer |
EL0237 | BCYRN1 | non-small-cell lung cancer | RT-PCR, knowdown, over-expression, ChIP | non-small-cell lung cancer (NSCLC) | up-regulated | expression | These findings uncover a regulatory mechanism in NSCLC cells involving the metastasis-promoting lncRNA BCYRN1 that improves expressions of the key metastasis-supporting proteins MMP9 and MMP13. | 25866480 | |
EL0239 | BDNF-AS | obesity | N/A | N/A | N/A | mutation | Association identified by GWAS (rs4074134, A118887G). | 19079260 | LncRNADisease |
EL0239 | BDNF-AS | obesity | N/A | N/A | N/A | locus | This locus maps near key hypothalamic regulators of energy balance, may be associated with obesity. | 20935630 | LncRNADisease |
EL0239 | BDNF-AS | depression | N/A | N/A | N/A | regulation | The lncRNA BDNF-AS is related to many neurological disorders, including Huntington's disease (HD), schizophrenia, and depression. | 23562612 | LncRNADisease |
EL0239 | BDNF-AS | Huntington's disease | N/A | N/A | N/A | regulation | The lncRNA BDNF-AS is related to many neurological disorders, including Huntington's disease (HD), schizophrenia, and depression. | 23562612 | LncRNADisease |
EL0239 | BDNF-AS | schizophrenia | N/A | N/A | N/A | regulation | The lncRNA BDNF-AS is related to many neurological disorders, including Huntington's disease (HD), schizophrenia, and depression. | 23562612 | LncRNADisease |
EL0239 | BDNF-AS | psychiatric disease | N/A | N/A | N/A | regulation | Examples of recently discovered chromatin-bound long non-coding RNAs important for neuronal health and function include the brain-derived neurotrophic factor antisense transcript (Bdnf-AS) which regulates expression of the corresponding sense transcript, and LOC389023 which is associated with human-specific histone methylation signatures at the chromosome 2q14.1 neurodevelopmental risk locus by regulating expression of DPP10, an auxillary subunit for voltage-gated K(+) channels. | 23831425 | LncRNADisease |
EL0239 | BDNF-AS | Huntington's disease | N/A | N/A | N/A | regulation | Thus, BDNF-AS inhibits BDNF transcription by recruiting EZH2 to the BDNF promoter region and in that way plays an important role in the development of HD. | 24624135 | LncRNADisease |
EL0240 | BE503655 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0242 | BGLT3 | chronic myeloid leukemia | microarray, qPCR, Western blot etc. | cell lines (K562) | up-regulated | N/A | We observed that lncRNA-BGL3 was highly induced in response to disruption of Bcr-Abl expression or by inhibiting Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML patients. Ectopic expression of lncRNA-BGL3 sensitized leukemic cells to undergo apoptosis and inhibited Bcr-Abl-induced tumorigenesis. | 24837367 | Lnc2Cancer |
EL0243 | BISPR | virus infection | RNA-seq, qRT-PCR | cells infected with hepatitis C virus and in the liver of infected patients | up-regulated | expression | lncBST2/BISPR, are increased in cells infected with hepatitis C virus and in the liver of infected patients. These results allow us to hypothesize that several lncRNAs could be activated by IFN to control the potency of the antiviral IFN response. | 25620967 | |
EL0244 | BLACAT1 | bladder cancer | microarray, qPCR, knockdown, ISH etc. | bladder cancer tissue, cell lines (J82, UMUC-3, HT-1376, T24, 5637 etc.) | up-regulated | N/A | qPCR confirmed that linc-UBC1 expression is up-regulated in 60 cases (58.8%) in bladder cancer tissues compared with normal adjacent tissues, and its overexpression correlates with lymph node metastasis and poor survival. Further functional analysis demonstrated that knockdown of linc-UBC1 attenuates bladder cancer cell proliferation, motility, invasion, colony formation ability, tumorigenicity and metastatic potential. RIP and ChIP assay confirmed that linc-UBC1 physically associates with PRC2 complex and regulates histone modification status of target genes. | 23688781 | Lnc2Cancer |
EL0244 | BLACAT1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
EL0244 | BLACAT1 | gastric cancer | qPCR, knockdown etc. | gastric cancer tissue, cell lines (BGC-823, SGC-7901, AGS, MKN-45, HGC-27 etc.) | up-regulated | expression | We found that linc-UBC1 was significantly upregulated in gastric cancer tissues compared to adjacent normal tissues. Furthermore, high linc-UBC1 expression was associated with lymph-node metastasis, tumor size, TNM stage and poorer prognosis. Inhibition of linc-UBC1 suppressed the proliferation, motility and invasion of gastric cancer cells.Inhibition of linc-UBC1 suppressed the proliferation, motility and invasion of gastric cancer cells. | 25755750 | Lnc2Cancer |
EL0245 | BM742401 | gastric cancer | RNA-seq, qPCR, in vitro knockdown etc. | gastric cancer tissue, cell lines (B16F1) | down-regulated | N/A | BM742401 was downregulated in cancer, and its downregulation was associated with poor survival in gastric cancer patients. Ectopic overexpression of BM742401 inhibited metastasis-related phenotypes and decreased the concentration of extracellular MMP9. | 23846333 | Lnc2Cancer |
EL0246 | BOK-AS1 | cancer | N/A | N/A | N/A | expression | The expression of BOKAS was found in testis and certain cancer tissues but not in other normal adult tissues. Overexpression of BOKAS was able to inhibit Bok-induced apoptosis in HeLa cells. | 24757675 | LncRNADisease |
EL0246 | BOK-AS1 | testicular cancer | qPCR etc. | cell line (Hela) | up-regulated | expression | A natural antisense transcript, BOKAS, regulates the pro-apoptotic activity of human Bok. The mRNA expression of BOKAS was only detected in testis and certain cancer tissues but not in other normal adult tissues examined. | 19287972 | LncRNADisease Lnc2Cancer |
EL0246 | BOK-AS1 | esophageal squamous cell carcinoma | qPCR, Western blot, RIP etc. | ESCC tissue | up-regulated | interaction | LncRNA BOKAS was up-regulated following radiation and promoted WISP1 expression and resultant radioresistance.WISP1 facilitated its own expression in response to radiation, creating a positive feedback loop and increased radioresistance. Our study revealed WISP1 as a potential target to overcome radioresistance in ESCC. | 25749038 | Lnc2Cancer |
EL0248 | BPESC1 | blepharophimosis syndrome | N/A | N/A | N/A | mutation | BPESC1 is disrupted by a balanced chromosomal translocation, t(3;4)(q23;p15.2), in a patient with BPES. | 10995571 | LncRNADisease |
EL0250 | Bvht | cardiac lineage | N/A | N/A | N/A | regulation | Boyer et al at Massachusetts Institute of Technology have begun to study lncRNAs important for heart development and have identified a novel lncRNA (AK143260) required for specification of the cardiac lineage in vitro | 23104877 | LncRNADisease |
EL0250 | Bvht | cardiovascular disease | N/A | N/A | N/A | expression | Here, we identified Braveheart (Bvht), a heart-associated lncRNA in mouse. Using multiple embryonic stem cell (ESC) differentiation strategies, we show that Bvht is required for progression of nascent mesoderm toward a cardiac fate. | 23352431 | LncRNADisease |
EL0251 | BX647187 | prostate cancer | qPCR, Western bolt, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, PC3, Du145) | differential expression | interaction | Our results showed that Hec1 mRNA and protein were significantly overexpressed in Human PCa tissues and several PCa cell lines. Silencing Hec1 markedly suppressed proliferation, promoted apoptosis and induced cell-cycle arrest in G2/M-phase in PCa cells. Through bioinformatics analysis and knockdown Hec1 in PCa cells, we found LncRNA BX647187 was positively regulated by Hec1. We further demonstrated that suppression of BX647187 in PCa cells significantly reduced cell proliferation and promoted apoptosis. | 26612002 | Lnc2Cancer |
EL0252 | BX648207 | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116 ,SW1116) | down-regulated | N/A | Functional experiments demonstrated three dysregulated lncRNAs, AK123657, BX648207 and BX649059 were required for efficient invasion and proliferation suppression in CRC cell lines. | 24809982 | Lnc2Cancer |
EL0254 | C1401f132 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
EL0255 | C14orf132 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | down-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL0256 | C1orf74 | gastric cancer | qPCR, Western blot etc. | cell lines (SGC7901, BGC823, SGC7901/DDP, BGC823/DDP etc.) | up-regulated | interaction | The expression of lncRNA AK022798 was significantly higher in all pcDNA3-Notch 1 plasmid treatment groups than in the pcDNA3 plasmid treatment group (P< 0.01).Overexpression of lncRNA AK022798 promotes SGC7901/DDP and BGC823/DDP cells apoptosis.the expression of MRP1 and P-glycoprotein decreased significantly in SGC7901/DDP and BGC823/DDP cells, and their apoptosis as well as the expressions of caspase 3 and caspase 8. | 25763542 | Lnc2Cancer |
EL0257 | PCOTH | prostate cancer | qPCR, Northern blot etc. | prostate cancer tissue, cell lines (LNCaP, DU145, PC-3CaP etc.) | up-regulated | expression | PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. | 15930275 | LncRNADisease Lnc2Cancer |
EL0258 | C2dat1 | cerebral ischemia | knockdown | mouse cortical penumbra | up-regulated | N/A | lncRNA C2dat1 that modulates the expression of CaMKIIδ to impact neuronal survival | 27031970 | |
EL0259 | C530045E16Rik | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 5 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0260 | C5orf66-AS1 | esophageal squamous cell carcinoma | microarray, qPCR etc. | cell lines (KYSE510, KYSE450, KYSE150, KYSE30, EC109, TE-1) | down-regulated | expression | We identified a novel nuclear-retained lncRNA, named Epist, which is generally highly expressed in esophagus, and which is down-regulated during ESCC progression. Epist over-expression and knockdown studies further suggest that Epist inhibits the metastasis, acting as a tumor suppressor in ESCC. Collectively | 26158411 | Lnc2Cancer |
EL0260 | C5orf66-AS1 | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | down-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
EL0261 | C5T1lncRNA | rheumatoid arthritis | knockdown | RA-relevant cell types | N/A | interaction | N/A | 26673966 | |
EL0264 | CACNAICAS3 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | up-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL0265 | CADM1 | clear cell renal cell carcinoma | qPCR, knockdown etc. | renal cancer tissue, cell lines(786-O, ACHN etc.) | down-regulated | interaction | The results showed that CADM1-AS1 expression was down-regulated in tumor tissues in 64 patients with ccRCC compared with adjacent non-tumor tissues. Furthermore, the expression of CADM1-AS1 was positively correlated with the expression of mRNA CADM1 in ccRCC specimens. Decreased CADM1-AS1 expression was correlated with the progression of AJCC stage and worse survival of ccRCC patients. Also, multivariate analysis identified low CADM1-AS1 expression as an independent prognostic factor for ccRCC.CADM1-AS1 is a new tumor suppressor in ccRCC which regulates cell proliferation, apoptosis and migration via the expression pattern of CADM1-AS1/CADM1 mRNA gene pairs. | 25031695 | Lnc2Cancer |
EL0265 | CADM1 | glioma | qPCR, knockdown etc. | glioma cancer tissue, cell lines ( U87, U251, SNB-19 etc.) | down-regulated | expression | The data showed that TSLC1-AS1 expression was down-regulated in tumor tissues compared with that in adjacent normal tissues, and negatively associated with the WHO criteria of the tumors. Overexpression of TSLC1-AS1 resulted in up-regulation of TSLC1 and significant inhibition of cell proliferation, migration and invasion in U87 cells, while knockdown of TSLC1-AS1 in SNB-19 cells showed the opposite effetc. The expression of TSLC1-AS1 was also positively correlated with other tumor suppressors NF1, VHL, PIK3R1 and negatively correlated with the oncogene BRAF. | 25031725 | Lnc2Cancer |
EL0266 | CADM3-AS1 | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | down-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
EL0267 | CAHM | colorectal cancer | qPCR, qMSP etc. | blood, colorectal cancer tissue | down-regulated | N/A | A reverse transcriptase-qPCR assay showed that CAHM RNA levels correlated negatively with CAHM % methylation, and therefore CAHM gene expression is typically decreased in CRC. Both the frequency of detection and the amount of methylated CAHM DNA released into plasma increased with increasing cancer stage. | 24799664 | Lnc2Cancer |
EL0268 | CAI2 | neuroblastoma | qPCR etc. | neuroblastoma tissue, cell line (NMB7) | up-regulated | N/A | Concordant expression of CAI2 with p16 and ARF in normal tissue along with the ability of CAI2 to induce p16 expression suggested that CAI2 may regulate p16 and/or ARF. In neuroblastoma cells transformed by serial passage in vitro, leading to more rapid proliferation, CAI2, p16, and ARF expression all increased dramatically. Consistent with its association with high-risk disease, CAI2 expression was also significantly associated with poor clinical outcomes, although this effect was reduced when adjusted for MYCN amplification. | 25028366 | Lnc2Cancer |
EL0271 | CASC15 | neuroblastoma | RNA-seq, qPCR, knockdown, Luciferase reporter assay, RNA-FISH etc. | Neuroblastoma cell lines | down-regulated | mutation | Here we report that the most highly significant single-nucleotide polymorphism (SNP) associations reside within CASC15, a long noncoding RNA that we define as a tumor suppressor at 6p22. Low-level expression of a short CASC15 isoform (CASC15-S) associated highly with advanced neuroblastoma and poor patient survival. | 26100672 | Lnc2Cancer |
EL0272 | CASC2 | endometrial cancer | N/A | N/A | N/A | mutation | CASC2, in a region of common allelic loss at chromosome 10q26 is a novel candidate gene in human endometrial cancer. | 15024726 | LncRNADisease |
EL0272 | CASC2 | glioma | qPCR, Luciferase reporter assay etc. | glioma tissue, cell lines (U251, U87) | down-regulated | regulation | In this study, we confirmed that CASC2 was lowly expressed in glioma tissues as well as in U251 and U87 glioma cell lines. Overexpression of CASC2 inhibited the malignancy of glioma cells, including proliferation, migration, and invasion, and promoted cell apoptosis.We found that up-regulated CASC2 decreased the expression of miR-21 significantly and there is a reciprocal repression between CASC2 and miR-21 in an Argonaute2-dependent manner. | 25446261 | Lnc2Cancer |
EL0272 | CASC2 | non-small cell lung cancer | qRT-PCR, overexpression | N/A | down-regulated | expression | CASC2 is involved in the development and progression of NSCLC and shows that CASC2 may be a potential diagnostic and target for new therapies in patients with NSCLC. | 26790438 | |
EL0273 | CASC9 | esophageal squamous cell carcinoma | LncRNA array, qRT-PCR, knockdown | Primary tumor tissue from four esophageal squamous cell carcinoma (ESCC) patients. | up-regulated | expression | ESCCAL-1 is overexpressed in 65% of an independent ESCC patient cohort (n=26). More over, knockdown of ESCCAL-1 expression increases esophageal cancer cell apoptosis and reduces the invasion in vitro. ESCCAL-1 is a novel putative onco-lncRNA in esophageal cancer development. | 25885227 | |
EL0273 | CASC9 | esophageal squamous cell carcinoma | lncRNA microarray, qRT-PCT | esophageal squamous cell carcinoma (ESCC) tissue | up-regulated | expression | ESCCAL_1 and HOTAIR may participate in the pathological process of ESCC. Furthermore, lncRNA could be potential diagnostic and prognostic biomarkers for ESCC. | 25297587 | |
EL0273 | CASC9 | esophageal squamous cell carcinoma | microarray, qPCR etc. | ESCC tissue | up-regulated | expression | In addition, we confirmed another two upregulated lncRNAs that are differentially expressed in ESCC and that we have named ESCCAL-1, and ESCCAL-5. | 24222893 | LncRNADisease Lnc2Cancer |
EL0274 | CBR3-AS1 | prostate cancer | N/A | N/A | N/A | regulation | Oncogene; putative therapeutic target | 24373479 | LncRNADisease |
EL0274 | CBR3-AS1 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (KYSE30, KYSE70, KYSE140, KYSE150, KYSE180 etc.) | up-regulated | expression | Upregulation of the long non-coding RNA PlncRNA-1 promotes esophageal squamous carcinoma cell proliferation and correlates with advanced clinical stage. | 24337686 | LncRNADisease Lnc2Cancer |
EL0274 | CBR3-AS1 | prostate cancer | qPCR, Western blot etc. | cell line (LNCaP, PC-3, C4-2 etc.) | up-regulated | Interaction | The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 (CBR3-AS1) modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. | 22264502 | LncRNADisease Lnc2Cancer |
EL0275 | CCAL | colorectal cancer | microarray, qPCR etc. | CRC tissue | up-regulated | interaction | We identified colorectal cancer-associated lncRNA (CCAL) as a key regulator of CRC progression. Patients whose tumours had high CCAL expression had a shorter overall survival and a worse response to adjuvant chemotherapy than patients whose tumours had low CCAL expression.Our results suggest that CCAL is a crucial oncogenic regulator involved in CRC tumorigenesis and progression. | 25994219 | Lnc2Cancer |
EL0276 | CCAT1 | acute myeloid leukemia | gain- and loss-of-function analysis | French-American-British M4 and M5 subtypes of adult AML patients | up-regulated | N/A | repressed monocytic differentiation and promoted cell growth of HL-60 | 26923190 | |
EL0276 | CCAT1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
EL0276 | CCAT1 | gastric cancer | N/A | gastric cancer (GC) cells and tissues | up-regulated | N/A | CCAT1 regulates miR-490 | 26825578 | |
EL0276 | CCAT1 | gastric cancer | N/A | N/A | N/A | expression | Level of lncRNA CCAT1 was markedly increased in gastric carcinoma tissue comparing with normal tissue, and overexpressed CCAT1 promoted cancer cell proliferation and migration | 24757675 | LncRNADisease |
EL0276 | CCAT1 | gastric cancer | N/A | N/A | N/A | expression | Another study reported that lncRNA CCAT1 was up-regulated in gastric carcinoma tissues, and its expression was closely related to the transcription factor c-Myc. | 24833871 | LncRNADisease |
EL0276 | CCAT1 | gastric cancer | qPCR etc. | gastric cancer tissue | up-regulated | expression | AGS human gastric carcinoma cell line showed an elevated level of CCAT1 expression. Expression levels of CCAT1 were approximately 10.8 fold higher in GC samples than in samples taken from the negative control group. Interestingly, CCAT1 expression was significantly overexpressed in adjacent normal tissues when compared to the negative control group. Tissues obtained from recurrent GC cases showed the highest expression levels. Expression levels increased with tumor stage, however this did not reach statistical significance. | 25561974 | Lnc2Cancer |
EL0276 | CCAT1 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | interaction | The expression of IncRNA-CCAT1 in tumor tissue was significantly higher than that in normal para-carcinoma tissue, and the expression level of CCAT1 was significantly correlated with local infiltration depth , tumor staging, vascular invasion and CA19-9 level, it mediates the EMT process of colorectal cancer. | 26064266 | Lnc2Cancer |
EL0276 | CCAT1 | hepatocelluar carcinoma | qPCR etc. | HCC tissue, cell lines (L-02, HepG2, SNU423, SMMC-7721, Hep3B) | up-regulated | expression | The results indicated that the expression of CCAT1 was significantly increased in HCC tissues and cells compared with controls. We also found that the abnormally expressed CCAT1 could promote cell proliferation, migration and invasion. Taken together, our findings demonstrated that the aberrant expression of CCAT1 promotes hepatocellular carcinoma in vitro | 26191246 | Lnc2Cancer |
EL0276 | CCAT1 | hepatocelluar carcinoma | qPCR etc. | Liver cancer cell lines (HepG2, Hep3B, SK-HEP1, SMMC7721, MHCC97-L, MHCC97-H, PLC/PRF/5, HCCLM3) | up-regulated | expression | The results showed that CARLo-5 levels were significantly overexpressed in HCC tissues compared to ANLT. Besides, high expression of CARLo-5 was associated with liver cirrhosis (P = 0.001), tumor number (P < 0.001), vascular invasion (P = 0.001), capsular formation (P = 0.014) and Edmondson-Steiner grade (P < 0.001), which proved that CARLo-5 was an independent risk factor for overall survival and disease-free survival. In addition, in highly metastatic HCC cell lines (HCCLM3 and MHCC97-L), CARLo-5 was up-regulated, but in lowly metastatic HCC cell lines (HepG2, SNU387), it showed down-regulated. Besides, by using gain and loss of function experiments in HCC cell lines (HCCLM3 and HepG2), the results showed that CARLo-5 overexpression significantly enhanced cell proliferation, migration and invasion in vitro. Our study also revealed that CARLo-5 was prominently up-regulated in HCC specimens and its high expression was associated with poor prognosis of HCC patients | 26433964 | Lnc2Cancer |
EL0276 | CCAT1 | breast cancer | qPCR etc. | BC tissue | up-regulated | expression | Expression levels of lncRNA CCAT1 in BC tissues were significantly higher than those in adjacent normal tissues. High expression of lncRNA CCAT1 was associated with differentiation grade, TNM stage, and lymph node metastases. Kaplan-Meier analysis with the log-rank test indicated that high expression of lncRNA CCAT1 had a decreased overall survival and progression-free survival. Multivariable analysis was further identified high expression of lncRNA CCAT1 as an independent prognosis factor for overall survival and progression-free survival. | 26464701 | Lnc2Cancer |
EL0276 | CCAT1 | colorectal cancer | qPCR, ISH etc. | cell lines (SW-480, HT-29, HT29, SW-480 etc.) | up-regulated | expression | Recently, colon cancer associated transcript 1 (CCAT1) lncRNA was found to be expressed in colorectal cancer (CRC) tumors but not in normal tissue. | 23416875 | LncRNADisease Lnc2Cancer |
EL0276 | CCAT1 | colon cancer | qPCR, ISH etc. | colonic adenoma-carcinoma tissue | up-regulated | N/A | CCAT1 is up-regulated across the colon adenoma-carcinoma sequence. This up-regulation is evident in pre-malignant conditions and through all disease stages, including advanced metastatic disease suggesting a role in both tumorigenesis and the metastatic process. | 23594791 | Lnc2Cancer |
EL0276 | CCAT1 | colorectal cancer | qPCR, knockdown etc. | primary prostatecancer tissue | up-regulated | N/A | CARLo-5 is highly expressed in CRC-derived cell lines compared with normal colon-derived fibroblasts and CRC primary tissues compared with their matched normal adjacent tissues (NATs). In addition, CARLo-5 is highly expressed in prostate cancer (PC) tissues compared with their NATs. CARLo-5 is significantly correlated with the rs6983267 allele associated with increased cancer susceptibility. We also found the MYC enhancer region physically interacts with the active regulatory region of the CARLo-5 promoter, suggesting long-range interaction of MYC enhancer with the CARLo-5 promoter regulates CARLo-5 expression. | 24594601 | Lnc2Cancer |
EL0276 | CCAT1 | gallbladder cancer | qPCR, Luciferase reporter assay, Western blot etc. | gallbladder cancer tissue | up-regulated | expression | In this study, we demonstrated that CCAT1 was upregulated in gallbladder cancer (GBC) tissues. CCAT1 silencing downregulated, whereas CCAT1 overexpression enhanced the expression of miRNA-218-5p target gene Bmi1 through competitively 'spongeing' miRNA-218-5p. Our data revealed that CCAT1 knockdown impaired the proliferation and invasiveness of GBC cells, at least in part through affetcing miRNA-218-5p-mediated regulation of Bmi1. Moreover, CCAT1 transcript level was correlated with Bmi1 mRNA level in GBC tissues. | 25569100 | Lnc2Cancer |
EL0276 | CCAT1 | gastric cancer | qPCR, Western blot, in vitro knockdown etc. | gastric cancer tissue | up-regulated | expression | In the present study, a great upregulation of CARLo-5 was observed in gastric cancer compared to paired adjacent normal tissues. Knockdown of CARLo-5 in gastric cancer cell lines significantly inhibited the cell proliferation via inducing G0/G1 cell-cycle arrest and apoptosis. | 25674211 | Lnc2Cancer |
EL0276 | CCAT1 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1, NCI-H1975) | up-regulated | interaction | In the present study, a great upregulation of CARLo-5 was observed in cancer tissues compared to their adjacent normal tissues. Meanwhile, patients with high CARLo-5 expression have significantly poorer prognosis than those with low expression. Inhibition of CARLo-5 by siRNA suppressed the proliferation, migration, and invasion in NSCLC cell lines in vitro. In addition, silencing of CARLo-5 reversed the epithelial-mesenchymal transition in NSCLC cell line. | 25129441 | Lnc2Cancer |
EL0276 | CCAT1 | gastric cancer | qPCR, Western bolt, knockdown, Luciferase reporter assay, RIP etc. | gastric carcinoma tissue, cell lines (AGS, MKN45) | up-regulated | regulation | Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. | 23143645 | LncRNADisease Lnc2Cancer |
EL0277 | CCAT1-L | colorectal cancer | qPCR, in vitro knockdown etc. | cell lines (HT29, HCT116) | up-regulated | N/A | CCAT1-L plays a role in MYC transcriptional regulation and promotes long-range chromatin looping. Importantly, the CCAT1-L locus is located within a strong super-enhancer and is spatially close to MYC. Knockdown of CCAT1-L reduced long-range interactions between the MYC promoter and its enhancers. In addition, CCAT1-L interacts with CTCF and modulates chromatin conformation at these loop regions. | 24662484 | Lnc2Cancer |
EL0278 | CCAT2 | breast cancer | microarray, qPCR, knockdown etc. | breast cancer tissue, cell lines (SUM149, SUM190, MDA-MB-231, MDA-MB-436 etc.) | up-regulated | expression | CCAT2, a novel long non-coding RNA in breast cancer. | 24077681 | LncRNADisease Lnc2Cancer |
EL0278 | CCAT2 | colon cancer | qPCR etc. | colon cancer tissue | up-regulated | interaction | Our results revealed that CCAT1 was significantly overexpressed in colon cancer tissues when compared with normal tissues, and its increased expression was correlated with patients' clinical stage, lymph nodes metastasis, and survival time after surgery. Moreover, c-Myc could promote CCAT1 transcription by diretcly binding to its promoter region, and upregulation of CCAT1 expression in colon cancer cells promoted cell proliferation and invasion. | 25185650 | Lnc2Cancer |
EL0278 | CCAT2 | esophageal squamous cell carcinoma | qPCR etc. | ESCC tissue, cell lines (KYSE410) | up-regulated | expression | In silico analysis showed that no CpG island is found in the chromosome region of CCAT2, indicating that the expression of CCAT2 is possibly not regulated by DNA methylation.Compared with paired adjacent normal esophageal tissues, CCAT2 was significantly overexpressed in ESCC tissues with an average fold of 7.18. In ESCC cell lines, CCAT2 was mostly upregulated in KYSE410 cell when normalized to normal esophageal epithelium cell line (HEEC) and most CCAT2 transcripts were located in nucleus (>95 %). Statistical analysis showed that CCAT2 expression level was significantly associated with smoking status. | 25677908 | Lnc2Cancer |
EL0278 | CCAT2 | esophageal squamous cell carcinoma | qPCR etc. | ESCC tissue | up-regulated | expression | CCAT2 was upregulated in ESCC tissues, especially in cases with lymph node metastasis (LNM), advanced TNM stages, and MYC amplification. Furthermore, the level of CCAT2 was positively correlated with TNM stages, LNM, and the number of positive lymph nodes. High CCAT2 expression and MYC amplification were significantly associated with TNM stages and LNM. CCAT2 may have great potential prognostic value for assessing postoperative ESCC patients. | 25919911 | Lnc2Cancer |
EL0278 | CCAT2 | non-small cell lung cancer | qPCR, knockdown etc. | NSCLC tissue, cell lines (A549, NCI-H1975, NCI-H358, NCI-H1650, NCI-H1299, SK-MES-1 etc.) | up-regulated | regulation | CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. | 24504682 | LncRNADisease Lnc2Cancer |
EL0278 | CCAT2 | gastric cancer | qPCR, knockdown etc. | gastric cancer tissue, cell lines (BGC-823, SGC-7901, AGS, MKN-45, HGC-27 etc.) | up-regulated | expression | Expression levels of lncRNA CCAT2 in gastric cancer tissues were significantly higher than those in adjacent non-tumor tissues. By statistical analyses, high lncRNA CCAT2 expression was observed to be closely correlated with higher incidence of lymph node metastasis and distance metastasis. Moreover, patients with high lncRNA CCAT2 expression had shorter overall survival and progression-free survival compared with the low lncRNA CCAT2 group. | 25755774 | Lnc2Cancer |
EL0278 | CCAT2 | colorectal cancer | qPCR, RIP etc. | CRC tissue, cell lines (COLO320DM, HCT116, RKO, HEK293 etc.) | up-regulated | N/A | Here, we report that CCAT2, a novel long noncoding RNA transcript (lncRNA) encompassing the rs6983267 SNP, is highly overexpressed in microsatellite-stable colorectal cancer and promotes tumor growth, metastasis, and chromosomal instability. Our results support a new mechanism of MYC and WNT regulation by the novel lncRNA CCAT2 in colorectal cancer pathogenesis, and provide an alternative explanation on the SNP-conferred cancer risk. | 23796952 | Lnc2Cancer |
EL0278 | CCAT2 | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue and adjacent normal breast tissue, cell lines (MDA-MB-231, MCF-7) | up-regulated | interaction | We first confirmed the high expression level of CCAT2 in breast cancer tissues and breast cancer cell lines by reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay, and we further analyzed the relationship between CCAT2 expression and clinical prognostic factors. Also, the biological function of CCAT2 was explored and the results showed silencing of CCAT2 could suppress cell growth in vitro and tumor formation in vivo. Finally, our results revealed that the abnormal expression of CCAT2 could influence the Wnt signaling pathway. | 26442763 | Lnc2Cancer |
EL0278 | CCAT2 | cervical squamous cell cancer | qRT-PCR | 123 cervical squamous cell tumor specimens | up-regulated | expression | High expression of lncRNA CCAT2 is related to the prognosis of cervical squamous cell cancer. | 26722527 | |
EL0278 | CCAT2 | cervical cancer | quantitative real-time PCR | cervical cancer cell lines | up-regulated | N/A | CCAT2 knockdown inhibited cell proliferation in HeLa, CaSki and SiHa cells | 26983975 | |
EL0279 | CCAT3 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
EL0280 | CCAT7 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | down-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
EL0281 | CCAT8 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | down-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
EL0282 | CCDC26 | acute myeloid leukemia | microarray, qPCR, Western blot etc. | cell lines (HL-60, K562 etc.) | up-regulated | interaction | We found that CCDC26 transcripts were abundant in the nuclear fraction of K562 human myeloid leukemia cells. We suggest that CCDC26 controls growth of myeloid leukemia cells through regulation of KIT expression.A KIT inhibitor might be an effective treatment against the forms of AML in which CCDC26 is altered. | 25928165 | Lnc2Cancer |
EL0282 | CCDC26 | glioma | N/A | N/A | N/A | mutation | In the pooled analysis, the odds ratio for low-grade glioma associated with rs55705857 was 4.3 (P = 2.31 脳 10(-94)). rs55705857 maps to a highly evolutionarily conserved sequence within the long non-coding RNA CCDC26 raising the possibility of direct functionality. | 23399484 | LncRNADisease |
EL0283 | CCEPR | cervical cancer | qPCR, Western blot, knockdown, RNA pull-down assay etc. | cervical cancer tissue, cell lines (HeLa, SiHa) | up-regulated | interaction | In this study, we found that cervical carcinoma high-expressed lncRNA 1 (lncRNA-CCHE1) was significantly upregulated in cervical cancer tissues. The higher expression of CCHE1 was significantly correlated with large tumor size, advanced Federation of Gynecology and Obstetrics stage, uterine corpus invasion, and poor survival. CCHE1 plays a pivotal role in cervical cancer cell proliferation via increasing PCNA expression and serves as a potential prognostic biomarker and therapeutic target in human cervical cancer. | 25921283 | Lnc2Cancer |
EL0285 | CCND1 | tumor | N/A | N/A | N/A | regulation | Binding to TLS protein induces TLS allosteric change, allowing interaction with cyclin D1, inhibiting CBP and p300 activity, and silencing cyclin D1 gene expression. | 22996375 | LncRNADisease |
EL0285 | CCND1 | cervical cancer | qPCR etc. | cell line (CaSki) | up-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | LncRNADisease Lnc2Cancer |
EL0287 | CD99P1 | idiopathic pulmonary fibrosis | RT-PCR | lungs of IPF (idiopathic pulmonary fibrosis) patients | up-regulated | expression | Further studies revealed that silencing the lncRNA CD99 molecule pseudogene 1 (CD99P1) inhibited proliferation and α-smooth muscle actin expression of lung fibroblasts | 26269497 | |
EL0288 | Cdc28 lncRNA | osmostress | whole-genome tiling arrays | N/A | N/A | interaction | Cdc28 lncRNA mediates the establishment of gene looping and the relocalization of Hog1 and RSC from the 3' UTR to the +1 nucleosome to induce CDC28 expression. | 24508389 | |
EL0289 | CDKN2B-AS1 | acute lymphoblastic leukemia | MassARRAY assay etc. | acute lymphoblastic leukemia tissue | differential expression | mutation | rs564398 (A>G), mapping to the CDKN2BAS locus that encodes for ANRIL antisense non-coding RNA, showed a statistically significant correlation with the ALL phenotype, with a risk pattern that was compatible with an overdominant model of disease susceptibility. | 21414664 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | neurofibromatosis type 1 | microarray, qPCR etc. | blood | up-regulated | mutation | Single-nucleotide polymorphism rs2151280 (C>T, located in ANRIL) was statistically significantly associated with the number of PNFs (P < .001) in NF1 patients. In addition, allele T of rs2151280 was statistically significantly associated with reduced ANRIL transcript levels (P < .001), suggesting that modulation of ANRIL expression mediates PNF susceptibility. | 22034633 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs (rs2891168, A>G) in the ANRIL locus on chromosome 9p. | 18048406 | LncRNADisease |
EL0289 | CDKN2B-AS1 | acute lymphoblastic leukemia | N/A | N/A | N/A | expression | Higher p15AS levels were often found in acute lymphoblastic (ALL) and myeloid leukemias (AML). | 21874119 | LncRNADisease |
EL0289 | CDKN2B-AS1 | acute myocardial infarction | N/A | N/A | N/A | N/A | Level of ANRIL was lower in patients with MI (P=0.003)Patients with ST-segment-elevation MI had lower level of ANRIL (P<0.001)when compared with patients with non-ST-segment-elevation MI. | 25035150 | LncRNADisease |
EL0289 | CDKN2B-AS1 | melanoma | N/A | N/A | N/A | mutation | Association identified by GWAS. | 17440112 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. | 17463248 | LncRNADisease |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Association identified by GWAS. | 17463249 | LncRNADisease |
EL0289 | CDKN2B-AS1 | myocardial infarction | N/A | N/A | N/A | mutation | Association identified by GWAS. | 17478679 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary disease | N/A | N/A | N/A | mutation | Association identified by GWAS (rs10757274, A>G;rs2383206, A>G). | 17478681 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary artery disease | N/A | N/A | N/A | mutation | Sequence polymorphisms in a 58-kilobase (kb) interval on chromosome 9p21 confer a markedly increased risk (rs3217992, A>G;rs1063192, C>T) of coronary artery disease (CAD), the leading cause of death worldwide. | 17554300 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary artery disease | N/A | N/A | N/A | mutation | Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs (rs2891168, A>G) in the ANRIL locus on chromosome 9p. | 18048406 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Alzheimer's disease | N/A | N/A | N/A | mutation | Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. | 18761660 | LncRNADisease |
EL0289 | CDKN2B-AS1 | intracranial aneurism | N/A | N/A | N/A | mutation | Association identified by GWAS (rs1333040, C>T). | 18997786 | LncRNADisease |
EL0289 | CDKN2B-AS1 | myocardial infarction | N/A | N/A | N/A | mutation | association identified by GWAS (rs4977574, A>G). | 19198609 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary disease | N/A | N/A | N/A | locus | CHD and periodontitis are genetically related by at least one susceptibility locus, which is possibly involved in ANRIL activity and independent of diabetes associated risk variants within this region. Elucidation of the interplay of ANRIL transcript variants and their involvement in increased susceptibility to the interactive diseases CHD and periodontitis promises new insight into the underlying shared pathogenic mechanisms of these complex common diseases. | 19214202 | LncRNADisease |
EL0289 | CDKN2B-AS1 | periodontitis | N/A | N/A | N/A | locus | CHD and periodontitis are genetically related by at least one susceptibility locus, which is possibly involved in ANRIL activity and independent of diabetes associated risk variants within this region. Elucidation of the interplay of ANRIL transcript variants and their involvement in increased susceptibility to the interactive diseases CHD and periodontitis promises new insight into the underlying shared pathogenic mechanisms of these complex common diseases. | 19214202 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | mutation | Genotypes of rs10757278 linked to increased risk of atherosclerotic diseases are also associated with decreased expression in PBTL of the INK4/ARF locus, near CDKN2B-AS1 locus. | 19343170 | LncRNADisease |
EL0289 | CDKN2B-AS1 | aortic aneurysm | N/A | N/A | N/A | expression | Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. | 19343170 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary artery disease | N/A | N/A | N/A | expression | Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. | 19343170 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Stroke | N/A | N/A | N/A | expression | Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. | 19343170 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glioma | N/A | N/A | N/A | mutation | Variants (rs1412829, C>T) in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. | 19578366 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glioma | N/A | N/A | N/A | mutation | Association identified by GWAS. | 19578367 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | expression | 9p21.3 may promote atherosclerosis by regulating expression of ANRIL, which in turn is associated with altered expression of genes controlling cellular proliferation pathways. | 19592466 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary artery disease | N/A | N/A | N/A | expression | Whole blood RNA expression of the short variants of ANRIL was increased by 2.2-fold whereas expression of the long ANRIL variant was decreased by 1.2-fold in healthy subjects homozygous for the risk allele. Expression levels of the long and short ANRIL variants were positively correlated with that of the cyclin-dependent kinase inhibitor, CDKN2B (p15) and TDGF1 (Cripto), respectively. | 19592466 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | mutation/expression | Transcripts EU741058 and NR_003529 of antisense noncoding RNA in the INK4 locus (ANRIL) were significantly increased in carriers of the risk haplotype. | 20056914 | LncRNADisease |
EL0289 | CDKN2B-AS1 | intracranial aneurism | N/A | N/A | N/A | locus | We also confirmed prior associations near CDKN2A-CDKN2B locus. | 20364137 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary disease | N/A | N/A | N/A | mutation | Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. | 20386740 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | Stroke | N/A | N/A | N/A | mutation | Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. | 20386740 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. | 20386740 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | familial and sporadic intracranial aneurysms | N/A | N/A | N/A | mutation | All 6 index cases from IA families had the rs1333040-T allele (C>T) in CDKN2BAS. | 20395613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | breast cancer | N/A | N/A | N/A | locus | A locus associated with breast cancer. | 20453838 | LncRNADisease |
EL0289 | CDKN2B-AS1 | nasopharyngeal carcinoma | N/A | N/A | N/A | mutation | A SNP rs1412829 (C49137T) at CDKN2A-CDKN2B gene cluster on 9p21 is associated with this disease. | 20512145 | LncRNADisease |
EL0289 | CDKN2B-AS1 | endometriosis | N/A | N/A | N/A | mutation | The authors identified a significant association of endometriosis with rs10965235 (A>C, P = 5.57 x 10(-12), odds ratio = 1.44), which is located in CDKN2BAS on chromosome 9p21, encoding the cyclin-dependent kinase inhibitor 2B antisense RNA.the SNP showing the strongest association was located in intron 16 of CDKN2BAS and was implicated in regulating the expression of p15, p16 and p14. | 20601957 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | Interaction | ANRIL abundantly expressed in atherosclerotic lesions. ANRIL DQ485454 which is not genetically determined by the 9p21 genotype was significantly correlated with MTAP expression. | 20637465 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cardiovascular disease | N/A | N/A | N/A | mutation | Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. | 20716961 | LncRNADisease |
EL0289 | CDKN2B-AS1 | basal cell carcinoma | N/A | N/A | N/A | mutation | More recent GWAS also identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for gliomas and basal cell carcinomas in accordance with the princeps observation. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | breast cancer | N/A | N/A | N/A | mutation | More recently, additional GWAS identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for several cancers including breast cancer, nasopharyngeal carcinoma, basal cell carcinoma, and glioma. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary disease | N/A | N/A | N/A | mutation | Common disease genome wide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T) shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glioma | N/A | N/A | N/A | mutation | More recent GWAS also identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for gliomas and basal cell carcinomas in accordance with the princeps observation. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | intracranial aneurism | N/A | N/A | N/A | mutation | Common disease genomewide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T)shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | nasopharyngeal carcinoma | N/A | N/A | N/A | mutation | More recently, additional GWAS identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for several cancers including breast cancer, nasopharyngeal carcinoma, basal cell carcinoma, and glioma. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Common disease genomewide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T) shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | basal cell carcinoma | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | breast cancer | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary disease | N/A | N/A | N/A | locus | A genetic susceptibility locus | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glioma | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | intracranial aneurism | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | melanoma | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | nasopharyngeal carcinoma | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
EL0289 | CDKN2B-AS1 | abdominal aortic aneurysm | N/A | N/A | N/A | mutation | Genetic risk (rs10757278, A>G) for abdominal aortic aneurysm. | 21146954 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | Interaction | RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15(INK4B) locus. | 21151178 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | mutation | Individuals homozygous for the atherosclerotic risk allele (rs3217992, A>G;rs1063192, C>T) show decreased expression of ANRIL. | 21151960 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glaucoma | N/A | N/A | N/A | mutation | Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1 (rs4977756, A>G). | 21532571 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | expression | Gene expression studies have found that expression levels of CDKN2A/CDKN2B/ANRIL are co-regulated and associated with the risk haplotype and atherosclerosis severity. | 21550161 | LncRNADisease |
EL0289 | CDKN2B-AS1 | melanoma | N/A | N/A | N/A | mutation | A large germline deletion (403231 bp) encompassing the INK4/ARF locus and the ANRIL lncRNA has been associated with hereditary cutaneous malignant melanoma (CMM) and neural system tumors (NST) syndrome. | 21550244 | LncRNADisease |
EL0289 | CDKN2B-AS1 | neural system tumors syndrome | N/A | N/A | N/A | mutation | A large germline deletion (403231 bp) encompassing the INK4/ARF locus and the ANRIL lncRNA has been associated with hereditary cutaneous malignant melanoma (CMM) and neural system tumors (NST) syndrome. | 21550244 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Stroke | N/A | N/A | N/A | mutation | Variants (rs3217992, A>G;rs1063192, C>T) on chromosome 9p21.3 correlated with ANRIL expression contribute to stroke risk and recurrence in a large prospective stroke population. | 22034006 | LncRNADisease |
EL0289 | CDKN2B-AS1 | peripheral artery disease | N/A | N/A | N/A | mutation | SNP rs2383207 on ANRIL was most significantly associated with lower ABI. | 22122968 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | mutation | The risk alleles for atherosclerosis-related phenotypes were consistently associated with a lower expression of ANRIL when evaluating exons 1-2. Common carotid artery stenosis was associated with a significantly lower (P<0.01) expression of ANRIL (exons 1-2). ANRIL knock-down in VSMC caused significant variation in expression of CDKN2A/B (P<0.05) and reduction of cell growth (P<0.05) in vitro. | 22178423 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glioma | N/A | N/A | N/A | mutation | Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders | 22814587 | LncRNADisease |
EL0289 | CDKN2B-AS1 | plexiform neurofibroma | N/A | N/A | N/A | mutation | Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders | 22814587 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Stroke | N/A | N/A | N/A | mutation | Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders | 22814587 | LncRNADisease |
EL0289 | CDKN2B-AS1 | acute lymphoblastic leukemia | N/A | N/A | N/A | expression | Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate | 22817756 | LncRNADisease |
EL0289 | CDKN2B-AS1 | melanoma | N/A | N/A | N/A | expression | Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate | 22817756 | LncRNADisease |
EL0289 | CDKN2B-AS1 | neuroblastoma | N/A | N/A | N/A | expression | Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate | 22817756 | LncRNADisease |
EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate | 22817756 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Stroke | N/A | N/A | N/A | expression | Genetic variants that affect the expression of the ANRIL transcript have been correlated with stroke risk and recurrence in a large prospective study | 22817756 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | mutation | Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T4D | 22928560 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary disease | N/A | N/A | N/A | mutation | Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T2D | 22928560 | LncRNADisease |
EL0289 | CDKN2B-AS1 | intracranial aneurism | N/A | N/A | N/A | mutation | Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T3D | 22928560 | LncRNADisease |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T5D | 22928560 | LncRNADisease |
EL0289 | CDKN2B-AS1 | leukemia | N/A | N/A | N/A | regulation | Gene silencing of INK4b-ARF-INK4a and p15/CDKN2B by recruitment of PRC1 and PRC2. | 22996375 | LncRNADisease |
EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | regulation | Gene silencing of INK4b-ARF-INK4a and p15/CDKN2B by recruitment of PRC1 and PRC2. | 22996375 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | expression | ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. | 23104877 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cardiovascular disease | N/A | N/A | N/A | expression | ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. | 23104877 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary artery disease | N/A | N/A | N/A | expression | However, overexpression of 1 ANRIL variant altered the expression of many genes involved in nuclear regulation and chromatin architecture, indicating diverse trans-regulatory effects that go beyond the cis-effects seen at 9p21. | 23104877 | LncRNADisease |
EL0289 | CDKN2B-AS1 | diabetes mellitus | N/A | N/A | N/A | expression | ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. | 23104877 | LncRNADisease |
EL0289 | CDKN2B-AS1 | endometriosis | N/A | N/A | N/A | expression | ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. | 23104877 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glaucoma | N/A | N/A | N/A | expression | ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. | 23104877 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glaucoma | N/A | N/A | N/A | mutation | CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States. | 23111177 | LncRNADisease |
EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | ANRIL, also upregulated in prostate cancer, is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15. | 23463798 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | expression | Another lncRNA associated with human cancers is ANRIL, a long, antisense transcript found in the INK4a/Arf locus. ANRIL is overexpressed in human leukemias and prostate cancers, and its expression leads to epigenetic silencing of the nearby tumor suppressor p15 (Yu et al., 2008; Yap et al., 2010). | 23473599 | LncRNADisease |
EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT1: colorectal cancer). | 23660942 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Alzheimer's disease | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | diabetes mellitus | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glaucoma | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | glioma | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | intracranial aneurism | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | plexiform neurofibroma | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Stroke | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | regulation | The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. | 23813974 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | regulation | The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. | 23813974 | LncRNADisease |
EL0289 | CDKN2B-AS1 | periodontitis | N/A | N/A | N/A | regulation | The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. | 23813974 | LncRNADisease |
EL0289 | CDKN2B-AS1 | atherosclerosis | N/A | N/A | N/A | mutation | Chr9p21 encodes the long non-coding RNA (ncRNA) antisense non-coding RNA in the INK4 locus (ANRIL). ANRIL expression is associated with the Chr9p21 genotype and correlated with atherosclerosis severity | 23861667 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cardiovascular disease | N/A | N/A | N/A | regulation | Recently, ANRIL, a multi-exonic lncRNA, has been shown to be implicated in epigenetic modulation in cardiac development and adult heart and also it has been associated with a locus implicated in cardiovascular disease. | 24113581 | LncRNADisease |
EL0289 | CDKN2B-AS1 | Stroke | N/A | N/A | N/A | expression | Levels of CDKN2B-AS1/ANRIL in human carotid atherosclerotic plaques and peripheral blood T lymphocytes are linked to rates of ischemic and hemorrhagic stroke. | 24145019 | LncRNADisease |
EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | regulation | ANRIL is an antisense lncRNA elevated in PCa that overlaps this locus, interacting directly with polycomb repressive complex 1 and histone H3K27 methylation to repress CDKN2A-CDKN2B expression | 24146262 | LncRNADisease |
EL0289 | CDKN2B-AS1 | ischemic stroke | N/A | N/A | N/A | regulation | Regulation of CARD8 expression by ANRIL and association of CARD8 single nucleotide polymorphism rs2043211 (p.C10X) with ischemic stroke. | 24385277 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cardiovascular disease | N/A | N/A | N/A | mutation | Aberrant ANRIL transcripts and mutations were associated with cardiovascular disease and cancer . | 24531795 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cardiovascular disease | N/A | N/A | N/A | mutation | Aberrant ANRIL transcripts and mutations were associated with cardiovascular disease and cancer . | 24531795 | LncRNADisease |
EL0289 | CDKN2B-AS1 | hereditary cutaneous malignant melanoma | N/A | N/A | N/A | N/A | Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). | 24624135 | LncRNADisease |
EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | N/A | Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). | 24624135 | LncRNADisease |
EL0289 | CDKN2B-AS1 | tumor | N/A | N/A | N/A | N/A | Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). | 24624135 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | locus | Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. | 24624135 | LncRNADisease |
EL0289 | CDKN2B-AS1 | coronary disease | N/A | N/A | N/A | locus | Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. | 24624135 | LncRNADisease |
EL0289 | CDKN2B-AS1 | intracranial aneurism | N/A | N/A | N/A | locus | Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. | 24624135 | LncRNADisease |
EL0289 | CDKN2B-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | locus | Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. | 24624135 | LncRNADisease |
EL0289 | CDKN2B-AS1 | tumor | N/A | N/A | N/A | regulation | ANRIL, GAS5 and lincRNA-p23 are involved in the escape of growth suppression by regulating tumor suppressor genes (ANRIL) or apoptosis regulators. | 24667321 | LncRNADisease |
EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | ANRIL is upregulated in prostate cancer and is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15 (Yap et al., 2010; Kotake et al., 2011). | 24721780 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | expression | High expression of ANRIL has been found in certain cancer tissues such as melanoma and prostate cancers? | 24757675 | LncRNADisease |
EL0289 | CDKN2B-AS1 | nasopharyngeal carcinoma | N/A | N/A | N/A | mutation | In recent years, GWAS has identified ANRIL as a risk locus for NPC and other cancers. | 24817925 | LncRNADisease |
EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | regulation | It has also been shown that the tumor suppressor gene p15 is silenced by its natural antisense RNA, a lncRNA ANRIL. | 24829860 | LncRNADisease |
EL0289 | CDKN2B-AS1 | endometriosis | N/A | N/A | N/A | mutation | Rs10965235 SNP in the CDKN2B-AS gene was significantly associated with endometriosis in this Korean population. | 25154675 | LncRNADisease |
EL0289 | CDKN2B-AS1 | breast cancer | qPCR etc. | breast cancer tissue | up-regulated | expression | Expression of ANRIL mainly coclustered with p14/ARF both in physiologic (various normal human tissues) and in pathologic conditions (human breast tumors). | 17440112 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | melanoma | qPCR etc. | melanoma tissue | differential expression | mutation | Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. | 20386740 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | glioma | qPCR etc. | glioma tissue | differential expression | mutation | Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. | 20386740 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | prostate cancer | qPCR etc. | cell lines (PC3, MEFs, IMR90 etc.) | up-regulated | Interaction | Here we report that chromobox 7 (CBX7) within the polycomb repressive complex 1 binds to ANRIL, and both CBX7 and ANRIL are found at elevated levels in prostate cancer tissues. | 20541999 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | cervical cancer | qPCR etc. | cell line (CaSki) | up-regulated | expression | Down-regulated in cells were incubated in the presence of BLM for 24 h or irradiated. | 22487937 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | up-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | acute lymphoblastic leukemia | qPCR, knockdown etc. | cell lines (KG-1, Kasumi-1) | up-regulated | N/A | We found an inverse relation between p15 antisense (p15AS) and p15 sense expression in leukaemia. A p15AS expression construct induced p15 silencing in cis and in trans through heterochromatin formation but not DNA methylation; the silencing persisted after p15AS was turned off, although methylation and heterochromatin inhibitors reversed this process. Moreover, 11 out of 16 patient samples (69%) showed relatively increased expression of p15AS and downregulated p15 expression (6/11 in acute myeloid leukaemia and 5/5 in acute lymphoblastic leukaemia). In contrast, 16 normal controls showed high expression of p15 but relatively low expression of the p15AS. Additionally, the two acute myeloid leukaemia lines, which displayed high p15AS and low p15 expression. | 18185590 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | acute myeloid leukemia | qPCR, knockdown etc. | cell lines (KG-1, Kasumi-1) | up-regulated | N/A | We found an inverse relation between p15 antisense (p15AS) and p15 sense expression in leukaemia. A p15AS expression construct induced p16 silencing in cis and in trans through heterochromatin formation but not DNA methylation; the silencing persisted aftp15AS was turned off, although methylation and heterochromatin inhibitors reversed this process. Moreover, 11 out of 16 patient samples (69%) showed relatively increased expression of p15AS and downregulated p15 expression (6/11 in acute myeloid leukaemia and 5/5 in acute lymphoblastic leukaemia). In contrast, 16 normal controls showed high expression of p15 but relatively low expression of the p15AS. Additionally, the two acute myeloid leukaemia lines, which displayed high p15AS and low p15 expression.on. | 18185590 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | hepatocelluar carcinoma | qPCR, knockdown etc. | HCC tissue, cell lines ((HepG2 etc.) | up-regulated | expression | LncRNA ANRIL expression in HCC tissues was significantly higher than in the adjacent non-tumor tissues (P < 0.05). The expression of lncRNA ANRIL was remarkably associated with the histologic grade and TNM stage of HCC patients (P < 0.05). In addition, HCC patients with higher lncRNA ANRIL expression had significantly poorer overall survival (P < 0.05).Moreover, in vitro assays revealed that the decreased expression of lncRNA ANRIL could suppress the cell proliferation, migration and invasion HCC cells. | 26045820 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | cervical cancer | qPCR, knockdown etc. | cell lines (HeLa) | up-regulated | interaction | qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. | 26408699 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | non-small cell lung cancer | qPCR, knockdown etc. | cell lines (ABC-1, H1299) | up-regulated | expression | qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. | 26408699 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | osteosarcoma | qPCR, knockdown etc. | cell lines (Saos-2) | up-regulated | expression | qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. | 26408699 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | non-small cell lung cancer | qPCR, Western blot etc. | NSCLC tissue, cell lines (PC9, SPC-A1, NCI-H1975, H1299, H358) | up-regulated | expression | In this study, we reported that ANRIL expression was increased in NSCLC tissues and Its expression level was significantly correlated with TNM stages and tumor size. Moreover, patients with high levels of ANRIL expression had a relatively poor prognosis. In addition, taking advantage of loss of function experiments in NSCLC cells, we found that knockdown of ANRIL expression could impair cell proliferation and induce cell apoptosis both in vitro and vivo. | 25504755 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | bladder cancer | qPCR, Western blot etc. | bladder cancer specimens and the corresponding adjacent non-tumor tissues | up-regulated | interaction | Our results showed up-regulation of ANRIL in bladder cancer tissues versus the corresponding adjacent non-tumor tissues. Knockdown of ANRIL repressed cell proliferation and increased cell apoptosis, along with decreased expression of Bcl-2 and increased expressions of Bax, cytoplasmic cytochrome c and Smac and cleaved caspase-9, caspase-3 and PARP. | 26449463 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | esophageal squamous cell carcinoma | qPCR, Western blot, knockdown etc. | ESCC tissue, cell lines (TE1, ECA109) | up-regulated | regulation | ANRIL inhibits p15INK4b through the TGFβ1 signaling pathway in human esophageal squamous cell carcinoma. | 24747824 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | serous ovarian cancer | qPCR, Western blot, knockdown etc. | SOC tissue, cell lines (SK-OV-3, HO8910) | up-regulated | interaction | We found that ANRIL levels were elevated in SOC tissues compared with normal controls and were highly correlated with advanced FIGO stage, high histological grade, lymph node metastasis, and poor prognosis. Functional studies suggest a critical role of ANRIL in the control of SOC cell migration/invasion at least in part through regulation of MET and MMP3. | 25845387 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | gastric cancer | qPCR, Western blot, knockdown, RIP etc. | gastric cancer tissue, cell lines (SGC7901, BGC823, MGC803) | up-regulated | regulation | Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. | 24810364 | LncRNADisease Lnc2Cancer |
EL0289 | CDKN2B-AS1 | hepatocelluar carcinoma | qPCR, Western blot, knockdown, RIP etc. | HCC tissue, cell lines (HepG2, Hep3B, MHCC-97H) | up-regulated | interaction | ANRIL expression was up-regulated in HCC tissues, and the higher expression of ANRIL was significantly correlated with tumor size and Barcelona Clinic Liver Cancer (BCLC) stage. Moreover, taking advantage of loss of function experiments in HCC cells, we found that knockdown of ANRIL expression could impair cell proliferation and invasion and induce cell apoptosis both in vitro and in vivo. | 25966845 | Lnc2Cancer |
EL0289 | CDKN2B-AS1 | non-small cell lung cancer | qRT-PCR | 87 NSCLC tissues and three lung cancer cell lines | up-regulated | expression | The expression level of lncRNA ANRIL was higher in NSCLC tissues and lung cancer cells than in adjacent non-tumor tissues and normal human bronchial epithelial cells. Higher expression of lncRNA ANRIL in NSCLC tissues was associated with higher TNM stage and advanced lymph node metastasis. Our results suggested that lncRNA ANRIL was a potential biomarker for NSCLC prognosis. | 25889788 | |
EL0289 | CDKN2B-AS1 | non-small-cell lung cancer | qRT-PCR | patients suffering from non-small-cell lung cancer (NSCLC) | up-regulated | expression | N/A | 26448925 | |
EL0289 | CDKN2B-AS1 | invasive breast carcinomas | qRT-PCR and immunohistochemistry (IHC) | invasive breast carcinomas | N/A | N/A | N/A | 27102007 | |
EL0289 | CDKN2B-AS1 | gastric cancer | silencing ; qRT-PCR and western blotting | gastric cancer tissues of cisplatin-resistant and 5-fluorouracil (5-FU)-resistant patients | up-regulated | N/A | ANRIL positively correlated with the expression in gastic cell; silencing ANRIL decreased the IC50 values in gastric cancer cells | 27121324 | |
EL0291 | CECR3 | cat eye syndrome | N/A | N/A | N/A | N/A | Cat eye syndrome chromosome region, candidate 3 | 11381032 | LncRNADisease |
EL0292 | CECR9 | cat eye syndrome | N/A | N/A | N/A | N/A | Cat eye syndrome chromosome region, candidate 9 | 11381032 | LncRNADisease |
EL0293 | ceruloplasmin | ovarian cancer | knockdown | orthotopic mouse model of ovarian cancer | up-regulated | interaction | NRCP was highly upregulated in ovarian tumors, and knockdown of NRCP resulted in significantly increased apoptosis, decreased cell proliferation, and decreased glycolysis compared with control cancer cells. In an orthotopic mouse model of ovarian cancer, siNRCP delivered via a liposomal carrier significantly reduced tumor growth compared with control treatment. | 26686630 | |
EL0294 | CES1P1 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL0295 | CHL1-AS2 | adolescent idiopathic scoliosis | N/A | N/A | N/A | mutation | We found strongest evidence of association with chromosome 3p26.3 SNPs (rs1400180,A>C) in the proximity of the CHL1 gene (P < 8*10^(-8) for rs1400180). | 21216876 | LncRNADisease |
EL0296 | CHRF | cardiac hypertrophy | N/A | N/A | N/A | regulation | The Long Noncoding RNA CHRF Regulates Cardiac Hypertrophy by Targeting miR-489. | 24557880 | LncRNADisease |
EL0298 | COL3A1 | gastric cancer | microarray, qPCR, knockdown etc. | gastric cancer tissue | up-regulated | N/A | LncRNA M59227 and 3 mRNAs, PLK1, PTTG1 and VCAN, were overexpressed in GC. In contrast, the expression of 4 lncRNAs, LOC150622, AKR7 L, DQ192290 and BC040587, and 2 mRNAs, DRD5 and GDF5, were downregulated in GC.The results indicated that TUSC7 is a p53-regulated tumour suppressor that acts in part by repressing miR-23b and that TUSC7 may be a key regulatory hub in GC. | 25765901 | LncRNADisease Lnc2Cancer |
EL0301 | CPS1-IT1 | intrahepatic cholangiocarcinoma | qPCR, Western blot, knockdown, Flow cytometry assay etc. | ICC tissue, cell line(L-02, Huh-7, Bel-7402) | up-regulated | interaction | Carbamoyl-phosphate synthase 1 (CPS1) and its lncRNA CPS1 intronic transcript 1 (CPS1-IT1) were observed to be upregulated in ICC. CPS1 and CPS1-IT1 were co-upregulated in ICC tissues compared with non-cancerous tissues. Knockdown of CPS1 andor CPS1-IT1 reduced the proliferation and increased the apoptosis of ICC-9810 cells. Additionally, clinical analysis indicated that CPS1 and CPS1-IT1 were associated with poor liver function and reduced survival rates when the relative expression values were greater than 4 in cancer tissues. | 26499888 | Lnc2Cancer |
EL0302 | CR613944 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | down-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL0303 | CR619813 | pancreatic cancer | microarray, qPCR etc. | cell lines (SW1990, SWl990/GZ etc.) | down-regulated | expression | Six lncRNAs (RP11-58D2.1, lincRNA-ZNF532, AP000221.1, CTC-338M12.5, CR619813, DDX6P) were selected to validate the microarray consistency by using qPCR. The results demonstrated that RP11-58D2.1, lincRNA-ZNF532 and AP000221.1 were upregulated and that CTC-338M12.5, DDX6P and CR619813 were downregulated in the SW1990/GZ cells compared with SW1990 cells (Figure 6). | 25755691 | Lnc2Cancer |
EL0305 | CRNDE | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116, HT29, LS174T etc.) | up-regulated | N/A | In colorectal cancer cells, we demonstrate that treatment with insulin and insulin-like growth factors (IGF) repressed CRNDE nuclear transcripts, including those encompassing gVC-In4. These repressive effects were negated by use of inhibitors against either the PI3K/Akt/mTOR pathway or Raf/MAPK pathway, suggesting CRNDE is a downstream target of both signaling cascades. | 24184209 | Lnc2Cancer |
EL0305 | CRNDE | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | expression | An uncharacterized gene locus (Chr16:hCG_1815491), now named colorectal neoplasia differentially expressed (gene symbol CRNDE), is activated early in colorectal neoplasia. | 22393467 | LncRNADisease Lnc2Cancer |
EL0305 | CRNDE | glioma | qPCR, Western blot, ChIP, Flow cytometry assay etc. | glioma tissue, cell lines(U87MG, U251) | up-regulated | expression | Overexpression of specific CRNDE transcript promotes cell growth and migration in vitro while knockdown of CRNDE expression manifests a repressive function during these cellular processes. Mechanistic studies further revealed that histone acetylation in the promoter region might account for the upregulation of CRNDE, and the level of CRNDE expression could be modulated by mammalian Target of Rapamycin (mTOR) signaling in glioma. | 25813405 | Lnc2Cancer |
EL0305 | CRNDE | colorectal cancer | quantitative real-time | 142 CRC tissues and 142 paired adjacent nontumorous tissues | up-regulated | N/A | upregulation of lncRNA CRNDE-h was significantly correlated with large tumor size | 27042112 | |
EL0307 | AC130456.2 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL0308 | CTB-167B5.2 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | expression | We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. | 26540467 | Lnc2Cancer |
EL0309 | AC021078.1 | prostate cancer | integrating analysis of sequence features and gene expression profiles | prostate cancer | N/A | N/A | The tumour-suppressive function of two lncRNAs (TUG1 and CTB-89H12.4) and their regulation of PTEN expression in prostate cancer. | 26975529 | |
EL0310 | CTBP1-AS | prostate cancer | N/A | N/A | N/A | regulation | Oncogene | 24373479 | LncRNADisease |
EL0310 | CTBP1-AS | prostate cancer | N/A | N/A | N/A | regulation | The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. | 24531795 | LncRNADisease |
EL0310 | CTBP1-AS | polycystic ovary syndrome | N/A | N/A | N/A | N/A | C-Terminal binding protein 1 antisense (CTBP1-AS) was a novel long noncoding RNA (lncRNA) to regulate AR activity. Expression level of CTBP1-AS in peripheral blood leukocytes was significantly higher in women with PCOS than that in controls after adjustment for age and body mass index (BMI). | 25552498 | LncRNADisease |
EL0310 | CTBP1-AS | prostate cancer | qPCR, Western bolt, Northern bolt, RIP etc. | prostate cancer tissue, cell lines (VCaP, LNCaP, DU145, RWPE etc.) | up-regulated | N/A | CTBP1-AS is predominantly localized in the nucleus and its expression is generally upregulated in prostate cancer. CTBP1-AS promotes both hormone-dependent and castration-resistant tumour growth. Mechanistically, CTBP1-AS directly represses CTBP1 expression by recruiting the RNA-binding transcriptional repressor PSF together with histone deacetylases. CTBP1-AS also exhibits global androgen-dependent functions by inhibiting tumour-suppressor genes via the PSF-dependent mechanism thus promoting cell cycle progression. | 23644382 | Lnc2Cancer |
EL0310 | CTBP1-AS | hepatocellular carcinoma | RT-qPCR | serum | N/A | N/A | high sensitivity and specificity for discriminating HCC from healthy controls and also from CHC patients | 27113935 | |
EL0310 | CTBP1-AS | chronic hepatitis C | RT-qPCR | serum | N/A | N/A | high sensitivity and specificity for discriminating HCC from healthy controls and also from CHC patients | 27113935 | |
EL0311 | CTD-3080P12.3 | gastric cancer | microarray, qPCR, Western blot, Luciferase reporter assay etc. | gastric cancer tissue, cell lines (KATO-III, SGC-7901, MKN28, AGS, MKN45) | up-regulated | interaction | Here, we report that BC032469, a novel lncRNA, expressed highly in gastric cancer tissues, and the upregulation was clinically associated with larger tumor size, poor differentiation and shorter survival of gastric cancer patients. Mechanistically, BC032469 could directly bind to miR-1207-5p and effectively functioned as a sponge for miR-1207-5p to modulate the derepression of hTERT. Thus, BC032469 may function as a ceRNA to impair miR-1207-5p-dependent hTERT downregulation, suggesting that it may be clinically valuable as a poor prognostic biomarker of gastric cancer. | 26549025 | Lnc2Cancer |
EL0312 | CTD903 | metastatic colorectal cancer | silencing or overexpression of CTD903 in CRC cell lines | CRC cell lines | up-regulated | N/A | CTD903 acts as a tumor suppressor in CRC and can inhibit cell invasion and migration through repressing Wnt/β-catenin signalin | 27035092 | |
EL0320 | CYP2C91 | obesity | Weighted Gene Co-expression Network Analysis (WGCNA) | N/A | N/A | expression | In the current exploratory analysis, we show how a lncRNA - cyp2c91 contributes to the transcriptional regulation localized to cytoplasm thereby making refractory environment for transcription. | 26284111 | |
EL0320 | CYP2C91 | systemic lupus erythematosus | Weighted Gene Co-expression Network Analysis (WGCNA) | N/A | N/A | expression | In the current exploratory analysis, we show how a lncRNA - cyp2c91 contributes to the transcriptional regulation localized to cytoplasm thereby making refractory environment for transcription. | 26284111 | |
EL0322 | Cyp4b1-ps2 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 29 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0323 | CYP51A1-AS1 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | down-regulated | N/A | We chose the lncRNAs AK096725 (upregulated) and ENST00000453068 (downregulated) to confirm their differential expression levels in 70 paired RCC tissues and adjacent non-tumor tissues. Levels of AK096725 were significantly greater in RCC tissues while those of ENST00000453068 was significantly lower compared to the non-tumor tissues. These results are consistent with the microarray data. | 24905231 | Lnc2Cancer |
EL0325 | CYTOR | gastric cancer | microarray, qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (HCG-27, SGC-7901) | up-regulated | expression | Linc00152 was validated to be increased in 59 paired gastric cancer specimens (Fig. 3C), and the high levels of Linc00152 expression correlated with larger tumor size. | 26237576 | Lnc2Cancer |
EL0325 | CYTOR | hepatocelluar carcinoma | microarray, qPCR, Western blot, Luciferase reporter assay etc. | HCC tissue, cell lines ( HepG2, Hep3B, SNU-423 cells. Huh7, L02, SMMC-7721, MHCC-97H) | up-regulated | interaction | Here, based on the increased level of LINC00152 in HCC tissues, we found that LINC00152 could promote cell proliferation in vitro and tumor growth in vivo. Furthermore, microarray-based analysis indicated that LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-N/BoxB reporter system. | 26540343 | Lnc2Cancer |
EL0325 | CYTOR | gastric cancer | qPCR etc. | blood(serum) | up-regulated | expression | The levels of plasma LINC00152 were significantly elevated in gastric cancer patients compared with healthy controls. The sensitivity and specificity of plasma LINC00152 in the diagnosis of gastric cancer were 48.1 and 85.2 %, respetcively. LINC00152 levels in preoperative plasma samples were lower than those in postoperative ones. | 25391424 | Lnc2Cancer |
EL0325 | CYTOR | hepatocelluar carcinoma | qPCR etc. | blood (plasma), HCC tissue | up-regulated | expression | Circulating HULC and Linc00152 were significantly up-regulated in plasma samples of HCC patients during training set and validation set. | 26356260 | Lnc2Cancer |
EL0325 | CYTOR | gastric cancer | qPCR, Western blot, ISH, RIP, RNA pull-down assay etc. | gastric cancer tissue, cell lines (MGC803, HGC-27) | up-regulated | interaction | In this study, we first confirmed the upregulation of cytoplasmic expressed Linc00152 in 72 pair tissues of gastric patients. A suppression of cell proliferation and tumor growth was obtained in MGC803 and HGC-27 cells treated with Linc00152 shRNA. RNA pull-down and RIP assay revealed that Linc00152 could directly bind with EGFR which caused an activation of PI3K/AKT signaling. | 26538117 | Lnc2Cancer |
EL0325 | CYTOR | pancreatic cancer | qPCR, Western blot, knockdown etc. | PDAC tissue | up-regulated | expression | The upregulation of LINC00152 (MACE log2fc: 2.3, qPCR: 1.5) and downregulation of LINC00261 (MACE log2fc: 5.3, qPCR: 4.4) in PDAC tissues was confirmed by qPCR. | 25910082 | Lnc2Cancer |
EL0325 | CYTOR | gastric cancer | qPCR, Western blot, Northern blot, knockdown etc. | gastric cancer tissue, cell lines (AGS, BGC-823, MGC-803, SGC-7901 etc.) | up-regulated | N/A | The results showed that the expression level of LINC00152 in gastric carcinoma was significantly increased, compared with matched normal tissue (P=0.045) and normal mucosa from health control (P=0.004), respectively. Levels of LINC00152 in gastric cancer cell lines, BGC-823, MGC-803, and SGC-7901, were significantly higher than those in human normal gastric epithelial cell line GES-1. In addition, high expression of LINC00152 was correlated with invasion (P=0.042). LINC00152 levels in gastric juice from patients with gastric cancer were further found significantly higher than those from normal controls (P=0.002). | 24523021 | Lnc2Cancer |
EL0327 | DACOR1 | colon cancer | RNA-seq, qPCR, ChIRP-seq, Western blot, RIP etc. | colon cancer tissue, cell line (HCT116) | down-regulated | interaction | DACOR1 shows high, tissue-specific expression in the normal colon but was repressed in a panel of colon tumors and patient-derived colon cancer cell lines. Induction of DACOR1 in colon cancer cell lines significantly reduced their ability to form colonies in vitro, suggesting a growth suppressor function. Induction of DACOR1 led to the activation of tumor-suppressor pathways and attenuation of cancer-associated metabolic pathways. | 26307088 | Lnc2Cancer |
EL0329 | DANCR | osteosarcoma | Lentivirus-mediated (shRNA) to silence osteosarcoma cell lines U2OS and Saos-2 | osteosarcoma cell lines U2OS and Saos-2 | up-regulated | N/A | knockdown of ANCR significantly inhibited the proliferation of U2OS and Saos cells and colony formation of U2OS cells | 26986815 | |
EL0329 | DANCR | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0329 | DANCR | bone diseases | N/A | N/A | N/A | expression | These data suggest that ANCR is an essential mediator of osteoblast differentiation, thus offering a new target for the development of therapeutic agents to treat bone diseases. | 23438432 | LncRNADisease |
EL0329 | DANCR | postmenopausal osteoporosis | N/A | N/A | N/A | N/A | DANCR promoted the expression of IL6 and TNF-alpha at both mRNA level and protein level in MNCs. DANCR level was correlated with IL6 and TNF-alpha in postmenopausal women with low BMD | 25660720 | LncRNADisease |
EL0329 | DANCR | hepatocelluar carcinoma | qPCR etc. | HCC cell lines | up-regulated | interaction | We found that lncRNA-DANCR is over-expressed in stem-like HCC cells and this can serve as a prognostic biomarker for HCC patients. Experiments showed that DANCR markedly increased stemness features of HCC cells to promote tumorigenesis and intra-/extra-hepatic tumor colonization.Our studies reveal a significance and mechanism of DANCR action in increasing stemness features and offer a potential prognostic marker and a therapeutic target for HCC. | 25964079 | Lnc2Cancer |
EL0329 | DANCR | colorectal cancer | qPCR etc. | colorectal cancer tissues and paired adjacent non-tumor tissues | up-regulated | expression | Our results showed that lncRNA DANCR expression was increased in CRC tissues compared with that in adjacent normal tissues (P<0.05). In addition, tumors with high lncRNA DANCR expression was correlated with TNM stage, histologic grade, and lymph node metastasis (P<0.05). Kaplan-Meier analysis showed that patients with high lncRNA DANCR expression had a shorter overall survival (OS) and disease-free survival (DFS) compared with the low lncRNA DANCR expression group (P<0.05). Moreover, in a multivariate Cox model, our results showed that lncRNA DANCR expression was an independent poor prognostic factor for both OS and DFS in CRC. | 26617879 | Lnc2Cancer |
EL0330 | DAOA-AS1 | bipolar disorder | N/A | N/A | N/A | mutation | Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. | 12647258 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | expression | Markers of the G72/G30 genes are associated with schizophrenia in a non-Caucasian population. | 15194506 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | N/A | Association with schizophrenia. | 15271585 | LncRNADisease |
EL0330 | DAOA-AS1 | panic disorder | N/A | N/A | N/A | N/A | Panic disorder associated. | 15477870 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | N/A | G72/G30 (DAOA-AS1) are important candidate genes for explaining schizophrenia in the Han Chinese population. | 15653269 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | N/A | G72/G30 genes are involved in conferring susceptibility to schizophrenia. | 16402132 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | mutation | Transmission disequilibrium analysis revealed a significant association between the rs947267 polymorphism (A>C) and schizophrenia (P=0.016), with the A allele more commonly transmitted to patients. | 16791105 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | mutation | Meta-analysis revealed that there is weak evidence of association between the G72/G30 genes and schizophrenia. | 17179078 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | mutation | Significant associations of schizophrenia with the A allele of rs947267 (A>C,P=0.012) and haplotype A-A-G (rs2391191-rs947267-rs778294) (P=0.008) were found in early-onset schizophrenic patients. | 17179866 | LncRNADisease |
EL0330 | DAOA-AS1 | schizophrenia | N/A | N/A | N/A | mutation | rs778294 (A>G) and rs947267 (A>C), were found to be associated with the risk of schizophrenia. | 17651942 | LncRNADisease |
EL0331 | DAPK1 | pancreatic ductal adenocarcinoma | microarray, qPCR etc. | cell line (MIA PaCa-2 ) | up-regulated | expression | Differential expression | 22078386 | LncRNADisease Lnc2Cancer |
EL0332 | DBET | Facioscapulohumeral muscular dystrophy | Gene expression study in human cells to build pathways involved by DBE-T in FSHD patients | N/A | N/A | N/A | DBE-T, a chromatin-associated noncoding RNA produced selectively in FSHD patients that coordinates de-repression of 4q35 genes. DBE-T recruits the Trithorax group protein Ash1L to the FSHD locus, driving histone H3 lysine 36 dimethylation, chromatin remodeling, and 4q35 gene transcription. | 22541069 | |
EL0332 | DBET | Facioscapulohumeral muscular dystrophy | N/A | N/A | N/A | mutation | The activatory long non-coding RNA DBE-T reveals the epigenetic etiology of facioscapulohumeral muscular dystrophy. | 22710800 | LncRNADisease |
EL0332 | DBET | Facioscapulohumeral muscular dystrophy | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0332 | DBET | Facioscapulohumeral muscular dystrophy | N/A | N/A | N/A | regulation | In contrast, in FSHD patients, a deletion of D4Z4 repeats results in cis production of the DBE-T lncRNA that binds to protein complexes, reorganizes the chromatin state of the FSHD locus, and reactivates the repressed 4q35 genes. | 24667321 | LncRNADisease |
EL0332 | DBET | Facioscapulohumeral muscular dystrophy | N/A | N/A | N/A | expression | As a result, this region becomes more prone to transcription and gives rise to the activatory lncRNA DBE-T. DBE-T is mainly produced in FSHD patients and mediates the aberrant activation of the FSHD locus. | 24685002 | LncRNADisease |
EL0333 | DBH-AS1 | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | HCC tissue, cell lines (HepG2, SMMC-7721, Hep3B, MHCC97H, SK-Hep1) | up-regulated | interaction | The levels of DBH-AS1 were positively correlated with hepatitis B surface antigen (HBsAg) and tumor size in HCC tissues. Overexpression of DBH-AS1 induced cell cycle progression by accelerating G1/S and G2/M transition concomitantly with upregulation of CDK6, CCND1, CCNE1 and downregulation of p16, p21 and p27. We also provide evidence that DBH-AS1 could be significantly induced by HBx protein and markedly down-regulated by p53. Thus, we concluded that DBH-AS1 can be induced by HBx and inactivated by p53, and consequently promote cell proliferation and cell survival through activation of MAPK signaling in HCC. | 26393879 | Lnc2Cancer |
EL0334 | DDR2 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL0335 | DDX6P1 | pancreatic cancer | microarray, qPCR etc. | cell lines (SW1990, SWl990/GZ etc.) | down-regulated | expression | Six lncRNAs (RP11-58D2.1, lincRNA-ZNF532, AP000221.1, CTC-338M12.5, CR619813, DDX6P) were selected to validate the microarray consistency by using qPCR. The results demonstrated that RP11-58D2.1, lincRNA-ZNF532 and AP000221.1 were upregulated and that CTC-338M12.5, DDX6P and CR619813 were downregulated in the SW1990/GZ cells compared with SW1990 cells (Figure 6). | 25755691 | Lnc2Cancer |
EL0336 | DGCR5 | clear cell renal cell carcinoma | microarray, qPCR etc. | renal clear cell carcinoma tissue | up-regulated | N/A | ENST00000456816, X91348, BC029135, NR_024418 were evaluated by qPCR in sixty-three pairs of RCCC and NT samples. The results demonstrated that ENST00000456816, X91348 were up-regulated and BC029135, NR_024418 were down-regulated in RCCC samples compared with NT samples (p<0.001 for each lncRNAs). | 22879955 | Lnc2Cancer |
EL0336 | DGCR5 | DiGeorge syndrome | N/A | N/A | N/A | expression | The DiGeorge syndrome-associated noncoding RNA, DGCR5, is repressed by REST through a proximal upstream binding site. | 19050060 | LncRNADisease |
EL0336 | DGCR5 | velocardiofacial syndrome | N/A | N/A | N/A | N/A | Association | 20380817 | LncRNADisease |
EL0336 | DGCR5 | Huntington's disease | N/A | N/A | N/A | expression | Interestingly, many of these lncRNAs contain genomic binding sites for the transcriptional repressor REST, a key mediator of transcriptional changes in HD, including the known REST target lncRNA, DGCR5. | 23346095 | LncRNADisease |
EL0336 | DGCR5 | DiGeorge syndrome | N/A | N/A | N/A | mutation | DGCR5 is disrupted by the patient ADU breakpoint. | 8659529 | LncRNADisease |
EL0341 | DISC2 | Autism spectrum disorder | N/A | N/A | N/A | regulation | DISC1 is regulated by its lncRNA, DISC6, which may also represent an excellent candidate for susceptibility to these disorders. | 22817756 | LncRNADisease |
EL0341 | DISC2 | schizophrenia | N/A | N/A | N/A | locus | DISC2 should be considered a formal candidate gene for susceptibility to psychiatric illness (schizophrenia). | 10814723 | LncRNADisease |
EL0341 | DISC2 | schizophrenia | N/A | N/A | N/A | mutation | The Disrupted in Schizophrenia (DISC) locus on human chromosome 1q42 has been strongly implicated by genetic studies as a susceptibility locus for major mental illnesses.DISC2, a putative noncoding transcript partially antisense to DISC1, is not conserved. | 12573262 | LncRNADisease |
EL0341 | DISC2 | affective disorders | N/A | N/A | N/A | N/A | DISC2 is a likely susceptibility locus for both schizophrenia and affective disorders. | 15478311 | LncRNADisease |
EL0341 | DISC2 | schizophrenia | N/A | N/A | N/A | N/A | DISC2 is a likely susceptibility locus for both schizophrenia and affective disorders. | 15478311 | LncRNADisease |
EL0341 | DISC2 | bipolar disorder | N/A | N/A | N/A | locus | The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. | 17912248 | LncRNADisease |
EL0341 | DISC2 | depression | N/A | N/A | N/A | locus | The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. | 17912248 | LncRNADisease |
EL0341 | DISC2 | schizophrenia | N/A | N/A | N/A | locus | The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. | 17912248 | LncRNADisease |
EL0341 | DISC2 | Autism spectrum disorder | N/A | N/A | N/A | locus | The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. | 19606485 | LncRNADisease |
EL0341 | DISC2 | schizophrenia | N/A | N/A | N/A | locus | The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. | 20380817 | LncRNADisease |
EL0341 | DISC2 | bipolar disorder | N/A | N/A | N/A | regulation | DISC1 is regulated by its lncRNA, DISC4, which may also represent an excellent candidate for susceptibility to these disorders. | 22817756 | LncRNADisease |
EL0341 | DISC2 | major depression | N/A | N/A | N/A | regulation | DISC1 is regulated by its lncRNA, DISC5, which may also represent an excellent candidate for susceptibility to these disorders. | 22817756 | LncRNADisease |
EL0341 | DISC2 | schizophrenia | N/A | N/A | N/A | regulation | DISC1 is regulated by its lncRNA, DISC3, which may also represent an excellent candidate for susceptibility to these disorders. | 22817756 | LncRNADisease |
EL0341 | DISC2 | Autism spectrum disorder | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0341 | DISC2 | bipolar disorder | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0341 | DISC2 | major depression | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0341 | DISC2 | schizophrenia | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0342 | DKFZP434K028 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue, cell lines (HCG-27, SGC-7901) | down-regulated | expression | Linc00261, DKFZP434K028 and RPL34-AS1 had lower expression levels in gastric cancer tissues than the normal counterparts. In gastric cell lines, the three lncRNAs were also down-regulated compared with the respective normal gastric epithelial cell line GES-1. Moreover, the low expression levels of DKFZP434K028 and RPL34-AS1 positively correlated with the larger tumor size. | 26237576 | Lnc2Cancer |
EL0343 | DLEU1 | B cell chronic lymphocytic leukemia | a combination of genomic and cDNA library screening, RT-PCR, Northern blotting | N/A | N/A | N/A | As no mutations have been detected for leu1 or any other transcript so far described, we cannot exclude the existence of control elements within the rmd that may regulate expression of genes lying in this region. | 12094250 | |
EL0343 | DLEU1 | chronic lymphocytic leukemia | chromatin-immunoprecipitation (ChIP) that are associated with activated transcription; semi-quantitative and quantitative methods (aPRIMES, BioCOBRA, MCIp, MassARRAY, and bisulfite sequencing) | CLL cells | N/A | N/A | the tumor suppressor mechanism at 13q14.3 is a cluster of genes controlled by two lncRNA | 23593011 | |
EL0343 | DLEU1 | multiple myeloma | FISH | myeloma cases | N/A | locus | A cdr of approximately 350 kb was identified at 13q14 with the proximal border approximately 120 kb centromeric from d13s319, encompassing an area rich in expressed sequence tagged sites and containing dleu1, dleu2, and rfp2 genes. | 12461754 | |
EL0343 | DLEU1 | breast cancer | microarray, qRT-PCR | MCF-7 (ER-positive) and MDA-MB-231 cells (ER- negative) | up-regulated | interaction | MiR-19a might be co-expressed with lncRNA-DLEU1 to co-regulate the expression of ESR1, which influences the occurrence and development of breast cancer cells with different levels of ER expression. | 26416600 | |
EL0343 | DLEU1 | head and neck squamous-cell carcinoma | microsatellite repeat polymorphisms and PCR | N/A | N/A | locus | Multiplexed pcr revealed homozygous deletion of leu1 in one oral cavity tumor. | 10684931 | |
EL0343 | DLEU1 | B-cell chronic lymphocytic leukemia | N/A | N/A | N/A | expression | Sequence analysis of the rna variants suggests that bcms transcripts belong to the group of non-coding rnas. | 11406609 | |
EL0343 | DLEU1 | B-cell chronic lymphocytic leukemia | N/A | N/A | N/A | expression | Since their putative involvement in b-cll was controversial, our present study provide support for reconsidering the dleu1 and dleu2 genes as b-cll candidate genes | 11691637 | |
EL0343 | DLEU1 | inherited bone marrow failure disorder | oligonucleotide microarray | N/A | up-regulated | expression | several oncogenes were found to be upregulated, including LARG, TAL1 and MLL, and of several tumour suppressor genes were downregulated, including DLEU1, RUNX1, FANCD2 and DKC1. Real time polymerase chain reaction confirmed statistically higher expression of LARG and TAL1 in SDS marrows. | 17539775 | |
EL0343 | DLEU1 | chronic lymphocytic leukemia | qPCR etc. | blood | differential expression | locus | In 13q14.3, where several tumor suppressor genes, including the miRNA genes miR-16-1 and miR-15a, are co-regulated by the two long non-coding RNA genes DLEU1 and DLEU2 that span the critical region. | 19347735 | LncRNADisease Lnc2Cancer |
EL0343 | DLEU1 | chronic lymphocytic leukemia | qPCR, FISH etc. | blood | down-regulated | mutation | Frequently deleted in B-cell chronic lymphocytic leukemia. | 11161783 | LncRNADisease Lnc2Cancer |
EL0343 | DLEU1 | chronic lymphocytic leukemia | qPCR, FISH etc. | blood | differential expression | N/A | Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis. | 9395242 | LncRNADisease Lnc2Cancer |
EL0344 | DLEU2 | chronic lymphocytic leukemia | chromatin immunoprecipitation assay, small interfering RNA-mediated repression | CLL patients, Human Burkitt’s lymphoma cell line Daudi | down-regulated | N/A | The transcription factor BSAP (B-cell-specific activator protein) directly interacts with Dleu2, the host gene containing the miR-15a/16-1 loci, and by negative regulation of the Dleu2 promoter, results in repression of miR-15a/16-1 expression. | 23995789 | |
EL0344 | DLEU2 | chronic lymphocytic leukemia | chromatin-immunoprecipitation (ChIP) that are associated with activated transcription; semi-quantitative and quantitative methods (aPRIMES, BioCOBRA, MCIp, MassARRAY, and bisulfite sequencing) | CLL cells | N/A | N/A | the tumor suppressor mechanism at 13q14.3 is a cluster of genes controlled by two lncRNA | 23593011 | |
EL0344 | DLEU2 | multiple myeloma | FISH | myeloma cases | N/A | locus | A cdr of approximately 350 kb was identified at 13q14 with the proximal border approximately 120 kb centromeric from d13s319, encompassing an area rich in expressed sequence tagged sites and containing dleu1, dleu2, and rfp2 genes. | 12461754 | |
EL0344 | DLEU2 | B-cell chronic lymphocytic leukemia | N/A | N/A | N/A | mutation | B-cell chronic lymphocytic leukemia: frequent chromosomal imbalance. | 11072235 | LncRNADisease |
EL0344 | DLEU2 | mantle-cell lymphoma | N/A | N/A | N/A | mutation | mantle-cell lymphoma: frequent chromosomal imbalance. | 11072235 | LncRNADisease |
EL0344 | DLEU2 | B-cell chronic lymphocytic leukemia | N/A | N/A | N/A | N/A | No expression of 1b4/leu2 was detectable in b-cll, regardless of the 13q14 status. these results indicate that allelic loss and mutation of a gene within the mdr is an unlikely pathogenetic mechanism for b-cll. | 11264177 | |
EL0344 | DLEU2 | lymphocytic leukemia | N/A | N/A | N/A | locus | Dleu2 is an antisense transcript that encompasses the Kcnrg and Trim13 genes, as well as two microRNA genes, Mirn16-1 and Mirn15a, which have been previously identified in lymphocytic leukemia. | 18562676 | LncRNADisease |
EL0344 | DLEU2 | chronic lymphocytic leukemia | N/A | N/A | N/A | N/A | DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia | 23551855 | |
EL0344 | DLEU2 | chronic lymphocytic leukemia | qPCR etc. | blood | differential expression | locus | In 13q14.3, where several tumor suppressor genes, including the miRNA genes miR-16-1 and miR-15a, are co-regulated by the two long non-coding RNA genes DLEU1 and DLEU2 that span the critical region. | 19347735 | LncRNADisease Lnc2Cancer |
EL0344 | DLEU2 | chronic lymphocytic leukemia | qPCR, FISH etc. | blood | down-regulated | mutation | Frequently deleted in B-cell chronic lymphocytic leukemia. | 11161783 | LncRNADisease Lnc2Cancer |
EL0344 | DLEU2 | chronic lymphocytic leukemia | qPCR, FISH etc. | blood | differential expression | N/A | Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis. | 9395242 | LncRNADisease Lnc2Cancer |
EL0344 | DLEU2 | myeloma | qPCR, Western blot, Northern blot, Luciferase reporter assay etc. | myeloma tissue, cell lines (HEK293, U2OS etc.) | down-regulated | expression | The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma. DLEU2 negatively regulates the G1 Cyclins E1 and D1 through miR-15a/miR-16-1 and provide evidence that these oncoproteins are subject to miR-15a/miR-16-1-mediated repression under normal conditions. We also demonstrate that DLEU2 overexpression blocks cellular proliferation and inhibits the colony-forming ability of tumor cell lines in a miR-15a/miR-16-1-dependent way. | 19591824 | LncRNADisease Lnc2Cancer |
EL0344 | DLEU2 | chronic lymphocytic leukemia | qPCR, Western blot, Northern blot, Luciferase reporter assay etc. | blood, cell lines (HEK293, U2OS etc.) | down-regulated | expression | The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma. DLEU2 negatively regulates the G1 Cyclins E1 and D1 through miR-15a/miR-16-1 and provide evidence that these oncoproteins are subject to miR-15a/miR-16-1-mediated repression under normal conditions. We also demonstrate that DLEU2 overexpression blocks cellular proliferation and inhibits the colony-forming ability of tumor cell lines in a miR-15a/miR-16-1-dependent way. | 19591824 | LncRNADisease Lnc2Cancer |
EL0344 | DLEU2 | lymphoma | qPCR, Western blot, Northern blot, Luciferase reporter assay etc. | cell lines (HEK293, U2OS etc.) | down-regulated | expression | The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma. DLEU2 negatively regulates the G1 Cyclins E1 and D1 through miR-15a/miR-16-1 and provide evidence that these oncoproteins are subject to miR-15a/miR-16-1-mediated repression under normal conditions. We also demonstrate that DLEU2 overexpression blocks cellular proliferation and inhibits the colony-forming ability of tumor cell lines in a miR-15a/miR-16-1-dependent way. | 19591824 | LncRNADisease Lnc2Cancer |
EL0344 | DLEU2 | non-small cell lung cancer | qRT-PCR, Small interfering RNA (siRNA) transfection, Western blotting, ChIP assays | Pair-matched tumorous and adjacent nontumorous lung tissues from 27 patients, A549 and H1299 | up-regulated | N/A | Histone deacetylases, HDACs inhibitors trichostatin A (TSA) and sodium butyrate upregulated the expression of miR-15a/16-1, among class Ι HDACs subtypes, only knockdown of HDAC3 by specific siRNA increased the hyperacetylation of Dleu2/miR-15a/16-1 promoter region and finally resulted in the upregulation of miR-15a/16-1.overexpression of miR-15a/16-1, which were always deleted or downregulated in lung cancer cells, effectively suppressed cell growth and reduced colony formation | 23867991 | |
EL0346 | DLG2-AS1 | schizophrenia | N/A | N/A | N/A | locus | These results suggest that PSZA11q14 may be considered a candidate gene for schizophrenia acting as an antisense regulator of DLG-2, which controls assembling functional N-methyl-D-aspartate (NMDA) receptors. | 13130513 | LncRNADisease |
EL0346 | DLG2-AS1 | myotonic dystrophy type 1 | N/A | N/A | N/A | mutation | The mutant DMPK transcript causes myotonic dystrophy type 1 (DM1), which is encoded by a protein-coding gene containing a CUG expansion repeat in its 3'-untranslated region. | 19909263 | LncRNADisease |
EL0346 | DLG2-AS1 | heart failure | N/A | N/A | N/A | expression | it is clear that Nkx2-5 is a genetic modifier of myotonic muscular dystrophy RNA toxicity and indicates important functionality of this 3'UTR, independent of its mRNA, in heart dysfunction. | 23104877 | LncRNADisease |
EL0349 | DLX6-AS1 | lung adenocarcinoma | microarray, qPCR, Western blot etc. | lung cancer tissue, cell lines(A549, H1650 etc.) | up-regulated | expression | The expression level of lncRNA DLX6-AS1 in LAC tissues was significantly higher compared to paired adjacent normal lung tissues. In addition, its expression level was closed correlated with both histological differentiation and TNM stage. Down-regulation of lncRNA DLX6-AS1 expression decreased the DLX6 mRNA and protein levels. | 26052251 | Lnc2Cancer |
EL0349 | DLX6-AS1 | Split Hand/Split Foot malformation disorder | N/A | N/A | N/A | Interaction | The lncRNA EVF2, which recruits the transcription factor Dlx2 to activate the protein coding genes DLX5 and DLX6 that are associated with the Split Hand/ Split Foot malformation disorder. | 20930520 | LncRNADisease |
EL0352 | Dmrt2 | cancer | N/A | N/A | N/A | regulation | In many cancer cells TERRA is downregulated, providing a possible link to the longevity of cancer cells by telomerase-mediated lengthening of chromosomal ends. | 23660942 | LncRNADisease |
EL0353 | DMTF1 | gastric cancer | microarray, qPCR, Western blot etc. | cell lines (SGC7901) | up-regulated | N/A | We show here that the lncRNA MRUL, was significantly upregulated in two multidrug-resistant GC cell sublines, SGC7901/ADR and SGC7901/VCR. Furthermore, the relative expression levels of MRUL in GC tissues were negatively correlated with in vitro growth inhibition rates of GC specimens treated with chemotherapeutic drugs and indicated a poor prognosis for GC patients. MRUL plays a positive role in the regulation of ABCB1 expression and is a potential target to reverse the MDR phenotype of GC MDR cell sublines. | 24958102 | Lnc2Cancer |
EL0354 | DNM3OS | epithelial ovarian cancer | qPCR etc. | cell lines (type I, type II etc.) | up-regulated | locus | pri-miR-199a2 within the human Dnm3os gene. The regulation of MIR199A2/214 expression may be used as a potential therapeutic approach in EOC (epithelial ovarian cancer) patients. | 20400975 | LncRNADisease Lnc2Cancer |
EL0355 | DQ786243 | hepatocelluar carcinoma | microarray, qPCR, RIP, RNA pulldown assay etc. | HCC tissue | up-regulated | N/A | AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. | 21769904 | Lnc2Cancer |
EL0355 | DQ786243 | Crohn's disease | N/A | N/A | N/A | regulation | LncRNA DQ786243 affects Treg related CREB and Foxp3 expression in Crohn's disease. | 24289115 | LncRNADisease |
EL0355 | DQ786243 | colorectal cancer | quantitative real-time polymerase | CRC tissues and cell lines | up-regulated | N/A | DQ786243 is an oncogene | 26934980 | |
EL0356 | DRAIC | prostate cancer | qPCR, Western blot etc. | cell lines (VCap, PC3M-luc, LNCaP etc.) | down-regulated | N/A | The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus. Prostate cancers persisting in patients after androgen deprivation therapy (ADT) select for decreased DRAIC expression, and higher levels of DRAIC in prostate cancer are associated with longer disease-free survival (DFS). DRAIC expression predicts good prognosis in a wide range of malignancies, including bladder cancer, low-grade gliomas, lung adenocarcinoma, stomach adenocarcinoma, renal clear cell carcinoma, hepatocellular carcinoma, skin melanoma, and stomach adenocarcinoma. | 25700553 | LncRNADisease Lnc2Cancer |
EL0357 | Dreh | hepatocelluar carcinoma | microarray, qPCR, in vitro knockdown, RIP etc. | HCC tissue | down-regulated | N/A | We identified an lncRNA, down-regulated expression by HBx (termed lncRNA-Dreh), which can inhibit HCC growth and metastasis in vitro and in vivo, act as a tumor suppressor in the development of HBV-HCC. LncRNA-Dreh could combine with the intermediate filament protein vimentin and repress its expression, further change the normal cytoskeleton structure to inhibit tumor metastasis. | 23239537 | Lnc2Cancer |
EL0357 | Dreh | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | Further experiments showed that Dreh can specifically bind to vimentin, a type III intermediate filament and the major cytoskeletal component of mesenchymal cells and then inhibit HCC metastasis by modifying the expression and reorganization of vimentin. | 24296588 | LncRNADisease |
EL0357 | Dreh | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | lncRNA-Dreh could bind to the intermediate filament protein vimentin, repress its expression, and thus change the cytoskeleton structure and inhibit tumor metastasis. It acts as a tumor suppressor in the development of HBV-HCC, which inhibits HCC growth and metastasis?in vitro?and?in vivo. These findings support a role of lncRNA-Dreh in tumor suppression and survival prediction of HCC patients. | 24757675 | LncRNADisease |
EL0358 | DSCAM-AS1 | breast cancer | cell cultures or fresh tumor biopsies | MCF-8 cells in absence of hormones Erα | N/A | expression | Down-regulation of DSCAM-AS1 recapitulated, in part, the effect of silencing ERα, i.e. growth arrest and induction of EMT markers. | 26621851 | |
EL0358 | DSCAM-AS1 | adolescent idiopathic scoliosis | N/A | N/A | N/A | mutation | Other top associations in our GWAS were with SNPs (rs2222973, C>T) in the DSCAM gene. | 21216876 | LncRNADisease |
EL0358 | DSCAM-AS1 | breast cancer | qPCR, Northern blot, ISH etc. | cell lines (MCF-7, T47D, ZR-75-1 etc.) | up-regulated | expression | M41 (DSCAM-AS1) mRNA is expressed at a statistically significantly higher level in human breast cancer specimens than in normal human breast and benign lesions. | 12177779 | LncRNADisease Lnc2Cancer |
EL0361 | EBER | Epstein-Barr virus | isothermal titration calorimetry and gel electrophoresis | N/A | N/A | N/A | N/A | 16580685 | |
EL0362 | EEF1A1P9 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0363 | EFNA3 | breast cancer | qPCR, RIP etc. | breast cancer tissue | up-regulated | N/A | We demonstrate that sustained expression of both Ephrin-A3 and novel EFNA3 lncRNAs increased the metastatic potential of human breast cancer cells, possibly by increasing the ability of tumor cells to extravasate from the blood vessels into surrounding tissue. In agreement, we found a strong correlation between high EFNA3 expression and shorter metastasis-free survival in breast cancer patients. hypoxia could contribute to metastatic spread of breast cancer via HIF-mediated induction ofEFNA3lncRNAs and subsequent Ephrin-A3 protein accumulation. | 25023702 | Lnc2Cancer |
EL0364 | EGFLAM-AS1 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (SGC-7901, AGS, BGC-823, HG-27, GES-1) | down-regulated | interaction | Significantly reduced expression of lncRNA-LOWEG was found in gastric cancer tissues and cell lines (SGC-7901, AGS, BGC-823 and HG-27) compared with patient-matched nontumorous adjacent tissues (P < 0.01) or the normal gastric cell line GES-1 (P < 0.05). Lastly, western blot and real-time PCR analysis suggested that lncRNA-LOWEG is positively correlated with the expression of leukemia inhibitory factor receptor (LIFR) gene at the translational level. | 26537802 | Lnc2Cancer |
EL0365 | EGFR-AS1 | hepatocelluar carcinoma | microarray, qPCR, Western blot, knockdown, FCA etc. | HCC tissue, cell lines of (SMMC-7721, LM-9, Huh-7, HepG2) | up-regulated | interaction | It was verified that EGFR and EGFR-AS1 were relatively upregulated in HCC tissue, and they were significantly related to some clinical characteristics and patient prognosis. Furthermore, EGFR-AS1 was determined to promote HCC development by improving the ability of invasion and proliferation of HCC cells in vitro, and it was also found to affect the cell cycle. Our study identified that EGFR-AS1 may promote HCC genesis and development. EGFR-AS1 may act as a prognostic factor in HCC. | 26271667 | Lnc2Cancer |
EL0366 | EGOT | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0366 | EGOT | breast cancer | qPCR etc. | breast cancer tissues, | down-regulated | expression | EGOT expression was lower in breast cancer compared with the adjacent noncancerous tissues, and low levels of EGOT expression were significantly correlated with larger tumor size, more lymph node metastasis, and higher Ki-67 expression. Moreover, patients with low levels of EGOT expression showed significantly worse prognosis for overall survival. Multivariate analysis suggested that low levels of EGOT were a poor independent prognostic predictor for breast cancer patients | 26159853 | Lnc2Cancer |
EL0367 | EHHADH-AS1 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
EL0368 | ELFN1-AS1 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
EL0371 | ENO1 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0391 | KCP | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0392 | TTTY7 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0393 | AC079610.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0394 | LINC00336 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0395 | AL445248.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0396 | AC006305.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0397 | LINC01020 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0398 | FAM66B | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0399 | LINC01139 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0400 | LINC00323 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0401 | LINC01204 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0402 | LINC01721 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0403 | ENSG00000230544.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0404 | ENSG00000231133.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0405 | SPRY4-AS1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0406 | LEF1-AS1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0407 | LINC01798 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0408 | ENSG00000232956.3 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0409 | LINC01762 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0410 | LOC100129434 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0411 | SMIM2-IT1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0412 | ENSG00000237036.3 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0413 | TTLL11-IT1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0414 | ENSG00000240453.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0415 | AC093620.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0416 | ENSG00000245910.3 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0417 | AC109349.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0418 | LOC101928858 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0419 | AC026427.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0420 | LOC105377448 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0421 | LOC339874 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0422 | AL359075.2 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0423 | AP001528.2 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0424 | AC007848.2 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0425 | LINC00929 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0426 | LINC00596 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0427 | ENSG00000259484.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0428 | ENSG00000259758.1 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0429 | LINC00667 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0430 | AC016876.2 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0431 | LINC01538 | hereditary haemorrhagic telangiectasia | N/A | N/A | N/A | expression | Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. | 24603890 | LncRNADisease |
EL0432 | Gm6768 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 28 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0433 | ENSMUST00000041159 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 31 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0434 | Tdpx-ps1 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 30 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0435 | Gm15054 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 15 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0436 | Gm12919 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 24 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0437 | Gm7327 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 14 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0438 | Gm14155 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 8 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0439 | Gm14089 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 17 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0440 | ENSMUST00000142855 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 6 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0441 | Gm13133 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 9 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0442 | Gm11827 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL0443 | Gm15834 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 23 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0444 | ENSMUST00000167632 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 20 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0445 | ENST00000318333 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0446 | RPL12P1 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0447 | ENST00000395084 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
EL0448 | AL353608.3 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | up-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL0449 | ENST00000414355 | cadmium toxicology | knockdown | 35th Cd-induced cells and untreated 16HBE cells | up-regulated | interaction | SiRNA-mediated knockdown of ENST00000414355 inhibited the growth of DNA-damaged cells and decreased the expressions of DNA-damage related genes (ATM, ATR and ATRIP), while increased the expressions of DNA-repair related genes (DDB1, DDB2, OGG1, ERCC1, MSH2, RAD50, XRCC1 and BARD1). A significant positive correlation was observed between blood ENST00000414355 expression and urinary/blood Cd concentrations, and there were significant correlations of lncRNA-ENST00000414355 expression with the expressions of target genes in the lung of Cd-exposed rats and the blood of Cd exposed workers. | 26464647 | |
EL0450 | AL355581.1 | pediatric acute myeloid leukemia | qRT-PCR | three bone marrow samples obtained from each pediatric AML patient | down-regulated | interaction | Dysregulated lncRNAs and mRNAs in pediatric AML versus normal controls that could form gene pathways to regulate cell cycle progression and immunoresponse. | 26573779 | |
EL0451 | POM121L13P | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | down-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0452 | LINC01384 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | down-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0453 | LINC01852 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL0454 | ENST00000435885.1 | esophageal squamous cell carcinoma | microarray, qPCR etc. | OSCC tissue | differential expression | N/A | we identified a three-lncRNA signature (including the lncRNAs ENST00000435885.1, XLOC_013014 and ENST00000547963.1) which classified the patients into two groups with significantly different overall survival . The signature was applied to the test group (median survival 21.5 months vs >60 months, p=0.0030) and independent cohort (median survival 25.8 months vs >48 months, p=0.0187) and showed similar prognostic values in both. | 24522499 | Lnc2Cancer |
EL0455 | ENST00000442037 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL0456 | TDGF1P1 | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | up-regulated | expression | The results showed that seven of these lncRNAs were in accordance with microarray data, including three up-regulated lncRNAs (uc003xut., uc021re1.1, ENST00000445734) and four down-regulated ones (uc002nbr.3, ENST00000502941, ENST00000448093, ENST00000503710). | 26131074 | Lnc2Cancer |
EL0457 | ZNRD1ASP | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | down-regulated | expression | The results showed that seven of these lncRNAs were in accordance with microarray data, including three up-regulated lncRNAs (uc003xut., uc021re1.1, ENST00000445734) and four down-regulated ones (uc002nbr.3, ENST00000502941, ENST00000448093, ENST00000503710). | 26131074 | Lnc2Cancer |
EL0458 | MTCO3P10 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0459 | AL133244.1 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0460 | AC096915.1 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0461 | LINC00887 | clear cell renal cell carcinoma | microarray, qPCR etc. | renal clear cell carcinoma tissue | up-regulated | N/A | ENST00000456816, X91348, BC029135, NR_024418 were evaluated by qPCR in sixty-three pairs of RCCC and NT samples. The results demonstrated that ENST00000456816, X91348 were up-regulated and BC029135, NR_024418 were down-regulated in RCCC samples compared with NT samples (p<0.001 for each lncRNAs). | 22879955 | Lnc2Cancer |
EL0462 | ENST00000460164 | triple-negative breast cancer | microarray, qPCR etc. | triple-negative breast cancer tissue | up-regulated | expression | We found that the expression levels of TCONS_l2_00003938, ENST00000460164, ENST00000425295, MALAT1 and HOTAIR were significantly higher in tumor tissues than non-tumor tissues, whereas there were no significant differences in the expression levels of the other 3 lncRNAs. Our study identified a set of lncRNAs that were consistently aberrantly expressed in TNBC, and these dysregulated lncRNAs may be involved in the development and/or progression of TNBC. | 25996380 | Lnc2Cancer |
EL0463 | AC004893.2 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
EL0464 | ENST00000501583 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | N/A | To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. | 24876753 | Lnc2Cancer |
EL0465 | HAND2-AS1 | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | down-regulated | expression | The results showed that seven of these lncRNAs were in accordance with microarray data, including three up-regulated lncRNAs (uc003xut., uc021re1.1, ENST00000445734) and four down-regulated ones (uc002nbr.3, ENST00000502941, ENST00000448093, ENST00000503710). | 26131074 | Lnc2Cancer |
EL0466 | AC012312.1 | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | down-regulated | expression | The results showed that seven of these lncRNAs were in accordance with microarray data, including three up-regulated lncRNAs (uc003xut., uc021re1.1, ENST00000445734) and four down-regulated ones (uc002nbr.3, ENST00000502941, ENST00000448093, ENST00000503710). | 26131074 | Lnc2Cancer |
EL0467 | LINC01096 | triple-negative breast cancer | microarray, qPCR etc. | TNBC tissue | down-regulated | expression | The results demonstrated that lncRNAs NONHSAT125629 and ENST00000503938 were upregulated and that XR_250621.1 and NONHSAT012762 were down-regulated in the tumor samples compared with NT samples. These qPCR results are consistent with the microarray data. | 26078338 | Lnc2Cancer |
EL0468 | ENST00000537266 | papillary thyroid carcinoma | microarrays, CCK-8 assay, colony formation assay and EdU assay, Flow Cytometry, Transwell and scratch assay | Papillary thyroid cancer cell line | N/A | expression | lncRNAs (ENST00000537266 and ENST00000426615) could inhibit cell proliferation. lncRNAs (ENST00000426615 and ENST00000537266) might be important regulators of PTC cell proliferation and motility, which might provide new insight into the understanding of PTC pathogenesis. | 26824456 | |
EL0469 | AC022075.3 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
EL0470 | AC026369.2 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL0471 | LINC02446 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
EL0472 | ENST00000545440 | astrocytoma | lncRNA microarray, qRT-PCR, | astrocytoma samples | up-regulated | expression | The upregulation of ENST00000545440 and NR_002809 was associated with advanced clinical stages of astrocytoma. | 26252651 | |
EL0473 | LINC01234 | esophageal squamous cell carcinoma | microarray, qPCR etc. | OSCC tissue | differential expression | N/A | we identified a three-lncRNA signature (including the lncRNAs ENST00000435885.1, XLOC_013014 and ENST00000547963.1) which classified the patients into two groups with significantly different overall survival . The signature was applied to the test group (median survival 21.5 months vs >60 months, p=0.0030) and independent cohort (median survival 25.8 months vs >48 months, p=0.0187) and showed similar prognostic values in both. | 24522499 | Lnc2Cancer |
EL0474 | LINC02086 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
EL0475 | EPB41L4A-AS1 | cancer | N/A | N/A | N/A | expression | Ectopic expression of TIGA1 (EPB41L4A-AS1) inhibited not only tumor cell proliferation but also anchorage-independent growth of cancer cell lines. | 16973895 | LncRNADisease |
EL0476 | EPB41L4A-AS2 | breast cancer | evaluated its relationship with the clinicopathological features | breast cancer tissues | up-regulated | N/A | processes associated with tumor biology | 26980733 | |
EL0477 | EPOR | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | down-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0478 | ERCC1 | gastric cancer | qPCR etc. | gastric cancer tissues, cell lines (AGS, SGC-7901, BGC-823, HG27) | down-regulated | expression | The results showed that the expression level of AC138128.1 in GC was significantly decreased compared to that in NAT. Levels of AC138128.1 in the GC cell lines, AGS BGC-823, HG27, and SGC-7901 were lower than those in the human normal gastric epithelial cell line GES-1. lncRNA AC138128.1 might be a novel biomarker for predicting GC. | 25260808 | Lnc2Cancer |
EL0479 | ERICD | retinoblastoma | activation / knockdown of either E2F1 or E2F3 | N/A | down-regulated | N/A | ERIC is transcriptionally regulated by E2Fs, and restricts apoptosis induced by E2F1, as well as by DNA damage. | 24168400 | |
EL0480 | DLGAP2 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future. | 26393913 | Lnc2Cancer |
EL0481 | ESCCAL-5 | esophageal squamous cell carcinoma | microarray, qPCR etc. | ESCC tissue | up-regulated | expression | In addition, we confirmed another two upregulated lncRNAs that are differentially expressed in ESCC and that we have named ESCCAL-1, and ESCCAL-5. | 24222893 | LncRNADisease Lnc2Cancer |
EL0482 | ESRG | intracranial aneurism | N/A | N/A | N/A | expression | HESRG was expressed strongly and diffusively in the nuclei of tumor cells in intracranial germinoma and embryonal carcinoma as well as in human embryonic stem cells.In germinomas, 25 of 31 showed intensive (3+) expression, four cases showed moderate (2+) immunostaining and the remaining 2 cases showed weak (1+) immunostaining. | 21861197 | LncRNADisease Lnc2Cancer |
EL0482 | ESRG | embryonal carcinoma | qPCR etc. | central nervous system tumor tissue, cell lines (H1, H9) | up-regulated | expression | HESRG was expressed strongly and diffusively in the nuclei of tumor cells in intracranial germinoma and embryonal carcinoma as well as in human embryonic stem cells.In embryonal carcinoma, 6 of 9 showed intensive (3+) immunostaining and 3 of 9 showed moderate (2+) immunostaining. | 21861197 | LncRNADisease Lnc2Cancer |
EL0483 | EVADR | colon, rectal, lung, pancreas and stomach adenocarcinomas | RNA-seq, qRT-PCR | colorectal tumors | up-regulated | expression | Moderate to high levels of EVADR were detected in 25 to 53% of colon, rectal, lung, pancreas and stomach adenocarcinomas (mean=30 to 144 FPKM), and EVADR expression correlated with decreased patient survival (Cox regression; hazard ratio=1.47, 95% confidence interval=1.06 to 2.04, P=0.02). | 25821520 | |
EL0484 | EWSAT1 | Ewing sarcoma | microarray, qPCR, Western blot, RIP etc. | cell lines (pMPCs, PSS090 and TC71) | up-regulated | regulation | Expression of EWS-FLI1 and EWSAT1 repressed gene expression, and a substantial fraction of targets that were repressed by EWS-FLI1 were also repressed by EWSAT1. Analysis of RNAseq data from primary human Ewing sarcoma further supported a role for EWSAT1 in mediating gene repression. We identified heterogeneous nuclear ribonucleoprotein (HNRNPK) as an RNA-binding protein that interacts with EWSAT1 and found a marked overlap in HNRNPK-repressed genes and those repressed by EWS-FLI1 and EWSAT1, suggesting that HNRNPK participates in EWSAT1-mediated gene repression. | 25401475 | Lnc2Cancer |
EL0485 | FADS1 | lipid metabolism disorder | N/A | N/A | N/A | regulation | The expression of FADS, and its lncRNA, reverse D5-desaturase, were found to be reciprocally regulated by the dietary fat content in animal models | 22817756 | LncRNADisease |
EL0486 | FALEC | ovarian cancer | knockdown | ovarian cancer cell lines | up-regulated | expression | These results demonstrate the utility of this integrated approach to identify oncogenic lncRNAs and suggest that FAL1 may represent a prognostic biomarker and therapeutic target in ovarian cancer. FAL1 is an oncogenic lncRNA that promotes cancer cell growth in part via repression of p21. | 25367941 | |
EL0486 | FALEC | ovarian cancer | qPCR | N/A | N/A | interaction | FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a number of genes including CDKN1A. The oncogenic activity of FAL1 is partially attributable to its repression of p21. FAL1- specific siRNAs significantly inhibit tumor growth in vivo. | 25203321 | |
EL0486 | FALEC | papillary thyroid carcinoma | qRT-PCR | PTC and normal thyroid tissues | up-regulated | N/A | FAL1 expression was significantly higher in PTC | 26825907 | |
EL0487 | FAM30A | gallbladder cancer | qPCR etc. | GBC cell sublines(GBC-SD, GBC-SD/M) | up-regulated | interaction | We found the differential expression of a lncRNA, namely, KIAA0125, in a pair of GBC cell sublines which possess different metastatic potentials. Then the effects of KIAA0125 on GBC cell migration, invasion, and epithelial-mesenchymal transitions (EMT) were investigated by using a lentivirus-mediated RNA interference (RNAi) system. Notably, cell migration and invasion were strongly inhibited by KIAA0125 suppression. Moreover, the expression of β-catenin was increased and the expression of Vimentin was decreased in GBC-SD/M cells after KIAA0125 knockdown. | 26448925 | Lnc2Cancer |
EL0488 | FAM3D-AS1 | tongue cancer | RNA-seq, qPCR etc. | cell lines (UMSCC-10B, HN-12) | down-regulated | N/A | We confirmed the dysregulation of these noncoding RNAs in head and neck cancer cell lines derived from different anatomic sites, and determined that ectopic expression of the two lncRNAs inhibited key EMT and stem cell genes and reduced cellular proliferation and migration. | 25904139 | LncRNADisease Lnc2Cancer |
EL0488 | FAM3D-AS1 | pharyngeal cancer | RNA-seq, qPCR etc. | cell lines (HN-1, HN-30) | down-regulated | N/A | Overexpression of lnc-KCTD6-3 reduced the expression of NANOG | 25904139 | LncRNADisease Lnc2Cancer |
EL0488 | FAM3D-AS1 | laryngeal cancer | RNA-seq, qPCR etc. | cell lines (UMSCC-22B) | down-regulated | N/A | Ectopic expression of lnc-LCE5A-1 increased the expression of CDH-1 in HNSCC cells, while decreasing the expression of OCT-4, NANOG, and VIM. | 25904139 | LncRNADisease Lnc2Cancer |
EL0489 | FAM83A-AS1 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
EL0490 | FAR2P1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | RP11-133F8.2 expression of EGFR exon 19 deletions in lung adenocarcinoma was significantly higher than wild-type EGFR tissues, while LOC440905 expression of EGFR exon 19 deletions in lung adenocarcinoma was significantly lower than wild-type EGFR tissues. RP11-325I22.2 and LOC440905 might play an important role in the mechanism of EGFR exon 19 deletion in lung adenocarcinoma. | 25085781 | Lnc2Cancer |
EL0490 | FAR2P1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL0491 | FAS-AS1 | ataxia telangiectasia | N/A | human T lymphocytes from patient with ataxia telangiectasia (AT) | up-regulated | expression | FAS-AS1 was up-regulated up to fivefold by 5 Gy irradiation. This is the first study to report that FAS-AS1 lncRNA is up-regulated by radiation exposure in an ATM-dependent fashion in human T lymphocytes. | 25738893 | |
EL0492 | FENDRR | Xuanwei lung cancer | High throughput microarray assay, qRT-PCR | Xuanwei lung cancer (XWLC) tissues | N/A | expression | N/A | 26642714 | |
EL0492 | FENDRR | gastric cancer | qPCR, Western blot etc. | gastric cancer tissue, cell lines (MGC803, BGC823, MKN28, MKN45, SGC7901) | down-regulated | interaction | FENDRR was downregulated in gastric cancer cell lines and cancerous tissues, as compared with normal gastric epithelial cells and adjacent noncancerous tissue samples. Low FENDRR expression was correlated with deeper tumor invasion, higher tumor stage, and lymphatic metastasis. Histone deacetylation was involved in the downregulation of FENDRR in gastric cancer cells. FENDER overexpression suppressed invasion and migration by gastric cancer cells in vitro, by downregulating FN1 and MMP2/MMP9 expression. | 25167886 | Lnc2Cancer |
EL0493 | Fendrr | heart failure | N/A | N/A | N/A | expression | The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. | 23369715 | LncRNADisease |
EL0494 | FER1L4 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | down-regulated | N/A | FER1L4 expression levels in gastric cancer tissues are significantly decreased. The low FER1L4 level were associated with tumor size, histologic grade, general classification, depth of invasion, lymphatic metastasis , distant metastasis, TNM stage, vessel or nerve invasion.FER1L4 might play a crucial role in human gastric cancer and may be a new potential biomarker for clinical prognosis evaluation. | 24961353 | Lnc2Cancer |
EL0494 | FER1L4 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (AGS, MGC-803, SGC-7901) | down-regulated | interaction | We observed that FER1L4 was downregulated in gastric cancer and that its level corresponded with that of PTEN mRNA. Both FER1L4 and PTEN mRNA were targets of miR-106a-5p. Further experiments demonstrated that FER1L4 downregulation liberates miR-106a-5p and decreases the abundances of PTEN mRNA and protein. More importantly, FER1L4 downregulation accelerated cell proliferation by promoting the G0/G1 to S phase transition. | 26306906 | Lnc2Cancer |
EL0495 | FEZF1-AS1 | colorectal cancer | N/A | primary colorectal carcinoma (CRC) | up-regulated | N/A | the downregulation of FEZF1-AS1 expression significantly; FEZF1 knockdown also significantly suppressed CRC cell proliferation | 26848625 | |
EL0496 | FFAR2 | enterovirus 71 infection | N/A | N/A | N/A | expression | A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation | 23220233 | LncRNADisease |
EL0497 | FGF10-AS1 | Ventricular septal defects | N/A | N/A | N/A | expression | Furthermore, our established filtering pipeline indicated an association of two lncRNAs, ENST00000513542 and RP11-473L15.2, with VSD. | 24147006 | LncRNADisease |
EL0498 | FGF14-AS2 | breast cancer | Reduced expression | breast cancer tissue | down-regulated | expression | FGF14-AS2 involved in the progress of breast cancer and might act as a tumor suppressor gene. | 26820525 | |
EL0499 | FGFR3-AS1 | osteosarcoma | real-time quantitative PCR | osteosarcoma | up-regulated | N/A | FGFR3-AS1 inhibits xenograft tumor growth of osteosarcoma cells | 27022737 | |
EL0500 | FH | non-small cell lung cancer | NSCLC lines 95D and 95C by using high throughput LncRNA chip | 95C, 95D cells and NSCLC tumor tissues | up-regulated | N/A | TATDN1 expression is associated with 95D cells' higher potential of invasion and metastasis | 26943769 | |
EL0502 | FKBP10 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0504 | FMR1-AS1 | neurological disorders | genome-wide chromatin immunoprecipitation experiments | N/A | up-regulated | N/A | alters the chromatin state and the expression of several hundred genes in trans | 27001315 | |
EL0504 | FMR1-AS1 | fragile X syndrome | N/A | N/A | N/A | expression | ASFMR1 is silenced in FXS patients and up regulated in pre-mutation carriers suggesting that a common process is responsible for regulating the expression these transcripts. | 17921506 | LncRNADisease |
EL0504 | FMR1-AS1 | fragile X syndrome | N/A | N/A | N/A | expression | A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. | 18213394 | LncRNADisease |
EL0504 | FMR1-AS1 | fragile X syndrome | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0504 | FMR1-AS1 | Fragile X-associated tremor and ataxia syndrome | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL0505 | FMR5 | fragile X syndrome | N/A | N/A | N/A | expression | Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. | 24005575 | LncRNADisease |
EL0505 | FMR5 | Fragile X-associated tremor and ataxia syndrome | N/A | N/A | N/A | expression | Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. | 24005575 | LncRNADisease |
EL0506 | FMR6 | fragile X syndrome | N/A | N/A | N/A | expression | Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. | 24005575 | LncRNADisease |
EL0506 | FMR6 | Fragile X-associated tremor and ataxia syndrome | N/A | N/A | N/A | expression | Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. | 24005575 | LncRNADisease |
EL0507 | FOSB | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | N/A | To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. | 24876753 | Lnc2Cancer |
EL0508 | FOXC2-AS1 | osteosarcoma | microarray, qPCR, Western blot, knockdown etc. | cell lines (MG63, SaoS2, U-2OS) | up-regulated | interaction | lncRNA ODRUL was higher in different doxorubicin-resistant OS cell lines and lower in different doxorubicin-sensitive OS cell lines. Moreover, we showed that lncRNA ODRUL was increased in specimens of OS patients with a poor chemoresponse and lung metastasis. We further demonstrated that lncRNA ODRUL inhibition could inhibit OS cell proliferation, migration, and partly reversed doxorubicin resistance in vitro. In addition, we found that the expression of classical drug resistance-related ATP-binding cassette, subfamily B, member 1 (ABCB1) gene was decreased after the lncRNA ODRUL knockdown. Thus, we concluded that lncRNA ODRUL may act as a pro-doxorubicin-resistant molecule through inducing the expression of the classical multidrug resistance-related ABCB1 gene in osteosarcoma cells. | 26408180 | Lnc2Cancer |
EL0508 | FOXC2-AS1 | osteosarcoma | microarray, qRT-PCR | three sets of doxorubicin-resistant MG63/DXR and their paired parental MG63 cells (fold-change >2.0, P<0.05 and FDR <0.05). | up-regulated | expression | The patients of lower expression of it may survive longer than those of higher expression, which suggest that it may serve as a biomarker to predict the chemoresponse and prognosis of steosarcoma patients. | 26463625 | |
EL0509 | FOXCUT | esophageal squamous cell carcinoma | qPCR, knockdown etc. | esophageal suqmous cell cancer tissue, cell lines (KYSE30, KYSE70, KYSE140, KYSE150, KYSE180 etc.) | up-regulated | expression | Notably elevated FOXCUT and FOXC1 expression levels were observed in cancerous tissues compared to adjacent noncancerous tissues, showing strong correlations with poor differentiation, advanced lymph node classification and metastasis. The expression of FOXCUT was positively correlated with expression of FOXC1 in ESCC specimens. And the expression of FOXC1 was also decreased as the FOXCUT expression was silenced by siRNA. Assays in vitro demonstrated that knockdown of either FOXCUT or FOXC1 remarkably inhibited cell proliferation, colony formation, migration, invasion in ESCC cells. | 25031703 | Lnc2Cancer |
EL0509 | FOXCUT | basal-like breast cancer | qPCR, knockdown etc. | cell lines (MDA-MB-231, MDA-MB-468) | up-regulated | interaction | The results showed that the expression of FOXCUT and FOXC1 were positively correlated. When the expression of FOXCUT was downregulated by small interfering RNA, the expression of FOXC1 was similarly reduced. Furthermore, in MDA-MB-231 and MDA-MB-468 breast cancer cells, knockdown of FOXCUT markedly inhibited cell proliferation and migration in vitro. In conclusion, FOXCUT lncRNA may be functionally involved in the tumor progression of BLBCs through the regulation of its paired mRNA, FOXC1, demonstrating that FOXCUT may serve as a novel biomarker and therapeutic target in BLBCs. | 25516208 | Lnc2Cancer |
EL0509 | FOXCUT | oral squamous cell carcinoma | qPCR, Western blot, knockdown etc. | OSCC tissue, cell lines (Tca8113, OSC-4, SCC1 etc.) | up-regulated | N/A | In this study, we report a new lncRNA FOXC1 upstream transcript (FOXCUT) that was remarkably overexpressed in 23 OSCC patients, as was the adjacent FOXC1 gene. The expressions of FOXC1 and FOXCUT were positively correlated. In conclusion, FOXC1 may be co-amplified with FOXCUT in OSCC, and both of them may be functionally involved in the tumor progression of OSCC. | 24889262 | Lnc2Cancer |
EL0510 | FR0257520 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | down-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
EL0511 | FR0348383 | prostate cancer | qRT-PCR | Post-digital rectal examination (DRE) first-catch urine specimens prior to prostate biopsies | up-regulated | expression | FR0348383 transcript in post-DRE urine may be a novel biomarker for detection of PCa with great diagnostic value, especially in the grey zone cohort. | 25597901 | |
EL0511 | FR0348383 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | up-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
EL0512 | FRLnc1 | gastric cancer | microarray, qPCR, knockdown etc. | gastric cancer tissue, cell lines (MGC803, AGS, BGC823, and SGC7901) | up-regulated | interaction | The RNA level of FRLnc1 is upregulated in 49 % (20/41) of cancer samples compared with neighboring non-cancerous stomach tissues. We also identified TGFb1 and Twist as the downstream effectors of FRLnc1 in the regulation of cell migration. Our findings suggest that FRLnc1 is involved in gastric cancer cell migration and for the first time set up the link between FOXM1 and LncRNA in cancer. | 25907137 | Lnc2Cancer |
EL0514 | FTX | hepatocelluar carcinoma | HCC tissues and cells; clinical analysis | HCC tissues and cells | up-regulated | N/A | pathway lncRNA Ftx/miR-545/RIG-I promotes HCC development by activating PI3K/Akt signaling | 26992218 | |
EL0514 | FTX | hepatocelluar carcinoma | N/A | HBV-related HCC tissue | up-regulated | expression | The overexpression of miR-545/374a cluster located in the Ftx lncRNA is partially responsible for a poor prognosis, and monitoring sera levels of miR-545/374a may be a useful diagnostic marker for HCC. | 25299640 | |
EL0514 | FTX | colorectal cancer | qPCR, knockdown etc | CRC and adjacent normal colorectal tissues, cell lines (HT-29, SW1116, SW480, COLO205) | up-regulated | expression | Long non-coding RNA FTX was significantly upregulated in colorectal cancer tissues, and low long non-coding RNA FTX expression was significantly correlated with differentiation grade, lymph vascular invasion, and clinical stage. Patients with high long non-coding RNA FTX showed poorer overall survival than those with low long non-coding RNA FTX. Multivariate analyses indicated that status of long non-coding RNA FTX was an independent prognostic factor for patients. Functional analyses showed that upregulation of long non-coding RNA FTX significantly promoted growth, migration, invasion, and increased colony formation in colorectal cancer cells. | 26629053 | Lnc2Cancer |
EL0518 | GACAT1 | gastric cancer | qPCR etc. | gastric cancer tissue | down-regulated | N/A | The results showed that AC096655.1-002 was significantly downregulated in gastric cancer tissues compared with paired adjacent non-tumorous tissues (P < 0.001). Its expression level was significantly correlated with lymph node metastasis (P < 0.001), distant metastasis (P < 0.001), tumor-node-metastasis stages (P < 0.001), and differentiation (P = 0.030). In a primary screen of global lncRNA expression profile in gastric cancer, we found that AC096655.1-002 (Ensembl: ENST00000419650) may contribute gastric cancer occurrence. | 23645148 | Lnc2Cancer |
EL0519 | GACAT2 | non-small cell lung cancer | qPCR etc. | NSCLC tissue, cell lines (A549, H157, HEK-293T) | down-regulated | expression | lncRNA HMlincRNA717 expression level was significantly decreased in NSCLC tissues in comparison to adjacent non-tumor tissues. It was also proved that HMlincRNA717 expression was to be associated with NSCLC histological grade, and lymph node metastasis. In addition, survival analysis proved that down-regulated HMlincRNA717 expression was associated with poor overall survival of NSCLC patients. HMlincRNA717 expression was an independent prognostic factor for patients with NSCLC, which might be a potential prognostic biomarker and therapeutic target for NSCLC. | 25674259 | Lnc2Cancer |
EL0519 | GACAT2 | gastric cancer | qPCR, PIR etc. | gastric cancer tissue, cell lines (AGS, BGC-823, HGC-27, MGC-803, SGC-7901 etc.) | down-regulated | N/A | The expression levels of HMlincRNA717 in five gastric cancer cell lines, AGS, BGC-823, HGC-27, MGC-803, and SGC-7901, were significantly downregulated than those in normal gastric mucosal epithelial cell line GES-1. More importantly, our results indicated that HMlincRNA717 expression levels were correlated with cancer distal metastasis (P = 0.034), venous invasion (P = 0.029), and nervous invasion (P = 0.024). lncRNA-HMlincRNA717 may play crucial roles during cancer occurrence and progression and may be a new potential biomarker of early gastric cancer. | 24961350 | Lnc2Cancer |
EL0520 | GACAT3 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines (AGS, BGC-823, MGC-803, SGC-7901 etc.) | up-regulated | N/A | AC130710 in gastric cancer was significantly higher. Its expression level was significantly associated with tumor size, tumor-node-metastasis (TNM) stages, and distal metastasis. miR-129-5p may play an important role in the downregulation of AC130710 in gastric cancer cells. These results indicated that lncRNA-AC130710 may be a potential tumor marker for gastric cancer prognosis. | 24969565 | Lnc2Cancer |
EL0521 | GADD45G | pituitary adenoma | qPCR etc. | pituitary tumor tissue | down-regulated | N/A | In summary, MEG3 and GADD45γexpression was significantly lost in most clinically non-functioning adenomas (78 and 92%, respetcively). Other assessed pituitary tumor phenotypes expressed both genes at significantly different levels, and, in some cases, with overexpression. | 21850407 | Lnc2Cancer |
EL0523 | GAPLINC | gastric cancer | microarray, ISH etc. | gastric cancer tissue | up-regulated | N/A | GAPLINC is a 924-bp-long lncRNA that is highly expressed in gastric cancer tissues. GAPLINC suppression and with gene expression profiling in gastric cancer cells revealed alterations in cell migration pathways, with CD44 expression the most highly correlated. Manipulating GAPLINC | 25277524 | LncRNADisease Lnc2Cancer |
EL0524 | GAS1RR | twist-positive breast cancer | microarray, qRT-PCR | Twist-positive mammosphere cells | N/A | interaction | lncRNA-Hh silence in Twist-positive breast cells attenuates the activated Shh-GLI1 signaling and decreases the CSC-associated SOX and OCT4 levels, thus reduces the MFE and tumorigenesis of transplanted tumor. | 26418365 | |
EL0525 | GAS2L3 | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116 ,SW1116) | down-regulated | N/A | Functional experiments demonstrated three dysregulated lncRNAs, AK123657, BX648207 and BX649059 were required for efficient invasion and proliferation suppression in CRC cell lines. | 24809982 | Lnc2Cancer |
EL0526 | GAS5 | breast cancer | GAS5 HREM sequence alone promotes the apoptosis of breast cancer cells | hormone-sensitive and -insensitive breast cancer cell lines | up-regulated | N/A | induce apoptosis in breast cancer cells | 26862727 | |
EL0526 | GAS5 | lymphoma | knockdown etc. | cell lines (Jeko-124 and Z-138) | down-regulated | N/A | Downregulation of GAS5 substantially reduced the effects of each rapalogue on cell viability, DNA synthesis, and colony-forming ability.Stimulation of expression of candidate tumor suppressor GAS5 is responsible for much of the cytotoxic and cytostatic effects of rapalogues in MCL, suggesting that improved targeting of this pathway may allow improvements in the therapy of this intractable lymphoma. | 24703244 | Lnc2Cancer |
EL0526 | GAS5 | type 2 diabetes mellitus | lncRNA arrays, quantitative PCR | Serum samples obtained from 96 participating veterans at JAH VA | N/A | expression | Decreased GAS5 levels in serum were associated with diabetes in a cohort of US military veterans. | 26674525 | |
EL0526 | GAS5 | hepatocelluar carcinoma | microarray, qPCR etc. | HBV-related HCC tissue | up-regulated | expression | Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. | 26109807 | Lnc2Cancer |
EL0526 | GAS5 | ovarian cancer | microarray, qPCR, knockdown etc. | EOC tissue, cell lines (HO8910, A2780) | down-regulated | interaction | The data show that no significant differences of GAS5 expression were observed between normal ovarian epithelium and benign epithelial lesions; however, GAS5 expression was lower in EOC tissues compared with normal ovarian epithelial tissues, which was closely related to lymph node metastasis and tumor node metastasis stage. Finally, through mitochondrial potential and western blot analyses, GAS5 could disrupt mitochondrial membrane potential and promote BAX, BAK, cleaved-caspase 3 and cleaved-caspase 9 expression. | 26503132 | Lnc2Cancer |
EL0526 | GAS5 | breast cancer | microarray, qRT-PCR | SKBR-3/Tr cells | down-regulated | N/A | GAS5 promoted SKBR-3 cell proliferation | 27034004 | |
EL0526 | GAS5 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0526 | GAS5 | stomach cancer | N/A | stomach cancer tissues | down-regulated | expression | In this study, we found that lncRNA GAS5 had lower expression in stomach cancer tissues than the normal counterparts. These results delineate a novel mechanism of lncRNA GAS5 in suppressing stomach carcinogenesis, and the lncRNA GAS5/YBX1/p21 pathway we discovered may provide useful targets for developing lncRNA-based therapies for stomach cancer. | 25959498 | |
EL0526 | GAS5 | lymphoma | N/A | N/A | N/A | mutation | The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma. | 18406879 | LncRNADisease |
EL0526 | GAS5 | lymphoma | N/A | N/A | N/A | mutation | Chromosomal translocations affecting the 1q25 locus containing the Gas5 gene have been detected in melanoma, B-cell lymphoma, and prostate and breast cancer. | 18836484 | LncRNADisease Lnc2Cancer |
EL0526 | GAS5 | melanoma | N/A | N/A | N/A | mutation | Chromosomal translocations affecting the 1q25 locus containing the Gas5 gene have been detected in melanoma, B-cell lymphoma, and prostate and breast cancer. | 18836484 | LncRNADisease Lnc2Cancer |
EL0526 | GAS5 | autoimmune disease | N/A | N/A | N/A | expression | Increased lncRNA Gas5 activity in immune cells could suppress GR-induced transcriptional activity and contribute to the development of autoimmune disease. | 20124551 | LncRNADisease |
EL0526 | GAS5 | tumor | N/A | N/A | N/A | regulation | Binding to GR as a decoy and blocking transcriptional induction by GR, induces growth arrest and apoptosis. | 22996375 | LncRNADisease |
EL0526 | GAS5 | kidney cancer | N/A | N/A | N/A | expression | Tumour suppressor | 24373479 | LncRNADisease |
EL0526 | GAS5 | prostate cancer | N/A | N/A | N/A | expression | Tumour suppressor; putative oncogene host | 24373479 | LncRNADisease |
EL0526 | GAS5 | tumor | N/A | N/A | N/A | regulation | ANRIL, GAS5 and lincRNA-p23 are involved in the escape of growth suppression by regulating tumor suppressor genes (ANRIL) or apoptosis regulators. | 24667321 | LncRNADisease |
EL0526 | GAS5 | tumor | N/A | N/A | N/A | regulation | Our own work suggests that while RoR (Zhang et al., 2013a) may function as an oncogene through suppression of p53 in response to DNA damage, loc285194 (Liu et al., 2013) and GAS5 (Zhang et al., 2013b) may play a tumor suppressive role through the “competitive endogenous RNA” (CeRNA) mechanism (Salmena et al., 2011). | 24721780 | LncRNADisease |
EL0526 | GAS5 | cancer | N/A | N/A | N/A | regulation | Pickard et al. showed that GAS5 promotes apoptosis of prostate cells after irradiation with UV, and low GAS5 expression therefore reduces the effectiveness of chemotherapeutic agents. | 24757675 | LncRNADisease |
EL0526 | GAS5 | liver fibrosis | overexpression | mouse, rat, and human fibrotic liver samples, activated hepatic stellate cell (HSC) | down-regulated | interaction | GAS5 increased the level of p27 protein by functioning as a competing endogenous RNA for miR-222, thereby inhibiting the activation and proliferation of HSCs. Overexpression of GAS5 suppressed the activation of primary HSCs in vitro and alleviated the accumulation of collagen in fibrotic liver tissues in vivo. GAS5 was identified as a target of microRNA-222 (miR-222) and showed that miR-222 could inhibit the expression of GAS5. GAS5 could also repress miR-222 expression. | 26446789 | |
EL0526 | GAS5 | prostate cancer | qPCR etc. | cell lines (HEK 293T, LNCaP, W7.2c etc.) | down-regulated | mutation | Chromosomal translocations affecting the 1q25 locus containing the Gas5 gene have been detected in melanoma, B-cell lymphoma, and prostate and breast cancer. | 18836484 | LncRNADisease Lnc2Cancer |
EL0526 | GAS5 | breast cancer | qPCR etc. | cell lines (HEK 293T, LNCaP, W7.2c etc.) | down-regulated | expression | GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. | 18836484 | LncRNADisease Lnc2Cancer |
EL0526 | GAS5 | cervical cancer | qPCR etc. | cell line (CaSki) | up-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | LncRNADisease Lnc2Cancer |
EL0526 | GAS5 | renal cell carcinoma | qPCR etc. | renal cell carcinoma tissue, cell lines (A498, HK-2 etc.) | down-regulated | N/A | The expression of GAS5 was lower in the RCC cell line A498 than that in normal renal cell line HK-2. Furthermore, using functional expression cloning, we found that overexpression of GAS5 in A498 cells inhibited cell proliferation, induced cell apoptosis and arrested cell cycling. Our study provided the first evidence that a decrease in GAS5 expression is associated with RCC genesis and progression and overexpression of GAS5 can act as a tumor suppressor for RCC, providing a potential attractive therapeutic approach for this malignancy. | 23621190 | Lnc2Cancer |
EL0526 | GAS5 | multiple myeloma | qPCR etc. | blood (plasma) | down-regulated | expression | HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. | 24583225 | LncRNADisease Lnc2Cancer |
EL0526 | GAS5 | hepatocelluar carcinoma | qPCR etc. | HCC tissue | down-regulated | expression | The expression level of GAS5 was reduced in HCC in comparison to normal matched tissues (P < 0.05). It is also proved that GAS5 expression was to be associated with HCC tumor size, lymphnode metastasis and clinical stage (P < 0.05). In addition, the Kaplan-Meier survival curves revealed that low GAS5 expression was associated with poor prognosis in HCC patients. GAS5 expression was an independent prognostic marker of overall HCC patient survival in a multivariate analysis. | 25120813 | Lnc2Cancer |
EL0526 | GAS5 | breast cancer | qPCR etc. | breast cancer tissues and postoperative blood samples | down-regulated | interaction | Analysis in the 39 paired preoperative and postoperative plasma samples showed that lower GAS5 levels appeared in the patients with a high Ki67 proliferation index before surgery and the patients with a positive lymph node metastasis state after surgery. Plasma lncRNA GAS5 may have the potential to assess the surgical effects and prognosis for BC patients | 26662314 | Lnc2Cancer |
EL0526 | GAS5 | colorectal cancer | qPCR, FCA etc. | CRC tissue | down-regulated | expression | The lower expression of GAS5 was significantly correlated with large tumor size, low histological grade and advanced TNM stage. Multivariate analyses revealed that GAS5 expression served as an independent predictor for overall survival. Further experiments revealed that overexpressed GAS5 significantly repressed the proliferation both in vitro and in vivo. | 25326054 | Lnc2Cancer |
EL0526 | GAS5 | prostate cancer | qPCR, knockdown etc. | cell lines (22Rv1, PC-3 etc.) | up-regulated | N/A | GAS5 promotes the apoptosis of prostate 34 cells, and exonic sequence, i.e. GAS5 lncRNA, is sufficient to mediate this activity. Abnormally low levels of 35 GAS5 expressionmay therefore reduce the effectiveness of chemotherapeutic agents. | 23676682 | Lnc2Cancer |
EL0526 | GAS5 | breast cancer | qPCR, knockdown etc. | cell lines (MCF7, T-47D) | down-regulated | regulation | GAS5?lncRNA?promoted the apoptosis of triple-negative and oestrogen receptor-positive cells but only dual PI3K/mTOR inhibition was able to enhance GAS5 levels in all cell types. Reduced GAS5 expression attenuates apoptosis induction by classical chemotherapeutic agents in breast cancer cells, providing an explanation for the relationship between GAS5 expression and breast cancer patient prognosis.? | 24789445 | LncRNADisease Lnc2Cancer |
EL0526 | GAS5 | malignant pleural mesothelioma | qPCR, knockdown etc. | MPM tissue, cell lines (SPC111, SPC212, ZL34, ZL55) | down-regulated | N/A | GAS5 expression was lower in MPM cell lines compared to normal mesothelial cells. GAS5 was upregulated upon growth arrest induced by inhibition of Hedgehog and PI3K/mTOR signalling in in vitro MPM models. The increase in GAS5 lncRNA was accompanied by increased promoter activity. Silencing of GAS5 increased the expression of glucocorticoid responsive genes glucocorticoid inducible leucine-zipper and serum/glucocorticoid-regulated kinase-1 and shortened the length of the cell cycle. Drug induced growth arrest was associated with GAS5 accumulation in the nuclei. GAS5 was abundant in tumoral quiescent cells and it was correlated to podoplanin expression. | 24885398 | Lnc2Cancer |
EL0526 | GAS5 | cervical cancer | qPCR, knockdown etc. | cervical cancer tissue | down-regulated | expression | We found that GAS5 expression was markedly downregulated in cervical cancer tissues than in corresponding adjacent normal tissues. Decreased GAS5 expression was significantly correlated with FIGO stage, vascular invasion and lymph node metastasis. Moreover, cervical cancer patients with GAS5 lower expression have shown significantly poorer overall survival than those with higher GAS5 expression. And GAS5 expression was an independent prognostic marker of overall survival in a multivariate analysis. | 25400758 | Lnc2Cancer |
EL0526 | GAS5 | lung adenocarcinoma | qPCR, Western blot etc. | lung cancer tissue, cell lines (A549, H1299, H1975, HCC827) | down-regulated | interaction | Our results showed that GAS5 was significantly downregulated in lung adenocarcinoma tissues compared with the paired adjacent non-tumorous tissue samples. Furthermore, lower GAS5 expression levels were associated with larger tumor sizes, poor tumor differentiation, and advanced pathological stages. GAS5 overexpression was inversely correlated with the expression of the EGFR pathway and IGF-1R proteins. | 25925741 | Lnc2Cancer |
EL0526 | GAS5 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, H1650, H1299, H1975, SK-MES etc.) | down-regulated | N/A | The results revealed that GAS5 expression was down-regulated in cancerous tissues compared to adjacent noncancerous tissues (P < 0.05) and was highly related to tumor size and TNM stage (P < 0.05). This correlation between GAS5 and clinicopathological parameters indicates that GAS5 might function as a tumor suppressor. Furthermore, GAS5 overexpression increased tumor cell growth arrest and induced apoptosis in vitro and in vivo. | 24357161 | Lnc2Cancer |
EL0526 | GAS5 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (SGC7901, BGC823, MGC803, MKN45, MKN28) | down-regulated | N/A | GAS5 expression was markedly downregulated in gastric cancer tissues. Moreover, ectopic expression of GAS5 was demonstrated to decrease gastric cancer cell proliferation and induce apoptosis, while downregulation of endogenous GAS5 could promote cell proliferation. GAS5 could influence gastric cancer cells proliferation, partly via regulating E2F1 and P21 expression. | 24884417 | Lnc2Cancer |
EL0526 | GAS5 | endometrial cancer | qPCR, Western blot, knockdown, Luciferase reporter assay, Flow cytometry assay etc. | endometrial cancer tissue, cell lines (HHUA, JEC) | down-regulated | interaction | We identified that GAS5 was down-regulated in endometrial cancer cells and stimulated the apoptosis of endometrial cancer cells. In summary, we demonstrate that GAS5 acts as an tumor suppressor lncRNA in endometrial cancer. Through inhibiting the expression of miR-103, GAS5 significantly enhanced the expression of PTEN to promote cancer cell apoptosis, and, thus, could be an important mediator in the pathogenesis of endometrial cancer. | 26511107 | Lnc2Cancer |
EL0526 | GAS5 | bladder cancer | qPCR, Western blot, knockdown, RIP etc. | bladder cancer tissue, cell lines (T24, DSH1, RT112, RT4, KU7, 253J etc.) | down-regulated | N/A | In the present study, we found that the GAS5 expression is commonly downregulated in bladder cancer cell lines and human specimens. Knockdown of GAS5 promotes bladder cancer cell proliferation, whereas forced expression of GAS5 suppresses cell proliferation. We further demonstrated that knockdown of GAS5 increases CDK6 mRNA and protein levels in bladder cancer cells. Expectedly, GAS5 inhibition induces a significant decrease in G0/G1 phase and an obvious increase in S phase. | 24069260 | Lnc2Cancer |
EL0526 | GAS5 | hepatocelluar carcinoma | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | cell lines (Sk-Hep-1, BEL-7404, Huh7) | up-regulated | expression | rs145204276 may contribute to hepatocarcinogenesis by affecting methylation status of the GAS5 promoter and subsequently its transcriptional activity thus serving as a potential therapy target for HCC. | 26163879 | Lnc2Cancer |
EL0526 | GAS5 | hepatocelluar carcinoma | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | HCC tissue, cell lines (Bel-7402, SMMC-7721, HCCLM3 etc.) | down-regulated | interaction | The present report demonstrates that there are lower levels of GAS5, PDCD4, and PTEN and higher levels of microRNA-21 (miR-21) in HCC tissues than in adjacent normal tissues. Then, overexpression of GAS5 suppresses the migration and invasion of HCC cells and high expression of miR-21 largely eliminates GAS5-mediated suppression of HCC cell migration and invasion. | 26404135 | Lnc2Cancer |
EL0526 | GAS5 | pancreatic cancer | qPCR, Western bolt etc. | pancreatic cancer tissue, cell lines (BxPC-3, PANC-1, AsPC-1, Hs766T etc.) | down-regulated | N/A | We verify that the expression level of gas5 is significantly decreased in pancreatic cancer tissues compared with normal control. Overexpression of gas5 in pancreatic cancer cells inhibits cell proliferation, whereas gas5 inhibition induces a significant decrease in G0/G1 phase and an increase in S phase. We further demonstrate that gas5 negatively regulates CDK6 expression in vitro and in vivo. More importantly, knockdown of CDK6 partially abrogates gas5-siRNA-induced cell proliferation. | 24026436 | Lnc2Cancer |
EL0526 | GAS5 | hepatocelluar carcinoma | Quantitative polymerase chain reaction and in situ hybridization | Hepatocellular carcinoma (HCC) tissues | down-regulated | interaction | Overexpression of GAS5 significantly suppressed the proliferation and invasion of hepatoma cells in vitro, promoted the apoptosis of hepatoma cells. | 26707238 | |
EL0526 | GAS5 | melanoma | quantitative real-time polymerase chain reaction | SK-Mel‑110 melanoma cell | down-regulated | N/A | Overexpressing lncRNA GAS5 inhibited the migration and invasion | 26846479 | |
EL0526 | GAS5 | breast cancer | RT-PCR (reverse transcription-polymerase chain reaction) array | breast tumor specimens, xenograft mouse model | N/A | interaction | GAS5 functions as a tumor suppressor. miR-21 is capable of suppressing the lncRNA growth arrest-specific 5 (GAS5). GAS5 can also repress miR-21 expression. | 23933812 | |
EL0526 | GAS5 | prostate cancer | siRNA | prostate cancer cells | up-regulated | expression | mTOR inhibition enhances GAS5 transcript levels in certain prostate cancer cell lines. This selectivity is likely to be related to endogenous GAS5 expression levels. | 25650269 | |
EL0526 | GAS5 | varicose great saphenous veins | siRNA | varicose great saphenous veins (GSVs) varicosities | down-regulated | expression | The low expression of lncRNA-GAS5 may facilitate HSVSMCs proliferation and migration through Annexin A2 and thereby the pathogenesis of GSV varicosities | 25806802 | |
EL0527 | Gas5 | systemic lupus erythaematosus | N/A | N/A | N/A | N/A | The Gas5 transcript has been linked with increased susceptibility to systemic lupus erythaematosus in mouse models, presumably as a result of its effect on the immunosuppressant role of glucocorticoids | 22817756 | LncRNADisease |
EL0528 | GAS6-AS1 | non-small cell lung cancer | qPCR etc. | NSCLC tissue | down-regulated | N/A | In this study, we reported a new lncRNA GAS6-AS1, whose expression was downregulated in tumor tissues in 50 patients with NSCLC compared with those in the adjacent normal tissues. Furthermore, decreased GAS6-AS1 expression was negatively correlated with lymph node metastasis and advanced tumor node metastasis stage. Univariate and multivariate analyses showed that GAS6-AS1 expression served as an independent predictor for overall survival. Altered lncRNA GAS6-AS1 expression might be involved in the development and progression of NSCLC by influencing its host gene and promised to be a potential diagnostic target in patients with NSCLC. | 23979857 | Lnc2Cancer |
EL0529 | GAS8-AS1 | papillary thyroid carcinoma | NGS | Chinese PTC using 402 tumor-normal pairs | N/A | N/A | higher capability to inhibit cancer cell growth | 26941397 | |
EL0530 | GATA3-AS1 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | down-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL0531 | GDNF-AS1 | Alzheimer's disease | N/A | N/A | N/A | expression | The findings of novel GDNF and GDNFOS isoforms and differences in tissue expression patterns dysregulated in AD brains may further reveal the role of endogenous GDNF in human brain diseases. | 22081608 | LncRNADisease |
EL0533 | GHET1 | gastric cancer | hypoxia-induced GC and normoxia conditions using microarrays | hypoxia-induced GC cells | up-regulated | N/A | lncRNA-AK123072/EGFR pathway in gastric cancer pathogenesis | 26884908 | |
EL0533 | GHET1 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) | up-regulated | expression | All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues. | 26096073 | Lnc2Cancer |
EL0533 | GHET1 | bladder cancer | qPCR, Western blot, in vitro knockdown etc. | bladder cancer tissue | up-regulated | expression | In this study, we demonstrated that GHET1 was upregulated in bladder cancer tissues compared to adjacent normal tissues and its over-expression correlates with tumor size, advanced tumor and lymph node status, and poor survival. GHET1 knockdown suppressed the proliferation and invasion of bladder cancer cells in vitro. In the meantime, inhibition of GHET1 reversed the epithelial-mesenchymal-transition in bladder cancer cell line. | 25400817 | Lnc2Cancer |
EL0533 | GHET1 | gastric cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | gastric cancer tissue, cell lines (MKN45, AGS etc.) | up-regulated | regulation | Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. | 24397586 | LncRNADisease Lnc2Cancer |
EL0534 | GHSR | non-small cell lung cancer | qPCR, Northern bolt etc. | lung cancer tissue, cell lines (A549, NCI-H1299, Beas-2B etc.) | up-regulated | N/A | Quantitative real-time RT-PCR revealed higher expression of GHSROS in lung cancer tissue compared to adjacent, non-tumour lung tissue. GHSROS function may be dependent on the oncogenic context. The identification of GHSROS, which is expressed in lung cancer and stimulates cell migration in lung cancer cell lines, contributes to the growing number of non-coding RNAs that play a role in the regulation of tumourigenesis and metastatic cancer progression. | 23722988 | Lnc2Cancer |
EL0536 | Gm10371 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 27 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0542 | Gm32592 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 11 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0543 | Gm6644 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 12 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0544 | GNAS-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL0544 | GNAS-AS1 | pseudohypoparathyroidism type Ib | N/A | N/A | N/A | mutation | Deletion of the nespas causes pseudohypoparathyroidism Type Ib. | 20444925 | LncRNADisease |
EL0551 | AF181450.1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | down-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL0552 | GSTT1-AS1 | Mycobacterium tuberculosis infection | knock-down | CD244(+)CD8(+) T-cell line | up-regulated | expression | CD244 expression/signaling in TB correlates with high levels of a long noncoding RNA (lncRNA)-BC050410 [named as lncRNA-AS-GSTT1 (1-72) or lncRNA-CD244] in the CD244(+)CD8(+) T-cell subpopulation. CD244 signaling drives lncRNA-CD244 expression via sustaining a permissive chromatin state in the lncRNA-CD244 locus. | 26150504 | |
EL0553 | GUCY1B2 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL0555 | H19 | overgrowth | transgenic | embryos of mice lacking H19 | down-regulated | mutation | Mice lacking H19 show an overgrowth phenotype, due to a cis effect of the H19 locus on the adjacent Igf2 gene. | 19762426 | |
EL0556 | H19 | colorectal cancer | a case-control study | N/A | N/A | N/A | N/A | 27027436 | |
EL0556 | H19 | gastric cancer | AGS cells, knock out of H19 | gastric cancer AGS cells | down-regulated | N/A | H19 or miR-675 enhanced RUNX1 expression | 26931432 | |
EL0556 | H19 | osteoarthritis | cDNA array and quantitative RT-PCR | OA and normal knee cartilage | up-regulated | interaction | LncRNA H19 acts as a metabolic correlate in cartilage and cultured chondrocytes, while the miR-675 may indirectly influence COL2A1 levels. H19 may not only be an attractive marker for cell anabolism but also a potential target to stimulate cartilage recovery | 22527881 | |
EL0556 | H19 | gallbladder cancer | gallbladder cancer | gallbladder cancer tissues and adjacent normal tissues | up-regulated | N/A | The overexpression of H19 in GBC cells enhanced tumor invasion and promoted EMT | 27073719 | |
EL0556 | H19 | bladder cancer | ISH etc. | bladder cancer tissue etc. | differential expression | expression | The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. | 11193051 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | gestational choriocarcinoma | ISH etc. | placenta tissue | up-regulated | expression | Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. | 8188082 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | trophoblastic tumor | ISH etc. | placenta tissue | up-regulated | expression | Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. | 8188082 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | laryngeal squamous cell carcinoma | knockdown | LSCC patients | up-regulated | N/A | The inhibition of LSCC progression induced by H19 knockdown required the activity | 26872375 | |
EL0556 | H19 | nasopharyngeal carcinoma | knockdown | NPC tissues | up-regulated | N/A | H19 regulated EZH2 expression suppressing the activity of miR-630 | 27040767 | |
EL0556 | H19 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We found that imbalances in levels of IGF2 and H19 transcripts were correlated with advanced tumor stage and poor outcome in HCC patients. | 15736456 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue, cell lines (GES-1, AGS, MGC-803, SGC-7901) | up-regulated | N/A | As shown in Figure 2D, comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). | 24063685 | Lnc2Cancer |
EL0556 | H19 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
EL0556 | H19 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | H19 expression level was 4.97 to 13.58-fold higher in GCa samples than the mean level in paired non-cancerous tissues. Moreover, the expression levels of H19 were increased significantly in the tumors of patients with advanced clinical stage (p < 0.001) and larger tumor size ( p < 0.001). | 24414129 | Lnc2Cancer |
EL0556 | H19 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue, cell lines (HCG-27, SGC-7901) | up-regulated | expression | H19 and HOTAIR displayed significantly higher levels and the up-regulation of HOTAIR was associated with lymphatic metastasis and poor differentiation. | 26237576 | Lnc2Cancer |
EL0556 | H19 | hepatocelluar carcinoma | microarray, qPCR, knockdown, ISH etc. | cell lines (T24P, HepG2, Hep3B etc.) | up-regulated | N/A | The H19 non-coding RNA is essential for human tumor growth. | 17786216 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | bladder cancer | microarray, qPCR, knockdown, ISH etc. | cell lines (T24P etc.) | up-regulated | N/A | The H19 non-coding RNA is essential for human tumor growth. | 17786216 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | ovarian cancer | microarray, qPCR, Western blot etc. | cell lines (OVCAR-3, OV-90 and SK-OV-3) | down-regulated | interaction | We find that overexpression of H1.3 decreases the growth rate and colony formation of OVCAR-3 cells. We identify histone H1.3 as a specific repressor for the noncoding oncogene H19. Overexpression of H1.3 suppresses H19 expression, and knockdown of H1.3 increases its expression in multiple ovarian epithelial cancer cell lines. Furthermore, we demonstrate that histone H1.3 overexpression leads to increased occupancy of H1.3 at the H19 regulator region encompassing the imprinting control region (ICR), concomitant with increased DNA methylation and reduced occupancy of the insulator protein CTCF at the ICR. Finally, we demonstrate that H1.3 overexpression and H19 knockdown synergistically decrease the growth rate of ovarian cancer cells | 25205099 | Lnc2Cancer |
EL0556 | H19 | glioma | microarray, qPCR, Western blot, knockdown, Luciferase reporter assay etc. | glioma tissue, cell lines (U87, U251 etc.) | up-regulated | regulation | Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. | 24466011 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | colorectal cancer | Multivariate analyses | 83 CRC patients | up-regulated | N/A | overexpression of H19 promoted the proliferation of CRC cells; growth regulator | 26989025 | |
EL0556 | H19 | choricarcinoma | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
EL0556 | H19 | type 2 diabetes mellitus | N/A | muscle of human subjects with type-2 diabetes and insulin resistant rodents. | down-regulated | expression | H19 is significantly decreased in muscle of human subjects with type-2 diabetes and insulin resistant rodents. This decrease leads to increased bioavailability of let-7, causing diminished expression of let-7 targets, which is recapitulated in vitro where H19 depletion results in impaired insulin signaling and decreased glucose uptake. | 25399420 | |
EL0556 | H19 | glioblastoma multiforme | N/A | GBM cell lines | up-regulated | N/A | H19 in contributing to GBM malignancy | 26983719 | |
EL0556 | H19 | cardiac hypertrophy | N/A | normal and diseased hearts | up-regulated | N/A | overexpression of H19 reduced cell size both at baseline and in response to PE; knockdown of H19 induced cardiomyocyte hypertroph | 27084844 | |
EL0556 | H19 | heart failure | N/A | normal and diseased hearts | up-regulated | N/A | overexpression of H19 reduced cell size both at baseline and in response to PE; knockdown of H19 induced cardiomyocyte hypertroph | 27084844 | |
EL0556 | H19 | myeloproliferative disease polycythaemia vera | N/A | N/A | N/A | expression | Expression of the imprinted tumour-suppressor gene H19 is tightly regulated during normal haematopoiesis and is reduced in haematopoietic precursors of patients with the myeloproliferative disease polycythaemia vera. | 10640993 | LncRNADisease |
EL0556 | H19 | Marek's disease | N/A | N/A | N/A | mutation | The mutant CVI/rpp38 was not only reactive with MAb H19 in IFA but also in immunoprecipitation. | 10696440 | LncRNADisease |
EL0556 | H19 | congenital hyperinsulinism | N/A | N/A | N/A | expression | In agreement with the loss of the maternal chromosome, the level of expression of a maternally expressed tumor suppressor gene, H19, was greatly reduced compared to the level of expression of the paternally expressed growth promoter gene, IGF2. | 11395395 | LncRNADisease |
EL0556 | H19 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | epigenetics | Mosaicism for 11p15 UPD and hypermethylation of the H19 gene in blood cells were associated with an increased risk of tumour. | 11436121 | LncRNADisease |
EL0556 | H19 | melanoma | N/A | N/A | N/A | expression | The study of 4 sensitive and 2 resistant cell lines allowed the identification of 4 genes (RCC1, IFI16, hox2 and h19) preferentially transcribed in sensitive ((IFN-alpha therapy) cells and 2 (SHB and PKC-zeta) preferentially expressed in resistant cells. | 11437411 | LncRNADisease |
EL0556 | H19 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | epigenetics | Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. | 11813134 | LncRNADisease |
EL0556 | H19 | gestational trophoblastic diseases | N/A | N/A | N/A | expression | LOI, deregulation of IGF2 promoters, and the altered expression levels of IGF2 and H19 genes might be associated with the progression of GTD. | 12648595 | LncRNADisease |
EL0556 | H19 | chronic myeloproliferative disorders | N/A | N/A | N/A | expression | Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders. | 12682647 | LncRNADisease |
EL0556 | H19 | biparental complete hydatidiform moles | N/A | N/A | N/A | epigenetics | H19 is abnormally methylated on the maternal alleles in BiCHMs. | 12783848 | LncRNADisease |
EL0556 | H19 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | mutation | Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. | 15314640 | LncRNADisease |
EL0556 | H19 | colon cancer | N/A | N/A | N/A | expression | DT-A was preferentially expressed in liver metastases after being transfected with H19 or IGF2-P3 promoter-driven DT-A expression plasmids, causing a very significant inhibition of tumor growth as a result of its cytotoxic effect. | 15521051 | LncRNADisease |
EL0556 | H19 | cancer | N/A | N/A | N/A | expression | The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. | 15618002 | LncRNADisease |
EL0556 | H19 | hyperhomocysteinemia | N/A | N/A | N/A | epigenetics | The effect of hyperhomocysteinemia on H19 DMD methylation was tissue-specific. hyperhomocysteinemia produces tissue-specific changes in H19 DMD methylation and increased vascular expression of H19 in adult mice. | 15899898 | LncRNADisease |
EL0556 | H19 | cancer | N/A | N/A | N/A | expression | H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival. | 16189152 | LncRNADisease |
EL0556 | H19 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | locus | The H19 locus acts in vivo as a tumor suppressor. | 18719115 | LncRNADisease |
EL0556 | H19 | Silver-Russell syndrome | N/A | N/A | N/A | mutation | Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome | 19066168 | LncRNADisease |
EL0556 | H19 | pre-eclampsia | N/A | N/A | N/A | mutation | LOI of H19 can be identified in pre-eclamptic placentas and is associated with maternal blood pressures, which implies the involvement of H19 gene LOI in the pathogenesis of pre-eclampsia and its potential relationship with the severity of the disease. | 19570415 | LncRNADisease |
EL0556 | H19 | melanoma | N/A | N/A | N/A | expression | H19 RNA downregulation stimulated melanogenesis in melasma. | 19968822 | LncRNADisease |
EL0556 | H19 | infertility | N/A | N/A | N/A | expression | H19 expression was lower in the infertility group as compared to the control group. | 20042264 | LncRNADisease |
EL0556 | H19 | growth restriction | N/A | N/A | N/A | epigenetics | A loss of methylation at H19. | 20104244 | LncRNADisease |
EL0556 | H19 | glioblastoma | N/A | N/A | N/A | expression | Another study performed in CD133+ and CD133- glioblastoma derived primary cell lines revealed levels of H19 expression that were relatively high and low, respectively. | 20380817 | LncRNADisease |
EL0556 | H19 | medulloblastoma | N/A | N/A | N/A | epigenetics | A study of medulloblastomas and medulloblastoma cell lines showed partial loss of imprinting (LOI) and biallelic expression of H19. | 20380817 | LncRNADisease |
EL0556 | H19 | meningioma | N/A | N/A | N/A | epigenetics | An examination of meningiomas (World Health Organization grades I-III) demonstrated more robustly that the imprinting status of H19 is perturbed with LOI in a significant number of these tumors. | 20380817 | LncRNADisease |
EL0556 | H19 | melanoma | N/A | N/A | N/A | mutation | Although the IGF2 and H19 genotypes/haplotypes were not significantly associated with melanoma, two of the most severe cases (very early onset or multiple melanomas) showed to be heterozygous for both genes. | 20483645 | LncRNADisease |
EL0556 | H19 | Wiedemann-Beckwith syndrome | N/A | N/A | N/A | epigenetics | Genetic analyses of the patient's blood showed hypermethylation at the H19 locus on chromosome 11p. | 21058226 | LncRNADisease |
EL0556 | H19 | Silver-Russell syndrome | N/A | N/A | N/A | epigenetics | The major finding (~44%) is a hypomethylation of the imprinting control region 1 (ICR1) in 11p15.5 affecting the expression of H19 and IGF2. 4-10% of the patients carry a maternal UPD of chromosome 7 (UPD(7)mat). | 21150838 | LncRNADisease |
EL0556 | H19 | liver cancer | N/A | N/A | N/A | epigenetics | H19 ICR showed loss-of-imprinting in two steps and allelic histone marker signature during tumorigenesis showed similarity with ES cells. | 21163252 | LncRNADisease |
EL0556 | H19 | Mullerian aplasia | N/A | N/A | N/A | epigenetics | Methylation of H19 and its imprinted control region (H19 ICR1) in Mullerian aplasia. | 21458801 | LncRNADisease |
EL0556 | H19 | colon cancer | N/A | N/A | N/A | N/A | Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver. | 21874233 | LncRNADisease |
EL0556 | H19 | pheochromocytoma | N/A | N/A | N/A | mutation | Tumor DNA from the index patient revealed loss of heterozygosity (LOH) at 11q23, causing loss of the wild-type paternal SDHD allele and LOH affecting maternal 11p15, including H19. | 21937622 | LncRNADisease |
EL0556 | H19 | atherosclerosis | N/A | N/A | N/A | epigenetics | The most pronounced differences of atherosclerotic plaques in DNA methylation levels were registered for a site which is located in CpG-island of imprinted gene H19. | 21954592 | LncRNADisease |
EL0556 | H19 | breast cancer | N/A | N/A | N/A | mutation | Different SNPs in LSP1 and H19 and in minor genes probably were associated with BC risk. | 21996731 | LncRNADisease |
EL0556 | H19 | adrenocortical carcinomas | N/A | N/A | N/A | epigenetics | This disease has been associated with structural abnormalities at the 11p15 locus, which harbors the IGF2 gene as well as the genes coding for insulin, H19, and p57kip2. | 22019903 | LncRNADisease |
EL0556 | H19 | neural tube defects | N/A | N/A | N/A | epigenetics | The methylation levels of H19 DMR1 in the NTD and control groups are 73.3%卤15.9 and 58.3%卤11.2, respectively. Hyper-methylation of the H19 DMR1 may be correlated with the occurrence of NTDs. | 22234160 | LncRNADisease |
EL0556 | H19 | obesity | N/A | N/A | N/A | epigenetics | Insulin-like Growth Factor 2/H19 Methylation at Birth and Risk of Overweight and Obesity in Children. | 22341586 | LncRNADisease |
EL0556 | H19 | Wilms' tumor | N/A | N/A | N/A | epigenetics | 37% of patients with Wilms' tumor were H19 epimutations. | 22470196 | LncRNADisease |
EL0556 | H19 | bladder cancer | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
EL0556 | H19 | breast cancer | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
EL0556 | H19 | colon cancer | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
EL0556 | H19 | esophageal squamous cell carcinoma | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
EL0556 | H19 | liver cancer | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
EL0556 | H19 | lung cancer | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
EL0556 | H19 | tumor | N/A | N/A | N/A | epigenetics | In recent years, we have extensively investigated the expression of the H19 gene in a number of human cancers and explored the role of H19 RNA in tumor development. | 23429271 | LncRNADisease |
EL0556 | H19 | tumor | N/A | N/A | N/A | expression | H19, a lncRNA with oncogenic properties, is upregulated in a wide range of tumours. | 23660942 | LncRNADisease |
EL0556 | H19 | glioma | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0556 | H19 | medulloblastoma | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0556 | H19 | meningioma | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0556 | H19 | neuroblastoma | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0556 | H19 | pituitary adenoma | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0556 | H19 | Prader-Willi syndrome | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0556 | H19 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
EL0556 | H19 | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Dysregulation and functional roles of lncRNAs in HCC | 24183851 | LncRNADisease |
EL0556 | H19 | kidney cancer | N/A | N/A | N/A | regulation | Tumour suppressor; tumour suppressor host | 24373479 | LncRNADisease |
EL0556 | H19 | bladder cancer | N/A | N/A | N/A | expression | Prognostic marker low-risk marker Oncogene targeted therapy agent | 24373479 | LncRNADisease |
EL0556 | H19 | prostate cancer | N/A | N/A | N/A | expression | Putative susceptibility and diagnostic marker | 24373479 | LncRNADisease |
EL0556 | H19 | bladder cancer | N/A | N/A | N/A | regulation | Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon | 24499465 | LncRNADisease |
EL0556 | H19 | liver cancer | N/A | N/A | N/A | regulation | Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon | 24499465 | LncRNADisease |
EL0556 | H19 | lung cancer | N/A | N/A | N/A | regulation | Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon | 24499465 | LncRNADisease |
EL0556 | H19 | tumor | N/A | N/A | N/A | regulation | Oncofetal H19 RNA promotes tumor metastasis. | 24703882 | LncRNADisease |
EL0556 | H19 | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Overexpression of H19 was found in hepatocellular carcinoma.? | 24757675 | LncRNADisease |
EL0556 | H19 | gastric cancer | N/A | N/A | N/A | regulation | Using real-time RT-PCR, flow cytometry, RNA immunoprecipitation and other methods, Yang et al confirmed that H19 expression in gastric cancer accelerated cell proliferation. | 24833871 | LncRNADisease |
EL0556 | H19 | coronary artery disease | N/A | N/A | N/A | N/A | Re-expression of H19 has been observed in patients with atherosclerosis. Common polymorphisms of H19 are associated with the risk and severity of CAD in a Chinese population. | 25772106 | LncRNADisease |
EL0556 | H19 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | epigenetics | Allelic methylation of H19 and IGF2 in the Beckwith-Wiedemann syndrome. | 7987305 | LncRNADisease |
EL0556 | H19 | cervical cancer | N/A | N/A | N/A | mutation | High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. | 8570220 | LncRNADisease |
EL0556 | H19 | breast adenocarcinomas | N/A | breast adenocarcinoma stromal cells | up-regulated | expression | An up-regulation of the h19 gene is significantly correlated with the tumor values and the presence of both estrogen and progesterone receptors | 9811352 | |
EL0556 | H19 | bladder cancer | PCR-RFLP etc. | blood | differential expression | mutation | A significantly decreased risk of bladder cancer was found for the rs2839698 TC genotype but not for CC homozygotes.The rs2839698 TC genotype was especially associated with a reduced risk of developing non-muscle-invasive disease. Borderline significantly | 18262338 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | meningioma | qPCR etc. | meningioma tissue | differential expression | N/A | In total, 24 meningiomas of WHO grade I, II and III were analysed. 15 meningiomas (63%) were informative for the ApaI polymorphism in the IGF2 gene. Monoallelic expression (MAE) for IGF2 was found in 11 out of 15 tumours (73%) which is in contrast to the lack of imprinting status of IGF2 in leptomeninges. Ten cases (42%) were heterozygous for the H19 gene and biallelic expression was found in 3 out of 10 meningiomas (30%). These results indicate that modulation of the imprinting status of IGF2 and H19 may play an important role for the development of meningiomas. | 10738131 | Lnc2Cancer |
EL0556 | H19 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | N/A | LOI of IGF2 correlated strongly with biallelic hypermethylation of a core of five CpG sites in the insulator region of IGF2/H19, which is a known CTCF-binding element. As this methylation-dependent LOI was present in both tumors and normal colonic mucosa, it is possible that hypermethylation creates a field defect predisposing to cancer. | 11120891 | Lnc2Cancer |
EL0556 | H19 | germ cell tumor | qPCR etc. | germ cell tumor tissue | differential expression | epigenetics | IGF2/H19 methylation status in GCTs might reflect preservation of the physiologic imprinting erasure in PGCs rather than a loss of imprinting in a sense that is accepted for somatic tumors. | 16001432 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | breast cancer | qPCR etc. | cell lines (MCF10A, RPMI 1640, DMEM H21 etc.) | up-regulated | expression | Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. | 16707459 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | lung cancer | qPCR etc. | cell lines (MCF10A, RPMI 1640, DMEM H21 etc.) | up-regulated | expression | Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. | 16707459 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | breast cancer | qPCR etc. | breast cancer tissue | differential expression | mutation | rs2107425 (C>T) near H19 was significantly associated with shorter metastasis-free survival in uni- and multi-variate analysis , with the more aggressive minor allele displaying a recessive trait. | 21748294 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines (HGC27) | up-regulated | N/A | Plasma H19 levels were significantly higher in patients than in healthy controls (p=0.029). Circulating lncRNAs can be detectable in plasma, and the detection of circulating lncRNAs may provide new complementary tumor markers for gastric cancer. | 23898077 | Lnc2Cancer |
EL0556 | H19 | hepatocelluar carcinoma | qPCR etc. | cell lines (SMMC-7721, HepG2) | up-regulated | N/A | Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). | 24063685 | Lnc2Cancer |
EL0556 | H19 | prostate cancer | qPCR etc. | cell lines ((Du-145, PC-3) | down-regulated | N/A | Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). | 24063685 | Lnc2Cancer |
EL0556 | H19 | lung cancer | qPCR etc. | cell lines (A549) | down-regulated | N/A | Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). | 24063685 | Lnc2Cancer |
EL0556 | H19 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) | up-regulated | expression | After validating in 20 pairs of tissues and plasma in training set, H19 was selected for further analysis in another 70 patients and 70 controls. Plasma level of H19 was significantly higher in GC patients compared with normal controls. | 26096073 | Lnc2Cancer |
EL0556 | H19 | liver cancer | qPCR etc. | hepatocellular carcinoma tissue | up-regulated | expression | LncRNA profiling revealed that CD90+ cells were enriched in lncRNA H19, and released this through exosomes.Experiments of gain and loss of function of H19 showed that this LncRNA plays an important role in the exosome-mediated phenotype of endothelial cells. Moreover, we suggest the lncRNA H19 as a putative therapeutic target in hepatocellular carcinoma. | 26272696 | Lnc2Cancer |
EL0556 | H19 | medulloblastoma | qPCR etc. | fetal cerebella tissue, cell lines (MEB-MED, D283 etc.) | differential expression | expression | Loss of imprinting of H19 occurred in 0 out of 4 informative fetal cerebella, 0 out of 1 informative adult cerebellum, 4 out of 8 informative medulloblastomas, and 1 out of 4 informative cell lines. The biallelic expression of H19 was only partial in two medulloblastomas, however, with one allele being significantly weaker than the other. | 8957451 | Lnc2Cancer |
EL0556 | H19 | breast cancer | qPCR, ISH etc. | MDA-MB-231 cell line | up-regulated | expression | Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. | 12419837 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | bladder cancer | qPCR, ISH etc. | cell lines (T24P, HT-1376 etc.) | up-regulated | N/A | Bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA. | 21162716 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | breast cancer | qPCR, knockdown etc. | breast cancer tissue, cell lines (MCF7, T47D, BT20 etc.) | up-regulated | expression | the transcript is stabilized in breast cancer cells and overexpressed in human breast tumors.91H expression is upregulated in breast cancer. | 18794369 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | ovarian cancer | qPCR, knockdown etc. | cell lines (PC3, C2C12 etc.) | up-regulated | expression | H19 RNA was detected in 90% of patients with OCAF (Ovarian cancer ascites fluid ) as determined by ISH. Intratumoral injection of DTA-H19 into ectopically developed tumors caused 40% inhibition of tumor growth. | 19656414 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | gastric cancer | qPCR, knockdown etc. | gastric cancer tissue, cell lines MGC-803, SGC-7901, GES-1) | up-regulated | regulation | c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. | 24671855 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (TE-1 ,Eca-109) | down-regulated | regulation | Long non-coding RNA 91H contributes to the occurrence and progression of esophageal squamous cell carcinoma by inhibiting IGF2 expression. | 24706416 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | colorectal cancer | qPCR, knockdown etc. | CRC tissue, cell lines ( HCT8, HT29, HCT116, SW620 etc.) | up-regulated | regulation | 91H was significantly overexpressed in cancerous tissue and CRC cell lines compared with adjacent normal tissue and a normal human intestinal epithelial cell line. Moreover, 91H overexpression was closely associated with distant metastasis and poor prognosis in patients with CRC, except for CNV of 91H. Multivariate analysis indicated that 91H expression was an independent prognostic indicator, as well as distant metastasis. 91H played an important role in the molecular etiology of CRC and might be regarded as a novel prognosis indicator in patients with CRC. | 25058480 | Lnc2Cancer |
EL0556 | H19 | skin cancer | qPCR, lncRNA array analysis | cultured mouse keratinocytes after deleting the vitamin D receptor (VDR) (∼90%) vs. control cells | up-regulated | expression | Several well-known oncogenes, including H19, HOTTIP and Nespas, are significantly increased (6.3-1.8-fold), whereas tumor suppressors (Kcnq1ot1, lincRNA-p21) are decreased (up to 50-70%) in VDR deleted keratinocytes. | 24342142 | |
EL0556 | H19 | bladder cancer | qPCR, Luciferase reporter assay, in vitro knockdown, RIP etc. | bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) | up-regulated | regulation | Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. | 23354591 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | gastric cancer | qPCR, Luciferase reporter assays, in vitro knockdown, RIP etc. | gastric cancer tissue,cell lines (AGS, MKN45, MGC803, SGC7901, GES-1 etc.) | up-regulated | N/A | We demonstrated that H19 levels were markedly increased in gastric cancer cells and gastric cancer tissues compared with normal controls. Moreover, ectopic expression of H19 increased cell proliferation, whereas H19 siRNA treatment contributed to cell apoptosis in AGS cell line. We further verified that H19 was associated with p53, and that this association resulted in partial p53 inactivation. | 22776265 | Lnc2Cancer |
EL0556 | H19 | gastric cancer | qPCR, Luciferase reporter assays, knockdown etc. | gastric cancer tissue | up-regulated | interaction | H19 expression was found to be inversely correlated to miR-141 expression in gastric cancer cells and tissues. H19 promotes malignancy including proliferation and invasion whereas miR-141 suppresses malignancy in human cancer cells. MiR-141 binds to H19 in a sequence specific manner, and suppresses H19 expression and functions including proliferation and invasion. MiR-141 could also regulate H19 target genes and miR-141 inhibitor restores H19 siRNA function, while H19 regulates miR-141 target gene ZEB1 | 26160158 | Lnc2Cancer |
EL0556 | H19 | non-small cell lung cancer | qPCR, Luciferase reporter assays, knockdown, ChIP etc. | NSCLC cell lines (A549, SPCA1) | up-regulated | interaction | The higher expression of H19 was positively correlated with advanced tumor-node-metastasis (TNM) stage and tumor size. Multivariate analyses found that H19 expression could serve as an independent prognostic factor for overall survival of NSCLC. Moreover, chromatin immunoprecipitation (ChIP) assays revealed that H19 was a direct transcriptional target of c-Myc. And, knockdown of H19 significantly inhibited NSCLC cell proliferation both in vitro and in vivo. | 26482621 | Lnc2Cancer |
EL0556 | H19 | glioblastoma | qPCR, Neurosphere Formation assay etc. | glioblastoma tissue, cell lines (U87, U373) | up-regulated | expression | H19 is significantly overexpressed in glioblastoma tissues, and the level of expression was associated with patient survival. In the subsequent investigations, the authors found that overexpression of H19 promotes glioblastoma cell invasion and angiogenesis in vitro. Interestingly, H19 was also significantly overexpressed in CD133+ glioblastoma cells, and overexpression of H19 was associated with increased neurosphere formation of glioblastoma cells. | 26274999 | Lnc2Cancer |
EL0556 | H19 | breast cancer | qPCR, Northern blot etc. | breast cancer tissue | differential expression | expression | H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-neoplastic WAP-CRD-BP mammary tissue. | 14729626 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | colon cancer | qPCR, Northern blot, ISH etc. | CRC tissue | up-regulated | locus | Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. | 19926638 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | colorectal cancer | qPCR, RFLP-PCR etc. | CRC tissue | up-regulated | N/A | The results of the present study suggest that LOI of IGF2 is important in the carcinogenesis of CRC. Hypomethylation of the sixth CTCF-binding site in the DMR of IGF2/H19 is linked to LOI and the common IGF2-H19 enhancer competition model for IGF2 imprinting does not apply to human CRC. | 22427002 | Lnc2Cancer |
EL0556 | H19 | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) | up-regulated | regulation | Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. | 23399020 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | chronic myeloid leukemia | qPCR, Western blot etc. | cell lines (K562) | up-regulated | N/A | We observed that H19 was highly expressed in Bcr-Abl-expressing primary CML cells derived from 4 patients, and imatinib treatment greatly decreased the expression of H19 in these cells but not in normal control cells. Loss of either Bcr-Abl expression or Abl kinase activity caused decrease of c-Myc levels with simultaneously reduced levels of H19. Furthermore, we demonstrated that depletion of c-Myc alone in K562 cells significantly decreased the level of H19, suggesting that H19 is expressed in a c-Myc dependent manner in K562 leukemic cells. | 24685695 | Lnc2Cancer |
EL0556 | H19 | prostate cancer | qPCR, Western blot etc. | cell lines (P69, M12) | down-regulated | N/A | In this study, we found that long non-coding RNA H19 (H19) and H19-derived microRNA-675 (miR-675) were significantly downregulated in the metastatic prostate cancer cell line M12 compared with the non-metastatic prostate epithelial cell line P69. Upregulation of H19 in P69 and PC3 cells significantly increased the level of miR-675 and repressed cell migration; however, ectopic expression of H19 in M12 cells could not increase the level of miR-675 and therefore had no effect on cell migration. | 24988946 | Lnc2Cancer |
EL0556 | H19 | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell lines (5637, UMUC-3, EJ) | up-regulated | interaction | YAP1 and H19 expression levels were markedly elevated in bladder cancer tissues and cells, and H19 expression was found to be significantly associated with YAP1 expression. YAP1 and H19 were overexpressed were associated with poorer clinicopathologic prognosis. In addition, YAP1 was found to enhance H19 expression, whereas H19 had no significant effect on YAP1 expression in bladder cancer cells. | 26163939 | Lnc2Cancer |
EL0556 | H19 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (AGS, MGC803 etc.) | up-regulated | N/A | The expression levels of H19 and miR-675 in five gastric cancer cell lines were correlated with each other (r = 0.9910, P = 0.0315, data not shown). We next assessed the correlation of miR-675 and H19 expression in 24 human gastric cancer tissues. The expression of H19 and miR-675 in gastric cancer tissues was correlated with each other (r = 0.8214, P < 0.01). | 24388988 | Lnc2Cancer |
EL0556 | H19 | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | cell lines (HepG2) | up-regulated | N/A | We found that AFB1 could up-regulate the expression of H19 and promote cell growth and invasion by hepatocellular carcinoma HepG2 cells. AFB1 induced the expression of E2F1 and its knock-down could down-regulate H19 expression and suppress cell growth and invasion in hepatocellular carcinoma HepG2 cells. E2F1 over-expression could up-regulate H19 expression and promote cell growth and invasion, with binding to the H19 promoter being demonstrated by chromatin immunoprecipitation assays. | 24761865 | Lnc2Cancer |
EL0556 | H19 | pancreatic ductal adenocarcinoma | qPCR, Western blot, knockdown etc. | pancreatic cancer tissue, cell lines (PANC-1, SW1990, AsPC-1, BxPC-3, CFPAC-1 etc.) | up-regulated | N/A | The levels of H19 was overexpressed in PDAC and was upregulated remarkably in primary tumors which subsequently metastasized, compared to those did not metastasis. H19 promoted PDAC cell invasion and migration. An important role of H19 in regulating metastasis of PDAC and provides some clues for elucidating the lncRNAmiRNA functional network in cancer. | 24920070 | Lnc2Cancer |
EL0556 | H19 | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | cell lines (Huh-7, MHCC-97H, HepG2 etc.) | up-regulated | N/A | The expression levels of LncRNAH19 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells as compared with the control group. Inhibition of LncRNAH19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3β/Cdc25A signaling pathway. | 24939300 | Lnc2Cancer |
EL0556 | H19 | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MCF-7, MDA-MB-231) | up-regulated | N/A | H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells; H19 lncRNA was much higher in estrogen receptor (ER)-positive MCF-7 breast cancer cells than in ER-negative MDA-MB-231 cells | 25846769 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | esophageal cancer | qPCR, Western blot, knockdown etc. | esophageal cancer tissue, cell lines (TE-1, TE-10, Eca-1, Eca-109, KYSE1170) | up-regulated | expression | The expression of H19 was significantly increased and associated with tumor depth and metastasis in 133 EC samples. In addition, it was identified that an upregulation of H19 induced epithelial-to-mesenchymal transition. In conclusion, H19 has a significant role in the development of EC and may serve as a potential prognostic marker and therapeutic target for EC. | 26171017 | Lnc2Cancer |
EL0556 | H19 | ovarian cancer | qPCR, Western blot, knockdown etc. | ovarian cancer tissues and adjacent normal tissues, cell lines (SKOV3, OV90, TOV112D, ES2) | up-regulated | expression | Our results demonstrated that that H19 silencing inhibited OV90 and SKOV3 OC cell proliferation in vitro. Further investigation into the mechanisms responsible for the growth inhibitory effects by H19 silencing revealed that its knockdown resulted in the induction of cell cycle arrest and apoptosis through certain cell cycle-related and apoptosis-related proteins | 26617715 | Lnc2Cancer |
EL0556 | H19 | colorectal cancer | qPCR, Western blot, Luciferase reporter assay, RIP etc. | CRC tissue, cell lines (SW620, HCT-116) | up-regulated | interaction | We found that H19 was highly expressed in mesenchymal-like cancer cells and primary CRC tissues. H19 modulated the expression of multiple genes involved in EMT by acting as a competing endogenous RNA, which may build up the missing link between the regulatory miRNA network, EMT progression and accelerates in vivo and in vitro tumor growth. | 26068968 | Lnc2Cancer |
EL0556 | H19 | gastric cancer | qPCR, Western blot, Luciferase reporter assays, knockdown etc. | gastric cancer tissue, cell lines (SGC7901, MKN45, MKN-28 etc.) | up-regulated | expression | Overexpression of?lncRNA?H19 enhances carcinogenesis and metastasis of gastric cancer. | 24810858 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | bladder cancer | qPCR, Western blot, Luciferase reporter assays, knockdown etc. | bladder cancer tissues, cell lines (RT4, HT-1376, 5637, 253J, TCCSUP, T24,and J82) | up-regulated | interaction | We found that miR-675 expression levels were remarkably increased in bladder cancer tissues as compared with adjacent noncancerous tissues or normal bladder tissue from health donors; moreover, enhanced miR-675 expression was also observed in bladder cancer cell lines. Ectopic expression of H19 significantly increased bladder cancer cell proliferation and miR-675 expression in vitro | 26198047 | Lnc2Cancer |
EL0556 | H19 | hepatocelluar carcinoma | qPCR, Western bolt, Northern bolt, in vitro knockdown, RIP etc. | HCC tissue, cell lines(SMMC7721, HCCLM3) | down-regulated | regulation | Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. | 23222811 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | clear cell renal cell carcinoma | qRT-PCR, siRNA | clear cell renal carcinoma (ccRCC) tissues and renal cancer cell lines | up-regulated | expression | lncRNA H19 might be considered as a potential prognostic indicator and a target for gene therapy of ccRCC. | 25866221 | |
EL0556 | H19 | gastric cancer | real-time quantitative polymerase chain reaction (qPCR) assay | gastric cancer (GC) tissues | up-regulated | expression | H19 might serve as a promising biomarker for early detection and prognosis prediction of GC. | 26774144 | |
EL0556 | H19 | breast cancer | RNA CISH etc. | breast cancer tissue | up-regulated | expression | HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. | 26323944 | Lnc2Cancer |
EL0556 | H19 | non-small cell lung cancer | RT-PCR, luciferase reporter assay, Chromosome immune coprecipitation (ChIP), disturbing and overexpressing the expression of H19, flow cytometry | NSCLC tissues and cells, the adjacent tissues and normal cells | up-regulated | interaction | lncRNA H19, which is induced by c-Myc, is up-regulated in NSCLC. H19 influences the mitotic progression of NSCLC cell lines. | 26722426 | |
EL0556 | H19 | Wilms' tumor | Southern blot, Northern blot etc. | Wilms' tumor tissue | differential expression | epigenetics | Gain of methylation at the H19 DMR is an early event in Wilms' tumorigenesis that is independent of chromosomal losses. | 16179496 | LncRNADisease Lnc2Cancer |
EL0556 | H19 | gastric cancer | stratified analyses | gastric cancer samples | up-regulated | mutation | We genotyped four lncRNA H19 single nucleotide polymorphisms (SNPs)(rs217727 C > T, rs2839698 C > T, rs3741216 A > T, rs3741219 T > C) in 500 GC patients and 500 healthy controls. These findings suggest that lncRNA H19 SNPs may contribute to susceptibility to GC. | 25944697 | |
EL0557 | HA117 | hirschsprung disease | N/A | N/A | N/A | N/A | HA117 expression in stenotic segment was higher compared to proximal anastomosis and dilated segment (p < 0.05); HA117 may be a factor exerting an anti-differentiation or anti-maturation role in the genesis of HSCR. | 25120773 | LncRNADisease |
EL0558 | HAGLR | neuroblastoma | microarray, qPCR, Northern blot, knockdown etc. | cell lines (SH-SY5Y) | up-regulated | regulation | One of these lncRNAs, termed HOXD-AS1, is encoded in HOXD cluster. HOXD-AS1 is overexpressed in neuroblastoma. We found that HOXD-AS1 is a subjetc to morphogenic regulation, is activated by PI3K/Akt pathway and itself is involved in control of RA-induced cell differentiation. Knock-down experiments revealed that HOXD-AS1 controls expression levels of clinically significant protein-coding genes involved in angiogenesis and inflammation, the hallmarks of metastatic cancer. | 25522241 | Lnc2Cancer |
EL0559 | HAGLROS | papillary thyroid carcinoma | microarrays, CCK-9 assay, colony formation assay and EdU assay, Flow Cytometry, Transwell and scratch assay | Papillary thyroid cancer cell line | N/A | expression | lncRNAs (ENST00000537266 and ENST00000426615) could inhibit cell proliferation. lncRNAs (ENST00000426615 and ENST00000537266) might be important regulators of PTC cell proliferation and motility, which might provide new insight into the understanding of PTC pathogenesis. ENST00000426615 could inhibit the cell motility | 26824456 | |
EL0561 | HAR1A | Huntington's disease | N/A | N/A | N/A | expression | HAR1, a deeply conserved genomic region consisting of a cis-antisense pair of structured lncRNAs (HAR1F and HAR1R) (2, 23) located ~80 kb from the neural microRNA, miR-124-3. HAR1 levels are significantly lower in the striatum of HD patients. | 20179156 | LncRNADisease |
EL0561 | HAR1A | Alzheimer's disease | N/A | N/A | N/A | N/A | Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 | 22817756 | LncRNADisease |
EL0561 | HAR1A | schizophrenia | N/A | N/A | N/A | N/A | Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 | 22817756 | LncRNADisease |
EL0561 | HAR1A | Huntington's disease | N/A | N/A | N/A | regulation | HAR1 has also been implicated in HD, where the transcriptional repressor RE-1-silencing transcription factor (REST) enters pathologically into the nucleus, leading to the repression of several important neuronal genes. | 23562612 | LncRNADisease |
EL0562 | HAR1B | Huntington's disease | N/A | N/A | N/A | expression | HAR1, a deeply conserved genomic region consisting of a cis-antisense pair of structured lncRNAs (HAR1F and HAR1R) (2, 23) located ~80 kb from the neural microRNA, miR-124-3. HAR1 levels are significantly lower in the striatum of HD patients. | 20179156 | LncRNADisease |
EL0562 | HAR1B | Alzheimer's disease | N/A | N/A | N/A | N/A | Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 | 22817756 | LncRNADisease |
EL0562 | HAR1B | schizophrenia | N/A | N/A | N/A | N/A | Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 | 22817756 | LncRNADisease |
EL0562 | HAR1B | Huntington's disease | N/A | N/A | N/A | regulation | HAR1 has also been implicated in HD, where the transcriptional repressor RE-1-silencing transcription factor (REST) enters pathologically into the nucleus, leading to the repression of several important neuronal genes. | 23562612 | LncRNADisease |
EL0564 | HCP5 | AIDS | N/A | N/A | N/A | mutation | HCP5 genotyping could serve as a simple screening tool for ABC-HSR. | 18684101 | LncRNADisease |
EL0564 | HCP5 | AIDS | N/A | N/A | N/A | mutation | A polymorphism (rs2395029, G824T) in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro. | 19935381 | LncRNADisease |
EL0564 | HCP5 | AIDS | N/A | N/A | N/A | expression | A total of 245 HIV patients were included in the study. A good correlation between HLA-B*5701 and HCP5 was observed (negative and positive predictive values of 100% and 93%, respectively). | 20534626 | LncRNADisease |
EL0565 | HEIH | hepatocelluar carcinoma | microarray, qPCR, RIP, RNA pulldown assay etc. | HCC tissue, cell lines (Huh7, HepG2) | up-regulated | N/A | The transcript levels of lncRNA-HEIH were higher in HCC tissues (p=0.010) when compared with the corresponding non-tumor liver tissues from the same donor. And we found that patients with high lncRNA-HEIH expression in HCC had significantly worse prognosis than those with low lncRNA-HEIH expression. | 21769904 | Lnc2Cancer |
EL0565 | HEIH | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Dr. Yang and his colleagues found that one lncRNA, named lncRNA-HEIH, was overexpressed in HCC tissue compared with normal liver tissues using microarray. | 24757675 | LncRNADisease |
EL0565 | HEIH | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | cell lines (MHCC97L, HepG2, cHL-7702) | up-regulated | expression | The expression of HEIH and HULC in hepatocellular carcinoma cell line was significantly increased compared with human normal hepatocyte line (P<0.05). The expression of HULC in HepG2 was higher than that in MHCC97L. The over-expression of HULC could enhance proliferation of MHCC97L and HepG2, however, the over-expression of HEIH could not. The over-expression of HULC and HEIH could promote invasion of MHCC97L and HepG2. Invasion of MHCC97L and HepG2 did not have significant change after down-regulating of HEIH and HULC by siRNA. Over-expression of HULC up-regulated the expression of Snail in HepG2. | 26550214 | Lnc2Cancer |
EL0567 | HELLS | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We noted that LINC01419 was characterized by a significant increase in transcript expression from dysplasia to early HCC. The lncRNA AK021443 was also up-regulated in advanced HCC samples when compared with early HCC. Moreover, expression of LINC01419 and AK021443 was up-regulated in HCC tissues when compared with non-tumor liver tissue. AF070632 expression was down-regulated in HCC and was decreased in advanced HCC when compared with early HCC. These results suggest that LINC01419 may be related to the initiation of HCC, whereas AK021443 and AF070632 may be associated with the progression of HCC. | 26540467 | Lnc2Cancer |
EL0569 | HIF1A-AS1 | kidney cancer | N/A | N/A | N/A | expression | Diagnostic and discriminative marker | 24373479 | LncRNADisease |
EL0569 | HIF1A-AS1 | Cardiovascular disease | N/A | N/A | N/A | N/A | Clopidogrel reduces apoptosis and promotes proliferation of human vascular endothelial cells induced by palmitic acid via suppression of the long non-coding RNA HIF1A-AS1 in vitro. | 25761653 | LncRNADisease |
EL0569 | HIF1A-AS1 | kidney cancer | qPCR etc. | renal cancer tissue | up-regulated | expression | The antitumor DNA topoisomerase I (Top1) inhibitor camptothecin (CPT) increases the cellular levels of two antisense lncRNAs at the 5' (5'aHIF-1 alpha) and 3' (3'aHIF-1 alpha) ends of the human HIF1A-AS1 gene. | 21897117 | LncRNADisease Lnc2Cancer |
EL0569 | HIF1A-AS1 | non-small cell lung cancer | qPCR etc. | blood (serum), NSCLC tissue | up-regulated | expression | The levels of XIST (P < 0.05) and HIF1A-AS1 (P < 0.05) were significantly increased in tumor tissues or serum from NSCLC patients as compared to those of control group. Moreover, serum levels of XIST and HIF1A-AS1 were significantly decreased after surgical treatment as compared to pre-operative. | 26339353 | Lnc2Cancer |
EL0569 | HIF1A-AS1 | aneurysm of the thoracoabdominal aorta | RT-PCR | VSMCs, serum of TAA patients | up-regulated | expression | HIF1a-AS1 was overexpressed in the thoracoabdominal aorta aneurysm and the interaction between HIF1a-AS1 and apoptotic proteins plays a key role in the proliferation and apoptosis of VSMCs in vitro, which may contribute to the pathogenesis of thoracoabdominal aorta aneurysm. | 25550800 | |
EL0570 | HIF1A-AS2 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0570 | HIF1A-AS2 | kidney cancer | N/A | N/A | N/A | expression | Diagnostic and discriminative marker | 24373479 | LncRNADisease |
EL0570 | HIF1A-AS2 | acute myocardial infarction | N/A | N/A | N/A | N/A | Level of hypoxia inducible factor 1A antisense RNA 2 was higher in patients with MI than in healthy volunteers (P<0.01) | 25035150 | LncRNADisease |
EL0570 | HIF1A-AS2 | gastric cancer | qPCR etc. | cancerous gastric tissue, blood (serum) | up-regulated | expression | The expression of HIF1A-AS2 was upregulated in GC tumorous tissues compared with the adjacent normal tissues (P < 0.001). Its overexpression was correlated with TNM stages (P = 0.008), tumor invasion (P = 0.016), lymph node metastasis (P = 0.042), and poor prognosis (P = 0.001). | 25686741 | Lnc2Cancer |
EL0570 | HIF1A-AS2 | renal cancer | qPCR etc. | renal cancer tissue | up-regulated | expression | overexpressed in human renal cancer and during hypoxia. | 9923855 | LncRNADisease Lnc2Cancer |
EL0570 | HIF1A-AS2 | bladder cancer | SV-HUC-1 cells | bladder cancer tissue and cells | up-regulated | N/A | Overexpression of HIF1A-AS2 in SV-HUC-1 cells could promote cell proliferation cell migration and anti-apoptosis | 27018306 | |
EL0571 | HIF2PUT | colorectal cancer | N/A | colorectal cancer (CRC) tissues | N/A | interaction | LncRNA-HIF2PUT small interfering RNA transfection resulted in decreased stemness genes expression, impaired colony formation, and spheroid formation ability, retarded migration, and invasion of the cells. | 26648739 | |
EL0571 | HIF2PUT | osteosarcoma | qPCR, knockdown etc. | osteosarcoma tissue, cell lines (SAOS2, MG63, U2OS) | differential expression | expression | HIF2PUT expression levels were positively correlated with HIF-2a in osteosarcoma tissues. Overexpression of HIF2PUT markedly inhibited cell proliferation and migration, decreased the percentage of CD133 expressing cells, and impaired the osteosarcoma stem sphere-forming ability of the MG63 cells. Furthermore, altering the expression of HIF2PUT resulted in a concomitant change to HIF-2a mRNA expression. | 25434862 | Lnc2Cancer |
EL0572 | HIV1230 | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | down-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL0573 | HLA-AS1 | psoriasis | N/A | N/A | N/A | mutation | HLA-Cw*0602 associates more strongly to psoriasis in the Swedish population than variants of the novel 6p21.3 gene PSORS1C3. | 15848982 | LncRNADisease |
EL0573 | HLA-AS1 | multiple sclerosis | N/A | N/A | N/A | mutation | We identified significant effects on MS susceptibility of HLA-A*2 , and two coding polymorphisms in the MOG gene after full conditioning on HLA-DRB1. | 17971048 | LncRNADisease |
EL0573 | HLA-AS1 | AIDS | N/A | N/A | N/A | mutation | HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. | 18982067 | LncRNADisease |
EL0573 | HLA-AS1 | liver injury | N/A | N/A | N/A | mutation | HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. | 19483685 | LncRNADisease |
EL0575 | HNF1A-AS1 | nasopharyngeal carcinoma | knockdown, colony-formation, wound-healing, and transwell assays, cell cycle analysis, western blot analysis | tumor tissues from 20 patients with nasopharyngeal carcinoma (NPC) as well as from cultured NPC cell lines | N/A | expression | LncRNA, HNF1A-AS potentially regulates NPC tumorigenesis. HNF1A-AS was found to be associated with epithelial to mesenchymal transition. | 26756620 | |
EL0575 | HNF1A-AS1 | gastric cancer | microarray, qPCR etc. | GC tissue, cell lines (AGS, BGC-823, MKN-45) | down-regulated | interaction | LncRNAs microarray analysis results exhibited that HNF1A-AS1 was downregulated in GCs tissues (mean fold change 2.06, p < 0.05), which was further confirmed by qRT-PCR. The results from qRT-PCR showed that the expression of HNF1A-AS1 was not only downregulated in three GC cell lines (AGS, BGC-823, and MKN-45) relative to that in a normal gastric mucosal epithelial cell line (GES-1), but also decreased in GC tissues relative to that in paired adjacent non-neoplastic tissues (low expression, 94 of 161; low expression rate, 58.38%). Furthermore, low HNF1A-AS1 expression was associated with tumor size/diameter (p = 0.005, multivariate analysis), levels of serum carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), and RRM1 expression in tissue samples | 26472090 | Lnc2Cancer |
EL0575 | HNF1A-AS1 | esophageal adenocarcinoma | microarray, RNA-seq, qPCR, Western bolt, knockdown etc. | esophageal adenocarcinoma tissue, cell lines (HEEpiC, SKGT-4, OE33 etc.) | up-regulated | regulation | Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. | 24000294 | LncRNADisease Lnc2Cancer |
EL0575 | HNF1A-AS1 | hepatocellular carcinoma | N/A | HCC tissue and cell line | up-regulated | N/A | sponging tumor-suppressive hsa-miR-30b-5p (miR-30b) and de-repressing Bcl-2 | 27084450 | |
EL0575 | HNF1A-AS1 | esophageal squamous cell carcinoma | qPCR etc. | blood (plasma and serum) | up-regulated | expression | Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients compared with normal controls.By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC (the area under the ROC curve (AUC), 0.842. | 25608466 | Lnc2Cancer |
EL0575 | HNF1A-AS1 | lung adenocarcinoma | qPCR, Western blot, knockdown, RIP etc. | lung adenocarcinoma tissue, cell lines (A549, SPC-A1, H1650) | up-regulated | interaction | HNF1A-AS1 was significantly up-regulated in lung adenocarcinoma tissues compared with corresponding non-tumor tissues, and its expression level was significantly correlated with TNM stage, tumor size, and lymph node metastasis. Moreover, HNF1A-AS1 was determined to promote tumor proliferation and metastasis, both in vitro and in vivo, by regulating cyclin D1, E-cadherin, N-cadherin and β-catenin expression. In addition, the binding of HNF1A-AS1 to DNMT1 may explain its regulation of E-cadherin. | 25863539 | Lnc2Cancer |
EL0577 | HOST2 | epithelial ovarian cancer | qPCR, Western blot etc. | ovarian cancer tissue, cells lines (OVCAR3) | up-regulated | N/A | EOC-specific lncRNA-HOST2, which acts as a miRNA sponge, sequesters let-7b to maintain the expression of oncogenes and further maintains EOC biological functions. | 25292198 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | nasopharyngeal carcinoma | knockdown | nasopharyngeal carcinoma cells | up-regulated | interaction | Hotair knockdown significantly attenuated both in vitro and in vivo tumor cell growth and angiogenesis. | 26717040 | |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | lncRNA microarray, qRT-PCT | esophageal squamous cell carcinoma (ESCC) tissue | up-regulated | expression | ESCCAL_1 and HOTAIR may participate in the pathological process of ESCC. Furthermore, lncRNA could be potential diagnostic and prognostic biomarkers for ESCC. | 25297587 | |
EL0578 | HOTAIR | prostate cancer | microarray, qPCR etc. | prostate cancer tissue, cell lines (LNCaP, PC3, DU145, RWPE-1 etc.) | up-regulated | N/A | LncRNA profiling showed that HOTAIR was highly regulated by genistein and its expression was higher in castration-resistant PCa cell lines than in normal prostate cells. Knockdown (siRNA) of HOTAIR decreased PCa cell proliferation, migration and invasion and induced apoptosis and cell cycle arrest. miR-34a was also up-regulated by genistein and may directly target HOTAIR in both PC3 and DU145 PCa cells. Our results indicated that genistein inhibited PCa cell growth through down-regulation of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a. These findings enhance understanding of how genistein regulates lncRNA HOTAIR and miR-34a in PCa. | 23936419 | Lnc2Cancer |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | microarray, qPCR etc. | ESCC tissue | up-regulated | expression | Expression of HOTAIR lncRNA is increased in various cancers, and it is also significantly increased in our analysis of ESCC. | 24222893 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | non-functioning pituitary adenoma | microarray, qPCR etc. | NFPA tissue | up-regulated | expression | Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. | 24469926 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | colorectal cancer | microarray, qPCR etc. | CRC tissue | up-regulated | regulation | Two of the lncRNAs, HOTAIR and a novel lncRNA, lncRNA-422 were confirmed in more samples. GSEA indicated that gene sets most correlated with them were those named up-regulated in KRAS-over, down-regulated in JAK2-knockout, down-regulated in PDGF-over and down-regulated in TBK1-knockout, all of which were cancer-related. Subsequently, GO analyses of most significantly correlated coding genes of HOTAIR and lncRNA-422 showed that these two lncRNAs may participate in carcinogenesis by regulating protein coding genes involved in special biological process relevant to cancer. | 25456707 | Lnc2Cancer |
EL0578 | HOTAIR | triple-negative breast cancer | microarray, qPCR etc. | triple-negative breast cancer tissue | up-regulated | expression | We found that the expression levels of TCONS_l2_00003938, ENST00000460164, ENST00000425295, MALAT1 and HOTAIR were significantly higher in tumor tissues than non-tumor tissues, whereas there were no significant differences in the expression levels of the other 3 lncRNAs. Our study identified a set of lncRNAs that were consistently aberrantly expressed in TNBC, and these dysregulated lncRNAs may be involved in the development and/or progression of TNBC. | 25996380 | Lnc2Cancer |
EL0578 | HOTAIR | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | Expression profiles of five lnc-RNAs (MEG3, HULC, HOTAIR, NEAT1, and MALAT-1) previously shown to be involved in cancer metastasis were detected by qPCR in 5 pairs of papillary thyroid cancer and 11 matched lymph node metastatic tissues. Among the five, MEG3 showed significant down-expression. Overexpression of MEG3 inhibits thyroid cancer cell migration and invasion. | 25997963 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | microarray, qPCR etc. | gastric cancer tissue, cell lines (HCG-27, SGC-7901) | up-regulated | expression | H19 and HOTAIR displayed significantly higher levels and the up-regulation of HOTAIR was associated with lymphatic metastasis and poor differentiation. | 26237576 | Lnc2Cancer |
EL0578 | HOTAIR | breast cancer | microarray, qPCR, ISH etc. | breast tumor tissue | up-regulated | N/A | Co-expression of HOTAIR and EZH2 trended with a worse outcome. In matched primary and metastatic cancers, both HOTAIR and EZH2 had increased expression in the metastatic carcinomas. This approach offers a method to make observations on lncRNAs that may influence the cancer epigenome in a tissue-based technique. | 23133536 | Lnc2Cancer |
EL0578 | HOTAIR | hepatocelluar carcinoma | microarray, qPCR, knockdown, Western blot etc. | cell lines (HepG2 ,Bel-7402) | up-regulated | regulation | Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells. | 24663081 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | cervical cancer | microarray, qPCR, RIP etc. | cervical cancer tissue, cell line (C33-A) | down-regulated | interaction | We identified significant linear trend of progressive HOTAIR down-regulation through HPV negative controls, HPV16 positive non-malignants and CaCx samples. Majority of CaCx cases portrayed HOTAIR down-regulation in comparison to HPV negative controls, with corresponding up-regulation of HOTAIR target, HOXD10, and enrichment of cancer related pathways. However, a small subset had significantly higher HOTAIR expression, concomitant with high E7 expression and enrichment of metastatic pathways. Expression of HOTAIR and PRC2-complex members (EZH2 and SUZ12), showed significant positive correlation with E7 expression in CaCx cases and E7 transfected C33A cell line, suggestive of interplay between E7 and HOTAIR. | 26152361 | Lnc2Cancer |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | microarray, qPCR, Western blot, knockdown etc. | ESCC tissue, cell lines (KYSE30, KYSE140, KYSE180, KYSE410, KYSE510) | up-regulated | N/A | It was found that there was a great upregulation of HOTAIR in ESCC compared to their adjacent normal esophageal tissues. Meanwhile, patients with high HOTAIR expression have a significantly poorer prognosis than those with low expression. Moreover, HOTAIR was further validated to promote migration and invasion of ESCC cells in vitro. | 24118380 | Lnc2Cancer |
EL0578 | HOTAIR | glioma | microarray, Western blot etc. | glioblastoma tissue | up-regulated | N/A | HOTAIR expression was significantly higher in HGG than in low-grade glioma (LGG; P < .001). Moreover, as shown in Fig. 1A, GBM demonstrated a significant increase in HOTAIR transcript levels, compared with that observed in normal tissues (P = .093), LGGs (P < .001), or AGs (P = .011). Our data establish that HOTAIR serves as a prognostic factor for glioma patient survival, as well as a biomarker for identifying glioma molecular subtypes, a critical regulator of cell cycle progression. | 24203894 | Lnc2Cancer |
EL0578 | HOTAIR | ovarian cancer | monitored double-strand breaks | recurrent platinum-resistant ovarian tumors vs primary ovarian tumors | N/A | N/A | HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment; HOTAIR regulates activation of NF-κB | 27041570 | |
EL0578 | HOTAIR | gastric cancer | N/A | gastric cancer cell lines and tissue samples | up-regulated | locus/expression | We found that the HOTAIR rs920778 TT carriers had a 1.66- and 1.87-fold increased gastric cancer risk in Jinan and Huaian populations compared with the CC carriers. | 25640751 | |
EL0578 | HOTAIR | triple-negative breast cancer | N/A | Triple-negative breast cancer (TNBC) samples | up-regulated | expression | HOTAIR has been known to induce tumor growth and metastasis in breast cancer. Depleting HOTAIR alone phenocopies the dual treatment in growth suppression. We show that expression of HOTAIR is regulated by β-catenin through a LEF1/TCF4-binding site. | 25883211 | |
EL0578 | HOTAIR | LPS-induced sepsis | N/A | cardiomyocytes from sepsis mice | up-regulated | interaction | HOTAIR silence preserved cardiac function of sepsis mice during LPS-induced sepsis. | 26806307 | |
EL0578 | HOTAIR | Temporomandibular joint osteoarthritis | N/A | the synovial fluid of TMJ OA patients | up-regulated | N/A | knockdown of HOTAIR in IL-1β-induced TMJ OA in vitro | 27063559 | |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | HOTAIR showed positive association with 'hang Serum Response'. | 19182780 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | A subsequent study revealed that HOTAIR is overexpressed in approximately one quarter of human breast cancers. | 20930520 | LncRNADisease |
EL0578 | HOTAIR | cancer | N/A | N/A | N/A | epigenetics | Epigenetically silences gene expression at many loci by recruitment of LSD1/CoREST/REST and PRC2 repressive chromatin modifying complexes. Oncogene: promotes tumour metastasis. | 21256239 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | The lncRNA HOTAIR is a strong predictor of metastasis in breast tumors and its over-expression in various breast carcinoma cell lines promotes invasion. | 21903344 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | Elevated expression of HOTAIR is observed in primary and metastatic breast cancer. | 21925379 | LncRNADisease |
EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | HOTAIR is causally involved in tumor progression. It is significantly overexpressed in metastatic breast cancer. | 22045689 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | On a more mechanistic level, recent studies have revealed the contribution of lncRNAs as proto-oncogenes, e.g. GAGE6, as tumor suppressor genes, e.g. 鈥榩15 antisense RNA and lincP21' (36,91), as drivers of metastatic transformation, e.g. HOTAIR in breast cancer, and as regulators of alternative splicing, e.g. MALAT1 | 22492512 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | The wellstudied lincRNA, HOTAIR, is highly expressed in breast cancer metastases, and its overexpression in various breast carcinoma cell lines promotes invasion | 22535282 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes | 22817756 | LncRNADisease |
EL0578 | HOTAIR | colorectal cancer | N/A | N/A | N/A | expression | Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes | 22817756 | LncRNADisease |
EL0578 | HOTAIR | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes | 22817756 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | Gene silencing by interacting with PRC2 and LSD1/CoREST complexes. | 22996375 | LncRNADisease |
EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | HOTAIR overexpression is associated with poor prognosis in breast (Gupta et al. 2010), liver (Z. Yang et al. 2011), colorectal (Kogo et al. 2011), gastrointestinal (Niinuma et al. 2012), and pancreatic (Kim et al. 2012) cancers and is proposed to increase tumor invasiveness and metastasis (Gupta et al. 2010). | 23463798 | LncRNADisease |
EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | HOTAIR overexpression has been linked to increased invasiveness and poorer outcomes in several human cancers. | 23473599 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT3: colorectal cancer). | 23660942 | LncRNADisease |
EL0578 | HOTAIR | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Dysregulation and functional roles of lncRNAs in HCC | 24183851 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | Epigenetically silences gene expression via LSD1/CoREST & PRC2; metastasis | 24499465 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | HOTAIR was proposed as a diagnostic marker in breast and colorectal cancer. Its depletion resulted in reduced invasiveness, and its expression level correlated with differentially regulated genes of the PRC2 complex. | 24531795 | LncRNADisease |
EL0578 | HOTAIR | colorectal cancer | N/A | N/A | N/A | expression | HOTAIR was proposed as a diagnostic marker in breast and colorectal cancer. Its depletion resulted in reduced invasiveness, and its expression level correlated with differentially regulated genes of the PRC2 complex. | 24531795 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
EL0578 | HOTAIR | colon cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
EL0578 | HOTAIR | colorectal cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
EL0578 | HOTAIR | gastrointestinal cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
EL0578 | HOTAIR | liver cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
EL0578 | HOTAIR | pancreatic cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | For example, HOTAIR is remarkably overexpressed in breast tumors and the expression of HOTAIR in primary breast tumors is a strong prognosis marker of patient outcomes such as metastasis and patient survival | 24721780 | LncRNADisease |
EL0578 | HOTAIR | rheumatoid arthritis | N/A | N/A | N/A | regulation | PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis. | 24722995 | LncRNADisease |
EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | Overexpression of HOTAIR was found in breast and colon cancers and was associated with metastasis and poor prognosis. | 24757675 | LncRNADisease |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | N/A | N/A | N/A | expression | Upregulation of HOTAIR is associated with metastasis of gastric cancer, lung cancer, and esophageal squamous cell carcinoma? | 24757675 | LncRNADisease |
EL0578 | HOTAIR | gastric cancer | N/A | N/A | N/A | expression | Upregulation of HOTAIR is associated with metastasis of gastric cancer, lung cancer, and esophageal squamous cell carcinoma? | 24757675 | LncRNADisease |
EL0578 | HOTAIR | lung cancer | N/A | N/A | N/A | expression | Upregulation of HOTAIR is associated with metastasis of gastric cancer, lung cancer, and esophageal squamous cell carcinoma? | 24757675 | LncRNADisease |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | N/A | N/A | N/A | expression | The result showed that the expression levels of HOTAIR were upregulated in samples from patients with higher tumor burdens, which were defined as those with larger tumors, advanced clinical staging, increased lymph node tumor burdens and the presence of distant metastases.? | 24817925 | LncRNADisease |
EL0578 | HOTAIR | laryngeal squamous cell carcinoma | N/A | N/A | N/A | expression | Inspired observed that HOTAIR was higher expressed in primary LSCC than in adjacent noncancerous tissues. It is noteworthy that over-expression of HOTAIR was related to poor differentiation, lymph node metastasis, or advanced clinical stages of LSCC. The results suggested that HOTAIR promotes the malignant progression of LSCC. | 24817925 | LncRNADisease |
EL0578 | HOTAIR | nasopharyngeal carcinoma | N/A | N/A | N/A | expression | The result showed that, the expression levels of HOTAIR wereup-regulated in NPC tissues than in non-cancerous tissues. Further study demonstrated that HOTAIR was up-regulated in NPC cell lines with high invasive potential and the capacity for migration, invasion and proliferation was suppressed after knocking down HOTAIR expression. | 24817925 | LncRNADisease |
EL0578 | HOTAIR | oral squamous cell carcinoma | N/A | N/A | N/A | expression | Subsequently, they confirmed that the expression levels of HOTAIR, NEAT-1 and UCA1 in metastasized samples was prominent higher than the non-metastatic samples.? | 24817925 | LncRNADisease |
EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | Gupta et al found that lncRNA HOTAIR overexpression was a strong predictor of breast tumor metastasis. | 24829860 | LncRNADisease |
EL0578 | HOTAIR | cancer | N/A | N/A | N/A | regulation | Forced expression of HOTAIR in epithelial cancer cells altered the localization of PRC2 on chromatin. Genome-wide studies revealed PRC2 localization more resembling occupancy in embryonic fibroblasts.? | 24829860 | LncRNADisease |
EL0578 | HOTAIR | lung adenocarcinoma | N/A | N/A | N/A | regulation | In this study, the lncRNA HOTAIR was upregualted in lung adenocarcinoma cells grown in 3-D cell culture supplemented with collagen.? | 24829860 | LncRNADisease |
EL0578 | HOTAIR | gastric cardia adenocarcinoma | PCR-RFLP, qPCR etc. | blood | up-regulated | mutation | Among three htSNPs of the HOTAIR gene (rs12826786 C>T, rs4759314 A>G, and rs10783618 C>T), only the T allele of rs12826786 was found to increase the risk of developing GCA and was associated with smoking habit and tumor-node-metastasis (TNM) stage. In addition, higher expression levels of HOTAIR were found in tumor tissues and rs12826786 SNP has a genotype-specific effetc on HOTAIR expression. A high HOTAIR expression level was associated with poor GCA patients' survival. | 25476857 | Lnc2Cancer |
EL0578 | HOTAIR | breast cancer | polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) and created-restriction-site PCR (CRS-RFLP) assays, multifactor dimensionality reduction (MDR) method | N/A | N/A | mutation | Subjects with Trs920778 had a significantly increased risk of breast cancer (OR: 1.41, 95%CI: 1.13, 1.75). We observed a significant interaction between rs920778 and reproductive factors, including age at menopause, number of abortions, and family history. Genetic variant rs920778 in HOTAIR significantly increased the risk of BC, and it may have apparent interaction with reproductive factors in the progression on BC. | 26547792 | |
EL0578 | HOTAIR | gastrointestinal stromal tumor | qPCR etc. | gastric cancer tissue | up-regulated | expression | Overexpression of HOTAIR was also strongly associated with high-risk grade and metastasis among GIST specimens. | 22258453 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | cervical cancer | qPCR etc. | cell line (CaSki) | down-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | breast cancer | qPCR etc. | breast cancer tissue | differential expression | N/A | A positive correlation was found between DNA methylation and HOTAIR expression. Methylation was associated with unfavorable disease characteristics, whereas no significant associations were found between HOTAIR expression and clinical or pathologic features. In multivariate, but not in univariate, Cox proportional hazard regression models, patients with high HOTAIR expression had lower risks of relapse and mortality than those with low HOTAIR expression. We found that patients with high levels of HOTAIR expression had lower risks of relapse and death than those with low expression. The results suggest that clinicopathological features and therapy treatments could modify the effect of HOTAIR. Large noncoding RNA HOTAIR, transcribed from the antisense strand of HOXC12, interacts with Polycomb Repressive Complex 2 (PRC2) in the regulation of gene activities. | 23124417 | Lnc2Cancer |
EL0578 | HOTAIR | oral squamous cell carcinoma | qPCR etc. | OSCC tissues | up-regulated | N/A | We found that most of the selected transcripts (4/6) were upregulated in tumors relative to matched adjacent nonmalignant tissue. One gene, MEG-3, was downregulated in cancer compared with its adjacent nonmalignant tissue. Expression of lncRNA (HOTAIR, NEAT-1 and UCA1) was significantly higher in the samples that subsequently metastasized compared with the non-metastatic samples. By contrast, MEG-3 was downregulated in the metastatic samples. These findings suggest that the detection of lncRNAs in saliva may be used as a noninvasive and rapid diagnostic tool for the diagnosis of oral cancer. | 23292713 | Lnc2Cancer |
EL0578 | HOTAIR | hepatocelluar carcinoma | qPCR etc. | HCC tissue, cell lines (HepG2 cell line) | up-regulated | expression | Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. | 23292722 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | ovarian cancer | qPCR etc. | ovarian cancer tissue | up-regulated | N/A | The expression of HOTAIR in ovarian cancer tissue was higher than that in normal ovarian tissue. The expression was statistically higher in poorly differentiated ovarian cancer than poorly-moderately, moderately-well, and well-differentiated ones (1.65 +/- 0.41 vs. 0.39 +/- 0.14, P < 0.05). | 23600210 | Lnc2Cancer |
EL0578 | HOTAIR | lung cancer | qPCR etc. | lung cancer tissue cell lines (A549, mK-ras-LE etc.) | up-regulated | N/A | In the current study, we demonstrate that the tumor-promoting lincRNA HOTAIR is induced by Col-1 and its expression inversely correlates with acinar morphogenesis, a differentiation feature of lung epithelial cells in rBM 3-D culture. These in vitro findings suggest that the elevated HOTAIR expression in tumor tissues results from cancer cells' response to Col-1 that is aberrantly enriched in the tumor microenvironment. Our findings indicate that tumor-promoting Col-1 up-regulates the expression of HOTAIR in NSCLC cells. These initial results warrant further investigation of HOTAIR and other lincRNA genes in lung tumorigenesis. | 23668363 | Lnc2Cancer |
EL0578 | HOTAIR | non-small cell lung cancer | qPCR etc. | NSCLC tissue, cell lines (A549) | up-regulated | N/A | High expression of HOTAIR (tumor/normal ratio >= 2) was detected in 17 patients (22.1%) and was frequently found in patients with advanced stage, lymph node metastasis or lymph-vascular invasion and short disease free interval. Furthermore, brain metastases show significantly higher HOTAIR expression compared to primary cancer tissues. HOTAIR-expressing A549 cells showed induced cell migration and anchorage independent cell growth in vitro. | 23743197 | Lnc2Cancer |
EL0578 | HOTAIR | gastric adenocarcinoma | qPCR etc. | gastric adenocarcinoma tissue | up-regulated | N/A | Here, we found aberrant up-regulation of HOTAIR in gastric adenocarcinoma samples compared with normal adjacent gastric epithelium tissues. Besides, we found that the aberrant expression of HOTAIR was associated with TNM staging and lymph node metastasis of gastric tumors. Here, a potential cooperative expression between HOTAIR SUZ12 genes in gastric adenocarcinoma tissues is deduced. This result suggests a role for HOTAIR long noncoding RNA in gastric cancer progression. | 23888369 | Lnc2Cancer |
EL0578 | HOTAIR | endometrial cancer | qPCR etc. | endometrial carcinoma tissue | up-regulated | expression | The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. | 24285342 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | pituitary adenoma | qPCR etc. | pituitary adenomas tissue | up-regulated | expression | Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. | 24469926 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | multiple myeloma | qPCR etc. | blood (plasma) | down-regulated | expression | HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. | 24583225 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | colorectal cancer | qPCR etc. | colorectal cancer tissue, blood | up-regulated | regulation | HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. | 24583926 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | cervical cancer | qPCR etc. | cervical cancer tissue | up-regulated | expression | Overexpression of?long?noncoding?RNA?HOTAIR predicts a poor prognosis in patients with cervical cancer. | 24748337 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR etc. | gastric cancer tissue | up-regulated | N/A | The expression of HOTAIR was markedly increased in gastric cancer tissues compared with adjacent non-tumoral tissues. We further showed that there was a positive significant correlation between the HOTAIR gene expression, TNM staging, perineural invasion, and distant metastasis, but not with other clinicopathological features of gastric tumors. HOTAIRexpression is modulated during gastric cancer progression and therefore may participate in molecular processes relevant to malignant transformation and metastasis in gastric carcinoma. | 24949306 | Lnc2Cancer |
EL0578 | HOTAIR | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | up-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
EL0578 | HOTAIR | breast cancer | qPCR etc. | cells lines (MCF-7) | up-regulated | interaction | When compared with MCF-7 cells, MCF-7-TNR cells exhibited an increase in the expression of HOTAIR, which correlated with characteristics of a luminal-like to basal-like transition as evidenced by dysregulated gene expression and accelerated growth. MCF-7-TNR cells exhibited reduced suppressive histone H3 lysine27 trimethylation on the HOTAIR promoter. Inhibition of HOTAIR and EZH2 attenuated the luminal-like to basal-like transition in terms of gene expression and growth in MCF-7-TNR cells. HOTAIR was robustly expressed in the native basal-like breast cancer cells and inhibition of HOTAIR reduced the basal-like gene expression and growth. | 25328122 | Lnc2Cancer |
EL0578 | HOTAIR | cervical cancer | qPCR etc. | blood (serum) | up-regulated | expression | Compared with normal control, the expression of HOTAIR was significantly upregulated in the sera of cervical cancer patients. In addition, elevated HOTAIR was associated with advanced tumor stages, adenocarcinoma, lymphatic vascular space invasion, and lymphatic node metastasis. In addition, our follow-up data showed that high HOTAIR was notably correlated with tumor recurrence and short overall survival. | 25366139 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) | up-regulated | expression | All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues. | 26096073 | Lnc2Cancer |
EL0578 | HOTAIR | gastric adenocarcinoma | qPCR etc. | gastric cancer tissue | up-regulated | expression | HOTAIR was significantly upregulated in GA tissues, especially in more advanced cases. High HOTAIR expression was an independent poor prognostic factor for patients with advanced GA. Further stratification analyses revealed that the association between HOTAIR expression and survival in patients with advanced GA remained significant in the subgroup of patients with TNM stages IIIA and IIIB, poorly differentiated, and smaller tumors. | 26328013 | Lnc2Cancer |
EL0578 | HOTAIR | ovarian cancer | qPCR etc. | ovarian cancer tissue | up-regulated | expression | HOTAIR expression was significantly associated with poor survival in carboplatin-treated patients with adjusted hazard ratios for death of 3.64 in the discovery and 1.63 in the validation set. This effect was not seen in patients who did not receive carboplatin. HOTAIR expression or its surrogate DNAme signature predicted poor outcome in all additional sets of carboplatin-treated ovarian cancer patients while HOTAIR expressors responded preferentially to cisplatin. | 26497652 | Lnc2Cancer |
EL0578 | HOTAIR | breast cancer | qPCR, ChIP-chip etc. | cell lines (SUZ12, EZH2, PRC2 etc.) | up-regulated | expression | HOTAIR expression level in primary tumors is a powerful predictor of eventual metastasis and death. | 20393566 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | laryngeal squamous cell carcinoma | qPCR, in vitro knockdown etc. | cell lines (Hep-2) | up-regulated | N/A | HOTAIR levels were significantly higher in LSCC than in corresponding adjacent non-neoplastic tissues, and patients with poor histological grade or advanced clinical stage had higher HOTAIR expression. PTEN methylation was significantly reduced in Hep-2 cells depleted of HOTAIR. Taken together, these results suggest that the oncogenic role of HOTAIR in LSCC is related to promotion of PTEN methylation. | 23141928 | Lnc2Cancer |
EL0578 | HOTAIR | melanoma | qPCR, in vitro knockdown etc. | melanoma tissue, cell lines (A375 etc.) | up-regulated | N/A | Among the tested lncRNAs, HOTAIR was the most highly expressed in lymph node metastasis. The role of HOTAIR in melanoma cell motility and invasion was further evaluated by knocking down HOTAIR with siRNAs. Knockdown of HOTAIR resulted in the reduction of motility and invasion of human melanoma cell line A375, as assessed by wound healing assay and Matrigel-based invasion assay. siHOTAIR also suppressed the degradation of gelatin matrix, suggesting that HOTAIR promotes gelatinase activity. Together, our study shows thatHOTAIR is overexpressed in metastatic tissue, which is associated with the ability of HOTAIR to promote melanoma cell motility and invasion. | 23862139 | Lnc2Cancer |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | qPCR, in vitro knockdown etc. | ESCC tissu, cell lines (TE1, TE3, TE7, TE8, KYSE30, KYSE180 etc.) | up-regulated | regulation | Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. | 24022190 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | nasopharyngeal carcinoma | qPCR, ISH etc. | primary NPC tissue | up-regulated | N/A | Quantified using qPCR, HOTAIR expression levels in fresh tissue and paraffin-embedded samples were 5.2 ~ 48.4-fold higher compared with non-cancer tissue samples. Moreover, HOTAIR expression levels increased with clinical stage progression, which was consistent with ISH findings in the paraffin-embedded tissue. Most importantly, NPC patients with higher HOTAIR levels had a poor prognosis for overall survival using univariate and multivariate analysis. In addition, HOTAIR mediated the migration, invasion and proliferation of NPC cells in vitro. | 23281836 | Lnc2Cancer |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | qPCR, ISH etc. | ESCC tissue | up-regulated | N/A | High expression levels of HOTAIR in ESCC patients correlated positively with clinical stage, TNM classification, histological differentiation and vital status. HOTAIR expression was found to be an independent prognostic factor in ESCC patients. ESCC patients who expressed high levels of HOTAIR had substantially lower overall 5-year survival rates than HOTAIR-negative patients. In vitro assays of ESCC cell lines demonstrated that HOTAIR mediated the proliferation, colony formation and migratory capacity of ESCC cells. | 23717443 | Lnc2Cancer |
EL0578 | HOTAIR | breast cancer | qPCR, ISH, RIP, ChIP etc. | breast cancer tissue, cell lines (MCF7, T47D) | up-regulated | interaction | In this study, we report that HOTAIR (HOX antisense intergenic RNA) is upregulated in tamoxifen-resistant breast cancer tissues compared to their primary counterparts. Mechanistically, HOTAIR is a direct target of ER-mediated transcriptional repression and is thus restored upon the blockade of ER signaling, either by hormone deprivation or by tamoxifen treatment. Interestingly, this elevated HOTAIR increases ER protein level and thus enhances ER occupancy on the chromatin and potentiates its downstream gene regulation. | 26364613 | Lnc2Cancer |
EL0578 | HOTAIR | hepatocelluar carcinoma | qPCR, knockdown etc. | HCC tissue, cell lines (SMMC-7721, HepG2, Hep3B etc.) | up-regulated | expression | Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. | 21327457 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | colorectal cancer | qPCR, knockdown etc. | CRC tissue, (HEK293T, HCT116, SW480) | up-regulated | epigenetics | Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers.patients with high HOTAIR expression had a relatively poorer prognosis. | 21862635 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR, knockdown etc. | gastric cancer tissue, cell lines(MKN74, KATO III etc.) | up-regulated | N/A | The expression of HOTAIR was significantly higher in cancer lesions than in adjacent non-cancerous tissues in human gastric cancers. In the diffuse type of gastric cancer, the High-HOTAIR group (HOTAIR/GAPDH > 1) showed significantly more venous invasion, frequent lymph node metastases and a lower overall survival rate compared to the Low-HOTAIR group (HOTAIR/GAPDH < 1). | 24130837 | Lnc2Cancer |
EL0578 | HOTAIR | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (KYSE30, KYSE150, KYSE450, KYSE510, KYSE180 etc.) | up-regulated | N/A | Notably elevated HOTAIR expression levels were observed in cancerous tissues compared to adjacent noncancerous tissues (96%, P < 0.01), showing a high correlation with cancer metastasis (P < 0.01), elevated TNM (2009) stage classification (P < 0.01), and lowered overall survival rates (P = 0.003). Multivariate analysis revealed that HOTAIR expression (P = 0.003) is also an independent prognostic factor for comparison of TNM stage (P = 0.024) and lymph node metastasis (P = 0.010). | 24151120 | Lnc2Cancer |
EL0578 | HOTAIR | small cell lung cancer | qPCR, knockdown etc. | cell lines (COLO-668, COR-L51, COR-L88, DMS-79, DMS-53 etc.) | up-regulated | regulation | Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. | 24591352 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | endometrial cancer | qPCR, knockdown etc. | endometrioid carcinoma tissues, cell lines (HEC-1A, HEC-1B, Ishikawa, RL-952) | up-regulated | regulation | Lentivirus-Mediated?RNA?Interference Targeting the?Long?Noncoding?RNA?HOTAIR Inhibits Proliferation and Invasion of Endometrial Carcinoma Cells In Vitro and In Vivo. | 24758900 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | lung cancer | qPCR, knockdown etc. | lung cancer tissue | up-regulated | N/A | Among the tested lncRNAs, HOTAIR and NEAT1 were most highly expressed in lymph node metastasis. However, only HOTAIR was subsequently found to be involved in lung cancer cell motility and invasion, as assessed by in vitro migration and invasion assay. | 25010625 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR, knockdown etc. | gastric cancer tissue, cell lines (MKN7, MKN45, MKN74, NUGC4, AZ521, AGS, KATOIII) | up-regulated | interaction | Expression of both lncRNAs was significantly higher in cancerous tissues than in corresponding normal mucosa, and higher expression of these lncRNAs significantly correlated with peritoneal metastasis in GC patients. In addition, elevated HOTAIR expression emerged both as an independent prognostic and risk factor for peritoneal dissemination. SiRNA knockdown of HOTAIR in GC cells significantly inhibited cell proliferation, migration and invasion, but concurrently enhanced the anoikis rate in transfetced cells. | 25280565 | Lnc2Cancer |
EL0578 | HOTAIR | colorectal cancer | qPCR, knockdown etc. | CRC tissue | up-regulated | expression | Our study showed that genetic variants in HOTAIR were associated with risk of colorectal cancer and rs7958904 may act as a potential biomarker for predicting the risk of colorectal cancer. | 25432874 | Lnc2Cancer |
EL0578 | HOTAIR | serous ovarian cancer | qPCR, knockdown etc. | cell lines (A2780, Hey, SKOV3, OVCA429, OVCA433, OVCAR3) | up-regulated | expression | We found that HOTAIR levels were overexpressed in SOC tissues compared with normal controls and that HOTAIR overexpression was correlated with an advanced FIGO stage and a high histological grade. HOTAIR knockdown resulted in the induction of cell cycle arrest and apoptosis through certain cell cycle-related and apoptosis-related proteins. | 25796453 | Lnc2Cancer |
EL0578 | HOTAIR | acute myeloid leukemia | qPCR, knockdown etc. | bone marrow, cell lines (HL60, K562) | up-regulated | expression | We found that HOTAIR is significantly upregulated in de novo AML patients compared with those of AML-CR patients and normal controls; the reduction of HOTAIR by small interfering RNA (siRNA) repressed the proliferation of HL-60 and K562; the higher expression level of HOTAIR in AML patients was significantly correlated with NCCN high risk group. | 26261618 | Lnc2Cancer |
EL0578 | HOTAIR | lung adenocarcinoma | qPCR, knockdown etc. | NSCLC and adjacent non-tumor lung tissues, cell lines (A549, PC9, H1299, H520, HBE) | up-regulated | interaction | HOTAIR regulates the ratio of FOXA1 to FOXA2 and migration and invasion. HOTAIR and the ratio of FOXA1 to FOXA2 are negatively correlated. HOTAIR knockdown inhibits migration and invasion. HOTAIR is associated with LSH, and this association linked with the binding of LSH in the promoter of FOXA1, not FOXA2. Targeted inhibition of HOTAIR suppresses the migratory and invasive properties | 26658322 | Lnc2Cancer |
EL0578 | HOTAIR | pancreatic cancer | qPCR, Luciferase reporter assay, in vitro knockdown etc. | cell lines (Panc1, MiaPaCa2, Panc28, L3.6pl) | up-regulated | N/A | We show that HOTAIR expression is increased in pancreatic tumors compared with non-tumor tissue and is associated with more aggressive tumors. Knockdown of HOTAIR (siHOTAIR) by RNA interference shows that HOTAIR has an important role in pancreatic cancer cell invasion, as reported in other cancer cell lines. HOTAIR knockdown in Panc1 and L3.6pL pancreatic cancer cells that overexpress this lincRNA decreased cell proliferation, altered cell cycle progression and induced apoptosis, demonstrating an expanded function of HOTAIR in pancreatic cancer cells compared with other cancer cell lines. HOTAIR uniquely suppressed several interferon-related genes and gene sets related to cell cycle progression in pancreatic cancer cells and tumors. | 22614017 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR, Luciferase reporter assay, knockdown, ELISA etc. | gastric cancer tissue, cell lines (SGC7901, MGC-803) | up-regulated | interaction | Significant HOTAIR overexpression was observed in GC tissues, as well as strong positive correlations with HLA-G levels in both tissue and peripheral blood samples. HOTAIR overexpression might also get involved in tumor escape mechanisms, involving HLA-G upregulation via inhibiting miR-152. | 26187665 | Lnc2Cancer |
EL0578 | HOTAIR | gallbladder cancer | qPCR, Northern blot, in vitro knockdown, RIP etc. | gallbladder cancer tissue, cell lines (GBC-SD, SGC-996,NOZ, EH-GB2 etc.) | up-regulated | N/A | The HOTAIR transcripts were expressed at higher levels in the tumor tissues compared with adjacent normal tissues (p < 0.0001), indicating that HOTAIR was frequently up-regulated in GBC.A positive correlation between c-Myc and HOTAIR mRNA levels was observed in gallbladder cancer tissues. HOTAIR is a c-Myc-activated driver of malignancy, which acts in part through repression of miRNA-130a. | 24953832 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR, Northern blot, knockdown etc. | gastric cancer tissue | up-regulated | N/A | HOTAIR Long Noncoding RNA Promotes Gastric Cancer Metastasis through Suppression of Poly r(C)-Binding Protein (PCBP) 1. Our findings provide mechanistic evidence for HOTAIR overexpression and PCBP1 downregulation and the ensuing malignant phenotype in both cultured and xenograft gastric cancer cells. | 25612617 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | prostate cancer | qPCR, RNA Pull-Down Assay, RIP, ChIP etc. | prostate cancer tissue | up-regulated | interaction | Here, we report HOTAIR as an androgen-repressed lncRNA, and, as such, it is markedly upregulated following androgen deprivation therapies and in CRPC. Functionally, HOTAIR overexpression increases, whereas HOTAIR knockdown decreases, prostate cancer cell growth and invasion. Taken together, our results provide compelling evidence of lncRNAs as drivers of androgen-independent AR activity and CRPC progression, and they support the potential of lncRNAs as therapeutic targets. | 26411689 | Lnc2Cancer |
EL0578 | HOTAIR | aortic valve calcification | qPCR, siRNA, DNA microarray | BAVs, human aortic interstitial cells (AVICs) | down-regulated | expression | Reducing HOTAIR levels via siRNA in AVICs results in increased expression of calcification genes. | 24788418 | |
EL0578 | HOTAIR | sarcoma | qPCR, Western blot etc. | Primary and metastatic sarcoma tumor tissue | up-regulated | N/A | High level expression of both of MTDH/AEG1 and HOTAIR in the primary tumor correlated with a likelihood to metastasize. High levels of both MTDH/AEG-1 and HOTAIR in primary sarcoma are correlated with a high probability of metastasis. By contrast, reduced expression of both MTDH/ AEG-1 and HOTAIR is correlated with a good response to treatment in terms of necrosis, suggesting that levels of MTDH and HOTAIR are potential biomarkers for treatment efficacy. | 23543869 | Lnc2Cancer |
EL0578 | HOTAIR | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell lines (T24, J82, BIU-87 etc.) | up-regulated | expression | Ninety out of 110 specimens were detected in HOTAIR high expression. Histological grade and expression levels of HOTAIR were positively correlated with the recurrence rate. HOTAIR expression (hazard ratio 4.712; 95 % CI 2.894-8.714; P < 0.001) was an independent predictor of recurrence rate in multivariate Cox regression analysis. HOTAIR expression is correlated with patients' poor prognosis. | 25030736 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR, Western blot etc. | gastric cancer tissue, gastric cell lines | up-regulated | interaction | The expression of HOTAIR was significantly elevated in various gastric cancer cell lines and tissues compared to normal control. Lymphovascular invasion and lymph node metastasis were more common in the high level of HOTAIR group. si-HOTAIR significantly decreased invasiveness and migration. si-HOTAIR led to differential expression of epithelial to mesenchymal transition markers. HOTAIR was involved in inhibition of apoptosis and promoted invasiveness, supporting a role for HOTAIR in carcinogenesis and progression of gastric cancer. | 25063030 | Lnc2Cancer |
EL0578 | HOTAIR | laryngeal squamous cell carcinoma | qPCR, Western blot etc. | blood (serum) | up-regulated | N/A | The expression of exosomal miR-21 and HOTAIR was significantly higher in patients with laryngeal squamous cell carcinomaLSCC than those with vocal cord polyps; The patients with lymph node metastasis had higher serum exosomal miR-21 and HOTAIR expressions than those without. | 25099764 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | cervical cancer | qPCR, Western blot etc. | cervical cancer tissue, cell lines (HeLa, SiHa, C33A, CaSki) | differential expression | regulation | Stable knockdown of HOTAIR significantly suppressed tumor growth and sensitized cervical cancer to radiotherapy in vivo. | 25547435 | Lnc2Cancer |
EL0578 | HOTAIR | hepatocelluar carcinoma | qPCR, Western blot etc. | cell lines (HepG2, Bel7404, PLC5, Huh7 etc.) | up-regulated | interaction | We found that Hotair was increased in HCC tissues compared to their adjacent non-tumor tissues and the normal liver tissues. Increased Hotair negatively regulated miR-218 expression in HCC, which might be mediated through an EZH2-targeting-miR-218-2 promoter regulatory axis. Further investigation revealed that Hotair knockdown dramatically inhibited cell viability and induced G1-phase arrest in vitro and suppressed tumorigenicity in vivo by promoting miR-218 expression. | 26024833 | Lnc2Cancer |
EL0578 | HOTAIR | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue | up-regulated | interaction | Our findings indicate that HOTAIR expression has prognostic value for bladder cancer progression, recurrence, and survival and suggest that HOTAIR plays active roles in modulating the cancer epigenome, becoming an interesting candidate as a target for cancer diagnosis and therapy. The observed HOTAIR regulation by EZH2 and the possibility of modulating EZH2 activity with specific inhibitors open new possible paths to be explored in bladder cancer therapy | 26457124 | Lnc2Cancer |
EL0578 | HOTAIR | head and neck squamous cell carcinoma | qPCR, Western blot, Flow cytometry assay etc. | cell lines (Tca8113, Tca8113P160, Tb3.1) | differential expression | interaction | We employed a HOTAIR specific siRNA to deplete its expression in two human HNSCC cell lines, Tca8113 and Tscca. The flow cytometry (FCM) analysis showed that HOTAIR depletion induced tumor cell apoptosis in vitro. JC-1 probe examination showed that the mitochondrial membrane potential was changed significantly by HOTAIR blockage. Mitochondrial calcium uptake 1(MICU1) dependent cell death was induced by HOTAIR depletion. Protein expression analysis indicated that mitochondrial related cell death pathway (Bcl-2, BAX, Caspase-3, Cleaved Caspase-3, Cytochrome c) involved in HOTAIR dependent apoptosis process. Moreover, a Tscca derived xenograft tumor model was employed to further validate that injection of HOTAIR siRNA inhibited tumor growth. In summary, we suggested that HOTAIR inhibition could be developed as a new therapeutic in HNSCC treatments. | 26592246 | Lnc2Cancer |
EL0578 | HOTAIR | hepatocelluar carcinoma | qPCR, Western blot, in vitro knockdown etc. | cell line (Bel7402) | up-regulated | expression | The HOTAIR gene was significantly overexpressed in HCC tissues compared with adjacent non-tumour tissues. Patients with high HOTAIR gene expression in their tumours had an increased risk of recurrence after hepatectomy. | 22289527 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1,NCI-H1975 etc.) | up-regulated | N/A | HOTAIR was highly expressed both in NSCLC samples and cell lines compared with corresponding normal counterparts. HOTAIR upregulation was correlated with NSCLC advanced pathological stage and lymph-node metastasis. Moreover, patients with high levels of HOTAIR expression had a relatively poor prognosis. | 24103700 | Lnc2Cancer |
EL0578 | HOTAIR | lung adenocarcinoma | qPCR, Western blot, knockdown etc. | lung adenocarcinoma tissue, cell lines (A549/DDP, SPC-A1 etc.) | up-regulated | N/A | In this study, we show that HOTAIR expression was significantly upregulated in cisplatin-resistant A549/DDP cells compared with in parental A549 cells. Knockdown of HOTAIR by RNA interference could resensitize the responses of A549/DDP cells to cisplatin both in vitro and in vivo. In contrast, overexpression of HOTAIR could decrease the sensitivity of A549 and SPC-A1 cells to cisplatin. | 24155936 | Lnc2Cancer |
EL0578 | HOTAIR | ovarian cancer | qPCR, Western blot, knockdown etc. | epithelial ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | up-regulated | expression | Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. | 24662839 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | colon cancer | qPCR, Western blot, knockdown etc. | colon cancer tissue, cell lines (SW480, HT29) | up-regulated | expression | Long?non-coding?RNA?HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. | 24840737 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | cervical cancer | qPCR, Western blot, knockdown etc. | cervical cancer tissue, cell lines (SiHa, HeLa, Caski) | up-regulated | expression | The expression level of HOTAIR in cervical cancer tissues was higher than that in corresponding non-cancerous tissues. High HOTAIR expression correlated with lymph node metastasis, and reduced overall survival. Moreover, HOTAIR regulated the expression of vascular endothelial growth factor, matrix metalloproteinase-9 and epithelial-to-mesenchymal transition (EMT)-related genes, which are important for cell motility and metastasis. | 25405331 | Lnc2Cancer |
EL0578 | HOTAIR | ovarian cancer | qPCR, Western blot, knockdown etc. | cell lines (SKOV3) | up-regulated | interaction | The results demonstrated that the HOTAIR expression in clinical EOC tissues and SKOV3 CD117(+)CD44(+)CSCs was higher than in SKOV3 tumor tissues and non-CD117(+)CD44(+)CSCs. | 25792974 | Lnc2Cancer |
EL0578 | HOTAIR | oral squamous cell carcinoma | qPCR, Western blot, knockdown etc. | OSCC tissue, cell lines (TSCCA, Tca8223 etc.) | up-regulated | N/A | Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. | 25901533 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | colorectal cancer | qPCR, Western blot, knockdown etc. | CRC tissue, cell lines (FHC, CCL244, HCT116, SW480, LOVO) | up-regulated | expression | Results showed that CRC patients had higher HOTAIR expression in tumor tissues compared with adjacent normal tissues. In vitro, downregulation of HOTAIR reduced proliferation, migration and invasiveness while enhanced apoptosis and radio-sensitivity of CRC cells. Taken together, our findings suggest that long non-coding RNA HOTAIR expression is closely associated with tumor invasion and radiosensitivity, indicating the potential role in diagnostics and therapeutics of CRC. | 26549670 | Lnc2Cancer |
EL0578 | HOTAIR | renal cell carcinoma | qPCR, Western blot, knockdown, ChIP etc. | cell lines (A-498, OS-RC-2) | up-regulated | N/A | Suppressed expression of long non-coding RNA HOTAIR inhibits proliferation and tumourigenicity of renal carcinoma cells. | 25149152 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | ovarian cancer | qPCR, Western blot, knockdown, MTT assay etc. | ovarian cancer tissue, cell lines (A2780, 3AO, OVCAR3, SKOV3, HO-8910) | up-regulated | interaction | HOTAIR overexpression promoted cell cycle progression (and thus cell proliferation) by activating the Wnt/β-Catenin signaling pathway. Likewise, knockdown of HOTAIR suppressed cell proliferation and arrested cell cycle at G1 phase via inhibition of Wnt/β-Catenin signaling. Moreover, the results of primary culture demonstrated that elevated HOTAIR expression correlated positively with chemoresistance in ovarian cancer. | 26341496 | Lnc2Cancer |
EL0578 | HOTAIR | acute myeloid leukemia | qPCR, Western blot, knockdown, RIP etc. | cell lines | up-regulated | interaction | We report that HOTAIR expression was obviously increased in leukemic cell lines and primary AML blasts. Clinically, AML patients with higher HOTAIR predicted worse clinical outcome compared with those with lower HOTAIR. Importantly, HOTAIR knockdown by small hairpin RNA inhibited cell growth, induced apoptosis, and decreased number of colony formation. Finally, HOTAIR modulated c-KIT expression by competitively binding miR-193a. | 25979172 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | gastric cancer tissue, cell lines (MGC-803, SGC-7901, BGC-823, AGS) | up-regulated | regulation | Lnc RNA HOTAIR functions as a competing endogenous?RNA?to regulate HER2 expression by sponging miR-331-3p in gastric cancer. | 24775712 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | non-small cell lung cancer | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | cell lines (A549, SK-MES-1) | up-regulated | interaction | In the present study, we demonstrated that HOTAIR was upregulated by hypoxia in NSCLC cells. HOTAIR is a direct target of HIF-1αthrough interaction with putative HREs in the upstream region of HOTAIR in NSCLC cells. Furthermore, HIF-1α knockdown or inhibition could prevent HOTAIR upregulation under hypoxic conditions. Under hypoxic conditions, HOTAIR enhanced cancer cell proliferation, migration, and invasion. | 26088446 | Lnc2Cancer |
EL0578 | HOTAIR | liver cancer | qPCR, Western blot, Luciferase reporter assay, RIP etc. | liver cancer tissue, cell line (hLCSC) | up-regulated | interaction | HOTAIR level was significantly higher in human hepatocarocinoma tissues and play tumorigenesis roles by downregulating SETD2 in liver cancer stem cells. HOTAIR may also mediate changes at an epigenetic level to affect gene expression and contribute to tumor aetiology. | 26172293 | Lnc2Cancer |
EL0578 | HOTAIR | bladder cancer | qPCR, Western blot, Northern blot etc. | cell lines(HCV29, 5637, T24, J82, SW780 ) | up-regulated | interaction | We have identified cyclin J (CCNJ) gene, which is involved in cell cycle regulation, as a novel target for miR-205. Furthermore, a long non-coding RNA HOTAIR (HOX transcript antisense RNA) was observed to participate in the silencing of miR-205 in bladder cancer cells by breaking the balance of histone modification between H3K4me3 (histone H3 at lysine 4 methylation) and H3K27me3 on miR-205 promoter. | 26469956 | Lnc2Cancer |
EL0578 | HOTAIR | renal cancer | qPCR, Western blot, RIP etc. | cell lines (86-O, ACHN) | up-regulated | expression | Long Non-coding RNA HOTAIR Is Targeted and Regulated by miR-141 in Human Cancer Cells. | 24616104 | LncRNADisease Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | qPCR, Western bolt, in vitro knockdown etc. | gastric cancer tissue, cell lines (GES-1, AGS, SGC-7901, MKN-45, HGC-27 etc.) | up-regulated | N/A | The expression level of HOTAIR in cancer tissues was higher than that in adjacent noncancerous tissues. Expression level of HOTAIR was significantly correlated with lymph node metastasis and TNM stage. Furthermore, high expression level of HOTAIR was a predictor of poor over-all survival in GC patients. In vitro, inhibition of HOTAIR in GC cells could reduce invasiveness, as well as the expression of MMP1 and MMP3. In addition, suppression of HOTAIR could reverse EMT process. | 23847441 | Lnc2Cancer |
EL0578 | HOTAIR | glioma | qRT-PCR, knock-down | glioma U87 and U251 cell lines | up-regulated | expression | knock-down of HOTAIR exerted tumor-suppressive function in glioma cells. Further, HOTAIR was confirmed to be the target of miR-326 and miR-326 mediated the tumor-suppressive effects of HOTAIR knock-down on glioma cell lines | 26183397 | |
EL0578 | HOTAIR | pre-eclampsia | qRT-PCR, knockdown, overexpression | placentas from pre-eclampsia (PE) pregnant women | up-regulated | expression | HOTAIR is probably involved in the onset of preeclampsia by regulating proliferation, invasion and apoptosis of trophoblast cells. | 25807808 | |
EL0578 | HOTAIR | bladder transitional cell carcinoma | quantitative real-time PCR, MTT assay, Dual-color flow cytometric method | bladder transitional cell carcinoma (TCC) tissues and cell lines | up-regulated | expression | HOTAIR over-expression promoted cell proliferation and inhibited chemosensitivity to doxorubicin and cell apoptosis induced by doxorubicin; silence of HOTAIR showed opposite regulative effects. lncRNA HOTAIR was an independent prognostic biomarker of overall survival in TCC patients and could regulate chemosensitivity to doxorubicin of human TCC cells. | 26781446 | |
EL0578 | HOTAIR | breast cancer | real-time polymerase chain reaction (PCR) using TaqMan assay | 123 BC patients and 122 age-matched healthy controls | N/A | mutation | TT genotype of HOTAIR rs12826786 C>T polymorphism was significantly related with multiple clinicopathological characteristics concerned with worse BC progression such as advanced TNM stage (III and IV), larger tumor size (T3 and T4), and distant metastasis (M1), as well as poor histological grade (III) (P < 0.05). | 26577852 | |
EL0578 | HOTAIR | breast cancer | RNA CISH etc. | breast cancer tissue | up-regulated | expression | HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. | 26323944 | Lnc2Cancer |
EL0578 | HOTAIR | infiltrating ductal carcinomas | RNA-seq, qRT-PCR | human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7 | up-regulated | expression | The lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup. | 25296969 | |
EL0578 | HOTAIR | endometrial cancer | RT-qPCR | 156 consecutive, stage I-IV EC patients | N/A | N/A | high HOTAIR expression correlated with shorter overall survival | 26868332 | |
EL0578 | HOTAIR | breast cancer | TaqMan allelic discrimination assay etc. | blood | differential expression | expression | We found that the CC genotype of HOTAIR rs920778 polymorphism significantly increased the risk of BC in both codominant and recessive inheritance genetic models. Our research also indicated an association between the CC genotype of HOTAIR rs920778 polymorphism and clinicopathologic features of tumor, including advanced tumor-node-metastasis (TNM) stage, larger tumor size, distant metastasis, and poor histological grade. CC genotype of HOTAIR rs920778 polymorphism might play important roles in genetic susceptibility to BC development and aggressiveness in a Turkish population. | 25586347 | Lnc2Cancer |
EL0578 | HOTAIR | gastric cancer | TaqMan RT-PCR | gastric cancer samples | N/A | mutation | A naturally occurring functional single nucleotide polymorphism (SNP) rs920,778 (C→T) in the intronic enhancer of HOTAIR gene has been demonstrated to affect HOTAIR expression and cancer susceptibility. Our results demonstrate that the HOTAIR rs920778 polymorphism has not been in any major role in genetic susceptibility to gastric carcinogenesis, at least in the population studied here. | 25980897 | |
EL0578 | HOTAIR | diffuse large B-cell lymphoma | The reverse transcription‑polymerase chain reaction & Western blotting | N/A | up-regulated | N/A | HOTAIR was significantly correlated with tumor size, clinical stage, B symptoms and International Prognostic Index scores | 27122348 | |
EL0578 | HOTAIR | colorectal cancer | the tumorigenicity of CD133(+)-shHOTAIR were evaluated by the MTT | CD133(+)CSCs cell | down-regulated | N/A | down-regulating the HOTAIR expression in CD133(+)CSCs could serve as a potential anti-cancer regimen to inhibit the invasiveness and metastasis of CRC CSCs | 27069543 | |
EL0579 | Hotair | homeotic transformation of the spine and malformation of metacarpal-carpal bone | knockdown, RNA-sequencing | N/A | N/A | interaction | Targeted deletion of mouse Hotair lncRNA leads to derepression of hundreds of genes, resulting in homeotic transformation of the spine and malformation of metacarpal-carpal bones. | 24075995 | |
EL0580 | HOTAIRM1 | acute myeloid leukemia | N/A | 241 AML patients, 215 intermediate-risk AML (IR-AML) patients | N/A | interaction | In 215 IR-AML patients, high HOTAIRM1 expression was independently associated with shorter overall survival (OR:2.04;P = 0.001), shorter leukemia-free survival (OR:2.56; P < 0.001) and a higher cumulative incidence of relapse (OR:1.67; P = 0.046). HOTAIRM1 was overexpressed in NPM1-mutated AML (P < 0.001) and within this group retained its prognostic value (OR: 2.21; P = 0.01). miR-196b and HOTAIRM1 in combination as a prognostic factor can classify patients as high-, intermediate-, or low-risk (5-year OS: 24% vs 42% vs 70%; P = 0.004). | 26433964 | |
EL0580 | HOTAIRM1 | pancreatic ductal adenocarcinoma | N/A | pancreatic ductal adenocarcinoma (PDAC) tissues | up-regulated | expression | The expression level of long intergenic non-coding RNA HOTAIRM1 was upregulated in 12 PDAC tissues samples compared with matched adjacent non-tumor samples by qRT-PCR. The revelation of an association between HOTAIRM1 expression and PDAC is especially noteworthy. | 26676849 | |
EL0580 | HOTAIRM1 | acute promyelocytic leukemia | qPCR, knockdown etc. | cell lines (NB4, HEK293) | up-regulated | N/A | HOTAIRM1 is Highly expressed and provides a regulatory link in myeloid maturation by modulating integrin-controlled cell cycle progression at the gene expression level. | 24824789 | Lnc2Cancer |
EL0580 | HOTAIRM1 | promyelocytic leukemia | qPCR, knockdown etc. | cell lines (NB4 and HEK293) | down-regulated | N/A | HOTAIRM1 knockdown resulted in retained expression of many otherwise ATRA-suppressed cell cycle and DNA replication genes, and abated ATRA induction of cell surface leukocyte activation, defense response, and other maturation-related genes. Resistance to ATRA-induced cell cycle arrest at the G1/S phase transition in knockdown cells was accompanied by retained expression of ITGA4 (CD49d) and decreased induction of ITGAX (CD11c). The coupling of cell cycle progression with temporal dynamics in the expression patterns of these integrin genes suggests a regulated switch to control the transit from the proliferative phase to granulocytic maturation. Furthermore, ITGAX was among a small number of genes showing perturbation in transcript levels upon HOTAIRM1 knockdown even without ATRA treatment, suggesting a direct pathway of regulation | 24824789 | Lnc2Cancer |
EL0580 | HOTAIRM1 | infiltrating ductal carcinomas | RNA-seq, qRT-PCR | human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7 | up-regulated | expression | The lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. | 25296969 | |
EL0582 | HOTTIP | hepatocelluar carcinoma | dual luciferase reporter gene assays | HCC tissue specimens, mouse xenograft model | up-regulated | interaction | Tthe miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. | 26710269 | |
EL0582 | HOTTIP | pancreatic cancer | microarray, qPCR, Western blot, knockdown etc. | cell lines (Panc1, ASPC1, BxPC3 etc.) | up-regulated | interaction | HOTTIP is expressed in pancreatic cancer cell lines and knockdown of HOTTIP by RNA interference (siHOTTIP) in Panc1 pancreatic cancer cells decreased proliferation, induced apoptosis and decreased migration. HOTTIP functions in pancreatic cancer cells are due, in part, to regulation of some HOX genes including HOXA10, HOXB2, HOXA11, HOXA9 and HOXA1. | 25912306 | Lnc2Cancer |
EL0582 | HOTTIP | pancreatic ductal adenocarcinoma | microarray, qRT-PCR | eight human pancreatic ductal adenocarcinoma (PDAC) tissues and four pancreatic tissues. | up-regulated | expression | Functionally, HOTTIP silencing resulted in proliferation arrest by altering cell-cycle progression, and impaired cell invasion by inhibiting epithelial-mesenchymal transition in pancreatic cancer. HOTTIP promotes cell proliferation, invasion, and chemoresistance by modulating HOXA13. Therefore, the HOTTIP/HOXA13 axis is a potential therapeutic target and molecular biomarker for PDAC. | 25889214 | |
EL0582 | HOTTIP | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0582 | HOTTIP | lung cancer | N/A | lung cancer cell line A549 and NCI-H446; tissue of lung cancer | up-regulated | expression | Initially, we found that expression of HOTTIP was significantly elevated in 20 cases of lung cancer.Tumor growth in vivo was also suppressed after depletion of HOTTIP in a mouse model of lung cancer. Moreover, depletion of HOTTIP caused cell cycle arrest in G0/G1 phase and induced significant cell apoptosis. | 26265284 | |
EL0582 | HOTTIP | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Currently, upregulated HOTTIP and HOXA13 expressions were associated with the prognosis and progression of the hepatocellular carcinoma (HCC). | 24531795 | LncRNADisease |
EL0582 | HOTTIP | tongue squamous cell carcinoma | qPCR etc. | tongue cancer tissue | up-regulated | expression | In our study, results indicated that lncRNA HOTTIP was highly expressed in TSCC compared with adjacent non-malignant tissues and positively correlated with T stage, clinical stage, and distant metastasis in TSCC patients. | 26058875 | Lnc2Cancer |
EL0582 | HOTTIP | colorectal cancer | qPCR etc. | colorectal cancer samples and 21 adjacent non-malignant samples | up-regulated | expression | Our results indicated that lncRNA HOTTIP was highly expressed in CRC compared with adjacent non-malignant tissues (P<0.001), and positively correlated with T stage (T1-2 vs. T3-4, P = 0.001), clinical stage (I-II stages vs. III-IV stages, P = 0.003), and distant metastasis (absent vs. present, P = 0.014) in CRC patients. Furthermore, we also observed that increased lncRNA HOTTIP expression was an unfavorable prognostic factor in CRC patients (P = 0.001), regardless of T stage, distant metastasis and clinical stage. Finally, overexpression of lncRNA HOTTIP was supposed to be an independent poor prognostic factor for CRC patients through multivariate analysis (P = 0.017). | 26617875 | Lnc2Cancer |
EL0582 | HOTTIP | osteosarcoma | qPCR, knockdown etc | osteosarcomas tissues and matched adjacent non-tumor tissues, cell lines(MG-63, HOS) | up-regulated | expression | We found that HOTTIP expression was up-regulated in OS tissues, and correlated with advanced clinical stage and distant metastasis. OS patients with high HOTTIP expression level had poorer overall survival than those with low HOTTIP expression. Multivariable Cox proportional hazards regression analysis suggested that increased HOTTIP expression was an independent prognostic factor of overall survival in OS patients. Moreover, the results of in vitro assays showed that the suppression of HOTTIP in OS cells significantly reduced cell proliferation, migration and invasion ability | 26617868 | Lnc2Cancer |
EL0582 | HOTTIP | hepatocelluar carcinoma | qPCR, Luciferase reporter assay etc. | cell lines (BEL7402, MHCC97H, MHCC97H-Luc) | up-regulated | regulation | In our profiling study, HOTTIP was identified as the most significantly up-regulated lncRNA in human HCCs, even in early stage of HCC formation. HOTTIP is a novel oncogenic lncRNA, which negatively regulated by miR-125b. Overexpression of HOTTIP contributes to hepatocarcinogenesis by regulating the expression of its neighboring protein-coding genes. | 25424744 | Lnc2Cancer |
EL0582 | HOTTIP | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | HCC tissue, cell lines (SNU182, SNU449, SNU423, SNU387, SNU475 etc.) | up-regulated | expression | Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. | 24114970 | LncRNADisease Lnc2Cancer |
EL0582 | HOTTIP | colorectal cancer | qPCR, Western blot, knockdown etc. | CRC and adjacent non-tumor colorectal samples, cell lines (DLD-1, SW480, SW620, HCT116) | up-regulated | interaction | We found that overexpression of HOTTIP is correlated with an advanced pathological stage and a larger tumor size. Moreover, functional analyses revealed that the knockdown of HOTTIP expression by small interfering RNA (siRNA) or small hairpin RNA (shRNA) could inhibit cell proliferation and induce cell apoptosis. More importantly, we observed that HOTTIP knockdown induced a marked increase in the number of cells in the G0/G1 phase and a reduction in the number of cells in the S phase in both DLD-1 cells and SW480 cells. An in vivo experiment also revealed that the knockdown of HOTTIP inhibited tumor growth. Western blot and immunohistochemistry analyses indicated that HOTTIP potentially contributed to CRC cell growth partially through the silencing of p21 expression. | 26678886 | Lnc2Cancer |
EL0582 | HOTTIP | hirschsprung disease | qRT-PCR, Small RNA interference | colon tissues rom 79 patients with Hirschsprung disease (HSCR) | down-regulated | expression | LncRNA HOTTIP and HOXA13 were significantly down-regulated in HSCR compared to the controls. Meanwhile, the declined extent of their expression levels makes sense between two main phenotype of HSCR. Our study demonstrates that aberrant reduction of HOTTIP and HOXA13, which have a bidirectional regulatory loop, may play an important role in the pathogenesis of HSCR. | 26043692 | |
EL0582 | HOTTIP | prostate cancer | sciliencing or knockdown of HOTTIP | prostate cancer tumorigenesis | down-regulated | N/A | down-regulation of HOTTIP and HOXA13 was associated with cell growth and cell cycle. | 27064878 | |
EL0583 | Hottip | skin cancer | qPCR, lncRNA array analysis | cultured mouse keratinocytes after deleting the vitamin D receptor (VDR) (∼90%) vs. control cells | up-regulated | expression | protect by vitamin D receptor | 24342142 | |
EL0584 | HOXA11-AS | ovarian cancer | qPCR, Western blot etc. | ovarian cancer tissue | down-regulated | mutation | Functional studies of ectopic expression of HOXA11-AS minor allele T in EOC cells showed decreased survival, proliferation, migration, and invasion compared to common allele A expression. Additionally, stable expression of HOXA11-AS minor allele T reduced primary tumor growth in mouse xenograft models to a greater extent than common allele A. Furthermore, HOXA11-AS expression levels were significantly lower in human EOC tumors than normal ovarian tissues (p < 0.05), suggesting that HOXA11-AS has a tumor suppressor function in EOC which may be enhanced by the T allele | 26430965 | Lnc2Cancer |
EL0586 | HOXA13 | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | HCC tissue, cell lines (SNU182, SNU449, SNU423, SNU387, SNU475 etc.) | up-regulated | expression | lncRNA HOTTIP / HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. | 24114970 | LncRNADisease Lnc2Cancer |
EL0588 | HOXA-AS2 | gastric cancer | microarray, qPCR, Western blot, Luciferase reporter assay etc. | gastric cancer tissue, cell lines (BGC823, SGC7901, AGS) | up-regulated | interaction | Here, we reported that HOXA cluster antisense RNA2 (HOXA-AS2), a 1048bp RNA, was upregulated in GC. Increased HOXA-AS2 expression in GC was associated with larger tumor size and higher clinical stage; patients with higher levels of HOXA-AS2 expression had a relatively poor prognosis. HOXA-AS2 could be an oncogene for GC partly through suppressing P21, PLK3, and DDIT3 expression; HOXA-AS2 may be served as a candidate prognostic biomarker and target for new therapies in human GC. | 26384350 | Lnc2Cancer |
EL0589 | Hoxaas3 | Idiopathic pulmonary fibrosis | overexpression | a mouse model of pulmonary injury and progressive interstitial fibrosis via intraperitoneal injection of paraquat, a widely used herbicide known to cause pulmonary fibrosis in human. | up-regulated | interaction | Overexpression of uc.77 or 2700086A06Rik in human lung epithelial cells induced EMT as demonstrated by changes in gene and protein expression of various EMT markers and cell morphology. | 26824344 | |
EL0593 | Hsromega | polyglutamine diseases | RNA interference | N/A | down-regulated | interaction | Loss of hsromega-n RNA not only suppresses the eye-specific degeneration mediated by GMR-GAL4 driven expression of the 127Q or MJDtr-Q78 or ataxin1 82Q or httex1p Q93 transgene, but also rescues premature death of flies expressing the expanded polyQ proteins pan-neuronally using the elav-GAL4 driver. | 19667761 | |
EL0596 | HTT-AS | Huntington's disease | N/A | N/A | N/A | expression | Levels of HTTAS_v1 are reduced in human HD frontal cortex. In cell systems, overexpression of HTTAS_v1 specifically reduces endogenous HTT transcript levels, while siRNA knockdown of HTTAS_v1 increases HTT transcript levels. | 21672921 | LncRNADisease |
EL0597 | HTTAS_v1 | Huntington's disease | N/A | N/A | N/A | regulation | Long ncRNA HTTAS_v1 is regulating the expression of Hungtiontonin (HTT) and is potentially involved in the development of HD. | 24624135 | LncRNADisease |
EL0600 | HULC | diffuse large B-cell lymphoma | in a cohort of DLBCL | DLBCL tissues and cell lines | up-regulated | N/A | HULC was closely related to DLBCL characteristics | 27044827 | |
EL0600 | HULC | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | Expression profiles of five lnc-RNAs (MEG3, HULC, HOTAIR, NEAT1, and MALAT-1) previously shown to be involved in cancer metastasis were detected by qPCR in 5 pairs of papillary thyroid cancer and 11 matched lymph node metastatic tissues. Among the five, MEG3 showed significant down-expression. Overexpression of MEG3 inhibits thyroid cancer cell migration and invasion. | 25997963 | Lnc2Cancer |
EL0600 | HULC | hepatocelluar carcinoma | microarray, qPCR, knockdown etc. | cell lines (HepG2, Huh7 etc.) | up-regulated | N/A | The relative expression level of HULC, as determined by qPCR, was about 8-fold higher in HCC samples than in normal liver tissue. Depletion of IGF2BP1 led to an increased HULC half-life and higher steady-state expression levels, indicating a post-transcriptional regulatory mechanism. Importantly, HULC represents the first IGF2BP substrate that is destabilized. To elucidate the mechanism by which IGF2BP1 destabilizes HULC, the CNOT1 protein was identified as a novel interaction partner of IGF2BP1. CNOT1 is the scaffold of the human CCR4-NOT deadenylase complex, a major component of the cytoplasmic RNA decay machinery. Indeed, depletion of CNOT1 increased HULC half-life and expression. Thus, IGF2BP1 acts as an adaptor protein that recruits the CCR4-NOT complex and thereby initiates the degradation of the lncRNA HULC. | 23728852 | Lnc2Cancer |
EL0600 | HULC | hepatocelluar carcinoma | microarray, qPCR, Northern blot, ISH, knockdown etc. | HCC tissue, blood | up-regulated | expression | Highly up-regulated in liver cancer. | 17241883 | LncRNADisease Lnc2Cancer |
EL0600 | HULC | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0600 | HULC | glioma | N/A | glioma patient tissues | up-regulated | N/A | positively correlated with grade dependency in glioma patient tissues | 26894862 | |
EL0600 | HULC | atherosclerosis | N/A | liver cancer | up-regulated | N/A | HULC regulated TNF-α-induced apoptosis through regulation of miR-9 expression | 26981838 | |
EL0600 | HULC | hepatocelluar carcinoma | N/A | N/A | N/A | expression | A similar genome-wide differential expression screen in hepatocellular carcinoma (HCC) has uncovered another cancer-associated lncRNA, Highly Upregulated in Liver Cancer, or HULC. | 20951849 | LncRNADisease |
EL0600 | HULC | hepatocelluar carcinoma | N/A | N/A | N/A | expression | The lncRNA HULC is one of the most upregulated of all genes in hepatocellular carcinoma. | 21802130 | LncRNADisease |
EL0600 | HULC | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Dysregulation and functional roles of lncRNAs in HCC | 24183851 | LncRNADisease |
EL0600 | HULC | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | Here we focus on two best-characterized lncRNAs-HULC and LALR, which can impact proliferation through targeting various key regulators in different pathways. | 24296588 | LncRNADisease |
EL0600 | HULC | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | Moreover, HULC correlated with upregulated hepatitis B virus X protein (HBx) that importantly contributes to HCC and that was able to promote HULC expression. The HULC-mediated downregulation of the tumor suppressor p18 supported the HCC proliferation. | 24531795 | LncRNADisease |
EL0600 | HULC | liver cancer | N/A | N/A | N/A | expression | The highly upregulated lncRNA HULC in liver cancer was found in the blood of HCC patients, promising a potential biomarker. | 24531795 | LncRNADisease |
EL0600 | HULC | liver cancer | N/A | N/A | N/A | N/A | PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 4) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. | 24667321 | LncRNADisease |
EL0600 | HULC | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | A lncRNA, highly upregulated in liver cancer (HULC), was found to contribute to tumorigenesis of HCC. | 24757675 | LncRNADisease |
EL0600 | HULC | colorectal cancer | qPCR etc. | cell lines (HepG2, Hep3B, SKOV3 etc.) | up-regulated | expression | HULC expression is not confined to HCC, but also to those colorectal carcinomas that metastasize to the liver. | 19445043 | LncRNADisease Lnc2Cancer |
EL0600 | HULC | hepatocelluar carcinoma | qPCR etc. | HCC tissue | up-regulated | N/A | In this study, we demonstrate that HULC expression is significantly higher in HCC tumors compared to normal liver tissues. Among the tumor tissues, higher HULC expression is positively associated with Edmondson histological grades or with hepatitis B (HBV) positive status. Moreover, HULC lncRNA is detected with higher frequency in the plasma of HCC patients compared to healthy controls. Higher HULC detection rates are observed in the plasma of patients with higher Edmondson grades or with HBV+ status. | 23762823 | Lnc2Cancer |
EL0600 | HULC | osteosarcoma | qPCR etc. | osteosarcoma tissue, cell lines(MG-63, U2OS, SAOS-2 etc.) | up-regulated | expression | In the present study, we demonstrated that HULC was significantly up-regulated in osteosarcoma tissues and cell lines compared with normal controls, and over-expression of HULC was correlated with clinical stage and distant metastasis. Moreover, higher HULC expression was associated with shorter overall survival of osteosarcoma patients.e, decreased expression of HULC markedly suppressed osteosarcoma cell proliferation, migration, and invasion. | 26045809 | Lnc2Cancer |
EL0600 | HULC | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) | up-regulated | expression | All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues. | 26096073 | Lnc2Cancer |
EL0600 | HULC | hepatocelluar carcinoma | qPCR etc. | blood (plasma), HCC tissue | up-regulated | expression | Circulating HULC and Linc00152 were significantly up-regulated in plasma samples of HCC patients during training set and validation set. | 26356260 | Lnc2Cancer |
EL0600 | HULC | pancreatic cancer | qPCR, knockdown etc. | pancreatic cancer tissue, cell lines (MIAPace-2, CFPAC-1, PANC-1, AsPC-1 etc.) | up-regulated | expression | The higher expression of HULC was significantly correlated with large tumor size, advanced lymph node metastasis and vascular invasion. Multivariate analyses revealed that HULC expression served as an independent predictor for overall survival. Further experiments revealed that HULC knockdown significantly repressed cell proliferation of PC in vitro. | 25412939 | Lnc2Cancer |
EL0600 | HULC | liver cancer | qPCR, Luciferase reporter assay, Western blot etc. | liver cancer tissue, cell lines (CREB, HULC, Prkacb etc.) | up-regulated | expression | Long non-coding RNA (lncRNA), highly up-regulated in liver cancer (HULC) plays an important role in tumorigenesis. Depletion of HULC resulted in a significant deregulation of several genes involved in liver cancer. Although up-regulation of HULC expression. | 20423907 | LncRNADisease Lnc2Cancer |
EL0600 | HULC | gastric cancer | qPCR, Western blot etc. | gastric cancer tissue, cell lines (GES-1, SGC7901, MKN28, MKN45, AGS, BGC823 etc.) | up-regulated | N/A | In the present study, we demonstrated that HULC was significantly overexpressed in GC cell lines, compared with normal controls, and this overexpression was correlated with lymph node metastasis, distant metastasis and advanced tumor node metastasis stages.Additionally, HULC contributed to the malignant phenotype of GC cells through its regulation of diverse cellular processes, including proliferation, apoptosis, migration and invasion. | 24247585 | Lnc2Cancer |
EL0600 | HULC | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | cell lines (MHCC97L, HepG2, cHL-7702) | up-regulated | expression | The expression of HEIH and HULC in hepatocellular carcinoma cell line was significantly increased compared with human normal hepatocyte line (P<0.05). The expression of HULC in HepG2 was higher than that in MHCC97L. The over-expression of HULC could enhance proliferation of MHCC97L and HepG2, however, the over-expression of HEIH could not. The over-expression of HULC and HEIH could promote invasion of MHCC97L and HepG2. Invasion of MHCC97L and HepG2 did not have significant change after down-regulating of HEIH and HULC by siRNA. Over-expression of HULC up-regulated the expression of Snail in HepG2. | 26550214 | Lnc2Cancer |
EL0600 | HULC | liver cancer | qPCR, Western blot, knockdown, ChIP, Luciferase reporter assay etc. | HCC tissue, cell lines (HepG2, Huh7, HepG2.2.15 etc.) | up-regulated | interaction | Levels of HULC were positively correlated with levels of SPHK1 and its product, sphingosine-1-phosphate (S1P), in patients HCC samples. HULC increased SPHK1 in hepatoma cells. Mechanistically, HULC activated the promoter of SPHK1 in hepatoma cells through the transcription factor E2F1. Chromatin immunoprecipitation (ChIP) and electrophoretic mobility shift assay (EMSA) further showed that E2F1 was capable of binding to the E2F1 element in the SPHK1 promoter. HULC increased the expression of E2F1 in hepatoma cells and levels of HULC were positively correlated with those of E2F1 in HCC tissues. Intriguingly, HULC sequestered miR-107, which targeted E2F1 mRNA 3'UTR, by complementary base pairing. Functionally, si-SPHK1 remarkably abolished the HULC-enhanced tumor angiogenesis in vitro and in vivo. Taken together, we conclude that HULC promotes tumor angiogenesis in liver cancer through miR-107/E2F1/SPHK1 signaling. | 26540633 | Lnc2Cancer |
EL0600 | HULC | hepatocellular carcinoma | qPCR, Western blot, Luciferase reporter assay etc. | HCC tissue, cell lines (L-O2 cell line, L-O2-X) | up-regulated | expression | Our data show that an lncRNA, HULC, is responsible for the perturbations in circadian rhythm through upregulating circadian oscillator CLOCK in hepatoma cells, resulting in the promotion of hepatocarcinogenesis. Mechanistically, the complementary base pairing between HULC and the 5'untranslated region of CLOCK mRNA underlay the HULC-modulated expression of CLOCK, and the mutants in the complementary region failed to achieve the event. | 25622901 | Lnc2Cancer |
EL0600 | HULC | hepatocelluar carcinoma | qPCR, Western bolt, Luciferase reporter assayRIP etc. | liver cancer tissue, cell lines (Panc1, MiaPaCa2, Panc28, L3.6pl etc.) | up-regulated | N/A | We found that the expression levels of HULC were positively correlated with those of HBx in clinical HCC tissues. Moreover, we revealed that HBx up-regulated HULC in human immortalized normal liver L-O2 cells and hepatoma HepG2 cells. Luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) assay showed that HBx activated the HULC promoter via cAMP-responsive element-binding protein. We further demonstrated that HULC promoted cell proliferation by methyl thiazolyl tetrazolium, 5-ethynyl-2'-deoxyuridine, colony formation assay, and tumorigenicity assay. Then, we validated that HULC down-regulated p18, which was involved in the HULC-enhanced cell proliferation in vitro and in vivo. In a word, HULC play function through regulating a tumor suppressor gene p18 located near HULC in the same chromosome. | 22685290 | Lnc2Cancer |
EL0600 | HULC | HBV-related liver cirrhosis | RT-qPCR, RIP | HBV-related liver cirrhosis patients | up-regulated | expression | We confirmed the effects of HULC on Tregs differentiation in HBV-related liver cirrhosis. In addition, it was proved that HULC regulates the function of Tregs through down-regulated the level of p18 directly. | 25952928 | |
EL0600 | HULC | hepatocelluar carcinoma | TaqMan SNP array etc. | HCC tissue | differential expression | mutation | We conducted a case-control study and genotyped two SNPs, rs7763881 in HULC and rs619586 in MALAT1 Furthermore, the variant genotypes of rs619586 was associated with decreased HCC risk with a borderline significance. | 22493738 | LncRNADisease Lnc2Cancer |
EL0601 | human immunodeficiency virus-encoded antisense RNA | HIV | pcr, suppression | N/A | N/A | epigenetics | This viral expressed antisense lncRNA is involved in modulating human immunodeficiency virus gene expression and that this regulatory effectis due to an alteration in the epigenetic landscape at the viral promoter. It functions as an epigenetic brake to modulate viral transcription. | 24576854 | |
EL0604 | HYMAI | transient neonatal diabetes mellitus | N/A | N/A | N/A | expression | In TNDM fibroblasts, the monoallelic expression of both ZAC and HYMAI is relaxed, providing strong supportive evidence that the presence of two unmethylated alleles of this locus is indeed associated with the inappropriate gene expression of neighbouring genes. | 11935319 | LncRNADisease |
EL0605 | ICR | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue, cell lines(CSQT-2, Huh7, Hep3B) | up-regulated | interaction | Compared with the corresponding primary tumors, PVTT expressed different lncRNAs and mRNAs, including the up-regulated lncRNA ICR and ICAM-1. ICR regulated ICAM-1 expression by increasing the stability of its mRNA through RNA duplex formation, which modulated the CSC properties of ICAM-1+ HCC cells. ICR transcription in ICAM-1+ HCC cells was regulated by Nanog and inhibition of ICR in situ significantly reduced ICAM-1 expression and ICAM-1+ HCC cells in tumors in vivo. Moreover, elevated ICR and ICAM-1 expression in tumors was correlated with PVTT development and poor clinical outcomes | 26667486 | Lnc2Cancer |
EL0607 | IFNG-AS1 | Sjögren syndrome | N/A | CD4(+) T cells of 25 Sjögren syndrome (SS) patients and 25 healthy donors | up-regulated | expression | The level of expression of TMEVPG1 was correlated with the level of SSA, ESR and IgG. | 26440590 | |
EL0607 | IFNG-AS1 | Hashimoto's Thyroiditis | N/A | Twenty-eight HT patients and 20 healthy controls | up-regulated | interaction | Enhanced expression of lncRNA-IFNG-AS1 contributes to Th1 cell response in HT patients and may be involved in the pathogenesis of HT. | 26634912 | |
EL0607 | IFNG-AS1 | multiple sclerosis | N/A | N/A | N/A | N/A | Tmevpg1 (IFNG-AS1) is another lncRNA that may be involved in MS. | 12719555 | LncRNADisease |
EL0608 | IGF2-AS | type 1 diabetes mellitus | N/A | N/A | N/A | mutation | Association identified by GWAS. | 17554260 | LncRNADisease |
EL0608 | IGF2-AS | prostate cancer | N/A | N/A | N/A | mutation | Association identified by GWAS. | 19767753 | LncRNADisease |
EL0608 | IGF2-AS | Wilms' tumor | qPCR, Northern blot etc. | Wilms' tumor tissue | up-regulated | expression | PEG8/IGF2AS and IGF2 were found to be overexpressed in Wilms' tumor samples, at levels over ten and a hundred times higher than that in normal kidney tissues neighboring the tumors, respectively. | 10731720 | LncRNADisease Lnc2Cancer |
EL0608 | IGF2-AS | Wilms' tumor | qPCR, Northern blot etc. | Wilms' tumor tissue | down-regulated | N/A | IGF2-AS was expressed at levels comparable with IGF2 sense expression derived from promoters P1 and P2 in normal tissue and in breast, ovarian, and Wilms' tumor tissues. In Wilms' tumors that demonstrate maintenance of imprinting of IGF2, IGF2-AS was imprinted. | 12702581 | LncRNADisease Lnc2Cancer |
EL0608 | IGF2-AS | liver cancer | qPCR, Northern blot etc. | liver cancer tissue | up-regulated | expression | Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. | 12702581 | LncRNADisease Lnc2Cancer |
EL0608 | IGF2-AS | hepatocelluar carcinoma | qPCR, Southern blot etc. | SMMC-7721 cell line | differential expression | N/A | IGF-IR and IGF-IIR antisense genes could significantly restrain the malignant behavior of human hepatoma cells and might be useful in investigating a potential route for hepatocellular carcinoma gene therapy. | 12603530 | LncRNADisease Lnc2Cancer |
EL0611 | INTS7 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | up-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL0618 | IPW | Prader-Willi syndrome | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0618 | IPW | Prader-Willi syndrome | N/A | N/A | N/A | expression | Subsequently, we determined that IPW, along?noncoding?RNA?in the critical region of the PWS locus, is a regulator of the DLK1-DIO3 region, as its overexpression in PWS and parthenogenetic iPSCs resulted in downregulation of MEGs in this locus.? | 24816254 | LncRNADisease |
EL0618 | IPW | Prader-Willi syndrome | N/A | N/A | N/A | locus | IPW (Imprinted gene in the Prader-Willi syndrome region) was isolated using the direct selection method and yeast artificial chromosomes localized to the deletion region. the mRNA product of IPW may play a role in the imprinting process. | 7849716 | LncRNADisease |
EL0618 | IPW | Prader-Willi syndrome | N/A | N/A | N/A | expression | The Prader-Willi syndrome (PWS) is caused by genomic alterations that inactivate imprinted, paternally expressed genes in human chromosome region 15q11-q13. IPW, a paternally expressed gene cloned from this region, is not expressed in individuals with PWS. | 9063754 | LncRNADisease |
EL0619 | IRAIN | non small cell lung cancer | knockdown | non-small cell lung cancer (NSCLC) tissues | up-regulated | expression | Knockdown of IRAIN suppressed NSCLC cells proliferation in vitro. | 26722412 | |
EL0619 | IRAIN | breast cancer | qPCR etc. | breast cancer tissue | down-regulated | locus | In breast cancer tissues, we found that IRAIN lncRNA was transcribed from an intronic promoter in an antisense diretcion as compared to the IGF1R coding mRNA. Unlike the IGF1R coding RNA, this non-coding RNA was imprinted, with monoallelic expression from the paternal allele. IRAIN was aberrantly imprinted in both tumours and peripheral blood leucocytes, exhibiting a pattern of allele-switch: the allele expressed in normal tissues was inactivated and the normally imprinted allele was expressed. | 25465188 | Lnc2Cancer |
EL0619 | IRAIN | acute myeloid leukemia | qPCR, Northern blot, in vitro knockdown, ChIP etc. | blood, cell lines (K562, KG-1, KG-1a, HL60, TF1) | down-regulated | interaction | We demonstrate that this lncRNA interacts with chromatin DNA and is involved in the formation of an intrachromosomal enhancer/promoter loop. In addition, IRAIN was downregulated both in leukemia cell lines and in blood obtained from high-risk AML patients. Activating the IGF1R gene, lead to growth advantage and tumor progression. | 25092925 | Lnc2Cancer |
EL0620 | JADRR | breast cancer | microarray, qPCR, Western blot, in vitro knockdown, RIP etc. | breast cancer tissue, cell lines (293T, NIH3T3, MCF7, 4T1-luciferase etc.) | up-regulated | N/A | Markedly higher levels of lncRNA-JADE were observed in human breast tumours in comparison with normal breast tissues. Knockdown of lncRNA-JADE significantly inhibited breast tumour growth in vivo. | 24097061 | Lnc2Cancer |
EL0623 | Kcna2-AS | neuropathic pain | N/A | N/A | N/A | regulation | A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons. | 23792947 | LncRNADisease |
EL0624 | KCNE2 | gastric cancer | microarray, qPCR, knockdown etc. | gastric cancer tissue | down-regulated | N/A | LncRNA M59227 and 3 mRNAs, PLK1, PTTG1 and VCAN, were overexpressed in GC. In contrast, the expression of 4 lncRNAs, LOC150622, AKR7 L, DQ192290 and BC040587, and 2 mRNAs, DRD5 and GDF5, were downregulated in GC.The results indicated that TUSC7 is a p53-regulated tumour suppressor that acts in part by repressing miR-23b and that TUSC7 may be a key regulatory hub in GC. | 25765901 | LncRNADisease Lnc2Cancer |
EL0627 | KCNQ1DN | Wilms' tumor | qPCR etc. | Wilms' tumor tissue | down-regulated | expression | A novel imprinted gene, KCNQ1DN, within the WT2 critical region of human chromosome 11p15.5 and its reduced expression in Wilms' tumors. | 11056398 | LncRNADisease Lnc2Cancer |
EL0628 | KCNQ1OT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | locus | KvDMR1 and/or its associated antisense RNA (KvLQT1-AS) represents an additional imprinting control element or center in the human 11p15.5 and mouse distal 7 imprinted domains. | 10393948 | LncRNADisease |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | locus | The LIT1 CpG island can act as a negative regulator in cis for coordinate imprinting at the centromeric domain, thereby suggesting a role for the LIT1 locus in a BWS pathway leading to functional inactivation of p57(KIP2). | 10958646 | LncRNADisease |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | epigenetics | The 5'end of the KCNQ1OT1 gene is hypomethylated in the Beckwith-Wiedemann syndrome. | 12136243 | LncRNADisease |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | N/A | In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene. | 12746837 | LncRNADisease |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | locus | In the human and mouse BWS imprinting regions, two major elements for regulation of imprinted gene expression have been identified athe imprinting centers IC1 and IC2.IC2 appears to be the promoter of the paternally expressed probably noncoding transcript. | 15590939 | LncRNADisease |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | N/A | LIT1 (KCNQ1OT1) may play a role in Beckwith-Wiedemann syndrome. | 15888726 | LncRNADisease |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | epigenetics | In Beckwith-Wiedemann syndrome (BWS), approximately 50% of patients show loss of DNA methylation accompanied by loss of histone H3 Lys9 dimethylation on maternal KCNQ1OT-DMR, namely an imprinting disruption, leading to diminished expression of CDKN1C. | 16575194 | LncRNADisease |
EL0628 | KCNQ1OT1 | colorectal cancer | N/A | N/A | N/A | expression | Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT4: colorectal cancer). | 23660942 | LncRNADisease |
EL0628 | KCNQ1OT1 | Beckwith-Wiedemann syndrome | N/A | N/A | N/A | regulation | Epigenetic deregulation of lncRNAs genes is associated with disease | 23791884 | LncRNADisease |
EL0628 | KCNQ1OT1 | kidney cancer | N/A | N/A | N/A | regulation | Oncogene | 24373479 | LncRNADisease |
EL0628 | KCNQ1OT1 | acute myocardial infarction | N/A | N/A | N/A | N/A | Level of KCNQ1OT1 was higher in patients with MI than in healthy volunteers (P<0.01);Patients with ST-segment-elevation MI had lower levels of KCNQ1OT1 (P<0.001)when compared with patients with non-ST-segment-elevation | 25035150 | LncRNADisease |
EL0628 | KCNQ1OT1 | colorectal cancer | overexpression | colorectal cancer cells | up-regulated | N/A | β-catenin can promote KCNQ1OT1 transcription through direct binding to the KCNQ1OT1 promoter | 26868975 | |
EL0628 | KCNQ1OT1 | hepatocelluar carcinoma | qPCR etc. | HCC tissue | differential expression | mutation | A novel tetranucleotide repeat polymorphism within KCNQ1OT1 confers risk for hepatocellular carcinoma. | 23984860 | LncRNADisease Lnc2Cancer |
EL0628 | KCNQ1OT1 | colorectal cancer | qPCR, FISH etc. | CRC tissue, cell lines (FBS, DLD-1, HCT-15 etc.) | differential expression | epigenetics | epigenetic disruption | 16965397 | LncRNADisease Lnc2Cancer |
EL0628 | KCNQ1OT1 | breast cancer | RNA CISH etc. | breast cancer tissue | up-regulated | expression | HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. | 26323944 | Lnc2Cancer |
EL0633 | KRAS1P | cancer | N/A | N/A | N/A | regulation | Similarly, KRAS and KRAS1P transcript levels were found to be positively correlated, corroborating that pseudogene functions mirror the role of their cognate genes as explained by the miRNA decoy mechanism.? | 24757675 | LncRNADisease |
EL0634 | KRT18P55 | gastric cancer | N/A | GC cell lines (SGC-7901, MGC-803, BGC-823, AGS, and HG27) and 97 GC tissue | up-regulated | N/A | upregulation was observed in GC cell lines | 26855593 | |
EL0635 | KRT19P3 | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | up-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
EL0637 | LA16c-313D11.11 | endometrial cancer | N/A | endometrial cancer (EC) | down-regulated | interaction | Two novel genes RP11-395G23.3 and LA16c-313D11.11 associated with endometrial cancer were identified and proved to be non-coding RNAs. | 26807189 | |
EL0638 | LALR | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | Here we focus on two best-characterized lncRNAs-HULC and LALR, which can impact proliferation through targeting various key regulators in different pathways. | 24296588 | LncRNADisease |
EL0639 | LBX2-AS1 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | up-regulated | N/A | We chose the lncRNAs AK096725 (upregulated) and ENST00000453068 (downregulated) to confirm their differential expression levels in 70 paired RCC tissues and adjacent non-tumor tissues. Levels of AK096725 were significantly greater in RCC tissues while those of ENST00000453068 was significantly lower compared to the non-tumor tissues. These results are consistent with the microarray data. | 24905231 | Lnc2Cancer |
EL0640 | LCAL1 | lung cancer | RNA-Seq, qPCR, knockdown etc. | lung cancer tissue | up-regulated | expression | Stable overexpression of LCAL1, using two different clones, in the control cell line BEAS-2B showed a significant increase in cellular proliferation starting on day 2 and continuing until the end of the experiment at day 6 with a 38% and 43% growth increase, respetcively. Overexpression of LCAL1 in normal BEAS-2B cells is proof of principle that this lncRNA is sufficient to affetc cellular growth independently of other common cancer mutations, thus highlighting the importance of LCAL1 in lung cancer biology. | 25116943 | Lnc2Cancer |
EL0642 | LDMAR | photoperiod-sensitive male sterility | N/A | N/A | N/A | N/A | A lncRNA of 1,236 bases in length, referred to as long-day-specific male-fertility-associated RNA (LDMAR), regulates PSMS (photoperiod-sensitive male sterility) in rice. | 22308482 | LncRNADisease |
EL0644 | LEIGC | gastric cancer | microarray, qPCR, in vitro knockdown etc. | gastric cancer tissue, cell lines (MGC-803, AGS, SGC-7901) | up-regulated | expression | We found that there were significantly lower levels of LEIGC expression in gastric cancer tissue. Overexpression of LEIGC suppressed tumor growth and cell proliferation, and enhanced the sensitivity of gastric cancer cells to 5-fluorouracil (5-FU), whereas knockdown of LEIGC showed the opposite effetc. We further demonstrated LEIGC functions by inhibiting the epithelial-to-mesenchymal transition (EMT) in gastric cancer. | 25496320 | Lnc2Cancer |
EL0645 | LGALS3 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0646 | LINC00032 | narcolepsy | N/A | N/A | N/A | mutation | Association identified by GWAS. | 16826516 | LncRNADisease |
EL0646 | LINC00032 | melanoma | N/A | N/A | N/A | mutation | An analysis of genome-wide DNA copy number alterations in melanoma tumors revealed the loss of the C9orf14 locus, located proximal to CDKN2A, in approximately one-fourth of tumors. | 17099875 | LncRNADisease |
EL0647 | LINC00160 | breast cancer | Single-molecule sequencing, chromatin immunoprecipitation and quantitative real-time PCR | luminal A-type human breast cancer cell lines MCF7 and T47D | up-regulated | interaction | Silencing of LINC00160 results in reduced proliferation, demonstrating that lncRNA expression have functional consequences. | 26423156 | |
EL0648 | LINC00173 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | down-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL0649 | LINC00210 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | up-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL0650 | LINC00237 | MOMO (macrosomia, obesity, macrocephaly, and ocular abnormalities) syndrome | Expression study in lymphocytes of control and case individuals | MOMO patient | up-regulated | expression | LINC00237 was expressed in lymphocytes of control individuals while normal transcripts were absent in lymphocytes of our MOMO patient. | 23034868 | |
EL0651 | LINC00261 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | Furthermore, the levels of LINC00261 and TP73-AS1 were significantly differently expressed in subgroups of NSCLC samples.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
EL0651 | LINC00261 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue, cell lines (HCG-27, SGC-7901) | down-regulated | expression | Linc00261, DKFZP434K028 and RPL34-AS1 had lower expression levels in gastric cancer tissues than the normal counterparts. In gastric cell lines, the three lncRNAs were also down-regulated compared with the respective normal gastric epithelial cell line GES-1. Moreover, the low expression levels of DKFZP434K028 and RPL34-AS1 positively correlated with the larger tumor size. | 26237576 | Lnc2Cancer |
EL0651 | LINC00261 | pancreatic cancer | qPCR, Western blot, knockdown etc. | PDAC tissue | down-regulated | expression | The upregulation of LINC00152 (MACE log2fc: 2.3, qPCR: 1.5) and downregulation of LINC00261 (MACE log2fc: 5.3, qPCR: 4.4) in PDAC tissues was confirmed by qPCR. | 25910082 | Lnc2Cancer |
EL0652 | LINC00271 | schizophrenia | N/A | N/A | N/A | mutation | This gene is associated with susceptibility to schizophrenia. | 16773125 | LncRNADisease |
EL0652 | LINC00271 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Association identified by GWAS. | 17668382 | LncRNADisease |
EL0653 | LINC00299 | neurodevelopmental disabilities | DNA capture followed by next-generation sequencing | all tissues ,most abundantly in brain | N/A | N/A | these subjects with disruption of LINC00299 implicate this particular noncoding RNA in brain development and raise the possibility that, as a class, abnormalities of lincRNAs may play a significant role in human developmental disorders. | 23217328 | |
EL0653 | LINC00299 | intellectual and developmental disability | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0654 | LINC00312 | nasopharyngeal carcinoma | microarray, ISH etc. | NPC, TMA tissue | down-regulated | expression | Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. | 23529758 | LncRNADisease Lnc2Cancer |
EL0654 | LINC00312 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
EL0654 | LINC00312 | nasopharyngeal carcinoma | N/A | N/A | N/A | expression | NAG-7 is a novel gene downregulated in human nasopharyngeal carcinoma. | 11780420 | LncRNADisease |
EL0654 | LINC00312 | nasopharyngeal carcinoma | Northern blot, Western blot etc. | HNE1 cell line | down-regulated | expression | NAG7 (LINC00312) gene re-expression could inhibit overproliferation of NPC cell by delaying the progression of G1 into S in cell cycle and inducing cell apoptosis. | 12452030 | LncRNADisease Lnc2Cancer |
EL0654 | LINC00312 | nasopharyngeal carcinoma | qPCR, Western blot, Luciferase reporter assay, ISH etc. | cell line (HNE1) | up-regulated | Interaction | NAG7 (LINC00312) promotes human nasopharyngeal carcinoma invasion through inhibition of estrogen receptor alpha and up-regulation of JNK2/AP-1/MMP1 pathways. | 19591174 | LncRNADisease Lnc2Cancer |
EL0655 | LINC00313 | lung cancer | microarray, qRT-PCR | tissues from 181 early-stage lung cancer patients | up-regulated | expression | Notably, a novel lncRNA, LINC00313, was highly expressed in both T2- and N1-stage lung cancers. On the other hand, LINC00313 was also upregulated in lung cancer and metastasized lung cancer tissues, compared with adjacent lung tissues and primary lung cancer tissues. LINC00313 could be a biomarker for lung cancer. | 26178480 | |
EL0657 | LINC00467 | neuroblastoma | microarray, qPCR, Luciferase reporter assay, knockdown etc. | cell lines (BE(2)-C ) | differential expression | N/A | Chromatin immunoprecipitation and luciferase assays showed that N-Myc suppressed linc00467 gene expression through direct binding to the linc00467 gene promoter and reducing linc00467 promoter activity. While N-Myc suppressed the expression of RD3, the protein-coding gene immediately down-stream of linc00467 gene, through direct binding to the RD3 gene promoter and reducing RD3 promoter activity, linc00467 reduced RD3 mRNA expression. Importantly, knocking-down linc00467 expression with siRNA in neuroblastoma cells reduced the number of viable cells and increased the percentage of apoptotic cells, and co-transfection with DKK1 siRNA blocked the effects. | 24586304 | Lnc2Cancer |
EL0658 | LINC00473 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | down-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL0659 | LINC00491 | pancreatic ductal adenocarcinoma | microarray, qPCR etc. | PDAC tissue | down-regulated | expression | We found that the expression level of lncRNA BC008363 was significantly lower (23-fold) in PDAC tissues compared to corresponding nontumor pancreatic tissues, and patients with high levels of lncRNA BC008363 expression had significantly better survival rates than those with low levels of lncRNA BC008363 expression. lncRNA BC008363 may be a novel biomarker for the prognosis of pancreatic cancer. | 25200694 | Lnc2Cancer |
EL0660 | LINC00538 | cancer | N/A | N/A | N/A | expression | Expression profiling revealed a general and regulated expression pattern of Yiya in major tissues, and more interestingly, identified elevated mRNA levels in different cancers. | 22258142 | LncRNADisease |
EL0662 | LINC00581 | West Syndrome | N/A | N/A | N/A | mutation | A de novo balanced t(2;6)(p15;p22.3) in a patient with West Syndrome disrupts a lnc-RNA, BX118339. | 22245136 | LncRNADisease |
EL0662 | LINC00581 | West Syndrome | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL0663 | LINC00635 | non-small cell lung cancer | microarray, qRT-PCR | gefitinib-sensitive HCC827 cells and gefitinib-resistant HCC827-8-1 cells | up-regulated | interaction | Silencing of LINC00635-001 alone did not remarkably impact HCC827-8-1 cells, but its combination with gefitinib treatment inhibited Akt activation and sensitized HCC827-8-1 cells to gefitinib-induced cytotoxicity. | 26792719 | |
EL0664 | LINC00659 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
EL0666 | LINC00668 | gastric cancer | knockdown | n vitro and in vivo | up-regulated | N/A | LINC00668 knockdown significantly repressed proliferation, both in vitro and in vivo | 27036039 | |
EL0667 | LINC00673 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | The expression level of ADAMTS9-AS2, C1401f132 and LINC00312 in NSCLC tumors were indeed significantly down-regulated when compared with those in normal lung tissues, while LINC00673 was significantly up-regulated in NSCLC tumors compared with normal lung tissues.These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
EL0668 | LINC00850 | Duchenne muscular dystrophy | N/A | N/A | N/A | mutation | Molecular characterization of an X(p21.2;q28) chromosomal inversion in a Duchenne muscular dystrophy patient with mental retardation reveals a novel long non-coding gene on Xq28 | 23223008 | LncRNADisease |
EL0668 | LINC00850 | Duchenne muscular dystrophy | N/A | N/A | N/A | expression | KUCG1 is a 648-bp nuclear lncRNA expressed in a tissue specific manner. Since it is normally expressed in the brain, its deregulation could contribute to the neurological impairment of the patient as already reported for other pathologies. | 24685002 | LncRNADisease |
EL0670 | LINC00901 | osteosarcoma | microarray, qPCR, FISH etc. | osteosarcoma tissue, cell lines (U2OS, SAOS-2, HOS etc.) | down-regulated | mutation | These CNAs (copy number alterations) in osteosarcoma often involve the noncoding RNAs LOC285194 and BC040587. | 20048075 | LncRNADisease Lnc2Cancer |
EL0670 | LINC00901 | gastric cancer | microarray, qPCR, knockdown etc. | gastric cancer tissue | down-regulated | N/A | LncRNA M59227 and 3 mRNAs, PLK1, PTTG1 and VCAN, were overexpressed in GC. In contrast, the expression of 4 lncRNAs, LOC150622, AKR7 L, DQ192290 and BC040587, and 2 mRNAs, DRD5 and GDF5, were downregulated in GC.The results indicated that TUSC7 is a p53-regulated tumour suppressor that acts in part by repressing miR-23b and that TUSC7 may be a key regulatory hub in GC. | 25765901 | LncRNADisease Lnc2Cancer |
EL0670 | LINC00901 | breast cancer | qPCR etc. | breast cancer tissue, cell lines (ZR-75-30, MCF-7, SKBR-3, T47D cells) | down-regulated | expression | It showed that BC040587 expression was down regulated both in BC samples and in BC cell lines compared with corresponding normal control. BC040587 expression was correlated with menopausal status and tumor differentiation. Furthermore, expression of BC040587 was significantly associated with worse prognosis and was shown to be an independent prognostic marker breast cancer. | 25435812 | Lnc2Cancer |
EL0671 | LINC00942 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
EL0672 | LINC00951 | esophageal squamous cell carcinoma | biochemical assays | N/A | N/A | N/A | functional polymorphism rs11752942A>G in lincRNA-uc003opf.1 exon might be a genetic modifier for the development of ESCC. | 23872665 | |
EL0673 | LINC00963 | prostate cancer | microarray, qPCR, knockdown, Western blot etc. | cell lines (LNCaP ,C4-3) | up-regulated | regulation | Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. | 24691949 | LncRNADisease Lnc2Cancer |
EL0674 | LINC00964 | colorectal cancer | qPCR etc. | CRC tissue | down-regulated | interaction | Furthermore, the authors observed that mRNA expression levels of LNC00964-3 were significantly lower in CRC tissues than in corresponding normal tissues. The current findings reveal the possibility that piR-015551 may be generated from LNC00964-3, which may be involved in the development of CRC | 25740697 | Lnc2Cancer |
EL0675 | LINC00970 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL0676 | LINC00974 | hepatocelluar carcinoma | qPCR, in vitro knockdown, RIP etc. | HCC tissue, blood(plasma) | up-regulated | interaction | Knockdown of Linc00974 resulted in an inhibition of cell proliferation and invasion with an activation of apoptosis and cell cycle arrest in vitro.The combination of Linc00974 and KRT19 may be novel indices for clinical diagnosis of tumor growth and metastasis in HCC, while Linc00974 may become a potential therapeutic target for the prevention of HCC progression. We also discovered Linc00974F-1 stably expressed in the plasma. | 25476897 | Lnc2Cancer |
EL0677 | LINC00982 | gastric cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | gastric cancer tissue, cell lines (SGC7901, BGC823, MGC803, AGS, MKN45) | down-regulated | interaction | In this study, we identified a novel lncRNA LINC00982, whose expression was downregulated in tumor tissues in 106 patients with gastric cancer (GC) compared with those in the adjacent normal tissues (P < 0.001). Furthermore, knockdown of LINC00982 expression by small interfering RNA (siRNA) could promote cell proliferation and cell cycle progression, while ectopic expression of LINC00982 inhibited cell proliferation and rendered cell cycle arrest in GC cells partly via regulating P15 and P16 protein expressions. | 26334618 | Lnc2Cancer |
EL0678 | LINC00987 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL0679 | LINC01016 | breast cancer | Single-molecule sequencing, chromatin immunoprecipitation and quantitative real-time PCR | luminal A-type human breast cancer cell lines MCF7 and T47D | up-regulated | expression | LINC01016 and LINC00160 are direct transcriptional targets of ERα, correlate with Erα expression in clinical samples, and show prognostic significance in relation to breast cancer survival. | 26423156 | |
EL0680 | LINC01018 | hepatocelluar carcinoma | qPCR etc. | HCC tissue, cell lines (BEL-7402, SK-Hep1, Huh7, MHCC-97H) | down-regulated | mutation | We found that a lower SRHC expression level was significantly more frequent in tissues with a high serum a-fetoprotein level and a low degree of differentiated tumors. Furthermore, we found that the promoter region of SRHC contains a CpG-rich island and that SRHC is down-regulated in tumors by DNA methylation. | 25512078 | Lnc2Cancer |
EL0681 | LINC01021 | colorectal cancer | RNA-seq, pSILAC, qPCR, Western Blot, Luciferase reporter assay etc. | cell line (SW480) | up-regulated | interaction | Ectopic LINC01021 expression inhibited proliferation in SW480 cells. | 26183718 | Lnc2Cancer |
EL0682 | LINC01024 | lung cancer | qPCR, Western blot, knockdown etc. | cell lines (H1299) | up-regulated | interaction | We employed qPCR to analyze MA-linc1 levels in four cell lines: U2OS and H1299 cells, as well as the human embryonic lung fibroblasts, WI38, and another human osteosarcoma cell line, SAOS-2, each expressing the conditionally active E2F1. This analysis demonstrated that activation of the ectopic E2F1 resulted in a significant increase in MA-linc1 RNA levels in all four cell lines. | 26337085 | Lnc2Cancer |
EL0682 | LINC01024 | osteosarcoma | qPCR, Western blot, knockdown etc. | cell lines (U2OS, SAOS-2) | up-regulated | expression | We employed qPCR to analyze MA-linc1 levels in four cell lines: U2OS and H1299 cells, as well as the human embryonic lung fibroblasts, WI38, and another human osteosarcoma cell line, SAOS-2, each expressing the conditionally active E2F1. This analysis demonstrated that activation of the ectopic E2F1 resulted in a significant increase in MA-linc1 RNA levels in all four cell lines. | 26337085 | Lnc2Cancer |
EL0683 | SLC44A3-AS1 | colorectal cancer | microarray, qPCR etc. | blood (plasma) | up-regulated | expression | The expression of three lncRNAs in plasma of CRC were all significantly higher than those in controls. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future. | 26328256 | Lnc2Cancer |
EL0684 | LINC01105 | gastric cancer | microarray, qPCR, knockdown etc. | gastric cancer tissue | down-regulated | N/A | LncRNA M59227 and 3 mRNAs, PLK1, PTTG1 and VCAN, were overexpressed in GC. In contrast, the expression of 4 lncRNAs, LOC150622, AKR7 L, DQ192290 and BC040587, and 2 mRNAs, DRD5 and GDF5, were downregulated in GC.The results indicated that TUSC7 is a p53-regulated tumour suppressor that acts in part by repressing miR-23b and that TUSC7 may be a key regulatory hub in GC. | 25765901 | LncRNADisease Lnc2Cancer |
EL0685 | LINC01125 | uremia | microarray assay, qRT-PCR | peripheral blood mononuclear cells of uremia patients | N/A | expression | Differential expression of ZAP70 and BC133674 (ZAP70-ncRNA) was confirmed by RT-PCR. | 23100179 | |
EL0686 | LINC01133 | lung squamous cell carcinoma | microarray, qPCR, knockdown etc. | NSCLC tissue, cell lines (H1703) | up-regulated | N/A | LSCC patients with higher expression level of LINC01133 had shorter survival time. LINC01133 is upregulated in lung squamous cell cancer and predicts survival | 25908174 | LncRNADisease Lnc2Cancer |
EL0687 | LINC01158 | gastric cancer | microarray, qRT-PCR | peripheral blood regulatory T cells (T-reg) in gastric cancer | up-regulated | interaction | linc-POU3F3 could promote the distribution of Tregs in peripheral blood T cell which caused an enhanced cell proliferation of gastric cancer cells by recruiting TGF-beta as well as activating TGF-beta signal pathway. | 26807174 | |
EL0688 | LINC01207 | lung adenocarcinoma | qPCR, Western blot, knockdown, RIP, ChIP etc. | NSCLC tissues and adjacent non-tumor tissues, cell lines(A549) | up-regulated | interaction | LINC01207 was significantly up-regulated in LAD tissues compared with paired non-tumor tissues, while there was no significant differences between LSCC tissues and adjacent non-tumor tissues. The expression level of LINC01207 was associated with TNM stage of LAD patients, and higher LINC01207 level indicated advanced TNM stage and shorter survival. | 26693067 | Lnc2Cancer |
EL0689 | LINC01225 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future. | 25714016 | Lnc2Cancer |
EL0690 | LINC01233 | esophageal squamous cell carcinoma | microarray, qPCR etc. | OSCC tissue | differential expression | N/A | we identified a three-lncRNA signature (including the lncRNAs ENST00000435885.1, XLOC_013014 and ENST00000547963.1) which classified the patients into two groups with significantly different overall survival . The signature was applied to the test group (median survival 21.5 months vs >60 months, p=0.0030) and independent cohort (median survival 25.8 months vs >48 months, p=0.0187) and showed similar prognostic values in both. | 24522499 | Lnc2Cancer |
EL0691 | LINC01262 | Parkinson's disease | N/A | N/A | N/A | expression | These included the U1 spliceosomal lncRNA and RP11-462G22.1, each entailing sequence complementarity to numerous microRNAs. | 24651478 | LncRNADisease |
EL0692 | LINC01315 | nasopharyngeal carcinoma | microarray, qPCR etc. | NPC tissue | up-regulated | expression | Results. In primary NPC, upregulation of?lnc-C22orf32-1,?lnc-AL355149.1-1, and?lnc-ZNF674-1 was observed. High levels of?lnc-C22orf32-1 and?lnc-AL355149.1-1 were significantly associated with the male patients | 24822202 | LncRNADisease Lnc2Cancer |
EL0693 | LINC01370 | type 2 diabetes mellitus | N/A | N/A | N/A | regulation | Depletion of HI-LNC25, a 尾 cell-specific lncRNA, downregulated GLIS3 mRNA, thus exemplifying a gene regulatory function of islet lncRNAs. Finally, selected islet lncRNAs were dysregulated in type 2 diabetes or mapped to genetic loci underlying diabetes susceptibility. | 23040067 | LncRNADisease |
EL0694 | LINC01419 | hepatocelluar carcinoma | microarray, qPCR etc. | HBV-related HCC tissue | up-regulated | expression | Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. | 26109807 | Lnc2Cancer |
EL0694 | LINC01419 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We noted that LINC01419 was characterized by a significant increase in transcript expression from dysplasia to early HCC. The lncRNA AK021443 was also up-regulated in advanced HCC samples when compared with early HCC. Moreover, expression of LINC01419 and AK021443 was up-regulated in HCC tissues when compared with non-tumor liver tissue. AF070632 expression was down-regulated in HCC and was decreased in advanced HCC when compared with early HCC. These results suggest that LINC01419 may be related to the initiation of HCC, whereas AK021443 and AF070632 may be associated with the progression of HCC. | 26540467 | Lnc2Cancer |
EL0695 | LINC01426 | esophageal squamous cell carcinoma | qPCR, Luciferase reporter assay, Western blot etc. | ESCC tissue | up-regulated | expression | We found that lincRNA-uc002yug.2 was commonly overexpressed in ESCC. Moreover, lincRNA-uc002yug.2 promoted a combination of RUNX1 and alternative splicing (AS) factors in the nucleus to produce more RUNX1a, the short isoform and inhibitor of RUNX1, and reduce CEBPa (CCAAT/enhancer-binding protein-a) gene expression, thereby promoting ESCC progression. The expression levels of lincRNA-uc002yug.2 in ESCC might be a prognostic factor for survival. | 25486427 | Lnc2Cancer |
EL0696 | LINC01433 | lung cancer | microarray, qPCR, Western blot, knockdown etc. | cell line (16HBE) | up-regulated | N/A | LOC728228 was upregulated relative to its expression in control untransformed16HBE (16HBE-N) cells. | 25820656 | LncRNADisease Lnc2Cancer |
EL0697 | LINC01451 | hepatocelluar carcinoma | microarray, qPCR, RIP, RNA pulldown assay etc. | HCC tissue | up-regulated | N/A | AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. | 21769904 | Lnc2Cancer |
EL0698 | LINC01468 | tongue squamous cell carcinoma | microarray, qPCR etc. | tongue SCC tissue | up-regulated | regulation | Overexpression of lnc-SPRR2D-1 and lnc-PPP2R4-5 was found in the tongue SCC tissue. Overexpression of the lnc-MBL2-4:3 in the tongue SCC was highly significant in comparison with the paired normal epithelia. Lnc-AL355149.1-1 was the only lncRNA found to be downregulated in the tongue SCC tissues.The association of lncRNA with the T-stage and nodal status of tongue SCC patients suggested that lncRNA deregulation was involved in the pathogenesis of tongue SCC. | 25045670 | Lnc2Cancer |
EL0699 | LINC01503 | tongue squamous cell carcinoma | microarray, qPCR etc. | tongue SCC tissue | up-regulated | regulation | Overexpression of lnc-SPRR2D-1 and lnc-PPP2R4-5 was found in the tongue SCC tissue. Overexpression of the lnc-MBL2-4:3 in the tongue SCC was highly significant in comparison with the paired normal epithelia. Lnc-AL355149.1-1 was the only lncRNA found to be downregulated in the tongue SCC tissues.The association of lncRNA with the T-stage and nodal status of tongue SCC patients suggested that lncRNA deregulation was involved in the pathogenesis of tongue SCC. | 25045670 | Lnc2Cancer |
EL0700 | LINC01511 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | up-regulated | expression | RP11-133F8.2 expression of EGFR exon 19 deletions in lung adenocarcinoma was significantly higher than wild-type EGFR tissues, while LOC440905 expression of EGFR exon 19 deletions in lung adenocarcinoma was significantly lower than wild-type EGFR tissues. RP11-325I22.2 and LOC440905 might play an important role in the mechanism of EGFR exon 19 deletion in lung adenocarcinoma. | 25085781 | Lnc2Cancer |
EL0701 | LINC01512 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | up-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL0702 | LINC01527 | tongue squamous cell carcinoma | microarray, qPCR etc. | tongue SCC tissue | up-regulated | regulation | Overexpression of lnc-SPRR2D-1 and lnc-PPP2R4-5 was found in the tongue SCC tissue. Overexpression of the lnc-MBL2-4:3 in the tongue SCC was highly significant in comparison with the paired normal epithelia. Lnc-AL355149.1-1 was the only lncRNA found to be downregulated in the tongue SCC tissues.The association of lncRNA with the T-stage and nodal status of tongue SCC patients suggested that lncRNA deregulation was involved in the pathogenesis of tongue SCC. | 25045670 | Lnc2Cancer |
EL0703 | LINC01550 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | down-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL0704 | LINC01564 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
EL0706 | LINC01616 | Alzheimer's disease | Gene set enrichment analysis | postmortem tissue samples of AD patients | down-regulated | expression | lncRNA n341006 in association with protein ubiquitination pathway | 26318290 | |
EL0707 | LINC01617 | colorectal cancer | microarray, qPCR etc. | blood (plasma) | up-regulated | expression | The expression of three lncRNAs in plasma of CRC were all significantly higher than those in controls. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future. | 26328256 | Lnc2Cancer |
EL0708 | LINC01618 | colorectal cancer | microarray, qPCR etc. | blood (plasma) of CRC tissue | up-regulated | expression | The expression of three lncRNAs in plasma of CRC were all significantly higher than those in controls. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future. | 26328256 | Lnc2Cancer |
EL0709 | LINC01628 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future. | 26393913 | Lnc2Cancer |
EL0710 | LINC01630 | colorectal cancer | qPCR etc. | colorectal cancer tissue | down-regulated | expression | The qRT-PCR results revealed the misregulation of these genes during tumorigenesis. Their relative expression levels were significantly lower in tumor tissues than adjacent tumor-free tissues. However, the analysis found no significant correlation between reduced expression of these genes | 26429648 | Lnc2Cancer |
EL0710 | LINC01630 | colorectal cancer | Quantitativereal-time-PCR (qRT-PCR) | colorectal tissue | down-regulated | N/A | LOC100287225 expressed in the intestinal tissue | 27062707 | |
EL0715 | linc-CBR1-2 | lung cancer | microarray, qPCR, knockdown etc. | lung cancer tissue | up-regulated | N/A | To validate our findings, we selected one lincRNA and three mRNAs for validation. Of these, linc-CBR1-2, and two mRNAs, RAB25 and HMBG3 were up-regulated in AIS compared to nomal tisssu. | 24735754 | Lnc2Cancer |
EL0718 | linc-ITGB1 | breast cancer | qPCR, Western blot, knockdown, Flow cytometry assay etc. | breast cancer tissue, cell lines (MDA-MB-231, MCF-7, T47D, ZR-75-30, 1590 etc.) | up-regulated | interaction | The expression of linc-ITGB1 was significantly upregulated in both clinical breast cancer tissues and cultured breast cancer cell lines. Linc-ITGB1 depletion caused cell accumulation in the G0/G1 phase. Furthermore, the linc-ITGB1 knockdown decreased the expression of mesenchymal markers N-cadherin and vimentin while increasing the expression of the epithelial marker E-cadherin. Key cell cycle regulators Cdc25C and Cyclin B1 were also decreased by the linc-ITGB1 knockdown. These data suggest that linc-ITGB1 promotes breast cancer progression by inducing cell-cycle arrest and interrupting the epithelial-to-mesenchymal transition (EMT) process. | 26601916 | Lnc2Cancer |
EL0719 | LINCMD1 | Duchenne muscular dystrophy | N/A | N/A | N/A | expression | Interestingly, the levels of linc-MD1 are strongly reduced in primary myoblasts of DMD patients and its ectopic expression rescues the myogenic differentiation potential of these cells, restoring the correct expression pattern of MAML1, MEF2C, MYOG and MHC. | 24685002 | LncRNADisease |
EL0721 | LINC-PINT | colorectal cancer | microarray, qPCR, RIP etc. | cell lines (KrasLA2/+, Trp53LSL/LSL, Rosa26-CreERT2 etc.) | down-regulated | N/A | In this study, we have identified and characterized the lincRNA named Pint, abona fidep53 transcriptional target that acts as negative modulator of the p53 response.We found a significant downregulation of PINT in colorectal tumors compared with normal tissue, suggesting a potential role of the lincRNA as a tumor suppressor. Pint binds directly to PRC2, and is required for the targeting of PRC2 to specific genes for H3K27 tri-methylation and repression. Of the total number of genes affected by Pint inhibition, 39% were upregulated and 61% downregulated upon Pint knockdown. | 24070194 | Lnc2Cancer |
EL0721 | LINC-PINT | heart failure | N/A | N/A | N/A | expression | Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure.The mitochondrial long noncoding RNA uc022bqs.1 (LIPCAR) was downregulated early after myocardial infarction but upregulated during later stages. LIPCAR levels identified patients developing cardiac remodeling and were independently to other risk markers associated with future cardiovascular deaths. | 24663402 | LncRNADisease |
EL0739 | lincRNA-BC2 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | up-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
EL0740 | lincRNA-BC4 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | down-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
EL0741 | lincRNA-BC5 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | up-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
EL0742 | lincRNA-BC8 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | down-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
EL0743 | lincRNA-CALCA | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | down-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL0744 | lincRNA-LALR1 | liver cancer | qPCR, RIP etc. | liver cancer tissue | up-regulated | regulation | LncRNA-LALR1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/尾-Catenin signaling | 23483581 | LncRNADisease Lnc2Cancer |
EL0745 | lincRNA-TSPAN8 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | down-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. Among them, lincRNA-TSPAN8 and TSPAN8 were found highly expressed in high lung metastatic potential HCC cells, while lowly expressed in no or low lung metastatic potential HCC cells. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL0746 | lincRNA-ZNF532 | pancreatic cancer | microarray, qPCR etc. | cell lines (SW1990, SWl990/GZ etc.) | up-regulated | expression | Six lncRNAs (RP11-58D2.1, lincRNA-ZNF532, AP000221.1, CTC-338M12.5, CR619813, DDX6P) were selected to validate the microarray consistency by using qPCR. The results demonstrated that RP11-58D2.1, lincRNA-ZNF532 and AP000221.1 were upregulated and that CTC-338M12.5, DDX6P and CR619813 were downregulated in the SW1990/GZ cells compared with SW1990 cells (Figure 6). | 25755691 | Lnc2Cancer |
EL0747 | LINC-ROR | triple-negative breast cancer | microarray, qPCR, Western blot etc. | breast cancer tissue, cell lines (HEK293T, MCF-7, HS578T, MDA-MB-231) | up-regulated | N/A | LincRNA-RoR is upregulated in TNBC and in metastatic disease and knockdown restores miR-145 expression.The lincRNA-RoR/miR-145/ARF6 pathway is critical to TNBC metastasis and could serve as biomarkers or therapeutic targets for improving survival. | 25253741 | LncRNADisease Lnc2Cancer |
EL0747 | LINC-ROR | hepatocelluar carcinoma | qPCR, Luciferase reporter assays, knockdown etc. | cell lines (HepG2, PLC-PRF5) | up-regulated | N/A | lincRNA-ROR (linc-ROR), a stress-responsive lncRNA was highly expressed in HCC cells and enriched within extracellular vesicles derived from tumor cells. Incubation with HCC-derived extracellular vesicles increased linc-ROR expression and reduced chemotherapy-induced cell death in recipient cells. Sorafenib increased linc-ROR expression in both tumor cells and extracellular vesicles, whereas siRNA to linc-ROR increased chemotherapy-induced apoptosis and cytotoxicity. | 24918061 | Lnc2Cancer |
EL0747 | LINC-ROR | breast cancer | qPCR, vivo knockdown, PIR etc. | breast cancer tissue | up-regulated | N/A | linc-ROR was upregulated in breast tumor and ectopic overexpression of linc-ROR in immortalized human mammary epithelial cells induced an epithelial-to-mesenchymal transition (EMT) program. Moreover,linc-ROR enhanced breast cancer cell migration and invasion. Linc-ROR was associated with miRNPs and functioned as a competing endogenous RNA to mi-205. linc-ROR functions as an important regulator of EMT and can promote breast cancer progression and metastasis through regulation of miRNAs. | 24922071 | Lnc2Cancer |
EL0747 | LINC-ROR | colorectal cancer | qPCR, Western blot, knockdown etc. | cell lines (HT29, HRT-18) | up-regulated | interaction | we found that the expression of ROR was significantly increased in a series of tumor cells, whereas all of the negative controls remained weakly expressed. | 26169368 | Lnc2Cancer |
EL0747 | LINC-ROR | malignant melanoma | qPCR, Western blot, knockdown etc. | cell lines (OM431, MUM2B) | up-regulated | expression | we found that the expression of ROR was significantly increased in a series of tumor cells, whereas all of the negative controls remained weakly expressed. | 26169368 | Lnc2Cancer |
EL0747 | LINC-ROR | gastric cancer | qPCR, Western blot, knockdown etc. | cell line (AGS) | up-regulated | expression | we found that the expression of ROR was significantly increased in a series of tumor cells, whereas all of the negative controls remained weakly expressed. | 26169368 | Lnc2Cancer |
EL0747 | LINC-ROR | pancreatic cancer | qRT-PCR, RNA interference approaches, luciferase assays and RNA binding protein immunoprecipitation, immunohistochemistry assay | 61 paired cancerous and noncancerous tissue samples, pancreatic cancer stem cells (PCSCs) | up-regulated | expression | Knockdown of ROR by RNA interference in PCSCs inhibited proliferation, induced apoptosis and decreased migration. Moreover, ROR silencing resulted in significantly decreased tumourigenicity of PCSCs in nude mice than controls. | 26636540 | |
EL0747 | LINC-ROR | liver cancer | RT-PCR, knockdown | N/A | up-regulated | interaction | linc-RoR is a hypoxia-responsive lncRNA that is functionally linked to hypoxia signaling in HCC through a miR-145-HIF-1α signaling module. | 24463816 | |
EL0750 | LINK-A | triple-negative breast cancer | N/A | N/A | N/A | interaction | Both LINK-A expression and LINK-A-dependent signalling pathway activation correlate with triple-negative breast cancer (TNBC), promoting breast cancer glycolysis reprogramming and tumorigenesis. | 26751287 | |
EL0752 | Llme23 | melanoma | qPCR, Western bolt, Northern bolt, knockdown, RIP etc. | cell lines (MCF10A, HEK293, A2058, SKmel28, YU-SIT1, YUSAC etc.) | differential expression | N/A | The specific binding of Llme23 to both recombinant and native PSF protein was confirmed in vitro and in vivo. The expression of PSF-binding Llme23 is exclusively detected in human melanoma lines. Knocking down Llme23 remarkably suppressed the malignant property of YUSAC cells, accompanied by the repressed expression of proto-oncogene Rab23. These results may indicate that Llme23 can function as an oncogenic RNA and directly associate the PSF-binding lncRNA with human melanoma. | 23618401 | Lnc2Cancer |
EL0753 | lnc13 | celiac disease | N/A | small intestinal biopsy samples from patients with | down-regulated | N/A | Lnc13 regulates gene expression by binding to hnRNPD a member of a family of ubiquitously expressed heterogeneous nuclear | 27034373 | |
EL0758 | Lnc34a | colon cancer | N/A | colon cancer stem cells (CCSCs) | up-regulated | N/A | Lnc34a recruits Dnmt3a via PHB2 and HDAC1 to methylate and deacetylate the miR-34a promoter simultaneously | 27077950 | |
EL0760 | lnc-ACACA-1 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | down-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0761 | lnc-AF085935 | hepatocelluar carcinoma | qPCR etc. | blood (serum) | up-regulated | expression | The level of serum lncRNA-uc003wbd and lncRNA-AF085935 was significantly upregulated in HCC patients and HBV patients compared with that in normal controls.In addition, higher expressions of lncRNAs were observed in HCC patients than in HBV patients. LncRNA-uc003wbd and lncRNA-AF085935 were observed with an aberrant serum level in HCC and HBV patients, which is showing that both lncRNA-uc003wbd and lncRNA-AF085935 are able to be potential biomarkers for HCC and HBV screening. | 25501706 | Lnc2Cancer |
EL0762 | lnc-AL355149.1-1 | nasopharyngeal carcinoma | microarray, qPCR etc. | NPC tissue | up-regulated | expression | Results. In primary NPC, upregulation of?lnc-C22orf32-1,?lnc-AL355149.1-1, and?lnc-ZNF674-1 was observed. High levels of?lnc-C22orf32-1 and?lnc-AL355149.1-1 were significantly associated with the male patients | 24822202 | LncRNADisease Lnc2Cancer |
EL0762 | lnc-AL355149.1-1 | tongue squamous cell carcinoma | microarray, qPCR etc. | tongue SCC tissue | down-regulated | regulation | Overexpression of lnc-SPRR2D-1 and lnc-PPP2R4-5 was found in the tongue SCC tissue. Overexpression of the lnc-MBL2-4:3 in the tongue SCC was highly significant in comparison with the paired normal epithelia. Lnc-AL355149.1-1 was the only lncRNA found to be downregulated in the tongue SCC tissues.The association of lncRNA with the T-stage and nodal status of tongue SCC patients suggested that lncRNA deregulation was involved in the pathogenesis of tongue SCC. | 25045670 | Lnc2Cancer |
EL0763 | lncARSR | sunitinib resistance | N/A | renal cell carcinoma (RCC). | N/A | N/A | promoted sunitinib resistance via competitively binding miR-34/miR-449 facilitate AXL and c-MET expression in RCC cells | 27117758 | |
EL0764 | lnc-bc060912 | lung cancer | qPCR, Northern blot, knockdown, RIP etc. | cell lines (H1299, A549, 293T) | up-regulated | interaction | Here we have identified a lncRNA termed Lnc-bc060912 whose expression is increased in human lung and other tumors. Lnc-bc060912 suppressed cell apoptosis. Lnc-bc060912 via PARP1 and NPM1, affects cell apoptosis and may play important roles in tumorigenesis and cancer progression. | 25848691 | Lnc2Cancer |
EL0765 | lnc-BMP2-2 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | up-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0766 | lnc-CPN2-1 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | up-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0767 | lnc-CYP4A22-2/3 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | up-regulated | expression | lnc-ZNF180-2 levels were similar in localized ccRCC and normal renal tissue, but we observed a significant increase of lnc-ZNF180-2 expression in advanced ccRCC tissue. Furthermore, lnc-ZNF180-2 expression levels were an independent predictor of progression-free survival, cancer-specific survival and overall survival in ccRCC patients. We also observed that lnc-CYP4A22-2/3 expression levels allowed discrimination of ccRCC and normal renal tissue. In conclusion, lncRNAs are involved in renal carcinogenesis, and quantification of lnc-ZNF180-2 may be useful for the prediction of ccRCC patients outcome following nephrectomy. | 26609485 | Lnc2Cancer |
EL0768 | lnc-DILC | liver cancer | real-time PCR; pull down assay and oligoribonucleotides or oligodeoxynucleotides treatment | N/A | down-regulated | interaction | Depletion of lnc-DILC markedly enhanced LCSC expansion and facilitated HCC initiation and progression, whereas ectopic expression of lnc-DILC dramatically inhibited LCSC expansion. Mechanistically, lnc-DILC inhibited the autocrine IL-6/STAT3 signaling. | 26812074 | |
EL0769 | lnc-FOXG1-2 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | down-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0770 | lnc-FZD1-2 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | up-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0771 | lnc-ITPR2-3 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | up-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0772 | lnc-KCMF1-2:1 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | down-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0773 | lnc-LCE5A-1 | tongue cancer | RNA-seq, qPCR etc. | cell lines (UMSCC-10B, HN-12) | down-regulated | N/A | We confirmed the dysregulation of these noncoding RNAs in head and neck cancer cell lines derived from different anatomic sites, and determined that ectopic expression of the two lncRNAs inhibited key EMT and stem cell genes and reduced cellular proliferation and migration. | 25904139 | LncRNADisease Lnc2Cancer |
EL0773 | lnc-LCE5A-1 | pharyngeal cancer | RNA-seq, qPCR etc. | cell lines (HN-1, HN-30) | down-regulated | N/A | We confirmed the dysregulation of these noncoding RNAs in head and neck cancer cell lines derived from different anatomic sites, and determined that ectopic expression of the two lncRNAs inhibited key EMT and stem cell genes and reduced cellular proliferation and migration. | 25904139 | LncRNADisease Lnc2Cancer |
EL0773 | lnc-LCE5A-1 | laryngeal cancer | RNA-seq, qPCR etc. | cell lines (UMSCC-22B) | down-regulated | N/A | We confirmed the dysregulation of these noncoding RNAs in head and neck cancer cell lines derived from different anatomic sites, and determined that ectopic expression of the two lncRNAs inhibited key EMT and stem cell genes and reduced cellular proliferation and migration. | 25904139 | LncRNADisease Lnc2Cancer |
EL0774 | lnc-LCP2-2 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | down-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0776 | lnc-LLPH-2:1 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0777 | lnc-MX1-1 | prostate cancer | real-time quantitative PCR, knockdown | prostate cancer cells | up-regulated | expression | There was a significant association between over-expression of lnc-MX1-1 and patients' clinical features such as PSA, Gleason score, metastasis, and recurrence free survival. knockdown of lnc-MX1-1 reduced both proliferation and invasiveness of LNCaP and 22Rv1 cells. | 26797523 | |
EL0778 | lnc-PLA2R1-1:1 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | down-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0779 | lnc-PSD4-1:14 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | down-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0791 | lncRNA-422 | colorectal cancer | microarray, qPCR etc. | CRC tissue | up-regulated | regulation | Two of the lncRNAs, HOTAIR and a novel lncRNA, lncRNA-422 were confirmed in more samples. GSEA indicated that gene sets most correlated with them were those named up-regulated in KRAS-over, down-regulated in JAK2-knockout, down-regulated in PDGF-over and down-regulated in TBK1-knockout, all of which were cancer-related. Subsequently, GO analyses of most significantly correlated coding genes of HOTAIR and lncRNA-422 showed that these two lncRNAs may participate in carcinogenesis by regulating protein coding genes involved in special biological process relevant to cancer. | 25456707 | Lnc2Cancer |
EL0797 | lncRNA-AK058803 | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MCF-7) | up-regulated | interaction | The expression levels of lncRNA-AK058003 were increased significantly in the breast cancer tissues and were found to strongly correlate with the severity of the breast cancer clinical stage. | 26136884 | Lnc2Cancer |
EL0798 | LncRNA-AP001631.9 | gastric cancer | qPCR, knockdown etc. | gastric cancer tissue, cell lines (AGS, MGC803, BGC823, SGC7901) | up-regulated | expression | The qRT-PCR data indicated that the LncRNA-AP001631.9 expression was frequently increased in gastric cancer tissues. The expression level of LncRNA-AP001631.9 was positively correlated with that of FOXM1. The transwell and wound healing assays indicated that LncRNA-AP001631.9 was required for the migration of gastric cancer cells. The downregulation of LncRNA-AP001631.9 by small interference RNA suppressed the migratory ability of MGC803 and AGS cells, while the overexpression of LncRNA-AP001631.9 promoted the movement of BGC823 and SGC7901 cells. | 26261500 | Lnc2Cancer |
EL0799 | lncRNA-ATB | hepatocelluar carcinoma | immunohistochemistry quantitative RT-PCR analysis | keloid tissue and keloid fibroblasts | N/A | N/A | lncRNA-ATB governs the autocrine secretion of TGF-β2 in KFs | 27090737 | |
EL0799 | lncRNA-ATB | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue, cell lines (SMMC-7721) | up-regulated | regulation | Thus, these findings suggest that?lncRNA-ATB, a mediator of TGF-β signaling, could predispose HCC patients to metastases and may serve as a potential target for antimetastatic therapies. | 24768205 | LncRNADisease Lnc2Cancer |
EL0799 | lncRNA-ATB | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | N/A | High lncRNA-ATB expression was significantly associated with greater tumor size, depth of tumor invasion, lymphatic invasion, vascular invasion, and lymph node metastasis. Additionally, levels of lncRNA-ATB expression were significantly higher in patients with hematogenous metastases. | 25750289 | LncRNADisease Lnc2Cancer |
EL0799 | lncRNA-ATB | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines (MKN1, MKN7, MKN28, MKN45, MKN74 etc.) | differential expression | interaction | The high lncRNA-ATB group experienced a lower overall survival rate compared with the low lncRNA-ATB group, and multivariate analysis indicated that lncRNA-ATB was an independent prognostic factor (hazard ratio 3.50; 95 % CI 1.73-7.44; p = 0.0004).LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGFb/miR-200s/ZEB axis, resulting in a poor prognosis in GC.LncRNA-ATB is a novel biomarker of lncRNA, indicative of a poor prognosis in GC patients. | 25986864 | Lnc2Cancer |
EL0799 | lncRNA-ATB | pancreatic cancer | qPCR etc. | pancreatic cancer and paired adjacent normal pancreatic tissues, cell lines (HPDE6c-7) | down-regulated | expression | We found that lncRNA-ATB expression was decreased in pancreatic cancer tissues and pancreatic cancer cell lines. Low lncRNA-ATB expression levels were significantly correlated with lymph node metastases (yes vs. no, P = 0.009), neural invasion (positive vs. negative, P = 0.049), and clinical stage (early stage vs. advanced stage, P = 0.014). Moreover, patients with low lncRNA-ATB expression levels exhibited markedly worse overall survival prognoses (P < 0.001). Multivariate analysis indicated that decreased lncRNA-ATB expression was an independent predictor of poor prognosis in pancreatic cancer patients (P = 0.005). | 26482611 | Lnc2Cancer |
EL0799 | lncRNA-ATB | colon cancer | qPCR etc. | colon cancer tissues | up-regulated | interaction | LncRNA-ATB was upregulated in colon cancer tissues compared with adjacent mucosa. LncRNA-ATB levels were also higher in metastatic cancer tissues. Among the three highly invasive colon cancer cell lines, lncRNA-ATB levels were relatively higher with concurrent low levels of E-cad compared with levels in the three low-invasive cell lines. LncRNA-ATB expression correlated with pN stage and AJCC stage. Striking differences were observed in overall survival and disease-free survival in cases with both high lncRNA-ATB expression and low E-cad expression. Reduction of lncRNA-ATB increased expression of epithelial markers E-cad, ZO-1, and decreased expression of mesenchymal markers ZEB1 and N-cadherin (N-cad), and significantly influenced colon cancer cell progression. Plasma lncRNA-ATB was upregulated in colon cancer patients one month after surgery. | 26487301 | Lnc2Cancer |
EL0800 | lncRNA-DQ786227 | lung cancer | microarray, qPCR, in vitro knockdown etc. | cell lines (A549, QG56 etc.) | up-regulated | N/A | Expression of lncRNA-DQ786227 in both lung cancer cells differed from that in BEAS-2B cells. Expression of lncRNA-DQ786227 was significantly higher in the A549 and QG56 cells compared with the BEAS-2B cells.Our findings revealed that lncRNA-DQ786227 might act as an oncogene. Our study provides a new insight regarding the oncogenic properties of lncRNA in B[a]P-induced cell transformation. | 24084393 | Lnc2Cancer |
EL0802 | lncRNA-n336928 | bladder cancer | microarray, qPCR etc. | bladder cancer tissue | up-regulated | expression | Results showed that the expression level of lncRNA-n336928 (noncode database ID: n336928) was significantly higher in bladder cancer tissues compared to that in adjacent noncancerous tissues (P < 0.001). Collectively, our study shows that high expression of lncRNA-n336928 is associated with the progression of bladder cancer, and that lncRNA-n336928 might serve as a biomarker for prognosis of bladder cancer. | 26551459 | Lnc2Cancer |
EL0805 | lnc-RP3-368B9 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | down-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0806 | lnc-SLC30A4-1 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | up-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0807 | lnc-SPAM1-6 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | up-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0808 | lnc-TTC34-3 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | down-regulated | expression | Among these, aberrant expression was validated using PCR: lnc-BMP2-2, lnc-CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, and lnc-SPAM1-6 were highly overexpressed in ccRCC, whereas lnc-ACACA-1, lnc-FOXG1-2, lnc-LCP2-2, lnc-RP3-368B9, and lnc-TTC34-3 were downregulated. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing of RNA. | 25685243 | Lnc2Cancer |
EL0809 | lnc-uc003wbd | hepatocelluar carcinoma | qPCR etc. | blood (serum) | up-regulated | expression | The level of serum lncRNA-uc003wbd and lncRNA-AF085935 was significantly upregulated in HCC patients and HBV patients compared with that in normal controls.In addition, higher expressions of lncRNAs were observed in HCC patients than in HBV patients. LncRNA-uc003wbd and lncRNA-AF085935 were observed with an aberrant serum level in HCC and HBV patients, which is showing that both lncRNA-uc003wbd and lncRNA-AF085935 are able to be potential biomarkers for HCC and HBV screening. | 25501706 | Lnc2Cancer |
EL0810 | lnc-ZNF180-2 | clear cell renal cell carcinoma | microarray, qPCR etc. | ccRCC tissue | down-regulated | expression | lnc-ZNF180-2 levels were similar in localized ccRCC and normal renal tissue, but we observed a significant increase of lnc-ZNF180-2 expression in advanced ccRCC tissue. Furthermore, lnc-ZNF180-2 expression levels were an independent predictor of progression-free survival, cancer-specific survival and overall survival in ccRCC patients. We also observed that lnc-CYP4A22-2/3 expression levels allowed discrimination of ccRCC and normal renal tissue. In conclusion, lncRNAs are involved in renal carcinogenesis, and quantification of lnc-ZNF180-2 may be useful for the prediction of ccRCC patients outcome following nephrectomy. | 26609485 | Lnc2Cancer |
EL0811 | lnc-ZNF674-1 | nasopharyngeal carcinoma | microarray, qPCR etc. | NPC tissue | up-regulated | expression | Results. In primary NPC, upregulation of?lnc-C22orf32-1,?lnc-AL355149.1-1, and?lnc-ZNF674-1 was observed. High levels of?lnc-C22orf32-1 and?lnc-AL355149.1-1 were significantly associated with the male patients | 24822202 | LncRNADisease Lnc2Cancer |
EL0813 | LOC100131831 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL0814 | LOC100287482 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
EL0816 | LOC100506974 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL0818 | LINC01844 | hirschsprung disease | qRT-PCR to detect the relative expression of LOC101926975 in 80 pairs of HSCR bowel tissues and matched normal bowel tissues | HSCR bowel tissues and matched normal bowel tissues | down-regulated | N/A | Dysregulation of LOC101926975 suppressed cell proliferation and induced G0/G1 arrest without impact on cell apoptosis or migration | 27076786 | |
EL0819 | LOC101927497 | pediatric acute myeloid leukemia | qRT-PCR | three bone marrow samples obtained from each pediatric AML patient | up-regulated | interaction | Dysregulated lncRNAs and mRNAs in pediatric AML versus normal controls that could form gene pathways to regulate cell cycle progression and immunoresponse. | 26573779 | |
EL0821 | LOC103692984 | sciatic nerve injury | microarray analysis,quantitative real-time polymerase chain reaction and in situ hybridization, silencing | Dorsal root ganglia (DRG) | N/A | N/A | these 24 lncRNAs were found to be mainly involved in cell phenotype modulation, including glial cell migration, purinergic nucleotide receptor signaling pathway, vasodilation, regulation of multi-organism process, and neuropeptide signaling pathway, and also to be potentially associated with several key regeneration signaling pathways, including MAPK signaling pathway, and neuroactive ligand-receptor interaction,lncRNA had a particular promoting effect on neurite outgrowth. | 23274483 | |
EL0823 | LOC105372753 | pancreatic cancer | microarray, qPCR etc. | cell lines (SW1990, SWl990/GZ etc.) | up-regulated | expression | Six lncRNAs (RP11-58D2.1, lincRNA-ZNF532, AP000221.1, CTC-338M12.5, CR619813, DDX6P) were selected to validate the microarray consistency by using qPCR. The results demonstrated that RP11-58D2.1, lincRNA-ZNF532 and AP000221.1 were upregulated and that CTC-338M12.5, DDX6P and CR619813 were downregulated in the SW1990/GZ cells compared with SW1990 cells (Figure 6). | 25755691 | Lnc2Cancer |
EL0824 | LOC105374631 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | down-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL0825 | LOC105377769 | pancreatic cancer | microarray, qPCR etc. | cell lines (SW1990, SWl990/GZ etc.) | down-regulated | expression | Six lncRNAs (RP11-58D2.1, lincRNA-ZNF532, AP000221.1, CTC-338M12.5, CR619813, DDX6P) were selected to validate the microarray consistency by using qPCR. The results demonstrated that RP11-58D2.1, lincRNA-ZNF532 and AP000221.1 were upregulated and that CTC-338M12.5, DDX6P and CR619813 were downregulated in the SW1990/GZ cells compared with SW1990 cells (Figure 6). | 25755691 | Lnc2Cancer |
EL0827 | LOC389023 | psychiatric disease | N/A | N/A | N/A | regulation | Examples of recently discovered chromatin-bound long non-coding RNAs important for neuronal health and function include the brain-derived neurotrophic factor antisense transcript (Bdnf-AS) which regulates expression of the corresponding sense transcript, and LOC389023 which is associated with human-specific histone methylation signatures at the chromosome 2q14.1 neurodevelopmental risk locus by regulating expression of DPP10, an auxillary subunit for voltage-gated K(+) channels. | 23831425 | LncRNADisease |
EL0828 | LOC389332 | clear cell renal cell carcinoma | microarray, qPCR etc. | renal clear cell carcinoma tissue | down-regulated | N/A | ENST00000456816, X91348, BC029135, NR_024418 were evaluated by qPCR in sixty-three pairs of RCCC and NT samples. The results demonstrated that ENST00000456816, X91348 were up-regulated and BC029135, NR_024418 were down-regulated in RCCC samples compared with NT samples (p<0.001 for each lncRNAs). | 22879955 | Lnc2Cancer |
EL0829 | AC100861.1 | pancreatic ductal adenocarcinoma | knockdown, overexpression | pancreatic ductal adenocarcinoma (PDAC) tissues and cell lines | up-regulated | interaction | Knockdown of LOC389641 impaired cell proliferation and invasion and induced cell apoptosis in vitro, whereas overexpression of LOC389641 had the opposite effect. LOC389641 promotes PDAC progression and increases cell invasion by regulating E-cadherin with the possible involvement of TNFRSF10A. | 26708505 | |
EL0830 | LOC400891 | prostate cancer | lncRNAs expression chips screening, quantitative real-time PCR (qRT-PCR) | prostate cancer (Pca) tissues and cell lines | up-regulated | expression | Knockdown of LOC400891 could inhibit cell proliferation, migration, and invasion in vitro study. | 26797783 | |
EL0831 | LOC401317 | nasopharyngeal carcinoma | microarray, qPCR, Western blot, knockdown, Luciferase reporter assay etc. | cell lines (HNE2, HNE1, CNE2) | up-regulated | regulation | LOC401317 was the most significantly upregulated lncRNA. Further studies indicated that LOC401317 is diretcly regulated by p53 and that etcopic expression of LOC401317 inhibits HNE2 cell proliferation in vitro and in vivo by inducing cell cycle arrest and apoptosis. LOC401317 inhibited cell cycle progression by increasing p21 expression and decreasing cyclin D1 and cyclin E1 expression and promoted apoptosis through the induction of poly(ADP-ribose) polymerase and caspase-3 cleavage. | 25422887 | Lnc2Cancer |
EL0833 | LOC652276 | colorectal cancer | microarray, qPCR etc. | cell lines (T29, SW480, RKO, Lovo, HCTll6) | differential expression | expression | The radiosensitivity order of these 5 cell lines from low to high (SF2 value from high to low) was HT29, SW480, RKO, Lovo, HCT116. Among them, expression levels of R05532, NR_015441 and NR_033374 were positively correlated with radiation resistance(all P<0.01),which may be used as the predictiv marker of radiosensitivity of coloretcal cancer cells. | 25421768 | Lnc2Cancer |
EL0835 | Lrrc9 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 21 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL0836 | LSINCT1 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0836 | LSINCT1 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0837 | LSINCT10 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0837 | LSINCT10 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0838 | LSINCT11 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0838 | LSINCT11 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0839 | LSINCT12 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0839 | LSINCT12 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0840 | LSINCT2 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0840 | LSINCT2 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0841 | LSINCT3 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0841 | LSINCT3 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0842 | LSINCT4 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0842 | LSINCT4 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0843 | LSINCT5 | breast cancer | N/A | N/A | N/A | expression | Ovarian and breast tumours have also been associated with the expression of the LSINCT5 lncRNA; this transcript acts to target several other transcripts, including the antisense RNA NEAT-1 and the PSPC1 gene, which codes for a splicing regulatory factor | 22817756 | LncRNADisease |
EL0843 | LSINCT5 | ovarian cancer | N/A | N/A | N/A | expression | Ovarian and breast tumours have also been associated with the expression of the LSINCT5 lncRNA; this transcript acts to target several other transcripts, including the antisense RNA NEAT-1 and the PSPC1 gene, which codes for a splicing regulatory factor | 22817756 | LncRNADisease |
EL0843 | LSINCT5 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines (AGS, MKN-45, MGC-803, BGC-823, HGC-27) | up-regulated | N/A | The expression of LSINCT5 is significantly upregulated in gastrointestinal cancer tissues and cell lines relative to their normal counterparts. In addition, increased LSINCT5 expression was correlated with a larger tumor size, deeper tumor depth, and advanced clinical stage. | 25526476 | LncRNADisease Lnc2Cancer |
EL0843 | LSINCT5 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (LoVo, Caco-2, DLD1,HCT-8, HCT-116) | up-regulated | N/A | The expression of LSINCT5 is significantly upregulated in gastrointestinal cancer tissues and cell lines relative to their normal counterparts. Increased LSINCT5 expression was correlated with a larger tumor size, deeper tumor depth, and advanced clinical stage. Gastric cancer (GC) and colorectal cancer (CRC) patients with higher LSINCT5 expression levels have worse disease-free survival (DFS) and disease-specific survival (DSS) rates. | 25526476 | LncRNADisease Lnc2Cancer |
EL0843 | LSINCT5 | gastric cancer | qPCR etc. | cancerous gastric tissue, blood (serum) | up-regulated | expression | A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC. | 25694351 | Lnc2Cancer |
EL0843 | LSINCT5 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0843 | LSINCT5 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0843 | LSINCT5 | breast cancer | qPCR, Northern blot, etc. | cell lines (HMEC, MCF7, MDA157 etc.) | up-regulated | expression | LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues. | 21532345 | LncRNADisease Lnc2Cancer |
EL0843 | LSINCT5 | ovarian cancer | qPCR, Northern blot, etc. | cell lines (OVCAR5, NHBE etc.) | up-regulated | expression | LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues. | 21532345 | LncRNADisease Lnc2Cancer |
EL0843 | LSINCT5 | breast cancer | qPCR, Northern blot, knock-down, Microarray | human bronchial epithelial (NHBE) cells, breast cancer cell line, ovarian cancer cell line | up-regulated | expression | knock-down of LSINCT5 expression decreased proliferation in human breast and ovarian cancer cells; Using a genome tiling array to identify noncoding sequences upregulated in normal human bronchial epithelial (NHBE) cells exposed to a DNA-damaging tobacco carcinogen | 26323562 | |
EL0843 | LSINCT5 | ovarian cancer | qPCR, Northern blot, knock-down, Microarray | human bronchial epithelial (NHBE) cells, breast cancer cell line, ovarian cancer cell line | up-regulated | expression | knock-down of LSINCT5 expression decreased proliferation in human breast and ovarian cancer cells; Using a genome tiling array to identify noncoding sequences upregulated in normal human bronchial epithelial (NHBE) cells exposed to a DNA-damaging tobacco carcinogen | 26323562 | |
EL0844 | LSINCT6 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0844 | LSINCT6 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0845 | LSINCT7 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0845 | LSINCT7 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0846 | LSINCT8 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0846 | LSINCT8 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0847 | LSINCT9 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0847 | LSINCT9 | lung cancer | qPCR, Northern blot etc. | cell lines (T47D, BT474, NCF10A etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
EL0848 | LUADT1 | lung adenocarcinoma | microarray, qPCR, Western blot, knockdown, Luciferase reporter assay etc. | lung cancer tissues and adjacent non-tumor tissues, cell lines ( A549, H1975, H358, H1650 and H1299A549, H1975, H358, H1650 and H1299 ) | up-regulated | interaction | LUADT1 may regulate cell cycle progression by epigenetically inhibiting the expression of p27. RNA immunoprecipitation and chromatin immunoprecipitation assays confirmed that LUADT1 binds to SUZ12, a core component of polycomb repressive complex 2, and mediates the trimethylation of H3K27 at the promoter region of p27. The negative correlation between LUADT1 and p27 expression was confirmed in LUAD tissue samples. LUADT1 is an oncogenic lncRNA that regulates LUAD progression, suggesting that dysregulated lncRNAs may serve as key regulatory factors in LUAD progression | 26291312 | Lnc2Cancer |
EL0849 | LUCAT1 | lung cancer | qPCR, Western bolt, RIP etc. | cell lines (A549, CL1-0, CL1-5, H1975, HCC-827, NCI-H292 etc.) | up-regulated | N/A | We found that XLOC_004924 was elevated in the airway epithelia of cigarette smokers versus nonsmokers in both of these datasets. In the first dataset, five nonsmokers were compared with six smokers. In the second study, the smokers' epithelia demonstrated a 3.9-fold increase in XLOC_004924, compared with nonsmokers. Functionally,siRNA knockdown of SCAL1 in HBE1 cells shows significant potentiation of cytotoxicity induced by CSE in vitro. Altogether, these results identify a novel and intriguing new non-coding RNA that may act downstream of NRF2 to regulate gene expression and mediate oxidative stress protection in airway epithelial cells. | 23672216 | Lnc2Cancer |
EL0850 | LUNAR1 | diffuse large B-cell lymphoma | Quantitative real-time PCR, knockdown | Diffuse large B-cell lymphoma (DLBCL) tissues and cell lines | N/A | interaction | The higher expression of LUNAR1 was significantly correlated with stage, rituximab and IPI. Univariate and multivariate analyses showed that LUNAR1 expression served as an independent predictor for overall survival and progression-free survival. LUNAR1 may serve as a candidate prognostic biomarker through growth regulation in DLBCL. | 26796267 | |
EL0850 | LUNAR1 | T cell acute lymphoblastic leukemia | RNA-seq, qPCR etc. | blood | up-regulated | interaction | We have shown that one specific Notch-regulated lncRNA, LUNAR1, is required for efficient T-ALL growth in vitro and in vivo due to its ability to enhance IGF1R mRNA expression and sustain IGF1 signaling. | 25083870 | Lnc2Cancer |
EL0851 | M14574 | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | down-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL0852 | MAFA-AS1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | up-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL0852 | MAFA-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL0853 | MALAT1 | paraspeckle disintegration | Immunoprecipitation of Ribonucleoprotein Complex,knockdown | HeLa cell | down-regulated | mutation | Successful removal of MENepsilon/beta by a refined knockdown method resulted in paraspeckle disintegration. Furthermore, the reassembly of paraspeckles disassembled by transcriptional arrest appeared to be unsuccessful in the absence of MENepsilon/beta. | 19188602 | |
EL0853 | MALAT1 | lung cancer | knockdown | human bronchial epithelial (HBE) cells | up-regulated | interaction | Cigarette smoke extract (CSE) caused decreases of miR-217 levels and increases in lncRNA MALAT1 levels. The CSE-induced increase of MALAT1 expression was blocked by an miR-217 mimic, indicating that miR-217 negatively regulates MALAT1 expression. | 26415832 | |
EL0853 | MALAT1 | breast cancer | MALAT1-siRNA | breast cancer tissues and cells | up-regulated | N/A | MALAT1-siRNA inhibited breast cancer cell proliferation and cell cycle progression in vitro and in vivo; and downregulating miR-124 expression | 26918449 | |
EL0853 | MALAT1 | non-small cell lung cancer | Meta-analysis | non-small cell lung cancer and pancreatic cancer | up-regulated | expression | From subgroup analyses,we present evidence that lncRNA MALAT1 overexpression was an unfavorable prognostic factor for patients' overall survival in non-small cell lung cancer and pancreatic cancer, the pooled HRs (95% CI) were 1.86 (95% CI 1.27-2.73) and 1.78 (95% CI 1.30-2.44), respectively. In conclusion, lncRNA MALAT1 is a potential prognostic factor in human cancers. | 26131129 | |
EL0853 | MALAT1 | pancreatic cancer | Meta-analysis | non-small cell lung cancer and pancreatic cancer | up-regulated | expression | From subgroup analyses,we present evidence that lncRNA MALAT1 overexpression was an unfavorable prognostic factor for patients' overall survival in non-small cell lung cancer and pancreatic cancer, the pooled HRs (95% CI) were 1.86 (95% CI 1.27-2.73) and 1.78 (95% CI 1.30-2.44), respectively. In conclusion, lncRNA MALAT1 is a potential prognostic factor in human cancers. | 26131129 | |
EL0853 | MALAT1 | cervical cancer | Microarray, knockdown, RT-PCR, western blot, and immunofluorescence | cervical cancer (CC) cells and tissues | up-regulated | expression | The down-regulation of MALAT1 by shRNA in CC cells inhibited the invasion and metastasis in vitro and in vivo. MALAT1 functions to promote cervical cancer invasion and metastasis via induction of EMT, and it may be a target for the prevention and therapy of cervical cancers. | 26798987 | |
EL0853 | MALAT1 | neuroblastoma | microarray, qPCR etc. | cell line (SK-N-SH ) | down-regulated | expression | We identified a shorter transcriptional initiation site and found that CREB binds to the defined proximal promoter of the MALAT1 gene. The expression of the tumor marker MALAT1 ncRNA is sensitive to cell surface receptor activation by oxytocin in a neuroblastoma cell line. | 20149803 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
EL0853 | MALAT1 | triple-negative breast cancer | microarray, qPCR etc. | triple-negative breast cancer tissue | up-regulated | expression | We found that the expression levels of TCONS_l2_00003938, ENST00000460164, ENST00000425295, MALAT1 and HOTAIR were significantly higher in tumor tissues than non-tumor tissues, whereas there were no significant differences in the expression levels of the other 3 lncRNAs. Our study identified a set of lncRNAs that were consistently aberrantly expressed in TNBC, and these dysregulated lncRNAs may be involved in the development and/or progression of TNBC. | 25996380 | Lnc2Cancer |
EL0853 | MALAT1 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | down-regulated | expression | Expression profiles of five lnc-RNAs (MEG3, HULC, HOTAIR, NEAT1, and MALAT-1) previously shown to be involved in cancer metastasis were detected by qPCR in 5 pairs of papillary thyroid cancer and 11 matched lymph node metastatic tissues. Among the five, MEG3 showed significant down-expression. Overexpression of MEG3 inhibits thyroid cancer cell migration and invasion. | 25997963 | Lnc2Cancer |
EL0853 | MALAT1 | neuroblastoma | microarray, qPCR, knockdown etc. | cell lines (BE(2)-C, CHP134) | up-regulated | N/A | Here we demonstrated that N-Myc up-regulated the expression of JMJD1A in N-Myc oncogene-amplified human neuroblastoma cells by directly binding to the JMJD1A gene promoter. Affymetrix microarray studies revealed that the gene second most significantly up-regulated by JMJD1A was MALAT1. Consistent with this finding, RT-PCR and chromatin immunoprecipitation assays showed that JMJD1A bound to the MALAT1 gene promoter and demethylated histone H3K9 at the MALAT1 gene promoter. | 24742640 | Lnc2Cancer |
EL0853 | MALAT1 | colon cancer | microarray, qPCR, knockdown etc. | blood, cell lines (SW480 and SW620) | up-regulated | regulation | The stimulation of colon cancer progression by TADC-derived CCL5 was associated with the up-regulation of non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), which subsequently increased the expression of Snail. Blocking MALAT-1 significantly decreased the TADC-conditioned medium and CCL5-mediated migration and invasion by decreasing the enhancement of Snail, suggesting that the MALAT-1/Snail pathway plays a critical role in TADC-mediated cancer progression | 25546229 | Lnc2Cancer |
EL0853 | MALAT1 | colorectal cancer | microarray, qPCR, Western blot etc. | CRC tissue, cell lines (HCT116, SW480, SW620, LoVo, CaCo-2 etc.) | up-regulated | regulation | In the present study, we found that MALAT1 was up-regulated in human primary CRC tissues with lymph node metastasis. Knockdown of MALAT1 inhibited CRC tumor growth and metastasis. MALAT1 regulated at least 243 genes in CRC cells in a genome-wide expression profiling. Among these genes, PRKA kinase anchor protein 9 (AKAP-9) was significantly up-regulated at both mRNA and protein levels. AKAP-9 was highly expressed in CRC cells with metastatic potential and human primary CRC tissues with lymph node metastasis. | 25446987 | Lnc2Cancer |
EL0853 | MALAT1 | glioma | microarray, qPCR, Western blot, knockdown etc. | cell line SHG139S | down-regulated | interaction | Our results showed that downregulation of MALAT1 suppressed the expression of Sox2 and Nestin which are related to stemness, while downregulation of MALAT1 promoted the proliferation in SHG139S. Further research on the underlying mechanism showed that the effects of MALAT1 downregulation on SHG139S were through regulating ERK/MAPk signaling activity. And we also found that downregulation of MALAT1 could activate ERK/MAPK signaling and promoted proliferation in SHG139 cells. | 26649728 | Lnc2Cancer |
EL0853 | MALAT1 | liver cancer | microarray, qPCR, Western blot, Luciferase reporter assay, RIP etc. | liver cancer tissue, cell lines (HepG2, Bel-7402, SMMC-7721, HEK-293T etc.) | differential expression | regulation | Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. | 24468535 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | proliferative vitreoretinopathy | Microarray, qRT-PCR | biofluid of PVR (Proliferative VitreoRetinopathy) patients | up-regulated | expression | MALAT1 was significantly up-regulated in the cellular and plasma fraction of peripheral blood in PVR patients. In vitro experiments revealed the role of MALAT1 in regulating RPE proliferation and migration, which is critical for ERMs formation. MALAT1 is a potential prognostic indicator and a target for the diagnosis and gene therapy for PVR diseases. | 26241674 | |
EL0853 | MALAT1 | non-small-cell lung cancer | microarray, qRT-PCR | tumor samples from 383 NSCLC patients | N/A | interaction | Gene expression analysis of A549 adenocarcinoma cells with differential MALAT-1 lncRNA expression demonstrated an influence on the expression of Bcl-2 and its interacting proteins. | 25036876 | |
EL0853 | MALAT1 | non-small cell lung cancer | N/A | N/A | N/A | expression | In NSCLC metastasizing tumors, MALAT-1 expression is three-fold higher than in non-metastasizing tumors. Furthermore, in patients with stage I disease, MALAT-1 expression is closely correlated with poor prognosis. | 21550244 | LncRNADisease |
EL0853 | MALAT1 | hepatocellular carcinoma | N/A | hepatocellular carcinoma (HCC) tissues | up-regulated | interaction | N/A | 26352013 | |
EL0853 | MALAT1 | breast cancer | N/A | breast cancer cells | up-regulated | N/A | MALAT1 induced migration and invasion of breast cancer | 26926567 | |
EL0853 | MALAT1 | hepatocelluar carcinoma | N/A | N/A | N/A | expression | HCC and HPBL have clearly different patterns of gene expression, with genes IGF2, Fibronectin, DLK1, TGFb1, MALAT1 and MIG6 being over-expressed in HPBL versus HCC | 17006932 | LncRNADisease |
EL0853 | MALAT1 | lung adenocarcinoma | N/A | N/A | N/A | expression | Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro. | 19690017 | LncRNADisease |
EL0853 | MALAT1 | cancer | N/A | N/A | N/A | expression | The expression of the long ncRNA MALAT1 correlates with tumor development, progression or survival in lung, liver and breast cancer. | 20711585 | LncRNADisease |
EL0853 | MALAT1 | cancer | N/A | N/A | N/A | expression | MALAT1 is a highly conserved long ncRNA originally identified as a transcript overexpressed in many cancers. | 20864030 | LncRNADisease |
EL0853 | MALAT1 | osteosarcoma | N/A | N/A | N/A | expression | Osteosarcoma patients' survival is significantly associated with MALAT-1 expression levels. | 20951849 | LncRNADisease |
EL0853 | MALAT1 | non-small cell lung cancer | N/A | N/A | N/A | expression | Specific lncRNAs can serve as predictors of tumor outcome, as shown with the expression of the lncRNA MALAT-1 in early-stage non-small cell lung cancer. | 21903344 | LncRNADisease |
EL0853 | MALAT1 | breast cancer | N/A | N/A | N/A | regulation | On a more mechanistic level, recent studies have revealed the contribution of lncRNAs as proto-oncogenes, e.g. GAGE6, as tumor suppressor genes, e.g. 鈥榩15 antisense RNA and lincP21' (36,91), as drivers of metastatic transformation, e.g. HOTAIR in breast cancer, and as regulators of alternative splicing, e.g. MALAT1 | 22492512 | LncRNADisease |
EL0853 | MALAT1 | hepatocelluar carcinoma | N/A | N/A | N/A | mutation | We conducted a case-control study and genotyped two SNPs, rs7763881 in HULC and rs619586 in MALAT1 Furthermore, the variant genotypes of rs619586 was associated with decreased HCC risk with a borderline significance. | 22493738 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | non-small cell lung cancer | N/A | N/A | N/A | expression | lncRNA-associated disruption to alternative splicing has also been reported in non-small cell lung cancer by virtue of overexpression of MALAT1 | 22817756 | LncRNADisease |
EL0853 | MALAT1 | small cell lung cancer | N/A | N/A | N/A | expression | For other LncRNAs, specific targets have yet to be identified. This is the case of MALAT1, a LncRNA whose expression is three times higher in metastasizing early-stage non-small cell lung cancer vs. non-metastasizing tumours | 22928560 | LncRNADisease |
EL0853 | MALAT1 | breast cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | colon cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | liver cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | lung cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | osteosarcoma | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | pancreatic cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | prostate cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | uterus cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
EL0853 | MALAT1 | cancer | N/A | N/A | N/A | regulation | MALAT1 (metastasis-associated lung adenocarcinoma transcript 1),another lncRNA associated with various cancers and metastasis (Ji et al. 2003; Lin et al. 2011)锛?, is found to affect the transcriptional and post-transcriptional regulation of cytoskeletal and extracellular matrix genes. | 23463798 | LncRNADisease |
EL0853 | MALAT1 | decreased myogenesis | N/A | N/A | N/A | expression | The myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis. | 23485710 | LncRNADisease |
EL0853 | MALAT1 | cancer | N/A | N/A | N/A | expression | MALAT1 is upregulated in several cancer types and its overexpression has been linked to an increase in cell proliferation and migration in lung and colorectal cancer cells. | 23660942 | LncRNADisease |
EL0853 | MALAT1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
EL0853 | MALAT1 | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Dysregulation and functional roles of lncRNAs in HCC | 24183851 | LncRNADisease |
EL0853 | MALAT1 | bladder cancer | N/A | N/A | N/A | regulation | Oncogene | 24373479 | LncRNADisease |
EL0853 | MALAT1 | kidney cancer | N/A | N/A | N/A | regulation | Oncogene | 24373479 | LncRNADisease |
EL0853 | MALAT1 | prostate cancer | N/A | N/A | N/A | regulation | Putative marker | 24373479 | LncRNADisease |
EL0853 | MALAT1 | diabetes mellitus | N/A | N/A | N/A | expression | In addition, MALAT1, a conserved lncRNA, was significantly upregulated in an RF/6A cell model of hyperglycemia, in the aqueous humor samples, and in fibrovascular membranes of diabetic patients. | 24436191 | LncRNADisease |
EL0853 | MALAT1 | breast cancer | N/A | N/A | N/A | regulation | invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma | 24499465 | LncRNADisease |
EL0853 | MALAT1 | lung cancer | N/A | N/A | N/A | regulation | invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma | 24499465 | LncRNADisease |
EL0853 | MALAT1 | uterus cancer | N/A | N/A | N/A | regulation | invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma | 24499465 | LncRNADisease |
EL0853 | MALAT1 | lung cancer | N/A | N/A | N/A | expression | MALAT1, also known as NEAT2 (nuclear-enriched abundant transcript 2), was initially discovered as a predictive biomarker for metastasis development in lung cancer. | 24667321 | LncRNADisease |
EL0853 | MALAT1 | tumor | N/A | N/A | N/A | regulation | MALAT1 plays a role in cell migration and tumor metastasis, as demonstrated by knockout of MALAT1 in lung cancer cell lines (Gutschner et al., 2013). | 24721780 | LncRNADisease |
EL0853 | MALAT1 | cancer | N/A | N/A | N/A | regulation | They found that MALAT1 did not alter alternative splicing but rather actively regulated gene expression including a set of metastasis-associated genes. Consequently, MALAT1-deficient cells were impaired in migration and formed fewer tumor nodules in mouse xenograft. Antisense oligonucleotides (ASO) that block MALAT1 prevented metastasis formation after tumor implantation. | 24757675 | LncRNADisease |
EL0853 | MALAT1 | cervical cancer | N/A | N/A | N/A | expression | Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. | 24757675 | LncRNADisease |
EL0853 | MALAT1 | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. | 24757675 | LncRNADisease |
EL0853 | MALAT1 | lung cancer | N/A | N/A | N/A | expression | Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. | 24757675 | LncRNADisease |
EL0853 | MALAT1 | laryngeal squamous cell carcinoma | N/A | N/A | N/A | expression | The result suggested that the MALAT1 was up-regulated in primary LSCC compared with adjacent non-cancerous tissues. | 24817925 | LncRNADisease |
EL0853 | MALAT1 | nasopharyngeal carcinoma | N/A | N/A | N/A | expression | The result found that MALAT1 was most highly expressed in 5-8F cells (high rate to be tumor and metastasis), and up-regulated in CNE-2, C666-1 and HONE-1 which is higher malignant and poorly differentiated nasopharyngeal squamous cell carcinoma, while least expressed in NP69 epithelial cells of the eternal life. The data indicated that MALAT1 might be related to the metastasis and differentiation of NPC cells. | 24817925 | LncRNADisease |
EL0853 | MALAT1 | acute myocardial infarction | N/A | N/A | N/A | N/A | Level of metastasis-associated lung adenocarcinoma transcript 1 was higher in patients with MI than in healthy volunteers (P<0.01); Patients with ST-segment-elevation MI had lower levels of metastasis-associated lung adenocarcinoma transcript 1 (P=0.005) when compared with patients with non-ST-segment-elevation | 25035150 | LncRNADisease |
EL0853 | MALAT1 | diabetes mellitus | N/A | N/A | N/A | N/A | MALAT1 expression is significantly upregulated in the retinas of STZ-induced diabetic rats and db/db mice. MALAT1 knockdown could obviously ameliorate DR in vivo, as shown by pericyte loss, capillary degeneration, microvascular leakage, and retinal inflammation. Moreover, MALAT1 knockdown could regulate retinal endothelial cell proliferation, migration, and tube formation in vitro. The crosstalk between MALAT1 and p38 MAPK signaling pathway is involved in the regulation of endothelial cell function. | 25356875 | LncRNADisease |
EL0853 | MALAT1 | glioblastoma | N/A | N/A | N/A | N/A | Extensive microRNA-mediated crosstalk between lncRNAs and mRNAs in mouse WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. | 25772239 | LncRNADisease |
EL0853 | MALAT1 | non-small cell lung cancer | qPCR etc. | NSCLC tissue | up-regulated | expression | Increased expression of the lncRNA MALAT-1 has been observed in several types of tumors, including metastatic non-small cell lung cancer. | 12970751 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | osteosarcoma | qPCR etc. | osteosarcoma tissue | up-regulated | N/A | The expression of MALAT-1, IMPDH2, FTL and RHOA significantly correlated with response to chemotherapy. Expression of all four genes was increased in the poor responder group that are valuable markers for the prediction of osteosarcoma therapy outcome. Especially IMPDH2 and FTL are promising candidates for the stratification of osteosarcoma patients into low- and high-risk groups. Owing to their involvement in drug action these genes may further be potential targets for the modulation of drug sensitivity. | 17660802 | Lnc2Cancer |
EL0853 | MALAT1 | cervical cancer | qPCR etc. | cell line (CaSki) | up-regulated | Interaction | MALAT1 was involved in cervical cancer cell growth, cell cycle progression, and invasion through the regulation of gene expression, such as caspase-3, -8, Bax, Bcl-2, and BclxL. | 20213048 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | lung adenocarcinoma | qPCR etc. | cell line (A549 ) | differential expression | interaction | MALAT-1 is a novel class of non-coding RNA that promotes cell motility of lung adenocarcinoma cells through transcriptional and post-transcriptional regulation of motility related gene expression. | 20937273 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (SW620, SW480 etc.) | differential expression | N/A | The 3' end of MALAT-1 is an important biological motif in the invasion and metastasis of CRC cells. | 21503572 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | non-small cell lung cancer | qPCR etc. | cell lines (A549, plat-E, HTB-58 etc.) | up-regulated | expression | The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. | 22088988 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | cervical cancer | qPCR etc. | cell line (CaSki) | down-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | lung cancer | qPCR etc. | cell lines (A549, A549 MALAT1 KO, EBC-1 etc.) | up-regulated | regulation | The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. | 23243023 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | prostate cancer | qPCR etc. | prostate cancer tissue, cell lines (22RV1, LNCAP-AI etc.) | up-regulated | N/A | MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. | 23845456 | Lnc2Cancer |
EL0853 | MALAT1 | non-small cell lung cancer | qPCR etc. | NSCLC tissue | up-regulated | N/A | MALAT1 was shown to be detectable in the cellular fraction of peripheral human blood, showing different expression levels between cancer patients and cancer-free controls. For the discrimination of NSCLC patients from cancer-free controls a sensitivity of 56% was calculated conditional on a high specificity of 96%. The results of this study indicate that MALAT1 complies with key characteristics of diagnostic biomarkers, i.e., minimal invasiveness, high specificity, and robustness. | 24313945 | Lnc2Cancer |
EL0853 | MALAT1 | pituitary adenoma | qPCR etc. | pituitary adenomas tissue | up-regulated | expression | Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. | 24469926 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | multiple myeloma | qPCR etc. | blood (plasma) | down-regulated | expression | HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. | 24583225 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | pancreatic ductal adenocarcinoma | qPCR etc. | PADC tissue, cell lines (Panc-1, Bxpc-3, HPDE6C-7 etc.) | up-regulated | N/A | The relative level of MALAT1 was significantly higher in PDAC compared to the adjacent normal pancreatic tissues. When comparing the MALAT1 level in the cultured cell lines, remarkably higher expression of MALAT1 was found in aspc-1 PDAC cells compared with the immortal pancreatic duct epithelial cell line HPDE6c-7. Furthermore, MALAT1 expression level showed significant correlation with tumor size, tumor stage and depth of invasion. Kaplan-Meier analysis revealed that patients with higher MALAT1 expression had a poorer disease free survival. | 24815433 | Lnc2Cancer |
EL0853 | MALAT1 | cervical cancer | qPCR etc. | cervical cancer tissue, cell lines (HeLa, CaSki, SiHa, HCC94 etc.) | up-regulated | N/A | In the present study, it was identified that MALAT1 expression was upregulated in cervical cancer cell lines compared with normal cervical squamous cell samples. Further study into the effect of MALAT1 on cellular phenotype revealed that MALAT1 was able to promote cell migration and proliferation. HPV correlates with MALAT1 deregulation in cervical cancer. | 24932303 | Lnc2Cancer |
EL0853 | MALAT1 | colorectal cancer | qPCR etc. | colorectal cancer tissue | up-regulated | regulation | The MALAT1 levels in cancerous tissues were 2.26 times higher than those measured in noncancerous tissues, and this difference was statistically significant. Based on their expression level of MALAT1, the patients were divided into a high MALAT1 expression group and a low expression group. Patients with tumours harbouring higher expression of MALAT1 showed a significantly worse prognosis with a HR of 2.863 for DFS and 3.968 for OS. Furthermore, patients with perineural invasion demonstrated significantly worse DFS and OS than those without perineural invasion. | 25031737 | Lnc2Cancer |
EL0853 | MALAT1 | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | up-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
EL0853 | MALAT1 | multiple myeloma | qPCR etc. | Bone marrow | up-regulated | N/A | MALAT1 was overexpressed in the newly diagnosed patients compared with post-treatment patients and healthy individuals. The expression of MALAT1 strongly correlated with disease status, and the magnitude of change in MALAT1 post-treatment had prognostic relevance. The patients with early progression had a significantly smaller change in MALAT1 after treatment. | 25369863 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | pancreatic cancer | qPCR etc. | pancreatic cancer tissue | up-regulated | expression | Our results indicated that lncRNA MALAT1 was highly expressed in pancreatic cancer compared with adjacent non-cancerous tissues, and positively correlated with clinical stage, tumor size, lymph node metastasis, and distant metastasis in pancreatic cancer patients. Furthermore, we also found that lncRNA MALAT1 overexpression was an unfavorable prognostic factor in pancreatic cancer patients, regardless of clinical stage, tumor size, lymph node metastasis, and distant metastasis. Finally, increased lncRNA MALAT1 expression was an independent poor prognostic factor for pancreatic patients through multivariate analysis. | 25481511 | Lnc2Cancer |
EL0853 | MALAT1 | glioma | qPCR etc. | glioma tissue | up-regulated | expression | LncRNA MALAT1 expression was increased in glioma tissues compared with paired adjacent brain normal tissues. Furthermore, lncRNA MALAT1 was associated significantly with WHO grade (I-II vs. III-IV; P = 0.007) and tumor size. Moreover, the level of lncRNA MALAT1 expression was markedly correlated with the glioma patients' overall survival. Multivariate analysis suggested that increased lncRNA MALAT1 expression was a poor independent prognostic predictor for glioma patients. | 25613066 | Lnc2Cancer |
EL0853 | MALAT1 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) | up-regulated | expression | All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues. | 26096073 | Lnc2Cancer |
EL0853 | MALAT1 | lung cancer | qPCR etc. | blood | down-regulated | expression | The expression of MALAT1 in the whole blood of lung cancer patients with metastasis was stronger compared to non-metastasis, which showed that MALAT1 promotes the tumor metastasis and additionally, the whole blood with lymph node metastasis represented a lower expression of MALAT1 compared to bone or brain metastasis. | 26137228 | Lnc2Cancer |
EL0853 | MALAT1 | breast cancer | qPCR etc. | breast cancer and adjacent non-cancerous specimens, cell lines (MDA-MB-231 and MDA-MB-453) | down-regulated | interaction | We found that MALAT1 was downregulated in breast tumor cell lines and cancer tissue, and showed that knockdown of MALAT1 in breast cancer cell lines induced an epithelial-to-mesenchymal transition (EMT) program via phosphatidylinositide-3 kinase-AKT pathways. Furthermore, lower expression of MALAT1 in breast cancer patients was associated with shorter relapse-free survival | 26191181 | Lnc2Cancer |
EL0853 | MALAT1 | esophageal squamous cell carcinoma | qPCR etc. | ESCC tissue | up-regulated | expression | MALAT1 expression was increased in ESCC tissue than in adjacent normal tissue samples (P< 0.001). MALAT1 level was positively related to pT stage (P= 0.01). | 26406400 | Lnc2Cancer |
EL0853 | MALAT1 | renal cancer | qPCR etc. | clear cell renal cell carcinoma and corresponding noncancerous tissues | up-regulated | interaction | We found that MALAT1 exist a higher fold change (Tumor/Normal) in clear cell kidney carcinoma (KIRC) from The Cancer Genome Atlas (TCGA) Data Portal and a negative correlation with miR-200s family. We further demonstrated MALAT1 promote KIRC proliferation and metastasis through sponging miR-200s in vitro and in vivo. In addition, miR-200c can partly reverse the MALAT1's stimulation on proliferation and metastasis in KIRC. In summary we unveil a branch of the MALAT1/miR-200s/ZEB2 pathway that regulates the progression of KIRC. | 26461224 | Lnc2Cancer |
EL0853 | MALAT1 | colorectal cancer | qPCR, in vitro knockdown, RIP etc. | cell lines (LoVo, HCT116 ) | up-regulated | N/A | We found that overexpression of MALAT1 could promote cell proliferation and migration in vitro, and promote tumour growth and metastasis in nude mice. In CRC, MALAT1 could bind to SFPQ, thus releasing PTBP2 from the SFPQ/PTBP2 complex. In turn, the increased SFPQ-detached PTBP2 promoted cell proliferation and migration. SFPQ critically mediated the regulatory effects of MALAT1. Moreover, in CRC tissues, MALAT1 and PTBP2 were overexpressed, both of which were associated closely with the invasion and metastasis of CRC. MALAT1 might be a potential predictor for tumour metastasis and prognosis.Furthermore, the interaction between MALAT1 and SFPQ could be a novel therapeutic target for CRC. | 25025966 | Lnc2Cancer |
EL0853 | MALAT1 | endometrial stromal sarcoma | qPCR, ISH etc. | ESS tissue | up-regulated | expression | MALAT-1 gene is one of the major genes upregulated in ESS. | 16441420 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | cervical cancer | qPCR, knockdown etc | Tumor and adjacent normal tissues, cervical cancer cell lines(HeLa, CaSki) | up-regulated | expression | MALAT1 expression is significantly increased in cervical cancer than in normal tissues. Its expression in the cancerous tissues is also significantly higher than in adjacent normal tissues. MALAT1 expression is correlated with tumor size, FIGO stage, vascular invasion and lymph nodes metastasis and is an independent predictor for overall survival of cervical cancer. When endogenous MALAT1 was knocked down, the cancer cells had significantly reduced proliferation and invasion and increased apoptosis | 26400521 | Lnc2Cancer |
EL0853 | MALAT1 | hepatocelluar carcinoma | qPCR, knockdown etc. | HCC tissue | up-regulated | expression | Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. | 21678027 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | urothelial carcinoma of the bladder | qPCR, knockdown etc. | cell lines (T24, 5737) | up-regulated | N/A | MALAT1 was upregulated in bladder urothelial carcinoma compared with matched normal urothelium (P=.008). The MALAT1 expression levels were greater in high-grade carcinomas than in low-grade carcinoma (P=.001). The MALAT1 expression levels were greater in invasive carcinoma than in noninvasive carcinoma (P=.018). MALAT1 plays an oncogenic role in urothelial carcinoma of the bladder. | 23153939 | Lnc2Cancer |
EL0853 | MALAT1 | melanoma | qPCR, knockdown etc. | melanoma tissue, cell line (A-375) | up-regulated | N/A | highly expressed,can promote the metastasis of melanoma. The expression levels of UCA1 and Malat-1 lncRNAs had the potential to be prognostic indicators in metastasis of melanomas. | 24892958 | Lnc2Cancer |
EL0853 | MALAT1 | gastric cancer | qPCR, knockdown etc. | gastric cancer tissue, cell lines (MKN7, MKN45, MKN74, NUGC4, AZ521, AGS, KATOIII) | up-regulated | interaction | Expression of both lncRNAs was significantly higher in cancerous tissues than in corresponding normal mucosa, and higher expression of these lncRNAs significantly correlated with peritoneal metastasis in GC patients. Elevated HOTAIR expression emerged both as an independent prognostic and risk factor for peritoneal dissemination. SiRNA knockdown of HOTAIR in GC cells significantly inhibited cell proliferation, migration and invasion, but concurrently enhanced the anoikis rate in transfetced cells. | 25280565 | Lnc2Cancer |
EL0853 | MALAT1 | clear cell renal cell carcinoma | qPCR, knockdown etc. | ccRCC tissue, cell line (HK-2) | up-regulated | expression | The expression level of MALAT1 was higher in ccRCC tissues and renal cancer cells compared to adjacent non-tumor tissues and normal human proximal tubule epithelial cells HK-2. The ccRCC patients with higher MALAT1 expression had an advanced clinical features and a shorter overall survival time than those with lower MALAT1 expression. Additionally, our data indicated that knockdown expression of MALAT1 decreased renal cancer cell proliferation, migration, and invasion. | 25480417 | Lnc2Cancer |
EL0853 | MALAT1 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | esophageal squamous cell carcinoma and adjacent nonneoplastic tissues, cell lines(TE1, KYSE30, KYSE70, KYSE150, KYSE270, KYSE410, EC9706) | up-regulated | expression | Human esophageal carcinoma cell lines EC9706 and KYSE150 were transfected with MALAT-1 small interference RNA. Cell proliferation, migration/invasion ability, cell cycle, and apoptosis were assessed. MALAT-1 expressed higher levels in esophageal cancer tissues when compared with paired adjacent normal tissues. This high expression was associated with a decreased survival rate. MALAT-1 knockdown induced a decrease in proliferation-enhanced apoptosis, inhibited migration/invasion, and reduced colony formation and led to cell cycle arrest at the G2/M phase | 26493997 | Lnc2Cancer |
EL0853 | MALAT1 | osteosarcoma | qPCR, knockdown etc. | osteosarcoma tissue, cell lines (MG63, Saos-2, hFOB1.19, MNNG/HOS) | up-regulated | expression | We observed that MALAT1 expression was up-regulated in human osteosarcoma cell lines and tissues. In vitro knockdown of MALAT1 by siRNA significantly inhibited cell proliferation and migration, and induced cell cycle arrest and apoptosis in osteosarcoma cells. In addition, MALAT1 knockdown markedly suppressed the formation of tubular network structures and caused breakage of stress fibers in osteosarcoma cell lines U2OS and MNNG/HOS. | 26575981 | Lnc2Cancer |
EL0853 | MALAT1 | non-small cell lung cancer | qPCR, knockdown, Luciferase reporter assay etc. | NSCLC tissue, cell lines (A549, YTLMC-9) | up-regulated | interaction | MALAT1 is a non-coding RNA overexpressed in non-small cell lung cancer (NSCLC). TDP-43 is a ubiquitously expressed, MALAT1-binding protein implicated in cancer development. TDP-43 overexpression markedly increased MALAT1 transcript level. In summary, these findings demonstrated that MALAT1 expression by regulation of TDP-43 controls cellular growth, migration, and invasion of NSCLCs. | 26265046 | Lnc2Cancer |
EL0853 | MALAT1 | esophageal squamous cell carcinoma | qPCR, Luciferase reporter assay etc. | ESCC tissue, cell lines (KYSE30, KYSE150, KYSE450) | up-regulated | regulation | In this study, we provide first evidences that a posttranscriptional regulation mechanism of MALAT1 by miR-101 and miR-217 exists in ESCC cells. This posttranscriptional silencing of MALAT1 could significantly suppress the proliferation of ESCC cells through the arrest of G2/M cell cycle, which may be due to MALAT1-mediated upregulation of P21 and P27 expression and the inhibition of B-MYB expression. | 25538231 | Lnc2Cancer |
EL0853 | MALAT1 | renal cell carcinoma | qPCR, Luciferase reporter assay etc. | RCC tissue | up-regulated | N/A | Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. MALAT1 expression was higher in human RCC tissues, where it was associated with reduced patient survival. | 25600645 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | multiple myeloma | qPCR, Luciferase reporter assay, ELISA, knockdown etc. | bone marrow | up-regulated | expression | The expression of MALAT1 was assessed by quantitative qPCR. Consistently higher expression level of MALAT1 was found in MSCs from all 25 patient samples relative to that from healthy donors. lncRNA MALAT1 directly interacted with Sp1 and LTBP3 promoter to increase expression of LTBP3 gene. The specificity and efficiency of activation were ensured by the formation of a stable complex between MALAT1 and the LTBP3 promoter, direct interaction of MALAT1 with Sp1 and recruitment of Sp1 to the promoter. | 25187517 | Lnc2Cancer |
EL0853 | MALAT1 | cervical cancer | qPCR, Luciferase reporter assays, knockdown, RIP, RNA pull-down assay etc. | cervical cancer tissue, cell lines (HeLa and CaSki) | up-regulated | interaction | We found MALAT1 expression was significantly higher in radioresistant than in radiosensitive cancer cases. In addition, MALAT1 and miR-145 expression inversely changed in response to irradiation in HR-HPV+ cervical cancer cells. By using clonogenic assay and flow cytometry analysis of cell cycle distribution and apoptosis, we found CaSki and Hela cells with knockdown of MALAT1 had significantly lower colony formation, higher ratio of G2/M phase block and higher ratio of cell apoptosis. | 26311052 | Lnc2Cancer |
EL0853 | MALAT1 | lung cancer | qPCR, Northern blot, etc. | cell lines (H1299, H1975 etc.) | differential expression | N/A | We first examined the decay of MALAT-1 in various cancer cells (H1299, H1975, A549, HT1080, and HeLa TO cells) by DRB chase experiments using 7SK RNA as a control. Half-lives of MALAT-1 in H1299, H1975, A549, HT1080, and HeLa TO cells were > 12, 12, 12, 12, and 9 h, respectively. MALAT-1 stabilities varied in various cancer cells. | 22491206 | Lnc2Cancer |
EL0853 | MALAT1 | fibrosarcoma | qPCR, Northern blot, etc. | cell line (HT1080) | differential expression | N/A | We first examined the decay of MALAT-1 in various cancer cells (H1299, H1975, A549, HT1080, and HeLa TO cells) by DRB chase experiments using 7SK RNA as a control. Half-lives of MALAT-1 in H1299, H1975, A549, HT1080, and HeLa TO cells were > 12, 12, 12, 12, and 9 h, respectively. MALAT-1 stabilities varied in various cancer cells. | 22491206 | Lnc2Cancer |
EL0853 | MALAT1 | cervical cancer | qPCR, Northern blot, etc. | cell line (HeLa) | differential expression | N/A | We first examined the decay of MALAT-1 in various cancer cells (H1299, H1975, A549, HT1080, and HeLa TO cells) by DRB chase experiments using 7SK RNA as a control. Half-lives of MALAT-1 in H1299, H1975, A549, HT1080, and HeLa TO cells were > 12, 12, 12, 12, and 9 h, respectively. MALAT-1 stabilities varied in various cancer cells. | 22491206 | Lnc2Cancer |
EL0853 | MALAT1 | hepatocelluar carcinoma | qPCR, Northern blot, ISH etc. | HCC tissue, cell line (CT26) | up-regulated | expression | Quantitative analyses indicated a 6-7-fold increased RNA level in HCCs versus uninvolved liver, advancing this as a molecule of interest. | 16878148 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | prostate cancer | qPCR, Northern bolt etc. | prostate cancer tissue, cell lines (LNCap-AD, 22Rv1, PC-3, DU145, C4-2 etc.) | up-regulated | N/A | qPCR was used to assess the PCA3 and MALAT-1 expression levels in an additional set of 10 pairs of PCa and adjacent normal tissues. Comparing the PCA3 and MALAT-1 expression levels in the 10 paired tissue samples revealed that PCA3 and MALAT-1 were highly expressed in most of the PCa tissues. Plasma lncRNAs probably exist in the form of fragments in a stable form. MD-miniRNA enters cell culture medium at measurable levels, and MD-miniRNA derived from human PCa xenografts actually enters the circulation in vivo and can be measured to distinguish xenografted mice from controls. | 23726266 | Lnc2Cancer |
EL0853 | MALAT1 | prostate cancer | qPCR, RIP-Seq, knockdown, ChIP etc. | cell lines (C4-2, PC-3, LNCaP) | up-regulated | interaction | We showed that MALAT1 enhances expression of PRC2-independent target genes of EZH2 in CRPC cells in culture and patient-derived xenografts. Together, these data indicate that MALAT1 may be a crucial RNA cofactor of EZH2 and that the EZH2-MALAT1 association may provide a new avenue for development new strategies for treatment of CRPC. | 26516927 | Lnc2Cancer |
EL0853 | MALAT1 | gallbladder cancer | qPCR, Western blot etc. | GBC tissue, cell lines (SGC-996, NOZ) | up-regulated | regulation | MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. | 24658096 | LncRNADisease Lnc2Cancer |
EL0853 | MALAT1 | non-small cell lung cancer | qPCR, Western blot etc. | NSCLC tissue, cell lines (H1915) | up-regulated | expression | We observed that the level of MALAT1 was significantly higher in brain metastasis than that of non brain metastasis samples. The level of MALAT1 was associated with patients' survival. We found that MALAT1 is increased in highly invasive subline of brain metastasis lung cancer cells. Further functional studies indicate that silencing MALAT1 inhibits highly invasive subline of brain metastasis lung cancer cell migration and metastasis by inducing epithelial-mesenchymal transition (EMT). | 25217850 | Lnc2Cancer |
EL0853 | MALAT1 | pancreatic cancer | qPCR, Western blot etc. | cell lines (AsPC-1, CFPAC-1) | up-regulated | expression | In this study, our data showed that MALAT-1 could increase the proportion of pancreatic CSCs, maintain self-renewing capacity, decrease the chemosensitivity to anticancer drugs, and accelerate tumor angiogenesis in vitro. In addition, subcutaneous nude mouse xenografts revealed that MALAT-1 could promote tumorigenicity of pancreatic cancer cells in vivo. The underlying mechanisms may involve in increased expression of self-renewal related factors Sox2. | 25811929 | Lnc2Cancer |
EL0853 | MALAT1 | pancreatic cancer | qPCR, Western blot, FCA etc. | pancreatic cancer tissue, cell lines (BxPC-3, CFPAC-1, CAPAN-1, SW1990 etc.) | up-regulated | expression | In the present study, our results showed that MALAT-1 expression levels were upregulated in pancreatic cancer tissues compared with adjacent noncancerous controls. Further function analysis revealed that downregulation of MALAT-1 could inhibit tumor cell proliferation and decrease cell migration and invasion in vitro. | 25269958 | Lnc2Cancer |
EL0853 | MALAT1 | gastric cancer | qPCR, Western blot, knockdown etc. | cell lines (SGC-7901, MKN-45, SUN-16) | up-regulated | N/A | In this study, we found that MALAT1 was aberrantly highly expressed in GC cell lines (SGC-7901, MKN-45 and SUN-16), and induced specific distribution and over-expression of SF2/ASF in nucleolus. Knock-down of MALAT1 or SF2/ASF in SGC-7901 cells respectively induced significant arrest of cell cycle in G0/G1 phase along with a remarkable suppression of cell proliferation, and the nuclear distribution and expression of SF2/ASF was significantly impaired when MALAT1 was depleted. However, over-expression of SF2/ASF exhibited no effect on rescuing the cell proliferation suppression by MALAT1 depletion. | 24857172 | Lnc2Cancer |
EL0853 | MALAT1 | osteosarcoma | qPCR, Western blot, knockdown etc. | osteosarcoma tissue, cell lines (SAOS2, MG63, U2OS) | up-regulated | expression | In our research, the MALAT1 messenger RNA (mRNA) was highly expressed in human osteosarcoma tissues, and its expression level was closely correlated with pulmonary metastasis. Knockdown of MALAT1 inhibited the proliferation and invasion of human osteosarcoma cell and suppressed its metastasis in vitro and vivo. MALAT1 might suppress the tumor growth and metastasis via PI3K/AKT signaling pathway. | 25431257 | Lnc2Cancer |
EL0853 | MALAT1 | esophageal squamous cell carcinoma | qPCR, Western blot, knockdown etc. | ESCC tissue, cell lines (EC109, EC9706, KYSE150, KYSE450) | up-regulated | expression | MALAT1 was over-expressed in 46.3% of ESCC tissues, mostly in the high-stage tumor samples. Enhanced MALAT1 expression levels were positively correlated with clinical stages, primary tumor size, and lymph node metastasis. Inhibition of MALAT1 suppressed tumor proliferation in vitro and in vivo, as well as the migratory and invasive capacity.MALAT1 serves as an oncogene in ESCC, and it regulates ESCC growth by modifying the ATM-CHK2 pathway. | 25613496 | Lnc2Cancer |
EL0853 | MALAT1 | oral squamous cell carcinoma | qPCR, Western blot, knockdown etc. | OSCC tissue, cell lines (Tscca, Tca8113P160, Tca8113, Hep-2) | up-regulated | interaction | We found that MALAT1 is overexpressed in OSCC tissues compared to normal oral mucosa by real-time PCR. MALAT1 served as a new prognostic factor in OSCC patients. When knockdown by small interfering RNA (siRNA) in OSCC cell lines TSCCA and Tca8113, MALAT1 was shown to be required for maintaining epithelial-mesenchymal transition (EMT) mediated cell migration and invasion. Western blot and immunofluorescence staining showed that MALAT1 knockdown significantly suppressed N-cadherin and Vimentin expression but induced E-cadherin expression in vitro. Meanwhile, both nucleus and cytoplasm levels of β-catenin and NF-B were attenuated, while elevated MALAT1 level triggered the expression of β-catenin and NF-B. More importantly, targeting MALAT1 inhibited TSCCA cell-induced xenograft tumor growth in vivo. | 26522444 | Lnc2Cancer |
EL0853 | MALAT1 | cervical cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, FCA etc. | HR-HPV+ cervical cancer tisssue, cell lines (HeLa, CaSki, SiHa) | up-regulated | interaction | Findings of this study confirmed higher MALAT1 expression in HR-HPV (+) cervical cancer. Knockdown of endogenous MALAT1 significantly reduced cell growth rate and invasion and increased cell apoptosis of Hela and siHa cells. Besides, knockdown of MALAT1 increased the expression of miRNA-124, while ectopic expression of miR-124 decreased MALAT1 expression. MALAT1 can indirectly modulate GRB2 expression via competing miR-124. Knockdown of GRB2 reduced cell invasion and increased cell apoptosis. In conclusion, MALAT1 can promote HR-HPV (+) cancer cell growth and invasion at least partially through the MALAT1-miR-124-RBG2 axis. | 26242259 | Lnc2Cancer |
EL0853 | MALAT1 | colorectal cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | CRC tissue, cell lines (LoVo etc.) | up-regulated | N/A | Using in situ hybridization, we found there was higher expression of MALAT1 in the CRC than the adjacent normal colorectal tissue. We next conducted correlation analysis between MALAT1 expression and clinicopathological characteristics of CRC. A statistically significant association was observed between MALAT1 expression and extent of metastasis and invasion. In contrast to adjacent normal tissues, the MALAT1 expression in CRC tissues resected from patients with metastatic diseases was higher than those with no metastasis. | 24244343 | Lnc2Cancer |
EL0853 | MALAT1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | bladder cancer tissue, cell lines (T24, RT4 etc.) | up-regulated | N/A | TGFβ1 induces malat1 expression and EMT in bladder cancer cells. malat1 overexpression is significantly correlated with poor survival in patients with bladder cancer. malat1 and E-cadherin expression is negatively correlated in vitro and in vivo. malat1 knockdown inhibits TGFβ1 induced EMT. malat1 is associated with suz12, and this association results in decrease of E-cadherin expression and increase of N-cadherin and fibronectin expression. Targeted inhibition of malat1 or suz12 suppresses the migratory and invasive properties induced by TGFβ1 We demonstrated that malat1 or suz12 knockdown inhibits tumor metastasis in animal models. | 24449823 | Lnc2Cancer |
EL0853 | MALAT1 | breast cancer | qPCR, Western blot, Luciferase reporter assays etc. | breast cancer patients tissues | down-regulated | interaction | The effects of up-regulation of miR-1 were similar to that of silencing K-RAS and MALAT1 in breast cancer cells | 26275461 | Lnc2Cancer |
EL0853 | MALAT1 | nasopharyngeal carcinoma | qPCR, Western blot, Luciferase reporter assays, RIP etc. | NPC cell lines (5-8F, CNE-2, HONE-1, SUNE-1), NPE cell line (NP-69) | up-regulated | interaction | We found that MALAT1 regulated radioresistance by modulating cancer stem cell (CSC) activity. Furthermore, we found that there was reciprocal repression between MALAT1 and miR-1, and slug was identified as a downstream target of miR-1. Taking these observations into consideration, we proposed that MALAT1 regulated CSC activity and radioresistance by modulating miR-1/slug axis, which indicated that MALAT1 could act as a therapeutic target for NPC patients | 26482776 | Lnc2Cancer |
EL0853 | MALAT1 | breast cancer | qPCR, Western blot, Luciferase reporter assays, RIP etc. | breast cancer specimens and adjacent normal breast tissue | up-regulated | interaction | We reported that MALAT1 was upregulated in triple-negative breast cancer (TNBC) tissues. Knockdown of MALAT1 inhibited proliferation, motility, and increased apoptosis in vitro. In vivo study indicated that knockdown of MALAT1 inhibited tumor growth and metastasis. Patients with high MALAT1 expression had poorer overall survival time than those with low MALAT1 expression. In addition, our findings demonstrate a reciprocal negative control relationship between MALAT1 and miR-1: downregulation of MALAT1 increased expression of microRNA-1 (miR-1), while overexpression of miR-1 decreased MALAT1 expression. Slug was identified as a direct target of miR-1. | 26676637 | Lnc2Cancer |
EL0853 | MALAT1 | glioma | qPCR, Western blot, Luciferase reporter assays, RIP, ChIP etc. | glioma samples and normal brain tissues, cell lines (hCMEC/D3, ECs) | up-regulated | interaction | Our results proved that MALAT1 expression was up-regulated in brain microvessels of human glioma and glioma endothelial cells (GECs) which were obtained by co-culturing endothelial cells with glioma cells. Functionally, knockdown of MALAT1 resulted in an impairment and increased the permeability of BTB as well as decreased the expression of ZO-1, occludin and claudin-5 in GECs. Further, there was reciprocal repression between MALAT1 and miR-140, and miR-140 mediated the effects that MALAT1 knockdown exerted. Mechanistic investigations defined that nuclear factor YA (NFYA), a CCAAT box-binding transcription factor, was a direct and functional downstream target of miR-140, which was involved in the MALAT1 knockdown induced regulation of BTB function. Furthermore, NFYA could up-regulate the promoter activities and bind to the promoters of ZO-1, occludin and claudin-5 in GECs. | 26619802 | Lnc2Cancer |
EL0853 | MALAT1 | breast cancer | qPCR, Western blot, Northern blot, knockdown etc. | cell lines (MB231, MCF7 etc.) | up-regulated | N/A | Specifically, we looked for the changes of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 (MALAT-1), which is found extensively and highly expressed in several kinds of tumor cells, including breast carcinoma. It was observed that proliferation, migration and invasion of breast cells were greatly affected by high concentration E2 treatment and were not affected by low concentration E2 treatment in an ERa independent way. We found that the high concentration E2 treatment largely decreased MALAT-1 RNA level. Interestingly, MALAT-1 decreasing by knocking down showed similar effects on proliferation, migration and invasion. | 24525122 | Lnc2Cancer |
EL0853 | MALAT1 | nasopharyngeal carcinoma | qPCR, Western bolt etc. | cell lines (5-8F, 6-10B, CNE-1, CNE-2 etc.) | up-regulated | N/A | MALAT1 was highly expressed in 5-8F cells with a high metastatic potential, and lowly expressed in normal nasopharyngeal epithelium cells. Overexpression of MALAT1 by RNAa suppressed the expression of E-cadherin, promoted the expression of vimentin and enhanced the proliferation, invasion, and metastasis of CNE-1 cells. | 23688988 | Lnc2Cancer |
EL0853 | MALAT1 | bladder cancer | qPCR, Western bolt, Luciferase reporter assay etc. | bladder cancer tissue, cell line (T24) | up-regulated | N/A | We verified that MALAT-1 levels were upregulated in bladder cancer tissues compared with adjacent normal tissues, and MALAT-1 expression was remarkably increased in primary tumors that subsequently metastasized, when compared to those primary tumors that did not metastasize. levels. We further demonstrated that MALAT-1 promoted EMT by activating Wnt signaling in vitro. | 22722759 | Lnc2Cancer |
EL0853 | MALAT1 | esophageal squamous cell carcinoma | qRT-PCR | 106 paired ESCC tissues | down-regulated | N/A | MALAT1 decreased tumor formation and improved survival | 27015363 | |
EL0853 | MALAT1 | gastric cancer | RNA immunoprecipitation RIP-seq | gastric cancer cell lines | N/A | N/A | suppresses the tumor suppressor PCDH10 and promotes gastric cellular migration and invasion | 26871474 | |
EL0853 | MALAT1 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | up-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
EL0853 | MALAT1 | pre-eclampsia | short interfering RNA (siRNA) | placentas from the patients with preeclampsia, EG-3 trophoblast cell line | down-regulated | interaction | Silencing of MALAT-1 in JEG-3 cells suppressed proliferation and induced cell cycle arrest at G0/G1 phase. The migration rate and the invasiveness of JEG-3 cells were suppressed when MALAT-1 was downregulated. MALAT-1 may play an important role in the regulation of proliferation, cell cycle, apoptosis, migration and invasion of trophoblast cells, and under-expression of MALAT-1 during early placentation may be involved in the pathogenesis of preeclampsia. | 26722461 | |
EL0853 | MALAT1 | triple-negative breast cancer | tissue microarray; immunoblotting, polymerase chain reaction, loss and gain of gene | MDA-MB-231 cells | up-regulated | N/A | N/A | 26917489 | |
EL0854 | Malat1 | hereditary degenerative disease myotonic dystrophy type 1 | knockdown | a transgenic mouse model of DM1 | N/A | expression | Systemically administered ASOs were also effective for muscle knockdown of Malat1, a long non-coding RNA (lncRNA) that is retained in the nucleus. | 22859208 | |
EL0854 | Malat1 | mammary carcinoma | knockdown | MMTV (mouse mammary tumor virus)-PyMT mouse mammary carcinoma model | N/A | expression | Malat1 loss results in a reduction of branching morphogenesis in MMTV-PyMT- and Her2/neu-amplified tumor organoids, increased cell adhesion, and loss of migration. | 26701265 | |
EL0854 | Malat1 | Flavivirus infection | N/A | N/A | N/A | expression | Activation of Malat1 following infection by two flaviviruses, both of which activate the UPR in host cells. | 26634309 | |
EL0855 | MALAT2 | gastric cancer | qPCR, Western blot etc. | gastric cancer tissue | up-regulated | N/A | MALAT2-activated long noncoding RNA indicates a biomarker of poor prognosis in gastric cancer. MALAT2 was frequently over-expressed in cancer tissues and this over-expression was found to significantly correlate with lymph node metastasis and tumor stage. | 25721209 | LncRNADisease Lnc2Cancer |
EL0856 | MAP3K14 | pancreatic ductal adenocarcinoma | microarray, qPCR etc. | cell line (MIA PaCa-2 ) | up-regulated | expression | Differential expression | 22078386 | LncRNADisease Lnc2Cancer |
EL0859 | MDC1-AS1 | bladder cancer | microarray, qPCR etc. | bladder cancer tissue | down-regulated | interaction | The expression levels of MDC1-AS and MDC1 was down-regulated in bladder cancer. After over-expression of MDC1-AS, increased levels of MDC1 were observed in bladder cancer cells. We also found a remarkably inhibitory role of antisense lncRNA MDC1-AS on malignant cell behaviors in bladder cancer cells EJ and T24. | 25514464 | Lnc2Cancer |
EL0861 | MEG3 | pancreatic cancer | genome-wide LncRNA microarray analysis | pancreatic cancer cell lines | down-regulated | N/A | overexpression of MEG3 induced cells death and increased p53 expression | 26850851 | |
EL0861 | MEG3 | non-functioning pituitary adenoma | inducible and constitutively active expression systems | PDFS cells derived from a human NFA (non-functioning pituitary adenomas) | up-regulated | expression | MEG3 expression significantly suppressed xenograft tumor growth in vivo in nude mice. When induced in culture, MEG3 caused cell cycle arrest at the G1 phase. | 26284494 | |
EL0861 | MEG3 | multiple myeloma | knockdown, overexpression, ChIP, RIP | bone marrow mesenchymal stromal cells (MSCs) | down-regulated | expression | Our data provided novel evidence for the biological and clinical significance of lncRNA MEG3 expression as a potential biomarker for identifying patients with MM and as a potential therapeutic target in MM. | 25753650 | |
EL0861 | MEG3 | hepatocellular carcinoma | methylation specific PCR (MSP), qRT-PCR, RNA pulldown and western blot analysis, MTT assay, fluorescence microscopy and flow cytometry, improved MS2 biotin tagged RNA affinity purification method | hepatoma HepG2 and Huh7 cells | up-regulated | interaction | Ectopic expression of MEG3 inhibited hepatoma cell growth in a time-dependent manner, resulted in cell cycle arrest and induced apoptosis. Adenosine increases MEG3 expression by inhibition of DNA methylation and its antitumor effects is involved in MEG3 activation. | 26647875 | |
EL0861 | MEG3 | tongue squamous cell carcinoma | microarray, MSP, Western blot, knockdown etc. | TSCC tissue, cell lines (SCC-15, CAL27 etc.) | down-regulated | N/A | We report here that miR-26a and lncRNA MEG3 gene expression were both strongly reduced in TSCC compared with levels in matched nonmalignant tissues, and combined low expression levels of both miR-26a and MEG3 emerged as an independent prognostic factor for poor clinical outcome in TSCC patients. | 24343426 | Lnc2Cancer |
EL0861 | MEG3 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | expression | Enforced expression of MEG3 in HCC cells significantly decreased both anchorage-dependent and -independent cell growth, and induced apoptosis. Methylation-dependent tissue-specific regulation of the lncRNA MEG3 by miR-29a may contribute to HCC growth. | 21625215 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | non-functioning pituitary adenoma | microarray, qPCR etc. | NFPA tissue | down-regulated | N/A | qPCR analyses showed that MEG3 expression was lost in 32 of 52 NFPAs (61.5 %). In addition, MEG3 lncRNA levels were significantly decreased in invasive NFPAs and non-invasive NFPAs compared to normal anterior pituitaries. Furthermore, MEG3 expression was significantly decreased in invasive NFPAs compared to non-invasive NFPAs. | 24469926 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | down-regulated | interaction | Expression profiles of five lnc-RNAs (MEG3, HULC, HOTAIR, NEAT1, and MALAT-1) previously shown to be involved in cancer metastasis were detected by qPCR in 5 pairs of papillary thyroid cancer and 11 matched lymph node metastatic tissues. Among the five, MEG3 showed significant down-expression. Overexpression of MEG3 inhibits thyroid cancer cell migration and invasion.Thus, this study suggests that MEG3 acts as novel suppressor of migration and invasion by targeting Rac1 gene. | 25997963 | Lnc2Cancer |
EL0861 | MEG3 | lung adenocarcinoma | microarray, qPCR, Western blot etc. | lung cancer tissue, cell lines (A549 etc.) | down-regulated | interaction | MEG3 expression was markedly decreased in cisplatin-resistant A549/DDP cells compared with parental A549 cells as shown by an lncRNA microarray. MEG3 overexpression in A549/DDP cells increased their chemosensitivity to cisplatin both in vitro and in vivo by inhibiting cell proliferation and inducing apoptosis. Moreover, MEG3 was decreased in cisplatin-insensitive LAD tissues while p53 protein levels were decreased and Bcl-xl protein levels increased. | 25992654 | Lnc2Cancer |
EL0861 | MEG3 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0861 | MEG3 | acute myeloid leukemia | MSP etc. | bone marrow | down-regulated | epigenetics | MEG3 hypermethylation occurred in 15 MDS patients (34.9%), and in 20 AML patients (47.6%). | 19595458 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | glioma | N/A | gliomas tissues | down-regulated | epigenetics | The downregulation of MEG3 expression due to hypermethylation of MEG3 was observed in gliomas tissues. Treatment of glioma cells with the DNA methylation inhibitor 5-Aza-2'-deoxycytidine (5-AzadC) decreased aberrant hypermethylation of the MEG3 promoter and prevented the loss of MEG3 expression. | 26676363 | |
EL0861 | MEG3 | hepatocelluar carcinoma | N/A | MS2 virus-like particles (VLPs) crosslinked with GE11 polypeptide | N/A | N/A | N/A | 26992211 | |
EL0861 | MEG3 | myelodysplastic syndrome | N/A | N/A | N/A | epigenetics | MEG3 hypermethylation occurred in 15 MDS patients (34.9%), and in 20 AML patients (47.6%). | 19595458 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | type 1 diabetes mellitus | N/A | N/A | N/A | locus | The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. | 19966805 | LncRNADisease |
EL0861 | MEG3 | heroin abuse | N/A | N/A | N/A | mutation | Intriguingly a genome-wide association study has implicated MEG3 in the vulnerability to heroin addiction. | 21128942 | LncRNADisease |
EL0861 | MEG3 | cancer | N/A | N/A | N/A | N/A | MEG3 could represent a tumor suppressor gene located in chromosome 14q32 and its association with tumorigenesis is growing every day. | 21400503 | LncRNADisease |
EL0861 | MEG3 | cancer | N/A | N/A | N/A | N/A | MEG3 functions as a novel lncRNA tumor suppressor. | 22393162 | LncRNADisease |
EL0861 | MEG3 | meningioma | N/A | N/A | N/A | regulation | MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. | 23307326 | LncRNADisease |
EL0861 | MEG3 | Huntington's disease | N/A | N/A | N/A | expression | LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. | 23346095 | LncRNADisease |
EL0861 | MEG3 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
EL0861 | MEG3 | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Braconi et al. found that the expression of maternally expressed gene 3 (MEG3) is markedly reduced in four human HCC cell lines compared with normal hepatocytes and enforced expression of MEG3 in HCC cells significantly induce apoptosis. | 24296588 | LncRNADisease |
EL0861 | MEG3 | bladder cancer | N/A | N/A | N/A | regulation | Tumour suppressor | 24373479 | LncRNADisease |
EL0861 | MEG3 | kidney cancer | N/A | N/A | N/A | expression | Tumour suppressor | 24373479 | LncRNADisease |
EL0861 | MEG3 | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | Expression of MEG3 in tumor cells results in growth suppression, p53 protein increase, and activation of p53 downstream targets. | 24757675 | LncRNADisease |
EL0861 | MEG3 | pituitary adenoma | N/A | N/A | N/A | expression | Another potential angiogenic lncRNA, Maternally expressed gene 3 (MEG3) was found to be silenced in pituitary adenomas.? | 24829860 | LncRNADisease |
EL0861 | MEG3 | pancreatic neuroendocrine tumors | overexpression, microarray | pancreatic neuroendocrine tumors (PNETs) cells | N/A | epigenetics | The epigenetic activation of lncRNA MEG3 and/or inactivation of c-MET could be therapeutic for treating PNETs and insulinomas. | 25565142 | |
EL0861 | MEG3 | non-functioning pituitary adenoma | qPCR etc. | pituitary tumor tissue | down-regulated | epigenetics | Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. | 15644399 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | phaeochromocytoma | qPCR etc. | phaeochromocytoma tissue | down-regulated | N/A | Hypermethylation of the GTL2 promoter DMR was detected in 25% of neuroblastomas, 10% of phaeochromocytoma and 2.5% of Wilms' tumours. Tumours with GTL2 promoter DMR hypermethylation also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element. | 15798773 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | Wilms' tumor | qPCR etc. | Wilms' tumor tissue | down-regulated | N/A | Hypermethylation of the GTL2 promoter DMR was detected in 25% of neuroblastomas, 10% of phaeochromocytoma and 2.5% of Wilms' tumours. Tumours with GTL2 promoter DMR hypermethylation also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element. | 15798773 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | neuroblastoma | qPCR etc. | neuroblastoma tissue | down-regulated | epigenetics | MEG3-DMR is completely methylated in neuroblastoma cell lines. | 15798773 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | non-functioning pituitary adenoma | qPCR etc. | pituitary tumor tissue | down-regulated | expression | Maternally Expressed Gene 3 (MEG3), which is specifically associated with clinically non-functioning pituitary adenomas of a gonadotroph lineage. | 20211686 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | pituitary adenoma | qPCR etc. | pituitary tumor tissue | down-regulated | N/A | In summary, MEG3 and GADD45γ expression was significantly lost in most clinically non-functioning adenomas (78 and 92%, respetcively). Other assessed pituitary tumor phenotypes expressed both genes at significantly different levels, and, in some cases, with overexpression. | 21850407 | Lnc2Cancer |
EL0861 | MEG3 | non-functioning pituitary adenoma | qPCR etc. | pituitary adenoma tissue | down-regulated | expression | The DLK1-MEG3 locus is silenced in NFAs (nonfunctioning adenomas). The DLK1-MEG3 locus plays a tumor suppressor role in human NFAs. | 21871428 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | cervical cancer | qPCR etc. | cell line (CaSki) | up-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | oral squamous cell carcinoma | qPCR etc. | OSCC tissues | down-regulated | N/A | We found that most of the selected transcripts (4/6) were upregulated in tumors relative to matched adjacent nonmalignant tissue. One gene, MEG-3, was downregulated in cancer compared with its adjacent nonmalignant tissue. Expression of lncRNA (HOTAIR, NEAT-1 and UCA1) was significantly higher in the samples that subsequently metastasized compared with the non-metastatic samples. By contrast, MEG-3 was downregulated in the metastatic samples. These findings suggest that the detection of lncRNAs in saliva may be used as a noninvasive and rapid diagnostic tool for the diagnosis of oral cancer. | 23292713 | Lnc2Cancer |
EL0861 | MEG3 | pituitary adenoma | qPCR etc. | pituitary adenomas tissue | up-regulated | N/A | MEG3 lncRNA levels gradually decreased whereas HOTAIR lncRNA levels gradually increased from normal anterior pituitaries to non-invasive NFPAs to invasive NFPAs. There was a significant association between MEG3 (P < 0.01) and HOTAIR (P < 0.05) expression and the biological behavior of the tumor. Furthermore, PCNA mRNA levels markedly increased in invasive NFPAs compared to non-invasive ones (P < 0.01). In addition, PCNA mRNA negatively correlated with MEG3 lncRNA levels | 24469926 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | glioma | qPCR etc. | cell lines(U251, U87) | up-regulated | expression | MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. | 25645334 | Lnc2Cancer |
EL0861 | MEG3 | cervical cancer | qPCR, ISH etc. | cervical cancer tissue | down-regulated | N/A | A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | pituitary adenoma | qPCR, ISH etc. | pituitary tumor tissue | down-regulated | N/A | Therefore, RT-PCR was used to detect specific MEG3a isoform expression in different human pituitary tumor phenotypes. Figure 4B shows that there was no MEG3a expression in three GH-secreting tumors and eight clinically nonfunctioning pituitary tumors, in contrast to the five normal human pituitaries. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | prostate cancer | qPCR, ISH etc. | prostate cancer tissue | down-regulated | N/A | MEG3 mRNA is expressed in the normal human fibroblast cells but is undetectable in human cancer cell lines by Northern blot. Lanes 110, Human carcinoma cells HeLa, MCF-7, T47-D, T24, 5637, Du145, K562, HT29, H1299, H4; lanes 11 and 12, human normal fibroblasts HS-27 and WI38. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | breast cancer | qPCR, ISH etc. | bladder cancer tissue | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | bladder cancer | qPCR, ISH etc. | breast cancer tissue | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | colon cancer | qPCR, ISH etc. | colon cancer tissue | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | glioma | qPCR, ISH etc. | neuroglioma tissue | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | lung cancer | qPCR, ISH etc. | lung cancer tissue | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | chronic myeloid leukemia | qPCR, ISH etc. | blood | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | non-functioning pituitary adenoma | qPCR, ISH etc. | pituitary tumor tissue | down-regulated | epigenetics | Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. | 18628527 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | glioma | qPCR, Luciferase reporter assay etc. | cell lines (U251, U87 etc.) | down-regulated | expression | Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. | 22234798 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | meningioma | qPCR, Luciferase reporter assay, ISH etc. | meningioma tissue | down-regulated | epigenetics | Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. | 20179190 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | gastric cancer | qPCR, Luciferase reporter assay, RNA pull-down assay etc. | gastric cancer tissue, cell lines (MGC-803, HGC-27, MKN-45, SGC-7901, BGC-823, AGS) | down-regulated | interaction | MEG3 is decreased in GC patients and cell lines, and its expression was associated with metastatic GC. Furthermore, ectopic expression of MEG3 in HGC-27 and MGC-803 cells inhibited cell proliferation, migration, invasion, and promoted cell apoptosis, which might be due to MEG3 sequestering oncogenic miR-181 s in GC cells. Furthermore, MEG3 could up-regulated Bcl-2 via its competing endogenous RNA (ceRNA) activity on miR-181a. | 26253106 | Lnc2Cancer |
EL0861 | MEG3 | epithelial ovarian cancer | qPCR, MSP, Western blot, Luciferase reporter assay etc. | epithelial ovarian cancer tissue, cell lines (OVCAR3, SKOV3, HP8910, ES-2) | down-regulated | N/A | In contrast to normal ovarian tissues, the expression of MEG3 was absent or decreased in most EOC tissues as well as in human EOC cell lines, and the promoter of the MEG3 gene was highly methylated in both cancer tissues and cell lines. In addition, ectopic expression of MEG3 suppressed the proliferation and growth of OVCAR3 cells and promoted apoptosis. Finally, MEG3 activated p53 in OVCAR3 cells. | 24859196 | Lnc2Cancer |
EL0861 | MEG3 | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell line (T24) | down-regulated | regulation | Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. | 23295831 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | non-small cell lung cancer | qPCR, Western blot etc. | NSCLC tissue, cell lines (A549, SPC-A1,NCI-H1650, NCI-H358, NCI-H1299, NCI-H1975 etc.) | down-regulated | N/A | MEG3 is significantly down-regulated in NSCLC tissues that could be affected by DNA methylation. Overexpression of MEG3 decreased NSCLC cells proliferation and induced apoptosis.Partially via the activition of p53. Thus, MEG3 may represent a new marker of poor prognosis and is a potential therapeutic target for NSCLC intervention. | 24098911 | Lnc2Cancer |
EL0861 | MEG3 | gastric cancer | qPCR, Western blot etc. | gastric cancer tissue, cell line (GES-1) | down-regulated | interaction | We found that expression of both miR-141 and MEG3 was significantly reduced in GC compared with levels in matched nonmalignant tissues. Positive correlation between miR-141 and MEG3 was found in both tumor tissues and control tissues. Furthermore, the over-expression of either miR-141 or MEG3 in 7901 and MKN45 cells inhibited cell proliferation and cell cycle progression and promoted cell apoptosis. E2F3 was identified as a target of miR-141, and its inhibition significantly reduced MEG3 expression. E2F3 over-expression partly reversed the changes caused by transfection of miR-141 mimic, and inhibition of miR-141 or MEG3 overrides MEG3- or miR-141-induced modulation of cell growth in GC. | 26233544 | Lnc2Cancer |
EL0861 | MEG3 | colorectal cancer | qPCR, Western blot, FCA etc. | CRC tissue | down-regulated | expression | The lower expression of MEG3 was remarkably correlated with low histological grade, deep tumor invasion, and advanced tumor node metastasis (TNM) stage. Multivariate analyses revealed that MEG3 expression served as an independent predictor for overall survival. Further experiments revealed that overexpressed MEG3 significantly inhibited CRC cell proliferation both in vitro and in vivo. MEG3 is involved in the development and progression of colorectal cancer by regulating cell proliferation and shows that MEG3 may be a potential diagnostic and prognostic target in patients with colorectal cancer. | 25636452 | Lnc2Cancer |
EL0861 | MEG3 | clear cell renal cell carcinoma | qPCR, Western blot, FCA etc. | ccRCC tissue, cell lines (786-0, SN1) | down-regulated | interaction | The results showed that MEG3 was downregulated in RCC tissues and RCC cell lines. Overexpression of MEG3 could reduce the expression of Bcl-2 and procaspase-9 proteins, enhance the expression of cleaved caspase-9 protein, and promote the release of cytochrome c protein to cytoplasm. Additionally, Bcl-2 mRNA level was declined by MEG3 overexpression. It was concluded that MEG3 induces the apoptosis of RCC cells possibly by activating the mitochondrial pathway. | 26223924 | Lnc2Cancer |
EL0861 | MEG3 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (SGC-7901, BGC-823, GES-1 etc.) | down-regulated | N/A | We examined the expression of MEG3 in 52 gastric cancer samples using quantitative qPCR and found the down-regulation of MEG3 in both gastric cancer tissues and cell lines. The positive correlation of MEG3 and miR-148a was further confirmed in SGC-7901 and BGC-823 gastric cancer cell lines. Hypermethylation of MEG3 differentially methylated regions was identified by methylation-specific PCR, and MEG3 expression was increased with the inhibition of methylation with siRNA to DNMT-1 in gastric cancer cells. In addition, transfection of MEG3 siRNA into gastric cancer cells diminished the suppression of proliferation induced by overexpression of miR-148a. | 24515776 | Lnc2Cancer |
EL0861 | MEG3 | cervical cancer | qPCR, Western blot, knockdown etc. | cervical cancer, cell lines (HeLa, CaSki) | down-regulated | interaction | We observed that MEG3 was downregulated in cervical cancer tissues, compared to the adjacent normal tissues, and was negatively related with FIGO stages, tumor size, lymphatic metastasis, HR-HPV infection and the expression of homo sapiens microRNA-21 (miR-21). Furthermore, we focused on the function and molecular mechanism of MEG3, finding that overexpression of MEG3 reduced the level of miR-21-5p expression, causing inhibition of proliferation and increased apoptosis in cervical cancer cells. In summary, our findings indicate that MEG3 function as a tumor suppressor by regulating miR-21-5p, resulting in the inhibition of tumor growth in cervical cancer. | 26574780 | Lnc2Cancer |
EL0861 | MEG3 | prostate cancer | qPCR, Western blot, knockdown, Flow cytometry assay etc. | prostate cancer tissue, cell lines (PC3, Du145) | down-regulated | interaction | MEG3 decreased significantly in prostate cancer tissues relative to adjacent normal tissues. MEG3 inhibited intrinsic cell survival pathway in vitro and in vivo by reducing the protein expression of Bcl-2, enhancing Bax and activating caspase 3. We further demonstrated that MEG3 inhibited the expression of cell cycle regulatory protein Cyclin D1 and induced cell cycle arrest in G0/G1 phase. | 26610246 | Lnc2Cancer |
EL0861 | MEG3 | cervical cancer | qPCR, Western bolt etc. | cervical cancer tissue, cell lines (HeLa, C-33A, HCC94 etc.) | down-regulated | N/A | qPCR results showed high expression levels of MEG3 in non-neoplastic tissues, but markedly lower levels in cancer tissues. Ectopic expression of MEG3 inhibited the proliferation of human cervical carcinoma cells HeLa and C-33A in vitro. On the other hand, knockdown of MEG3 promoted the growth of well-differentiated cervical carcinoma HCC94 cells. Further investigation into the mechanisms responsible for the growth inhibitory effects revealed that overexpression of MEG3 resulted in the induction of G2/M cell cycle arrest and apoptosis. | 23790166 | Lnc2Cancer |
EL0861 | MEG3 | gastric cancer | qPCR, Western bolt, knockdown etc. | gastric cancer tissue, cell lines (SGC7901, AGS, MGC803, MKN45, BGC823 etc.) | down-regulated | expression | Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. | 24006224 | LncRNADisease Lnc2Cancer |
EL0861 | MEG3 | osteosarcoma | quantitative real-time PCR (qRT-PCR) | osteosarcoma tissues | down-regulated | expression | The expression of lncRNA MEG3 was associated with clinical stage and istant metastasis (P<0.05). Kaplan-Meier analysis showed that patients with low lncRNA MEG3 expression had a shorter overall survival (log-rank test, P<0.05). Furthermore, multivariate analysis revealed that decreased expression of lncRNA MEG3, advanced clinical stage and distant metastasis were all independent predictors to overall survival of osteosarcoma patients. Downregulation of lncRNA MEG3 was associated with poor overall survival of osteosarcoma. LncRNA MEG3 could be a useful biomarker for progression and prognosis of osteosarcoma. | 26823857 | |
EL0861 | MEG3 | type 2 diabetes mellitus | real-time PCR, western blotting | High-fat diet mice, ob/ob mice and mice primary hepatocytes | up-regulated | interaction | MEG3 interference could reverse the up-regulation of triglyceride as well as impaired glucose tolerance and down-regulation of glucogen content in high-fat diet mice or ob/ob mice. Upregulation of lncRNA MEG3 enhances hepatic insulin resistance via increasing foxO1 expression, suggesting that MEG3 may be a potential target and therapeutic strategy for diabetes. | 26603935 | |
EL0861 | MEG3 | osteoarthritis | RT-PCR | articular cartilage samples from 20 Osteoarthritis (OA) patients | down-regulated | expression | Maternally expressed gene 3 (MEG3) is a maternally expressed lncRNA and may function as a tumor suppressor by inhibiting angiogenesis. The results show that human MEG3 is significantly downregulated in OA patients compared to normal cartilage samples. MEG3 may be involved in OA development through the regulation of angiogenesis。 | 26090403 | |
EL0862 | Meg3 | diabetes mellitus | MEG3 knockdown | STZ-induced diabetic mice | N/A | N/A | knockdown also regulates retinal endothelial cell proliferation, migration, and tube formation in vitro | 26845358 | |
EL0862 | Meg3 | non-functioning pituitary adenoma | Quantitative RT-PCR immunohistological | Meg3 knockout mice | up-regulated | expression | Meg3 may play an important role in control of vascularization in the brain and may function as a tumor suppressor in part by inhibiting angiogenesis | 20392836 | |
EL0864 | MESTIT1 | Silver-Russell syndrome | N/A | N/A | N/A | N/A | Association | 12746419 | LncRNADisease |
EL0867 | MHRT | acute myocardial infarction | knockdown | the blood from acute myocardial infarction (AMI) patients, neonatal rat cardiac myocytes injury induced by H2O2 | up-regulated | expression | Knockdown of MHRT led to significant more apoptotic cells than the non-target control ((**) p<0.01), indicating that the lncRNA MHRT is a protective factor for cardiomyocyte and the plasma concentration of MHRT may serve as a biomarker for myocardial infarction diagnosis in humans AMI. | 26759697 | |
EL0868 | Mhrt | heart hypertrophy | Northern blot and in situ Hybridization,ChIP–qPCR | N/A | N/A | interaction | Pathological stress activates the Brg1-Hdac-Parp chromatin repressor complex to inhibit Mhrt transcription in the heart. Such stress-induced Mhrt repression is essential for cardiomyopathy to develop. | 25119045 | |
EL0869 | MIAT | myocardial infarction | N/A | N/A | N/A | mutation | In vitro functional analyses revealed that the minor variant of one SNP in exon 5 increased transcriptional level of MIAT. Moreover, unidentified nuclear protein(s) bound more intensely to risk allele than non-risk allele. These results indicate that the altered expression of MIAT by the SNP may play some role in the pathogenesis of MI. | 17066261 | LncRNADisease |
EL0869 | MIAT | myocardial infarction | N/A | N/A | N/A | mutation | SNPs associated with myocardial infarction localized to a haplotype block that encompassed the last 3 exons of MIAT. | 20951849 | LncRNADisease |
EL0869 | MIAT | drug abuse | N/A | N/A | N/A | expression | MIAT turned out to be one of the top twenty-five, of nearly 39,000, transcripts differentially expressed in the nucleus accumbens,a midbrain region pivotal in drug abuse, in a case-control study of human heroin and cocaine abusers. | 20951849 | LncRNADisease |
EL0869 | MIAT | heroin abuse | N/A | N/A | N/A | expression | The lncRNA MIAT is upregulated in heroin abusers. | 21128942 | LncRNADisease |
EL0869 | MIAT | myocardial infarction | N/A | N/A | N/A | mutation | MIAT lincRNA Variants Confer Susceptibility to Myocardial Infarction | 23104877 | LncRNADisease |
EL0869 | MIAT | schizophrenia | N/A | N/A | N/A | expression | Finally, we show that Gomafu is downregulated in post-mortem cortical gray matter from the superior temporal gyrus in SZ. | 23628989 | LncRNADisease |
EL0869 | MIAT | myocardial infarction | N/A | N/A | N/A | regulation | A myocardial infarction-associated transcript (MIAT), also known as RNCR2 or Gomafu, is a long intergenic non-coding RNA that presents many genetic variants implicated in different processes. A large scale case-control association study regarding cardiovascular disease demonstrates that a MIAT variant (rs2301523) confers susceptibility to myocardial infarction. | 24113581 | LncRNADisease |
EL0869 | MIAT | cancer | N/A | N/A | N/A | regulation | Another lncRNA serving as oncogene is retinal noncoding RNA 2 (RNCR2). | 24757675 | LncRNADisease |
EL0869 | MIAT | acute myocardial infarction | N/A | N/A | N/A | N/A | Patients with ST-segment-elevation MI had lower levels of myocardial infarction-associated transcript (P<0.001)when compared with patients with non-ST-segment-elevation | 25035150 | LncRNADisease |
EL0869 | MIAT | diabetes mellitus-induced microvascular dysfunction | qPCR, RIP | diabetic retinas and endothelial cells cultured in high glucose medium | up-regulated | expression | This study highlights the involvement of lncRNA-MIAT in pathological angiogenesis and facilitates the development of lncRNA-directed diagnostics and therapeutics against neovascular diseases. | 25587098 | |
EL0869 | MIAT | paranoid schizophrenia | two-stage association analysis | sample from patients with paranoid schizophrenia | N/A | expression | Long non-coding RNAs (LncRNAs) are involved in multiple processes critical to normal cellular function and dysfunction of lncRNA MIAT may contribute to the pathophysiology of schizophrenia. The present studies showed that lncRNA MIAT was a novel susceptibility gene for paranoid schizophrenia in the Chinese Han population. | 26004688 | |
EL0870 | Miat | neuropsychiatric disorders | RNA-seq, qRT-PCR, knockdown, ChIP, RIP | prefrontal cortex of adult mice | down-regulated | expression | lncRNAs plays an important role in the epigenetic regulation of adaptive behavior, and the perturbation of Gomafu may be related to anxiety and the development of neuropsychiatric disorders | 25792222 | |
EL0872 | MINA | esophageal squamous cell carcinoma | N/A | N/A | N/A | regulation | Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? | 24757675 | LncRNADisease |
EL0872 | MINA | gastric cancer | N/A | N/A | N/A | regulation | Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? | 24757675 | LncRNADisease |
EL0872 | MINA | lung cancer | N/A | N/A | N/A | regulation | Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? | 24757675 | LncRNADisease |
EL0872 | MINA | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? | 24757675 | LncRNADisease |
EL0873 | MINCR | Burkitt's lymphoma | knockdown | two MYC-inducible cell lines and a cohort of 91 B-cell lymphomas with or without genetic variants resulting in MYC overexpression | N/A | interaction | MINCR knockdown is associated with an impairment in cell cycle progression. Differential gene expression analysis after RNAi showed a significant enrichment of cell cycle genes among the genes down-regulated after MINCR knockdown. Down-regulation of Aurora kinases A and B and chromatin licensing and DNA replication factor 1 may explain the reduction in cellular proliferation observed on MINCR knockdown. | 26351698 | |
EL0874 | MIR100HG | myopia | N/A | N/A | N/A | locus | LOC399959 was identified within a 200-kb DNA encompassing rs577948. | 19779542 | LncRNADisease |
EL0874 | MIR100HG | acute megakaryoblastic leukemia | qPCR etc. | blood, cell lines (CMK, Meg-01, K562, HT1080 and 293 T etc.) | up-regulated | N/A | Here we report that lncRNAs MONC and MIR100HG are highly expressed in AMKL blasts. The transcripts were mainly localized in the nucleus and their expression correlated with the corresponding miRNA clusters. Knockdown of MONC or MIR100HG impeded leukemic growth of AMKL cell lines and primary patient samples. Our study reveals an unprecedented function of lncRNAs MONC and MIR100HG as regulators of hematopoiesis and oncogenes in the development of myeloid leukemia. | 25027842 | Lnc2Cancer |
EL0877 | MIR155HG | chronic lymphocytic leukemia | N/A | N/A | N/A | Interaction | MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. | 21296997 | LncRNADisease |
EL0877 | MIR155HG | glioma | qPCR etc. | cell lines(U251, U87) | down-regulated | expression | MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. | 25645334 | Lnc2Cancer |
EL0878 | MIR17HG | cancer | N/A | N/A | N/A | locus | Aurora kinase A induces miR-17-92 cluster through regulation of E2F1 transcription factor. | 20300951 | LncRNADisease |
EL0878 | MIR17HG | syndromic developmental defect | N/A | N/A | N/A | locus | Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-17~92 polycistronic miRNA cluster, in individuals with microcephaly, short stature and digital abnormalities. | 21892160 | LncRNADisease |
EL0878 | MIR17HG | diffuse large B-cell lymphoma | qPCR, Northern blot etc. | cell lines (OCI-Ly4, OCI-Ly7, OCI-ly8 etc.) | up-regulated | locus | C13orf25 (MIR17HG) is a target for 13q31-q32 amplification in malignant lymphoma. | 15126345 | LncRNADisease Lnc2Cancer |
EL0879 | MIR21 | laryngeal squamous cell carcinoma | N/A | N/A | N/A | N/A | The expression of exosomal miR-21 and HOTAIR was significantly higher in patients with laryngeal squamous cell carcinomaLSCC than those with vocal cord polyps; The patients with lymph node metastasis had higher serum exosomal miR-21 and HOTAIR expressions than those without. | 25099764 | LncRNADisease Lnc2Cancer |
EL0880 | MIR31HG | breast cancer | qPCR etc. | cell line (MCF10A) | down-regulated | epigenetics | miR-31 and its host gene lncRNA LOC554202 (MIR31HG) are regulated by promoter hypermethylation in triple-negative breast cancer.Both miR-31 and the host gene LOC554202 are down-regulated in the TNBC cell lines of basal subtype and over-expressed in the luminal counterparts. | 22289355 | LncRNADisease Lnc2Cancer |
EL0880 | MIR31HG | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MDA-MB-231, MDA-MB-435S etc.) | up-regulated | regulation | Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells. | 24631686 | LncRNADisease Lnc2Cancer |
EL0880 | MIR31HG | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (SGC7901, BGC823, MGC803, MKN45, GES-1) | down-regulated | interaction | We found that MIR31HG expression is decreased in gastric cancer tissues and associated with larger tumor size and advanced pathological stage. Patients with lower MIR31HG expression had a relatively poor prognosis. Furthermore, ectopic over-expression of MIR31HG could inhibit gastric cancer (GC) cell proliferation both in vitro and in vivo, while knockdown of MIR31HG by small interfering RNA (siRNA) promoted cell proliferation in GC cells partly via regulating E2F1 and p21 expression. | 26692098 | Lnc2Cancer |
EL0880 | MIR31HG | colorectal cancer | qPCR, Western blot, knockdown, IHC, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, DLD1, SW480, RKO, HT-29) | down-regulated | interaction | LOC554202 was significantly downregulated in cancerous tissues and CRC cell lines compared with adjacent normal tissue and a normal human intestinal epithelial cell line. Low LOC554202 expression was closely associated with advanced pathologic stage and a larger tumor size. The overexpression of LOC554202 decreased the cell proliferation and induced apoptosis in vitro and hindered tumorigenesis in vivo. LOC554202 regulated cell apoptosis partly through the activation of specific caspase cleavage cascades. | 26362196 | Lnc2Cancer |
EL0881 | MIR4435-2HG | lung cancer | microarray, qRT-PCR | lung cancer tissues and A549 cell lines | up-regulated | expression | We observed a significant reduction in cell viability in lung cancer cells and a slow growth in the tumorigenesis following AK001796 knockdown. We also found that AK001796 knockdown caused a cell-cycle arrest, with significant increases in the percentage of cells in G0/G1 in lung cancer cells. Reduced lncRNA AK001796 level potentially impaired the inhibitory effect of resveratrol on cell proliferation. | 25888808 | |
EL0882 | MIR7-3HG | liver cancer | microarray, qPCR etc. | liver cancer tissue, cell lines (Huh7, Bel7402, Bel7721, HepG2 etc.) | down-regulated | N/A | Compared with normal human hepatocytes and adjacent noncancerous tissues, uc002mbe.2 expression level was significantly lower in the HCC cell lines and liver cancer tissues. The TSA-induced uc002mbe.2 expression was positively correlated with the apoptotic effect of TSA in HCC cells. Therefore, TSA-induced apoptosis of HCC cells is uc002mbe.2 dependent and reduced expression of uc002mbe.2 may be associated with liver carcinogenesis. | 23643933 | Lnc2Cancer |
EL0882 | MIR7-3HG | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Besides, another study showed that liver cancer-downregulated lncRNA uc002mbe.2 could be induced by trichostatin A (TSA) treatment and its expression is positively correlated with the apoptotic effect of TSA in HCC cells. | 24296588 | LncRNADisease |
EL0883 | MIR99AHG | acute megakaryoblastic leukemia | qPCR etc. | blood, cell lines (CMK, Meg-01, K562, HT1080 and 293 T etc.) | up-regulated | N/A | Here we report that lncRNAs MONC and MIR100HG are highly expressed in AMKL blasts. The transcripts were mainly localized in the nucleus and their expression correlated with the corresponding miRNA clusters. Knockdown of MONC or MIR100HG impeded leukemic growth of AMKL cell lines and primary patient samples. Our study reveals an unprecedented function of lncRNAs MONC and MIR100HG as regulators of hematopoiesis and oncogenes in the development of myeloid leukemia. | 25027842 | Lnc2Cancer |
EL0884 | Mira | mixed lineage leukemia 1 | N/A | mouse embryonic stem cells (mESC) | N/A | N/A | the long, noncoding RNA (lncRNA) Mistral (Mira) activates transcription of the homeotic genes Hoxa6 and Hoxa7 in mouse embryonic stem cells (mESC) by recruiting MLL1 to chromatin. | 21925392 | |
EL0885 | MKRN3-AS1 | Prader-Willi syndrome | N/A | N/A | N/A | epigenetics | ZNF127 and ZNF127AS are imprinted genes that may be associated with some of the clinical features of the polygenic Prader-Willi syndrome. | 10196367 | LncRNADisease |
EL0932 | MNX1-AS1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
EL0932 | MNX1-AS1 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
EL0933 | MR1 | Loeys-Dietz syndrome (LDS) | RT-PCR | aortic aneurysm patients | differential expression | interaction | LncRNA AK056155 was differentially expressed in peripheral blood circulating endothelial cells between normal patients and LDS patients by bioinformatics. AK056155 was also overexpressed in aortic aneurysm patients by RT-PCR. | 26617788 | |
EL0934 | MRAK052686 | Nonalcoholic fatty liver disease | N/A | N/A | N/A | N/A | Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. MRAK052686, was found strongly correlated with the antioxidant factor Nrf2, and both genes were down-regulated by the steatotic liver. The reduced expression of MRAK052686 and Nrf2 was completely reversed by BBR treatment, suggesting a new mechanism accounting for the therapeutic effect of BBR. | 25623289 | LncRNADisease |
EL0937 | MSUR1 | amyotrophic lateral sclerosis | 3 RACE,Northern blot ,Western blot | nontransgenic (strain B6SJLF1/J) mice | N/A | expression | In vitro expression experiments show that MSUR1 is able to rescue SOD1(G93A)-mediated cell death. Expression of MSUR1 significantly reduces SOD1(G93A)-induced free radical levels and oxidative damage. Further, MSUR1 can reduce hydrogen peroxide-mediated cytotoxicity. MSUR1 does not encode a protein, suggesting its role as a functional noncoding RNA | 17957031 | |
EL0940 | MT1DP | liver cancer | qPCR, Western blot, Luciferase reporter assay etc. | cell lines (SMMC-7721, Bel-7402, Huh7, HepG2, DLD-1, LS174T) | down-regulated | interaction | Overexpression of MT1DP resulted in reduced cell proliferation and colony formation in soft agar, but increased apoptosis in liver cancer cells, whereas knockdown of this lncRNA had the opposite effetc, indicating that MT1DP acts as a tumor suppressor. Furthermore, MT1DP was revealed as a negative regulator of Alfa-fetoprotein (AFP), a classic liver cancer tumor marker, through inhibiting protein synthesis of Forkhead box A1 (FoxA1), an important transcription factor in liver development and cancer progression. | 25261601 | Lnc2Cancer |
EL0950 | MVIH | hepatocelluar carcinoma | N/A | N/A | N/A | regulation | Dr. Yuan et al. found that lncRNA-MVIH could promote tumor growth and intrahepatic metastasis by contributing to active angiogenesis both?in vitro?and?in vivo?through the inhibition of phosphoglycerate kinase 1 (PGK1) secretion | 24757675 | LncRNADisease |
EL0950 | MVIH | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Yuan et al discovered that the lncRNA MVIH (long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma) was overexpressed in hepatocellular carcinoma. | 24829860 | LncRNADisease |
EL0950 | MVIH | hepatocelluar carcinoma | qPCR etc. | HCC tissues | up-regulated | N/A | In this study, we found that lncRNA MVIH was generally overexpressed in HCC. In a cohort of 215 HCC patients, the overexpression of MVIH was associated with frequent microvascular invasion and a higher tumor node metastasis stage as well as decreased recurrence-free survival (RFS) and overall survival. We also found that MVIH could promote tumor growth and intrahepatic metastasis by activating angiogenesis in mouse models. Subsequent investigations indicated that MVIH could activate tumor-inducing angiogenesis by inhibiting the secretion of phosphoglycerate kinase 1(PGK1). | 22706893 | Lnc2Cancer |
EL0950 | MVIH | breast cancer | qPCR, knockdown, Flow cytometry assay etc. | breast cancer tissue, cell lines (MDA-MB-231, MCF-7, T47D, BT-549, UACC-812) | up-regulated | interaction | Our research revealed that the expression levels of MVIH in breast cancer tissues were higher than in adjacent noncancerous tissues, and high MVIH expression was correlated with Ki67 expression. Moreover, breast cancer patients with high MVIH expression levels showed poor overall survival and disease-free survival. Multivariate analysis results indicated that MVIH was an independent prognostic factor in breast cancer. In addition, upregulated MVIH expression levels promoted cell proliferation and cell cycle, and inhibited cell apoptosis, while reduced MVIH expression showed the converse. | 26555546 | Lnc2Cancer |
EL0950 | MVIH | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC tissue, cell lines (A549, SPC-A1, NCI-H1975, H1299 etc.) | up-regulated | regulation | Long?non-coding?RNA?MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. | 24793017 | LncRNADisease Lnc2Cancer |
EL0950 | MVIH | microvascular invasion in hepatocellular carcinoma | real-time polymerase chain reaction (PCR), Luciferase reporter assay and RNA immunoprecipitation experiment | tumor tissue of HCC patients and in HCC cells, including SMMC7721 and HepG2 cells. | up-regulated | expression | Si-MVIH inhibited HCC cell viability and promoted cell apoptosis, but this effect was reversed by miR-199a inhibitor. In nude mice with transplantation, the tumor volume was reduced by si-MVIH, and miR-199a inhibitor canceled this decrease. | 26347410 | |
EL0951 | MYCNOS | neuroblastoma | qPCR, Western blot etc. | neuroblastoma tissue | up-regulated | expression | Both DeltaMYCN and MYCNOS are expressed in all NBs examined. In NBs with MYCN-amplification, these transcripts are significantly higher expressed. the ratio of MYCNOS:MYCN expression is directly correlated with NB disease stage (p = 0.007). In the more advanced NB stages and NBs with MYCN-amplification, relatively more MYCNOS is present as compared to MYCN. Expression of the antisense gene MYCNOS might be relevant to the progression of NB. | 19615087 | LncRNADisease Lnc2Cancer |
EL0952 | MYCNUT | neuroblastoma | qPCR, knockdown etc. | neuroblastoma tissue | up-regulated | N/A | The lncUSMycN gene was coamplified with MYCN in 88 of 341 human neuroblastoma tissues. lncUSMycN RNA bound to the RNA-binding protein NonO, leading to N-Myc RNA upregulation and neuroblastoma cell proliferation. High levels of lncUSMycN and NonO expression in human neuroblastoma tissues independently predicted poor patient prognoses. Treatment with antisense oligonucleotides targeting lncUSMycN in neuroblastoma-bearing mice statistically significantly hindered tumor progression. | 24906397 | Lnc2Cancer |
EL0954 | MYHAS | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
EL0955 | MYLK-AS1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | down-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL0956 | n335550 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | down-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0957 | n340790 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0958 | n386477 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL0959 | NALT1 | pediatric T cell acute lymphoblastic leukemia | CCK8 assay and EDU stain, western blot | pediatric T cell acute lymphoblastic leukemia cells | N/A | interaction | Increased expression of NALT dramatically promoted cell proliferation in cell lines via CCK8 assay and EDU stain. Gal4-λN/BoxB reporter system revealed that the nuclear located NALT could function as a transcription activator which caused an activation of NOTCH signal pathway as confirmed by western blot. | 26330272 | |
EL0960 | NAMA | papillary thyroid carcinoma | qPCR, knockdown, RIP, FCA etc. | PTC tissue, cell line (IHH-4) | down-regulated | expression | The expression of BANCR was significantly up-regulated while PTCSC3 and NAMA were significantly down-regulated in papillary thyroid carcinoma (PTC) compared to that in normal tissue. | 26323637 | Lnc2Cancer |
EL0960 | NAMA | papillary thyroid carcinoma | qPCR, Western blot, Northern blot, knockdown etc. | PTA tissue tissue, cell lines (NPA87, K1, K2 etc.) | down-regulated | expression | Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. | 17415708 | LncRNADisease Lnc2Cancer |
EL0961 | NBAT1 | breast cancer | microarray, qPCR, Western blot, RIP, ChIP etc. | cell lines (MCF-7, T47D, ZR75-1, BT-474, MDA-MB-453, BT-549, SK-BR-3 etc.) | down-regulated | interaction | Here, we report that NBAT1 is down-regulated in various types of cancer. Particularly, reduced NBAT1 in breast cancer is associated with tumor metastasis and poor patient prognosis. In vitro, ectopic NBAT1 inhibits migration and invasion of breast cancer cells. Mechanistic study shows that NBAT1 is associated with PRC2 member EZH2 and regulates global gene expression profile. Among them, DKK1 (dickkopf WNT signaling pathway inhibitor 1) is found to be regulated by NBAT1 in a PRC2 dependent manner, and is responsible for NBAT1's effects in inhibiting migration and invasion of breast cancer cells. | 26378045 | Lnc2Cancer |
EL0961 | NBAT1 | neuroblastoma | N/A | N/A | N/A | N/A | The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Loss of NBAT-1 increases cellular proliferation and invasion. | 25517750 | LncRNADisease |
EL0961 | NBAT1 | clear cell renal cell carcinoma | qPCR, knockdown etc. | ccRCC tissue, cell lines (786-O, ACHN, Caki-1 etc.) | down-regulated | expression | NBAT-1 expression is significantly decreased in ccRCC tissues and renal cancer cells compared with adjacent normal tissues and normal human proximal tubule epithelial cell line HK-2, and its low level is associated with advanced features and poor prognosis. NBAT-1 is a novel molecular correlated with ccRCC progression and it may represent a prognostic biomarker and therapeutic target in renal cancer diagnosis and treatment. | 26097558 | Lnc2Cancer |
EL0962 | NBR2 | cancer | N/A | N/A | down-regulated | interaction | involving checked cell cycling, altered apoptosis/autophagy response, and tumor development in vivo | 26999735 | |
EL0963 | ncC11orf49 | renal cell carcinoma | microarray, qPCR, Western blot etc. | RCC tissue | up-regulated | N/A | Four lncRNAs mapping to intronic regions, namely ncC11orf49, ncHDAC5, ncRAB31 and ncSRPK1, showed a significant (p <0.05) differential expression between tumor and nontumor paired samples as measured by qPCR. | 24238219 | Lnc2Cancer |
EL0964 | ncHDAC5 | renal cell carcinoma | microarray, qPCR, Western blot etc. | RCC tissue | up-regulated | N/A | Four lncRNAs mapping to intronic regions, namely ncC11orf49, ncHDAC5, ncRAB31 and ncSRPK1, showed a significant (p <0.05) differential expression between tumor and nontumor paired samples as measured by qPCR. | 24238219 | Lnc2Cancer |
EL0965 | ncNRFR | colorectal cancer | qPCR, Northern bolt, in vitro knockdown etc. | colonic epithelial cell tumor tissue | up-regulated | N/A | Stable overexpression of ncNRFR in non-transformed, conditionally immortalized mouse colonocytes results in malignant transformation, as determined by growth in soft agar and formation of highly invasive tumors in nude mice. Moreover, ncNRFR appears to inhibit the function of the tumor suppressor let-7. These results suggest precise regulation of ncNRFR is necessary for proper cell growth in the colonic crypt, and its misregulation results in neoplastic transformation. | 24045012 | Lnc2Cancer |
EL0966 | ncRAB31 | renal cell carcinoma | microarray, qPCR, Western blot etc. | RCC tissue | up-regulated | N/A | Four lncRNAs mapping to intronic regions, namely ncC11orf49, ncHDAC5, ncRAB31 and ncSRPK1, showed a significant (p <0.05) differential expression between tumor and nontumor paired samples as measured by qPCR. | 24238219 | Lnc2Cancer |
EL0969 | NCRUPAR | gastric cancer | qPCR etc. | gastric cancer tissue | down-regulated | N/A | The level of ncRuPAR in gastric cancer was low, and its expression level was associated with invasion depth, lymph node metastasis, distant metastasis, tumor size, and TNM stage. These findings indicate that ncRuPAR might be a potential marker for gastric cancer diagnosis. ncRuPAR might also be a tumor suppressor because it regulates the expression of PAR-1. | 24817013 | Lnc2Cancer |
EL0969 | NCRUPAR | colorectal cancer | qPCR, Immunohistochemistry etc. | CRC tissue | down-regulated | interaction | Our results indicated that the expression of ncRuPAR was significantly downregulated in CRC compared with paired adjacent nontumor tissues, but the level of PAR-1 mRNA in cancerous tissues was significantly higher than in adjacent normal areas. The expression of ncRuPAR was significantly correlated with lymph node metastasis, distant metastasis, Duck's stage, differentiation, and TNM stage and was potentially negatively associated with the mRNA levels and EI scores of PAR-1. | 25119598 | Lnc2Cancer |
EL0970 | ncSRPK1 | renal cell carcinoma | microarray, qPCR, Western blot etc. | RCC tissue | up-regulated | N/A | Four lncRNAs mapping to intronic regions, namely ncC11orf49, ncHDAC5, ncRAB31 and ncSRPK1, showed a significant (p <0.05) differential expression between tumor and nontumor paired samples as measured by qPCR. | 24238219 | Lnc2Cancer |
EL0972 | NDM29 | neuroblastoma | N/A | N/A | N/A | expression | In humans, ndm29 maps in a genomic region whose deletion has been shown to be involved in neuroblastoma development. | 16000168 | |
EL0972 | NDM29 | neuroblastoma | qPCR etc. | cell lines (NB, NIE-115, SKNBE2 etc.) | up-regulated | expression | The synthesis of a pol III-transcribed noncoding (nc) RNA (NDM29) strongly restricts NB development by promoting cell differentiation, a drop of malignancy processes. NDM29 expression leads to NB cell differentiation. | 20581224 | LncRNADisease Lnc2Cancer |
EL0973 | NEAT1 | gastric adenocarcinoma | GAC tissues and matched adjacent normal qRT-PCR | gastric adenocarcinomas (GACs) | up-regulated | N/A | Expression of NEAT1 lncRNA was enhanced in GACs and influence GAC progression by promoting tumor growth | 26911892 | |
EL0973 | NEAT1 | gastric cancer | gastric cancer samples and cell lines by real-time PCR | gastric cancer tissues and cell lines | up-regulated | N/A | LncRNA NEAT1 was overexpressed in gastric cancer tissues and cell lines and corrected with clinical stage, histological type, lymph node metastasis, and distant metastasis | 27095450 | |
EL0973 | NEAT1 | paraspeckle disintegration | Immunoprecipitation of Ribonucleoprotein Complex,knockdown | HeLa cell | down-regulated | mutation | Successful removal of MENepsilon/beta by a refined knockdown method resulted in paraspeckle disintegration. Furthermore, the reassembly of paraspeckles disassembled by transcriptional arrest appeared to be unsuccessful in the absence of MENepsilon/beta. | 19188602 | |
EL0973 | NEAT1 | ovarian cancer | knockdown of NEAT1_1 | OC patients and OVCAR-3 cell lines | up-regulated | N/A | lncRNA NEAT1, whose expression was collaboratively controlled by HuR and miR-124-3p, could regulate ovarian carcinogenesis | 27075229 | |
EL0973 | NEAT1 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL0973 | NEAT1 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | Expression profiles of five lnc-RNAs (MEG3, HULC, HOTAIR, NEAT1, and MALAT-1) previously shown to be involved in cancer metastasis were detected by qPCR in 5 pairs of papillary thyroid cancer and 11 matched lymph node metastatic tissues. Among the five, MEG3 showed significant down-expression. Overexpression of MEG3 inhibits thyroid cancer cell migration and invasion. | 25997963 | Lnc2Cancer |
EL0973 | NEAT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL0973 | NEAT1 | nasopharyngeal carcinoma | N/A | NPC cell lines and tissues | up-regulated | N/A | significantly upregulated in NPC cell lines and tissues | 27020592 | |
EL0973 | NEAT1 | frontotemporal lobar degeneration | N/A | N/A | N/A | Interaction | Analysis of RNA binding by TDP-43 in brains from subjects with FTLD revealed that the greatest increases in binding were to the MALAT1 and NEAT-1 noncoding RNAs. | 20581224 | LncRNADisease Lnc2Cancer |
EL0973 | NEAT1 | Huntington's disease | N/A | N/A | N/A | expression | LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. | 23346095 | LncRNADisease |
EL0973 | NEAT1 | AIDS | N/A | N/A | N/A | expression | We found NEAT-1 to be one of several lncRNAs whose expression is changed by HIV-1 infection, and we have characterized its role in HIV-1 replication. | 23362321 | LncRNADisease |
EL0973 | NEAT1 | amyotrophic lateral sclerosis | N/A | N/A | N/A | regulation | The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis. | 23835137 | LncRNADisease |
EL0973 | NEAT1 | intrauterine growth restriction | N/A | N/A | N/A | expression | The long non-coding RNA NEAT-1 is increased in IUGR placentas, leading to potential new hypotheses of IUGR origin/development. | 24280234 | LncRNADisease |
EL0973 | NEAT1 | oral squamous cell carcinoma | N/A | N/A | N/A | expression | Subsequently, they confirmed that the expression levels of HOTAIR, NEAT-1 and UCA2 in metastasized samples was prominent higher than the non-metastatic samples.? | 24817925 | LncRNADisease |
EL0973 | NEAT1 | oral squamous cell carcinoma | qPCR etc. | OSCC tissues | up-regulated | N/A | We found that most of the selected transcripts (4/6) were upregulated in tumors relative to matched adjacent nonmalignant tissue. One gene, MEG-3, was downregulated in cancer compared with its adjacent nonmalignant tissue. Expression of lncRNA (HOTAIR, NEAT-1 and UCA1) was significantly higher in the samples that subsequently metastasized compared with the non-metastatic samples. By contrast, MEG-3 was downregulated in the metastatic samples. These findings suggest that the detection of lncRNAs in saliva may be used as a noninvasive and rapid diagnostic tool for the diagnosis of oral cancer. | 23292713 | Lnc2Cancer |
EL0973 | NEAT1 | non-small cell lung cancer | qPCR etc. | lung cancer tissue | up-regulated | expression | The relative level of NEAT1 in NSCLC tissues was significantly elevated as compared to that of the adjacent non-cancer lung tissues. NEAT1 expression was positively correlated with patient age, lymphatic metastasis, vascular invasion and clinical TNM stage. lncRNA NEAT1 may act as a oncogene, which plays an important role in the tumorigenesis and deterioration of human NSCLC. | 25854373 | Lnc2Cancer |
EL0973 | NEAT1 | hepatocelluar carcinoma | qPCR etc. | HCC tissue | up-regulated | interaction | Our results revealed that NEAT1 appeared to have higher expression in the HCC tissues, compared with the adjacent non-cancerous liver tissues. High levels of NEAT1 promoted the clinical features of HCC, including the number of tumor nodes, metastasis, clinical TNM stage, the status of portal vein tumor embolus, vaso-invasion and the infiltration of tumor cells. Additionally, high NEAT1 expression levels were significantly associated with the expression level of MDTH, NM23 and MALAT1 | 26191242 | Lnc2Cancer |
EL0973 | NEAT1 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | expression | Results showed that NEAT1 expression in colorectal cancer was up-regulated in 72.0% (172/239) cases compared with corresponding normal counterparts, and related to tumor differentiation, invasion, metastasis and TNM stage. | 26314847 | Lnc2Cancer |
EL0973 | NEAT1 | glioma | qPCR etc. | glioma tissue | up-regulated | expression | In our results, the relative level of NEAT1 expression was higher in cancer tissues compared with adjacent noncancerous tissues (p < 0.001). High NEAT1 expression was observed to be closely correlated with larger tumor size (p = 0.023), higher WHO grade (p = 0.005), and recurrence (p = 0.011). | 26582084 | Lnc2Cancer |
EL0973 | NEAT1 | breast cancer | qPCR, ISH etc. | cell lines (MCF-7, MDA-MB-231, MDAMB-468) | up-regulated | expression | Induction of NEAT1 in hypoxia also leads to accelerated cellular proliferation, improved clonogenic survival and reduced apoptosis, all of which are hallmarks of increased tumorigenesis. Furthermore, in patients with breast cancer, high tumor NEAT1 expression correlates with poor survival, all of which are hallmarks of increased tumorigenesis. | 25417700 | Lnc2Cancer |
EL0973 | NEAT1 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (SHEE, SHEEC) | up-regulated | expression | We found that the expression of NEAT1 was higher in ESCC tissues and cells compared with the normal counterparts. Pearson analysis showed that elevated NEAT1 levels were extraordinarily correlated with the tumor size (P=0.026), lymph node metastasis (P=0.035) and clinical stage (P=0.004). | 26609486 | Lnc2Cancer |
EL0973 | NEAT1 | acute promyelocytic leukemia | qPCR, Western blot etc. | blood, cell lines (NB4, NB4-R2, U937-PR9) | down-regulated | expression | We found that NEAT1 is significantly repressed in de novo APL samples compared with those of healthy donors. We further provide evidence that NEAT1 expression was repressed by PML-RAR抅 Furthermore, significant NEAT1 upregulation was observed during all-trans retinoic acid (ATRA)-induced NB4 cell differentiation. | 25245097 | Lnc2Cancer |
EL0973 | NEAT1 | Burkitt's lymphoma | qPCR, Western blot, knockdown etc. | blood | up-regulated | interaction | NEAT1 expression levels were validated by qPCR, demonstrating high baseline expression (average Cp = 21.3), and confirming p53-dependent induction . lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma. | 25971364 | Lnc2Cancer |
EL0973 | NEAT1 | chronic lymphocytic leukemia | qPCR, Western blot, knockdown etc. | blood | up-regulated | expression | NEAT1 expression levels were validated by qPCR, demonstrating high baseline expression (average Cp = 21.3), and confirming p53-dependent induction .lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma. | 25971364 | Lnc2Cancer |
EL0973 | NEAT1 | lung cancer | qRT-PCR | lung carcinoma cell lines | N/A | expression | Our data indicate that miR-449a may function as a suppressor of lung cancer, and affects the expression of NEAT1 in lung cancer cells. | 25818739 | |
EL0973 | NEAT1 | non-small-cell lung cancer | qRT-PCR | patients suffering from non-small-cell lung cancer (NSCLC) | up-regulated | expression | N/A | 26448925 | |
EL0973 | NEAT1 | obesity | reexpression | adipocyte-derived stem cells (ADSCs) isolated from wild-type and microRNA 140 (miR-140) knockout mice | N/A | expression | MiR-140 knockout ADSCs have dramatically decreased adipogenic capabilities associated with downregulation of NEAT1 expression. Reexpression of NEAT1 in miR-140 knockout ADSCs is sufficient to restore their ability to undergo differentiation. | 26457124 | |
EL0973 | NEAT1 | prostate cancer | RNA-seq, qPCR, ChIP etc. | prostate cancer tissue, cell lines (LnCaP, PC3) | up-regulated | expression | Among putatively ERa-regulated intergenic long non-coding RNAs (lncRNAs), we identified nuclear enriched abundant transcript 1 (NEAT1) as the most significantly overexpressed lncRNA in prostate cancer. Prostate cancer cells expressing high levels of NEAT1 were recalcitrant to androgen or AR antagonists. NEAT1 drives oncogenic growth by altering the epigenetic landscape of target gene promoters to favour transcription. | 25415230 | Lnc2Cancer |
EL0974 | Neat1 | infertility | N/A | N/A | N/A | N/A | Neat1 knockout (KO) mice stochastically fail to become pregnant despite normal ovulation. Unilateral transplantation of wild-type ovaries or the administration of progesterone partially rescued the phenotype, suggesting that corpus luteum dysfunction and concomitant low progesterone were the primary causes of the decreased fertility. In contrast to the faint expression observed in most of the adult tissues, Neat1 was highly expressed in the corpus luteum, and the formation of luteal tissue was severely impaired in nearly half of the Neat1 KO mice | 25359727 | LncRNADisease |
EL0977 | NKILA | nasopharyngeal carcinoma | microarray, qPCR, knockdown etc. | nasopharyngeal carcinoma tissue, cell lines (CNE-2 etc.) | up-regulated | expression | Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294008) were confirmed by qPCR. | 24379026 | LncRNADisease Lnc2Cancer |
EL0977 | NKILA | breast cancer | qPCR, knockdown, RIP etc. | breast cancer tissue | down-regulated | interaction | Importantly, NKILA is essential to prevent over-activation of NF-B pathway in inflammation-stimulated breast epithelial cells. Furthermore, low NKILA expression is associated with breast cancer metastasis and poor patient prognosis. Therefore, lncRNAs can directly interact with functional domains of signaling proteins, serving as a class of NF-B modulators to suppress cancer metastasis. | 25759022 | Lnc2Cancer |
EL0979 | NONHSAT012762 | triple-negative breast cancer | microarray, qPCR etc. | TNBC tissue | up-regulated | expression | The results demonstrated that lncRNAs NONHSAT125629 and ENST00000503938 were upregulated and that XR_250621.1 and NONHSAT012762 were down-regulated in the tumor samples compared with NT samples. These qPCR results are consistent with the microarray data. | 26078338 | Lnc2Cancer |
EL0980 | NONHSAT037832 | papillary thyroid carcinoma | qPCR etc. | PTC tissue, cell line (IHH-4, K1, B-CPAP, Nthyori 3-1) | down-regulated | expression | The results suggested that the expression level of NONHSAT037832 was significantly decreased in PTC compared with paired noncancerous tissues (P < 0.01). And, NONHSAT037832 was also significantly downregulated in two PTC cell lines (K1 and IHH-4) compared to normal thyroid follicular epithelial cell line Nthy-ori 3-1 (P < 0.01). Downregulated NONHSAT037832 was significantly associated with lymph node metastasis (P = 0.015) and tumor size (P = 0.032). | 26611646 | Lnc2Cancer |
EL0981 | NONHSAT073641 | vascular diseases | knockdown and overexpression | In vascular samples of patients with chronic thromboembolic pulmonary hypertension (CTEPH) | up-regulated | expression | N/A | 27124368 | |
EL0982 | NONHSAT123350 | renal clear cell carcinoma | qRT-PCR | renal clear cell carcinoma (RCCC) | N/A | expression | NONHSAT123350 could be involved in the pathogenesis of RCCC and its expression level was closely related to disease-free survival (DFS) and overall survival (OS) in patients without distant metastasis. | 26765468 | |
EL0983 | NONHSAT125629 | triple-negative breast cancer | microarray, qPCR etc. | TNBC tissue | down-regulated | expression | The results demonstrated that lncRNAs NONHSAT125629 and ENST00000503938 were upregulated and that XR_250621.1 and NONHSAT012762 were down-regulated in the tumor samples compared with NT samples. These qPCR results are consistent with the microarray data. | 26078338 | Lnc2Cancer |
EL0984 | NONRATT021972 | type 2 diabetes mellitus | N/A | Type 2 diabetes mellitus (T2DM) rat model, T2DM patient serum | up-regulated | interaction | MWT and TWL in T2DM rats treated with NONRATT021972 siRNA were higher compared with those in T2DM rats. NONRATT021972 siRNA treatment may suppress the upregulated expression and activation of the P2X3 receptor and reduce the hyperalgesia potentiated by the pro-inflammatory cytokine TNF-α in T2DM rats. | 26742527 | |
EL0984 | NONRATT021972 | diabetic neuropathic pain | NONRATT021972 siRNA treatment in type 2 DM rats | diabetes mellitus (DM) group and control group | up-regulated | N/A | NONRATT021972 siRNA treatment can decrease the expression levels of P2X7 mRNA and protein and inhibit the activation of satellite glial cells (SGCs) | 27107575 | |
EL0984 | NONRATT021972 | P2X7-mediated PC12 neuronal injury | PC12 cells under OGD conditions | PC12 cells | N/A | N/A | Treatment with NONRATT021972 siRNA reversed the decreased viability of PC12 cells under OGD conditions | 27100355 | |
EL0986 | NOS2 | glioblastoma | qPCR etc. | glioblastoma tissue | up-regulated | expression | anti-NOS2A is a lncRNA that is expressed in meningiomas and glioblastomas from a genomic locus that evolved by duplication of the NOS2A gene followed by internal DNA inversion. | 18820242 | LncRNADisease Lnc2Cancer |
EL0986 | NOS2 | meningioma | qPCR etc. | meningioma tissue | up-regulated | expression | anti-NOS2A is a lncRNA that is expressed in meningiomas and glioblastomas from a genomic locus that evolved by duplication of the NOS2A gene followed by internal DNA inversion. | 18820242 | LncRNADisease Lnc2Cancer |
EL0987 | np_17856 | progressive kidney injury | N/A | N/A | N/A | regulation | Real-time PCR confirmed these findings and revealed the functional link between Smad3-dependent lncRNAs np_5318/np_17856 and progressive kidney injury. | 24262754 | LncRNADisease |
EL0988 | np_5318 | progressive kidney injury | N/A | N/A | N/A | regulation | Real-time PCR confirmed these findings and revealed the functional link between Smad3-dependent lncRNAs np_5318/np_17856 and progressive kidney injury. | 24262754 | LncRNADisease |
EL0989 | NPAP1 | Angelman syndrome | N/A | N/A | N/A | expression | C15orf2 and a novel noncoding transcript from the Prader-Willi/Angelman syndrome region show monoallelic expression in fetal brain. | 17337158 | LncRNADisease |
EL0989 | NPAP1 | Prader-Willi syndrome | N/A | N/A | N/A | expression | C15orf2 and a novel noncoding transcript from the Prader-Willi/Angelman syndrome region show monoallelic expression in fetal brain. | 17337158 | LncRNADisease |
EL1006 | NPPA-AS1 | cardiovascular disease | N/A | N/A | N/A | N/A | The NPPA-AS lncRNA has been shown to be a modulator of the alternative splicing of the NPPA gene. This lncRNA thus has potential to be involved in cardiovascular disease | 22817756 | LncRNADisease |
EL1007 | NPTN-IT1 | hepatocelluar carcinoma | microarray, qPCR, RIP, RNA pulldown assay etc. | HCC tissue | down-regulated | N/A | AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. | 21769904 | Lnc2Cancer |
EL1007 | NPTN-IT1 | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Importantly, another lncRNA-LET (lncRNA low expression in tumor) is found to play a critical role in hypoxia-induced metastasis in HCC | 24296588 | LncRNADisease |
EL1007 | NPTN-IT1 | gastric cancer | qPCR etc. | gastric cancer tissue | down-regulated | expression | We found that lncRNA LET expression was markedly down-regulated in tumor tissues compared with adjacent non-tumor tissues, and associated with depth of invasion, lymph node metastasis, distant metastasis, and TNM stage. Univariate and multivariate analyses showed that low lncRNA LET expression was an independent poor prognostic factor for gastric cancer patients. | 25674261 | Lnc2Cancer |
EL1007 | NPTN-IT1 | cervical cancer | qPCR etc. | cervical cancer tissue | down-regulated | expression | The results showed that lncRNA LET expression in cervical cancer tissues was significantly down-regulated compared with the adjacent non-tumor tissues (P < 0.05). Decreased lncRNA LET expression was significantly correlated with FIGO stage, lymph node metastasis, and depth of cervical invasion (P < 0.05), but not other clinical characteristics. | 25755778 | Lnc2Cancer |
EL1007 | NPTN-IT1 | gallbladder cancer | qPCR, Western blot, FCA etc. | gallbladder cancer tissue, cell lines (GBC-SD, SGC-996, NOZ, EH-GB2) | down-regulated | expression | In the present study, an obvious down-regulation of lncRNA-LET was observed in gallbladder cancer compared to their adjacent normal tissues. Meanwhile, patients with low expression of lncRNA-LET have significantly poorer prognosis than those with high expression. We confirmed that hypoxia decreased lncRNA-LET levels in gallbladder cancer cells. Moreover, lncRNA-LET overexpression was further validated to inhibit the invasion of gallbladder cancer cells under hypoxic or normoxic conditions in vitro. We demonstrated that lncRNA-LET overexpression conferred a proliferative advantage to tumor cells under hypoxic conditions. | 25213660 | Lnc2Cancer |
EL1007 | NPTN-IT1 | lung squamous cell carcinoma | qPCR, Western blot, in vitro knockdown, RIP etc. | LSCC tissue, cell lines (QSG-7701, LO2, SMMC-7721 etc.) | down-regulated | expression | In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. | 23395002 | LncRNADisease Lnc2Cancer |
EL1007 | NPTN-IT1 | colorectal cancer | qPCR, Western blot, in vitro knockdown, RIP etc. | CRC tissue, cell lines (QSG-7701, LO2, SMMC-7721 etc.) | down-regulated | expression | Aberrant Expression of lncRNA-LET in Tumor Tissue. In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. | 23395002 | LncRNADisease Lnc2Cancer |
EL1007 | NPTN-IT1 | hepatocelluar carcinoma | qPCR, Western blot, in vitro knockdown, RIP etc. | HCC tissue, cell lines (QSG-7701, LO2, SMMC-7721 etc.) | down-regulated | expression | In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. | 23395002 | LncRNADisease Lnc2Cancer |
EL1007 | NPTN-IT1 | nasopharyngeal carcinoma | qPCR, Western blot, knockdown etc. | NPC tissue, cell lines (CNE2, HNE2) | down-regulated | interaction | We found that lncRNA-LET was significantly downregulated in nasopharyngeal carcinoma (NPC) tissues compared with corresponding normal tissues. Decreased LET expression is significantly correlated with advanced clinical stage, larger tumor size, increased lymph node tumor burden, and poor survival of NPC patients. Knockdown of LET promoted NPC cells proliferation and inhibited cell apoptosis. Importantly, we found lncRNA-LET is transcriptional repressed by EZH2-mediated H3K27 histone methylation on the LET promoter. The expressions of EZH2 and lncRNA-LET are significantly inversely correlated in NPC tissues. | 26243049 | Lnc2Cancer |
EL1007 | NPTN-IT1 | esophageal squamous cell carcinoma | reverse transcription‑quantitative polymerase chain reaction | primary ESCC tissues and healthy tissues | down-regulated | N/A | LET was observed to inhibit the migration and invasion of ESCC cells | 26935396 | |
EL1008 | NR_038125 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL1009 | NR024118 | rheumatoid arthritis | RT-RCR, overexpression | Severe polyarticular arthritis was induced in Balb/c female mice | N/A | expression | NR024118 overexpression and interference significantly changed SOCS3 expression and NR024118 interference could reverse regulation of shikonin on SOCS3, proinflammatory cytokines, and MMPs expression level in MH7A cells. | 26640499 | |
EL1011 | NRG1 | lung cancer | qPCR etc. | lung cancer tissue | up-regulated | N/A | High expression was observed in cancer tissues, which was consistent with our previous study that NRG1 was highly expressed in lung cancer induced by nickel. NRG1 was located on chromosome 2q12, within intron2 of ADAMTS6, a disintegrin and metalloproteinase with thrombospondin motifs. And, NRG1 had a high level of homology (76 %) to rat LINE1 sequence RL1.3 (long interspersed middle repetitive DNA) | 22665269 | Lnc2Cancer |
EL1012 | NRIR | chronic hepatitis C | qRT-PCR | liver sample | up-regulated | N/A | high serum iron concentration and correlated with higher hepatic expression of lncRNA NRIR | 27125837 | |
EL1013 | NRON | Down's syndrome | N/A | N/A | N/A | expression | NRON is a lncRNA that mediates the cytoplasmic to nuclear shuttling of the NFAT transcription factor . In animal models, deregulation of the DSCR1 and DYRK1A genes act synergistically to prevent nuclear occupancy of NFATc transcription factors leading to reduced NFATc activity and to many features of DS, suggesting a potential link between NRON activity and DS pathophysiology. | 16141075 | LncRNADisease |
EL1013 | NRON | AIDS | N/A | N/A | N/A | N/A | The lncRNA NRON modulates HIV-1 replication in a NFAT-dependent manner and is differentially regulated by early and late viral proteins. Its expression was significantly altered following HIV-1 infection. Its levels were reduced by the early viral accessory protein Nef and increased by the late protein Vpu. | 25728138 | LncRNADisease |
EL1019 | OGT | colon cancer | N/A | N/A | up-regulated | N/A | HINCUT-1 supports cell proliferation specifically under hypoxic conditions and may be critical for optimal O-GlcNAcylation of proteins when oxygen tension is limiting. | 24037088 | |
EL1021 | OR3A4P | gastric cancer | microarray analysis qRT-PCR | gastric cancer cells | up-regulated | N/A | significantly associated with lymphatic metastasis; OR3A4 promoted cancer cell growth | 26863570 | |
EL1022 | ORAOV1 | nasopharyngeal carcinoma | microarray, qPCR, knockdown etc. | nasopharyngeal carcinoma tissue, cell lines (CNE-2 etc.) | up-regulated | expression | Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294009) were confirmed by qPCR. | 24379026 | LncRNADisease Lnc2Cancer |
EL1023 | OS9 | pancreatic ductal adenocarcinoma | qPCR, Western blot, Luciferase reporter assay, ELISA etc. | PDAC tissue | down-regulated | N/A | the ENST00000480739 expression level was remarkably | 25314054 | LncRNADisease Lnc2Cancer |
EL1027 | OVAAL | ovarian cancer | RNA-seq, qPCR etc. | ovarian cancer tissue | down-regulated | N/A | OVAL expression was low or absent in both normal fallopian tube (Figure S3 in File S1) and in the majority of tumors, including most cases with wide 1q amplification. However, focal amplification of the OVAL locus coincided strikingly with OVAL transcriptional activation. | 24265805 | Lnc2Cancer |
EL1028 | P14695 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1029 | P16984 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | down-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1030 | P19780 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | down-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1031 | P23099 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1032 | P24363 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1033 | P28210 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1034 | P2rx3 | type 2 diabetes mellitus | rat lncRNA array profiling | type 2 diabetic rats | up-regulated | N/A | lncRNA uc.48+ siRNA regulating the expression of P2X7 and ERK signaling in SCG. | 27118262 | |
EL1034 | P2rx3 | diabetes mellitus | reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemistry, and western blotting | diabetic rat dorsal root ganglia (DRG) Diabetes mellitus (DM) patients' serum samples | up-regulated | interaction | Uc.48+ siRNA treatment may alleviate the DNP by inhibiting the excitatory transmission mediated by the P2X3 receptor in DRG. | 26686228 | |
EL1035 | P33863 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | down-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1036 | P4091 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1037 | P6391 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1038 | P6488 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | down-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1039 | P700 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | down-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1040 | P8611 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | down-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1041 | P8725 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1042 | P8860 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1043 | P9745 | hepatocelluar carcinoma | microarray, qPCR etc. | primary HCC tissue, cell lines (MHCC97H, MHCC97L) | up-regulated | expression | We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). | 25900874 | Lnc2Cancer |
EL1044 | PACERR | cancer | ChIP, qPCR, RACE | primary human mammary epithelial cells and monocyte/macrophage cell lines | N/A | interaction | The lncRNA associates with p50, a repressive subunit of NF-κB, and occludes it from the COX-2 promoter, potentially facilitating interaction with activation-competent NF-κB p65/p50 dimers. | 24843008 | |
EL1045 | PAN | Kaposi's sarcoma | N/A | N/A | N/A | expression | KSHV infected cells express a highly abundant long noncoding transcript referred to as polyadenylated nuclear RNA (PAN RNA). | 23468496 | LncRNADisease |
EL1046 | PANDAR | breast cancer | knockdown of PANDAR | breast cancer tissues and cell lines | up-regulated | N/A | PANDAR in regulating the progression of breast cancer | 26927017 | |
EL1046 | PANDAR | cancer | N/A | N/A | N/A | expression | Another DNA damage-responsive, p53-induced lncRNA that lies upstream of p21, PANDA (P21 associated ncRNA DNA damage activated), is also implicated in the repression of pro-apoptotic genes, such as FAS and BIK, by acting as a decoy for the transcription factor NF-YA. In some cancer types, p53 mutations have been found that maintain the protein's ability to induce the PANDA pathway (and its antiapoptotic effects) while abolishing its ability to induce p21 and its promotion of cell-cycle arrest, thus leading to increased tumor cell survival (Hung et al. 2011). | 23463798 | LncRNADisease |
EL1046 | PANDAR | hepatocelluar carcinoma | qPCR, knockdown etc. | HCC tissue, cell lines (HCCLM3, Hep3B, HepG2) | up-regulated | expression | PANDAR was overexpressed in HCC tissues and cell lines. Moreover, its expression level was significantly correlated with liver cirrhosis, HBsAg, AFP, tumor nodule, vascular invasion and TNM stage. PANDAR overexpression was associated with poorer survival and shorter recurrence and served as an independent prognostic marker of patients with HCC. | 26054684 | Lnc2Cancer |
EL1046 | PANDAR | non-small cell lung cancer | qPCR, Western blot, RIP etc. | lung cancer tissue, cell lines (A549, SPC-A1, NCI-H1299, SK-MES-1 etc.) | down-regulated | interaction | In a cohort of 140 NSCLC patients, decreased PANDAR expression was negatively correlated with greater tumor size (P<0.001) and advanced TNM stage (P=0.002). Moreover, PANDAR could serve as an independent predictor for overall survival in NSCLC (P=0.015). PANDAR-mediated growth regulation is in part due to the transcriptional modulation of Bcl-2 by interacting with NF-YA, thus affecting NSCLC cell apoptosis. | 25719249 | Lnc2Cancer |
EL1046 | PANDAR | gastric cancer | Quantitative Real-time PCR | 100 paired gastric cancer tissues | up-regulated | N/A | high expression of PANDAR was correlated with depth of invasion, TNM stage and lymphatic metastasis | 26898439 | |
EL1047 | PARTICL | low-dose irradiation | In situ hybridization, surface plasmon resonance, Bromouridine tracing | samples from radiotherapy-treated patients | up-regulated | expression | Exposure to low-dose irradiation causes transiently elevated expression of the long ncRNA PARTICLE (gene PARTICLE, promoter of MAT2A-antisense radiation-induced circulating lncRNA). The interplay of PARTICLE with MAT2A implicates this lncRNA in intercellular communication and as a recruitment platform for gene-silencing machineries through triplex formation in response to irradiation. | 25900080 | |
EL1049 | PAWR | acute lymphoblastic leukemia | qPCR, Western blot, knockdown etc. | T-ALL jurkat cell | up-regulated | N/A | T-ALL-R-LncR1 was not observed in human normal tissues. However, an obvious expression was observed in some tumor tissues. T-ALL-R-LncR1 was markedly expressed in neoplastic T lymphocytes of 11 cases out of 21 children with T-ALL, indicating that T-ALL-R-LncR1 might be associated with T-ALL. T-ALL-R-LncR1 knockdown predisposed Jurkat cells to undergo pro-apoptotic factor Par-4-induced apoptosis. Further studies revealed that T-ALL-R-LncR1 knockdown facilitated the formation of a Par-4/THAP1 protein complex, resulting in the activation of caspase-3 and an increase of pro-apoptotic Smac protein in T-ALL cells | 23906015 | Lnc2Cancer |
EL1050 | PAX8-AS1 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | Measurement of lncRNA PCA3 in patient urine samples has been shown to allow more sensitive and specific diagnosis of prostate cancer than the widely used marker prostate-specific antigen (PSA). | 15245811 | LncRNADisease |
EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | The PCA3 assay is insensitive to pre-analytical factors, performs well analytically and correctly classifies a high percent of subjects with known prostate cancer status across research sites. | 18054202 | LncRNADisease |
EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa. | 18602209 | LncRNADisease |
EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | Patients with a positive biopsy showed significantly higher PCA3 values. | 20424427 | LncRNADisease |
EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | PCA3 scores were significantly lower in low-volume disease and insignificant PCa. Higher PCA3 scores were associated with aggressive disease. | 20980098 | LncRNADisease |
EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | Diagnostic marker | 24373479 | LncRNADisease |
EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | N/A | PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 2) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. | 24667321 | LncRNADisease |
EL1051 | PCA3 | prostate cancer | Northern blot etc. | prostate cancer tissue | up-regulated | expression | PCA3 is a highly prostate cancer-specific gene. | 14607216 | LncRNADisease Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | PROGENSA PCA3 assay etc. | blood, urine | up-regulated | expression | A PCA3 score threshold of 20 may have the highest utility for selecting men with clinically insignificant prostate cancer in whom active surveillance may be appropriate; a PCA3 score threshold of 50 may be used to identify men at high risk of harbouring significant prostate cancer who are candidates for RP. | 21883822 | LncRNADisease Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | Upregulation of two new PCA3 isoforms in PCa tissues improves discrimination between PCa and BPH. | 19319183 | LncRNADisease Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | PCA3 mRNA is prostate cancer specific and shows increased expression in prostate cancer. | 20114043 | LncRNADisease Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | It was found that the levels of the mRNA expression of DD3(PCA3) were significantly higher (p<0.045) in patients with PCa than in patients with benign prostatic hyperplasia. | 20332487 | LncRNADisease Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | qPCR etc. | blood | differential expression | mutation | The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region may be a risk factor for prostate cancer in the Chinese population. | 21655300 | LncRNADisease Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | qPCR, in vitro knockdown etc. | cell lines (LNCaP, PC3, RWPE-1, PrEC etc.) | up-regulated | N/A | PCA3 is a non-coding RNA (ncRNA) that is highly expressed in prostate cancer (PCa) cells, LNCaP siPCA3-transfected cells significantly inhibited cell growth and viability, and increased the proportion of cells in the sub G0/G1 phase of the cell cycle and the percentage of pyknotic nuclei, compared to those transfected with scramble siRNA (siSCr)-transfected cells. Our findings suggest that the ncRNA PCA3 is involved in the control of PCa cell survival, in part through modulating AR signaling, which may raise new possibilities of using PCA3 knockdown as an additional therapeutic strategy for PCa control. | 23130941 | Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | qPCR, Northern blot etc. | BPH, prostatic tumor tissue | up-regulated | expression | PCA3 is one of the most prostate cancer-specific genes yet described, and this makes DD3 a promising marker for the early diagnosis of prostate cancer and provides a powerful tool for the development of new treatment strategies for prostate cancer patients. | 10606244 | LncRNADisease Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | qPCR, Northern bolt etc. | prostate cancer tissue, cell lines (LNCap-AD, 22Rv1, PC-3, DU145, C4-2 etc.) | up-regulated | N/A | qPCR was used to assess the PCA3 and MALAT-1 expression levels in an additional set of 10 pairs of PCa and adjacent normal tissues. Comparing the PCA3 and MALAT-1 expression levels in the 10 paired tissue samples revealed that PCA3 and MALAT-1 were highly expressed in most of the PCa tissues. Plasma lncRNAs probably exist in the form of fragments in a stable form. MD-miniRNA enters cell culture medium at measurable levels, and MD-miniRNA derived from human PCa xenografts actually enters the circulation in vivo and can be measured to distinguish xenografted mice from controls. | 23726266 | Lnc2Cancer |
EL1051 | PCA3 | cancer | qRT-PCR | LNCaP cell | up-regulated | N/A | PCA3 silencing modulates the expression of key cancer-related genes | 26960690 | |
EL1051 | PCA3 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | up-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
EL1051 | PCA3 | prostate cancer | Sequencing etc. | prostate cancer tissue, blood(leukocytes) | up-regulated | N/A | By PCR-based cloning and sequencing in paired peripheral blood leukocytes and prostate tissues,5 PCA3 TAAA STR polymorphisms and 8 genotypes were found in both peripheral blood leukocytes and prostate tissues, the carriers with more TAAA repeats were associated with increased risk for PCa than individuals having less TAAA repeats | 25445501 | LncRNADisease Lnc2Cancer |
EL1052 | PCAT1 | prostate cancer | microarray, qPCR, Western blot, knockdown, Luciferase reporter assay etc. | prostate tissue, cell lines (Du145-derived, RWPE-derived, LNCAP-derived, PC3-derived etc.) | up-regulated | regulation | PCAT1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. | 24473064 | LncRNADisease Lnc2Cancer |
EL1052 | PCAT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL1052 | PCAT1 | prostate cancer | N/A | N/A | N/A | regulation | They described PCAT1,a novel PCa lincRNA on 8q24, in the locality of well-characterized PCa risk-related SNPs and the c-MYC oncogene. | 24146262 | LncRNADisease |
EL1052 | PCAT1 | prostate cancer | N/A | N/A | N/A | expression | Putative marker and oncogene | 24373479 | LncRNADisease |
EL1052 | PCAT1 | prostate cancer | N/A | N/A | N/A | regulation | The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. | 24531795 | LncRNADisease |
EL1052 | PCAT1 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | N/A | Our results showed that PCAT-1 expression in CRC tissues was significantly upregulated compared with the matched normal tissues and the overexpression of PCAT-1 was found in 64 % (62/81) of CRC. In addition, there was a significant association between PCAT-1 expression and distant metastasis. More important, CRC patients with PCAT-1 higher expression have shown significantly poorer overall survival than those with lower PCAT-1 expression. In conclusion, our results suggest that high expression of PCAT-1 is involved in CRC progression and could be a novel biomarker of poor prognosis in patient with colorectal cancer. | 23640607 | Lnc2Cancer |
EL1052 | PCAT1 | esophageal squamous cell carcinoma | qPCR etc. | ESCC tissue | up-regulated | interaction | The expression of PCAT-1 was significantly higher in human ESCC compared with the adjacent noncancerous tissues (70.8 %, p < 0.01), and the high level of PCAT-1 expression was significantly correlated with invasion of the tumor (p = 0.024), advanced clinical stage (p = 0.003), lymph node metastasis (p = 0.032), and poor prognosis. | 25731728 | Lnc2Cancer |
EL1052 | PCAT1 | bladder cancer | qPCR etc. | bladder cancer tissue, cell lines (T24, 5637 etc.) | up-regulated | expression | In this study, we found that PCAT-1 was up-regulated in bladder cancer compared to paired normal urothelium.PCAT-1 plays oncogenic roles. | 25934337 | Lnc2Cancer |
EL1052 | PCAT1 | prostate cancer | qPCR, Luciferase reporter assay, knockdown etc. | cell lines (LNCaP) | up-regulated | regulation | We show that PCAT-1 promotes prostate cell proliferation and that this phenotype is mediated through up-regulation of the cMyc protein (encoded by the MYC gene). Antagonism of cMyc is able to reverse PCAT-1mediated cell proliferation. We show that PCAT-1 regulates cMyc post-transcriptionally through the MYC 3' untranslated region (UTR). Further, we find a protetcive effetc of PCAT-1 on cMyc by interfering with the regulation of MYC by miR-34a. | 25425964 | Lnc2Cancer |
EL1052 | PCAT1 | non-small cell lung cancer | quantitative real-time PCR (QRT-PCR), suppression | non-small cell lung cancer cells | up-regulated | expression | PCAT-1 suppression using PCAT-1 small hairpin RNA (shRNA) with A549 cells inhibited cell proliferation, migration and invasion, while over-expression of PCAT-1 by synthetic plasmid vectors was shown to promote cell proliferation, migration and invasion. Our data suggested that PCAT-1 could play an oncogenic role in NSCLC progression. Silencing PCAT-1 is a potential novel therapeutic approach for lung cancer. | 26770456 | |
EL1052 | PCAT1 | prostate cancer | RNA-seq, qPCR, Western blot etc. | prostate cancer tissue, cell lines (VCaP, LNCaP) | up-regulated | expression | PCAT1 is markedly overexpressed in a subset of prostate cancers, particularly metastases, and may contribute to cell proliferation in these tumors. | 21804560 | LncRNADisease Lnc2Cancer |
EL1052 | PCAT1 | hepatocelluar carcinoma | the reverse transcription-quantitative polymerase chain reaction | HCC tissue samples and HepG2 and Bel‑7402 cell lines | up-regulated | N/A | Overexpression of PCAT‑1 induced synthetic plasmid vectors | 27035680 | |
EL1053 | PCAT18 | prostate cancer | microarray, qPCR, knockdown etc. | cell lines (LTL313B, LTL313H etc.) | up-regulated | expression | The most highly up-regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues (p<0.05) and up-regulated in PCa compared to 15 other neoplasms (p<0.001). | 24519926 | LncRNADisease Lnc2Cancer |
EL1054 | PCAT29 | prostate cancer | microarray, qPCR etc. | cell lines (Glutamax(Invitrogen), LNCaP, DU145 etc.) | down-regulated | N/A | PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. PCAT29 as an androgen-regulated tumor suppressor in prostate cancer. | 25030374 | Lnc2Cancer |
EL1054 | PCAT29 | prostate cancer | qPCR, Western blot etc. | cell lines (VCap, PC3M-luc, LNCaP etc.) | down-regulated | N/A | This study reveals a novel tumor suppressive locus encoding two hormone-regulated lncRNAs, DRAIC and PCAT30, that are prognostic for a wide variety of cancer types.This study reveals a novel tumor suppressive locus encoding two hormone-regulated lncRNAs, DRAICand PCAT29, that are prognostic for a wide variety of cancer types. | 25700553 | LncRNADisease Lnc2Cancer |
EL1055 | PCAT5 | prostate cancer | RNA-seq, qPCR, knockdown etc. | cell lines (PC-3, 22Rv1) | up-regulated | interaction | In vitro validation of these alterations revealed a complex integrated phenotype affecting cell growth, migration, invasion, colony-forming potential and apoptosis. Our findings reveal a key molecular determinant of differences between PC and CRPC at the level of the transcriptome. Further, they establish PCAT5 as a novel oncogenic lncRNA in ERG-positive prostate cancers, with implications for defining CRPC biomarkers and new therapeutic interventions. | 26282172 | Lnc2Cancer |
EL1056 | PCAT6 | triple-negative breast cancer | microarray, qPCR etc. | triple-negative breast cancer tissue | up-regulated | expression | We found that the expression levels of TCONS_l2_00003938, ENST00000460164, ENST00000425295, MALAT1 and HOTAIR were significantly higher in tumor tissues than non-tumor tissues, whereas there were no significant differences in the expression levels of the other 3 lncRNAs. Our study identified a set of lncRNAs that were consistently aberrantly expressed in TNBC, and these dysregulated lncRNAs may be involved in the development and/or progression of TNBC. | 25996380 | Lnc2Cancer |
EL1056 | PCAT6 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Both lncRNA showed positive correlation between gene expression and SCNA. The criteria of increasing expression from normal to primary to metastatic prostate cancer aimed to uncover lncRNA that may be important therapeutic targets for both primary and metastatic cancers. | 23728290 | Lnc2Cancer |
EL1057 | PCAT7 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Both lncRNA showed positive correlation between gene expression and SCNA. The criteria of increasing expression from normal to primary to metastatic prostate cancer aimed to uncover lncRNA that may be important therapeutic targets for both primary and metastatic cancers. | 23728290 | Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | expression | PCGEM1 was originally discovered in a genome-wide gene expression screen as a cDNA sequence with prostate cancer overexpression and highly specific localization to glandular epithelial cells. | 20951849 | LncRNADisease |
EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | regulation | One of the earliest lncRNAs described in PCa, was PCGEM1(prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). One of the earliest lncRNAs described in PCa, was PCGEM1 (prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). | 24146262 | LncRNADisease |
EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | regulation | High-risk and predictive marker Oncogene | 24373479 | LncRNADisease |
EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | N/A | PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 1) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. | 24667321 | LncRNADisease |
EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | regulation | The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). | 24713835 | LncRNADisease |
EL1058 | PCGEM1 | prostate cancer | Northern blot etc. | cell line (LNCaP) | up-regulated | N/A | A prostate-specific and prostate cancer-associated noncoding gene, PCGEM1 regulates apoptosis. | 16569192 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. | 14724589 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | The biomarkers had sensitivities ranging from 91% to 100%. Clinical specificities evaluated with the BPH tissue were the following: hTERT mRNA (93%), DD3 mRNA (57%), Survivin (29%) and PCGEM1 (14%). | 16515751 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR etc. | cell lines (PC-3, DU145 etc.) | up-regulated | Interaction | Phytosterol inhibition of PCGEM1 and cell growth and the overexpression of caveolin-1, suggests that poor disease prognosis anchors on the ability of caveolin-1 to regulate downstream oncogene(s) and apoptosis genes. | 19186008 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | Expression profiles of genes in CRPC support a role for the transcriptional activity of the PCGEM1. | 20868494 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | differential expression | mutation | We found a significantly decreased risk of PCa for rs6434568 AC and AC/AA genotype, as well as rs16834898 AC and AC/CC genotype, compared with the CC and AA genotypes, respectively. | 23459097 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR etc. | cell lines (LNCaP) | up-regulated | N/A | PCGEM1 overexpression is highly associated with prostate tumors. CGEM1 tumorigenic potential has been recently shown to be in part due to its ability to activate androgen receptor (AR). Here, we report a novel function of PCGEM1 that provides growth advantages for cancer cells by regulating tumor metabolism via c-Myc activation. PCGEM1 promotes glucose uptake for aerobic glycolysis, coupling with the pentose phosphate shunt to facilitate biosynthesis of nucleotide and lipid, and generates NADPH for redox homeostasis. | 25512540 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR, Northern blot, FISH, ISH etc. | prostate cancer tissue, cell lines (LNCaP, DU145, PC-3CaP etc.) | up-regulated | expression | PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. | 11050243 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | qPCR, RIP etc. | prostate cancer tissue,cell lines (LNCaP, LNCaP-cds1, LNCaP-cds2, CWR22Rv1 etc.), tissues (prostate tumour tissues) | up-regulated | expression | Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. | 23945587 | LncRNADisease Lnc2Cancer |
EL1058 | PCGEM1 | prostate cancer | RNA-seq, qRT-PCR | N/A | N/A | N/A | not implicated in castration resistant prostate cancer. | 24727738 | |
EL1058 | PCGEM1 | prostate cancer | RT-PCR, luciferase reporter assay, MTT assay and flow cytometry, transwell assays | LNCaP cells and noncancerous RWPE-1 prostate cells, (nu/nu) mouse model | up-regulated | interaction | We demonstrate a reciprocal negative control relationship between PCGEM1 and miR-145 that regulates both LNCaP cell proliferation and nu/nu PCa tumor growth. | 25200485 | |
EL1059 | PCNA-AS1 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Huh7, SMMC7721) | up-regulated | regulation | Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. | 24704293 | LncRNADisease Lnc2Cancer |
EL1060 | PCNCR1 | prostate cancer | N/A | N/A | N/A | N/A | Accumulating evidence indicated that prostate cancer non-coding RNA 1 (PCNCR1) lncRNA was identified in a gene deserton chromosome 8q24.2 and is associated with susceptibility to prostate cancer | 22535282 | LncRNADisease |
EL1060 | PCNCR1 | prostate cancer | N/A | N/A | N/A | N/A | PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 3) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. | 24667321 | LncRNADisease |
EL1061 | PDLIM3 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL1062 | PDZRN3-AS1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | SNP rs11128347 (C>G) in PDZRN3 is associated with African-Americans with type 2 diabetes. | 21546767 | LncRNADisease |
EL1063 | PEG10 | diffuse large B-cell lymphoma | qPCR, knockdown etc. | DLBCL tissue, cell lines (OCI-LY-3, OCI-LY-7, OCI-LY-10 etc.) | up-regulated | expression | We first found that the expression of PEG10 was upregulated in DLBCL tumorous tissues and that cell lines compared with the normal. Moreover, we illustrated that PEG10 was significantly correlated with B symptoms, IPI score, CHOP-like treatment and rituximab. | 25864113 | Lnc2Cancer |
EL1063 | PEG10 | esophageal cancer | qPCR, Western blot etc. | esophageal cancer tissue, cell lines (EC9706, KYSE150) | up-regulated | expression | LncRNA PEG10 was expressed at higher levels in esophageal cancer tissues than in adjacent non-neoplastic tissues (P<0.05). This relatively high expression was significantly associated with the occurrence of lymph node metastases (P<0.05). Apoptosis and migration rates were significantly decreased in two esophageal cancer cell lines (EC9706 and KYSE150) transfetced with si-LncRNA PEG10 (P<0.05). | 25591808 | Lnc2Cancer |
EL1067 | PICSAR | testicular embryonal carcinoma | microarray, qPCR, knockdown, Western blot, Northern blot, RIP, RNA pull-down assay etc. | testicular tissue, cell lines(NTERA-2, NCCIT, HEK293 T cell) | down-regulated | interaction | NLC1-C, also known as long intergenic non-protein-coding RNA162 (LINC00162), was down-regulated in the cytoplasm and accumulated in the nucleus of spermatogonia and primary spermatocytes in the testes of infertile men with mixed patterns of MA compared with normal control. The accumulation of NLC1-C in the nucleus repressed miR-320a and miR-383 transcript and promoted testicular embryonal carcinoma cell proliferation by binding to Nucleolin. | 26539909 | Lnc2Cancer |
EL1068 | Pinc | breast cancer | N/A | N/A | N/A | N/A | In a finding of relevance to breast cancer pathogenesis, the mammary gland lncRNA PINC, whose genomic structure is substantially different between primates and rodents has been shown to function in both cell survival and cell cycle progression. | 20951849 | LncRNADisease |
EL1069 | Pinci1-1 | late blight | Suppression subtractive hybridization (SSH),Real-time RT-PCR | N/A | N/A | N/A | N/A | 17322195 | |
EL1070 | PINK1-AS | Parkinson's disease | N/A | N/A | N/A | Interaction | Mutations in the PTEN induced putative kinase 1 (PINK1) are implicated in early-onset Parkinson's disease. Welective targeting of naPINK1 results in loss of the PINK1 splice variant in neuronal cell lines. | 17362513 | LncRNADisease |
EL1070 | PINK1-AS | glucose metabolism disorder | N/A | N/A | N/A | expression | As the name suggests, PINK1 is induced by PTEN, which is an important inhibitor of insulin signalling. PINK1 depletion has been associated with diabetes status, impaired glucose uptake in neuronal cell lines and with mitochondrial gene expression in adipocytes , raising the possibility that disruption to naPINK1 may impact on glucose metabolism. | 22817756 | LncRNADisease |
EL1071 | PISRT1 | blepharophimosis syndrome | N/A | N/A | N/A | mutation | The blepharophimosis syndrome (BPES) is driven by dysregulation of the FOXL2 gene, numerous extragenic mutations have been reported in patients. One particular deletion occurring 283 kb away from FOXL2 disrupts a lncRNA, PISRT1, that was shown by chromatin confirmation capture to physically loop with FOXL2. | 20930520 | LncRNADisease |
EL1073 | PLEC | chronic obstructive pulmonary disease | Agilent Human lncRNA + mRNA Array v2.0 system | lung tissue of smokers with COPD | down-regulated | expression | N/A | 25542208 | |
EL1074 | PMS2P5 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL1076 | POT1-AS1 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL1077 | linc-POU3F3 | glioma | qPCR etc. | glioma tissue, cell lines (T98G, A172) | up-regulated | N/A | By using real-time PCR and gain-/loss-of-function studies,the authors revealed that linc-POU3F3 levels were extraordinarily associated with the tumor WHO grade.In related biochemical assays, overexpression of linc-POU3F3 promotes cell viability and proliferation in glioma cells, whereas knockdown of linc-POU3F3 showed the opposite effect. As expected, they also found that linc-POU3F3 expression was negatively correlated with the mRNA level of POU3F3. | 25445282 | LncRNADisease Lnc2Cancer |
EL1077 | linc-POU3F3 | esophageal squamous cell carcinoma | qPCR etc. | blood (plasma and serum) | up-regulated | expression | Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients compared with normal controls.By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC (the area under the ROC curve (AUC), 0.842. | 25608466 | Lnc2Cancer |
EL1077 | linc-POU3F3 | esophageal squamous cell carcinoma | qPCR, Western blot, Luciferase reporter assay, RIP etc. | ESCC tissue | up-regulated | N/A | Levels of a lincRNA encoded by a gene located next to POU3F3 (linc-POU3F3) were significantly higher in ESCC than neighboring nontumor tissues. In RNA immunoprecipitation assays, linc-POU3F3 was associated with the EZH2 messenger RNA (mRNA). Overexpression of linc-POU3F3 in cell lines increased their proliferation and ability to form colonies, and reduced the expression of POU3F3 mRNA, whereas knockdown of linc-POU3F3 increased the levels of POU3F3 mRNA. | 24631494 | Lnc2Cancer |
EL1078 | POU5F1P4 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | N/A | POU5F1P1 was found to be the only member of the POU5F1 family to be expressed in prostate with over-expression in prostatic carcinoma compared to surrounding prostatic tissue probably because of an increased density of expressing cells. The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa. | 20017164 | Lnc2Cancer |
EL1079 | POU6F2-AS2 | oesophageal squamous cell carcinoma | N/A | N/A | N/A | N/A | DNA damage response and regulates cells survival after ionizing radiation | 27033944 | |
EL1081 | PPP3CB | pancreatic ductal adenocarcinoma | microarray, qPCR etc. | cell line (MIA PaCa-2 ) | up-regulated | expression | Differential expression | 22078386 | LncRNADisease Lnc2Cancer |
EL1082 | PRAL | hepatocelluar carcinoma | qPCR, Western blot etc. | hepatocellular carcinoma tissues | down-regulated | interaction | We found that lncRNA-PRAL could inhibit HCC growth and induce apoptosis in vivo and in vitro through p53. Subsequent investigations indicated that the three stem-loop motifs at the 5' end of lncRNA-PRAL facilitated the combination of HSP90 and p53, and thus competitively inhibited the MDM2-dependent p53 ubiquitination, resulting in the enhanced p53 stability. Additionally, in vivo lncRNA-PRAL delivery efficiently reduced the intrinsic tumors, indicating its potential therapeutic application. | 26663434 | Lnc2Cancer |
EL1083 | PRAS | colon cancer | qPCR etc. | cell lines (SNU-C4R, SNU-C5R etc.) | down-regulated | N/A | We selected three lncRNAs, snaR, BACE1AS, and PRAS, and we detected their expression by RT-qPCR using specific primer sets. SnaR and BACE1AS were significantly down-regulated in both resistant cell lines (SNU-C4R and SNU-C5R), whereas PRAS was down-regulated in SNU-C4R cells but not in SNU-C5R cells. Down-regulation of snaR decreased cell death after 5-FU treatment, which indicates that snaR loss decreases in vitro sensitivity to 5-FU. | 25078450 | Lnc2Cancer |
EL1085 | PRINS | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL1085 | PRINS | psoriasis | N/A | N/A | N/A | N/A | PRINS is a psoriasis susceptibility-related noncoding RNA gene. | 15855153 | LncRNADisease |
EL1085 | PRINS | psoriasis | N/A | N/A | N/A | expression | The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non-coding RNA, PRINS. | 20377629 | LncRNADisease |
EL1085 | PRINS | psoriasis | N/A | N/A | N/A | expression | In an effort to identify novel susceptibility factors for the hyperproliferative skin disorder psoriasis, Sonkoly et al. analyzed differential gene expression of unaffected epidermis from psoriasis patients compared to specimens from healthy subjects and identified a novel lncRNA called psoriasis susceptibility-related RNA gene induced by stress (PRINS) involved in psoriasis susceptibility | 24115003 | LncRNADisease |
EL1085 | PRINS | psoriasis | silenced with small interfering RNA (siRNA) | normal human keratinocytes (NHKs) and HaCaT cells | N/A | N/A | PRINS expression responded differentially to various stress signals and microbial agents in HaCaT cells and in NHKs: after translational inhibition and UV-B treatment, similar induction of PRINS expression occurred with different time courses while after microbial agent treatment, the PRINS expression was significantly induced in HaCaT cells, whereas we could not detect similar changes in NHKs. Silencing of PRINS had no effect on LPS-induced NF-κB activity either in HaCaT cells or in NHKs PRINS probably affects keratinocytes functions independently of NF-κB signalling | 21750967 | |
EL1086 | Prion-associated RNAs | prion disease | N/A | N/A | N/A | expression | Host-encoded stimulatory rna molecules may have a role in the pathogenesis of prion disease. | 14562104 | |
EL1088 | PRNCR1 | prostate cancer | N/A | N/A | N/A | regulation | That same year, Chung et al reported PCa susceptibility SNPs within a 13 kb intron-less lincRNA also on 8q24, which they termed PRNCR1. | 24146262 | LncRNADisease |
EL1088 | PRNCR1 | prostate cancer | N/A | N/A | N/A | regulation | Susceptibility marker oncogene | 24373479 | LncRNADisease |
EL1088 | PRNCR1 | prostate cancer | N/A | N/A | N/A | regulation | The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). | 24713835 | LncRNADisease |
EL1088 | PRNCR1 | colorectal cancer | PCR-RFLP etc. | CRC tissue | differential expression | N/A | In overall analyses, we found that the rs13252298 and rs1456315 were associated with significantly decreased risks of CRC. In stratification analyses, we found that CRC patients carrying the rs1456315G were likely to have a tumor size of greater than 5 cm (G vs. A: adjusted OR = 1.56, 95% CI: 1.10-2.23). Additionally, patients with the rs7007694C and rs16901946G had decreased risks to develop poorly differentiated CRC, whereas patients with the rs1456315G had an increased risk to develop poorly differentiated CRC. | 24330491 | Lnc2Cancer |
EL1088 | PRNCR1 | gastric cancer | qPCR etc. | gastric cancer tissue | differential expression | mutation | We found that patients with the rs13252298AG genotype displayed a 1.50-fold increased risk of GC. Interestingly, the rs7007694CT and CC and the rs1456315GG genotypes displayed a decreased risk of GC. Our results suggest that SNPs in the lncRNA PRNCR1 may be a biomarker for the etiology of GC | 26206497 | Lnc2Cancer |
EL1088 | PRNCR1 | colorectal cancer | qPCR, Flow cytometry assay etc. | CRC tissue, cell lines (SW620, HCT116, SW480, LoVo, HT29) | up-regulated | expression | PRNCR1 was significantly overexpressed in CRC tissues compared with the expression in adjacent tissues, with an average fold increase of 10.55. Additionally, a high level of PRNCR1 was associated with large tumor volume. Compared with the normal human colorectal epithelial cell line (FHC), PRNCR1 was upregulated in most CRC cell lines (HCT116, SW480, LoVo and HT 29). | 26530130 | Lnc2Cancer |
EL1088 | PRNCR1 | prostate cancer | qPCR, Northern blot etc. | cell lines (LNCaP, 22Rv1, PC-3 etc.) | up-regulated | N/A | PRNCR1 expression was upregulated in some of the PC cells as well as precursor lesion prostatic intraepithelial neoplasia. Knockdown of PRNCR1 by siRNA attenuated the viability of PC cells and the transactivation activity of androgen receptor, which indicates that PRNCR1 could be involved in prostate carcinogenesis possibly through androgen receptor activity. | 20874843 | Lnc2Cancer |
EL1088 | PRNCR1 | prostate cancer | qPCR, RIP etc. | prostate cancer tissue,cell lines (LNCaP, LNCaP-cds1, LNCaP-cds2, CWR22Rv1 etc.), tissues (prostate tumour tissues) | up-regulated | expression | Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. | 23945587 | LncRNADisease Lnc2Cancer |
EL1088 | PRNCR1 | prostate cancer | RNA-seq, qRT-PCR | N/A | N/A | N/A | not implicated in castration resistant prostate cancer. | 24727738 | |
EL1089 | PRR26 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
EL1090 | PRSS21 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | up-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL1092 | PSORS1C3 | psoriasis | N/A | N/A | N/A | N/A | Psoriasis susceptibility 1 candidate 3 | 15848982 | LncRNADisease |
EL1092 | PSORS1C3 | psoriasis | N/A | N/A | N/A | mutation | The PSORS1C3*582A allele, an SNP in the 3'-untranslated region of the PSORS1C3 gene, was a major psoriasis vulgaris susceptibility allele in the Chinese population, and the association was much stronger in patients with early-onset psoriasis vulgaris. | 16965413 | LncRNADisease |
EL1094 | PTCSC1 | papillary thyroid carcinoma | qPCR etc. | PTA tissue tissue | up-regulated | expression | Gene expression analysis indicated that AK023948 is significantly down-regulated in most PTC tumors. The putative noncoding RNA gene AK023948 is a candidate susceptibility gene for PTC. | 19147577 | LncRNADisease Lnc2Cancer |
EL1095 | PTCSC2 | papillary thyroid carcinoma | microarray, qPCR etc. | PTC tissue, blood | down-regulated | expression | Transcripts of PTCSC2 are down-regulated in PTC tumors. We also observed a significant association of age and CLT with PTCSC2 unspliced transcript levels.Forced expression of PTCSC2 in the BCPAP cell line affected the expression of a subset of non-coding and coding transcripts with enrichment of genes functionally involved in cell cycle and cancer. | 25303483 | Lnc2Cancer |
EL1096 | PTCSC3 | papillary thyroid carcinoma | microarray, qPCR, Western blot etc. | thyroid cancer tissue, cell line (TPC-1) | up-regulated | interaction | Expression data from PTC cell lines pinpointed S100A4 as the most significantly downregulated gene in the presence of PTCSC3. S100A4 was upregulated in tumor tissue while PTCSC3 was strongly downregulated. S100A4 transcription was moderately correlated with PTCSC3 expression in unaffected thyroid tissue, and strongly in unaffected tissue of patients with the risk allele of rs944289. S100A4, VEGF and MMP-9 were suppressed in the presence of PTCSC3. PTC cells expressing PTCSC3 showed reduction in motility and invasiveness. | 26274343 | Lnc2Cancer |
EL1096 | PTCSC3 | thyroid cancer | microarray, qPCR, Western blot etc. | thyroid tissue, cell lines (PTC) | down-regulated | expression | Expression data from PTC cell lines pinpointed S100A4 as the most significantly downregulated gene in the presence of PTCSC3. S100A4 was upregulated in tumor tissue while PTCSC3 was strongly downregulated. S100A4 transcription was moderately correlated with PTCSC3 expression in unaffected thyroid tissue (r = 0.429, P = .0001), and strongly in unaffected tissue of patients with the risk allele of rs944289. S100A4, VEGF, and MMP-9 were suppressed in the presence of PTCSC3 (P = .0051, P = .0090, and P =.0037, respectively). PTC cells expressing PTCSC3 showed reduction in motility and invasiveness | 26274343 | Lnc2Cancer |
EL1096 | PTCSC3 | papillary thyroid carcinoma | N/A | N/A | N/A | mutation | A thyroid-specific lncRNA, termed PTC susceptibility candidate 3 (PTCSC3), that was strongly downregulated in PTC was identified in this region and it was found that the repression was caused by the associated SNP. | 23660942 | LncRNADisease |
EL1096 | PTCSC3 | papillary thyroid carcinoma | N/A | N/A | N/A | expression | The study showed that the expression of PTCSC3 in six thyroid cancer cell lines is lower and no expression was detected in any of them.? | 24817925 | LncRNADisease |
EL1096 | PTCSC3 | thyroid cancer | qPCR etc. | thyroid cancer tissue, cell lines (BCPAP, FTC133, 8505C etc.) | differential expression | N/A | Following transfection with PTCSC3, all three thyroid cancer cells originating from various pathological types of thyroid cancers demonstrated significant growth inhibition, cell cycle arrest and increased apoptosis. So PTCSC3 as a tumor suppressor was investigated as a competing endogenous RNA for miR-574-5p. | 23599737 | Lnc2Cancer |
EL1096 | PTCSC3 | papillary thyroid carcinoma | qPCR, knockdown, RIP, FCA etc. | PTC tissue, cell line (IHH-4) | down-regulated | expression | The expression of BANCR was significantly up-regulated while PTCSC3 and NAMA were significantly down-regulated in papillary thyroid carcinoma (PTC) compared to that in normal tissue. | 26323637 | Lnc2Cancer |
EL1097 | PTENP1 | tumor | N/A | N/A | N/A | regulation | An example of this mechanism is represented by the tumour suppressor gene PTEN and its pseudogene PTENP1. | 23660942 | LncRNADisease |
EL1097 | PTENP1 | prostate cancer | N/A | N/A | N/A | regulation | Oncogene; tumour suppressor | 24373479 | LncRNADisease |
EL1097 | PTENP1 | cancer | N/A | N/A | N/A | regulation | PTENP1 pseudogene belongs to the group of competing endogenous RNAs (ceRNAs). It may act as “decoy” by protecting PTEN mRNA from binding to common miRNA and therefore allowing expression of the tumor suppressor protein.? | 24757675 | LncRNADisease |
EL1097 | PTENP1 | gastric cancer | qPCR etc. | cancerous gastric tissue, blood (serum) | up-regulated | expression | A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC. | 25694351 | Lnc2Cancer |
EL1097 | PTENP1 | hepatocelluar carcinoma | qPCR, Western blot etc. | HCC cell lines | down-regulated | expression | Here we confirmed that PTENP1 and PTEN were downregulated in several HCC cells.These data colletcively unveiled the molecular mechanisms of how PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vetcor for PTENP1 lncRNA modulation and HCC therapy.PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vector for PTENP1 lncRNA modulation and HCC therapy. | 25617127 | Lnc2Cancer |
EL1098 | PTENP1-AS | tumor | N/A | N/A | N/A | regulation | We characterize a previously unidentified PTENpg1-encoded antisense RNA (asRNA), which regulates PTEN transcription and PTEN mRNA stability. We find two PTENpg1 asRNA isoforms, α and β. The α isoform functions in trans, localizes to the PTEN promoter and epigenetically modulates PTEN transcription by the recruitment of DNA methyltransferase 3a and Enhancer of Zeste. In contrast, the β isoform interacts with PTENpg1 through an RNA-RNA pairing interaction, which affects PTEN protein output through changes of PTENpg1 stability and microRNA sponge activity. | 23435381 | LncRNADisease |
EL1100 | PTHLH | brachydactyly | N/A | N/A | N/A | expression | Silencing of the lncRNA, PTHLH, or SOX9 revealed a feedback mechanism involving an expression-dependent network in humans. In the BDE patients, the human lncRNA was upregulated by the disrupted chromosomal association. | 23093776 | LncRNADisease |
EL1102 | PVT1 | acute promyelocytic leukemia | knockdown | peripheral blood cells from 28 patients with de novo APL | up-regulated | interaction | Significantly lower MYC and PVT1 expression was observed during all-trans retinoic acid (ATRA)-induced differentiation and cell cycle arrest in the APL cell line. MYC knockdown in NB4 cells led to PVT1 downregulation. Moreover, PVT1 knockdown by RNA interference led to suppression of the MYC protein level, and cell proliferation was inhibited. | 26544536 | |
EL1102 | PVT1 | non-small cell lung cancer | knockdown of PVT1 inhibited NSCLC cell proliferation and induced apoptosis both in vitro and in vivo | 105 human NSCLC tissues | up-regulated | N/A | High expression of PVT1 was associated with a higher TNM stage and tumor size | 26908628 | |
EL1102 | PVT1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissues, cell lines (SGC7901) | up-regulated | expression | PVT1 showed higher expression in human gastric cancer tissues than in adjacent non-cancerous tissues and in SGC7901 paclitaxel-resistant cells compared with SGC7901 cells. PVT1 expression was correlated with lymph node invasion of gastric cancer. | 25258543 | Lnc2Cancer |
EL1102 | PVT1 | malignant pleural mesothelioma | microarray, qPCR, knockdown etc. | MPM tissue, MPM cell lines | up-regulated | N/A | Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM, with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis. | 24926545 | Lnc2Cancer |
EL1102 | PVT1 | colorectal cancer | microarray, qPCR, Western blot, knockdown etc. | CRC tissue, cell lines (RKO, HCT116 etc.) | up-regulated | N/A | CRC cells transfected with PVT-1 siRNA exhibited significant loss of their proliferation and invasion capabilities. In these cells, the TGFβ1 signalling pathway and apoptotic signals were significantly activated. In addition, univariate and multivariate analysis revealed that PVT-1 expression level was an independent risk factor for overall survival of colorectal cancer patients. | 24196785 | Lnc2Cancer |
EL1102 | PVT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL1102 | PVT1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | Identification of PVT1 (rs2720709, A>G) as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. | 17395743 | LncRNADisease |
EL1102 | PVT1 | Burkitt's lymphoma | N/A | N/A | N/A | mutation | PVT1 is frequently involved in the translocations occurring in variant Burkitt's lymphomas and murine plasmacytomas. | 17503467 | LncRNADisease |
EL1102 | PVT1 | murine plasmacytomas | N/A | N/A | N/A | mutation | PVT1 is frequently involved in the translocations occurring in variant Burkitt's lymphomas and murine plasmacytomas. | 17503467 | LncRNADisease |
EL1102 | PVT1 | renal cancer | N/A | N/A | N/A | mutation | Variants (rs13447075, A>C;rs2648862, A>C) in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. | 17881614 | LncRNADisease |
EL1102 | PVT1 | cleft lip | N/A | N/A | N/A | mutation | Association identified by GWAS (rs987525,A>G). | 19270707 | LncRNADisease |
EL1102 | PVT1 | Hodgkin's lymphoma | N/A | N/A | N/A | N/A | PVT1 is a new susceptibility loci for this disease. | 21037568 | LncRNADisease |
EL1102 | PVT1 | type 1 diabetes mellitus | N/A | N/A | N/A | mutation | There is association between variants (rs2720709, A>G) in the plasmacytoma variant translocation 1 gene (PVT1) and end-stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes. | 21526116 | LncRNADisease |
EL1102 | PVT1 | type 2 diabetes mellitus | N/A | N/A | N/A | mutation | There is association between variants (rs2720709, A>G) in the plasmacytoma variant translocation 1 gene (PVT1) and end-stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes. | 21526116 | LncRNADisease |
EL1102 | PVT1 | diabetic nephropathy | N/A | N/A | N/A | Interaction | PVT1 may mediate the development and progression of diabetic nephropathy through mechanisms involving ECM accumulation. | 21526116 | LncRNADisease |
EL1102 | PVT1 | diabetic nephropathy | N/A | N/A | N/A | regulation | Role of MicroRNA 1207-5P and Its Host Gene, the Long Non-Coding RNA Pvt1, as Mediators of Extracellular Matrix Accumulation in the Kidney: Implications for Diabetic Nephropathy. | 24204837 | LncRNADisease |
EL1102 | PVT1 | lymphoma | N/A | N/A | N/A | N/A | Burkitt lymphoma association | 2470097 | LncRNADisease |
EL1102 | PVT1 | cancer | N/A | N/A | N/A | N/A | A single supernumerary segment encompassing all four genes(Myc gene or the region encompassing Pvt1, Ccdc26 and Gsdmc ) successfully promotes cancer; PVT1 RNA and MYC protein expression correlated in primary human tumours, and copy number of PVT1 was co-increased in more than 98% of MYC-copy-increase cancers. | 25043044 | LncRNADisease |
EL1102 | PVT1 | cancer | N/A | N/A | N/A | expression | The PVT gene frequently amplifies with MYC in tumor cells. | 2725491 | LncRNADisease |
EL1102 | PVT1 | lymphoma | N/A | N/A | N/A | N/A | Burkitt lymphoma association | 3024964 | LncRNADisease |
EL1102 | PVT1 | breast cancer | qPCR etc. | cell lines (A2780, DOV13, PA-1 etc.) | up-regulated | expression | Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. | 17908964 | LncRNADisease Lnc2Cancer |
EL1102 | PVT1 | ovarian cancer | qPCR etc. | cell lines (A2780, DOV13, PA-1 etc.) | up-regulated | expression | Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. | 17908964 | LncRNADisease Lnc2Cancer |
EL1102 | PVT1 | pancreatic cancer | qPCR etc. | cell line (ASPC-1) | up-regulated | expression | PVT1 gene as a regulator of Gemcitabine sensitivity and showed that functional inactivation of the PVT1 gene led to enhanced Gemcitabine sensitivity in human pancreatic cancer ASPC-1 cells. | 21316338 | LncRNADisease Lnc2Cancer |
EL1102 | PVT1 | breast cancer | qPCR etc. | breast cancer tissue, cell lines (BRF71T1, HCC38, HCC1143 etc.) | up-regulated | N/A | In the 43 breast cancer tissues, PVT1 expression was significantly higher in those with the GG genotype than that in the GA or AA genotype. Compared to normal tissues with any of the genotypes, PVT1 expression was also higher in the tumors with the GG genotype. These findings suggest that the GG genotype of SNP rs13281615 influences breast cancer development likely by modulating PVT1 expression. | 24780616 | Lnc2Cancer |
EL1102 | PVT1 | hepatocelluar carcinoma | qPCR etc. | cell lines (HepG2, LM3, SMMC-7721) | up-regulated | N/A | Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2 | 25043274 | LncRNADisease Lnc2Cancer |
EL1102 | PVT1 | hepatocelluar carcinoma | qPCR etc. | HCC tissue, cell lines (Huh7, SK-hep1, SMMC-7721, HepG2, Hep3B, PLC/PRF/5, Bel-7402) | up-regulated | expression | The relative expression levels of PVT1 were significantly higher in cancerous tissues compared with the corresponding non-cancerous tissues. Furthermore, overexpression of PVT1 was associated with a higher serum a-fetoprotein expression level and a higher recurrence rate. Kaplan-Meier analysis indicated that the patients with high PVT1 expression exhibited poor recurrence-free survival, and multivariate analysis demonstrated that high levels of PVT1 expression are an independent predictor for HCC recurrence. | 25624916 | Lnc2Cancer |
EL1102 | PVT1 | pancreatic ductal adenocarcinoma | qPCR etc. | PDAC tissue | up-regulated | expression | The study results showed that the PVT1 expression was significantly increased in PDAC tissues compared to adjacent nontumor tissues. The expression of PVT1 was associated with clinical stage and N-classification (P<0.05). Patients with high PVT1 expression level had shorter overall survival times compared to those with low PVT1 expression level (P<0.05). | 25668599 | Lnc2Cancer |
EL1102 | PVT1 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) | up-regulated | expression | All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues. | 26096073 | Lnc2Cancer |
EL1102 | PVT1 | prostate cancer | qPCR, ChIP etc. | cell lines (PC3, 1542-CP) | differential expression | mutation | The risk allele (G) of rs378854 (A>G) reduces binding of the transcription factor YY1 in vitro. The region surrounding rs378854 interacts with the MYC and PVT1 promoters.Expression of the PVT1 oncogene in normal prostate tissue increased with the presence of the risk allele of rs378854, while expression of MYC was not affected. | 21814516 | LncRNADisease Lnc2Cancer |
EL1102 | PVT1 | multiple myeloma | qPCR, FISH etc. | cell lines (AMU-MM1, KMS-12-BM, KMS-18, KMS-20 etc.) | differential expression | N/A | PVT1 rearrangements were most common and found in 7 of 12 patients (58.3%) and 5 of 8 cell lines (62.5%) with 8q24 abnormalities. A combination of spectral karyotyping (SKY), FISH, and oligonucleotide array identified several partner loci of PVT1 rearrangements, such as 4p16, 4q13, 13q13, 14q32, and 16q23-24. The PVT1-NBEA chimera in which PVT1 exon 1 was fused to NBEA exon 2 and the PVT1-WWOX in which PVT1 exon 1 was fused to WWOX exon 9 were associated with the expression of abnormal NBEA and WWOX lacking their N-terminus, respectively. These findings suggest that PVT1 rearrangements may represent a novel molecular paradigm underlying the pathology of 8q24 rearrangement-positive multiple myeloma. | 22869583 | Lnc2Cancer |
EL1102 | PVT1 | non-small cell lung cancer | qPCR, knockdown etc. | NSCLC tissue, cell lines (A549, H157, HEK-293T) | up-regulated | expression | lncRNA PVT1 expression was significantly upregulated in NSCLC tissues and lung cancer cells. Increased PVT1 expression was significantly correlated with histological grade and lymph node metastasis. In addition, NSCLC patients with PVT1 higher expression have shown significantly poorer overall survival than those with lower PVT1 expression. In vitro assays our results indicated that knockdown of PVT1 inhibited cell proliferation, migration, and invasion. | 25400777 | Lnc2Cancer |
EL1102 | PVT1 | bladder cancer | qPCR, knockdown, Flow cytometry assay etc. | bladder cancer tissue, cell lines (T24, 5637) | up-regulated | expression | Here, we found that PVT1 was upregulated in bladder cancer tissues and cells. Further experiments revealed that PVT1 promoted cell proliferation and suppressed cell apoptosis. | 26517688 | Lnc2Cancer |
EL1102 | PVT1 | gastric cancer | qPCR, Western blot etc. | gastric cancer tissue, cell lines (BGC823, SGC7901 etc.) | up-regulated | N/A | Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance | 25956062 | LncRNADisease Lnc2Cancer |
EL1102 | PVT1 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | NSCLC lines (A549, H157, H226, H460, HCC827) | up-regulated | expression | Our results indicated that PVT1 expression was significantly increased in NSCLC tissues and cell lines, and its upregulation was associated with advanced T-stage and tumor-node-metastasis (TNM) stage and regional lymph node metastasis. PVT1 expression levels were robust in differentiating NSCLC tissues from controls | 26493997 | Lnc2Cancer |
EL1102 | PVT1 | thyroid cancer | qPCR, Western blot, RIP, ChIP etc. | thyroid cancer tissues, cell lines (IHH-4, FTC-133, 8505C) | up-regulated | interaction | Compared to the controls, lncRNA PVT1 was significantly up-regulated in thyroid tissues, as well as in three kinds of tumor cell lines (P < 0.05). Silenced PVT1 significantly inhibited thyroid cell line IHH-4, FTC-133, and 8505C cell proliferation and arrested cell cycle at G0/G1 stage and significantly decreased cyclin D1 and TSHR expressions (P < 0.05). Moreover, lncRNA PVT1 could be enriched by EZH2, and silencing PVT1 resulted in the decreased recruitment of EZH2 | 26427660 | Lnc2Cancer |
EL1102 | PVT1 | ovarian cancer | qRT-PCR | ovarian cancer tissues of cisplatin-resistant patients and cisplatin-sensitive patients | up-regulated | N/A | Overexpression of LncRNA PVT1 in ovarian cancer promotes cisplatin resistance by regulating apoptotic pathways | 26884974 | |
EL1102 | PVT1 | gastric cancer | QRT-PCR assay | 111pairs of gastric cancer and adjacent normal tissues | up-regulated | N/A | up-regulation was significantly correlated to invasion depth and regional lymph nodes metastasis | 26925791 | |
EL1102 | PVT1 | gastric cancer | qRT-PCR, MTT and colony formation assays, RIP | GC tissues and cell lines | up-regulated | expression | The higher expression of PVT1 was significantly correlated with deeper invasion depth and advanced TNM stage. Further experiments demonstrated that PVT1 knockdown significantly inhibited the proliferation both in vitro and in vivo. These results suggest that lncRNA PVT1 may serve as a candidate prognostic biomarker and target for new therapies in human gastric cancer. | 25890171 | |
EL1104 | R05532 | colorectal cancer | microarray, qPCR etc. | cell lines (T29, SW480, RKO, Lovo, HCTll6) | differential expression | expression | The radiosensitivity order of these 5 cell lines from low to high (SF2 value from high to low) was HT29, SW480, RKO, Lovo, HCT116. Among them, expression levels of R05532, NR_015441 and NR_033374 were positively correlated with radiation resistance(all P<0.01),which may be used as the predictiv marker of radiosensitivity of coloretcal cancer cells. | 25421768 | Lnc2Cancer |
EL1105 | RAB4B-EGLN2 | cancer | Genotype-phenotype correlation studies | N/A | N/A | N/A | overexpressing RERT-lncRNA upregulated EGLN2 | 23026137 | |
EL1106 | RAD1 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
EL1107 | RAD51-AS1 | breast cancer | over-expression | Hela cells | up-regulated | locus | Our results identify TPIP as a novel E2F1 co-activator, suggest a similar role for other TPTEs, and indicate that the TODRA lncRNA affects RAD51 dysregulation and RAD51-dependent DSB repair in malignancy . Our results identify TPIP as a novel E2F1 co-activator, suggest a similar role for other TPTEs, and indicate that the TODRA lncRNA affects RAD51 dysregulation and RAD51-dependent DSB repair in malignancy. | 26230935 | |
EL1109 | RBM5-AS1 | tumour | Northern blot analyses,PCR | N/A | up-regulated | interaction | Je2, which mapped to the antisense strand of intron 6 of the putative tumour suppressor gene RBM5/LUCA-15/H37, and functioned as an apoptosis suppressor. | 19559772 | |
EL1110 | RCCRT1 | renal cell carcinoma | qPCR, knockdown etc. | RCC tissue, cell lines (ACHN, A498) | up-regulated | expression | Compared with adjacent noncancerous tissues, RCCRT1 is upregulated remarkably in RCC, particularly in high-grade RCC tissues. RCCRT1 is associated with clinicopathologic findings such as tumor size, pathologic T stage, tumor grade, lymph node metastasis, and distant metastasis. | 25168566 | Lnc2Cancer |
EL1113 | REST/CoREST-regulated lncRNAs | Huntington's disease | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease |
EL1114 | RGMB-AS1 | lung cancer | In vivo experiments | lung adenocarcinoma cells | up-regulated | N/A | lncRNA RGMB-AS1 downregulation significantly suppressed the growth of lung adenocarcinoma | 26950071 | |
EL1114 | RGMB-AS1 | non-small cell lung cancer | microarray, qPCR, Western blot etc. | NSCLC tissue, cell lines (A549 and SPC-A-1) | up-regulated | interaction | LncRNA RGMB-AS1 expression was significantly higher in NSCLC tissues than in adjacent normal tissues, lncRNA RGMB-AS1 and RGMB expression levels in NSCLC tissues were associated with the occurrence of differentiation status, lymph node metastases and TNM stage. Studies also indicated that lncRNA RGMB-AS1and RGMB were inversely correlated. | 26055877 | Lnc2Cancer |
EL1119 | RMST | rhabdomyosarcoma | qPCR, Northern blot etc. | rhabdomyosarcoma tissue | differential expression | expression | NCRMS (RMST) on chromosome 12q21 shows differential expression between rhabdomyosarcoma subtypes. | 12082533 | LncRNADisease Lnc2Cancer |
EL1120 | RN7SK | cancer | N/A | N/A | N/A | Interaction | Together with the HEXIM proteins, 7SK RNA associates with and sequesters a fraction of cellular P-TEFb into a catalytically inactive complex. Active and inactive forms of P-TEFb are kept in a functional and dynamic equilibrium tightly linked to the transcriptional requirement of the cell. Importantly, cardiac hypertrophy and development of various types of human malignancies have been associated with increased P-TEFb activity, consequence of a disruption of this regulatory equilibrium. | 22377309 | LncRNADisease |
EL1120 | RN7SK | AIDS | N/A | N/A | N/A | Interaction | HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. | 20471949 | LncRNADisease |
EL1120 | RN7SK | AIDS | N/A | N/A | N/A | Interaction | Tat efficiently replaces HEXIM1 on the 7SK snRNA in vivo and therefore, it promotes the disassembly of the 7SK/HEXIM/P-TEFb negative transcriptional regulatory snRNP to augment the nuclear level of active P-TEFb. The human 7SK snRNA carries a TAR RNA-like Tat-binding element that is essential for the normal transcriptional regulatory function of 7SK questions the viability of HIV therapeutic approaches based on small drugs blocking the Tat-binding site of HIV TAR. | 20976203 | LncRNADisease |
EL1120 | RN7SK | AIDS | N/A | N/A | N/A | Interaction | The 7SK-HMGA1 interaction not only adds an essential facet to the comprehension of transcriptional plasticity at the coupling of initiation and elongation, but also might provide a molecular link between HIV reprogramming of cellular gene expression-associated oncogenesis. | 21087998 | LncRNADisease |
EL1120 | RN7SK | AIDS | N/A | N/A | N/A | expression | Stable expression of cdNIPP1 increased CDK9 phosphorylation on Thr(186) and the association of CDK9 with 7SK RNA. The stable expression of cdNIPP1 disrupted the interaction of Tat and PP1 and inhibited HIV-1 transcription. Expression of cdNIPP1 as a part of the HIV-1 genome inhibited HIV-1 replication. | 21098020 | LncRNADisease |
EL1120 | RN7SK | AIDS | N/A | N/A | N/A | Interaction | The HIV-1 Tat protein also releases P-TEFb from the 7SK/HEXIM complex during viral infection to promote viral transcription and replication. | 22377309 | LncRNADisease |
EL1120 | RN7SK | cardiac hypertrophy | N/A | N/A | N/A | Interaction | Together with the HEXIM proteins, 7SK RNA associates with and sequesters a fraction of cellular P-TEFb into a catalytically inactive complex. Active and inactive forms of P-TEFb are kept in a functional and dynamic equilibrium tightly linked to the transcriptional requirement of the cell. Importantly, cardiac hypertrophy and development of various types of human malignancies have been associated with increased P-TEFb activity, consequence of a disruption of this regulatory equilibrium. | 22377309 | LncRNADisease |
EL1120 | RN7SK | gastric cancer | N/A | N/A | N/A | expression | Transfection of an siRNA directed against LARP7 (anti-LARP7 siRNA) into non-neoplastic gastric epithelial cells decreased 7sk levels by 72% relative to a control siRNA (P<0.01). | 22488152 | LncRNADisease |
EL1121 | RN7SL1 | Leishmania infection | N/A | N/A | N/A | expression | Down-regulation of 7SL RNA expression and impairment of vesicular protein transport pathways by Leishmania infection of macrophages. | 15955815 | LncRNADisease |
EL1121 | RN7SL1 | dermatomyositis | N/A | N/A | N/A | Interaction | Autoantibodies against signal recognition particle (SRP) are detected in patients with polymyositis/dermatomyositis (PM/DM). The SRP consists of 7SL RNA and 6 protein components. | 16142868 | LncRNADisease |
EL1121 | RN7SL1 | polymyositis | N/A | N/A | N/A | Interaction | Autoantibodies against signal recognition particle (SRP) are detected in patients with polymyositis/dermatomyositis (PM/DM). The SRP consists of 7SL RNA and 6 protein components. | 16142868 | LncRNADisease |
EL1121 | RN7SL1 | AIDS | N/A | N/A | N/A | Interaction | 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. | 16489186 | LncRNADisease |
EL1121 | RN7SL1 | Leishmania infection | N/A | N/A | N/A | expression | High-resolution melt analysis PCR (HRM PCR) for diagnosis of Old World Leishmania was developed using the 7SL RNA gene. Cutaneous leishmaniasis samples were analyzed. Sensitivity and specificity of HRM PCR were significantly better (P < 0.001) than those of internal transcribed spacer 1 PCR and similar to those of kinetoplast DNA PCR. | 20392923 | LncRNADisease |
EL1121 | RN7SL1 | Leishmania infection | N/A | N/A | N/A | N/A | The 7SL RNA PCR has proven useful for direct diagnosis of Old World leishmaniasis, especially when combined with the RBD assay for species identification. | 20561310 | LncRNADisease |
EL1121 | RN7SL1 | Leishmania infection | N/A | N/A | N/A | N/A | Leishmania 7SLRNA is an informative target for clinical and epidemiologic investigations of human leishmaniasis. | 20856851 | LncRNADisease |
EL1121 | RN7SL1 | AIDS | N/A | N/A | N/A | N/A | 7SL RNA binding is a conserved feature of human anti-HIV-1 cytidine deaminases. | 20926562 | LncRNADisease |
EL1122 | RNA polymerase III-dependent lncRNAs | diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease |
EL1123 | RNA44121|UCSC-2000-3182 | chronic obstructive pulmonary disease | Agilent Human lncRNA + mRNA Array v2.0 system | lung tissue of smokers with COPD | up-regulated | expression | N/A | 25542208 | |
EL1124 | RNA50010|UCSC-9199-1005 | chronic obstructive pulmonary disease | Agilent Human lncRNA + mRNA Array v2.0 system | lung tissue of smokers without Chronic obstructive pulmonary disease (COPD) | up-regulated | expression | N/A | 25542208 | |
EL1125 | RNA58351|CombinedLit_316_550 | chronic obstructive pulmonary disease | Agilent Human lncRNA + mRNA Array v2.0 system | lung tissue of non-smokers without COPD | down-regulated | expression | N/A | 25542208 | |
EL1126 | RNA-a | Opitz–Kaveggia syndrome | N/A | N/A | N/A | regulation | A recent study indicated that a subset of long ncRNAs, called activating long ncRNAs (RNA-a), is associated with Opitz–Kaveggia (also known as FG) syndrome, a X-linked intellectual disability syndrome, characterized by various neuronal pathologies as well as developmental abnormalities. | 24624135 | LncRNADisease |
EL1127 | RNase MRP | Cartilage Hair Hypoplaisia | N/A | N/A | N/A | mutation | Point mutations in RNase MRP cause human Cartilage Hair Hypoplaisia (CHH), and several disease-causing mutations map to RMRP-S1 and -S2. SHAPE chemical probing identified two alternative secondary structures altered by disease mutations. | 24009312 | LncRNADisease |
EL1129 | RNY1 | bladder, cervix, colon, kidney, lung and prostate cancer | quantitative RT-PCR,RNA interference | human solid tumour,nonmalignant normal tissues | up-regulated | expression | Degradation of hY1 and hY3 RNAs in human cell lines resulted in a significant cytostatic inhibition of cell proliferation. | 18283318 | |
EL1132 | RP11-1008C21.2 | non-small cell lung cancer | cancer tissues compared to adjacent normal tissues | cancer tissues compared to adjacent normal tissues | down-regulated | N/A | overexpression suppressed the proliferation and migration in NSCLC cell lines in vitro | 26883250 | |
EL1133 | RP11-119F7.4 | gastric cancer | qPCR etc. | gastric cancer tissue | down-regulated | expression | RP11-119F7.4 expression was significantly downregulated in the gastric cancer tissues compared with the matched NATs (P<0.001) and was significantly associated with the macroscopic type (P=0.041) and Lauren grade (P=0.020). LncRNA RP11-119F7.4 may be involved in carcinogenesis and may prove useful as a biomarker for diagnosis and prognostic significance in patients with gastric cancer. | 26170986 | Lnc2Cancer |
EL1134 | LOC102724601 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future. | 25714016 | Lnc2Cancer |
EL1135 | LINC01537 | laryngeal squamous cell carcinoma | microarray, qPCR etc. | LSCC tissue | up-regulated | expression | AC026166.2-001 and RP11-169D4.1-001 were distinctly dysregulated, with AC026166.2-001 exhibiting lower expression in cancer tissues and RP11-169D4.1-001 higher expression. We verified that both AC026166.2-001 and RP11-169D4.1-001 were expressed at a lower level in cervical lymph nodes compared with paired laryngeal cancer tissues and paired normal tissues. RP11-169D4.1-001 levels were positively correlated with lymph node metastasis. | 25243407 | Lnc2Cancer |
EL1136 | LINC01513 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1137 | RP11-284N8.3.1 | ovarian cancer | high-throughput molecular profiles | 399 Ovarian cancer (OV) patients | N/A | expression | Two protective lncRNAs, RP11-284N8.3.1 and AC104699.1.1, were not only differentially expressed throughout the progression of malignant OV but were also independently predictive of the survival of patients with different OV stages. A functional analysis of the two lncRNAs predicted their roles in immune system activation and other anti-tumor processes in the OV microenvironment. | 26629053 | |
EL1139 | KCNMB2-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | RP11-385J1.2 and TUBA4B were the most markedly changed of these candidate lncRNAs from 90 NSCLC and normal lung tissue samples. As shown in Fig. 4, RP11-385J1.2 expression in NSCLC was significantly higher than in the adjacent tissues, while TUBA4B expression in NSCLC was significantly lower than in the adjacent tissues. | 25394782 | Lnc2Cancer |
EL1140 | AC027031.2 | endometrial cancer | N/A | endometrial cancer (EC) | down-regulated | expression | Two novel genes RP11-395G23.3 and LA16c-313D11.11 associated with endometrial cancer were identified and proved to be non-coding RNAs. | 26807189 | |
EL1142 | LINC01627 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | up-regulated | expression | We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls. RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future. | 26393913 | Lnc2Cancer |
EL1143 | RP11-401P9.4 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. | 26540467 | Lnc2Cancer |
EL1144 | KCNK15-AS1 | breast cancer | qPCR etc. | breast cancer tissue | up-regulated | expression | In breast cancer patients, the expression level of lncRNA RP11-445H22.4 is significantly increased. Its expression levels were correlated with estrogen receptor (ER), progesterone receptor (PR), and menopausal status of the breast cancer patients (p < 0.05). | 25929808 | Lnc2Cancer |
EL1145 | AL355870.1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1147 | AC108134.4 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1148 | LINC00383 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | up-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. RP5- 1014O16.1 was highly expressed in high lymphatic metastatic potential HCC cell lines, while lowly expressed in no lymphatic metastatic potential HCC cell lines.We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL1149 | AL138930.1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | down-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL1150 | ZBTB20-AS4 | pancreatic cancer | microarray, qPCR etc. | cell lines (SW1990, SWl990/GZ etc.) | up-regulated | expression | Six lncRNAs (RP11-58D2.1, lincRNA-ZNF532, AP000221.1, CTC-338M12.5, CR619813, DDX6P) were selected to validate the microarray consistency by using qPCR. The results demonstrated that RP11-58D2.1, lincRNA-ZNF532 and AP000221.1 were upregulated and that CTC-338M12.5, DDX6P and CR619813 were downregulated in the SW1990/GZ cells compared with SW1990 cells (Figure 6). | 25755691 | Lnc2Cancer |
EL1151 | AC104590.1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | down-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL1152 | AL133217.1 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | up-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL1154 | LINC01612 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | down-regulated | interaction | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL1155 | Z95152.1 | nasopharyngeal carcinoma | microarray, qPCR, knockdown etc. | nasopharyngeal carcinoma tissue, cell lines (CNE-2 etc.) | up-regulated | expression | Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294006) were confirmed by qPCR. | 24379026 | LncRNADisease Lnc2Cancer |
EL1156 | LINC01969 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | up-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1157 | AL020996.1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL1158 | RP13-514E23.1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1159 | RP1-90D4.3 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1160 | AL021707.1 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL1161 | AL109741.3 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1162 | AL121845.1 | breast cancer | microarray, qPCR etc. | breast cancer tissue | up-regulated | interaction | RP4-583P15.10, an up-regulated lncRNA, was found to be located downstream of the natural antisense of the ZBTB46 gene, which may regulated breast cancer through influence immune system. | 25661361 | Lnc2Cancer |
EL1163 | RP4-620F22.3 | enterovirus 71 infection | N/A | N/A | N/A | expression | A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation | 23220233 | LncRNADisease |
EL1164 | AC244098.1 | hepatocelluar carcinoma | microarray, qPCR etc. | cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) | up-regulated | expression | The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. | 25556502 | Lnc2Cancer |
EL1165 | AL445307.1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1166 | RP5-833A20.1 | atherosclerosis | N/A | N/A | N/A | N/A | Using microarray analysis, the authors found that long noncoding RNA RP5-833A20.1 expression was upregulated, whereas nuclear factor IA (NFIA) expression was downregulated in human acute monocytic leukemia macrophage-derived foam cells. Moreover, they showed that long noncoding RNA RP5-833A20.1 maydecreases NFIA expression by inducing hsa-miR-382-5p expression in vitro. | 25265644 | LncRNADisease |
EL1167 | RP5-843L14.1 | enterovirus 71 infection | N/A | N/A | N/A | expression | A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation | 23220233 | LncRNADisease |
EL1168 | RPL34-AS1 | colorectal cancer | microarray, qPCR etc. | CRC tissue | down-regulated | N/A | We found that RP11-462C24.1 expression level was lower in cancer tissues compared with adjacent normal samples. Furthermore, its expression level was lower in CRC patients with metastasis than those without metastasis. That is, RP11-462C24.1 expression level decreased as the malignant degree of CRC increased. In addition, low expression of RP11-462C24.1 significantly correlated with more distant metastasis. | 24908062 | Lnc2Cancer |
EL1168 | RPL34-AS1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue, cell lines (HCG-27, SGC-7901) | down-regulated | expression | Linc00261, DKFZP434K028 and RPL34-AS1 had lower expression levels in gastric cancer tissues than the normal counterparts. In gastric cell lines, the three lncRNAs were also down-regulated compared with the respective normal gastric epithelial cell line GES-1. Moreover, the low expression levels of DKFZP434K028 and RPL34-AS1 positively correlated with the larger tumor size. | 26237576 | Lnc2Cancer |
EL1169 | RPLP0P2 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1171 | RRP1B | cancer | N/A | N/A | N/A | epigenetics | RRP1B, a tumor progression and metastasis susceptibility candidate gene, is potentially a dynamic modulator of transcription and chromatin structure. | 19710015 | LncRNADisease |
EL1171 | RRP1B | Spinocerebellar ataxia type 7 | N/A | N/A | N/A | expression | CTCF is required for SCAANT1 expression. Loss of SCAANT1 derepressed ataxin-7 sense transcription in a cis-dependent fashion and was accompanied by chromatin remodeling. | 21689595 | LncRNADisease |
EL1171 | RRP1B | Spinocerebellar ataxia type 7 | N/A | N/A | N/A | mutation | For example, SCA7/ATXN7 antisense RNA 1 (SCAANT1) is an lncRNA transcribed antisense to the gene mutated in spinocerebellar ataxia type 7 (ATXN7), and it functions as a repressor of ATXN7 transcription | 22814587 | LncRNADisease |
EL1171 | RRP1B | Spinocerebellar ataxia type 7 | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL1171 | RRP1B | Spinocerebellar ataxia type 7 | N/A | N/A | N/A | expression | Long ncRNA SCAANT1 is implicated in a type of polyglutamine disorder, spinocerebellar ataxia type 7 (SCA7). | 24624135 | LncRNADisease |
EL1171 | RRP1B | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | down-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
EL1173 | RUNX1 | acute myeloid leukemia | qPCR, RNA-ChIP etc. | bone marrow, cell lines (KG-1, KG-1a, Kasumi-1, K562) | up-regulated | regulation | RUNXOR utilizes its 3'-terminal fragment to directly interact with the RUNX1 promoter and enhancers and participates in the orchestration of an intrachromosomal loop. The 3' region of RUNXOR also participates in?long-range interchromosomal interactions with chromatin regions that are involved in multiple RUNX1 translocations. | 24752773 | LncRNADisease Lnc2Cancer |
EL1174 | RUNX1-IT1 | gastric cancer | microarray and quantitative real-time polymerase chain reaction (qRT-PCR), over-expression | metastatic lymph node tissues and normal lymph node tissues | up-regulated | expression | The expression levels of C21orF96 were associated with gross appearance, lymphatic metastasis and distal metastasis. C21orF96 promoted the tubular formation, migration and invasion. | 26567621 | |
EL1177 | SAMMSON | melanoma | exogenous SAMMSON ; SAMMSON knockdown | melanoma | N/A | N/A | exogenous SAMMSON increases the clonogenic potential | 27008969 | |
EL1178 | SARCC | renal cell carcinoma | a von Hippel-Lindau (VHL)-dependent manner both in RCC cell culture | RCC cell culture and clinical specimens | N/A | N/A | LncRNA-SARCC can post-transcriptionally regulate androgen receptor (AR) | 26973243 | |
EL1179 | Scarb2 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 18 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL1180 | SCHLAP1 | prostate cancer | microarray, ISH etc. | prostate cancer tissue | up-regulated | N/A | SChLAP1 expression increases with prostate cancer progression,and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate and multivariate Cox regression analyses. | 25499224 | LncRNADisease Lnc2Cancer |
EL1180 | SCHLAP1 | prostate cancer | microarray, qPCR etc. | prostate cancer tissue | up-regulated | N/A | The long non-coding RNA SChLAP1 was identified as the highest-ranked overexpressed gene in cancers with metastatic progression. | 25456366 | LncRNADisease Lnc2Cancer |
EL1180 | SCHLAP1 | prostate cancer | N/A | N/A | N/A | expression | Prensner et al found that the lncRNA SChLAP1 was overexpresed in prostate tumors and where it is critical for tumor cell metastasis. | 24829860 | LncRNADisease |
EL1180 | SCHLAP1 | bladder cancer | real-time qPCR | Bladder cancer T24 and 5637 cells | up-regulated | N/A | Cell growth arrest, apoptosis induction and migration inhibition | 26861061 | |
EL1180 | SCHLAP1 | prostate cancer | RNA-Seq, qPCR, in vitro knockdown etc. | prostate cancer tissue, prostate cell lines (PCAT-109, PCAT-114 etc.) | up-regulated | N/A | SChLAP1 contributes to the development of lethal cancer at least in part by antagonizing the tumor-suppressive functions of the SWI/SNF complex. | 24076601 | Lnc2Cancer |
EL1181 | Sema3g | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL1183 | sfRNA | Japanese encephalitis | Northern blot and real-time RT-PCR, Transfection | N/A | down-regulated | N/A | sfRNA modulates viral translation and replication in trans. | 22040380 | |
EL1185 | SGO1-AS1 | Xuanwei lung cancer | High throughput microarray assay, qRT-PCR | Xuanwei lung cancer (XWLC) tissues | N/A | expression | N/A | 26642714 | |
EL1206 | SIRT1-AS | hepatocelluar carcinoma | qPCR, Western blot, Northern blot, knockdown etc. | cell line (HCC-9903) | up-regulated | interaction | SIRT1-AS overexpression promoted the proliferation of the human HCC cell lines by upregulating the SIRT1 protein level. The mechanism was that SIRT1-AS bound to SIRT1 mRNA at 3'UTR, masked the miR-29c binding site and stabilized SIRT1 mRNA. | 26324025 | Lnc2Cancer |
EL1207 | SIRT1-AS 622C mutation | hepatocelluar carcinoma | qPCR, Western blot, Northern blot, knockdown etc. | cell line (HCC-9903) | up-regulated | mutation | The mutation led to a marked alteration in the secondary structure of SIRT1-AS and caused its inability to bind with SIRT1 mRNA. | 26324025 | Lnc2Cancer |
EL1209 | SKP2 | non-small cell lung cancer | qPCR, Western blot etc. | non-small cell lung cancer tissue, NSCLC cell lines(ATCC, Rockville, MD, USA) | differential expression | interaction | These data suggest that the Skp2 may be regulated by Meg3 at post-transcriptional level. Bioinformatics analyses showed that miR-3163 bound to 3'-UTR of Skp2 mRNA in NSCLC cells to inhibit its translation, which was supported by luciferase reporter assay. Meg3 augmented the effects of miR-3163 on Skp2 mRNA, possibly through binding-induced function enhancement, which was supported by the double fluorescent in situ hybridization showing co-localized intracellular Meg3 and miR-3163 signals in NSCLC cells. The miR-3163 levels in NSCLC were not different from in NT, suggesting that the regulation of Skp2 in NSCLC by miR-3163 may require coordination of Meg3 | 26482610 | Lnc2Cancer |
EL1210 | SLC25A25-AS1 | colorectal cancer | microarray, qPCR etc. | cell lines (T29, SW480, RKO, Lovo, HCTll6) | differential expression | expression | The radiosensitivity order of these 5 cell lines from low to high (SF2 value from high to low) was HT29, SW480, RKO, Lovo, HCT116. Among them, expression levels of R05532, NR_015441 and NR_033374 were positively correlated with radiation resistance(all P<0.01),which may be used as the predictiv marker of radiosensitivity of coloretcal cancer cells. | 25421768 | Lnc2Cancer |
EL1212 | SLC6A6 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL1213 | SLC7A2-IT1A/B | progressive encephalopathy with severe infantile anorexia | N/A | N/A | N/A | mutation | Genetic variation in lncRNA genes causes disease and influences susceptibility | 23791884 | LncRNADisease |
EL1214 | SLCO5A1 | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | up-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL1215 | SMAD1-AS1 | Ventricular septal defects | N/A | N/A | N/A | expression | Furthermore, our established filtering pipeline indicated an association of two lncRNAs, ENST00000513542 and RP11-473L15.2, with VSD. | 24147006 | LncRNADisease |
EL1216 | Smad7 | breast cancer | RNA sequencing, small interfering RNA | mouse mammary gland epithelial cell lines and breast cancer cell lines | N/A | interaction | lncRNA-Smad7 has anti-apoptotic functions, as a target of TGF-β. | 24863656 | |
EL1218 | SNAR-A1 | colon cancer | qPCR etc. | cell lines (SNU-C4R, SNU-C5R etc.) | down-regulated | interaction | We selected three lncRNAs, snaR, BACE1AS, and PRAS, and we detected their expression by RT-qPCR using specific primer sets. SnaR and BACE1AS were significantly down-regulated in both resistant cell lines (SNU-C4R and SNU-C5R), whereas PRAS was down-regulated in SNU-C4R cells but not in SNU-C5R cells. Down-regulation of snaR decreased cell death after 5-FU treatment, which indicates that snaR loss decreases in vitro sensitivity to 5-FU. | 25078450 | Lnc2Cancer |
EL1219 | SNCG | gastric cancer | microarray, qPCR, in vitro knockdown etc. | gastric cancer tissue, cell lines (SGC7901, MKN45, MKN28) | up-regulated | regulation | AK058003 is frequently upregulated in GC samples and promotes GC migration and invasion in vivo and in vitro. Next, we identified γ-synuclein. (SNCG), which is a metastasis-related gene regulated by AK058003. In addition, we found that the expression of SNCG is positively correlated with that of AK058003 in the clinical GC samples used in our study. Furthermore, we found that the SNCG gene CpG island methylation was significantly increased in GC cells depleted of AK058003. Intriguingly, SNCG expression is also increased by hypoxia, and SNCG upregulation by AK058003 mediates hypoxia-induced GC cell metastasis. | 25499222 | Lnc2Cancer |
EL1220 | SNED1 | Idiopathic pulmonary fibrosis | overexpression | human lung epithelial cells | up-regulated | expression | Overexpression of uc.77 or 2700086A05Rik in human lung epithelial cells induced EMT as demonstrated by changes in gene and protein expression of various EMT markers and cell morphology. | 26824344 | |
EL1221 | SNHG1 | non-small cell lung cancer | qPCR, knockdown etc. | cell lines (NL9980, L9981, A549, H1299, H460, SK-MES-1 etc.) | up-regulated | expression | Noncoding RNA SNHG1 expression was significantly upregulated in lung cancer cells when compared with normal bronchial epithelial cells. In addition, in vitro assays our results indicated that knockdown of SNHG1 inhibited cell proliferation. | 25818744 | Lnc2Cancer |
EL1222 | SNHG11 | obesity | N/A | N/A | N/A | mutation | New gene associated with obesity. | 20532202 | LncRNADisease |
EL1223 | SNHG12 | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | up-regulated | expression | ASLNC04080 was the most significantly upregulated lncRNA in microarray data, highly expressed in 22 out of 24 endometrial carcinoma tissues and HEC-1-B cell line. Moreover, the ASLNC04080 lncRNA expression was correlated with 19 coding genes, and may contribute to endometrial carcinoma genesis and progression by co-regulating with coding gene. Expression inhibition of lncRNA ASLNC04080 in HEC-1-B cells caused repression of cell proliferation, increased cell apoptosis, and G1 phase arrest. | 25695231 | Lnc2Cancer |
EL1223 | SNHG12 | osteosarcoma | western blot, quantitative real-time polymerase chain reaction, RNA interference, cell migration assays, flow cytometry | primary osteosarcoma (n = 20) and adjacent normal tissues (n = 20), the osteosarcoma cell lines, SAOS-2, MG-63, U-2 OS, and the human osteoblast cell line hFOB (OB3) | up-regulated | interaction | Upregulation of AMOT mRNA was associated with upregulation of SNHG12. Knockdown of SNHG12 reduced the expression of angiomotin in osteosarcoma cells and suppressed cell proliferation and migration but did not affect cell apoptosis. The lncRNA SNHG12 promotes cell proliferation and migration by upregulating AMOT gene expression in osteosarcoma cells in vivo and in vitro. | 26486328 | |
EL1224 | SNHG14 | Angelman syndrome | N/A | N/A | N/A | locus | Ube3a-as is a lncRNA transcribed antisense to the maternally expressed Ube3a gene, a candidate gene for AS, suggesting that Ube3a-as may be responsible for repressing paternal Ube3a expression. | 20380817 | LncRNADisease |
EL1224 | SNHG14 | Angelman syndrome | N/A | N/A | N/A | regulation | LncRNAs are also associated with imprinting disorders, such as ubiquitin protein ligase E3A (UBE3A)-ATS in Angelman syndrome. | 23562612 | LncRNADisease |
EL1224 | SNHG14 | Angelman syndrome | N/A | N/A | N/A | expression | Prader–Willi and Angelman syndromes, due to UBE3A expression, are affected due to the presence of a 20-kb NAT, which shares complementary sequences of UBE3A | 23781896 | LncRNADisease |
EL1224 | SNHG14 | Prader-Willi syndrome | N/A | N/A | N/A | expression | Prader–Willi and Angelman syndromes, due to UBE3A expression, are affected due to the presence of a 20-kb NAT, which shares complementary sequences of UBE3A | 23781896 | LncRNADisease |
EL1224 | SNHG14 | Angelman syndrome | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL1224 | SNHG14 | Angelman syndrome | N/A | N/A | N/A | mutation | Although in the majority of human tissues, both copies of the UBE3A gene are expressed, in neurons one copy is silenced by UBE3A-AS1 (ubiquitin-protein ligase E3A antisense RNA 1). In patients suffering from Angelman syndrome, the other (active) allele has either been deleted or inactivated. | 24667321 | LncRNADisease |
EL1225 | SNHG15 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric adenocarcinoma cancer cell lines (SGC7901, BGC823, MGC803, AGS, MKN45, GES-1) | up-regulated | interaction | We identified a novel lncRNA SNHG15, whose expression was upregulated in tumor tissues in 106 patients with gastric cancer (GC) compared with those in the adjacent normal tissues (P < 0.001). Furthermore, increased SNHG15 expression was positively correlated with invasion depth (P < 0.001), advanced tumor node metastasis (TNM) stage (P = 0.001), and lymph node metastasis (P = 0.019). SNHG15 levels were robust in differentiating GC tissues from controls (area under the curve (AUC) = 0.722; 95 % confidence interval (CI) = 0.657-0.782, P < 0.01). Kaplan-Meier analysis demonstrated that elevated SNHG15 expression contributed to poor overall survival (P < 0.01) and disease-free survival (P < 0.01) of patients. A multivariate survival analysis also indicated that SNHG15 could be an independent prognostic marker. Furthermore, knockdown of SNHG15 expression by siRNA could inhibit cell proliferation and invasion and induce apoptosis, while ectopic expression of SNHG15 promoted cell proliferation and invasion in GC cells partly via regulating MMP2 and MMP9 protein expression | 26662309 | Lnc2Cancer |
EL1226 | SNHG16 | neuroblastoma | N/A | N/A | N/A | regulation | It is now becoming increasingly evident that N-myc also regulates the expression of long noncoding RNAs such as T-UCRs and ncRAN. | 22936790 | LncRNADisease |
EL1226 | SNHG16 | bladder cancer | N/A | N/A | N/A | regulation | putative diagnostic, prognostic, and predictive marker | 24373479 | LncRNADisease |
EL1226 | SNHG16 | bladder cancer | qPCR etc. | bladder cancer tissue, cell lines (RT4, T24, J82 etc.) | up-regulated | N/A | Expression of ncRAN was significantly higher in bladder cancers compared with normal tissues and in invasive tumor compared with superficial ones (P < .01). Consistently, ncRAN expressed significantly higher in invasive bladder tumor cell lines (5637, T24, J82) than that in superficial tumor cell line (RT4). Overexpression of ncRAN in RT4 cells significantly enhanced cell proliferation, migration, and invasion. Silencing of ncRAN improved chemotherapy sensitivity in 5637 cells. | 21147498 | Lnc2Cancer |
EL1226 | SNHG16 | colorectal cancer | qPCR, knockdown etc. | CRC tissue, cell lines (LoVo, Caco-2, DLD1, SW620, SW480, HCT8, HCT116 etc.) | down-regulated | expression | Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. | 24519959 | LncRNADisease Lnc2Cancer |
EL1227 | SNHG19 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. | 26540467 | Lnc2Cancer |
EL1228 | SNHG3 | Alzheimer's disease | N/A | N/A | N/A | expression | We selected three differential signature genes specific for the early stage (Nudt19, Arl16, Aph1b), five common to both groups (Slc15a2, Agpat5, Sox2ot, 2210015, D19Rik, Wdfy1), and seven specific for late stage. | 21961160 | LncRNADisease |
EL1228 | SNHG3 | hepatocelluar carcinoma | RNA-seq, qPCR, ISH etc. | HCC tissue | up-regulated | expression | Our results showed that the expression level of SNHG3 was significantly upregulated in HCC tissues compared with paired noncancerous tissues from 51 HCC patients, increased SNHG3 expression is associated with malignant status and poor prognosis in HCC patients. | 26373735 | Lnc2Cancer |
EL1230 | SNHG4 | myelodysplastic syndrome | N/A | N/A | N/A | mutation | Association identified by GWAS. | 19240791 | LncRNADisease |
EL1231 | SNHG5 | lymphoma | N/A | N/A | N/A | locus | snhg5 is located at the breakpoint of chromosomal translocation t(3;6)(q27;q15) involved in human B-cell lymphoma. | 10792466 | LncRNADisease |
EL1233 | SNHG8 | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL1234 | SNORA17B | malignant pleural mesothelioma | microarray, qPCR etc. | MPM tissue, cell lines (H28, H226, H2052, H2452, MSTO etc.) | up-regulated | N/A | AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207, RT-qPCR = -1.6; AX746718 MA = -3.37, RT-qPCR = -4.6), with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly, BX648695, AK129685, EF177379, AK054908, AK130275, AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. | 23976967 | Lnc2Cancer |
EL1236 | SOX2-OT | Alzheimer's disease | N/A | N/A | N/A | expression | We selected three differential signature genes specific for the early stage (Nudt19, Arl16, Aph1b), five common to both groups (Slc15a2, Agpat5, Sox2ot, 2210015, D19Rik, Wdfy1), and seven specific for late stage (D14Ertd449, Tia1, Txnl4, 1810014B01Rik). | 21961160 | LncRNADisease |
EL1236 | SOX2-OT | Neurodevelopmental syndromes associated with the SOX2 locus | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL1236 | SOX2-OT | esophageal squamous cell carcinoma | N/A | N/A | N/A | expression | The results revealed a significant co-upregulation of SOX2OT along with SOX2 and OCT4 in tumor samples, compared to the non-tumor tissues obtained from the margin of same tumors. Therefore, the SOX2 gene might be a indicator for the early diagnosis of ESCC. | 24817925 | LncRNADisease |
EL1236 | SOX2-OT | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (NT2, U-87 MG etc.) | up-regulated | N/A | Our data revealed a high level of SOX2OT expression in tumor samples of ESCC, compared to that of apparently normal marginal tissues obtained from the same patients (P<0.01). All together, our data provide a novel regulatory mechanism governing the key stem cell pluripotency genes, SOX2 and OCT4, mediated by the lncRNA SOX2OT. | 24105929 | Lnc2Cancer |
EL1236 | SOX2-OT | hepatocelluar carcinoma | qPCR, knockdown etc. | HCC tissue, cell lines (HepG2, SMMC-7721) | up-regulated | expression | lncRNA Sox2ot expression level was significantly higher in HCC tissues compared with adjacent non-tumor tissues. High expression of lncRNA Sox2ot was associated with histological grade, TNM stage, and vein invasion. | 26097588 | Lnc2Cancer |
EL1236 | SOX2-OT | breast cancer | qPCR, Western blot etc. | cell lines (MCF10A) | up-regulated | N/A | The expression of SOX2 and SOX2OT is concordant in breast cancer, differentially expressed in estrogen receptor positive and negative breast cancer samples and that both are up-regulated in suspension culture conditions that favor growth of stem cell phenotypes. Importantly, ectopic expression of SOX2OT led to an almost 20-fold increase in SOX2 expression, together with a reduced proliferation and increased breast cancer cell anchorage-independent growth. | 25006803 | Lnc2Cancer |
EL1236 | SOX2-OT | lung squamous cell carcinoma | qPCR, Western blot, knockdown, RIP etc. | cell lines (A549, HCC827, SK-MES-1, NCI-H1299 etc.) | up-regulated | N/A | Sox2ot exprssion in lung cancer is significantly higher and promotes cancer cell proliferation. Sox2ot plays an important role in regulating lung cancer cell proliferation, and may represent a novel prognostic indicator for the disease. | 24927902 | Lnc2Cancer |
EL1236 | SOX2-OT | non-small cell lung cancer | real-time quantitative reverse transcription PCR (qRT-PCR) | lung tumor tissues | up-regulated | N/A | SOX2OT knockdown significantly reduced the colony formation ability of cancer cells | 26846097 | |
EL1237 | SOX2OT-S1 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (NT2, U-87 MG etc.) | up-regulated | N/A | The results of qPCR revealed that SOX2OT-S1 and SOX2OT-S2 were overexpressed in tumor samples of ESCC, compared to their marginal non-tumor tissue counterparts. Furthermore, overexpression of SOX2OT-S2 in tumor samples, similar to SOX2 and OCT4, was statistically significant (P<0.01). | 24105929 | Lnc2Cancer |
EL1238 | SOX2OT-S2 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (NT2, U-87 MG etc.) | up-regulated | N/A | The results of qPCR revealed that SOX2OT-S1 and SOX2OT-S2 were overexpressed in tumor samples of ESCC, compared to their marginal non-tumor tissue counterparts. Furthermore, overexpression of SOX2OT-S2 in tumor samples, similar to SOX2 and OCT4, was statistically significant (P<0.01). | 24105929 | Lnc2Cancer |
EL1239 | Sox4 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL1240 | SPRY4-IT1 | melanoma | knockdown, affinity purification, mass spectrometry | melanoma cells | up-regulated | expression | SPRY4-IT1 knockdown may induce apoptosis via lipin 2-mediated alterations in lipid metabolism leading to cellular lipotoxicity. | 25344859 | |
EL1240 | SPRY4-IT1 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
EL1240 | SPRY4-IT1 | breast cancer | microarray, qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MD-MB-231, MD-MB-435S, MCF-10A, MCF-7 etc.) | up-regulated | interaction | SPRY4-IT1 expression was significantly upregulated in 48 breast cancer tumor tissues comparedwith normal tissues. Additionally, increased SPRY4-IT1 expression was found to be associated with a larger tumor size and an advanced pathological stage in breast cancer patients. SPRY4-IT1 is a novel prognostic biomarker and a potential therapeutic candidate for breast cancer. | 25742952 | Lnc2Cancer |
EL1240 | SPRY4-IT1 | melanoma | N/A | N/A | N/A | expression | The lncRNA, SPRY4-IT1, which is up-regulated in human melanomas compared to melanocytes and keratinocytes, affects cell dynamics, including increased rate of wound closure upon ectopic expression. | 22492512 | LncRNADisease |
EL1240 | SPRY4-IT1 | melanoma | N/A | N/A | N/A | expression | Another elegant study by Khaitan et al. utilized a non-coding RNA microarray approach to identify differentially regulated lncRNAs in melanoma cells and identified a 687 bp single exon lncRNA named SPRY4-IT1 which was highly up-regulated in melanoma patient samples and cell lines. | 24115003 | LncRNADisease |
EL1240 | SPRY4-IT1 | esophageal squamous cell carcinoma | qPCR etc. | blood (plasma and serum) | up-regulated | expression | Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients compared with normal controls.By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC (the area under the ROC curve (AUC), 0.842. | 25608466 | Lnc2Cancer |
EL1240 | SPRY4-IT1 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (KYSE-450, KYSE-510, KYSE-150 etc.) | up-regulated | expression | Long?noncoding?RNA?SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. | 24810925 | LncRNADisease Lnc2Cancer |
EL1240 | SPRY4-IT1 | clear cell renal cell carcinoma | qPCR, knockdown etc. | ccRCC tissue, cell lines (786-O, ACHN, Caki-1, Caki-2) | up-regulated | expression | The relative level of SPRY4-IT1 was significantly higher in ccRCC tissues compared to the adjacent normal renal tissues. And higher expression of SPRY4-IT1 was found in renal cancer cell lines compared with the normal human proximal tubule epithelial cell line HK-2. The ccRCC patients with higher SPRY4-IT1 expression had an advanced clinical stage and poorer prognosis than those with lower SPRY4-IT1 expression. | 25337221 | Lnc2Cancer |
EL1240 | SPRY4-IT1 | bladder cancer | qPCR, knockdown etc. | bladder cancer tissue, cell lines (J82, T24, SW780, SV-40 etc.) | up-regulated | expression | SPRY4-IT1 levels were highly positively correlated with histological grade, tumor stage, and lymph node metastasis and reduced overall survival. A multivariate analysis showed that SPRY4-IT1 expression is an independent prognostic factor of overall survival in patients with UCB. | 25973088 | Lnc2Cancer |
EL1240 | SPRY4-IT1 | melanoma | qPCR, knockdown, FISH etc. | melanoma tissue | up-regulated | N/A | The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. | 21558391 | LncRNADisease Lnc2Cancer |
EL1240 | SPRY4-IT1 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines AGS, BGC-823, HGC-27, SGC-7901, MGC80-3, MKN-45) | up-regulated | N/A | SPRY4-IT1 expression was elevated in GC tissues and cell lines | 25835973 | LncRNADisease Lnc2Cancer |
EL1240 | SPRY4-IT1 | gastric cancer | qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (SGC7901, BGC823, MGC803, AGS, MKN45 etc.) | down-regulated | expression | SPRY4-IT1 expression is decreased in gastric cancer tissues and associated with larger tumor size, advanced pathological stage, deeper depth of invasion and lymphatic metastasis. Patients with lower SPRY4-IT1 expression had a relatively poor prognosis. DNA methylation may be a key factor in controlling the SPRY4-IT1 expression. Furthermore, SPRY4-IT1 contributed to gastric cancer cells metastasis might partly via regulating epithelial-mesenchymal transition (EMT) process. | 26238992 | Lnc2Cancer |
EL1240 | SPRY4-IT1 | glioma | qPCR, Western blot, knockdown etc. | glioma cell lines (U251, SF295) and the normal human astrocytes (NHA) | up-regulated | expression | We examined for the first time the expression and role of SPRY4-IT1 in glioma cells. The results of our study showed that SPRY4-IT1 was up-regulated in human glioma tissues and cell lines. Knockdown of SPRY4-IT1 could inhibit glioma cell growth and migration. Moreover, knockdown of SPRY4-IT1 could inhibit epithelial-mesenchymal transition (EMT) phenotype in glioma cells. | 26464658 | Lnc2Cancer |
EL1240 | SPRY4-IT1 | non-small-cell lung cancer | qRT-PCR | patients suffering from non-small-cell lung cancer (NSCLC) | up-regulated | expression | N/A | 26448925 | |
EL1240 | SPRY4-IT1 | melanoma | qRT-PCR, WB, knockdown | severe preeclamptic placenta, trophoblast cells HTR-8/SVneo | up-regulated | expression | SPRY4-IT1 knockdown enhanced the cell migration and proliferation, and reduced the response of cells to apoptosis. However, exogenous SPRY4-IT1 overexpression significantly decreased the cell migration and proliferation, while increased cell apoptosis. | 24223182 | |
EL1241 | SRA1 | breast cancer | N/A | N/A | N/A | expression | Our results demonstrate that full-length SRA-RNAs likely to encode stable proteins are widely expressed in breast cancer cell lines. | 12565891 | LncRNADisease |
EL1241 | SRA1 | cardiomyopathy | N/A | N/A | N/A | N/A | SRA1 results independently in a phenotype of myocardial contractile dysfunction. | 19064678 | LncRNADisease |
EL1241 | SRA1 | dilated cardiomyopathy | N/A | N/A | N/A | expression | RA also is present in a 600-kb linkage disequilibrium block associated with human dilated cardiomyopathy in 3 independent populations. | 23104877 | LncRNADisease |
EL1241 | SRA1 | breast cancer | N/A | N/A | N/A | regulation | Co-activator of steroid Receptors & other transcription Factors; associate with metastasis | 24499465 | LncRNADisease |
EL1241 | SRA1 | ovarian cancer | N/A | N/A | N/A | regulation | Co-activator of steroid Receptors & other transcription Factors; associate with metastasis | 24499465 | LncRNADisease |
EL1241 | SRA1 | uterus cancer | N/A | N/A | N/A | regulation | Co-activator of steroid Receptors & other transcription Factors; associate with metastasis | 24499465 | LncRNADisease |
EL1241 | SRA1 | breast cancer | qPCR etc. | cell lines (BT-20, MDA-MB-469, MDA-MB-231 etc.) | differential expression | expression | We recently reported a decreased estrogen receptor activity in breast cancer cells overexpressing SRAP, suggesting antagonist roles played by SRA1 RNA and SRAP. | 16848684 | LncRNADisease Lnc2Cancer |
EL1241 | SRA1 | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | down-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
EL1241 | SRA1 | breast cancer | qPCR, Western blot etc. | breast cancer tissue, cell line (T5) | up-regulated | locus | We have previously found that both fully-spliced SRAP-coding and intron-1-containing non-coding SRA RNAs co-exist in breast cancer cell lines. | 19483093 | LncRNADisease Lnc2Cancer |
EL1241 | SRA1 | breast cancer | Western blot etc. | cell line (HEK293T ) | differential expression | N/A | Disturbance of the balance between SRAP1-coding and non-coding SRA1 RNAs in breast tumor tissues might be involved in breast tumorigenesis. | 20079837 | LncRNADisease Lnc2Cancer |
EL1245 | Srsf9 | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL1246 | ST7-AS1 | autism | N/A | N/A | N/A | locus | The apparent noncoding genes at the ray1/st7 locus may be regulatory rnas. | 12213198 | |
EL1246 | ST7-AS1 | glioma | qPCR etc. | cell lines(U251, U87) | up-regulated | expression | MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. | 25645334 | Lnc2Cancer |
EL1247 | ST7-AS2 | autism | N/A | N/A | N/A | locus | The apparent noncoding genes at the ray1/st7 locus may be regulatory rnas. | 12213198 | |
EL1248 | ST7-OT3 | autism | N/A | N/A | N/A | locus | The apparent noncoding genes at the ray1/st7 locus may be regulatory rnas. | 12213198 | |
EL1249 | ST7-OT4 | autism | N/A | N/A | N/A | locus | The apparent noncoding genes at the ray1/st7 locus may be regulatory rnas. | 12213198 | |
EL1250 | SUMO1P3 | bladder cancer | N/A | bladder cancer tissues | up-regulated | expression | Up-regulated SUMO1P3 expression was positively correlated with greater histological grade (P<0.05) and advanced TNM stage (P<0.05). cell proliferation / migration inhibition and apoptosis induction were also observed in SUMO1P3 siRNA-transfected bladder cancer cells. SUMO1P3 plays oncogenic roles in bladder cancer and can be used as a potential prognostic and therapeutic target. | 26799188 | |
EL1250 | SUMO1P3 | gastric cancer | N/A | N/A | N/A | expression | Pseudogene-expressed lncRNAs are a major member of the lncRNA family. Recently, our group reported that small ubiquitin-like modifier (SUMO) 1 pseudogene 3, SUMO1P3, was markedly up-regulated in gastric cancer tissues compared with paired adjacent non-tumor tissues. | 24833871 | LncRNADisease |
EL1250 | SUMO1P3 | gastric cancer | qPCR etc. | gastric cancer tissue | up-regulated | regulation | Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. | 23996296 | LncRNADisease Lnc2Cancer |
EL1263 | TARID | cancer | N/A | N/A | N/A | N/A | Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. | 25087872 | LncRNADisease |
EL1266 | TC0100223 | epithelial ovarian cancer | microarray, qPCR etc. | epithelial ovarian cancer tissue, cell lines (SKOV3 etc.) | down-regulated | expression | Notably, three candidates (TC0100223, TC0101686 and TC0101441) were aberrantly expressed in ERα-positive compared to ERα-negative EOC tissues, showing correlations with some malignant cancer phenotypes such as advanced FIGO stage and/or high histological grade. | 24481591 | LncRNADisease Lnc2Cancer |
EL1267 | TC0101441 | epithelial ovarian cancer | microarray, qPCR etc. | epithelial ovarian cancer tissue, cell lines (SKOV3 etc.) | up-regulated | expression | Notably, three candidates (TC0100223, TC0101686 and TC0101441) were aberrantly expressed in ERα-positive compared to ERα-negative EOC tissues, showing correlations with some malignant cancer phenotypes such as advanced FIGO stage and/or high histological grade. | 24481591 | LncRNADisease Lnc2Cancer |
EL1267 | TC0101441 | epithelial ovarian cancer | microarray, qPCR, Western blot, knockdown etc. | epithelial ovarian cancer tissue, cell lines (SKOV3, A2780, PEO1 etc.) | up-regulated | N/A | The results showed that ERa-positive tissues had higher expression of TC0101441 and lower expression TC0101686. Low-expression of TC0101686 was significantly related to ERa-positive EOC tissues with advanced FIGO stage ( P< 0.05), while high-expression of TC0101441 was closely correlated with advanced FIGO stage, high histological grade and lymph node metastasis (P<0.01). | 24380700 | Lnc2Cancer |
EL1268 | TC0101686 | epithelial ovarian cancer | microarray, qPCR etc. | epithelial ovarian cancer tissue, cell lines (SKOV3 etc.) | down-regulated | expression | Notably, three candidates (TC0100223, TC0101686 and TC0101441) were aberrantly expressed in ERα-positive compared to ERα-negative EOC tissues, showing correlations with some malignant cancer phenotypes such as advanced FIGO stage and/or high histological grade. | 24481591 | LncRNADisease Lnc2Cancer |
EL1268 | TC0101686 | epithelial ovarian cancer | microarray, qPCR, Western blot, knockdown etc. | epithelial ovarian cancer tissue, cell lines (SKOV3, A2780, PEO1 etc.) | down-regulated | N/A | The results showed that ERa-positive tissues had higher expression of TC0101441 and lower expression TC0101686. Low-expression of TC0101686 was significantly related to ERa-positive EOC tissues with advanced FIGO stage ( P< 0.05), while high-expression of TC0101441 was closely correlated with advanced FIGO stage, high histological grade and lymph node metastasis (P<0.01). | 24380700 | Lnc2Cancer |
EL1269 | TC1500845 | ovarian cancer | microarray, qPCR etc. | epithelial ovarian cancer tissue, cell lines (SKOV3 etc.) | up-regulated | N/A | The results revealed that the expression levels of TC0100223 and TC0101686 were significantly downregulated by E2, whereas TC1500845 and TC0101441 were significantly upregulated by E2 in SKOV3 cells, consistent with the microarray results. | 24481591 | LncRNADisease Lnc2Cancer |
EL1270 | TCF7 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | down-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL1271 | TCL6 | acute T-lymphocytic leukemia | qPCR etc. | cell lines (COS7 ) | up-regulated | N/A | T-cell leukemia/lymphoma 6 | 10851082 | LncRNADisease Lnc2Cancer |
EL1273 | TCONS_00000966 | Sclerotinia stem rot caused by Sclerotinia sclerotiorum | qRT-PCR | responsive to S. sclerotiorum infection in B. napus at two time points after infection (24 hpi and 48 hpi) | N/A | expression | TCONS_00000966, having 90% overlap with a plant defensin gene, showed significant induction at both infection stages, suggesting its involvement in the transcriptional regulation of defense responsive genes under S. sclerotiorum infection. | 27388760 | |
EL1281 | TCONS_00014512 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | down-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1282 | AC069120.3 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | up-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1283 | TCONS_00018278 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | N/A | To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. | 24876753 | Lnc2Cancer |
EL1288 | TCONS_00024647 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | down-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1289 | TCONS_00026506 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | up-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
EL1309 | TCONS_00090092_MEG3 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | up-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1310 | TCONS_l2_00000179 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | up-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1311 | TCONS_l2_00003938 | triple-negative breast cancer | microarray, qPCR etc. | triple-negative breast cancer tissue | up-regulated | expression | We found that the expression levels of TCONS_l2_00003938, ENST00000460164, ENST00000425295, MALAT1 and HOTAIR were significantly higher in tumor tissues than non-tumor tissues, whereas there were no significant differences in the expression levels of the other 3 lncRNAs. Our study identified a set of lncRNAs that were consistently aberrantly expressed in TNBC, and these dysregulated lncRNAs may be involved in the development and/or progression of TNBC. | 25996380 | Lnc2Cancer |
EL1312 | TCONS_l2_00004424 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | up-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1313 | TCONS_l2_00006843 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | down-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1314 | TCONS_l2_00010365 | papillary thyroid carcinoma | microarray, qPCR etc. | papillary thyroid carcinoma tissue | up-regulated | expression | We randomly chose a total of 10 differentially expressed lncRNAs for qPCR, of which TCONS_l2_00010365, n386477, n340790, lnc-LLPH-2:1 and NR_003225.2 were up-regulated and lnc-PSD4-1:14, n335550, lnc-KCMF1-2:1, lnc-PLA2R1-1:1 and ENST00000422494.1 were down-regulated in PTC. The results of qPCR were consistent with those of the microarray, in that all 10 lncRNAs were differentially expressed with the same trend (up- or down-regulated) and reached statistical significance. | 26003293 | Lnc2Cancer |
EL1315 | TCONS_l2_00014091 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | up-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1316 | TCONS_l2_00018070 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | down-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1317 | TCONS_l2_00018071 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | down-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1318 | TCONS_l2_00020565 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | down-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1319 | TCONS_l2_00021262 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | up-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1320 | TCONS_l2_00030560 | hepatoblastoma | microarray, qPCR etc. | hepatoblastoma tissue | down-regulated | N/A | The results showed that expression of TCONS_00090092-MEG3, TCONS_l2_00000179, TCONS_l2_00014091, TCONS_l2_00004424, TCONS_l2_00021262, TCONS_00014978 and ESM1 were over-regulated, and TCONS_l2_00018070, TCONS_l2_00018071, TCONS_l2_00006843, TCONS_l2_00030560, TCONS_l2_00020565, TCONS_00024647, and TCONS_00014512 were downregulated in all four hepatoblastoma tissue samples relative to the paired distant noncancerous tissues (P<0.05). | 24465615 | Lnc2Cancer |
EL1321 | TDRG1 | testicular cancer | N/A | N/A | N/A | expression | The significantly reduced expression of the TDRG1 in patients with seminoma or teratoma indicates that TDRG1 may be a candidate cancer suppressor gene. | 21243750 | LncRNADisease |
EL1321 | TDRG1 | aplastic anemia | Reverse transcription‑quantitative polymerase chain, small interfering RNA | patients exhibiting AA | up-regulated | interaction | The decreased proliferation capability of BMSCs that were treated with Ad‑FGF1 and TDRG1‑small interfering RNA validated the vital effect of TDRG1 on the FGF1 regulatory process of BMSC differentiation. | 26460236 | |
EL1325 | TERC | dyskeratosis congenita | N/A | N/A | N/A | mutation | Mutations that alter the equilibrium between different conformational states of TERCs result in disease states such as dyskeratosis congenita, presumably through disruptions of the RNA scaffold structure into which are plugged modular binding sites for telomeric regulatory proteins. | 14630939 | LncRNADisease |
EL1325 | TERC | prostate cancer | N/A | N/A | N/A | expression | TERC is expressed in all human tissues regardless of telomerase activity, whereas TERT is highly expressed in >90% of tumor cells | 24146262 | LncRNADisease |
EL1328 | THRIL | Kawasaki disease | N/A | N/A | N/A | expression | Finally, THRIL expression was correlated with the severity of symptoms in patients with Kawasaki disease, an acute inflammatory disease of childhood. | 24371310 | LncRNADisease |
EL1329 | TI09485 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | down-regulated | N/A | LncRNA expression was then analyzed in CC cells and normal, primary cervical epithelial cells in the same manner. The levels of TI17313, TI13831, TI10124, and TI18318 were increased in 3 cancer cell lines (HeLa, SiHa, and CaSki) when compared with normal, primary cervical epithelial cells. Expression of the 5 other lncRNAs was below the level of detection in cultured cells. | 25007342 | Lnc2Cancer |
EL1330 | TI10124 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | up-regulated | N/A | LncRNA expression was then analyzed in CC cells and normal, primary cervical epithelial cells in the same manner. The levels of TI17313, TI13831, TI10124, and TI18318 were increased in 3 cancer cell lines (HeLa, SiHa, and CaSki) when compared with normal, primary cervical epithelial cells. Expression of the 5 other lncRNAs was below the level of detection in cultured cells. | 25007342 | Lnc2Cancer |
EL1331 | TI13831 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | up-regulated | N/A | LncRNA expression was then analyzed in CC cells and normal, primary cervical epithelial cells in the same manner. The levels of TI17313, TI13831, TI10124, and TI18318 were increased in 3 cancer cell lines (HeLa, SiHa, and CaSki) when compared with normal, primary cervical epithelial cells. Expression of the 5 other lncRNAs was below the level of detection in cultured cells. | 25007342 | Lnc2Cancer |
EL1332 | TI18318 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | up-regulated | N/A | LncRNA expression was then analyzed in CC cells and normal, primary cervical epithelial cells in the same manner. The levels of TI17313, TI13831, TI10124, and TI18318 were increased in 3 cancer cell lines (HeLa, SiHa, and CaSki) when compared with normal, primary cervical epithelial cells. Expression of the 5 other lncRNAs was below the level of detection in cultured cells. | 25007342 | Lnc2Cancer |
EL1333 | TI21327 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | down-regulated | N/A | LncRNA expression was then analyzed in CC cells and normal, primary cervical epithelial cells in the same manner. The levels of TI17313, TI13831, TI10124, and TI18318 were increased in 3 cancer cell lines (HeLa, SiHa, and CaSki) when compared with normal, primary cervical epithelial cells. Expression of the 5 other lncRNAs was below the level of detection in cultured cells. | 25007342 | Lnc2Cancer |
EL1334 | TI22687 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | down-regulated | N/A | LncRNA expression was then analyzed in CC cells and normal, primary cervical epithelial cells in the same manner. The levels of TI17313, TI13831, TI10124, and TI18318 were increased in 3 cancer cell lines (HeLa, SiHa, and CaSki) when compared with normal, primary cervical epithelial cells. Expression of the 5 other lncRNAs was below the level of detection in cultured cells. | 25007342 | Lnc2Cancer |
EL1336 | TINCR | skin desease | Genome-scale RNA interactome analysis, high-throughput screen | N/A | N/A | N/A | controls human epidermal differentiation by a post-transcriptional mechanism | 23201690 | |
EL1336 | TINCR | colorectal cancer | N/A | CRC tissues and metastatic CRC cell lines | up-regulated | N/A | TINCR was reversely correlated with CRC progression | 27009809 | |
EL1336 | TINCR | squamous cell carcinoma | N/A | N/A | N/A | expression | Interestingly, the lncRNA TINCR, which is highly induced during keratinocyte differentiation, is repressed in squamous cell carcinoma specimens compared to normal adjacent epidermis. | 24115003 | LncRNADisease |
EL1336 | TINCR | gastric cancer | RNA-seq, qPCR, Western blot, knockdown etc. | gastric cancer tissue, cell lines (MGC803, BGC823, MKN45, SGC7901 etc.) | up-regulated | N/A | TINCR is strongly upregulated in human gastric carcinoma (GC), where it was found to contribute to oncogenesis and cancer progression. TINCR overexpression is induced by nuclear transcription factor SP1. TINCR contributes to the oncogenic potential of GC and may constitute a potential therapeutic target in this disease. | 25728677 | LncRNADisease Lnc2Cancer |
EL1341 | Tmcc3 | diabetic nephropathy | Western blotting, and quantitative RT-PCR | mouse mesangial cells | down-regulated | interaction | downregulated ENSMUST00000147869 associated with Cyp4a12a | 27083175 | |
EL1342 | TMEM179 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | up-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL1343 | TMEM72 | clear cell renal cell carcinoma | microarray, qPCR etc. | renal clear cell carcinoma tissue | down-regulated | N/A | ENST00000456816, X91348, BC029135, NR_024418 were evaluated by qPCR in sixty-three pairs of RCCC and NT samples. The results demonstrated that ENST00000456816, X91348 were up-regulated and BC029135, NR_024418 were down-regulated in RCCC samples compared with NT samples (p<0.001 for each lncRNAs). | 22879955 | Lnc2Cancer |
EL1346 | TMPOP2 | cervical cancer | microarray, qPCR, Western blot, knockdown, RIP etc. | cervical cancer tissue, cell lines (HeLa, SiHa, CaSki) | up-regulated | N/A | lncRNA-EBIC was upregulated in cervical cancer. lncRNA-EBIC was an oncogenic lncRNA, which could promote tumor cell invasion in CC by binding to EZH2 and inhibiting E-cadherin expression. | 25007342 | Lnc2Cancer |
EL1347 | TNXA | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | down-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
EL1349 | TP53COR1 | colorectal cancer | limiting dilution and serial tumor formation assay | colorectal cancer stem cells | N/A | interaction | Large intergenic non-coding RNA p21 (lincRNA-p21) is a potent suppressor of stem-like traits of CSCs purified from both primary colorectal cancer (CRC) tissues and cell lines. Ad-lnc-p21-MRE significantly suppressed the self-renewal potential and tumorigenicity of CSCs in nude mice. | 26497997 | |
EL1349 | TP53COR1 | lung cancer | N/A | N/A | N/A | expression | lincRNAp21 is required for the global repression of genes that interfere with p53 function regulating cellular apoptosis. lincRNAp21 can mediate gene repression by physically interacting with the protein hnRNP-K, allowing its localization to promoters of genes to be repressed in a p53-dependent manner, and its overexpression in a lung cancer cell line sensitizes the cells to DNA | 22535282 | LncRNADisease |
EL1349 | TP53COR1 | atherosclerosis | N/A | N/A | N/A | N/A | The expression of lincRNA-p21 was dramatically downregulated in atherosclerotic plaques of ApoE(-/-) mice, an animal model for atherosclerosis. LincRNA-p21 represses cell proliferation and induces apoptosis in vascular smooth muscle cells and mouse mononuclear macrophage cells in vitro | 25156994 | LncRNADisease |
EL1349 | TP53COR1 | lung cancer | qPCR etc. | cell lines (wt MEFs, NIH/3T3 MEFs etc.) | down-regulated | expression | Gas5 has also been linked with breast cancer because Gas5 transcript levels are significantly reduced compared to unaffected normal breast epithelia. | 20673990 | LncRNADisease Lnc2Cancer |
EL1349 | TP53COR1 | cervical cancer | qPCR etc. | cell line (CaSki) | up-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | LncRNADisease Lnc2Cancer |
EL1349 | TP53COR1 | chronic lymphocytic leukemia | qPCR etc. | blood (plasma) | down-regulated | expression | HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. | 24583225 | LncRNADisease Lnc2Cancer |
EL1349 | TP53COR1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | The lincRNA-p21 levels were significantly higher in PCa than in BPH. Our data suggest that the discriminative potential of exosomal lincRNA-p21 levels may help to improve the diagnostic prediction of the malignant state for patients with PCa. | 25999983 | Lnc2Cancer |
EL1349 | TP53COR1 | B cell lymphoma | qPCR, Western blot etc. | B cell lymphoma tissue, DLBCL cell lines (SU-DHL-2, OCI-LY-3, OCILY-10, SU-DHL-4, OCI-LY-7) | down-regulated | interaction | We found that lincRNA-p21 levels were markedly decreased in DLBCL tissues compared with normal. Its expression level was significantly correlated with Ann Arbor stages, B symptoms, performance status, IPI score and serum LDH. Moreover, patients with high levels of LincRNA-p21 expression had a favorable overall survival and progression-free survival. Furthermore, ectopic expression of lincRNA-p21 inhibited cell proliferation, arrested cycle progression and modulated cyclin D1, CDK4 and p21 expression in DLBCL cell lines. These results demonstrated lincRNA-p21 can be identified as a potential novel prognostic biomarker for prognosis in DLBCL and regulate cell proliferation and cycle in vitro | 26475621 | Lnc2Cancer |
EL1349 | TP53COR1 | colorectal cancer | qPCR, Western blot, knockdown etc. | CRC tissue, cell lines (SW1116, SW620, LS 174T, HT29, LOVO etc.) | down-regulated | regulation | LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. | 24573322 | LncRNADisease Lnc2Cancer |
EL1349 | TP53COR1 | Burkitt's lymphoma | qPCR, Western blot, knockdown etc. | blood | up-regulated | expression | We analyzed its expression in CLL and lymphoma in the context of DNA damage. 24 hours after IR, lincRNA-p21 expression was strongly induced in a p53-dependent manner in a very large set of CLL patients (n = 73).lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma. | 25971364 | Lnc2Cancer |
EL1349 | TP53COR1 | chronic lymphocytic leukemia | qPCR, Western blot, knockdown etc. | blood | up-regulated | expression | We analyzed its expression in CLL and lymphoma in the context of DNA damage. 24 hours after IR, lincRNA-p21 expression was strongly induced in a p53-dependent manner in a very large set of CLL patients (n = 73).lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma. | 25971364 | Lnc2Cancer |
EL1349 | TP53COR1 | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | hepatocellular cancer tissue | down-regulated | expression | We demonstrated that lincRNA-p21 acted as a tumor suppressive lncRNA in human hepatocellular carcinoma. We firstly found the downregulation of lincRNA-p21 level in human hepatocellular carcinoma tissues, and showed that low expression of lincRNA-p21 was associated with high disease stage and predicted poor survival.We showed that lincRNA-p21 knockdown promoted proliferation and colony formation of HepG2, Huh7 and Bel-7042 cells in vitro, while lincRNA-p21 overexpression obtained oppose results.We demonstrated that ER stress accounted for lincRNA-p21 effects on apoptosis, proliferation and in vivo growth of hepatocellular carcinoma. | 26305675 | Lnc2Cancer |
EL1350 | TP53TG1 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL1350 | TP53TG1 | ataxia telangiectasia | N/A | human T lymphocytes from patient with ataxia telangiectasia (AT) | up-regulated | expression | TP53TG1 demonstrated a weak up-regulation, reaching a maximum of 1.5-fold at 24 h after radiation exposure | 25738893 | |
EL1351 | TP73-AS1 | multiple myeloma | methylation-specific PCR etc. | cell lines (KMS-12-PE, LP-1, NCI-H929, OPM-2, OCI-MY5) | differential expression | expression | Herein, by methylation-specific PCR, the putative KIAA0495 promoter was found unmethylated in all healthy controls (N = 14) but methylated in 50 % of myeloma cell lines (N = 10). KIAA0495 methylation was shown inversely correlated with KIAA0495 expression. However, KIAA0495 methylation was detected in none of both primary myeloma samples at diagnosis (N = 61) and at relapse/progression (N = 16). Collectively, despite frequently methylated in cell lines, KIAA0495 methylation appeared unimportant in the pathogenesis or progression of myeloma. | 26410378 | Lnc2Cancer |
EL1351 | TP73-AS1 | esophageal squamous cell carcinoma | microarray, knockdown | esophageal squamous cell carcinoma, mouse xenografts | up-regulated | interaction | In mouse xenografts, tumor size was reduced in lncRNA TP73-ASI siRNA-transfected tumors, suggesting that downregulation of lncRNA TP73-AS1 attenuated EC proliferation in vitro and in vivo. lncRNA TP73-AS1 knockdown enhanced the chemosensitivity of esophageal cancer cells to 5-FU and cisplatin. | 26799587 | |
EL1351 | TP73-AS1 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | Furthermore, the levels of LINC00261 and TP73-AS1 were significantly differently expressed in subgroups of NSCLC samples (P = 0.004 and P = 0.03, respetcively). These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. | 25590602 | Lnc2Cancer |
EL1355 | TRAF3IP2-AS1 | cocaine abuse | lncRNA microarray, qRT-PCR, in situ hybridization histochemistry | postmortem human midbrain tissues from chronic cocaine abusers | up-regulated | expression | The abundances of these transcripts were significantly correlated (left) suggesting that TRAF3IP2-AS1 may regulate TRAF3IP2 (tumor necrosis factor receptor-associated factor 3-interacting protein 2) gene expression, perhaps through local chromatin changes at this locus (right). | 26222413 | |
EL1355 | TRAF3IP2-AS1 | schizophrenia | N/A | N/A | N/A | N/A | Association | 10903453 | LncRNADisease |
EL1363 | TRERNA1 | hepatocellular carcinoma | N/A | hepatoma cells | N/A | expression | miR-190a can silence treRNA post-transcriptionally. Suppression of treRNA by miR-190a led to significant changes of mesenchymal-epithelial transition markers and impaired migration and invasion capability of hepatoma cells. | 26608035 | |
EL1364 | TRIM52-AS1 | renal cell carcinoma | reverse transcription‑quantitative polymerase chain reaction analysis | RCC cells | up-regulated | N/A | TRIM52‑AS1 functions as a tumor suppressor in RCC | 26934858 | |
EL1365 | Trp53cor1 | carcinogen furan | microarray analysis, quantitative RT-PCR | livers of female B6C3F1 mice exposed to the carcinogen furan at 0.0, 1.0, and 2.0mg/kg (noncarcinogenic doses) and at 4.0 and 8.0mg/kg (carcinogenic doses) for 3 weeks | up-regulated | expression | LincRNA-p21 is an antisense transcript that is 15kb downstream from Cdkn1a locus and appears to be cotranscribed with the protein coding gene Cdkn1a at 8.0mg/kg furan. | 23853263 | |
EL1365 | Trp53cor1 | tumor | N/A | N/A | N/A | regulation | Global gene repression in the p53 transcriptional response by binding hnRNP-K, inducing cellular apoptosis. | 22996375 | LncRNADisease |
EL1365 | Trp53cor1 | cancer | N/A | N/A | N/A | expression | lincRNA-p21 (named for its vicinity to the CDKN1A/p21 locus) is upregulated by p53 upon DNA damage and implicated in downstream repressive effects of the p53 pathway, particularly on genes regulating apoptosis, possibly by directing the recruitment of hnRNP-K to its genomic targets. | 23463798 | LncRNADisease |
EL1365 | Trp53cor1 | tumor | N/A | N/A | N/A | regulation | Thus, similar to its activator p53, lincRNA-p21 may play an important role in tumour suppression by operating as a transcriptional repressor. | 23660942 | LncRNADisease |
EL1365 | Trp53cor1 | tumor | N/A | N/A | N/A | regulation | Global gene regulation p53 repression via hnRNP-K; inducing cellular apoptosis | 24499465 | LncRNADisease |
EL1365 | Trp53cor1 | tumor | N/A | N/A | N/A | regulation | ANRIL, GAS5 and lincRNA-p23 are involved in the escape of growth suppression by regulating tumor suppressor genes (ANRIL) or apoptosis regulators. | 24667321 | LncRNADisease |
EL1365 | Trp53cor1 | cancer | N/A | N/A | N/A | regulation | They identified lincRNA-p21 as a direct p53 target. Furthermore, they found that lincRNA-p21 is critical in regulating many of the genes that are repressed in response to p53 activity and they found that lincRNA-p21 associates with hnRNP-K. The lincRNA-p21/hnRNP-K interaction was found to be necessary for hnRNP-K genomic localization at sites of gene repression. | 24829860 | LncRNADisease |
EL1365 | Trp53cor1 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (HCT-116 (p53t/t), HCT-116(p53-/-) etc.) | down-regulated | expression | One of them, lincRNA-p21, was regulated by p53 and contributed to apoptosis in mouse embryonic fibroblasts. | 24012455 | LncRNADisease Lnc2Cancer |
EL1366 | TRPM2-AS | prostate cancer | microarray, qPCR etc. | cell line (PC3) | differential expression | expression | This essential role, coupled to the TRPM2-AS low-expression levels in healthy tissues, makes this ncRNA a suitable therapeutic target for further clinical studies. To get insights into the survival mechanism controlled by this molecule, we ablated its expression in prostate cancer cells and performed a genome-wide analysis of the transcripts differentially regulated in dying cells. | 26484139 | Lnc2Cancer |
EL1366 | TRPM2-AS | prostate cancer | microarray, qPCR, knockdown etc. | prostate cancer tissue, cell lines (PNT1A, PC3 etc.) | up-regulated | N/A | TRPM2-AS is overexpressed in prostate cancer (PCa). The high expression of TRPM2-AS and its related gene signature were found to be linked to poor clinical outcome, with the related gene signature working also independently of the patient's Gleason score. Mechanistically, TRPM2-AS knockdown led to PCa cell apoptosis, with a transcriptional profile that indicated an unbearable increase in cellular stress in the dying cells, which was coupled to cell cycle arrest, an increase in intracellular hydrogen peroxide and activation of the sense TRPM2 gene. | 24931166 | Lnc2Cancer |
EL1367 | Trpm3 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 25 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL1368 | TSIX | systemic sclerosis | real-time PCR and in situ hybridization, immunoblotting | dermal fibroblasts, serum | up-regulated | interaction | TSIX siRNA reduced the mRNA expression of type I collagen in normal and SSc dermal fibroblasts, but not the levels of major disease-related cytokines. In addition, TSIX siRNA significantly reduced type I collagen mRNA stability, but not protein half-lives. TSIX is a new regulator of collagen expression which stabilizes the collagen mRNA. | 26566700 | |
EL1370 | TSNAX-DISC1 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | up-regulated | expression | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL1371 | TSPAN8 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | down-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL1396 | TUBA4B | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | RP11-385J1.2 and TUBA4B were the most markedly changed of these candidate lncRNAs from 90 NSCLC and normal lung tissue samples. As shown in Fig. 4, RP11-385J1.2 expression in NSCLC was significantly higher than in the adjacent tissues, while TUBA4B expression in NSCLC was significantly lower than in the adjacent tissues. | 25394782 | Lnc2Cancer |
EL1397 | TUC339 | hepatocelluar carcinoma | qPCR, knockdown etc. | HCC tissue, cell lines (Hep3B, HepG2, PLC/PRF/5 etc.) | up-regulated | N/A | The most highly significantly expressed ucRNA in HCC cell-derived extracellular vesicles was cloned and identified as a 1,198-bp ucRNA, termed TUC339. TUC339 was functionally implicated in modulating tumor cell growth and adhesion. Suppression of TUC339 by siRNA reduced HCC cell proliferation, clonogenic growth, and growth in soft agar. Thus, intercellular transfer of TUC339 represents a unique signaling mechanism by which tumor cells can promote HCC growth and spread. | 24167654 | Lnc2Cancer |
EL1398 | T-UCRs | neuroblastoma | N/A | N/A | N/A | regulation | It is now becoming increasingly evident that N-myc also regulates the expression of long noncoding RNAs such as T-UCRs and ncRAN. | 22936790 | LncRNADisease |
EL1399 | TUG1 | prostate cancer | integrating analysis of sequence features and gene expression profiles | prostate cancer | up-regulated | N/A | sub-cellular localization-dependent function | 26975529 | |
EL1399 | TUG1 | gastric cancer | knockdown of TUG1 repressed GC proliferation | non-small cell lung cancer | up-regulated | N/A | TUG1 was associated with PRC2 | 26913601 | |
EL1399 | TUG1 | Huntington's disease | N/A | N/A | N/A | expression | TUG1 is upregulated in Huntington's disease brains, which is from the reanalysis of the Affymetrix U133A and B microarray data on normal and HD brains in this review. | 22202438 | LncRNADisease |
EL1399 | TUG1 | Huntington's disease | N/A | N/A | N/A | expression | LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. | 23346095 | LncRNADisease |
EL1399 | TUG1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
EL1399 | TUG1 | bladder cancer | N/A | N/A | N/A | regulation | Putative diagnostic and prognostic marker; oncogene | 24373479 | LncRNADisease |
EL1399 | TUG1 | osteosarcoma | qPCR etc. | osteosarcoma tissue, cell lines (U2OS etc.) | up-regulated | N/A | We found significantly higher TUG1 and n377360 expression levels in osteosarcoma tissues compared with matched non-tumorous tissues. Suppression of TUG1 and n377360 expression by siRNA significantly impaired the cell proliferation potential of osteosarcoma cells. Furthermore, inhibition of TUG1 expression significantly promoted osteosarcoma cell apoptosis. The overexpression of TUG1 and n377360 in osteosarcoma specimens and the functional role of TUG1 and n377360 regarding cell proliferation and apoptosis in an osteosarcoma cell line provided evidence that the use of TUG1 or n377360 may be a viable but an as yet unexplored therapeutic strategy in tumors that over express these factors. | 23725133 | Lnc2Cancer |
EL1399 | TUG1 | multiple myeloma | qPCR etc. | blood (plasma) | up-regulated | N/A | In our study, TUG1 levels were investigated in cell free plasma samples and higher expression was only observed in the MM group although correlation with disease state was observed both in the CLL and MM groups. | 24583225 | LncRNADisease Lnc2Cancer |
EL1399 | TUG1 | glioma | qPCR etc. | cell lines(U251, U87) | down-regulated | expression | MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. | 25645334 | Lnc2Cancer |
EL1399 | TUG1 | urothelial carcinoma of the bladder | qPCR, knockdown etc. | cell lines (T24, 5637 etc. | up-regulated | expression | Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. | 22961206 | LncRNADisease Lnc2Cancer |
EL1399 | TUG1 | esophageal squamous cell carcinoma | qPCR, knockdown, FCA etc. | ESCC tissue | up-regulated | interaction | TUG1 was significantly overexpressed in ESCC tissues compared with paired adjacent normal tissues, and high expression level of TUG1 was associated with family history and upper segment of esophageal cancer. Further, in vitro silencing TUG1 via siRNA inhibited the proliferation and migration of ESCC cells and blocked the progression of cell cycle. | 25366138 | Lnc2Cancer |
EL1399 | TUG1 | non-small cell lung cancer | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | cell lines (A549, SK-MES-1, NCI-H1299 etc.) | down-regulated | regulation | P53-regulated?long?non-coding?RNA?TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. | 24853421 | LncRNADisease Lnc2Cancer |
EL1399 | TUG1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | bladder cancer tissue, | up-regulated | interaction | We confirmed that TUG1 was overexpressed in bladder cancer tissues and established cell lines. Knockdown of TUG1 inhibited bladder cancer cell metastasis both in vitro and in vivo. Furthermore, we found that TUG1 promoted cancer cell invasion and radioresistance through inducing epithelial-to-mesenchymal transition (EMT). Interestingly, TUG1 decreased the expression of miR-145 and there was a reciprocal repression between TUG1 and miR-145 in an Argonaute2-dependent manner. ZEB2 was identified as a down-stream target of miR-145 and TUG1 exerted its function through the miR-145/ZEB2 axis. | 26318860 | Lnc2Cancer |
EL1399 | TUG1 | hepatocelluar carcinoma | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | HCC tissue, cell lines (HepG2, MHCC-97H, Hep3B) | up-regulated | interaction | TUG1 expression was up-regulated in HCC tissues and the higher expression of TUG1 was significantly correlated with tumor size and Barcelona Clinic Liver Cancer (BCLC) stage. Moreover, silencing of TUG1 expression inhibited HCC cell proliferation, colony formation, tumorigenicity and induced apoptosis in HCC cell lines. We also found that TUG1 overexpression was induced by nuclear transcription factor SP1 and TUG1 could epigeneticly repress Kruppel-like factor 2 (KLF2) transcription in HCC cells by binding with PRC2 and recruiting it to KLF2 promoter region. | 26336870 | Lnc2Cancer |
EL1399 | TUG1 | colorectal cancer | quantitative real-time PCR | cultured representative CRC cell lines and 120 CRC patients | up-regulated | N/A | increased their colony formation, migration, and invasion in vitro | 26856330 | |
EL1399 | TUG1 | glioma | quantitative RT-PCR, Annexin V/PI staining and cell counting kit-8 assays | glioma tissues | down-regulated | interaction | The dysregulation of taurine upregulated gene 1 affected the apoptosis and cell proliferation of glioma cells. Taurine upregulated gene 1 promoted cell apoptosis of glioma cells by activating caspase-3 and -9-mediated intrinsic pathways and inhibiting Bcl-2-mediated anti-apoptotic pathways, acting as a tumor suppressor in human glioma. | 26748401 | |
EL1401 | TUNAR | breast cancer | qPCR, Western blot, Luciferase reporter assays, RNA Pull-Down Assay, RPI etc. | breast cancer tissues and adjacent nontumor tissues, cell lines (MCF7, T47D, BT474, and MDA-MB-468) | up-regulated | interaction | We found the human ortholog of TUNA, linc00617, was upregulated in breast cancer samples. Linc00617 promoted motility and invasion of breast cancer cells and induced epithelial-mesenchymal-transition (EMT), which was accompanied by generation of stem cell properties. Moreover, knockdown of linc00617 repressed lung metastasis in vivo. We demonstrated that linc00617 upregulated the expression of stemness factor Sox2 in breast cancer cells, which was shown to promote the oncogenic activity of breast cancer cells by stimulating epithelial-to-mesenchymal transition and enhancing the tumor-initiating capacity | 26207516 | Lnc2Cancer |
EL1402 | TUSC7 | osteosarcoma | Cell counting kit 8 (CCK-8) assay, western blot | osteosarcoma tissues | down-regulated | interaction | Cell counting kit 8 (CCK-8) assay revealed that after silence of TUSC7, cell proliferation ability increased and the colony formation ability also increased. After silence of TUSC7, the proapoptotic Bcl2 expression was downregulated. Compared with negative control group, silence of TUSC7 significantly promoted tumor growth in vivo. Thus, we demonstrated that TUSC7 could be a potential tumor suppressor in osteosarcoma. | 26781978 | |
EL1402 | TUSC7 | osteosarcoma | deletion analysis, reciprocal repression, quantitative PCR arrays and in situ hybridization of tissue microarrays | N/A | down-regulated | N/A | a tumor suppressor unit in osteosarcoma and to suppress tumor cell growth. ,loc285194 is a p53 transcription target; ectopic expression of loc285194 inhibits tumor cell growth both in vitro and in vivo..loc285194 is a p53-regulated tumor suppressor, which acts in part through repression of miR-211. | 23558749 | |
EL1402 | TUSC7 | colon cancer | deletion analysis, reciprocal repression, quantitative PCR arrays and in situ hybridization of tissue microarrays | N/A | down-regulated | N/A | a tumor suppressor unit in osteosarcoma and to suppress tumor cell growth. ,loc285194 is a p53 transcription target; ectopic expression of loc285194 inhibits tumor cell growth both in vitro and in vivo..loc285194 is a p53-regulated tumor suppressor, which acts in part through repression of miR-211. | 23558749 | |
EL1402 | TUSC7 | osteosarcoma | microarray, qPCR, FISH etc. | osteosarcoma tissue, cell lines (U2OS, SAOS-2, HOS etc.) | down-regulated | mutation | These CNAs (copy number alterations) in osteosarcoma often involve the noncoding RNAs LOC285194 and BC040587. | 20048075 | LncRNADisease Lnc2Cancer |
EL1402 | TUSC7 | gastric cancer | microarray, qPCR, knockdown etc. | gastric cancer tissue | down-regulated | N/A | The results indicated that TUSC7 was downregulated in GC samples and was an independent prognostic indicator of disease-free survival (DFS) and disease-specific survival (DSS) in GC patients.The results indicated that TUSC7 is a p53-regulated tumour suppressor that acts in part by repressing miR-23b and that TUSC7 may be a key regulatory hub in GC. | 25765901 | LncRNADisease Lnc2Cancer |
EL1402 | TUSC7 | hepatocelluar carcinoma | N/A | hepatocellular carcinoma | down-regulated | N/A | inhibited cell metastasis, invasion, and epithelial-to-mesenchymal | 27002617 | |
EL1402 | TUSC7 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (CaCO-2, HCT8, LoVo, CCC-HIE-2 etc.) | down-regulated | N/A | The relative expression levels of LOC285194 was significantly lower in tumor tissues (p<0.001) and colorectal cancer cell lines compared with adjacent normal tissues and normal intestinal mucous cell line. In addition, low expression of LOC285194 was correlated with larger tumor size, higher tumor stage (p=0.034), and more distant metastasis (p=0.046). Our data indicate that LOC285194 might be a novel prognostic indicator in colorectal cancer and may be a potential target for diagnosis and gene therapy. | 23680400 | Lnc2Cancer |
EL1402 | TUSC7 | esophageal squamous cell carcinoma | qPCR, knockdown etc | ESCC tissue, cell lines (KYSE30, KYSE 70, KYSE 150, KYSE510, Eca109) | down-regulated | N/A | LOC285194 expression was significantly down-regulated in ESCC tumor tissues when compared with the adjacent normal tissues. Low expression of LOC285194 was associated with larger tumor size, advanced TNM stage, more lymph node metastases and distant metastases. | 25169763 | LncRNADisease Lnc2Cancer |
EL1403 | TUSC8 | cervical cancer | qPCR, Western blot, knockdown etc. | cervical cancer tissue, cell lines (HeLa, SiHa, HCC94) | down-regulated | expression | Low expression of long noncoding XLOC_010588 indicates a poor prognosis and promotes proliferation through upregulation of c-Myc in cervical cancer. | 24667250 | LncRNADisease Lnc2Cancer |
EL1404 | U1 spliceosomal lncRNA | Parkinson's disease | N/A | N/A | N/A | expression | These included the U1 spliceosomal lncRNA and RP11-462G22.1, each entailing sequence complementarity to numerous microRNAs. | 24651478 | LncRNADisease |
EL1405 | Ube3a-ATS | Angelman syndrome | N/A | N/A | N/A | N/A | ASO treatment achieved specific reduction of Ube3a-ATS and sustained unsilencing of paternal Ube3a in neurons in vitro and in vivo. Partial restoration of UBE3A protein in an Angelman syndrome mouse model ameliorated some cognitive deficits associated with the disease. | 25470045 | LncRNADisease |
EL1406 | uc.115- | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 10 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL1407 | uc.173 | lead-induced nerve injury | overexpress, quantitative real-time PCR | a lead-induced nerve injury mouse model, N2a mouse nerve cell line | down-regulated | interaction | Uc.173 had an inhibitory effect on lead-induced apoptosis of N2a. | 26683706 | |
EL1408 | uc.184+ | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 19 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL1409 | uc.283-plus | glioma | microarray, qPCR etc. | glioma tissue | up-regulated | expression | Among the normal tissues, the uc.283 lncRNA was highly specific for pluripotent stem cells. Intriguingly, the uc.283-plus lncRNA was highly expressed in some solid cancers, particularly in one of the most untreatable types, glioma.uc.283-plus lncRNA might have a role in pluripotency of stem cells and in the biology of glioma. | 25352916 | Lnc2Cancer |
EL1410 | uc.341 | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | up-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL1411 | uc.388 | colorectal cancer | qPCR etc. | CRC tissue | down-regulated | N/A | Expression levels of uc.73 (p = 0.0139) and uc.388 (p = 0.0325) were significantly decreased in CRC tissue, and uc.73 indicated a positive correlation with overall survival. The lower expression of uc.388 was associated with the distal location of CRC (p = 0.0183). Our preliminary results suggest that uc.73 and uc.388 could be potential diagnostic and prognostic biomarkers in CRC patients. | 22328099 | Lnc2Cancer |
EL1412 | uc.73 | colorectal cancer | qPCR etc. | CRC tissue | down-regulated | N/A | Expression levels of uc.73 (p = 0.0139) and uc.388 (p = 0.0325) were significantly decreased in CRC tissue, and uc.73 indicated a positive correlation with overall survival. The lower expression of uc.388 was associated with the distal location of CRC (p = 0.0183). Our preliminary results suggest that uc.73 and uc.388 could be potential diagnostic and prognostic biomarkers in CRC patients. | 22328099 | Lnc2Cancer |
EL1413 | uc001aka.2 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | down-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL1414 | uc001gch.1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL1415 | uc001gzl.3 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | up-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL1416 | uc001lsz | gastric cancer | microarray, qPCR etc. | gastric cancer tissue, cell lines (GES-1, AGS, MGC-803, SGC-7901) | down-regulated | N/A | The most down-regulated lncRNAs in gastric cancer tissues were FER1L4, uc001lsz, BG491697, AF131784, uc009ycs, BG981369, AF147447, HMlincRNA1600, and AK054588; while the most up-regulated ones were H19, HMlincRNA717, BM709340, BQ213083, AK054978, and DB077273. | 24063685 | Lnc2Cancer |
EL1416 | uc001lsz | prostate cancer | qPCR etc. | cell lines ((Du-145, PC-3) | up-regulated | N/A | We found that comparing with respective normal cell line, uc001lsz was lowly expressed in gastric cancer (AGS, MGC-803 and SGC-7901), lung cancer (A549) and liver cancer (SMMC-7721 and HepG2) cell lines, while only highly expressed in prostate cancer (Du-145 and PC-3) cell lines. | 24063685 | Lnc2Cancer |
EL1416 | uc001lsz | liver cancer | qPCR etc. | cell lines (SMMC-7721, HepG2) | down-regulated | N/A | We found that comparing with respective normal cell line, uc001lsz was lowly expressed in gastric cancer (AGS, MGC-803 and SGC-7901), lung cancer (A549) and liver cancer (SMMC-7721 and HepG2) cell lines, while only highly expressed in prostate cancer (Du-145 and PC-3) cell lines (Figure 3C). | 24063685 | Lnc2Cancer |
EL1416 | uc001lsz | lung cancer | qPCR etc. | cell lines (A549) | down-regulated | N/A | We found that comparing with respective normal cell line, uc001lsz was lowly expressed in gastric cancer (AGS, MGC-803 and SGC-7901), lung cancer (A549) and liver cancer (SMMC-7721 and HepG2) cell lines, while only highly expressed in prostate cancer (Du-145 and PC-3) cell lines. | 24063685 | Lnc2Cancer |
EL1417 | uc001ncr | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | down-regulated | expression | We determined that a panel based on the expression of uc001ncr and AX800134 accurately diagnosed HBV-positive HCC (AUC values of 0.9494 and 0.9491 for the training and validation cohorts, respectively). The diagnostic performance of the panel remained high in patients with AFP>=400 ng/ml (AUC values of 0.9371 and 0.9527 for the training and validation cohorts, respectively). The panel also diagnosed early HCC (AUC values of 0.9450 and 0.9564 for the training and validation cohorts, respectively) | 26674525 | Lnc2Cancer |
EL1418 | LOC100288208 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | up-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL1419 | uc002nbr.3 | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | down-regulated | expression | The results showed that seven of these lncRNAs were in accordance with microarray data, including three up-regulated lncRNAs (uc003xut., uc021re1.1, ENST00000445734) and four down-regulated ones (uc002nbr.3, ENST00000502941, ENST00000448093, ENST00000503710). | 26131074 | Lnc2Cancer |
EL1420 | LINC01589 | non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | up-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer |
EL1421 | uc003erl.1 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | up-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL1422 | uc003iqu | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | up-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL1423 | uc003jfz.2 | gastric cardia adenocarcinoma | microarray, qPCR etc. | gastric cancer tissue | up-regulated | N/A | We found that ASHG19A3A029791, ASHG19A3A034382, ASHG19A3A028003, ASHG19A3A013479, ASHG19A3A022744, ASHG19A3A025864, ASHG19A3A043106 and ASHG19A3A03455, were up-regulated, and ASHG19A3A007791, ASHG19A3A050006, ASHG19A3A051125, ASHG19A3A011053 were down-regulated in the GCa samples compared with normal samples. Thus, the results from the qPCR analysis and the microarray data analysis were consistent (p < 0.05). | 24414129 | Lnc2Cancer |
EL1424 | uc003tfx | gastric cancer | microarray, qPCR etc. | primary gastric adenocarcinoma tissue | up-regulated | N/A | For the lncRNAs, the results demonstrated that uc003iqu, uc003tfx, AK022971 and uc.341 were upregulated and that HIV1230, BC011663, AK057054 and M14574 were downregulated in the GC tissues relative to their matched counterparts (all p<0.05). | 24819045 | Lnc2Cancer |
EL1425 | AC091173.1 | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | up-regulated | expression | The results showed that seven of these lncRNAs were in accordance with microarray data, including three up-regulated lncRNAs (uc003xut., uc021re1.1, ENST00000445734) and four down-regulated ones (uc002nbr.3, ENST00000502941, ENST00000448093, ENST00000503710). | 26131074 | Lnc2Cancer |
EL1426 | uc004bbl.1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL1427 | uc004bdv.3 | hepatocelluar carcinoma | microarray, qPCR etc. | HBV-related HCC tissue | up-regulated | expression | Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. | 26109807 | Lnc2Cancer |
EL1428 | uc009wkz.1 | renal cell carcinoma | microarray, qPCR etc. | RCC tissue | up-regulated | N/A | From five paired samples we identified hundreds of significantly differentiated lncRNAs. Specifically, the most upregulated lncRNAs were: uc001vjj.1, ENST00000414223, BC047917, uc003erl.1, and uc009wkz.1, of which uc001vjj.1 was the highest. The most highly downregulated were: ENST00000507950, uc001aka.2, NR_026860, NR_024256, and BC070168, of which ENST00000507950 showed the largest downregulation. | 24905231 | Lnc2Cancer |
EL1429 | uc021re1.1 | endometrial cancer | microarray, qPCR etc. | endometrial carcinoma tissue | up-regulated | expression | The results showed that seven of these lncRNAs were in accordance with microarray data, including three up-regulated lncRNAs (uc003xut., uc021re1.1, ENST00000445734) and four down-regulated ones (uc002nbr.3, ENST00000502941, ENST00000448093, ENST00000503710). | 26131074 | Lnc2Cancer |
EL1431 | UCA1 | colorectal cancer | in vitro and in vivo growth-promoting function | two CRC cohorts | up-regulated | N/A | UCA1 could sponge endogenous miR-204-5p and inhibit its activity | 27046651 | |
EL1431 | UCA1 | gastric cancer | microarray assay, real-time PCR assay | gastric tumor samples | N/A | expression | There was a significantly positive correlation of UCA1 expression levels between tumor tissues and plasma (r = 0.931). Plasma UCA1 provided the higher diagnostic performance for detection of GC (AUC = 0.928; P < 0.001) than PVT-1 (AUC = 0.731; P < 0.01). Plasma UCA1 levels could be a promising candidate of noninvasive biomarker for GC early diagnosis. | 26722487 | |
EL1431 | UCA1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
EL1431 | UCA1 | breast cancer | microarray, qPCR, knockdown, ISH etc. | breast cancer tissues and adjacent normal tissues, cell lines(MDA-MB-231) | up-regulated | interaction | UC1 was significantly upregulated, while miR-143 was significantly downregulated in the tumor tissues than in the adjacent normal tissues. There are direct interactions between miR-143 and the miRNA recognition sites of UCA1. UCA1 is present in Ago2-containing RNA-induced silencing complex (RISC), through association with miR-143. Through downregulating miR-143, UCA1 can modulate breast cancer cell growth and apoptosis | 26439035 | Lnc2Cancer |
EL1431 | UCA1 | colorectal cancer | microarray, qPCR, Luciferase reporter assay, knockdown etc. | CRC tissue, cell lines (HCT116, SW480, RKO, HCT8, LoVo etc.) | up-regulated | interaction | UCA1 was upregulated in CRC and the expression of UCA1 was statistically correlated with lymph node metastasis, distant metastasis and tumor stage. We also found that knockdown of UCA1 significantly suppressed cell proliferation and metastasis in CRC cells. Flow cytometry assays showed UCA1 silencing induced G0/G1 growth arrest and apoptosis of CRC cells. To further investigate the regulatory mechanisms of UCA1, we identified that Ets-2 bound to the UCA1 core promoter using luciferase assays. | 26238511 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | microarray, qPCR, Northern blot etc. | bladder cancer tissue, cell lines (TCC, BLS-211, BLZ-211 etc.) | up-regulated | expression | UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. | 18501714 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | breast cancer | microarray, qPCR, Western blot, knockdown, Luciferase reporter assay, RIP etc. | cell lines ( MCF-7, MDA-MB-231, HCT-116 p53-WT, HCT-116 etc.) | up-regulated | regulation | Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). | 24457952 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | microarray, qPCR, Western blot, Luciferase reporter assay, knockdown etc. | bladder cancer tissue, cell lines (RT4, T24 etc.) | up-regulated | regulation | Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. | 24495014 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
EL1431 | UCA1 | gastric cancer | microarray, RT-PCR | gastric tumor samples | up-regulated | expression | The expression level of 4 lncRNAs: UCA1, lincRNA-BBOX1-2, CR594506 and BC015134 were further confirmed in another cohort of 10 gastric patients by real-time PCR assay. A coding-non-coding co-expression network revealed that the four validated lncRNAs were correlated with twenty-six mRNAs which gave clues about the potential roles of these lncRNAs in the process of gastric cancer progression. | 25769450 | |
EL1431 | UCA1 | epithelial ovarian cancer | N/A | EOC tissues and cells | up-regulated | N/A | upregulated in EOC tissues and cells, but also correlated with status of lymph; an endogenous sponge | 26867765 | |
EL1431 | UCA1 | squamous cell carcinoma | N/A | N/A | N/A | expression | Cancer up-regulated drug resistant (CUDR) gene, was found to be overexpressed in a doxorubicin-resistant subline of human squamous carcinoma A431 and A10A cells. | 17416635 | LncRNADisease |
EL1431 | UCA1 | pancreaticobiliary maljunction | N/A | N/A | N/A | expression | Gene expression profiling reveals upregulated UCA1 and BMF in gallbladder epithelia of children with pancreaticobiliary maljunction. | 21593646 | LncRNADisease |
EL1431 | UCA1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
EL1431 | UCA1 | bladder cancer | N/A | N/A | N/A | expression | Diagnostic marker oncogene | 24373479 | LncRNADisease |
EL1431 | UCA1 | oral squamous cell carcinoma | N/A | N/A | N/A | expression | Subsequently, they confirmed that the expression levels of HOTAIR, NEAT-1 and UCA3 in metastasized samples was prominent higher than the non-metastatic samples.? | 24817925 | LncRNADisease |
EL1431 | UCA1 | tongue squamous cell carcinoma | N/A | N/A | N/A | expression | Meaningfully, the expression levels of UCA1 lncRNA were dramatically higher in TSCC tissues than those in paired ANTs.? | 24817925 | LncRNADisease |
EL1431 | UCA1 | urinary bladder cancer | N/A | N/A | N/A | N/A | UCA1 expression was found in T24 cell line and also found to be significantly higher in the cancer group as compared to the controls | 25123267 | LncRNADisease |
EL1431 | UCA1 | bladder cancer | qPCR etc. | bladder cancer tissue | up-regulated | expression | UCA1 was identified as a novel noncoding RNA gene dramatically up-regulated in TCC (bladder transitional cell carcinoma) and it is the most TCC-specific gene yet identified. | 16914571 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR etc. | cell line (BLZ-211) | up-regulated | N/A | After knocking down of UCA1 in BLZ-211 cells, several cell cycle-related genes (CDKN2B, EP300 and TGFβ-2) were screened by microarray assay and validated by qPCR. Taken together, we concluded that UCA1 regulated cell cycle through CREB via PI3K-AKT dependent pathway in bladder cancer. | 22285928 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR etc. | bladder cancer tissue | up-regulated | expression | With a high level of sensitivity and specificity, UCA1 is a promising urinary marker for the diagnosis of bladder cancer. | 22490897 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR etc. | cell lines (BLZ-211, 5637, UM-UC-2 etc.) | up-regulated | expression | Overexpression of UCA1a(CUDR) significantly enhanced proliferation, migration and invasion of the bladder cancer cell line UM-UC-2. | 22576688 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | oral squamous cell carcinoma | qPCR etc. | OSCC tissues | up-regulated | N/A | We found that most of the selected transcripts (4/6) were upregulated in tumors relative to matched adjacent nonmalignant tissue. One gene, MEG-3, was downregulated in cancer compared with its adjacent nonmalignant tissue. Expression of lncRNA (HOTAIR, NEAT-1 and UCA1) was significantly higher in the samples that subsequently metastasized compared with the non-metastatic samples. By contrast, MEG-3 was downregulated in the metastatic samples. These findings suggest that the detection of lncRNAs in saliva may be used as a noninvasive and rapid diagnostic tool for the diagnosis of oral cancer. | 23292713 | Lnc2Cancer |
EL1431 | UCA1 | tongue squamous cell carcinoma | qPCR etc. | TSCC tissue | up-regulated | N/A | The expression levels of lncRNA UCA1 were significantly elevated in TSCC tissues (P < .0001) and were statistically correlated with lymph node metastasis (P = .0371). Over-expression of UCA1 lncRNA could promote metastatic but not proliferation ability of TSCC cells. | 24332332 | Lnc2Cancer |
EL1431 | UCA1 | colorectal cancer | qPCR etc. | colorectal cancer tissue, cell lines (CaCO-2, SW480, HCT116, LoVo etc.) | up-regulated | N/A | UCA1 levels were markedly increased in CRC tissues, and this high level of UCA1 expression was significantly correlated with larger tumour size, less differentiated histology and greater tumour depth.an important role for UCA1 in the molecular aetiology of CRC and suggest a potential application for UCA1 in CRC diagnosis, progression and therapy. | 24977734 | Lnc2Cancer |
EL1431 | UCA1 | gastric cancer | qPCR etc. | cancerous gastric tissue, blood (serum) | up-regulated | expression | A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC. | 25694351 | Lnc2Cancer |
EL1431 | UCA1 | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines (SGC-7901, BGC-823, MKN-28) | up-regulated | N/A | UCA1 expression was remarkably increased in gastric cancer tissues and cell lines compared with that in the normal control; high UCA1 expression correlated with worse differentiation, tumor size, invasion depth and TNM stage in gastric cancer; increased UCA1 expression contributed to poor overall survival and disease-free survival of patients. | 25903045 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR etc. | urine | up-regulated | interaction | Compared to control groups, the malignant group had higher expression levels of miR-210, miR-96, and lncRNA-UCA1. | 26138586 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR etc. | urine | up-regulated | expression | The detected lncRNA-UCA1 level was significantly lower in healthy donors and benign groups compared to bladder cancer samples. | 26161701 | Lnc2Cancer |
EL1431 | UCA1 | lung cancer | qPCR etc. | NSCLC tissue | up-regulated | expression | The results showed that the expression of UCA1 in NSCLC tissues was obviously higher than that observed in pair-matched adjacent nontumourous tissues, (P < 0.001). In conclusion, the current results indicated that Plasma UCA1 could serve as a potential biomarker for diagnosis of NSCLC. UCA1 as a biomarker in clinical application might significantly improve the efficacy of human NSCLC screening. | 26380024 | Lnc2Cancer |
EL1431 | UCA1 | breast cancer | qPCR etc. | breast cancer tissue | up-regulated | expression | We found that treatment with macrophage CM induced the expression of numerous lncRNAs, including urothelial cancer associated 1 (UCA1). Knockdown of UCA1 using shRNA inhibited AKT phosphorylation and abolished invasiveness of tumor cells induced by macrophage CM. Consistent with these results; we further showed that UCA1 level was significantly enhanced in human primary breast tumors and correlated with advanced clinical stage, supporting its role in promoting carcinogenesis and progression of breast cancer | 26464647 | Lnc2Cancer |
EL1431 | UCA1 | hepatocelluar carcinoma | qPCR etc. | HCC tissue | up-regulated | expression | We found that lncRNA-UCA1 and lncRNA-WRAP53 were significantly higher in sera of HCC than those with chronic HCV infection or healthy volunteers. Our data suggested that the increased expression of UCA1 and WRAP53 was associated with advanced clinical parameters in HCC. | 26551349 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, ISH etc. | cell lines (BLS-211, BLX-211, BLZ-211 etc.) | up-regulated | expression | In adult human tissues, UCA1 gene was not expressed except in the heart and spleen. The expression level of UCA1 was increased in 8 common tumor tissues as compared with that in the corresponding normal tissues. | 20117985 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | melanoma | qPCR, knockdown etc. | melanoma tissue, cell line (A-375) | up-regulated | N/A | highly expressed,can promote the metastasis of melanoma. The expression levels of UCA1 and Malat-1 lncRNAs had the potential to be prognostic indicators in metastasis of melanomas. | 24892958 | Lnc2Cancer |
EL1431 | UCA1 | esophageal squamous cell carcinoma | qPCR, knockdown etc. | ESCC tissue, cell lines (EC109, EC9706, KYSE150, KYSE510) | up-regulated | expression | The relative level of UCA1 was significantly higher in ESCC tissues, and remarkably higher expression of UCA1 was found in esophageal cancer cell lines compared with the immortalized esophageal epithelial cell line NE1. The ESCC patients with higher UCA1 expression had an advanced clinical stage and a poorer prognosis than those with lower expression. In vitro assays, our data indicated that downregulation of UCA1 decrease cell proliferation, migration, and invasion ability. | 25550835 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, Luciferase reporter assays, knockdown etc. | cell lines (5637, T24, BLZ-211, BLS-211) | up-regulated | expression | Upregulation of long non-coding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein α contributes to bladder cancer cell growth and reduced apoptosis. | 24648007 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, Western blot, in vitro knockdown, RIP etc. | bladdder cancer tissue | up-regulated | N/A | In the present study, we first examined the function of UCA1 in 5637 bladder cancer cells, which express high levels of UCA1. We found that UCA1 plays an oncogene-like role in this bladder cancer cell line, which is consistent with previous reports. Furthermore, we found UCA1 promotes 5637 cell proliferation by antagonizing the activities of BRG1, by reducing its binding to the p21 promoter and inhibiting its chromatin remodeling activity.UCA1 impairs both binding of BRG1 to the p21 promoter and chromatin remodeling activity of BRG1. | 24993775 | Lnc2Cancer |
EL1431 | UCA1 | liver cancer | qPCR, Western blot, ISH, RIP, ChIP etc. | Human liver cancer stem cell line | up-regulated | interaction | Herein, we demonstrate excessive CUDR cooperates with excessive CyclinD1 or PTEN depletion to accelerate liver cancer stem cells growth and liver stem cell malignant transformation in vitro and in vivo. | 26513297 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, Western blot, knockdown etc. | bladder cancer cell lines | up-regulated | N/A | In this study, we show that lncRNA UCA1 promotes glycolysis in bladder cancer cells, and that UCA1-induced hexokinase 2 (HK2) functions as an important mediator in this process. We further show that UCA1 activates mTOR to regulate HK2 through both activation of STAT3 and repression of microRNA143. | 24890811 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, Western blot, knockdown etc. | bladder cancer tissue | up-regulated | N/A | Here, we report that downregulated hsa-miR-1 and upregulated lncRNA urothelial cancer associated 1 (UCA1) were inversely expressed in bladder cancer. Hsa-miR-1 decreased the expression of UCA1 in bladder cancer cells in an Ago2-slicer-dependent manner. The binding site between UCA1 and hsa-miR-1 was confirmed. Overexpression of hsa-miR-1 inhibited bladder cancer cell growth, induced apoptosis, and decreased cell motility. hsamiR-1 to play tumor suppressive roles via downregulating lncRNA UCA1 in bladder cancer, which may have potential therapeutic significance. | 25015192 | Lnc2Cancer |
EL1431 | UCA1 | non-small cell lung cancer | qPCR, Western blot, knockdown etc. | lung adenocarcinoma tissues, cell lines (PC9, H1975, H460, H23, H1299) | up-regulated | interaction | In our study, UCA1 expression was significantly increased in lung cancer cells and patients with acquired resistance to EGFR-TKIs. Over-expression of UCA1 was significantly associated with a shorter progression-free survival (PFS), in tumors with respond to EGFR-TKIs. | 26160838 | Lnc2Cancer |
EL1431 | UCA1 | prostate cancer | qPCR, Western blot, knockdown etc. | prostate cancer tissue, cell lines (22RV1, PC3, LNCaP) | up-regulated | interaction | Herein, we found that UCA1 was abnormally upregulated in tumor tissues from PC patients, and patients with high UCA1 levels had a significantly poorer prognosis. Intriguingly, the mRNA and protein levels of KLF4 were significantly increased in tumor tissues, which was highly correlated to UCA1 levels. Moreover, UCA1 depletion inhibited the growth and induced apoptosis in PC3 and LNCaP cell lines. In addition, UCA1 loss-of-function could decrease KLF4 expression, subsequently, the downregulation of KRT6 and KRT13. Taken together, our study indicated that UCA1 had a crucial role in the tumorigenesis of PC. | 26550172 | Lnc2Cancer |
EL1431 | UCA1 | hepatocelluar carcinoma | qPCR, Western blot, knockdown, RIP etc. | HCC tissue, cell lines (MHCC97L, SMMC7721, MHCC97H, HepG2, SK-Hep1 etc.) | up-regulated | N/A | Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. | 25760077 | LncRNADisease Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay etc. | bladder cancer tissue, cell lines (UMUC2, 5637) | up-regulated | interaction | Real-time reverse transcriptase-polymerase chain reaction demonstrated that the RNA level of urothelial carcinoma-associated 1 and GLS2 was positively correlated in bladder cancer tissues and cell lines. | 26373319 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay etc. | bladder cancer tissue, cell lines (5637, T24, UMUC2) | up-regulated | interaction | Here, we demonstrated that overexpression of lncRNA-UCA1 could induce epithelial to mesenchymal transition (EMT) and increase the migratory and invasive abilities of bladder cancer cells. Mechanistically, lncRNA-UCA1 induced EMT of bladder cancer cells by upregulating the expression levels of zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2), and regulated bladder cancer cell migration and invasion by tumor suppressive hsa-miR-145 and its target gene the actin-binding protein fascin homologue 1 (FSCN1). | 26544536 | Lnc2Cancer |
EL1431 | UCA1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | cell lines (5637, T24) | up-regulated | N/A | LncRNA-UCA1 was upregulated by hypoxia in bladder cancer cells. Under hypoxic conditions, lncRNA-UCA1 upregulation increased cell proliferation, migration, and invasion and inhibited apoptosis. The underlying mechanism of hypoxia-upregulated lncRNA-UCA1 expression was that HIF-1a specifically bound to HREs in the lncRNA-UCA1 promoter. Furthermore, HIF-1a knockdown or inhibition could prevent lncRNA-UCA1 upregulation under hypoxia. | 24737584 | Lnc2Cancer |
EL1431 | UCA1 | non-small cell lung cancer | qPCR, Western blot, Luciferase reporter assay, RIP etc. | NSCLC and adjacent non-tumor lung tissues, cell lines (A549, H1299, H446, H460, NCIH1650, BEAS-2B) | up-regulated | interaction | UCA1 overexpression enhanced, whereas UCA1 silencing impaired the proliferation and colony formation of NSCLC cells. Moreover, mechanistic investigations showed that UCA1 upregulated the expression of miR-193a-3p target gene ERBB4 through competitively 'spongeing' miR-193a-3p. Overall, we concluded that UCA1 functions as an oncogene in NSCLC, acting mechanistically by upregulating ERBB4 in part through 'spongeing' miR-193a-3p | 26655272 | Lnc2Cancer |
EL1431 | UCA1 | liver cancer | qPCR, Western blot, RIP etc. | cells line (MEL-2) | up-regulated | interaction | Herein, we demonstrate that SET1A cooperates with CUDR to accelerate hepatocarcinogenesis and promote malignant transformation of hepatocyte-like stem cells. Mechanistically, CUDR enhances the phosphorylation of RB1, C-myc expression, and the interplay between the SET1A and pRB1. Notably, CUDR acts as a sponge cushion that shows a link between SET1A and pRB1, producing a activated pRB1-SET1A complex. | 26581161 | Lnc2Cancer |
EL1431 | UCA1 | renal cell carcinoma | Quantitative polymerase chain reaction (qPCR | RCC cell lines compared with the human embryonic kidney 293T cell line | up-regulated | N/A | an oncogene in RCC | 26935146 | |
EL1431 | UCA1 | gastric cancer | quantitative real-time PCR | N/A | up-regulated | N/A | Silence of UCA1 could significantly inhibit the cell proliferation of gastric cancer | 27056384 | |
EL1431 | UCA1 | acute myeloid leukemia | RNA-seq, qPCR, in vitro knockdown, RIP etc. | cell lines(K562 , CEBPA, CEBPA-P30, K562etc.) | up-regulated | interaction | In this study, we identified the oncogenic urothelial carcinoma associated 1 (UCA1) lncRNA as a novel target of the C/EBPα-p30. While wild-type C/EBPα represses, C/EBPα-p30 can induce UCA1 transcription. Notably, we also show that UCA1 expression increases in cytogenetically normal AML cases carrying biallelic CEBPA mutations.Thus, we identified, for the first time, an oncogenic lncRNA functioning in concert with the dominant negative isoform of C/EBPα-p30 in AML. | 26053097 | Lnc2Cancer |
EL1432 | UCA1 | focal cardiac ischemia reperfusion injury | microarray, qPCR | primary cardiomyocytes after focal cardiac ischemia reperfusion injury (CIR) | down-regulated | expression | Reduction of UCA1 levels plays a pro-apoptotic role in primary cardiomyocytes partially through stimulation of p27 protein expression. These results are in agreement with the observed levels of UCA1, p27 and apoptosis after cardiac I/R injury, suggesting that UCA1 might have an important role during I/R injury | 25871510 | |
EL1433 | UCH1LAS | Parkinson's disease | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease |
EL1434 | UCHL1-AS1 | Parkinson's Disease | N/A | N/A | N/A | interaction | In Parkinson's Disease the lncRNA UCHL1-AS1 acts by directly promoting translation of UCHL1 protein leading to perturbation of the ubiquitin-proteasome system. | 27338628 | |
EL1435 | UFC1 | hepatocelluar carcinoma | microarray, qPCR, in vitro knockdown etc. | HCC tissue, cell lines (BEL-7402, SK-Hep1, Huh7, MHCC-97H) | up-regulated | regulation | Levels of the lincRNA-UFC1 were increased in HCC tissues compared with controls, and associated with tumor size, Barcelona Clinic Liver Cancer stage, and patient outcomes. Transgenic expression of the lincRNA-UFC1 in HCC cells promoted their proliferation and cell-cycle progression and inhibited apoptosis, whereas short hairpin RNA knockdown of lincRNA-UFC1 had opposite effetcs. | 25449213 | Lnc2Cancer |
EL1438 | ULK4P2 | hepatocelluar carcinoma | microarray, qPCR etc. | HBV-related HCC tissue | up-regulated | interaction | Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. The upregulated large intergenic noncoding RNA ULK4P2 was physically combined with enhancer of zeste homolog 2. Therefore, the lncRNAs may participate in regulating HBV-related HCC. | 26109807 | Lnc2Cancer |
EL1439 | URHC | hepatocelluar carcinoma | microarray, qPCR, Western blot etc. | hepatocellular cancer tissue, cell lines (DMEM, Gibco, Gaithersburg, MD, USA etc.) | up-regulated | N/A | We confirmed that URHC expression was up-regulated in 30 HCC cases (57.7%) and that its higher expression was correlated with poor overall survival. We further demonstrated that URHC inhibition reduced cell proliferation and promoted apoptosis. high URHC expression can promote cell proliferation and inhibit apoptosis by repressing ZAK expression through inactivation of the ERK/MAPK pathway. | 25013376 | Lnc2Cancer |
EL1443 | VIM2P | osteoarthritis | qPCR,microarray,Western blot, and immunofluorescence analyses | OA cartilage and normal cartilage | up-regulated | interaction | LncRNA-CIR contributes to ECM degradation and plays a key role in the pathogenesis of OA. | 24757148 | |
EL1444 | VL30 LTRs | hepatocelluar carcinoma | N/A | N/A | N/A | expression | Trim24 (Tif1) and Trim33 (Tif1) interact to form a co-repressor complex that suppresses murine hepatocellular carcinoma. Here we show that Trim24 and Trim33 cooperatively repress retinoic acid receptor-dependent activity of VL30-class endogenous retroviruses (ERVs) in liver. In Trim24-knockout hepatocytes, VL30 derepression leads to accumulation of reverse-transcribed VL30 cDNA in the cytoplasm that correlates with activation of the viral-defense interferon responses mimicking the preneoplastic inflammatory state seen in human liver following exogenous viral infection. Furthermore, upon derepression, VL30 long terminal repeats (LTRs) act as promoter and enhancer elements deregulating expression of neighboring genes and generating enhancer RNAs that are required for LTR enhancer activity in hepatocytes in vivo. | 23377542 | LncRNADisease |
EL1446 | VLDLR-AS1 | hepatocelluar carcinoma | qPCR, Western blot, knockdown etc. | cell lines (HepG2, Hep3B, PLC/PRF-5, Huh-7) | up-regulated | N/A | lincRNA-VLDLR (linc-VLDLR) was significantly upregulated in malignant hepatocytes. Exposure of HCC cells to diverse anticancer agents such as sorafenib, camptothecin, and doxorubicin increased linc-VLDLR expression in cells as well as within EVs released from these cells. Incubation with EVs reduced chemotherapy-induced cell death and also increased linc-VLDLR expression in recipient cells. RNAi-mediated knockdown of linc-VLDLR decreased cell viability and abrogated cell-cycle progression. | 24874432 | Lnc2Cancer |
EL1447 | VNN2 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | The remaining 10 lncRNAs, showed significantly different expression in the tumor samples. For 9 of these, expression was altered in the same direction as had been detected by microarray analysis (8 lower, and 1 higher, than NT samples; all p < 0.001; ).differentially expressed lncRNAs in early stage lung adenocarcinoma and suggest that lncRNAs may be novel candidate biomarkers for the early detection of this disease. | 25758555 | Lnc2Cancer |
EL1448 | VPS9D1-AS1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
EL1450 | VTRNA2-1 | gastric cancer | RNA-seq, qPCR etc. | gastric cancer tissue, gastric cell lines | down-regulated | N/A | Our real-time RT-PCR data (Fig 1A) indicated that the expression level of nc886 was lower in a subpopulation of tumor tissues than in normal tissues. nc886 inhibits cell proliferation when ectopically expressed in gastric cancer cells. | 25003254 | Lnc2Cancer |
EL1451 | Wbp1l | hypoxic-ischemic brain damage | Silencing | hypoxic-ischemic (HI) rat brains | up-regulated | interaction | N/A | 26349411 | |
EL1453 | WISP1 | colorectal cancer | N/A | HCT116, HCT8, and SW480 colorectal cancer cells | up-regulated | expression | AK027294 down-regulation significantly inhibited colorectal cancer cells proliferation and migration, but promoted cell apoptosis (P < 0.05) | 26820130 | |
EL1454 | WRAP53 | dyskeratosis congenita | N/A | N/A | N/A | mutation | Disruption of telomerase trafficking by WRAP53 mutation causes dyskeratosis congenita. | 21205863 | LncRNADisease |
EL1454 | WRAP53 | cancer | N/A | N/A | N/A | N/A | WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. | 21368886 | LncRNADisease |
EL1454 | WRAP53 | cancer | N/A | N/A | N/A | expression | A natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide. | 21441950 | LncRNADisease |
EL1454 | WRAP53 | hepatocelluar carcinoma | qPCR etc. | HCC tissue | up-regulated | expression | We found that lncRNA-UCA1 and lncRNA-WRAP53 were significantly higher in sera of HCC than those with chronic HCV infection or healthy volunteers. Our data suggested that the increased expression of UCA1 and WRAP53 was associated with advanced clinical parameters in HCC. | 26551349 | Lnc2Cancer |
EL1455 | WSPAR | hepatocelluar carcinoma | microarray, qPCR, Northern blot, FISH etc. | cell lines (Hep3B, Huh7, and PLC) | up-regulated | interaction | Here, using transcriptome microarray analysis, we identified a long noncoding RNA (lncRNA) termed lncTCF7 that is highly expressed in HCC tumors and liver CSCs. Mechanistically, lncTCF7 recruits the SWI/SNF complex to the promoter of TCF7 to regulate its expression, leading to activation of Wnt signaling. Our data suggest that lncTCF7-mediated Wnt signaling primes liver CSC self-renewal and tumor propagation. | 25842979 | Lnc2Cancer |
EL1455 | WSPAR | hepatocelluar carcinoma | qPCR, Western blot, Luciferase reporter assay etc. | HCC cell lines (SK-Hep-1, BEL-7402) | up-regulated | interaction | We demonstrate that IL-6 could induce lncTCF7 expression in a time- and dose-dependent manner, and we showed that IL-6 transcriptionally activated the expression of lncTCF7 in HCC cells by activating STAT3, a transcription activator which binds to promoter regions of lncTCF7. Furthermore, knocking-down STAT3 and inhibiting STAT3 activation reduced lncTCF7 expression. Importantly, RNA interference-based attenuation of lncTCF7 prevented IL-6-induced EMT and cell invasion. | 26452542 | Lnc2Cancer |
EL1456 | WT1-AS | Wilms' tumor | N/A | renal and haematopoietic cells | down-regulated | expression | Both wt1-as and the novel awt1 transcript are imprinted in normal kidney with expression confined to the paternal allele. | 14681303 | |
EL1456 | WT1-AS | acute myeloid leukemia | qPCR etc. | bone marrow tissue | differential expression | epigenetics | The incidence of WIT-1 methylation in primary refractory AML was significantly higher than that noted in chemosensitive AML. | 10340388 | LncRNADisease Lnc2Cancer |
EL1456 | WT1-AS | acute myeloid leukemia | qPCR etc. | Bone marrow | up-regulated | Interaction | In AML, there is often abnormal splicing of WT1-AS, which may play a role in the development of this malignancy. | 17940140 | LncRNADisease Lnc2Cancer |
EL1456 | WT1-AS | Wilms' tumor | qPCR etc. | Bone marrow | up-regulated | Interaction | WT1 is a gene that is mutated in Wilms' tumor (WT) and acute myeloid leukaemia (AML) and has an antisense transcript (WT1-AS), which was found to regulate WT1 protein levels. | 17940140 | LncRNADisease Lnc2Cancer |
EL1456 | WT1-AS | gastric cancer | qPCR etc. | gastric cancer tissue, cell lines (SGC7901, BGC823, MKN45, MKN28, NCI-N87, AGS, HS-746T, GES-1) | down-regulated | expression | We found that WT1-AS expression was significantly down-regulated in tumor tissues compared to matched adjacent non-tumor tissues. The WT1-AS expression level was also associated with tumor size and the clinicopathological stage. Cell proliferation, migration, and invasion were inhibited, and the proportion of G0/G1 cells increased when WT1-AS was ectopically-expressed in gastric cancer cells. Furthermore, ectopic expression of WT1-AS was demonstrated to inhibit tumor growth and metastasis in vivo. Finally, we found that WT1-AS overexpression could decrease ERK protein phosphorylation. | 26449525 | Lnc2Cancer |
EL1456 | WT1-AS | Wilms' tumor | qPCR, Southern blot, knockdown etc. | Wilms' tumor tissue | differential expression | epigenetics | A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis. | 17210670 | LncRNADisease Lnc2Cancer |
EL1456 | WT1-AS | hepatocelluar carcinoma | qPCR, Western blot, Luciferase reporter assay etc. | hepatocellular carcinoma tissue | down-regulated | interaction | WT1-AS expression correlated negatively with WT1 expression in HCC tumor tissue. Kaplan-Meier curve analysis revealed that WT1-AS expression is a reliable indicator of HCC prognosis. The downregulation of WT1 expression by WT1-AS promoted cell apoptosis by suppressing the JAK/STAT3 signaling pathway. Bioinformatics analysis showed that WT1-AS downregulates WT1 by binding to the TATA region of the WT1 promotor. WT1-AS was also able to reverse WT1-mediated resistance to Dox based chemotherapy in HCC cells | 26462627 | Lnc2Cancer |
EL1456 | WT1-AS | Wilms' tumor | Southern blot analysis, RT-PCR | kidney | up-regulated | epigenetics | Wts display hypomethylation and biallelic expression of wt1-as. | 10811108 | |
EL1457 | Wt1os | ischemia/reperfusion | N/A | N/A | N/A | expression | Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. | 24312245 | LncRNADisease |
EL1459 | XIST | colorectal cancer | microarray, FISH etc. | CRC tissue | differential expression | N/A | X inactive-specific transcript gene amplification has also been detected in microsatellite-unstable sporadic human CRC tissue when compared to matched normal colorectal epithelium. aCGH revealed distinct DNA copy number changes between sporadic CIN- and MIN-associated colorectal carcinomas. A differential role of these candidate oncogenes and tumor suppressor genes in tumor development and progression of sporadic CIN and MIN CRC is likely and may also be involved in the response or resistance to therapeutic interventions, such as shown for microsatellite instability and 5-FU. | 17143621 | Lnc2Cancer |
EL1459 | XIST | breast cancer | microarray, FISH etc. | breast cancer tissue | differential expression | mutation | The intratumoral and intertumoral variability in XIST RNA domain number in BRCA1 tumors correlates with chromosomal genetic abnormalities, including gains, losses, reduplications, and rearrangements of the X-chromosome. | 17545591 | LncRNADisease Lnc2Cancer |
EL1459 | XIST | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (ALST, CAOV3, OVCA3 etc.) | down-regulated | N/A | The clinical relevance of this observation is demonstrated by the strong association between XIST RNA levels and disease-free periods of ovarian cancer patients in a group of 21 ovarian cancer cases with Taxol in the therapeutic regiments. Cytogenetic studies on ovarian cancer cell lines indicated that loss of inactive X chromosome is one mechanism for the loss of XIST transcripts in the cell lines. Our data suggest that XIST expression may be a potential marker for chemotherapeutic responses in ovarian cancer. | 12492109 | Lnc2Cancer |
EL1459 | XIST | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (NOSE, EOC etc.) | down-regulated | N/A | A series of malignant ovarian tumor samples were investigated for XIST expression. XIST expression was detectable by RT-PCR in the majority of EOC samples tested but was expressed at very low levels in four of 15 (27%) EOC samples, TOV921G, TOV1118D, TOV837, and TOV1054G. | 17143508 | Lnc2Cancer |
EL1459 | XIST | renal collecting duct carcinoma | microarray, Western blot etc. | cell lines (AP3, AP8-CDC etc.) | up-regulated | N/A | In cell lines created from the tissue of both a male patient and a female patient with collecting duct carcinoma of the kidney, the XIST gene, along with several other chromosome X genes, was found to have an increase in copy number. The results suggest that TOP1 might be one of the molecular targets in AP8 CDC cells. Thus, these novel CDC cell lines will be useful for discovering therapeutic targets and developing effective anticancer drugs against CDC. | 19154479 | Lnc2Cancer |
EL1459 | XIST | Klinefelter's syndrome | N/A | N/A | N/A | expression | We demonstrated by quantitative RT-PCR an active XIST RNA expression in blood lymphocytes from Klinefelter patients, comparable to that observed in control females and over 30,000-fold greater than in control males. | 18854511 | LncRNADisease |
EL1459 | XIST | Klinefelter's syndrome | N/A | N/A | N/A | epigenetics | Severe XIST hypomethylation clearly distinguishes (SRY+) 46,XX-maleness from Klinefelter syndrome. | 19812237 | LncRNADisease |
EL1459 | XIST | female cancers | N/A | N/A | N/A | expression | Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT2: colorectal cancer). | 23660942 | LncRNADisease |
EL1459 | XIST | bladder cancer | N/A | N/A | N/A | regulation | Putative diagnostic and prognostic marker | 24373479 | LncRNADisease |
EL1459 | XIST | cancer | N/A | N/A | N/A | regulation | Dysfunction of XIST may trigger the chromatin instability and promote caner development. | 24757675 | LncRNADisease |
EL1459 | XIST | cancer | N/A | N/A | N/A | regulation | The lncRNA Xist was found to be a potent tumor suppressor of hematologic malignancies?in vivo. | 24829860 | LncRNADisease |
EL1459 | XIST | testicular germ cell tumor | qPCR etc. | testicular germ cell tumor tissue, cell lines (Team-2, JKT-1, ITO-II etc.) | up-regulated | expression | XIST expression was common in seminomatous testicular germ cell tumors but not in nonseminomatous testicular germ cell tumors. | 12629412 | LncRNADisease Lnc2Cancer |
EL1459 | XIST | non-small cell lung cancer | qPCR etc. | blood (serum), NSCLC tissue | up-regulated | expression | The levels of XIST (P < 0.05) and HIF1A-AS1 (P < 0.05) were significantly increased in tumor tissues or serum from NSCLC patients as compared to those of control group. Moreover, serum levels of XIST and HIF1A-AS1 were significantly decreased after surgical treatment as compared to pre-operative. | 26339353 | Lnc2Cancer |
EL1459 | XIST | glioblastoma | qPCR, Luciferase reporter assay, RIP etc. | glioblastoma tissue | up-regulated | expression | Our results proved that XIST expression was up-regulated in glioma tissues and GSCs. Functionally, knockdown of XIST exerted tumor-suppressive functions by reducing cell proliferation, migration and invasion as well as inducing apoptosis. | 25578780 | Lnc2Cancer |
EL1459 | XIST | cystic fibrosis | qRT-PCR | bronchial cells isolated from endobronchial brushings obtained from CF and non-CF individuals | N/A | expression | Dysregulation of some of these lncRNAs may play important roles in the chronic infection and inflammation that exists in the lungs of people with CF. | 24631641 | |
EL1460 | Xist | membranous nephropathy | N/A | N/A | N/A | N/A | Urinary Xist is significantly elevated in urine samples from patients with different types of glomerular nephritis, including MN, compared to normal counterparts. | 25157805 | LncRNADisease |
EL1462 | XLOC_000371 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL1464 | XLOC_000620 | H. pylori-related diseases | N/A | N/A | N/A | N/A | Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells | 25420666 | LncRNADisease |
EL1474 | XLOC_003286 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1475 | XLOC_003405 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | up-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1478 | XLOC_004122 | H. pylori-related diseases | N/A | N/A | N/A | N/A | Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells | 25420666 | LncRNADisease |
EL1484 | XLOC_004562 | H. pylori-related diseases | N/A | N/A | N/A | N/A | Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells | 25420666 | LncRNADisease |
EL1494 | XLOC_005912 | H. pylori-related diseases | N/A | N/A | N/A | N/A | Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells | 25420666 | LncRNADisease |
EL1496 | XLOC_007697 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
EL1497 | XLOC_008559 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
EL1499 | XLOC_009911 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
EL1500 | XLOC_010235 | gastric cancer | microarray, qPCR etc. | gastric cancer tissue | up-regulated | interaction | The expression levels of six up-regulated lncRNAs (XLOC_010235, CACNAICAS3, INTS7, AC104699.1, TSNAX-DISC1, and PRSS21) and six down-regulated lncRNAs (RP11-789C1.1, RP11-528G1.2, MYLK-AS1, RP11-643M14.1, GS1-5L10.1, and AP001439.2) were determined by using qPCR. | 26045391 | Lnc2Cancer |
EL1501 | XLOC_012255 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1502 | XLOC_014172 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | expression | We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future. | 25714016 | Lnc2Cancer |
EL1503 | XLOC_014388 | H. pylori-related diseases | N/A | N/A | N/A | N/A | Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells | 25420666 | LncRNADisease |
EL1511 | XR_250621.1 | triple-negative breast cancer | microarray, qPCR etc. | TNBC tissue | up-regulated | expression | The results demonstrated that lncRNAs NONHSAT125629 and ENST00000503938 were upregulated and that XR_250621.1 and NONHSAT012762 were down-regulated in the tumor samples compared with NT samples. These qPCR results are consistent with the microarray data. | 26078338 | Lnc2Cancer |
EL1514 | LOC105373051 | non-small cell lung cancer | microarray, qPCR etc. | NSCLC tissue | down-regulated | expression | we initially identified a number of significant candidate lncRNAs (including GUCY1B2, RP11-385J1.2, AC018865.8, RP11-909N17.3, GNAS-AS1, TUBA4B, Z82214.3, XLOC_000371, AC013264.2 and RP1-317E23.3) and verified the expression of these lncRNAs by RT-qPCR with GAPDH as the reference gene, by calculating the 2-CT values. | 25394782 | Lnc2Cancer |
EL1515 | ZEB1-AS1 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
EL1515 | ZEB1-AS1 | hepatocelluar carcinoma | microarray, qPCR, knockdown etc. | HCC tissue, cell lines (Huh7, HepG2, etc.) | up-regulated | interaction | We found that ZEB1-AS1 is frequently upregulated in HCC samples, especially in metastatic tumor tissues. ZEB1-AS1 promotes tumor growth and metastasis, acts as an oncogene in HCC. The ZEB1-AS1 gene is located in physical contiguity with ZEB1 and positively regulates the ZEB1 expression. ZEB1 inhibition partially abrogates ZEB1-AS1-induced epithelial to mesenchymal transition (EMT) and cancer metastasis. | 26073087 | Lnc2Cancer |
EL1515 | ZEB1-AS1 | esophageal squamous cell carcinoma | qPCR etc. | ESCC tissues and adjacent non-tumor tissues | up-regulated | expression | LNCRNA ZEB1-AS1 was found up-regulated in ESCC tissues compared to adjacent non-tumor tissues. Increased lncRNA ZEB1-AS1 expression was significantly associated with tumor grade, depth of invasion, and lymph node metastasis. Kaplan-Meier analysis revealed that ESCC patients with high ZEB1-AS1 expression had a poorer overall survival and disease-free survival. Furthermore, multivariate analysis suggested that ZEB1-AS1 expression was identified as an independent prognostic factor in patients with ESCC | 26617942 | Lnc2Cancer |
EL1516 | ZEB2-AS1 | bladder cancer | qPCR etc. | bladder cancer cell lines (T24, 5637 and J82) | up-regulated | interaction | A long non-coding RNA, ZEB2NAT, was demonstrated to be essential for this TGFβ1-dependent process. ZEB2NAT depletion reversed CAF-CM-induced EMT and invasion of cancer cells, as well as reduced the ZEB2 protein level. Consistently, TGFβ1 mRNA expression is positively correlated with ZEB2NAT transcript and ZEB2 protein levels in human bladder cancer specimens. | 26152796 | Lnc2Cancer |
EL1517 | ZFAS1 | breast cancer | microarray, Northern blot, ISH etc. | breast cancer tissue | down-regulated | expression | SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer.ZFAS1 is highly expressed in the mammary gland and is down-regulated in breast tumors compared to normal tissue. ZFAS1 is a putative tumor suppressor gene. | 21460236 | LncRNADisease Lnc2Cancer |
EL1517 | ZFAS1 | ductal carcinoma | N/A | N/A | N/A | expression | Human ZFAS1 levels are reduced in ductal carcinoma relative to normal breast tissue. | 21460236 | LncRNADisease Lnc2Cancer |
EL1517 | ZFAS1 | colorectal cancer | qPCR, knockdown, Western blot, Northern blot, RIP, RNA pull-down assay etc. | CRC tissue, cell lines ( HCT116+/+ (p53 wild type), HCT116-/- (p53 knockout), HT-29, DLD-1(p53241F), Colo-206, CaCO-2, SW-837, SW-620) | up-regulated | interaction | We determined expression of 83 long non-coding RNAs (lncRNAs) and identified ZFAS1 to be significantly up-regulated in colorectal cancer (CRC) tissue. We observed significant increase in p53 levels and PARP cleavage in CRC cell lines after ZFAS1 silencing indicating increase in apoptosis. Our data suggest that ZFAS1 may function as oncogene in CRC by two main actions: (i) via destabilization of p53 and through (ii) interaction with CDK1/cyclin B1 complex leading to cell cycle progression and inhibition of apoptosis. | 26506418 | Lnc2Cancer |
EL1517 | ZFAS1 | hepatocelluar carcinoma | qPCR, Luciferase reporter assay, RIP etc. | HCC tissue, cell lines (Huh7, HepG2, etc.) | up-regulated | interaction | ZFAS1 functions as an oncogene in HCC progression by binding miR-150 and abrogating its tumor suppressive function in this setting. miR-150 repressed HCC cell invasion by inhibiting ZEB1 and the matrix metalloproteinases MMP14 and MMP16. Conversely, ZFAS1 activated ZEB1, MMP14 and MMP16 expression, inhibiting these effects of miR-150. | 26069248 | Lnc2Cancer |
EL1518 | ZFAT-AS1 | autoimmune disease | N/A | N/A | N/A | mutation | SNPs in the promoter of a B cell-specific antisense transcript, SAS-ZFAT (ZFAT-AS1), determine susceptibility to autoimmune thyroid disease. | 15294872 | LncRNADisease |
EL1520 | Zim3 | heart failure | N/A | N/A | N/A | expression | Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 13 downregulated in HF hearts as compared with control hearts. | 24205036 | LncRNADisease |
EL1524 | ZMAT1 | gastric cancer | qPCR etc. | gastric cancer tissue | down-regulated | expression | We found for the first time that the lncRNA ZMAT1 transcript variant 2 is downregulated in gastric cancer tissues compared with adjacent normal tissues (P<0.001). The expression of ZMAT1 transcript variant 2 was inversely correlated with lymph node metastasis (P<0.05), depth of tumor invasion and tumor node metastasis stage (P<0.05). Univariate and multivariate analyses showed that ZMAT1 transcript variant 2 expression was an independent predictor for overall survival (P<0.05) | 26191264 | Lnc2Cancer |
EL1526 | ZNF295-AS1 | lung adenocarcinoma | microarray, qPCR etc. | lung adenocarcinoma tissue | down-regulated | expression | We initially identified a number of interesting candidate lncRNAs for further analysis. Of these, LOC100132354 and RPLP0P2 exhibited the most significantly changed expression in our analysis of 100 pairs of lung adenocarcinoma and normal lung tissue samples. The expression of LOC100132354 was significantly higher in lung adenocarcinoma than in the adjacent tissues, while the expression of RPLP0P2 was significantly lower in lung adenocarcinoma than in the adjacent tissues. | 25089627 | Lnc2Cancer |
EL1527 | ZNF350-AS1 | hepatocelluar carcinoma | microarray, qPCR, RIP, RNA pulldown assay etc. | HCC tissue | up-regulated | N/A | AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. | 21769904 | Lnc2Cancer |
EL1529 | ZNF674-AS1 | hepatocelluar carcinoma | microarray, qPCR etc. | HCC tissue | up-regulated | N/A | The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. | 25025236 | Lnc2Cancer |
Function (not disease relevant) | |||||||||
---|---|---|---|---|---|---|---|---|---|
ID | lncRNA Name |
Method | Sample | Expression pattern |
Function type |
Description | PMID | Source | |
EL0002 | 1700007L15Rik | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Involved in maintaining pluripotency in ESCs. | 21874018 | ||
EL0005 | 4930570G19Rik | knockdown, over-expression | N/A | N/A | interaction | In vitro knockdown of the long non-coding RNA resulted in significant down-regulation of Negr1 mRNA expression, NEGR1 protein levels and neurite length whereas over-expression enhanced Negr1 mRNA expression, NEGR1 protein levels and increased neurite length. The long non-coding RNA, BC048612, and microRNA-203 were determined to be positive and negative regulators of Negr1 gene expression respectively. | 26723899 | ||
EL0007 | 5430416N02Rik | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Mouse RNA was found to interact with a number of chromatin binding protein/complexes in mouse embryonic stem cells including PRC1, PRC2, JARID1B, ESET, SUV39H1, SETD8 and CBX1 with the general pattern being interaction with repressors of gene expression. | 21874018 | ||
EL0009 | 6430411K18Rik | N/A | N/A | N/A | interaction | Several additional mirnas are processed from antipeg11 and that these regulate rtl1/peg11 in trans by guiding risc-mediated cleavage of its mrna. | 15854907 | ||
EL0011 | 9530018H14Rik | ChIRP-seq, siRNA-mediated reductions | E 11 mouse embryos | up-regulated | interaction | Mechanistically the LncRNA-HIT siRNA treatments impacted pro-chondrogenic gene expression by reducing H3K27ac or p100 activity, confirming that LncRNA-HIT is essential for chondrogenic differentiation in the limb mesenchyme. | 26633036 | ||
EL0026 | AC058791.1 | strand-specific RNA-seq | single radial glia cells | up-regulated | N/A | regulates cell proliferation | 27081004 | ||
EL0033 | Adapt15 | methylmeth- anesulfonate and cis-platinum, X-irradiation | hamster HA-1 fibroblasts | up-regulated | expression | These rnas may act in concert to protect cells against the damaging effects of oxidative stress. | 8638945 | ||
EL0033 | Adapt15 | RT-PCR, knockdown, MTT assay | N/A | N/A | interaction | Gadd7 regulates the G1/S checkpoint in response to UV irradiation. | 23103768 | ||
EL0033 | Adapt15 | UV radiation, overexpression | Chinese hamster ovary (CHO) cells | up-regulated | expression | Overexpression of gadd7 led to a decrease in cell growth. interestingly, gadd7 cdna does not contain an appreciable open reading frame and does not appear to encode a protein product, but instead may function at the rna level. | 8649973 | ||
EL0040 | AFAP1-AS1 | N/A | hepatocellular carcinoma (HCC) tissues | up-regulated | expression | High AFAP1-AS1 expression was associated with tumor size, TNM stage, vascular invasion, and poor prognosis. Silencing of AFAP1-AS1 significantly reduced cell proliferation, clonal growth, cell migration, and invasion and increased apoptosis in vitro. AFAP1-AS1 silencing markedly reduced tumor growth in a murine allograft model in vivo. | 26803513 | ||
EL0041 | AGAP2-AS1 | RNA seq | human differentiated endothelial cells | up-regulated | expression | We have identified and functionally characterized 3 novel lncRNAs involved in vertebrate and human cardiovascular development, and we provide a comprehensive transcriptomic roadmap that sheds new light on the molecular mechanisms underlying human embryonic development, mesodermal commitment, and cardiovascular specification. | 25739401 | ||
EL0043 | AIRN | N/A | N/A | N/A | expression | Air rna is required for silencing. the truncated air allele maintains imprinted expression and methylation of the air promoter, but shows complete loss of silencing of the igf2r/slc22a2/slc22a3 gene cluster on the paternal chromosome. | 11845212 | ||
EL0044 | Airn | N/A | E6.5 epiblast | N/A | locus | Here we show lineage- and temporal-specific regulation of DNA methylation and histone modifications at the Igf2r/Airn locus correlating with differential establishment of imprinted expression during gastrulation. After gastrulation commences, the locus becomes imprinted in the embryonic lineage with the lncRNA Airn expressed from the paternal allele and Igf2r restricted to maternal allele expression. | 25918552 | ||
EL0044 | Airn | N/A | mouse placenta | up-regulated | interaction | Air accumulates at the Slc22a3 promoter in correlation with localized H3K9 methylation and transcriptional repression. Genetic ablation of G9a results in nonimprinted, biallelic transcription of Slc22a3. | 18988810 | ||
EL0060 | AK133540 | lncRNA microarray | brown adipose tissue (BAT) and white adipose tissue (WAT) | N/A | expression | We found that AK142386 and AK133540 may affect adipogenesis and metabolism. Our data indicate that AK142386 and AK133540 may be involved in BAT and WAT development through their target genes Hoxa3 and Acad10. | 25472036 | ||
EL0069 | alncRNA-EC7 | Depleting | differentiating mouse fetal liver red blood cells | N/A | N/A | alncRNA-EC7, is transcribed from an enhancer and is specifically needed for activation of the neighboring gene encoding BAND 3. | 24200680 | ||
EL0070 | alpha-250 and alpha-280 | Tissue culture transfection and cell-free transcription, Electrophoretic mobility shift experiments | N/A | N/A | interaction | Alpha-250 and alpha-280 stimulate s14 mrna transcription, whereas free ribosomal protein s14 inhibits it. | 7867928 | ||
EL0072 | alpha-MHC antisense transcripts | Northern blot, RT-PCR | neonatal rat heart | N/A | expression | In the neonatal heart naturally occurring antisense mrna may play a role in the regulation of mhc expression and, therefore, in the control of the energetical and contractile behaviour of the heart. | 9632112 | ||
EL0073 | Alu lncRNAs | Biochemical assays to probe the network of protein-DNA interactions | mouse B2 RNA and human Alu RNA | N/A | interaction | We conclude that B2 and Alu RNA prevent Pol II from properly engaging the DNA during closed complex formation, resulting in complexes with an altered conformation that are transcriptionally inert. In the absence of its normal contacts with the promoter, Pol II is likely held in these inactive complexes on DNA through interactions with promoter-bound TATA box-binding protein and transcription factor IIB. | 19307572 | ||
EL0074 | Ancr-1 | RNA fluorescent in situ hybridization, cDNA cloning | cortex | N/A | expression | Ancr-1 is involved in diverse organ functions. | 15208441 | ||
EL0075 | antisense TGF beta 3 | N/A | chick heart | N/A | expression | The temporally controlled appearance of rna complementary to tgf beta 3 suggests that this molecule may play a role in the regulation of tgf beta 3 production in the heart. | 1511174 | ||
EL0080 | APOA1-AS | Chromatin immunoprecipitation (ChIP) analyses, Targeting APOA1-AS with short antisense oligonucleotides | human and monkey liver cells | down-regulated | N/A | acts as a negative transcriptional regulator of APOA1 both in vitro and in vivo. Inhibition of APOA1-AS in cultured cells resulted in the increased expression of APOA1 and two neighboring genes in the APO cluster. | 24388749 | ||
EL0081 | APOLO | RT-PCR/RT-qPCR | Auxin-controlled development | down-regulated | N/A | The Arabidopsis long intergenic noncoding RNA (lincRNA) APOLO is transcribed by RNA polymerases II and V in response to auxin, a phytohormone controlling numerous facets of plant development. This dual APOLO transcription regulates the formation of a chromatin loop encompassing the promoter of its neighboring gene PID, a key regulator of polar auxin transport. | 25018019 | PLNlncRbase | |
EL0086 | ASAR6 | N/A | N/A | N/A | N/A | Disruption of the large non-coding RNA gene ASAR6 results in ate replication, an under-condensed appearance during mitosis, and structural instability of human chromosome 6. Similarly, disruption of the mouse Xist gene in adult somatic cells results in a late replication and instability phenotype on the X chromosome. ASAR6 shares many characteristics with Xist, including random mono-allelic expression and asynchronous replication timing. | 22706734 | ||
EL0087 | ASAR6 | Disruption of ASAR6 | N/A | N/A | N/A | Disruption of ASAR6 leads to the formation of bridged chromosomes, micronuclei, and structural instability of chromosome 6 | 23593023 | ||
EL0088 | ASCO-RNA | qRT-PCR | leaves | up-regulated | N/A | Double Atnsr mutants and ASCO overexpressors exhibit an altered ability to form LRs after auxin treatment. Interestingly, auxin induces a major change in AS patterns of many genes, a response largely dependent on NSRs. RNA immunoprecipitation assays demonstrate that AtNSRs interact not only with their alternatively spliced mRNA targets but also with the ASCO-RNA in vivo. The ASCO-RNA displaces an AS target from an NSR-containing complex in vitro. Expression of ASCO-RNA(lnc351) in Arabidopsis affects the splicing patterns of several NSR-regulated mRNA targets. Hence, lncRNA can hijack nuclear AS regulators to modulate AS patterns during development. Plants overexpressing the ASCO-RNA showed changes in isoform distribution of the auxin-related protein (At2G33830). (Bardou et al., 2014) Expression of the lncRNA ASCO-RNA do not promote lateral root growth. The lncRNA does not cause NSR relocalization but alters NSR activity through direct binding to NSRs and displacement of them from their mRNA targets. In other words, ASCO-RNA prevents the effects of NSRs on the regulation of alternative splicing in their transcript targets. ASCO-RNA overexpression in live plants duplicates the morphological effects observed in the nsra/nsrbdouble mutant, i.e., a decreased lateral root density when plants are grown on auxin. (Kornblihtt et al., 2014) | 25073154, 25073153 | PLNlncRbase | |
EL0089 | asHSFB2a | qRT-PCR/Southern blot hybridization | gametophyte development | up-regulated | N/A | HSFB2a expression was counteracted by a natural long non-coding antisense RNA, asHSFB2a. In leaves, the antisense RNA gene is only expressed after heat stress and dependent on the activity of HSFA1a/HSFA1b. HSFB2a and asHSFB2a RNAs were also present in the absence of heat stress in the female gametophyte. Transgenic overexpression of HSFB2a resulted in a complete knock down of the asHSFB2a expression. Conversely, asHSFB2a overexpression leads to the absence of HSFB2a RNA. The knockdown of HSFB2a by asHSFB2a correlated with an improved, knockdown of asHSFB2a by HSFB2a overexpression with an impaired biomass production early in vegetative development. In both cases the development of female gametophytes was impaired. | 24874772 | PLNlncRbase | |
EL0091 | ASL | RT-PCR | vernalization | down-regulated | N/A | Furthermore, AtRRP6L1 physically associates with the ASL transcript and directly interacts with the FLC locus. We propose that AtRRP6L proteins participate in the maintenance of H3K27me3 at FLC via regulating ASL. Furthermore, AtRRP6Ls might participate in multiple FLC silencing pathways by regulating diverse antisense RNAs derived from the FLC locus. | 25211139 | PLNlncRbase | |
EL0095 | AT102202 | Microarrays, RT-PCR | cultured human liver (HepG2) hepatocytes treated with epigallocatechin-3-gallate( EGCG) | up-regulated | expression | Using a real-time polymerase chain reaction technique, we confirmed that EGCG down-regulated mRNA expression level of the HMGCR and up-regulated expression of AT102202. After AT102202 knockdown in HepG2, weobserved that the level of HMGCR expression was significantly increased relative to the scrambled small interfering RNA control (P < 0.05). | 25563320 | ||
EL0096 | AT1G04425 | qRT-PCR/RT-PCR | heat and highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, AT1G04425 is downregulated by heat and highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0097 | AT1G10682 | qRT-PCR/RT-PCR | heat and highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, AT1G10682 is downregulated by heat and highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0098 | AT1G11175 | qRT-PCR/RT-PCR | cold/salt | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G11175 is downregulated by cold stress and upregulated by salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0099 | AT1G11185 | qRT-PCR/RT-PCR | drought and salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, and lncRNA AT1G11185 is upregulated by drought and salt stresses. (details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0100 | AT1G13448 | qRT-PCR/RT-PCR | cold, highlight and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, and lncRNA AT1G13448 is downregulated by cold/highlight/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0101 | AT1G15002 | qRT-PCR/RT-PCR | heat/cold | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT1G15002 is upregulated by cold/highlight stresses and downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0102 | AT1G15175 | qRT-PCR/RT-PCR | cold, heat and highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT1G15175 is downregulated by cold/heat/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0103 | AT1G15405 | qRT-PCR/RT-PCR | highlight/salt | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G15405 is upregulated by salt stress and downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0104 | AT1G16635 | qRT-PCR/RT-PCR | cold and highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G16635 is upregulated by cold/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0105 | AT1G18745 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, AT1G18745 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0106 | AT1G21529 | qRT-PCR/RT-PCR | heat | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, AT1G21529 is upregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0107 | AT1G26208 | qRT-PCR/RT-PCR | heat and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, AT1G26208 is downregulated by heat and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0108 | AT1G26558 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, AT1G26558 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0109 | AT1G31935 | qRT-PCR/RT-PCR | heat and highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G31935 is downregulated by heat and highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0110 | AT1G34418 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G34418 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0111 | AT1G43765 | qRT-PCR/RT-PCR | drought | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G43765 is upregulated by drought stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0112 | AT1G46554 | qRT-PCR/RT-PCR | drought/heat | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G46554 is upregulated by drought stress and downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0113 | AT1G57835 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G57835 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0114 | AT1G58590 | qRT-PCR/RT-PCR | heat and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G58590 is downregulated by heat and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0115 | AT1G64618 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G64618 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0116 | AT1G67105 | qRT-PCR/RT-PCR | drought and highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G67105 is upregulated by drought and highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0117 | AT1G67365 | qRT-PCR/RT-PCR | drought, heat and salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G67365 is upregulated by drought, heat and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0118 | AT1G69252 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G69252 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0119 | AT1G70518 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G70518 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0120 | AT1G74205 | qRT-PCR/RT-PCR | cold, drought and heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT1G74205 is downregulated by cold/drought/heat stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0121 | At1NC018710 | qRT-PCR/RNA-seq | roots | up-regulated | N/A | Figure 3. Expression Profiles of lincRNAs in Different Arabidopsis Plant Organs and in Response to Biotic and Abiotic Stresses. | 23136377 | PLNlncRbase | |
EL0122 | AT1TU075330 | qRT-PCR | light | up-regulated | N/A | Our qRT-PCR results confirmed that some lncNATs were significantly regulated by light and their expression profiles were also consistent with the results from ATH NAT arrays (Figure 2 C-F, Supplemental Figure 8 and Supplemental Table 3). | 24402519 | PLNlncRbase | |
EL0123 | AT1TU099900 | qRT-PCR | light | up-regulated | N/A | Our qRT-PCR results confirmed that some lncNATs were significantly regulated by light and their expression profiles were also consistent with the results from ATH NAT arrays (Figure 2 C-F, Supplemental Figure 8 and Supplemental Table 3). | 24402519 | PLNlncRbase | |
EL0124 | AT2G01422 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G01422 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0125 | AT2G06002 | qRT-PCR/RT-PCR | cold, drought, heat, highlight and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G06002 is downregulated by cold/drought/heat/highlight/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0126 | AT2G09795 | qRT-PCR/RT-PCR | heat and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G09795 is downregulated by heat and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0127 | AT2G14878 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G14878 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0128 | AT2G15292 | qRT-PCR/RT-PCR | heat and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G15292 is downregulated by heat and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0129 | AT2G15555 | qRT-PCR/RT-PCR | drought and highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G15555 is upregulated by drought and highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0130 | AT2G18735 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G18735 is downregulated by heat stress and upregulated by drought and highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0131 | AT2G26355 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G26355 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0132 | AT2G31585 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G31585 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0133 | AT2G32315 | qRT-PCR/RT-PCR | drought | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G32315 is upregulated by drought stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0134 | AT2G32795 | qRT-PCR/RT-PCR | cold and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G32795 is downregulated by cold/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0135 | AT2G41178 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G41178 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0136 | AT2G41312 | qRT-PCR/RT-PCR | cold and heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G41312 is downregulated by cold and heat stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0137 | AT2G42388 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G42388 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0138 | AT2G42485 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G42485 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0139 | AT2G43375 | qRT-PCR/RT-PCR | highlight/salt | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G43375 is upregulated by highlight stress and downregulated by salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0140 | AT2G44798 | qRT-PCR/RT-PCR | drought and highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G44798 is upregulated by drought and highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0141 | AT2G44995 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G44995 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0142 | AT2G45023 | qRT-PCR/RT-PCR | drought, heat and highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G45023 is downregulated by drought/heat/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0143 | AT2G45245 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G45245 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0144 | AT2G46192 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT2G46192 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0145 | At2NC044550 | qRT-PCR/RNA-seq | leaves | up-regulated | N/A | Figure 3. Expression Profiles of lincRNAs in Different Arabidopsis Plant Organs and in Response to Biotic and Abiotic Stresses. | 23136377 | PLNlncRbase | |
EL0146 | AT2TU076050 | qRT-PCR | hypocotyls | up-regulated | N/A | The majority of light-regulated NAT pairs at the two time points were different suggesting amplification of light signal and utilization of specific NAT pairs in short and long term light response. For example, SPA1, which encodes a light signaling repressor, was up-regulated more than eight times after 1h of light treatment in cotyledons. Its concordant antisense transcript, AT2TU076050, was also up-regulated more than four times at the same time point and in the same organ. Neither showed such strong induction at the other time point or organs. | 24402519 | PLNlncRbase | |
EL0147 | AT2TU077810 | qRT-PCR | hypocotyls | up-regulated | N/A | Our qRT-PCR results confirmed that some lncNATs were significantly regulated by light and their expression profiles were also consistent with the results from ATH NAT arrays (Figure 2 C-F, Supplemental Figure 8 and Supplemental Table 3). | 24402519 | PLNlncRbase | |
EL0148 | AT3G04485 | qRT-PCR/RT-PCR | drought, heat and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G04485 is downregulated by drought/heat/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0149 | AT3G06125 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G06125 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0150 | AT3G07215 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G07215 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0151 | AT3G13277 | qRT-PCR/RT-PCR | highlight/cold | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G13277 is upregulated by highlight stress and downregulated by cold and heat stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0152 | AT3G27884 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G27884 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0153 | AT3G27990 | qRT-PCR/RT-PCR | heat and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G27990 is downregulated by heat and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0154 | AT3G29644 | qRT-PCR/RT-PCR | highlight and salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G29644 is upregulated by highlight and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0155 | AT3G44798 | qRT-PCR/RT-PCR | salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G44798 is upregulated by salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0156 | AT3G45638 | qRT-PCR/RT-PCR | cold | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G45638 is upregulated by cold stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0157 | AT3G48115 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G48115 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0158 | AT3G52072 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions,and lncRNA AT3G52072 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0159 | AT3G52742 | qRT-PCR/RT-PCR | cold, drought and highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT3G52742 is upregulated by cold/drought/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0160 | AT3G52748 | qRT-PCR/RT-PCR | salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT3G52748 is downregulated by salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0161 | AT3G54366 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT3G54366 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0162 | AT3G57157 | qRT-PCR/RT-PCR | heat/highlight | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT3G57157 is upregulated by highlight stress and downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0163 | AT3G59765 | qRT-PCR/RT-PCR | drought, heat, highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT3G59765 is downregulated by drought/heat/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0164 | AT3G60972 | qRT-PCR/RT-PCR | drought | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT3G60972 is upregulated by drought stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0165 | AT3G61198 | qRT-PCR/RT-PCR | cold | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT3G61198 is downregulated by cold stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0166 | AT3TU028510 | qRT-PCR | hypocotyls | up-regulated | N/A | The majority of light-regulated NAT pairs at the two time points were different suggesting amplification of light signal and utilization of specific NAT pairs in short and long term light response. For example, SPA1, which encodes a light signaling repressor, was up-regulated more than eight times after 1 h of light treatment in cotyledons. Its concordant antisense transcript, AT2TU076050,was also up-regulated more than four times at the same time point and in the same organ. Neither showed such strong induction at the other time point or organs. Another example is HYH, a homolog of HY5, and its concordant NAT, AT3TU028510. At 1h, both HYH and AT3TU028510 were significantly induced in hypocotyls only; they were further induced at 6h in roots as well as hypocotyls. | 24402519 | PLNlncRbase | |
EL0167 | AT3TU075200 | qRT-PCR | hypocotyls | up-regulated | N/A | Genes coding for transcription factors were significantly over-represented after 1h of white light, whereas metabolism-related genes were over-represented after 6h of white light. For example, an mRNA coding the phototropic-responsive NPH3 family protein, AT3G49970, was specifically down-regulated in hypocotyls after 1h light accompanied by its up-regulated lncNAT, AT3TU075200. | 24402519 | PLNlncRbase | |
EL0168 | At4 | RT-PCR | roots | up-regulated | N/A | Loss of At4 lead to increased shoot Pi content and an increase in the shoot: root Pi ratio under low Pi conditions suggesting At4 affects Pi distribution and plant growth. (Shin et al., 2006) In Arabidopsis, the induced expression of ncRNAs of the IPS1/At4 family during phosphate starvation responses results in the accumulation of the PHO2 mRNA,a target of miR399 (micro-RNA 399). showed that a conserved motif of 23 nt in this ncRNA family is complementary to miR399 but has critical mismatches at positions. Therefore, IPS1/At4 RNAs are not cleaved by miR399 but instead sequester miR399 to inhibit its effect on PHO2 mRNA, in a mechanism known as target mimicry. PHO2 RNA encodes an E2 ubiquitin conjugase-related protein that negatively affects shoot phosphate content and remobilization in an unknown mechanism. (Au et al., 2011) The Arabidopsis pho1 mutant is impaired in its ability to load Pi into the xylem and therefore to translocate Pi to the shoot. At4 transcripts were abundant in pho1 plants receiving both low-Pi and high-Pi fertilizer. These results were observed in two independent experiments. Thus, the At4 transcript is not down-regulated in response to Pi in the pho1 mutant, suggesting that down-regulation is dependent on the translocation of Pi to the shoot. (Burleigh et al., 1999) At4 was designated as the TPSI1/Mt4 family because of their common characteristics. They are up-regulated by P limitation and rapidly down-regulated by supply of P or colonization of mycorrhizal fungi. This fact indicates the possibility that they have an important role on the strategies for low P adaptation, although their physiological function is not still clarified. (Jun et al., 2003) | 16460506, 21525783, 9880366 | PLNlncRbase | |
EL0169 | At4-1 | Northern blot/RT-PCR | roots | up-regulated | N/A | We also tested the effects of overexpressing a close IPS1 paralog, At4. As with IPS1I, At4 overexpression also resulted in decreased shoot Pi accumulation (Supplementary Fig. 4a online). This finding suggests redundancy between IPS1 and At4 and possibly among the other IPS1 family members, all of which are responsive to Pi starvation and contain a region of miR-399 complementarity (Supplementary Fig. 1). (Franco-Zorrilla et al., 2007) The second regulatory mechanism of lncRNAs in plants might work as a decoy of miRNAs, these kind of lncRNAs exert their functions by binding miRNAs in a target mimicry mechanism to sequestrate the miRNAs’ regulation roles on their target genes, such as lncRNAs IPS1 and at4. IPS1 is complementary to miR399, but contains a mismatch loop which makes it uncleavable when miR399 binding. It is induced by phosphate starvation in plants, and then allows the increased expression of miR399 targets including PHO2, consequently alters shoot phosphate content. IPS1 has many family members in a number of plant species, including At4, At4-1, At4-2 and At4-3 in Arabidopsis thaliana. At4 appears to be functionally redundant with IPS1, overexpression of one of them could result in the same phenotypic change as that when overexpressing both At4 and IPS1. (Zhang et al., 2013) | 17643101, 23726911 | PLNlncRbase | |
EL0170 | At4-2 | Northern blot/RT-PCR | roots | up-regulated | N/A | We also tested the effects of overexpressing a close IPS1 paralog, At4. As with IPS1I, At4 overexpression also resulted in decreased shoot Pi accumulation (Supplementary Fig. 4a online). This finding suggests redundancy between IPS1 and At4 and possibly among the other IPS1 family members, all of which are responsive to Pi starvation and contain a region of miR-399 complementarity (Supplementary Fig. 1). (Franco-Zorrilla et al., 2007) The second regulatory mechanism of lncRNAs in plants might work as a decoy of miRNAs, these kind of lncRNAs exert their functions by binding miRNAs in a target mimicry mechanism to sequestrate the miRNAs’ regulation roles on their target genes, such as lncRNAs IPS1 and at4. IPS1 is complementary to miR399, but contains a mismatch loop which makes it uncleavable when miR399 binding. It is induced by phosphate starvation in plants, and then allows the increased expression of miR399 targets including PHO2, consequently alters shoot phosphate content. IPS1 has many family members in a number of plant species, including At4, At4-1, At4-2 and At4-3 in Arabidopsis thaliana. At4 appears to be functionally redundant with IPS1, overexpression of one of them could result in the same phenotypic change as that when overexpressing both At4 and IPS1. (Zhang et al., 2013) | 17643101, 23726911 | PLNlncRbase | |
EL0171 | At4-3 | Northern blot/RT-PCR | roots | up-regulated | N/A | We also tested the effects of overexpressing a close IPS1 paralog, At4. As with IPS1I, At4 overexpression also resulted in decreased shoot Pi accumulation (Supplementary Fig. 4a online). This finding suggests redundancy between IPS1 and At4 and possibly among the other IPS1 family members, all of which are responsive to Pi starvation and contain a region of miR-399 complementarity (Supplementary Fig. 1). (Franco-Zorrilla et al., 2007) The second regulatory mechanism of lncRNAs in plants might work as a decoy of miRNAs, these kind of lncRNAs exert their functions by binding miRNAs in a target mimicry mechanism to sequestrate the miRNAs’ regulation roles on their target genes, such as lncRNAs IPS1 and at4. IPS1 is complementary to miR399, but contains a mismatch loop which makes it uncleavable when miR399 binding. It is induced by phosphate starvation in plants, and then allows the increased expression of miR399 targets including PHO2, consequently alters shoot phosphate content. IPS1 has many family members in a number of plant species, including At4, At4-1, At4-2 and At4-3 in Arabidopsis thaliana. At4 appears to be functionally redundant with IPS1, overexpression of one of them could result in the same phenotypic change as that when overexpressing both At4 and IPS1. (Zhang et al., 2013) | 17643101, 23726911 | PLNlncRbase | |
EL0172 | AT4G01533 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G01533 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0173 | AT4G01593 | qRT-PCR/RT-PCR | cold, heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G01593 is downregulated by cold and heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0174 | AT4G02005 | qRT-PCR/RT-PCR | salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G02005 is downregulated by salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0175 | AT4G03811 | qRT-PCR/RT-PCR | salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G03811 is upregulated by salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0176 | AT4G06701 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G06701 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0177 | AT4G08035 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G08035 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0178 | AT4G13495 | qRT-PCR/RT-PCR | heat, highlight, salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G13495 is downregulated by heat/highlight/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0179 | AT4G14548 | qRT-PCR/RT-PCR | drought, salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G14548 is downregulated by drought and salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0180 | AT4G15242 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G15242 is upregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0181 | AT4G20362 | qRT-PCR | hypocotyls | down-regulated | N/A | We also found 766 light-responsive discordant NAT pairs (Figure 3B&E and Supplemental Figure9). Here, the large number of light-responsive, discordant NAT pairs that were identified suggested a potentially widespread occurrence of negative regulation by NATs. | 24402519 | PLNlncRbase | |
EL0182 | AT4G30975 | qRT-PCR/RT-PCR | salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G30975 is downregulated by salt stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0183 | AT4G36648 | qRT-PCR/RT-PCR | heat | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G36648 is downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0184 | AT4G38932 | qRT-PCR/RT-PCR | salt/cold and higlight | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G38932 is upregulated by salt stress and downregulated by cold/highlight stresses .(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0185 | AT4G40065 | qRT-PCR/RT-PCR | heat/highlight | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT4G40065 is upregulated by highlight stress and downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0186 | At4NC047210 | qRT-PCR/RNA-seq | flowers | up-regulated | N/A | Figure 3. Expression Profiles of lincRNAs in Different Arabidopsis Plant Organs and in Response to Biotic and Abiotic Stresses. | 23136377 | PLNlncRbase | |
EL0187 | AT4TU030900 | qRT-PCR | hypocotyls | up-regulated | N/A | Our qRT-PCR results confirmed that some lncNATs were significantly regulated by light and their expression profiles were also consistent with the results from ATH NAT arrays (Figure 2 C-F, Supplemental Figure 8 and Supplemental Table 3). | 24402519 | PLNlncRbase | |
EL0188 | AT4TU034830 | qRT-PCR | hypocotyls | up-regulated | N/A | Our qRT-PCR results confirmed that some lncNATs were significantly regulated by light and their expression profiles were also consistent with the results from ATH NAT arrays (Figure 2 C-F, Supplemental Figure 8 and Supplemental Table 3). | 24402519 | PLNlncRbase | |
EL0189 | AT5G01175 | qRT-PCR/RT-PCR | cold | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G01175 is upregulated by cold stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0190 | AT5G03285 | qRT-PCR/RT-PCR | cold/heat | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G03285 is upregulated by heat stress and downregulated by cold.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0191 | AT5G06165 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G06165 is upregulated highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0192 | AT5G07322 | qRT-PCR/RT-PCR | drought, highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G07322 is downregulated by drought/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0193 | AT5G15022 | qRT-PCR/RT-PCR | highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G15022 is upregulated highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0194 | AT5G23410 | qRT-PCR/RT-PCR | heat/drought | down-regulated/up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G23410 is upregulated by drought stress and downregulated by heat stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0195 | AT5G24735 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G24735 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0196 | AT5G40316 | qRT-PCR/RT-PCR | highlight, salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G40316 is upregulated by highlight/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0197 | AT5G43403 | qRT-PCR/RT-PCR | drought, highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G43403 is upregulated by drought/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0198 | AT5G43725 | qRT-PCR/RT-PCR | heat, salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G43725 is downregulated by heat/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0199 | AT5G44569 | qRT-PCR/RT-PCR | drought/salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G44569 is upregulated by drought/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0200 | AT5G48412 | qRT-PCR/RT-PCR | highlight | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G48412 is downregulated by highlight stress.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0201 | AT5G50190 | qRT-PCR/RT-PCR | drought, highlight, salt | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT5G50190 is upregulated by drought/highlight/salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0202 | At5NC025190 | qRT-PCR/RNA-seq | drought and ABA | up-regulated | N/A | The expression of four representative lincRNAs by qRT-PCR (see Supplemental Figure 12 online). All of the four lincRNAs showed similar induction pattern during drought stress or ABA treatment. | 23136377 | PLNlncRbase | |
EL0203 | At5NC029980 | qRT-PCR/RNA-seq | drought and ABA | up-regulated | N/A | The expression of four representative lincRNAs by qRT-PCR (see Supplemental Figure 12 online). All of the four lincRNAs showed similar induction pattern during drought stress or ABA treatment. | 23136377 | PLNlncRbase | |
EL0204 | At5NC055270 | qRT-PCR/RNA-seq | drought and ABA | up-regulated | N/A | The expression of four representative lincRNAs by qRT-PCR (see Supplemental Figure 12 online). All of the four lincRNAs showed similar induction pattern during drought stress or ABA treatment. | 23136377 | PLNlncRbase | |
EL0205 | At5NC056820 | qRT-PCR/RNA-seq | flowers | up-regulated | N/A | Detection and experimental verification of At5NC056820, a predicted lincRNA. Expression levels are given with SD bars (n = 3). Note that At5NC056820 was highly induced by elf18 and moderately induced by ABA and drought treatment. | 23136377 | PLNlncRbase | |
EL0206 | AT5TU062110 | qRT-PCR | hypocotyls | up-regulated | N/A | Our qRT-PCR results confirmed that some lncNATs were significantly regulated by light and their expression profiles were also consistent with the results from ATH NAT arrays (Figure 2 C-F, Supplemental Figure 8 and Supplemental Table 3). | 24402519 | PLNlncRbase | |
EL0207 | AtCR20-1 | microarray, qRT-PCR | cytokinins/phosphate starvation | down-regulated/up-regulated | N/A | AtCR20-1 is regulated by biotic (down-regulated by cytokinins) and abiotic (up-regulated by phosphate starvation) signals. AtGUT15 and AtCR20-1 comprise two members of a family of genes that lack a long ORF. | 11706161 | PLNlncRbase | |
EL0208 | AtGUT15 | microarray, qRT-PCR | seeds | up-regulated | N/A | AtGUT15 is regulated by biotic (down-regulated by cytokinins) and abiotic (up-regulated by phosphate starvation) signals. AtGUT15 and AtCR20-1 comprise two members of a family of genes that lack a long ORF. | 11706161 | PLNlncRbase | |
EL0211 | AtR18 | RT-PCR | hypoxic stress | down-regulated | N/A | A specific Pol III-derived ncRNA (AtR18) responded negatively to hypoxic stress and this regulation was evidently different from that of U6 snRNA. Specifically, AtR18 was not processed into a smaller fragment and no small open reading frames (sORFs) were included. | 24252906 | PLNlncRbase | |
EL0212 | AtR18 | RT-PCR | hypoxic stress | down-regulated | N/A | AtR18, transcribed by RNA polymerase III (Pol III), were identified by efficient in vitro transcription in tobacco nuclear extracts. | 24914100 | PLNlncRbase | |
EL0213 | AtR8 | RT-PCR | roots and cytosol of cultured cells | down-regulated | N/A | A root-specific AtR8 RNA was found in Arabidopsis. AtR8 RNA was observed in the plant roots and cytosol of cultured cells. The RNA was not processed into a smaller fragment and no short open reading frame was included. AtR8 RNA are transcribed by Pol III and not by Pol II. The expression of the AtR8 RNA responded negatively to hypoxic stress, and this regulation evidently differed from that of U6 snRNA. AtR8 RNA expression respond to hypoxic stress. The AtR8 RNA levels gradually declined under the hypoxic conditions. | 22336715 | PLNlncRbase | |
EL0214 | AtR8 | RT-PCR | hypoxic stress | down-regulated | N/A | AtR8, transcribed by RNA polymerase III (Pol III), were identified by efficient in vitro transcription in tobacco nuclear extracts. | 24914100 | PLNlncRbase | |
EL0222 | B2 SINE RNA | electrophoretic mobility shift assays | plasmids | N/A | interaction | In vitro B2 RNA assembles into preinitiation complexes on promoter DNA via its interaction with the polymerase, thus rendering the complexes inactive. | 17307818 | ||
EL0222 | B2 SINE RNA | N/A | N/A | N/A | epigenetics | miR-468-mediated suppression of LSH leads to aberrant methylation of LINE1 and SINE B2. | 19959559 | LncRNADisease | |
EL0223 | B4GALT1-AS1 | cap analysis of gene expression (CAGE) | normal and malignant tissues | N/A | interaction | We identified at 5'-end of B4GALT1 a 1.454 kb sequence forming a transcription regulatory region, referred to by us as the TR1-PE1, had all characteristics of a bidirectional promoter directing the transcription of B4GALT1 in a divergent manner along with its long non-coding RNA (lncRNA) antisense counterpart B4GALT1-AS1. The five lncRNA B4GALT1-AS1 transcripts showed significant complementarity with B4GALT1 mRNA. | 26315939 | ||
EL0234 | Bc1 | Biochemical experiments | nerve cells | N/A | interaction | Bc1-mediated repression targets translation at the level of initiation. specifically, bc1 rna inhibited formation of the 48s preinitiation complex | 12451124 | ||
EL0234 | Bc1 | eliminate the BC1 RNA gene | N/A | N/A | expression | The lack of bc1 rna appears to reduce exploratory activity. | 12944471 | ||
EL0234 | Bc1 | N/A | N/A | N/A | interaction | Competition experiments using variants of bc1 and bc200 rnas demonstrated that the central adenosine-rich region of both rnas mediates binding to pabp. | 12162957 | ||
EL0234 | Bc1 | N/A | controls and knockout mice | N/A | expression | The neuron-specific non-messenger bc1 rna contributes to the aptive modulation of behaviour. | 15302134 | ||
EL0234 | Bc1 | N/A | rabbit reticulocyte lysate system, HeLa cells | N/A | interaction | In vivo, all bc1 rna appears to be complexed with pabp. nevertheless, in the micro-environment of dendritic spines of neuronal cells, bc1 rnps or bc200 rnps might mediate regulatory functions by differential interactions with locally limited pabp and/or directly or indirectly, with other translation initiation factors. | 16154588 | ||
EL0234 | Bc1 | Western-blot | Oocytes | N/A | interaction | Interactions of this domain with eukaryotic initiation factor 4A and poly(A) binding protein mediate repression;BC1 RNA modulates translation-dependent processes in neurons and germs cells by directly interacting with translation initiation factors. | 16330711 | ||
EL0236 | BcMF11 | RT-PCR | pollen development | up-regulated | N/A | A 828-bp full-length cDNA of BcMF11, a novel pollen-specific non-coding mRNA-like gene from Chinese cabbage. Antisense RNA transgenic plants displayed decreasing expression of BcMF11 and showed distinct morphological defects. Pollen germination test in vitro and in vivo of the transgenic plants suggested that inhibition of BcMF11 decreased pollen germination efficiency and delayed the pollen tubes’ extension in the style. Under scanning electron microscopy, many shrunken and collapsed pollen grains were detected in the antisense BcMF11 transgenic Chinese cabbage. Further cytological observation revealed abnormal pollen development process in transgenic plants, including delayed degradation of tapetum, asynchronous separation of microspore, and aborted development of pollen grain. These results suggest that BcMF11, as a non-coding RNA, plays an essential role in pollen development and male fertility. RT-PCR and Northern blotting analyses showed that BcMF11 was transcribed at most stages of pollen development. These results suggested that the BcMF11 is a novel non-coding RNA involved in pollen development of Chinese cabbage. (Song et al., 2013) The BcMF11 cDNA has a total length of 828 bp with poly (A) tail. Analysis of the sequence demonstrated that BcMF11 is a novel non-coding RNA which has no prominent open reading frame (ORF) or coding capacity. Transcription analysis indicated that BcMF11 is a novel pollen-specific ncRNA and may be involved in the pollen development of Chinese cabbage. BcMF11 was expressed in developing flower buds, flowers and anthers at a high level, but was not detected in roots, stems, leaves, pistils and developing siliques. Identical expression patterns were also showed in RT-PCR analysis. This indicated BcMF11 is a pollen-preferential expressed gene in Chinese cabbage. (Song et al., 2007) | 23064614, 17207554 | PLNlncRbase | |
EL0237 | BCYRN1 | BC200 truncations and RNase footprinting assays, pull-down assays | N/A | N/A | interaction | Tests performed to assess whether BC200 interferes with RHAU helicase activity have demonstrated the ability of BC200 to act as an acceptor of unwound quadruplexes via a cytosine-rich region near the 3'-end of the RNA. RHAU may direct BC200 to bind and exert regulatory functions at quadruplex-containing RNA or DNA sequences. | 26740632 | ||
EL0237 | BCYRN1 | N/A | N/A | N/A | interaction | Competition experiments using variants of bc1 and bc200 rnas demonstrated that the central adenosine-rich region of both rnas mediates binding to pabp. | 12162957 | ||
EL0237 | BCYRN1 | N/A | rabbit reticulocyte lysate system, HeLa cells | N/A | interaction | In vivo, all bc1 rna appears to be complexed with pabp. nevertheless, in the micro-environment of dendritic spines of neuronal cells, bc1 rnps or bc200 rnps might mediate regulatory functions by differential interactions with locally limited pabp and/or directly or indirectly, with other translation initiation factors. | 16154588 | ||
EL0237 | BCYRN1 | N/A | N/A | N/A | expression | In normal aging, BC200 levels in cortical areas were reduced by >60% between the ages of 49 and 86. In contrast, BC200 RNA was significantly up-regulated in AD brains, in comparison with age-matched normal brains. | 17553964 | LncRNADisease | |
EL0237 | BCYRN1 | N/A | N/A | N/A | interaction | A protein that binds bc200 rna in vivo is immunoreactive with antibodies against srp9. | 9605471 | ||
EL0237 | BCYRN1 | transgenic | transgenic mice | N/A | expression | when all upstream regions of the G22 gene were removed, expression was completely abolished, despite the presence of intact internal RNA polymerase III promoter elements | 17175535 | ||
EL0241 | bft | N/A | N/A | N/A | expression | Bft acts downstream of cut and tramtrack to implement correct bristle morphogenesis. | 12019237 | ||
EL0247 | Borg | In situ hybridization,RT-PCR | N/A | N/A | expression | Nuclear localization of BORG was mediated through a novel RNA motif consisting of the pentamer sequence AGCCC with sequence restrictions at positions -8 (T or A) and -3 (G or C) relative to the first nucleotide of the pentamer. | 24732794 | ||
EL0247 | Borg | N/A | C2C12 mouse myoblast cell line | N/A | expression | The transcript of borg lacks any extensive open reading frames and contains a cluster of multiple interspersed repetitive sequences in its middle part. | 9642273 | ||
EL0249 | BRCA1 | knockdown | human fibroblast cells | N/A | expression | Gene expression analysis after RNAi treatment targeted against DDSR1 revealed 119 genes that show differential expression. | 26697398 | ||
EL0249 | BRCA1 | microarray, qRT-PCR | N/A | N/A | interaction | Loss of DDSR1 impairs cell proliferation and DDR signaling and reduces DNA repair capacity by homologous recombination (HR). The HR defect in the absence of DDSR1 is marked by aberrant accumulation of BRCA1 and RAP80 at DSB sites. | 26411689 | ||
EL0262 | C730029A08Rik | knockdown | N/A | N/A | interaction | Blnc1 promotes brown and beige adipocyte differentiation and function | 25002143 | ||
EL0263 | C730036E19Rik | knockdown | mouse liver | up-regulated | expression | These data support a model in which lncLSTR regulates a TDP-43/FXR/apoC2-dependent pathway to maintain systemic lipid homeostasis. | 25738460 | ||
EL0270 | CARs | sequencing, Northern hybridization, ChRIP, qPCR, RACE, siRNA transfection | human fibroblast (HF) cells | N/A | N/A | regulates gene expression of neighboring genes through modulating the chromatin structure in cis. | 20404130 | ||
EL0284 | CCLS96.1 | RT-PCR/Northern blot | flower buds | up-regulated | N/A | A 1.8-kb transcript was observed not only in male flower buds but also in female flower buds. The hybridization signal of CCLS96.1 in the Northern blot analysis was so week that semi-quantitative RT-PCR was performed to analyze the expression patterns of CCLS96.1. CCLS96.1 was expressed also in male and female leaves.In the male plant, the expression of CCLS96.1 in flower buds was 2.67-to 3.42-fold higher than that in leaves. In contrast, in the female plant, the expression of CCLS96.1 in flower buds was 0.06-to 0.19-fold less than that in leaves. This suggests that the CCLS96.1 homologs play some role in the male flower bud. CCLS96.1 was also expressed in both male and female leaves. CCLS96.1 homologs are expressed in leaves and buds. The CCLS96.1 homologs play some role in the male flower bud. (Sugiyama et al., 2003) CCLS96.1 expressed in both genders in leaves and flowers, yet it is expressed 3-fold higher in male flowers than in female flowers, and 4-8-fold higher in female leaves than in male leaves suggestive that CCLS96.1 plays a role in male flowers and perhaps female leaves, a mode of action has yet to be ascertained. (Rymarquis et al., 2008) | 14686583, 18448381 | PLNlncRbase | |
EL0286 | CCND1 promoter-derived lncRNAs | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease | |
EL0289 | CDKN2B-AS1 | N/A | N/A | N/A | mutation | Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. | 17459456 | LncRNADisease | |
EL0290 | CDR1-AS | N/A | mouse brain | N/A | N/A | acts as a miR-7 sponge | 23446346 | ||
EL0290 | CDR1-AS | sequence and computationally analysis, knockdown | N/A | N/A | N/A | CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. | 23446348 | ||
EL0297 | cis-NATPHO1;2 | qRT-PCR | Phosphate homeostasis | up-regulated | N/A | PHOSPHATE1;2 (PHO1;2), a gene involved in phosphate loading into the xylem in rice, and its associated cis-NATPHO1;2 are both controlled by promoters active in the vascular cylinder of roots and leaves. While the PHO1;2 promoter is unresponsive to the plant phosphate status, the cis-NATPHO1;2 promoter is strongly upregulated under phosphate deficiency. | 24096344 | PLNlncRbase | |
EL0299 | COLDAIR | RT-PCR | vernalization | down-regulated | N/A | COLDAIR, an intronic long ncRNA of the FLC. COLDAIR is required for the vernalization-mediated epigenetic repression of FLC. COLDAIR physically associates with a component of PRC2 and targets PRC2 to FLC. Our results show that COLDAIR is required for establishing stable repressive chromatin at FLC through its interaction with PRC2. COLDAIR is required for proper repression of FLC during the course of vernalization. COLDAIR is necessary for the recruitment of CLF to FLC chromatin. (Heo et al., 2011) COLDAIR lncRNAs transcribed from the first intron of FLC are also transiently induced by the cold. The CLF subunit of PHD–PRC2 associates with COLDAIR, leading to the enrichment of this complex on FLC chromatin in the cold. A partial deletion of the COLDAIR promoter or knockdown of COLDAIR expression compromises FLC silencing. Thus, COLDAIR is required for FLC silencing by vernalization. (He et al., 2012) COLDAIR, provided the evidence that the lncRNA plays a crucial role in the regulation of flowering time by recruiting a chromatin remodeling complex to the proper target, FLC, for stable silencing by vernalization. COLDAIR, is transcribed from the first intron of FLC and its expression is increased by cold. COLDAIR physically interacts with PRC2 and is required for the enrichment of PRC2 at FLC chromatin by vernalization. Reduced COLDAIR expression by RNAi compromises the vernalization response. The interaction between COLDAIR and PRC2 increases transiently only during the cold exposure but COLDAIR is necessary for the stable maintenance of silenced FLC after cold. (Kim et al., 2012) COLDAIR play a role in the intragenerational repression of FLC. COLDAIR is an lncRNA that is expressed in the sense direction from the first intron of FLC. COLDAIR is induced during cold exposure and associates with PRC2. Its knockdown leads to a decrease in epigenetic silencing, less H3K27me3, implicating it as a required component in the recruitment of PRC2. (Jones et al., 2014) A sense intronic lncRNA named COLDAIR, participate in different phases of the cold-induced repression and the stable silencing of FLC by PRC2. Cold-induced COOLAIR-like and COLDAIR-like lncRNAs could be involved, respectively, in the initial downregulation of DAM genes and the function of PRC2 complexes. (Ríos et al., 2014) In Arabidopsis the COLDAIR lncRNA-triggered chromatin silencing of a central floral repressor known as FLC, involves H3K27me3, but not cytosine methylation. In response to a prolonged cold exposure, COLDAIR expression is induced from the first intron of FLC, and subsequently, this lncRNA recruits a PRC2-like complex to FLC chromatin to deposit H3K27me3, leading to FLC silencing. (He et al., 2013) A long intronic noncoding RNA, named COLD ASSISTED INTRONIC NONCODING RNA (COLDAIR), was shown to be required for the vernalization-mediated epigenetic repression of FLC. COLDAIR physically associates with CLF, suggesting that COLDAIR establishes stable repressive chromatin at FLC through recruiting PRC2 in H3K27me3 deposition. (Yao et al., 2011) In Arabidopsis, the floral repressor FLOWERING LOCUS C (FLC), a master regulator of flowering, is stably suppressed by prolonged exposure to cold, which promotes the enrichment of tri-methylated histone H3K27me3 at FLC locus. This process is mediated by the interaction of a long intronic noncoding RNA (named COLDAIR) to the FLC locus via recruitment of PRC2. (Pignatta et al., 2012) A long intronic noncoding RNA (COLD ASSISTED INTRONIC NONCODING RNA, COLDAIR) is also required for the stable repression of FLC after cold. COLDAIR is transcribed from the first intron of FLC during vernalization and it targets PRC2 to the FLC chromatin. (Justyna et al., 2012) The COLDAIR sense transcript is produced from within FLC intron 1, and plays a role in FLC silencing via recruitment of Polycomb repressing complex 2 (PRC2) to FLC during vernalization. The establishment of H3K27 trimethylation to silence FLC in vernalization requires COLDAIR. (Shin et al., 2014) long noncoding RNA called COLDAIR shown to be important in regulating vernalization responses in Arabidopsis. (Moghe et al., 2012) In mediating transcriptional regulation, histone modification can also involve ncRNAs such as COLDAIR, a cold-inducible long ncRNA that increases H3K27me3 marks at chromatin of the floral repressor FLC through recruitment of polycomb repressive complex 2. (Zhang et al., 2013) Two noncoding RNAs have now been implicated in vernalization induced recruitment of PHD-PRC2. One of these, termed COLDAIR, is a long (about 1 kb) noncoding sense RNA produced from sequences within the large first intron of FLC. Expression of COLDAIR is cold-induced and several observations suggest that it is functionally important for FLC silencing. In particular, transgenes with deletions that removed part or all of the COLDAIR gene showed fairly normal downregulation during cold treatments but regained activity when plants were returned to warm conditions. (Müller et al., 2011) | 21127216, 22658650, 22078062, 24808013, 24917873, 23000433, 25211139, 23132786, 23838953, 21876724 | PLNlncRbase | |
EL0300 | COOLAIR | N/A | N/A | N/A | interaction | N/A | 23641115 | ||
EL0300 | COOLAIR | N/A | N/A | N/A | interaction | N/A | 24799695 | ||
EL0300 | COOLAIR | RT-PCR | vernalization | up-regulated | N/A | longnpcRNA,COOLAIR (cold induced long antisense intragenic RNA), is cold induced FLC antisense transcripts, and has an early role in the epigenetic silencing of FLC and to silence FLC transcription transiently. COOLAIR suggested to function in early cold induced silencing of FLC transcription; COOLAIR promoter could silence some reporter genes. Suggests COOLAIR may function through transcriptional interference, although a function for the transcripts has not been tested. (Swiezewski et al., 2009) COOLAIR is expressed at A.thaliana FLOWERING LOCUS C(FLC) in response to winter temperatures. Its contribution to cold-induced silencing of FLC was proposed but its functional and evolutionary significance remain unclear. COOLAIR has been shown to participate in FLC downregulation by the autonomous pathway but its function in the cold-induced silencing of FLC is still unclear. Evolutionary conservation of COOLAIR and its seasonal expression in perennial A.alpina supports a significant role for this asRNA in repression of FLC gene expression during vernalization. The COLDAIR lncRNA transcribed from it were previously shown to be required for stable silencing of FLC in A.thaliana. (Castaings et al., 2014) COOLAIR comprises the Class I and II polyadenylated antisense FLC transcripts, and has been proposed to trigger vernalization-mediated FLC silencing by a co-transcriptional mechanism. A recent study using FLC mutants with insertional T-DNAs that can block the full-length transcription and separate the sense and antisense transcription, has revealed that elimination of COOLAIR transcription does not impair FLC silencing by vernalization. Thus, COOLAIR is not essential for FLC silencing. Of note, it is likely that COOLAIR might participate in vernalization-mediated FLC silencing via a co-transcriptional mechanism involving an overlapping transcription of sense and antisense transcripts. (He et al., 2012) COOLAIR is now used to describe the FLC antisense transcript generally, both in warm-and cold-treated plants. COOLAIR transcription is generally positively correlated with sense transcription in a range of flowering mutants that both upregulate (late-flowering mutants) and downregulate (early-flowering mutants) FLC expression. COOLAIR might modulate FLC expression. When vernalized for longer, COOLAIR expression and FLC mRNA decrease over time and remain stably silenced after return to the warm. The involvement of COOLAIR and COLDAIR in regulating FLC during vernalization. (Ietswaart et al., 2012) COOLAIR, produced at Arabidopsis FLOWERING LOCUS C (FLC). COOLAIR initiates just downstream of the major sense transcript poly(A) site and terminates either early or extends into the FLC promoter region. We now show that splicing of COOLAIR is functionally important. Since reduced use of the COOLAIR proximal poly(A) site disrupted transcriptional repression of FLC,we reasoned that reduced splicing efficiency of the COOLAIR class Ii intron, necessary to generate the exon containing that poly(A) site, might be an important factor in the increased expression of FLC in prp8. (Marquardt et al., 2014) COOLAIR is an antisense RNA that is transcribed in response to cold treatment. COOLAIR is alternatively polyadenylated at the 3' end, resulting in a proximal poly(A)site or a distal ploy(A) site. to reduce the H3K4me2 level at the FLC locus, leading to a transition from an active chromatin state to a repressive state. The reduction of H3K4me2 might benefit the H3K27me3 modification; thus, COOLAIR acts as an in direct recruiter of PRC2. However,how FLD is activated using the proximal site of COOLAIR remains unknown. (He et al., 2013) Two non coding RNAs(ncRNA) are involved in FLC repression. Early FLC silencing is mediated by COOLAIR (cold induced long antisense intragenic RNA), a cold-induced FLC antisense transcript expressed early during vernalization. (Bergonzi et al., 2012) | 20010688, 25030056, 22658650, 22785023, 24725596, 24312106 | PLNlncRbase | |
EL0304 | CRG | In situ hybridization, Northern blotting, Western blotting, RACE, RT-PCR and quantitative RT-PCR | N/A | N/A | interaction | CRG deficiency led to reduced locomotor activity and a defective climbing ability-phenotypes that are often seen in CASK mutant. | 23074190 | ||
EL0306 | Crxos | RT-PCR and RNA in situ hybridization | retina | N/A | interaction | We overexpressed another nat, crxos, in mouse adult retina using adeno-associated viral vectors and we observed a significant decrease in the expression levels of the corresponding sense gene, crx. | 15703187 | ||
EL0313 | CU1NC165 | hub-based and module-based methods | stress treatment | N/A | N/A | CU1NC165 is response to salicylic acid stimulus, osmotic stress, salt stress, jasmonic acid stimulus, wounding, water deprivation,oxidative stress.(to see table S5 for details) | 25799544 | PLNlncRbase | |
EL0314 | CU1NC272 | hub-based and module-based methods | stress treatment | N/A | N/A | For example, one of the cucumber lincRNAs (CU1NC272) targeted by csa-miRNA396b is presented (Fig. 4). | 25799544 | PLNlncRbase | |
EL0315 | CU1NC333 | hub-based and module-based methods | stress treatment | N/A | N/A | CU1NC333 is response to osmotic stress, water, salicylic acid stimulus.(to see table S5 for details) | 25799544 | PLNlncRbase | |
EL0316 | CU1NC355 | hub-based and module-based methods | stress treatment | N/A | N/A | CU1NC355 is response to fungus stress, salt stress, oxidative stress, osmotic stress.(to see table S5 for details) | 25799544 | PLNlncRbase | |
EL0317 | CU2NC636 | hub-based and module-based methods | stress treatment | N/A | N/A | CU2NC636 is response to salt stress, osmotic stress, jasmonic acid stimulus, oxidative stress, water deprivation, wounding.(to see table S5 for details) | 25799544 | PLNlncRbase | |
EL0318 | CU3NC1105 | hub-based and module-based methods | stress treatment | N/A | N/A | CU3NC1105 is response to water deprivation, wounding, water.(to see table S5 for details) | 25799544 | PLNlncRbase | |
EL0319 | CX3CL1 | RT-PCR, Southern blot and fluorescence in situ hybridization analyses | activated CD4+ T cells | N/A | expression | Ntt has no open reading frame larger than 270 bp. it is transcribed in a select subset of cd4+ t-cell clones propagated in vitro. | 9027504 | ||
EL0324 | CYP707A1 | Northern blot/RT-PCR/Microarray | ABA treatment | up-regulated | N/A | Fig. 3E shows a fSAT of an ABA-inducible gene, CYP707A1 (At4g19230) encoding ABA 8'-hydroxylase (Kushiro et al. 2004, Saito et al. 2004) and the novel ABA-inducible antisense TUs. The presence of novel ABA-inducible antisense TU was confirmed by real-time RT-PCR and Northern analyses using strand-specific RNA probes (Figs. 3F, 3G); The RD29A and CYP707A1 lancRNAs that were simultaneously accumulated with sense mRNAs, were accumulated by drought- and ABA treatments(Plant Cell Physiol.2008, 49, 1135–1149.). | 18625610 | PLNlncRbase | |
EL0328 | Dalir | N/A | neuroblastoma cells | up-regulated | expression | Dali is transcribed downstream of the Pou3f3 transcription factor gene and its depletion disrupts the differentiation of neuroblastoma cells. Locally, Dali transcript regulates transcription of the Pou3f3 locus. Distally, it preferentially targets active promoters and regulates expression of neural differentiation genes, in part through physical association with the POU3F3 protein. | 25415054 | ||
EL0329 | DANCR | knockdown | Synovium-derived mesenchymal stem cells (SMSCs) | N/A | interaction | N/A | 26514989 | ||
EL0329 | DANCR | microarray, quantitative real-time reverse transcription plus the polymerase chain reaction, overexpression | human dental pulp cells | down-regulated | interaction | N/A | 26646542 | ||
EL0337 | DHFR upstream transcripts | N/A | N/A | N/A | expression | The dhfr minor transcript may function in vivo (in cis) to regulate the transcriptional activity of the major (core) promoter. | 12461786 | ||
EL0338 | DHRS4-AS1 | gene duplication | N/A | N/A | N/A | AS1DHRS4 not only mediates deacetylation of histone H3 and demethylation of H3K4 in cis for the DHRS4 gene, but also interacts physically in trans with the epigenetic modifiers H3K9- and H3K27-specific histone methyltransferases G9a and EZH2, targeting the promoters of the downstream DHRS4L2 and DHRS4L1 genes to induce local repressive H3K9me2 and H3K27me3 histone modifications. | 22891334 | ||
EL0339 | DIO3OS | RT-PCR | N/A | N/A | locus | The dio3 gene may lie within the structure of the antisense gene, a complex arrangement often observed in imprinted loci. | 14962667 | ||
EL0340 | Dio3os | RT-PCR | N/A | N/A | locus | The dio3 gene may lie within the structure of the antisense gene, a complex arrangement often observed in imprinted loci. | 14962667 | ||
EL0343 | DLEU1 | N/A | N/A | N/A | expression | The nondeleted allele of the car and est70/leu1 genes was expressed in b-cll specimens, including those with monoallelic loss | 11264177 | ||
EL0347 | Dlx1as | Biochemical analysis | midgestation mouse brain | N/A | expression | Antisense dlx-1 and -6 have their highest expression in the svz. | 9415433 | ||
EL0347 | Dlx1as | compared between freshly-isolated and cultured dental mesenchymal cells | mouse dental mesenchymal cells | down-regulated in dental mesenchymal cells; up-regulated in odontogenic dental mesenchymal tissue | N/A | loss of odontogenic potential | 26986487 | ||
EL0347 | Dlx1as | RNA-seq, RNA CaptureSeq, and ChIP-seq | adult mouse subventricular zone neural stem cell lineage | N/A | expression | shRNA-mediated knockdown of two such lncRNAs, Six3os and Dlx1as, indicate roles for lncRNAs in the glial-neuronal lineage specification of multipotent adult stem cells. | 23583100 | ||
EL0347 | Dlx1as | RT-PCR | N/A | N/A | interaction | Mice devoid of Dlx1as RNA are viable and fertile, and display a mild skeletal and neurological phenotype reminiscent of a Dlx1 gain-of function phenotype, suggesting a role for this non-coding antisense RNA in modulating Dlx1 transcript levels and stability. | 23415800 | ||
EL0349 | DLX6-AS1 | N/A | N/A | N/A | locus | the Evf-2 ncRNA activates transcriptional activity by directly influencing Dlx-2 activity | 16705037 | ||
EL0351 | DMRT2 | a light-switching pyrene probe | living human cell | N/A | N/A | N/A | 20679250 | ||
EL0359 | dutA | Disruption of the dutA gene | N/A | N/A | N/A | Duta rna functions without being translated into protein. disruption of the duta gene did not cause phenotypic changes, suggesting that the function of duta is redundant. | 8127653 | ||
EL0369 | EMX2OS | N/A | endometrium | N/A | interaction | A biological function for emx2os, presumably to regulate emx2. | 12573261 | ||
EL0370 | Emx2os | N/A | endometrium | N/A | interaction | A biological function for emx2os, presumably to regulate emx2. | 12573261 | ||
EL0372 | enod40 | RT-PCR | Nodule formation | up-regulated | N/A | The absence of conserved sORFs in Brassicales enod40 sequences (A.thaliana, Thlaspi caerulescens and Brassica napus)could be related to the fact that, in contrast to the majority of angiosperms, these species in natural environment do not form effective symbiotic mycorrhizal associations with fungi. Mycorrhizal symbioses are probable evolutionary predecessors of nitrogen-fixing nodule symbioses, and enod40 seems to be involved in both. | 17452360 | PLNlncRbase | |
EL0373 | enod40 | RT-PCR | roots | up-regulated | N/A | The absence of conserved sORFs in Brassicales enod40 sequences (A.thaliana, Thlaspi caerulescensand Brassica napus)could be related to the fact that, in contrast to the majority of angiosperms, these species in natural environment do not form effective symbiotic mycorrhizal associations with fungi. Mycorrhizal symbioses are probable evolutionary predecessors of nitrogen-fixing nodule symbioses, and enod40 seems to be involved in both. | 17452360 | PLNlncRbase | |
EL0374 | enod40 | RT-PCR | Nodule formation | up-regulated | N/A | enod40 (BI452209) was isolated from a fungus extraradical mycelium during arbuscular mycorrhizal symbiosis with the plant. | 17452360 | PLNlncRbase | |
EL0375 | ENOD40 | Southern and PCR Analysis | Nodule formation | up-regulated | N/A | Cytokinin Induces ENOD Gene Expression in Uninoculated Roots. Earlier research had demonstrated that purified Nod factor induced the expression of ENOD40 in uninoculated vetch roots (see ref. 12). A similar response has been found for Glycine soja and alfalfa; ENOD40 transcripts were detected by RNA transfer blot analysis as early as 6 h after treatment (ref. 34; data not shown). Early nodulin genes are characteristically expressed during nodule morphogenesis. | 11038545 | PLNlncRbase | |
EL0376 | ENOD40 | a yeast three-hybrid screening, Immunolocalization | N/A | N/A | interaction | Enod40, a short open reading frame-containing mrna, induces cytoplasmic localization of a nuclear rna binding protein in medicago truncatula. | 15037734 | ||
EL0377 | ENOD40 | RT-PCR | lateral root development | up-regulated | N/A | ENOD40 transcripts are also detected at very early stages of lateral root development, in the dividing pericycle cells of the root stele that give rise to the lateral root primordia. In sections of nodules at this stage of development, the ENOD40 transcripts are localized in dividing cells of the root pericycle and in the forming connecting vascular bundle.The ENOD40 gene is expressed in the differentiating tissues of emerging lateral roots. Expression during nodule and lateral root development. ENOD40 is proven to be an important gene not only because it is involved in nodule development from very early stages, but also because it could serve as a tool in gaining access to mechanisms involved in the determination of other developmental processes in the plant. Furthermore, due to its differential expression in adventitious and acropetal lateral roots, ENOD40 gene could serve as a molecular marker in studies of lateral root initiation. | 8605294 | PLNlncRbase | |
EL0378 | ENOD40 | RT-PCR | Nodule formation | down-regulated | N/A | The expression of ENOD40 in Sesbania rostrata, an annual legume endemic to the Sahel region of West Africa and one of the few legume species that can be nodulated on stems as well as on roots. | 9620265 | PLNlncRbase | |
EL0379 | enod40 | RT-PCR | roots | up-regulated | N/A | The absence of conserved sORFs in Brassicales enod40 sequences (A.thaliana, Thlaspi caerulescens and Brassica napus)could be related to the fact that, in contrast to the majority of angiosperms, these species in natural environment do not form effective symbiotic mycorrhizal associations with fungi.Mycorrhizal symbioses are probable evolutionary predecessors of nitrogen-fixing nodule symbioses, and enod40 seems to be involved in both. | 17452360 | PLNlncRbase | |
EL0380 | ENOD40 | RT-PCR | roots | up-regulated | N/A | ENOD40, which are activated during early stages of Rhizobium-induced nodulation, are also induced during AM formation. These observations, together with the ancient nature of AM formation, suggest that some of the plant processes leading to nodulation may have evolved from those already established for fungal endosymbiosis. ENOD40, is also not very attractive for Nod factor signal transduction studies since it is activated in the root pericycle and it is unknown whether Nod factors are transported to this tissue. Furthermore, this gene can be activated by chitin fragments. Hence, this gene might be activated by fungal cell wall fragments, which makes it unclear whether its expression is of physiological meaning. | 10.1046/j.1365-313x.1998.00228.x | PLNlncRbase | |
EL0381 | ENOD40 | RT-PCR | roots | up-regulated | N/A | ENOD40, an early nodulin gene, is expressed following inoculation with Rhizobium meliloti or by adding R.meliloti-produced nodulation (Nod) factors or the plant hormone cytokinin to uninoculated roots. It is detectable in the root pericycle opposite the nodule primordium even before the appearance of infection threads, and is also found later on, associated with vascular strands in mature nodules. Comparison of the enod40 sequence isolated from several legumes and one non-legume did not reveal any conserved large ORF. Instead, a conserved region was found which may allow the production of a particularly stable cytoplasmic RNA. Therefore it has been proposed that enod40 encodes an RNA with regulatory function. In addition ENOD40 also shows a very short ORF of only 10–13 amino acids, but the 34-untranslated region appears to have important functions as a riboregulator. | 9847177 | PLNlncRbase | |
EL0382 | ENOD40 | RT-PCR | stem, lateral root primordia, embryonic tissue | up-regulated | N/A | ENOD40 still able to interact with mycorrhizal fungi. Furthermore, no phenotypic aberrations correlated to the presence of e40-mum1. ENOD40 expression is also observed in the stem, lateral root primordia, and in embryonic tissue, it is likely that ENOD40 is also involved in nonsymbiotic processes. | 14522083 | PLNlncRbase | |
EL0383 | enod40 | Northern blot/Southern blot | Nodule formation | down-regulated | N/A | The alb1 is a symbiotic mutant of lotus japonicus that form empty nodules, mature alb1 nodules exhibied very weak or no expression of enod40 in the peripheral cells of the undeveloped nodule vascular bundle. ENOD40 may play a role in the differentiation of nodule vascular bundles. Expression of enod40 in alb1 nodules is restricted to early stages of nodule initiation. Nodule initiation on alb1 root is accompanied by the expression of enod40 in the same spatial pattern as and at a level comparable to, those in the wild type nodules. (Imaizumi-Anraku et al., 2000) Knock-down of ENOD40 leads to severe suppression of nodule primordium initiation but does not affect early bacterial infection events, thus clearly indicating that ENOD40 is required for nodule primordium formation as well as for subsequent nodule rganogenesis. knockdown of two ENOD40s in L.japonicus caused strong inhibition of nodulation. (Kumagai et al., 2006) In situ localization of LjENOD40 genes transcripts in Lotus japonicus(Gifu B-129) root nodules, young seed pods, and embryos. ENOD40, an early nodulin gene, has been postulated to play a significant role in legume root nodule ontogenesis. High levels of ENOD40 gene transcripts were found in nonsymbiotic tissues such as stems, fully developed flowers, green seed pods, and hypocotyls. lower level of transcripts was observed in leaves, roots, and cotyledons. In mature nodules, transcripts of both ENOD40 genes accumulate in the nodule vascular system; in young seed pods strong signal is observed in the ovule, particularly in the phloem and epithelium, as well as in globular stage embryos. ENOD40 genes are indirectly triggered by Nod factors via an effect on the levels of common plant hormones such as auxin. The expression of ENOD40 in developing embryos, as well as in ovule tissues, of L.japonicus adds further proof to the suggestion that the ENOD40 gene is a plant gene involved in organogenesis. (Flemetakis et al., 2000) | 11129043, 16816411, 10975655 | PLNlncRbase | |
EL0384 | enod40 | RT-PCR | Nodule formation | up-regulated | N/A | enod40 is not an inducer of cell division per se, but other factors likely present only in the inner cortex are required to complete cell cycle activation. Stable constitutive expression of enod40 in transgenic plants resulted in a large proportion of dividing root cortical cells when grown under nitrogen-limited conditions Translation was observed in epidermal and outer cortical cells of intact roots. As well as accelerated nodulation. Further suggesting that our transient assay is related to the biological activity of enod40 in the root ortex. enod40 action in alfalfa roots. enod40 regulation in nodule organogenesis. (Sousa et al., 2001) Enod40 is a key regulatory gene expressed early during nodule organogenesis. Enod40 is one of the first molecular markers expressed at the onset of nodule organogenesis in the root pericycle and cortex. Enod40 has been proposed as one of the key regulatory genes involved in a signal transduction pathway activated during nodule initiation. (Jiménez-Zurdo et al., 2000) MsENOD40 transcripts can be detected within 24h after Rhizobium meliloti infection and are found not only in the root pericycle cells and nodule primordia as reported for both soybean and pea ENOD40, but also in cells typically classed as meristems: the distal ends of nodules and developing lateral roots, the margins of young leaf primordia, and the procambial cells of the stem and root.In 10-day-old nodules, MsENOD40 transcripts were restricted to the nodule meristem and to cells surrounding the vascular bundle (not shown). In mature (21-day or older) nodules, MsENOD40 transcripts were localized to the cells of the meristem and immediately adjacent to it, with the intensity of label decreasing in the invasion zone and older parts of the nodule. (Asad et al., 1994) Early nodulin genes are characteristically expressed during nodule morphogenesis. MsENOD40 would be expressed in mycorrhizal roots. because transcripts for these genes accumulate in the bacteria-free nodules elicited by R.Meliloti exopolysaccharide (exo) mutants or in alfalfa roots treated with auxin transport inhibitors. MsENOD40 transcripts accumulated in the cells of the pericycle and to a more limited extent in the epidermis and inner cortical cells, especially those containing immature arbuscules. Forming arbuscular mycorrhizae and Rhizobium-induced nodules.we show that mycorrhizae resemble nodules at the molecular level in that these two early nodulin genes are expressed. We also show that cytokinin induces both MsENOD2 and MsENOD40 expression in uninoculated roots,indicating this plant hormone may be part of the mechanism of signal transduction. (van et al., 1997) | 11113209, 10656590, 10.1007/BF01276808, 11038545 | PLNlncRbase | |
EL0385 | enod40 | RT-PCR | nodule initiation | up-regulated | N/A | enod40, expressed in spontaneous nodules nodule-related organs developed in the absence of Rhizobium on certain alfalfa plants during nitrogen limitation. This indicates that enod40 expression is associated to the nodule developmental program independently of any infection process. Interestingly, an enod40 homolog was recently found in tobacco whose expression increases auxin tolerance of tobacco protoplasts. enod40 is involved in the initiation of root nodule organogenesis. enod40 expression induced dedifferentiation and division of cortical cells under nitrogen-limiting conditions. Our results suggest that this early nodulin gene is involved in the initiation of nodule development. (Charon et al., 1997) enod40, has a regulatory function in nodule initiation. enod40 is highly conserved among leguminous plants and it has also been identied in the non-legumes tobacco, rice and maize. In the legume roots, it is expressed in the early stages of the interaction, specically in the pericycle adjacent to the protoxylem pole and well before the initiation of cortical cell divisions that lead to nodule formation. Furthermore, it is induced by NFs and chitin pentamers and the phytohormone cytokinin. (Girard et al., 2003) ENOD40 was identified as a candidate for such a plant factor with a regulatory role during nodulation. ENOD40 Bright Yellow-2 (BY-2) tobacco cell suspensions. ENOD40 action can be counteracted by an ethylene perception blocker, indicating that ethylene is a negative regulator of elongation growth in 35S:NtENOD40 cells, and that the NtENOD40-induced response is mediated by alteration of ethylene biosynthesis kinetics. (Ruttink et al., 2006) | 11038563, 12930950, 12930950 | PLNlncRbase | |
EL0386 | enod40 | RT-PCR | stems | up-regulated | N/A | Studies on rice enod40 suggest that legume and non-legume enod40 genes may share some common functions in differentiation and/or functions of vascular bundles, where rice enod40 is mostly accumulated. (Girard et al., 2003) Expression of OsENOD40 was detected only in stems. OsENOD40 is expressed only at the early stages of the development of lateral vascular bundles that conjoin the emerging leaf, and its expression is down-regulated after the onset of leaf expansion. OsENOD40 expression is restricted to lateral (large) vascular bundles only. (Kouchi et al., 1999) | 12930950, 10363365 | PLNlncRbase | |
EL0387 | enod40 | RT-PCR | Nodule formation | up-regulated | N/A | The over expression of enod40 in M.truncatula plants infected by Sinorhizobium melilotiresulted in fast nodulation of these transgenic plants. Altered levels of enod40 expression considerably affect nodule induction by S.meliloti. During this symbiotic interaction, overexpression of enod40 resulted in accelerated nodulation and enhanced root growth of transgenic plants. Those plants in which silencing of enod40 gene expression was detected exhibited reduced nodulation capacity. (Charon et al., 1999) Mycorrhizal colonization is regulated by enod40, an early nodulin gene known to be involved in the nodule symbiosis of legumes with nitrogen-fixing bacteria. Medicago truncatula plants overexpressing enod40 exhibited stimulated mycorrhizal colonization in comparison with control plants. Overexpression of enod40 promoted fungal growth in the root cortex and increased the frequency of arbuscule formation. enod40 might be a plant regulatory gene involved in the control of the mycorrhizal symbiosis. Overexpression of enod40 Promotes Development of Arbuscules. M.truncatula plants overexpressing enod40 exhibited accelerated mycorrhizal colonization.This paper shows that alteration in the transcript level of the enod40 gene has an effect on the growth of mycorrhizal fungi in the root and on the development of cells containing arbuscules. (Staehelin et al., 2001) ENOD40 expression was detected in cells surrounding the giant cells but not within the giant cells. ENOD40 up-regulation in giant cells and their surrounding cells. overexpressing ENOD40, increased initiation of nodule primordia was observed at early timepoints, which was accompanied by a proliferation response close to the root tip . ENOD40 induction is a limiting step in primordium formation, ENOD40 could play a role in transport of compounds. The early nodulin gene ENOD40 involved in primordium formation and the cell cycle gene CCS52a required for cell differentiation and endoreduplication, are expressed in galls of the host plant. (Favery et al., 2002) Overexpression of enod40 in Medicago truncatula results in a considerable increase of cortical cell divisions when plants are subjected to nitrogen-limiting conditions. Interestingly, such plants infected by Sinorhizobium meliloti nodulate faster and exhibit increased sensitivity to the Nod signals upon treatment with purified Nod factors or inoculation with S.meliloti mutants. In mature nodules, enod40 is expressed in the pericycle of the vascular bundles but also in several non-symbiotic tissues. (Girard et al., 2003) ENOD40 transcripts are required for correct subcellular localization of RNP particles in legume plants.Transgenic Medicago truncatula overexpressing enod40 exhibited accelerated nodulation, whereas plants with reduced amounts of enod40 transcripts formed only a few and modified nodule-like tructures.Mtenod40 was expressed in nodules at a high level, to a lesser extent in stems and roots,and was not detected in leaves. (Campalans et al., 2004) Under nitrogenlimiting conditions overexpression of Medicago truncatula (a model leguminous plant) enod40 (Mtenod40) induces cortical cell division in Medicago roots. These experiments also showed that transient expression of either region 1 carrying box I or a 3'sequence (region 2) spanning box II evoked a response similar to that evoked by the complete gene in alfalfa (Medicago sativa) roots. (Sousa et al., 2011) Transgenic Medicago truncatula plants overexpressing or silenced for ENOD40 exhibited accelerated nodulation or form only a few and modified nodule-like structures, respectively, suggesting that MtENOD40 regulates nodule development. The ENOD40 npcRNA was shown to re-localize a nuclear-speckle RBP from the nucleus to the cytoplasm in Medicago truncatula. Plant RBPs have been also implicated in RNA-mediated chromatin silencing in the FLC locus through interaction with specific antisense transcripts. (Charon et al., 2010) | 10521525, 11752473, 12437298, 12930950, 15037734, 11113209, 11113209 | PLNlncRbase | |
EL0388 | ENOD40-1 | RT-PCR | Nodule formation | up-regulated | N/A | GmENOD40 has a complex expression pattern during development of determinate soybean nodules. At early stages of development transcription is induced in dividing root cortical cells, the nodule primordium and the pericycle of the root vascular bundle. In mature soybean nodules, the gene is expressed in the uninfected cells of the central tissue and in the pericycle of the nodule vascular bundles. The GmENOD40 in the nodule vascular bundle requires the presence of intracellular bacteria or infection threads. GmENOD40 was localized in soybean roots at different time points after inoculation with B.japonicum USDA110 to determine where and when the gene is expressed during nodule formation. GmENOD40 gene expression in empty soybean nodule, which formed by B.japonicum mutant 3160. These nodules contain neither intracellular bacteria nor infection thresds. These empty nodules contain at the distal part a central vascular bundle. (Yang et al., 1993) ENOD40 expression was seen in dividing subepidermal cortical cells. ENOD40 expression in response to bacterial inoculation is first detectable in the pericycle of the central vascular system. ENOD40 expression in the pericycle can also be induced by nod signal addition in the absence of bacterial inoculation. ENOD40 express in soybean roots in response to various lipo-chitin signal molecules. (Minami et al., 1996) ENOD40 peptides are involved in the control of sucrose use in nitrogen-fixing nodules. Suggests that ENOD40 peptides may contribute to the control of photosynthate use in plants, which is consistent within situ hybridization studies that revealed that ENOD40 transcripts predominantly occur in the vascular bundles of mature soybean nodules. suggesting a role in the regulation of sucrose utilization in nodules. (Rohrig et al., 2002) The plant gene ENOD40 is one of the earliest nodulin genes specifically induced by nodulation factor-secreting rhizobia and appears to play an important role in root nodule organogenesis. ENOD40 is expressed at an early stage of root nodule organogenesis and has been postulated to play a central regulatory role in the Rhizobium-legume interaction. ENOD40 encoded peptides bind to SuSy suggest that these short translation products are involved in the control of sucrose utilization in nitrogen-fixing nodules. In addition to the two small peptides, the secondary structure of ENOD40 mRNA has been shown to be a key element in the signaling process underlying nodule organogenesis. Modification of sucrose synthase with ENOD40 peptide A activates sucrose cleavage activity whereas the synthesis activity of the enzyme is unaffected. The results are discussed in relation to the role of sucrose synthase in the control of sucrose utilization in nitrogen-fixing nodules. (Röhrig et al., 2004) | 8220464, 8758977, 11842184, 15541370 | PLNlncRbase | |
EL0389 | enod40-1 | RT-PCR | Nodule formation | up-regulated | N/A | LjENOD40-1 is highly expressed in the developing vascular bundles. In 21-day-old nodules, LjENOD40-1 gene transcripts accumulate in the vascular tissue surrounding the nodule. Additionally, in green young pods, LjENOD40-1 is up-regulated in the ovules and very strong hybridization signal is observed in the phloem tissue and epithelium cells. High expression was also observed at the globular stage embryo. In mature 21-day-old nodules LjENOD40-1 is highly expressed in vascular tissues of nodule. (Flemetakis et al., 2000) LjENOD40-1 is abundantly induced in very early stages of bacterial infection or Nod factor application, LjENOD40-1 is predominant in responding to Nod factors at the early stages of nodule formation. (Kumagai et al., 2006) | 10975655, 16816411 | PLNlncRbase | |
EL0390 | enod40-2 | RT-PCR | Nodule formation | up-regulated | N/A | LjENOD40-2 expression failed to be enhanced in nodule primordia induced by Nod factors, LjENOD40-2 showed a high level of expression in nodule primordia induced by rhizobia and in nodules. The results indicate that LjENOD40-2 is not a pseudogene, and has a role in nodule formation. | 15937327 | PLNlncRbase | |
EL0491 | FAS-AS1 | a culture model of human erythropoiesis | erythroblasts derived from CD34(+) hematopoietic stem cell progenitor cells of healthy donors | up-regulated | N/A | Fas-antisense 1 (Fas-AS1 or Saf) was induced during differentiation Fas-antisense 1 (Fas-AS1 or Saf) was induced during differentiation through the activity of essential erythroid transcription factors GATA-1 and KLF1 | 27067490 | ||
EL0491 | FAS-AS1 | orientation-specific RT-PCR and northern blot analysis | Jurkat cells | N/A | interaction | Saf might protect t lymphocytes from fas-mediated apoptosis by blocking the binding of fasl or its agonistic fas antibody. | 15829500 | ||
EL0501 | Firre | knockdown | mouse embryonic stem cells | N/A | epigenetics | Firre is X-linked and expressed from a macrosatellite repeat locus associated with a cluster of CTCF and cohesin binding sites, and is preferentially located adjacent to the nucleolus. Knockdown of Firre disrupts perinucleolar targeting and H3K27me3 levels in mouse fibroblasts, demonstrating a role in maintenance of an important epigenetic feature of the inactive X chromosome. | 25887447 | ||
EL0501 | Firre | weighted gene coexpression network analysis | mouse embryonic stem cells (ESCs) and neural progenitor cells (NPCs) | up-regulated | expression | Firre, a lncRNA highly enriched in the nucleoplasm and previously reported to mediate chromosomal contacts in ESCs, controls a network of genes related to RNA processing. | 26048247 | ||
EL0503 | FLC | N/A | N/A | N/A | interaction | The degradation of FRI (FRIGIDA) is accompanied by an increase in the levels of the long noncoding RNA ColdAIR, which reduces the level of histone H3Lys4 trimethylation (H3K4me3) in FLOWERING LOCUS C chromatin to promote flowering. | 25538183 | ||
EL0513 | frq antisense RNAs | N/A | wild-type strain, mutant strains | N/A | expression | These data provide an unexpected link between antisense rna and circadian timing and provide a new example of a eukaryotic cellular process regulated by naturally occurring antisense rna. | 12607002 | ||
EL0514 | FTX | N/A | N/A | Up-regulated | interaction | mutation cuasesalteration of transcript levels within the X-inactivation center and particularly important decreases in Xist RNA levels | 21118898 | ||
EL0517 | G730013B05Rik | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Involved in maintaining pluripotency in ESCs. | 21874018 | ||
EL0522 | GAL10 | N/A | N/A | N/A | interaction | The GAL lncRNAs could also promote transcriptional activation of the targeted GAL protein-coding genes. Interestingly, these lncRNAs help determine how quickly the GAL genes can be induced in response to galactose, without altering final steady-state transcript levels. | 24563719 | ||
EL0526 | GAS5 | knockdown | human glioma cells | down-regulated | interaction | The introduction of Gas5 by plasmid transfection increased the expression of tumor suppressor Bcl-2-modifying factor (bmf) and Plexin C1 via directly targeting and reducing the expression of miR-222. Downregulated expression of miR-222 inhibited U87 and U251 cell proliferation and promoted the apoptosis by upregulating bmf. Gas5 combined with the knockdown of miR-222 resulted in the smallest tumor volumes and the longest survivals of nude mice in vivo. | 26364613 | ||
EL0526 | GAS5 | N/A | N/A | Up-regulated | expression | nonprotein-coding RNA GAS5 in the inhibition of T-cell proliferation | 20421347 | ||
EL0530 | GATA3-AS1 | N/A | CD4+ T-cell | N/A | N/A | N/A | 23870669 | ||
EL0532 | Gfra1 | global expression profiling as responsive to glial cell-derived | Spermatogonial stem cells (SSCs) | up-regulated | N/A | an antisense transcript of the GDNF receptor alpha1 | 26962690 | ||
EL0537 | Gm15050 | lncRNA microarray | brown adipose tissue (BAT) and white adipose tissue (WAT) | N/A | expression | We found that AK142386 and AK133540 may affect adipogenesis and metabolism. Our data indicate that AK142386 and AK133540 may be involved in BAT and WAT development through their target genes Hoxa3 and Acad10. | 25472036 | ||
EL0538 | Gm15577 | Microarray analysis, RT-qPCR | neuronal specific Nbs1-deficient (Nbs1(CNS-del)) mouse model | N/A | interaction | N/A | 26705043 | ||
EL0540 | Gm2694 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Involved in maintaining pluripotency in ESCs. | 21874018 | ||
EL0541 | Gm30731 | knockdown | neural stem cell (NSC) in the embryonic and postnatal brain | N/A | Interaction | In NSCs, Pnky and PTBP1 regulate the expression and alternative splicing of a core set of transcripts that relates to the cellular phenotype. These data thus unveil Pnky as a conserved lncRNA that interacts with a key RNA processing factor and regulates neurogenesis from embryonic and postnatal NSC populations. | 25800779 | ||
EL0545 | GNG12-AS1 | multiple small interfering RNAs (siRNAs) to silence GNG12-AS1 | N/A | N/A | N/A | GNG12-AS1 transcripts alters MET signalling and cell migration | 26832224 | ||
EL0546 | GRMZM2G010274_T01 | RT-PCR/RNA-seq | pollens | N/A | N/A | Two of the lncRNAs (GRMZM2G010274_T01 and GRMZM2G518002_T01) showed additional isoforms in some of the tissues that may reflect tissue-specific splicing variants. | 24576388 | PLNlncRbase | |
EL0547 | GRMZM2G088590_T04 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | GRMZM2G088590_T04 which was down-regulated in root stressed for 5 h, was up-regulated in roots stressed for 10h as determined by qRT-PCR. | 24892290 | PLNlncRbase | |
EL0548 | GRMZM2G420571_T01 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | GRMZM2G420571_T01 is precursor sequences of MIR172c, GRMZM2G420571_T01 was an intragenic lncRNA, showed up-regulation in drought-stress leaves in comparison with RNA-seq. | 24892290 | PLNlncRbase | |
EL0549 | GRMZM2G518002_T01 | RT-PCR/RNA-seq | leaves | N/A | N/A | Two of the lncRNAs (GRMZM2G010274_T01 and GRMZM2G518002_T02) showed additional isoforms in some of the tissues that may reflect tissue-specific splicing variants. | 24576388 | PLNlncRbase | |
EL0550 | GRMZM2G580571_T01 | RT-PCR/RNA-seq | roots and shoot apical meristem | N/A | N/A | The B1 locus in maize identified a region located more than 100 kb upstream of the coding required sequence, GRMZM2G580571_T01 in the regulatory region of B1, which was previously identified as for B' paramutation. | 24576388 | PLNlncRbase | |
EL0554 | GUT15 | qRT-PCR/RT-PCR | heat and salt | down-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G18440 is downregulated by heat and salt stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL0555 | H19 | deletion of the H19 transcription | N/A | N/A | expression | The homozygous mutant animals are viable and fertile and display an overgrowth phenotype of 8% compared with wild-type littermates. | 9203585 | ||
EL0555 | H19 | genetic complementation approach | H19 KO myoblast cells | N/A | interaction | Ectopic expression of the mouse 91H RNA can up-regulate Igf2 expression in trans | 22662250 | ||
EL0555 | H19 | knockdown, overexpression | N/A | N/A | interaction | H19 modulates let-7 availability by acting as a molecular sponge. H19 depletion causes precocious muscle differentiation, a phenotype recapitulated by let-7 overexpression. | 24055342 | ||
EL0556 | H19 | ChIP-seq analysis | fetal liver cells | N/A | interaction | Long noncoding RNA H19 inhibits the proliferation of fetal liver cells and the Wnt signaling pathway. | 26801864 | ||
EL0556 | H19 | knockdown | N/A | N/A | interaction | H19 knockdown activates SAHH, leading to increased DNMT3B-mediated methylation of an lncRNA-encoding gene Nctc1 within the Igf2-H19-Nctc1 locus. Methylation changes at numerous gene loci consistent with SAHH modulation by H19. | 26687445 | ||
EL0556 | H19 | knockdown | gallbladder cancer cell, GBC-SD and NOZ cells | up-regulated | interaction | H19/miR-194-5p/AKT2 axis regulatory network might modulate cell proliferation in GBC. H19 elevation was significantly associated with tumor size. Cell proliferation decreased significantly after knockdown of H19 in GBC-SD and NOZ cells and after knockdown of AKT2 in NOZ cells. the S phase were significantly decreased after knockdown of H19 in NOZ cells but significantly elevated after overexpression of H19 in GBC-SD cells. | 26803515 | ||
EL0556 | H19 | lncRNA microarray | human bone marrow mesenchymal stem cells (MSCs) | up-regulated | expression | The results showed that the two up-regulated lncRNAs are likely to play important roles in osteogenic differentiation process。 | 25634249 | ||
EL0556 | H19 | LncRNA microarray | Dermal papilla (DP) cells | up-regulated | expression | RP11-766N7.3, H19 and HOTAIR are specific lncRNAs that were aberrantly expressed in DP cells and played an important role in regulating Wnt signaling | 25285630 | ||
EL0556 | H19 | N/A | undifferentiated multipotent mesenchymal C2C12 cells | N/A | expression | H19 operates as a molecular scaffold that facilitates effective association of KSRP with myogenin and otherlabile transcripts, and we propose that H19 works with KSRP to optimize an AKT-regulated posttranscriptional switch that controls myogenic differentiation. | 25385579 | ||
EL0556 | H19 | N/A | intestinal epithelial cell | up-regulated | N/A | controlling the intestinal epithelial barrier function by serving as a precursor for microRNA 675 (miR-675 | 26884465 | ||
EL0556 | H19 | N/A | N/A | N/A | interaction | Human h19 rna contains four attachment sites for the oncofetal igf-ii mrna-binding protein (imp) | 10875929 | ||
EL0556 | H19 | N/A | N/A | N/A | expression | Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. | 15645136 | LncRNADisease | |
EL0556 | H19 | N/A | N/A | N/A | N/A | N/A | 18587395 | ||
EL0556 | H19 | overexpression, knockdown | N/A | up-regulated | interaction | The novel pathway H19/miR-675/TGF-β1/Smad2/HDAC regulates osteogenic differentiation of hMSCs and may serve as a potential target for enhancing bone formation in vivo. | 26417995 | ||
EL0556 | H19 | RIP assays combined with luciferase reporter assays | osteogenesis in hMSCs | up-regulated | N/A | lncRNA H19 modulates Wnt/β-catenin pathway | 26853553 | ||
EL0556 | H19 | RNA interference | human K562 leukemia cells | N/A | interaction | Imp-3 protein associates with igf-ii leader-3 and leader-4 mrnas and h19 rna | 15753088 | ||
EL0556 | H19 | transfect | two embryonal tumour cell lines, RD and G401 | N/A | expression | Two embryonal tumour cell lines, rd and g401, showed growth retardation and morphological changes when transfected with an h19 expression construct. | 7692308 | ||
EL0560 | Halr1 | knockdown | mouse embryonic stem cells | N/A | interaction | Depletion of linc-HOXA1 RNA at its site of transcription increased transcription of the Hoxa1 gene cis to the chromosome and that exposure of cells to retinoic acid can disrupt this interaction. | 23723417 | ||
EL0560 | Halr1 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Involved in maintaining pluripotency in ESCs. | 21874018 | ||
EL0563 | HBB | N/A | N/A | N/A | expression | The human beta-globin locus is divided into three differentially activated chromatin subdomains. large transcripts precisely delineate the active domains at key cell cycle points associated with chromatin transitions and remodeling. | 10882078 | ||
EL0563 | HBB | N/A | N/A | N/A | interaction | Intergenic transcripts of the beta-globin gene cluster are specifically upregulated in dicer-deficient cells. | 16227618 | ||
EL0563 | HBB | nuclear run-on analysis, in situ hybridization analysis | erythroid cell lines, nonerythroid cell lines, erythroid tissue | N/A | expression | The plasmid colocalizes with the endogenous beta-globin locus providing insight into the mechanism of transinduction. | 9334315 | ||
EL0566 | HELLPAR | N/A | N/A | N/A | mutation | We identified a novel long intergenic noncoding RNA (lincRNA) transcript of 205,012 bases with (peri)nuclear expression in the extravillous trophoblast using strand-specific RT-PCR complemented with RACE and FISH. | 23093777 | LncRNADisease | |
EL0568 | HID1 | qRT-PCR | seedling photomorphogenesis | down-regulated | N/A | HID1(HIDDEN TREASURE 1), that modulates red-light-mediated seedling photomorphogenesis in Arabidopsis. Knocking down HID1 led to increased levels of PIF3 mRNA, which in turn correlated directly with the elongated hypocotyl phenotype observed in the hid1 mutant seedlings grown under cR. We further demonstrated that HID1 is a chromatin-bound RNA and functions as a direct repressor of PIF3 transcription in cR. Thus, to our knowledge, HID1 appears to be the first lncRNA identified as being involved in the precise control of light-mediated seedling development. HID1 was expressed ubiquitously throughout the Arabidopsis development processes. | 24982146 | PLNlncRbase | |
EL0569 | HIF1A-AS1 | Real‑time polymerase chain reaction (PCR), western blot analysis, lncRNA PCR arrays and chromatin immunoprecipitation | human bone marrow stromal cells | down-regulated | interaction | HIF1α‑AS1 is an essential mediator of osteoblast differentiation. | 26460121 | ||
EL0574 | Hm629797 | ChOP (Chromatin oligo affinity precipitation) | mouse spermatogonial Gc1-Spg cells | up-regulated | expression | Our findings in the Gc1-Spg cell line also correlate with the results from analysis of mouse testicular tissue which further highlights the in vivo physiological significance of mrhl RNA in the context of gene regulation during mammalian spermatogenesis. | 25584904 | ||
EL0574 | Hm629797 | N/A | N/A | N/A | locus | This meiotically active locus happens to be flanked by a transcribed region encoding a non-protein-coding rna polymerase ii transcript and the previously characterized repair site. | 15169920 | ||
EL0576 | Hog | qRT-PCR, ChIP on chip | cecal buds | N/A | interaction | N/A | 24075990 | ||
EL0578 | HOTAIR | Illumina microarrays and confirmed by RT-PCR | Abdominal and gluteal adipose tissue aspirates obtained from 35 subjects | N/A | interaction | Ectopic expression of HOTAIR in abdominal preadipocytes produced an increase in differentiation as reflected by a higher percentage of differentiated cells, and increased expression of key adipogenic genes including PPARγ and LPL | 24862299 | ||
EL0578 | HOTAIR | knockdown | urothelial bladder cancer (UBC), urine (Ues) | up-regulated | interaction | Knockdown of HOTAIR in UBC cell lines reduces in vitro migration and invasion. | 26800519 | ||
EL0578 | HOTAIR | knock-down | human cardiomyocytes | N/A | expression | up-regulation of HOTAIR could suppress the expression of CaV1.2 in human cardiomyocytes. However, HOTAIR knock-down promoted CaV1.2 expression in human cardiomyocytes. enforced expression of CaV1.2 increased the calcium level in cardiomyocytes overexpressing HOTAIR. These results for the first time demonstrate that HOTAIR inhibited the intracellular Ca2+ via regulation of CaV1.2 in human cardiomyocytes. | 26255135 | ||
EL0578 | HOTAIR | knockdown, Luciferase assays | 80 clinical colon cancer tissues | up-regulated | interaction | N/A | 26962687 | ||
EL0578 | HOTAIR | LncRNA microarray | Dermal papilla (DP) cells | up-regulated | expression | RP11-766N7.3, H19 and HOTAIR are specific lncRNAs that were aberrantly expressed in DP cells and played an important role in regulating Wnt signaling | 25285630 | ||
EL0578 | HOTAIR | N/A | breast cancer cells | N/A | interaction | Silencing of HBXIP, Hotair, or LSD1 was sufficient to block c-Myc-enhanced cancer cell growth in vitro and in vivo. Taken together, our results support a model in which the HBXIP/Hotair/LSD1 complex serves as a critical effector of c-Myc in activating transcription of its target genes, illuminating long-standing questions on how c-Myc drives carcinogenesis. | 26719542 | ||
EL0578 | HOTAIR | N/A | N/A | N/A | N/A | serve as scaffolds by providing binding surface | 20616235 | ||
EL0578 | HOTAIR | RT-PCR,Conventional ChIP and ChIP-chip ,In situ hybridization,RNA interference | N/A | N/A | N/A | We identified a 2.2 kilobase ncRNA residing in the HOXC locus, termed HOTAIR, which represses transcription in trans across 40 kilobases of the HOXD locus. HOTAIR interacts with Polycomb Repressive Complex 2 (PRC2) and is required for PRC2 occupancy and histone H3 lysine-27 trimethylation of HOXD locus. Thus, transcription of ncRNA may demarcate chromosomal domains of gene silencing at a distance; | 17604720 | ||
EL0579 | Hotair | N/A | N/A | N/A | N/A | regulate HOXD genes in trans via the recruitment of Polycomb Repressive Complex 2 (PRC2), followed by the trimethylation of lysine 27 of histone H3. | 21637793 | ||
EL0580 | HOTAIRM1 | sucrose gradient analysis | N/A | up-regulated | expression | Knockdown of HOTAIRM1 quantitatively blunted RA-induced expression of HOXA1 and HOXA4 during the myeloid differentiation of NB4 cells, and selectively attenuated induction of transcripts for the myeloid differentiation genes CD11b and CD18, but did not noticeably impact the more distal HOXA genes. | 19144990 | ||
EL0581 | Hotairm1 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Found to interact with a number of of chromatin binding proteins/complexes in mouse embryonic stem cells including PRC1, PRC2 and CBX1. | 21874018 | ||
EL0582 | HOTTIP | Strand-specific RT-PCR, RNA-FISH, RNA Interference, overexpression, RNA Immunoprecipitation, RNA chromatography | Primary human fibroblasts | N/A | N/A | driving histone H3 lysine 4 trimethylation and gene transcription | 21423168 | ||
EL0584 | HOXA11-AS | N/A | N/A | N/A | interaction | Hoxa11 antisense functions by transcriptional interference, repressing hoxa11 expression by competing for transcription of the common gene, rather than by sense/antisense interaction. | 12050232 | ||
EL0584 | HOXA11-AS | serial section and whole-mount in situ hybridizations | N/A | N/A | expression | In the developing limbs, the sense and antisense transcripts showed complementary expression patterns | 7789268 | ||
EL0585 | Hoxa11os | N/A | N/A | N/A | interaction | attempts to block hoxa11 function by transfection of the murine uterus with hoxa11 antisense oligonucleotides failed to interrupt normal uterine function, suggesting that hoxa11 antisense does not regulate hoxa11 mrna by formulation of sense/antisense duplexes. | 12050232 | ||
EL0587 | HOXA-AS | PCR | heart, lung, liver, kidney, colon, placenta, muscle, and brain | N/A | expression | This noncoding transcription is regulated by the retinoic acid morphogen and follows the colinear activation pattern of the cluster. Opening of the cluster at sites of activation of intergenic transcripts is accompanied by changes in histone modifications and a loss of interaction with Polycomb group (PcG) repressive complexes. | 17185360 | ||
EL0590 | HOXA-AS3 | RNA-seq, qRT-PCR | three different brain regions (cortex, white matter, and cerebellum) of human postmortem tissue | N/A | N/A | Thus, these 5 lncRNAs may be applicable as references for accurate normalisation of lncRNA profiling in multiple brain regions during long PMI, enabling the generation of highly reproducible datasets in lncRNA studies of the human brain. | 25528156 | ||
EL0591 | Hoxd3as | RNA blot analysis, in situ hybridization | hind brain, liver | N/A | expression | The earliest antisense expression was detected at 10.5 days p.c. in cdna libraries. at 12.5 days p.c., sense and antisense transcripts colocalized in the liver. | 7710686 | ||
EL0593 | Hsromega | Fluorescence RNA, In situ immunocytochemical staining | N/A | N/A | interaction | The hsromega-n transcripts play essential structural and functional roles in organizing and establishing the hnrnp-containing omega speckles and thus regulate the trafficking and availability of hnrnps and other related rna binding proteins in the cell nucleus. | 10984439 | ||
EL0593 | Hsromega | in situ hybridization | nonstressed cells | N/A | expression | Transcripts appear abruptly at the time that the zygotic genome becomes transcriptionally active, shortly before the formation of the cellular blastoderm. | 1704862 | ||
EL0593 | Hsromega | RNA in situ hybridization | somatic cyst cells | N/A | interaction | These results further support a significant role of the noncoding hsromega-n transcripts in basic cellular activities, namely regulation of the availability of hnrnps in active (chromatin bound) and inactive (in omega speckles) compartments. | 11910129 | ||
EL0594 | HSUR1 | Microarray and Northern analyses | N/A | N/A | interaction | An unexpected role for the hsurs in regulating a remarkably defined and physiologically relevant set of host targets involved in the activation of virally transformed t cells during latency. | 15916956 | ||
EL0594 | HSUR1 | N/A | T cells | N/A | Interaction | HSURs 1 and 2 interact with the predicted miRNAs in virally transformed T cells. | 20558719 | ||
EL0595 | HSUR2 | Microarray and Northern analyses | N/A | N/A | interaction | An unexpected role for the hsurs in regulating a remarkably defined and physiologically relevant set of host targets involved in the activation of virally transformed t cells during latency. | 15916956 | ||
EL0595 | HSUR2 | N/A | T cells | N/A | Interaction | HSURs 1 and 2 interact with the predicted miRNAs in virally transformed T cells. | 20558719 | ||
EL0598 | Huc1 | N/A | mesodermal tissues | N/A | expression | Mouse huc1 and huc2 act as potent enhancers capable of driving expression of an h19 reporter gene in a range of mesodermal tissues. | 11874916 | ||
EL0599 | Huc2 | N/A | mesodermal tissues | N/A | expression | Mouse huc1 and huc2 act as potent enhancers capable of driving expression of an h19 reporter gene in a range of mesodermal tissues. | 11874916 | ||
EL0602 | HvCesA6 | Strand-specific RT-PCR | Cell-wall synthesis | down-regulated | N/A | The increases in abundance of the CesA6 antisense transcript and the 21-nt and 24-nt siRNAs derived from the transcript are coincident with the down-regulation of primary wall CesAs, several Csl genes, and GT8 glycosyl transferase genes, and are correlated with the reduction in rates of cellulose and (1→3),(1→4)-β-D-glucan synthesis. The expression of individual members of the CesA/Csl superfamily and glycosyl transferases share common regulatory control points, and siRNAs from natural cis-antisense pairs derived from the CesA/Csl superfamily could function in this global regulation of cell-wall synthesis. | 19075248 | PLNlncRbase | |
EL0603 | HvISP1 | qRT-PCR | phosphate balance | up-regulated | N/A | HvIPS1 plays a distinct role in the regulation of the low-affinity Pi transporters. The expression of HvIPS1 is highly correlated with the expression of HvPHT1;3 and HvPHT1;6 in the four barley genotypes tested under low-P conditions (Figs. 4 and 6), suggesting that HvIPS1 plays a unique role in Pi remobilization. (Huang et al., 2011) The expression patterns of other members of the TPSI1/Mt4 family in monocots were also investigated. The induced expressions of OsIPS1, HvIPS1, ZmIPS2 and TalIPS2 were stronger than those of OsIPS2, HvIPS2 ZmIPS1 and TalIPS1 in roots after 4 or 10 d of Pi starvation, whereas higher induced expressions of OsIPS2, HvIPS1, ZmIPS1 and TalIPS1 were detected in shoots. (HOU et al., 2005) | 21606317 | PLNlncRbase | |
EL0608 | IGF2-AS | RNA-seq, qRT-PCR | three different brain regions (cortex, white matter, and cerebellum) of human postmortem tissue | N/A | N/A | Thus, these 5 lncRNAs may be applicable as references for accurate normalisation of lncRNA profiling in multiple brain regions during long PMI, enabling the generation of highly reproducible datasets in lncRNA studies of the human brain. | 25528156 | ||
EL0609 | IL7R | human lncRNA microarray assays | N/A | down-regulated | N/A | lnc-IL7R was capable of diminishing the LPS-induced inflammatory response | 24723426 | ||
EL0610 | ILF3 | overexpression | human fibroblast cells | down-regulated | interaction | Overexpression of SALNR delayed cellular senescence in fibroblast cells. Ras-induced stress promotes NF90 nucleolus translocation and suppresses its ability to suppress senescence-associated miRNA biogenesis, which could be rescued by SALNR overexpression. | 26487301 | ||
EL0612 | IPO5P1 | microarray, RT-qPCR | human monocyte-derived macrophages (MDMs) incubated in conditions causing activation toward M(IFN-γ + LPS) or M(IL-4) phenotypes. | up-regulated | expression | Knockdown of TCONS_00019715 following the activation of THP-1 cellls using IFN-γ and LPS diminished the expression of M(IFN-γ + LPS) markers, and elevated the expression of M(IL-4) markers. | 26796525 | ||
EL0613 | IPS1 | Northern blot/qRT-PCR | phosphate balance | up-regulated | N/A | Arabidopsis thaliana(AtIPS1) that is induced by Pi starvation, and studied the effect of cytokinin on its expression in response to Pi deprivation. AtIPS1 belongs to the TPSI1/Mt4 family, the members of which are induced by Pi starvation, and the RNAs of which contain only short, non-conserved open reading frames. AtIPS1 is induced by Pi starvation and expression in the root. The induction of AtIPS1 expression under Pi starvation is reversible. AtIPS1:GUS responsiveness to Pi starvationin roots is repressed by cytokinins. However, cytokinins did not repress the increase in root-hair number and length induced by Pi starvation, a response dependent on local Pi concentration rather than on whole-plant Pi status. Our results raise the possibility that cytokinins may be involved in the negative modulation of long-distance, systemically controlled Pi starvation responses, which are dependent on whole-plant Pi status. (Ana et al., 2002) The lncRNA, INDUCED BY PHOSPHATE STARVATIONA (IPS1), is a noncoding transcript that is intimately associated with the function of miRNA399. Under phosphate starvation, the expression PHO2, a target of miRNA399, is up-regulated due to increased binding and sequestering of miRNA399 by IPS1. IPS1 contains complementary sequences to the phosphate (Pi) starvation-induced miRNA399 and thus can compete with PHO2 transcripts for the binding of miRNA399. However, IPS1 is not cleaved by the miRNA because the paring with miRNA is interrupted by a mismatched loop at the expected miRNA cleavage site. (Kim et al., 2011) The effect of miR-399 on PHO2 mRNA was greatly suppressed by simultaneous IPS1 overexpression,suggesting that IPS1 antagonizes the effects of miR-399. In agreement with previous reports on the negative effect of PHO2 on shoot Pi content9-12, the shoot Pi content of IPS1-overexpressing plants was lower than that in their counterparts lacking IPS1 overexpression. And IPS1 contains a motif with sequence complementarity to the phosphate (Pi) starvation-induced miRNA miR-399,IPS1 over expression results in increased accumulation of the miR-399 target PHO2 mRNA and, concomitantly, in reduced shoot Pi content. (Franco-Zorrilla et al., 2007) Induced by Phosphate Starvation1(IPS1), which can bind to ath-miR399 with a three-nucleotide bulge between the 5'end 10th and 11th positions of ath-miR399. Such pairing abolished the cleavage effect of ath-miR399 on IPS1; thus, IPS1 can serve as a decoy for ath-miR399 to interfere with the binding of ath-miR399 to its other targets. (Wu et al., 2013) Under phosphate starvation, transcript levels of the natural target of miR399, PHO2, are increased because of the binding and sequestering of miR399 by IPS1. IPS1 contains a centrally bulged miR399-binding site (called 'target mimic’) that prevents IPS1 cleavage by miR399 and apparently inhibits recycling of the miR399 effector complex. (Brosnan et al., 2009) Induced by Phosphate Starvation 1 (IPS1) with a binding site for miR-399, a phosphate starvation-induced miRNA. However,miR-399 binding does not induce degradation of the IPS1 transcript due to mismatched nucleotides in the binding site, but rather results in sequestration of miR-399 from other target transcripts. Thus, IPS1 can effectively function as a sponge in hibiting the number of miR-399 molecules available for regulating its target PHO2 mRNA. The Arabidopsis thaliana pho2 mutant is aphosphate over-accumulator. This mutant carries a mutation in the PHO2 gene,encoding a ubiquitin-conjugating enzyme(UBC24), that leads to a reduction in full-length transcripts. In response to phosphate starvation, IPS1 RNAs are induced. The latter can sequester miR-399 resulting in stabilization and increased accumulation of PHO2 and, concomitantly, in reduced shoot phosphate content. (Kartha et al., 2014) | 22104407, 17643101, 23429259, 19447594, 24523727 | PLNlncRbase | |
EL0614 | IPS1 | Northern blot/RT-PCR | phosphate balance | up-regulated | N/A | IPS1 has complementarity to miR-399, but contains a mismatch loop that renders it uncleavable when miR-399 binds. Since target cleavage is the usual plant miRNA pathway the non-cleavable nature of IPS1 acts to sequester the miRNA; Competing endogenous RNA (ceRNA). IPS1 carries out target mimicry to sequester miR-399 and attenuate its effects allowing increased expression of miR-399 targets including PHO2. | 17643101 | PLNlncRbase | |
EL0615 | IPS1 | Northern blot/qRT-PCR | phosphate balance | up-regulated | N/A | The effect of miR-399 on PHO2: GFP was suppressed by simultaneous expression of IPS1, and a mutant form of IPS1 with reduced complementarity to miR-399 did not affect miR-399-mediated silencing of PHO2: GFP. Finally, we reconstituted the interaction between IPS1, miR-399 and PHO2 in a system in which complementary and compensatory mutations were introduced in all three components. | 17643101 | PLNlncRbase | |
EL0616 | IPS1 | Northern blot/qRT-PCR | phosphate balance | up-regulated | N/A | IPS1 RNA is not cleaved but instead sequesters miR-399. Thus, IPS1 overexpression results in increased accumulation of the miR-399 target PHO2 mRNA and, concomitantly, in reduced shoot Pi content5–8. Engineering of IPS1 to be cleavable abolishes its inhibitory activity on miR-399. | 17643101 | PLNlncRbase | |
EL0617 | IPS1 | Northern blot/qRT-PCR | phosphate balance | up-regulated | N/A | IPS1 RNA is not cleaved but instead sequesters miR-399. Thus, IPS1 overexpression results in increased accumulation of the miR-399 target PHO2 mRNA and, concomitantly, in reduced shoot Pi content5–8. Engineering of IPS1 to be cleavable abolishes its inhibitory activity on miR-399. | 17643101 | PLNlncRbase | |
EL0621 | JPX | knockdown, FISH, Quantitative RT-PCR, Allele-specific RT-PCR, Luciferase assay | ES cell lines | N/A | interaction | Jpx as an Xist activator | 21029862 | ||
EL0625 | KCNIP4-IT1 | N/A | cerebellum | N/A | expression | Like noncoding rnas, the porcine and human sequences have no common conserved open reading frame and share stretches of high homology interrupted by stretches with almost no homology. | 12515386 | ||
EL0626 | KCNIP4-IT1 | N/A | cerebellum | N/A | expression | Like noncoding rnas, the porcine and human sequences have no common conserved open reading frame and share stretches of high homology interrupted by stretches with almost no homology. | 12515386 | ||
EL0627 | KCNQ1DN | N/A | N/A | N/A | epigenetics | Continuously hypermethylated upon aging. | 22067257 | LncRNADisease | |
EL0628 | KCNQ1OT1 | CHIP, PCR, knockdown, RNA-guided chromatin conformation capture method | N/A | N/A | interaction | The 5' region of Kcnq1ot1 RNA orchestrates a long-range intrachromosomal loop between KvDMR1 and the Kcnq1 promoter that is required for maintenance of imprinting.PRC2 (polycomb repressive complex 2), which participates in the allelic repression of Kcnq1, is also recruited by Kcnq1ot1 RNA via EZH2. | 24395636 | ||
EL0628 | KCNQ1OT1 | ChIP,PCR,FISH,immuno-FISH | human placenta | N/A | interaction | The bidirectional silencing property of Kcnq1ot1 maps to a highly conserved repeat motif within the silencing domain, which directs transcriptional silencing by interaction with chromatin, resulting in histone H3 lysine 9 trimethylation. | 18299392 | ||
EL0628 | KCNQ1OT1 | Chromatin RNA Immunoprecipitation and RNA Immunoprecipitation,ImmunoDNA FISH,Chromatin Oligo-Affinity Precipitation | placenta and liver | N/A | interaction | our data describe a mechanism whereby Kcnq1ot1 establishes lineage-specific transcriptional silencing patterns through recruitment of chromatin remodeling complexes and maintenance of these patterns through subsequent cell divisions occurs via targeting the associated regions to the perinucleolar compartment. | 18951091 | ||
EL0629 | Kcnq1ot1 | N/A | a knockout mouse with a deletion encompassing an 890-bp silencing domain (Delta890) downstream of the Kcnq1ot1 promoter | N/A | N/A | Kcnq1ot1 RNA might mediate the silencing of ubiquitously imprinted genes by maintaining allele-specific methylation through its interactions with Dnmt1 | 20573698 | ||
EL0629 | Kcnq1ot1 | N/A | N/A | N/A | N/A | silence mulitple genes | 21345374 | ||
EL0629 | Kcnq1ot1 | N/A | an embryonic stem (ES) cell | N/A | N/A | t Kcnq1ot1 silencing extends nearly 300 kb further than previously reported and led us to examine other transcripts between IC1 and IC2 | 21576366 | ||
EL0629 | Kcnq1ot1 | RNA/DNA FISH | mouse embryo and placenta | N/A | epigenetics | The paternally expressed long noncoding RNA (ncRNA) Kcnq1ot1 regulates epigenetic gene silencing in an imprinted gene cluster in cis over a distance of 400 kb in the mouse embryo, whereas the silenced region extends over 780 kb in the placenta. Gene silencing by the Kcnq1ot1 RNA involves repressive histone modifications, including H3K9me2 and H3K27me3, which are partly brought about by the G9a and Ezh2 histone methyltransferases. | 19144718 | ||
EL0630 | Khps1 | N/A | N/A | N/A | interaction | Khps1 activates SPHK1 expression by recruiting the histone acetyltransferase p300/CBP to the SPHK1 promoter, which leads to local changes of the chromatin structure that ensures E2F1 binding and enhances transcription. | 26590717 | ||
EL0631 | Khps1a | N/A | N/A | N/A | expression | Overexpression of two fragments of khps1 caused demethylation of cg sites in the t-dmr. furthermore, this rna-directed demethylation was associated with dna methylation at three cc(a/t)gg sites in the t-dmr. | 15325271 | ||
EL0632 | KIR antisense lncRNA | N/A | Human NK cells | N/A | interaction | Overexpression of MZF-1 in developing NK cells led to decreased KIR expression, consistent with a role for the KIR antisense lncRNA in silencing KIR gene expression early in development. | 23863987 | ||
EL0636 | Ks-1 | RT-PCR, cDNA cloning, fluorescent in situ hybridization | honeybee brain | N/A | N/A | Ks-1 encodes a novel class of noncoding nuclear rna and is possibly involved in the regulation of neural functions. | 12088150 | ||
EL0641 | LDMAR | RT-PCR | normal pollen development | up-regulated | N/A | Long-day-specific male-fertility-associated RNA (LDMAR), regulates PSMS in rice. We found that sufficient amount of the LDMAR transcript is required for normal pollen development of plants grown under long-day conditions. LDMAR is required for male fertility under long day conditions. The spontaneous G→C mutation causing a SNP between 58N and 58S altered the RNA secondary structure of this region. This alteration eventually brought about heritable increased methylation in the promoter region of LDMAR, thus reducing the level of transcription specifically under long-day conditions. Such a reduced level of LDMAR results in premature PCD in anther development under long days, thus causing male sterility. (Ding et al., 2012) Photoperiod-sensitive male sterility (PSMS) is a valuable germplasm for hybrid rice breeding. Recently, we cloned pms3, a locus controlling PSMS, which encodes a long non-coding RNA called LDMAR required for normal male fertility of the rice plant under long-day conditions.Increased methylation in the promoter of LDMAR in the PSMS rice (Nongken 58S) relative to the wild-type (Nongken 58) reduced expression of LDMAR leading to male sterility under long-day conditions.all in all, reduced the expression of this lncRNA, resulting in male sterility under long-day conditions. LDMAR required for normal male fertility of the rice plant under long-day conditions. Reduction of LDMAR in Nongken 58S changed the critical day length for fertility recovery and delayed the fertility recovery under short-day conditions. This result added to our understanding of the molecular mechanism for PSMS. (Ding et al., 2012) A long non-coding RNA (lncRNA) named LDMAR. A sufficient amount of LDMAR is required for male fertility under long-day conditions. A spontaneous G-C mutation causing a SNP between NK58 and NK58S, eventually brings about heritable increased methylation in the promoter region of LDMAR, which reduces the level of LDMAR expression. This then results in premature programmed cell death (PCD) in anther development under long days, and hence male sterility. In addition, RNA-dependent DNA methylation (RdDM) is involved in the regulation of PGMS. Promoter siRNA of LDMAR derived from AK11270 is associated with the DNA methylation level of LDMAR, which reduces the expression level of LDMAR, and therefore male sterility in Nonken 58S under long-day conditions. (Wang et al., 2013) | 22308482, 23024213, 23596452 | PLNlncRbase | |
EL0643 | LeENOD40 | RT-PCR | vascular tissue | up-regulated | N/A | LeENOD40 is expressed in vascular tissue, expression of LeENOD40 in tomato is found in flowers and germinated seeds. Furthermore, it is active in vascular tissues of stems, young leaves (data not shown) and roots. In an early stage of lateral root development the lateral root primordium is flanked by regions of the vascular bundle where LeENOD40::GUS is expressed, whereas in the region where the primordium is located ENOD40 expression is low. LeENOD40::GUS is also expressed in a specific manner during flower development. LeENOD40 expression marks the time of pollination of the stigma. LeENOD40 expression also occurs in the petals after pollination. And based on our observations, we suggest that LeENOD40 could have a role in reducing ethylene production or in reducing local effects of ethylene production. | 14508686 | PLNlncRbase | |
EL0651 | LINC00261 | RNA-seq, knockdown | human endoderm and pancreatic cells | N/A | Interaction | DEANR1 contributes to endoderm differentiation by positively regulating expression of the endoderm factor FOXA2. Mechanistically, DEANR1 facilitates FOXA2 activation by facilitating SMAD2/3 recruitment to the FOXA2 promoter. | 25843708 | ||
EL0656 | LINC00461 | In Situ Hybridization, RT-PCR, knockdown | Visc-2 knockout mice | N/A | expression | Despite a neurodevelopmental expression pattern of Visc-2 that is highly localized to the cortex and sites of neurogenesis, anomalies in neither cytoarchitecture nor neuroproliferation were identified in knockout mice. These results are important because they contribute to a growing body of evidence that lncRNA loci contribute on average far less to brain and biological functions than protein-coding loci. | 25209608 | ||
EL0665 | LINC00663 | RT-PCR and qPCR methods | various cancer cell lines | N/A | expression | LINC00663 was shown to be differentially expressed in various human tissues and cancer cell lines. LINC00663 undergoes alternative splicing and the novel exonic region alters its secondary structure and its interactions with potential targeting miRNAs. | 26743782 | ||
EL0705 | LINC01613 | RT-PCR | lungs of IPF (idiopathic pulmonary fibrosis) patients | down-regulated | expression | while knock-down of the lncRNA n341773 increased collagen expression in lung fibroblasts. | 26269497 | ||
EL0711 | LINC02 | qRT-PCR | lint-fuzz/linted-fuzzless | up-regulated | N/A | Specifically, the expression of one lncRNA (LINC02) was highlighted, the expression of which might in part underlie the development of lint and fuzz fibres. This lncRNA produced significantly higher transcription levels in lint-fuzz/linted-fuzzless cottons than in lintless-fuzzless cottons (P < 0.05). | 25919642 | PLNlncRbase | |
EL0712 | linc1242 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Involved in maintaining pluripotency in ESCs. | 21874018 | ||
EL0713 | linc1257 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Found to interact with a number of chromatin binding proteins/complexes in mESCs including PRC1, PRC2, JARID1B, SUV39H1, SETD8 and CBX1, with the general pattern being interaction with repressors of gene expression. | 21874018 | ||
EL0714 | linc1368 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Involved in maintaining pluripotency in ESCs. | 21874018 | ||
EL0722 | Linc-rbe | N/A | cultured primary hippocampal neurons from adult rat | up-regulated | expression | AtRA-mediated transcriptional upregulation of endogenous expression of a novel long intergenic noncoding RNA-rat brain expressed (LINC-RBE) in cultured primary hippocampal neurons from adult rat. | 26572536 | ||
EL0722 | Linc-rbe | RT-PCR and RNA in situ hybridization | rat brain | N/A | expression | The expression pattern of the LINC-RBE showed distinct association with the specific neuro-anatomical regions, cell types and sub-cellular compartments of the rat brain in an age-related manner. Thus, its expression increased from immature stage to adulthood and declined further in old age. | 26363523 | ||
EL0723 | LincR-Ccr2-5'AS | N/A | T cell samples | N/A | N/A | LincR-Ccr2-5'AS, together with GATA-3, was an essential component of a regulatory circuit in gene expression specific to the TH2 subset of helper T cells and was important for the migration of TH2 cells. | 24056746 | ||
EL0724 | lincRNA1039 | RT-qPCR | drought and cold | up-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. Drought-induced lincRNA1039 is also up-regulated by cold stress. | 24948679 | PLNlncRbase | |
EL0725 | lincRNA1085 | RT-qPCR | drought | down-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. | 24948679 | PLNlncRbase | |
EL0726 | lincRNA1128 | RT-qPCR | drought and cold | N/A | N/A | lincRNA1128 regulated ptc-miR482a.1 as target mimics and inhibit its function. Ptc-miR482a.1 has been investigated previously and regulates specific disease-resistance proteins in P.trichocarpa. This miRNA is known to be responsive to four abiotic stresses (cold, heat, salt, and dehydration) in Populus. | 24948679 | PLNlncRbase | |
EL0727 | lincRNA1310 | RT-qPCR | stress treatments | N/A | N/A | LincRNA1310 is a target of ptc-miR476a. | 24948679 | PLNlncRbase | |
EL0728 | lincRNA1534 | RT-qPCR | drought | up-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. | 24948679 | PLNlncRbase | |
EL0729 | lincRNA1828 | RT-qPCR | drought and cold | N/A | N/A | lincRNA1828 regulated ptc-miR482a.1 as target mimics and inhibit its function. Ptc-miR482a.1 has been investigated previously and regulates specific disease-resistance proteins in P.trichocarpa. This miRNA is known to be responsive to four abiotic stresses (cold, heat, salt, and dehydration) in Populus. | 24948679 | PLNlncRbase | |
EL0730 | lincRNA20 | RT-qPCR | drought and cold | up-regulated | N/A | Drought-responsive lincRNA20 adsorbed ptc-miR476, which is a specific family in Populus. lincRNA20 is also specific to Populus, and may thus represent a Populus-specific regulatory mechanism. | 24948679 | PLNlncRbase | |
EL0731 | lincRNA2085 | RT-qPCR | drought | up-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. | 24948679 | PLNlncRbase | |
EL0732 | lincRNA2131 | RT-qPCR | drought | up-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. | 24948679 | PLNlncRbase | |
EL0733 | lincRNA2198 | RT-qPCR | drought | up-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. | 24948679 | PLNlncRbase | |
EL0734 | lincRNA262 | RT-qPCR | stress treatments | N/A | N/A | LincRNA262 is the target and target mimic of ptc-miR156c. | 24948679 | PLNlncRbase | |
EL0735 | lincRNA2623 | RT-qPCR | stress treatments | N/A | N/A | lincRNA2623 regulated ptc-miR482a.1 as target mimics and inhibit its function. Ptc-miR482a.1 has been investigated previously and regulates specific disease-resistance proteins in P.trichocarpa. This miRNA is known to be responsive to four abiotic stresses (cold, heat, salt, and dehydration) in Populus. | 24948679 | PLNlncRbase | |
EL0736 | lincRNA2752 | RT-qPCR | drought | up-regulated | N/A | Drought-responsive lincRNA2752 is a target mimic of ptc-miR169, and could reduce the expression of ptc-miR169. MiR169 is known to regulate the NF-YA transcription factor in plants, which is important in drought stress regulation. This network may be involved in the lincRNA2752-regulation of drought tolerance through miR169 and NF-YA. However, the specific regulatory mechanism requires further investigation, and knock out and over-expression of the lincRNA genes in P.trichocarpa should be performed to increase our understanding of the regulatory mechanisms. | 24948679 | PLNlncRbase | |
EL0737 | lincRNA2962 | RT-qPCR | drought | up-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. Drought-induced lincRNA2962 is also down-regulated by cold stress. | 24948679 | PLNlncRbase | |
EL0738 | lincRNA3241 | RT-qPCR | drought | up-regulated | N/A | A total of 504 lincRNAs were identified (see Supplementary Table S9 at JXB online), and eight were subjected to experimental validation by quantitative real-time polymerase chain reaction (RT-qPCR). As shown in Fig. 6, the expression patterns indicated by the sequencing and RT-qPCR results of drought-responsive lincRNAs were consistent, in a conclusion, those lncRNAs response to drought stress. LincRNA3241 is down-regulated by water and cold stress. | 24948679 | PLNlncRbase | |
EL0747 | LINC-ROR | knockdown | wild-type and NRF2 knockdown mammary stem cells | N/A | expression | NRF2 knockdown or ROR overexpression leads to increased stem cell self-renewal in mammary stem cells | 25231996 | ||
EL0748 | LINC-RSAS | RT-PCR, in situ RNA hybridization | rat brain | N/A | expression | N/A | 26750132 | ||
EL0751 | LL34 | N/A | lung and foregut endoderm | N/A | interaction | Two lncRNAs, LL18/NANCI (Nkx2.1-associated noncoding intergenic RNA) and LL34, play distinct roles in endoderm development by controlling expression of critical developmental transcription factors and pathways, including retinoic acid signaling | 24939938 | ||
EL0754 | lnc-168 | qRT-PCR | heat and salt | down-regulated | N/A | lnc-508 was down-regulated by heat and cold, while lnc-168 was down-regulated by heat and salt in Arabidopsis. | 10.3389/fpls.2015.00267 | PLNlncRbase | |
EL0755 | lnc-173 | qRT-PCR/RT-PCR | high light | up-regulated | N/A | lnc-173 and lnc-225,which are potentially regulated by high light and PIF transcription factors. | 25256571 | PLNlncRbase | |
EL0756 | lnc-225 | qRT-PCR/RT-PCR | high light | up-regulated | N/A | lnc-173 and lnc-225,which are potentially regulated by high light and PIF transcription factors. | 25256571 | PLNlncRbase | |
EL0757 | lnc-31 | Transcriptome analysis | mdx muscles | up-regulated | N/A | controlling the differentiation commitment of precursor myoblasts | 25512605 | ||
EL0759 | lnc-508 | qRT-PCR | heat and cold | down-regulated | N/A | lnc-508 was down-regulated by heat and cold, while lnc-168 was down-regulated by heat and salt in Arabidopsis. | 10.3389/fpls.2015.00267 | PLNlncRbase | |
EL0775 | lncLGR | lncLGR knockdown enhances GCK expression | fasted mice | up-regulated | N/A | lncLGR knockdown enhances GCK expression and glycogen storage lncLGR knockdown enhances GCK expression and glycogen storage | 26904944 | ||
EL0780 | lncRNA1329 | RNA-Seq/qRT–PCR | fruit ripening | down-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0781 | lncRNA1459 | RNA-Seq/qRT–PCR | fruit ripening | down-regulated | N/A | Moreover, down-regulation of the expression of some novel intergenic lncRNAs (lncRNA1459 and lncRNA1840) in wild-type tomato fruit induced an obvious delay of fruit ripening. | 25948705 | PLNlncRbase | |
EL0782 | lncRNA1471 | RNA-Seq/qRT–PCR | fruit ripening | down-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0783 | lncRNA1785 | RNA-Seq/qRT–PCR | fruit ripening | down-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0784 | lncRNA1840 | RNA-Seq/qRT–PCR | fruit ripening | down-regulated | N/A | Moreover, down-regulation of the expression of some novel intergenic lncRNAs (lncRNA1459 and lncRNA1840) in wild-type tomato fruit induced an obvious delay of fruit ripening. | 25948705 | PLNlncRbase | |
EL0785 | lncRNA2.7 | RT-PCR | human immunodeficiency virus-1 (HIV-1) | up-regulated | expression | stabilizes Complex I, reduced ROS production and inhibited EC apoptosis | 20036157 | ||
EL0786 | lncRNA246 | psRNATarget/psRobot | phosphate homeostasis | N/A | N/A | LncRNA246 was the eTM of slymiR399, a miRNA that plays an important role in regulating phosphate homeostasis. | 25948705 | PLNlncRbase | |
EL0787 | lncRNA2943 | RNA-Seq/qRT–PCR | fruit ripening | up-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0788 | LncRNA-314 | N/A | cultivar tomato Heinz1706 and its wild relative LA1589 | N/A | N/A | N/A | 26494192 | ||
EL0789 | lncRNA3294 | psRNATarget/psRobot | drought | N/A | N/A | In addition, lncRNA3294 was the target of sly-miR169 that is engaged in drought tolerance of tomato. | 25948705 | PLNlncRbase | |
EL0790 | lncRNA3613 | psRNATarget/psRobot | N/A | N/A | N/A | LncRNA3613 was the target of sly-miR5304 that has been only identified in solanaceous plants. | 25948705 | PLNlncRbase | |
EL0792 | lncRNA496 | RNA-Seq/qRT–PCR | fruit ripening | up-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0793 | lncRNA504 | psRNATarget/psRobot | plant immunity | N/A | N/A | Of these three miRNA targets, lncRNA504 was the target of slymiR6024 that was involved in plant immunity. | 25948705 | PLNlncRbase | |
EL0794 | lncRNA506 | RNA-Seq/qRT–PCR | fruit ripening | up-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0795 | lncRNA864 | RNA-Seq/qRT–PCR | fruit ripening | up-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0796 | lncRNA950 | RNA-Seq/qRT–PCR | fruit ripening | up-regulated | N/A | To investigate whether these differentially expressed lncRNAs are engaged in fruit ripening, 10 of them were arbitrarily selected, five from a highly up-regulated group and five from a down-regulated group. The differences in their expression levels observed by RNA-Seq were experimentally validated by qRT–PCR (Fig. 6). | 25948705 | PLNlncRbase | |
EL0801 | lncRNA-HSVIII | N/A | spermatocytes | N/A | N/A | upstream and downstream regions of the lncRNA-HSVIII sequence significantly increased Prss42/Tessp-2 promoter activity | 27111572 | ||
EL0803 | lncRNA-Rel | microarray, qRT-PCR | bone marrow-derived macrophages (BMDMs) | N/A | expression | Many identified LPS-regulated lncRNAs, such as lncRNA-Nfkb2 and lncRNA-Rel, locate near to immune response protein-coding genes. | 25652569 | ||
EL0804 | lncRNA-αGT | loss of function experiments | N/A | N/A | N/A | promotes full activation of adult gene expression in the chicken α-globin domain. by promoting an active chromatin structure. | 24196393 | ||
EL0812 | LOC100129973 | microarray, qRT-PCR | in the serum and FGF-2 starvation-induced apoptosis of VECs | up-regulated | N/A | lncRNA LOC100129973 upregulated the expression of two apoptosis repressors gene | 26887505 | ||
EL0815 | LOC100288798 | RT-qPCR and RNA-seq | haploid KBM7 cells | N/A | expression | Expression analysis from RNA-seq data shows significant deregulation of 41 protein-coding genes upon LOC100288798 truncation. | 26662309 | ||
EL0817 | LOC101211037 | Northern blot | cotyledons | down-regulated | N/A | The expression of the CR20 gene responded strongly to exogenous cytokinins in excised cotyledons of cucumber, and the level of expression changed in association with phenomena that have been to postulated to involve cytokinins, such as aging of leaves, greening, and responses to wounding. The level of the CR20 transcript decreased during the early phase of greening and soon after the wounding of cotyledons. The levels were much lower in young leaves than in mature or senescent leaves. Cytokinins are thought to control greening and aging of leaves and to mediate responses to wounding. (Teramoto et al., 1996) The CR20 RNA is a product of a cytokinin responsive gene that is repressed in response to cytokinins (plant hormones) or stress conditions and was first isolated from cucumber and later reported in several other plant species. (Szymański et al., 2002) | 8980532, 12049667 | PLNlncRbase | |
EL0820 | LOC103643717 | qRT-PCR/RNA-seq | leaves | down-regulated | N/A | This lncRNA was downregulated in drought-stress leaves(see Table S2 for details). | 24892290 | PLNlncRbase | |
EL0822 | LOC105246506 | combined full-length mESC transcriptome genomic mapping data with chromatin immunoprecipitation genomic location maps of the key mESC transcription factors | mouse embryonic stem cells (mESCs) | N/A | Interaction | potential roles in pluripotency | 20026622 | ||
EL0822 | LOC105246506 | in vitro knowdown, qRT-PCR | mESC (mouse embryonic stem cells), MSC (mice mesenchymal stem cells) | up-regulated | interaction | AK141205 positively promoted CXCL13 expression via acetylation of H4 histone in the promoter region;In summary, we report a completely novel role of AK141205/CXCL13 as a regulator of OGP-induced osteogenic differentiation of SMCs. Our finding provides a potential therapeutic targeting of AK141205 for enhancing disease-treatment effect of SMCs. (PMID:26321662). When overexpressed, AK141205 led to an increase in Oct4 mRNA and to a corresponding up-regulation of endodermal markers, in addition to initiating meso- and ectodermal differentiation. (PMID:20026622). | 26321662; 20026622 | ||
EL0826 | LOC105435934 | RT-PCR | cotyledons | up-regulated | N/A | The CsM10 gene was not expressed in the root tissues, but was expressed in the cotyledons. Originating in cucumber floral buds isolated by differential display and differential hybridization. The CsM10 transcript levels in the apical tissues varied with different seedling developmental stages. CsM10 expression does not depend on phytohormones. CsM10 is related to male sex differentiation in the cucumber. (Jeongki et al., 2005) CsM10 was isolated using differential display reverse transcription PCR, which showed differential expression patterns in different tissues, seedling developmental stages and photoperiods. CsM10 habours a 179 bp sequence with high sequence homology to a family of abiotic stress-associated ncRNAs known as the CR20-GUT15-Related (CGR) family, suggesting a role in the regulation of gene expression. (Au et al., 2011) | 21525783 | PLNlncRbase | |
EL0832 | LOC548136 | RT-PCR | Nodule formation | up-regulated | N/A | The polycistronic nature of enod40 mRNA was recently demonstrated biochemically, with in vitro translation in wheat germ extracts resulting in the de novo synthesis of two peptides of 12 and 24 amino acid residues, subsequently immunoprecipitated by antipeptide antibodies. Additionally, these peptides were shown to specifically bind sucrose synthase (SuSy), thus implicating them in the regulation of SuSy activity and/or its intracellular targeting. | 12930950 | PLNlncRbase | |
EL0834 | LpENOD40 | RT-PCR | stems | down-regulated | N/A | The LpENOD40 transcript encodes a putative dodecapeptide, similar to that identified in ENOD40s from leguminous plants and other dicots, and also to ENOD40s from monocots. high level of LpENOD40 gene transcript was found expressed in stem tissue. lower level was detected in leaves and only a very low expression in flowers of perennial ryegrass. No LpENOD40 transcript was detected in roots. | 12872490 | PLNlncRbase | |
EL0853 | MALAT1 | Depletion of MALAT1 or overexpression | N/A | N/A | N/A | MALAT1 regulates AS by modulating the levels of active SR | 20797886 | ||
EL0853 | MALAT1 | knockdown, siRNA | human fetal osteoblastic cell line hFOB 1.19 | up-regulated | expression | RANKL, binding to its receptor RANK, inhibited cell proliferation via MALAT1 upregulation in osteoblast cells in vitro. | 25817340 | ||
EL0853 | MALAT1 | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease | |
EL0853 | MALAT1 | nuclear magnetic resonance and Förster resonance energy transfer | N/A | N/A | mutation | An m(6)A site in the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was recently shown to induce a local change in structure that increases the accessibility of a U5-tract for recognition and binding by heterogeneous nuclear ribonucleoprotein C (HNRNPC). This m(6)A-dependent regulation of protein binding through a change in RNA structure, termed "m(6)A-switch", affects transcriptome-wide mRNA abundance and alternative splicing. The m(6)A-modified hairpin has a predisposed conformation that resembles the hairpin conformation in the RNA-HNRNPC complex more closely than the unmodified hairpin. | 26343757 | ||
EL0853 | MALAT1 | TaqMan gene expression assays, QPCR | human TK6 (p53 positive) and WTK1 (p53 negative) cells | up-regulated | interaction | The lncRNA MALAT1 and SOX2OT were induced in both TK6 and WTK1 cells | 23698766 | ||
EL0854 | Malat1 | compared between freshly-isolated and cultured dental mesenchymal cells | mouse dental mesenchymal cells | down-regulated in dental mesenchymal cells; up-regulated in odontogenic dental mesenchymal tissue | N/A | loss of odontogenic potential | 26986487 | ||
EL0854 | Malat1 | knock-down, DNA microarray analysis | hippocampal neurons | Up-regulated | regulation | modulates the recruitment of SR family pre-mRNA-splicing factors | 20729808 | ||
EL0854 | Malat1 | Northern blot,knockdown,RNA-seq | a Malat1 loss-of-function genetic model | N/A | interaction | Malat1 is not essential for mouse pre- and postnatal development. However, among a small number of genes that were dysregulated in adult Malat1 knockout mice, many were Malat1 neighboring genes, thus indicating a potential cis-regulatory role of Malat1 gene transcription. a potential cis-regulatory role of Malat1 gene transcription. | 22840402 | ||
EL0857 | MAR | RT-PCR | flower and leaf development | up-regulated | N/A | MAR(multiple-function-associated mlncRNA) could be involved in multiple complex networks in P.ginseng. The transcripts of MAR could be detected in all tissues analyzed at various levels with the highest in flowers, followed by leaves. It indicates the importance of MAR in flower and leaf development under normal growth conditions. | 25040236 | PLNlncRbase | |
EL0858 | Maternal somatic nucleus RNAs | N/A | N/A | N/A | expression | The degree of excision inhibition correlates with the copy number of the maternal internal eliminated sequences (iess), but each ies shows a characteristic inhibition efficiency. | 9819394 | ||
EL0860 | Mdrl | knockdown | N/A | N/A | interaction | MDRL affects the processing of miR-484 primary transcript in nucleus and regulates the mitochondrial network by targeting miR-361 and miR-484. MDRL inhibits mitochondrial fission and apoptosis by downregulating miR-361, which in turn relieves inhibition of miR-484 processing by miR-361. | 25057983 | ||
EL0861 | MEG3 | RT-qPCR | macrophages | N/A | interaction | Knockdown of MEG3 in macrophages resulted in induction of autophagy and enhanced eradication of intracellular M. bovis BCG. | 26757825 | ||
EL0861 | MEG3 | The luciferase reporter assay and RIP assay | EPCs of subjects with MetS | up-regulated | N/A | Pioglitazone up-regulated MEG3 expression to protect EPCs via decreasing miR-140-5p expression and increasing HDAC7 expression in MetS | 26898430 | ||
EL0862 | Meg3 | compared between freshly-isolated and cultured dental mesenchymal cells | mouse dental mesenchymal cells | down-regulated in dental mesenchymal cells; up-regulated in odontogenic dental mesenchymal tissue | N/A | loss of odontogenic potential | 26986487 | ||
EL0862 | Meg3 | Northern blot hybridizations | N/A | N/A | expression | None of the atg codons of these orfs is in the context of a strong kozak consensus sequence for initiation of translation, suggesting that gtl2 might function as an rna. primary gtl2 transcripts are differently processed in various cell types during development. | 9626496 | ||
EL0863 | MEG8 | N/A | rat brain | N/A | expression | Despite the finding that bsr rna appears to be conserved only among the rattus species, the specific expression pattern of bsr rna suggests that it might have some role in the rat cns. | 10095072 | ||
EL0863 | MEG8 | N/A | N/A | N/A | locus | This host gene, which encodes a previously reported noncoding rna, bsr, spans tandemly repeated 0.9-kilobase units including the snorna-containing intron. | 11346658 | ||
EL0865 | MHM | expression analysis and retroviral-mediated mis-expression,Northern blot,Whole mount in situ hybridization | chicken embryo | N/A | N/A | MHM has a role in chicken normal embryonic development, including gonadal sex differentiation. | 22546690 | ||
EL0866 | MHM-lncRNA | N/A | N/A | N/A | expression | The mhm region is transcribed only in the female from the particular strand into heterogeneous, high molecular-mass, non-coding rna, which is accumulated at the site of transcription, adjacent to the dmrt1 locus, in the nucleus. | 11321370 | ||
EL0869 | MIAT | knockdown,cross-link RNA precipitation analysis | neuroblastoma cell line Neuro2A | down-regulated | interaction | Gomafu indirectly modulates the function of the splicing factors SF1 and Celf3 by sequestering these proteins into separate nuclear bodies. | 25145264 | ||
EL0869 | MIAT | RT-PCR, knockdown | cataractous lens epithelial cells, plasma fraction of whole blood and aqueous humor of cataract patients | up-regulated | interaction | MIAT knockdown could affect the proliferation, apoptosis and migration of Human lens epithelial cells (HLECs) upon oxidative stress. MIAT knockdown could repress tumour necrosis factor-α-induced abnormal proliferation and migration of HLECs, suggesting a potential role of MIAT in PCO-related pathological process. MIAT acted as a ceRNA, and formed a feedback loop with Akt and miR-150-5p to regulate HLEC function. | 26818536 | ||
EL0869 | MIAT | TaqMan gene expression assays, QPCR | human TK6 (p53 positive) and WTK1 (p53 negative) cells | up-regulated | expression | The MIAT and PIWIL1 were upregulated in WTK1 cells. | 23698766 | ||
EL0870 | Miat | combined full-length mESC transcriptome genomic mapping data with chromatin immunoprecipitation genomic location maps of the key mESC transcription factors | mouse embryonic stem cells (mESCs) | N/A | Interaction | potential roles in pluripotency | 20026622 | ||
EL0870 | Miat | IRES-GFP fusion approach | mouse retinal cell | up-regulated | regulation | regulating mammalian retinal cell fate specification | 20459797 | ||
EL0871 | MIAT | Northern blot analysis and RNase H treatment, In situ hybridization, Immunoprecipitation and RT-PCR | E5 embryonic chicken brain | N/A | N/A | The tandem UACUAAC Gomafu RNA repeats bind to the SF1 splicing factor with a higher affinity than the divergent branch point sequence in mammals, which affects the kinetics of the splicing reaction in vitro. | 21463453 | ||
EL0875 | Mir124a-1hg | SAGE, in situ hybridization | developing retina | N/A | expression | Multiple transcripts that were evolutionarily conserved that did not appear to encode open reading frames of more than 100 amino acids in length ("noncoding rnas") were found to be dynamically and specifically expressed in developing and mature retinal cell types. | 15226823 | ||
EL0880 | MIR31HG | N/A | and in human Duchenne muscular dystrophy (DMD) myoblasts | up-regulated | N/A | controlling the differentiation commitment of precursor myoblasts | 25512605 | ||
EL0886 | mlncR1 | qRT-PCR | leaves | up-regulated | N/A | mlncR1 is abundant in leaves. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type A mlncRNAs, including mlncR1, mlncR2 and mlncR15, showed less than 2-fold changes between any two time-points. These mlncRNAs appears to be not responsive to cold. | 22233149 | PLNlncRbase | |
EL0887 | mlncR1 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0888 | mlncR10 | qRT-PCR | leaves | up-regulated | N/A | mlncR10 is abundant in leaves, response to cold stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. The highest level was reached, for most type C mlncRNAs, At 1 h after stress, or in a few cases, at 5 (mlncR30) or 10 hours (mlncR10). | 22233149 | PLNlncRbase | |
EL0889 | mlncR10 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0890 | mlncR11 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0891 | mlncR12 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0892 | mlncR13 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0893 | mlncR13 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0894 | mlncR14 | qRT-PCR | leaves and roots | up-regulated | N/A | Higher in leaves and roots than stems and flowers. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0895 | mlncR14 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. | 25601000 | PLNlncRbase | |
EL0896 | mlncR15 | qRT-PCR | leaves and stems | up-regulated | N/A | mlncR15 exhibit high expression in leaves and stems compared with that in flowers and roots. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type A mlncRNAs, including mlncR1, mlncR2 and mlncR15, showed less than 2-fold changes between any two time-points. These mlncRNAs appears to be not responsive to cold. | 22233149 | PLNlncRbase | |
EL0897 | mlncR15 | qRT-PCR | methyl jasmonate | down-regulated | N/A | This lncRNA is response to MeJA treatment in S. miltiorrhiza. (to see Fig 7 for details). | 25601000 | PLNlncRbase | |
EL0898 | mlncR16 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0899 | mlncR16 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. | 25601000 | PLNlncRbase | |
EL0900 | mlncR17 | qRT-PCR | roots | up-regulated | N/A | mlncR17 is expressed mainly in roots. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type B, such as mlncR17 and mlncR21, exhibited an immediate decrease after treatment for 1 hour. The decrease continued for at least 10 hours and then some of them, such as mlncR21, showed a trend of recovering to the level in untreated tissues. | 22233149 | PLNlncRbase | |
EL0901 | mlncR17 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. | 25601000 | PLNlncRbase | |
EL0902 | mlncR18 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0903 | mlncR18 | qRT-PCR | methyl jasmonate | down-regulated/up-regulated | N/A | Interestingly, the expression of mlncR18 fluctuated from time-point to time-point. It was significantly down-regulated at the time-point of 24-h treatment, while up-regulated at the time-point of 36-h treatment. These results suggest the significance of mlncRNAs in response to MeJA treatment in S. miltiorrhiza. | 25601000 | PLNlncRbase | |
EL0904 | mlncR19 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0905 | mlncR2 | qRT-PCR | leaves and roots | up-regulated | N/A | Higher in leaves and roots than stems and flowers. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type A mlncRNAs, including mlncR1, mlncR2 and mlncR15, showed less than 2-fold changes between any two time-points. These mlncRNAs appears to be not responsive to cold. | 22233149 | PLNlncRbase | |
EL0906 | mlncR2 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0907 | mlncR20 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0908 | mlncR21 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type B, such as mlncR17 and mlncR21, exhibited an immediate decrease after treatment for 1 hour. The decrease continued for at least 10 hours and then some of them, such as mlncR21, showed a trend of recovering to the level in untreated tissues. | 22233149 | PLNlncRbase | |
EL0909 | mlncR22 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to dehydration stress, mlncRNAs can also be roughly classified into 3 groups (Figure 9). The level of group I mlncRNAs, such as mlncR22, kept constant within the first 10 hours of dehydration stress and then increased at 24 hours, showing a relatively slow response. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0910 | mlncR23 | qRT-PCR | roots | up-regulated | N/A | mlncR23 is abundant in leaves. Based on the expression patterns in response to dehydration stress, mlncRNAs can also be roughly classified into 3 groups (Figure 9). Group III consists of 6 mlncRNAs, including mlncR6, mlncR8, mlncR23, mlncR24, mlncR28 and mlncR30. Expression of mlncRNAs in this group was induced at 1 hour of stress and then immediately downregulated to far below the level in untreated tissues. It is similar to the pattern of type C mlncRNAs in response to cold stress. mlncR23 showed much quicker responses to dehydration stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0911 | mlncR24 | qRT-PCR | leaves | up-regulated | N/A | mlncR24 is expressed mainly in roots. Based on the expression patterns in response to dehydration stress, mlncRNAs can also be roughly classified into 3 groups (Figure 9). Group III consists of 6 mlncRNAs, including mlncR6, mlncR8, mlncR23, mlncR24, mlncR28 and mlncR30. Expression of mlncRNAs in this group was induced at 1 hour of stress and then immediately downregulated to far below the level in untreated tissues. It is similar to the pattern of type C mlncRNAs in response to cold stress. mlncR24 showed much quicker responses to dehydration stress. mlncR24 was induced at 1 hour of stress and then immediately down regulated to far below the level in untreated tissues. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0912 | mlncR25 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0913 | mlncR26 | qRT-PCR | leaves and roots | up-regulated | N/A | Higher in leaves and roots than stems and flowers. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0914 | mlncR27 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0915 | mlncR28 | qRT-PCR | leaves and stems | up-regulated | N/A | mlncR28 exhibit high expression in leaves and stems compared with that in flowers and roots. Based on the expression patterns in response to dehydration stress, mlncRNAs can also be roughly classified into 3 groups (Figure 9). Group III consists of 6 mlncRNAs, including mlncR6, mlncR8, mlncR23, mlncR24, mlncR28 and mlncR30. Expression of mlncRNAs in this group was induced at 1 hour of stress and then immediately downregulated to far below the level in untreated tissues. It is similar to the pattern of type C mlncRNAs in response to cold stress. mlncR28 showed much quicker responses to dehydration stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0916 | mlncR29 | qRT-PCR | leaves | up-regulated | N/A | mlncR29 is abundant in leaves, mlncR29 showed response to cold stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0917 | mlncR3 | qRT-PCR | leaves and roots | up-regulated | N/A | Higher in leaves and roots than stems and flowers. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0918 | mlncR3 | qRT-PCR | methyl jasmonate | up-regulated | N/A | This lncRNA is response to MeJA treatment in S. miltiorrhiza.(to see Fig 7 for details). | 25601000 | PLNlncRbase | |
EL0919 | mlncR30 | qRT-PCR | leaves | up-regulated | N/A | mlncR30 is abundant in leaves. Based on the expression patterns in response to dehydration stress, mlncRNAs can also be roughly classified into 3 groups (Figure 9). Group III consists of 6 mlncRNAs, including mlncR6, mlncR8, mlncR23, mlncR24, mlncR28 and mlncR30. Expression of mlncRNAs in this group was induced at 1 hour of stress and then immediately downregulated to far below the level in untreated tissues. It is similar to the pattern of type C mlncRNAs in response to cold stress. mlncR30 showed much quicker responses to dehydration stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. The highest level was reached, for most type C mlncRNAs, At 1 h after stress, or in a few cases, at 5 (mlncR30). After reaching to a maximum, the mlncRNA levels quickly declined to near, or in most cases, far below the levels in untreated tissues. mlncR30 was induced at 1 hour of stress and then immediately down regulated to far below the level in untreated tissues. | 22233149 | PLNlncRbase | |
EL0920 | mlncR31 | qRT-PCR | roots | down-regulated | N/A | mlncR31, seems to play a role in post-transcriptional regulation of the corresponding protein-coding genes. It is evidenced by the negative correlation of expression between mlncR31 and the SPS gene after 5 hours of stress. | 22233149 | PLNlncRbase | |
EL0921 | mlncR4 | qRT-PCR | leaves | up-regulated | N/A | mlncR4 is abundant in leaves, mlncR4 showed response to cold stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0922 | mlncR4 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0923 | mlncR5 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0924 | mlncR5 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0925 | mlncR6 | qRT-PCR | cold | up-regulated | N/A | Based on the expression patterns in response to dehydration stress, mlncRNAs can also be roughly classified into 3 groups (Figure 9). Group III consists of 6 mlncRNAs, including mlncR6, mlncR8, mlncR23, mlncR24, mlncR28 and mlncR30. Expression of mlncRNAs in this group was induced at 1 hour of stress and then immediately downregulated to far below the level in untreated tissues. It is similar to the pattern of type C mlncRNAs in response to cold stress. mlncR6 showed much quicker responses to dehydration stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0926 | mlncR6 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. mlncR1 and mlncR4 at the time-point of 36-h treatment; mlncR5, mlncR10, mlncR11 and mlncR13 at the time-points of 24- and 36-h treatments; mlncR6 at the time-points of 12-, 36- and 48-h treatments; and mlncR2 at all four points of time. It suggests that the majority of mlncRNAs were down-regulated after MeJA treatment. | 25601000 | PLNlncRbase | |
EL0927 | mlncR7 | qRT-PCR | leaves, roots and seeds | up-regulated | N/A | mlncR7, an mlncRNA detected in leaves, stems and flowers of one-year old mature plants, and mlncR11, which was also undetected in the analyzed tissues of mature plants (Figure 7, 8 and 9). D.purpurea mlncR7 exhibited opposite expression patterns with mlncR8, which expressed in plantlets but not in the analyzed tissues of one-year-old plants. It suggests that the expression of both mlncR7 and mlncR8 is developmentally regulated, while their biological functions are distinct. | 22233149 | PLNlncRbase | |
EL0928 | mlncR7 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. | 25601000 | PLNlncRbase | |
EL0929 | mlncR8 | qRT-PCR | leaves | up-regulated | N/A | D.purpurea mlncR7 exhibited opposite expression patterns with mlncR8, which expressed in plantlets but not in the analyzed tissues of one-year-old plants. It suggests that the expression of both mlncR7 and mlncR8 is developmentally regulated, while their biological functions are distinct. Based on the expression patterns in response to dehydration stress, mlncRNAs can also be roughly classified into 3 groups (Figure 9). Group III consists of 6 mlncRNAs, including mlncR6, mlncR8, mlncR23, mlncR24, mlncR28 and mlncR30. Expression of mlncRNAs in this group was induced at 1 hour of stress and then immediately downregulated to far below the level in untreated tissues. It is similar to the pattern of type C mlncRNAs in response to cold stress. mlncR8 showed much quicker responses to dehydration stress. Based on the expression patterns in response to cold stress, mlncRNAs can be roughly categorized into three major types. Type C mlncRNAs,including mlncR3, mlncR4, mlncR5, mlncR6, mlncR8, mlncR10, mlncR12, mlncR13, mlncR14, mlncR16, mlncR18, mlncR19, mlncR20, mlncR22, mlncR23, mlncR24, mlncR25, mlncR26, mlncR27, mlncR28, mlncR29, mlncR30, accounting for more than 80% or 22 of the total 27 mlncRNAs, showed a rapid increase after treatment. | 22233149 | PLNlncRbase | |
EL0930 | mlncR8 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. | 25601000 | PLNlncRbase | |
EL0931 | mlncR9 | qRT-PCR | methyl jasmonate | down-regulated | N/A | MeJA(methyl jasmonate) is a significant regulator in plant response to biotic and abiotic stresses. These 15 mlncRNAs are considered as MeJA-responsive mlncRNAs, of which 12 were significantly down-regulated at different time-points of treatment, such as mlncR7,mlncR8, mlncR9, mlncR14, mlncR16 and mlncR17 at the time-point of 24-h treatment. | 25601000 | PLNlncRbase | |
EL0935 | MsENOD40-1 | Southern blot | Nodule formation | down-regulated | N/A | ENOD40, an early nodulin gene, is expressed following inoculation with Rhizobium meliloti or by adding R.meliloti-produced nodulation (Nod) factors or the plant hormone cytokinin to uninoculated roots. We isolated two MsENOD40 clones, designated MsENOD40–1 and MsENOD40–2, with distinct promoters from an alfalfa (Medicago sativa cv Chief) genomic library. The promoters were fused to the reporter gene uidA (gus), and the constructs were introduced into alfalfa. We observed that the MsENOD40–1 construct was expressed almost exclusively under symbiotic conditions. Under nonsymbiotic conditions MsENOD40–1 was usually not expressed in the uninoculated root of the transgenic alfalfa plants, but was activated when lateral roots or nodule primordia are initiated. The expression of MsENOD40–1 as well as MsENOD40–2 was induced by BAP or Nod factor treatment, and the extent of induction is similar for both genes (2- to 3-fold), although the basal level of MsENOD40–2 expression is generally higher (Fig. 6). In addition, both genes were also expressed in a similar pattern in roots following treatment with cytokinin or Nod factor for 4d (see Fig. 3, G–Q). | 9449836 | PLNlncRbase | |
EL0936 | MsENOD40-2 | Southern blot | Nodule formation | down-regulated | N/A | ENOD40, an early nodulin gene, is expressed following inoculation with Rhizobium meliloti or by adding R.meliloti-produced nodulation (Nod) factors or the plant hormone cytokinin to uninoculated roots. We isolated two MsENOD40 clones, designated MsENOD40–1 and MsENOD40–2, with distinct promoters from an alfalfa (Medicago sativa cv Chief) genomic library. The promoters were fused to the reporter gene uidA (gus), and the constructs were introduced into alfalfa. We observed that the MsENOD40–1 construct was expressed almost exclusively under symbiotic conditions. The MsENOD40–2 construct was transcribed under both symbiotic and nonsymbiotic conditions and in nonnodular and nodular tissues. In contrast, the expression of MsENOD40–2 is likely to be constitutive, because the promoter construct was expressed in the vascular tissues of the root and the stem even in the absence of R. meliloti (see Fig. 3). In addition, the expression of the MsENOD40–2 promoter construct was also detected at the root tip and throughout lateral root development (Fig. 3). Moreover, MsENOD40–2 was expressed in the root tip, including the root cap in some transgenic plants. The expression of MsENOD40–1 as well as MsENOD40–2 was induced by BAP or Nod factor treatment, and the extent of induction is similar for both genes (2- to 3-fold), although the basal level of MsENOD40–2 expression is generally higher (Fig. 6). In addition, both genes were also expressed in a similar pattern in roots following treatment with cytokinin or Nod factor for 4d (see Fig. 3, G–Q). | 9449836 | PLNlncRbase | |
EL0939 | Msx1os | In situ analysis | differentiated dental and bone cells, odontoblastic cell line (MO6-G3) | N/A | N/A | The ratio between msx1 sense and antisense rnas is a very important factor in the control of skeletal terminal differentiation. | 11390985 | ||
EL0939 | Msx1os | N/A | N/A | N/A | expression | The msx1 as rna involvement during tooth development and evidences a new degree of complexity in craniofacial developmental biology: the implication of endogenous as rnas. | 16157866 | ||
EL0939 | Msx1os | RT-PCR, Northern-blotting, In situ hybridization | dental and bone cells | N/A | interaction | The balance between antisense and sense msx1 mrnas appeared to control msx1 protein levels. | 12489151 | ||
EL0941 | MT1JP | applied to 76 pairs of matched normal and cancer tissue samples | tumor tissues | up-regulated | N/A | critical factor in restraining cell transformation by modulating p53 translation | 26909858 | ||
EL0942 | Mt4 | Northern blot/qRT-PCR | roots | up-regulated | N/A | This lncRNAs work as a decoy of miRNAs,and exert their functions by binding miRNAs in a target mimicry mechanism to sequestrate the miRNAs’ regulation roles on their target genes, such as lncRNAs IPS1 and at4. | 23726911 | PLNlncRbase | |
EL0943 | Mt4 | Northern blot/Southern blot | roots | down-regulated | N/A | Mt4 gene expression is regulated in response to colonization by mycorrhizal fungi: transcripts were detected in non-colonized roots and levels decreased in M.sativa(alfalfa) roots after colonization by G.versiforme. Transcript levels also decreased during the incomplete interaction between G.versiforme and a M.sativa mycorrhizal minus (myc-) line, indicating that the down-regulation of this gene occurs early during the interaction between the fungus and its host plant. Phosphate levels in the nutrient media also affected the expression of the Mt4 gene: transcripts were present in the roots of plants grown under phosphate-deficient conditions, but were undetectable in the roots of plants grown under phosphate sufficient conditions. Northern blot analyses indicate that Mt4 transcripts are present primarily in roots and barely detectable in stems or leaves. | 9207836 | PLNlncRbase | |
EL0944 | Mt4 | RT-PCR | roots | up-regulated | N/A | Mt4 is a cDNA representing a phosphate-starvation-inducible gene from Medicago truncatula that is down-regulated in roots in response to inorganic phosphate (Pi) fertilization and colonization by arbuscular mycorrhizal fungi. The expression of the Mt4 gene in M.truncatula roots is down-regulated systemically by both Pi fertilization and colonization by arbuscular mycorrhizal fungi. Analysis of the expression of the Mt4-like Arabidopsis gene, At4, in wild-type Arabidopsis and pho1, a mutant unable to load Pi into the xylem, suggests that Pi must first be translocated to the shoot for down-regulation to occur. The data from the pho1 and split-root studies are consistent with the presence of a translocatable shoot factor responsible for mediating the systemic downregulation of Mt4-like genes in roots. (Burleigh et al., 1999) Mt4, a phosphate starvation inducible cDNA from Medicago truncatula which is down-regulated in roots in response to phosphate fertilization as well as colonization by arbuscular mycorrhizal (AM) fungi. Expression was highly sensitive to exogenous applications of phosphate fertilizer; transcripts were abundant in roots fertilized with nutrient solution lacking phosphate. Mt4 is the first cDNA reported to show independent regulation by both phosphate and mycorrhizal fungi. Mt4 gene expression exhibited an inverse, exponential correlation with soluble phosphorus levels in the leaves. The Mt4 gene from M.truncatulais the first plant gene identified whose expression is down-regulated by both phosphate starvation and mycorrhizal colonization and as such may provide the means to elucidate the signal transduction pathways involved in these two processes. The phosphate fertilization experiment indicated that Mt4 gene expression in roots was maximal under conditions of P-starvation and dramatically reduced by relatively low levels of phosphate fertilization. The response of Mt4 expression to P-starvation was similar to that of MtPT2, a P-starvation inducible phosphate transporter from M.truncatula. (Burleigh et al., 1998) A cDNA clone (Mt4) was isolated as a result of a differential screen to identify genes showing altered expression during the interaction between Medicago truncatula and the vesicular-arbuscular mycorrhizal (VAM) fungus Glomus versiforme. Mt4 represents a M.truncatula mRNA that contains numerous short open reading frames, the two longest of which are predicted to encode polypeptides of 51 amino acids each. One of these open reading frames shares a short region of identity with a phosphate starvation-inducible gene from tomato. Mt4 gene expression is regulated in response to colonization by mycorrhizal fungi: transcripts were detected in non-colonized roots and levels decreased in both M.truncatula and M.sativa(alfalfa) roots after colonization by G.versiforme. Northern blot analyses indicate that Mt4 transcripts are present primarily in roots and barely detectable in stems or leaves, Thus, Mt4 represents a M.truncatula gene whose expression is regulated in response to both colonization by mycorrhizal fungi and to the phosphate status of the plant. (Burleigh et al., 1997) | 9880366, 9207836 | PLNlncRbase | |
EL0945 | MtENOD40-1 | RT-PCR | Nodule formation | down-regulated | N/A | In M.truncatula, knock-down of MtENOD40-1 expression led to a 50% reduction in the number of nodules. To reduce MtENOD40-1 and MtENOD40-2 gene expression, Agrobacterium rhizogenes-mediated RNAi was applied in M.truncatula hairy roots. To this end, one vector (pRRsil401) was designed that is expected to lead to a reduction in expression of MtENOD40-1, and a second vector (pRRsil402) that is expected to lead to a reduction in MtENOD40-2 expression. To knock-down transcription of both genes simultaneously, a third vector (pRRsil4012) was used. MtENOD40-1 as well as MtENOD40-2 is involved in nodule initiation. On roots,in which the expression of both MtENOD40-1 and MtENOD40-2 is reduced, the average number of nodules per root is 1.5 (75% reduction). Thus knocking down of the expression of both genes has an additive effect, suggesting that MtENOD40 acts in a dose-dependent manner. | 17452749 | PLNlncRbase | |
EL0946 | MtENOD40-2 | RT-PCR | Nodule formation | down-regulated | N/A | In sections of roots collected 2d post-inoculation, GUS activity was present in dividing cortical cells, indicating that MtENOD40-2 is expressed in cells of the nodule primordium (Fig. 2C). Whole-mount staining for GUS activity of nodules showed that GUS activity is detected near the apex of the nodule and in vascular bundles (Fig. 2D). To localize the site of expression of MtENOD40-2 precisely in the nodule, in situ hybridization using [35S]UTP-labelled antisense MtENOD40-2 RNA was conducted (Fig. 2A, B). This showed that MtENOD40-2 is expressed in cells of the infection zone (Fig. 2B, IZ). Thus, the MtENOD40-2 expression pattern is similar to the MtENOD40-1 expression pattern (Crespi et al., 1994). Furthermore, the GUS expression studies are consistent with the in situ hybridization data, indicating that the 1.8 kb DNA fragment used contains the elements required for the regulation of MtENOD40-2 expression. Based on the combination of expression data and the sequence homology between both genes, it is likely that MtENOD40-2 is functional in nodule initiation and development. | 17452749 | PLNlncRbase | |
EL0949 | Munc | knockdown | murine muscle | N/A | N/A | a promyogenic lncRNA that acts directly or indirectly on multiple promoters to increase myogenic gene expression | 25403490 | ||
EL0953 | Myh8 | Northern blot, RT-PCR | neonatal rat heart | N/A | expression | In the neonatal heart naturally occurring antisense mrna may play a role in the regulation of mhc expression and, therefore, in the control of the energetical and contractile behaviour of the heart. | 9632112 | ||
EL0971 | Nctc1 | ChIP, qRT-PCR | Myoblasts | N/A | N/A | Nctc1 is co-regulated with Igf2 and H19 and physically interacts with the shared muscle enhancer. In fact, all three co-regulated genes have the potential to interact not only with the shared enhancer but also with each other via their enhancer interactions | 23221643 | ||
EL0971 | Nctc1 | N/A | N/A | N/A | expression | enhancer function requires transcription in cis of a long non-coding RNA, Nctc1. | 23842673 | ||
EL0972 | NDM29 | RNA-seq, qRT-PCR | three different brain regions (cortex, white matter, and cerebellum) of human postmortem tissue | N/A | N/A | Thus, these 5 lncRNAs may be applicable as references for accurate normalisation of lncRNA profiling in multiple brain regions during long PMI, enabling the generation of highly reproducible datasets in lncRNA studies of the human brain. | 25528156 | ||
EL0973 | NEAT1 | EM observation | mammalian cells | N/A | Interaction | Paraspeckle formation is initiated by transcription of the NEAT1 chromosomal locus and proceeds in conjunction with NEAT1 lncRNA biogenesis and a subsequent assembly step involving >40 paraspeckle proteins (PSPs). | 25831520 | ||
EL0973 | NEAT1 | knockdown | HeLa epithelial adenocarcinoma,WI-38 normal female diploid fibroblast lung,Human EBV-transformed human lymphoblasts,primary mouse embryo fibroblasts | N/A | mutation | Depletion of NEAT1 RNA via RNAi eradicates paraspeckles, suggesting that it controls sequestration of the paraspeckle proteins PSP1 and p54, factors linked to A-I editing. Unlike overexpression of PSP1, NEAT1 overexpression increases paraspeckle number, and paraspeckles emanate exclusively from the NEAT1 transcription site | 19217333 | ||
EL0973 | NEAT1 | N/A | Human cell | N/A | N/A | paraspeckle formation | 20211624 | ||
EL0973 | NEAT1 | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease | |
EL0974 | Neat1 | expression patterns of two long noncoding RNAs; an animal model lacking NEAT1 | adult mouse tissues | N/A | N/A | architectural integrity of nuclear bodies | 21444682 | ||
EL0974 | Neat1 | expression patterns of two long noncoding RNAs;an animal model lacking NEAT1 | adult mouse tissues | N/A | N/A | architectural integrity of nuclear bodies | 21444682 | ||
EL0974 | Neat1 | N/A | mouse Neuro-2a cell line | N/A | N/A | the least stable lncRNAs is the well-characterized paraspeckle RNA Neat1, Neat1's instability contributes to the dynamic nature of this subnuclear domain. | 22406755 | ||
EL0974 | Neat1 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Neat1 has also been reported to interact with a number of chromatin binding protein/complexes in mouse embryonic stem cells including PRC1, PRC2, JARID1B, ESET and SUV39H1, with the general pattern being interaction with repressors of gene expression | 21874018 | ||
EL0974 | Neat1 | RT-PCR, siRNA, RIP | 3T3-L1 cells induced to differentiate by a media cocktail of insulin, dexamethasone, and isobutylmethyxanthine (IBMX) | down-regulated | expression | Levels of NEAT1 transcript, measured by RT-PCR, fluctuated in a temporal manner over the course of differentiation that suggested its role in alternative splicing of PPARγ mRNA, the major transcription factor driving adipogenesis. | 25437750 | ||
EL0976 | Nfkb2 | microarray, qRT-PCR | bone marrow-derived macrophages (BMDMs) | N/A | expression | Many identified LPS-regulated lncRNAs, such as lncRNA-Nfkb2 and lncRNA-Rel, locate near to immune response protein-coding genes. | 25652569 | ||
EL0985 | NORAD | N/A | previously karyotypically stable cell lines | N/A | interaction | Inactivation of NORAD triggers dramatic aneuploidy in previously karyotypically stable cell lines. | 26724866 | ||
EL0990 | npc15 | microarray/qRT-PCR | leaves | N/A | N/A | Differential expression of TAS3, npc43, and npc311 in roots and of npc15 and npc156 in leaves was confirmed, as we previously reported using semiquantitative RT-PCR. As the expression of several npcRNAs was affected by environmental stress, we explored the response to salt stress and phosphate starvation in lines overexpressing npc43, npc60, npc311, and npc536. | 18997003 | PLNlncRbase | |
EL0991 | npc156 | Microarray/qRT-PCR | leaves | up-regulated | N/A | Differential expression of TAS3, npc43, and npc311 in roots and of npc15 and npc156 in leaves was confirmed, as we previously reported using semiquantitative RT-PCR. As the expression of several npcRNAs was affected by environmental stress, we explored the response to salt stress and phosphate starvation in lines overexpressing npc43, npc60, npc311, and npc536. | 18997003 | PLNlncRbase | |
EL0992 | npc311 | Microarray/qRT-PCR | roots | down-regulated | N/A | Differential expression of TAS3, npc43, and npc311 in roots and of npc15 and npc156 in leaves was confirmed, as we previously reported using semiquantitative RT-PCR. As the expression of several npcRNAs was affected by environmental stress, we explored the response to salt stress and phosphate starvation in lines overexpressing npc43, npc60, npc311, and npc536. | 18997003 | PLNlncRbase | |
EL0993 | npc33 | RT-PCR | phosphate starvation | down-regulated | N/A | For the phosphate starvation assays, the up-regulation of npc43 and npc536 and the down-regulation of npc33 were confirmed (Fig. 5A). | 18997003 | PLNlncRbase | |
EL0994 | npc34 | RT-PCR | roots | up-regulated | N/A | Expression levels of npcRNAs 34 and 60 increased severalfold in phosphate-starved and in 6-benzylaminopurine (BA)-treated roots. | 16500993 | PLNlncRbase | |
EL0995 | npc351 | RT-PCR | stems | up-regulated | N/A | The majority of siRNAs deriving from this npcRNAs are 24 nt long and map to both DNA strands of the npcRNA region, suggesting that these npcRNAs correspond to 24-nt-small RNA precursors. Expression analysis in different organs revealed that npc351 is enriched in stems. Whereas the npc375 and npc523 levels appeared unchanged in the rdr2 rdr6 double mutant, the npc34 and npc351 were up-regulated in both seedlings and flowers of rdr2 rdr6 (Fig. 1, right panel), suggesting that RDR2 or RDR6 produces a dsRNA from these npcRNAs, consistent with small RNA production from both DNA strands of these loci. | 18997003 | PLNlncRbase | |
EL0996 | npc375 | RT-PCR | flowers | up-regulated | N/A | The majority of siRNAs deriving from these five npcRNAs are 24 nt long and map to both DNA strands of the npcRNA region, suggesting that these npcRNAs correspond to 24-nt-small RNA precursors. Expression analysis in different organs (Fig. 1) revealed that npc351 is enriched in stems and npc34 in aerial parts, whereas npc375 and npc523 show maximal levels in flowers. | 18997003 | PLNlncRbase | |
EL0997 | npc43 | Northern blot/RT-PCR | phosphate starvation | up-regulated | N/A | For the phosphate starvation assays, the up-regulation of npc43 and npc536 and the down-regulation of npc33 were confirmed (Fig. 5A). | 18997003 | PLNlncRbase | |
EL0998 | npc48 | qRT-PCR | leaf serration and flowering time | up-regulated | N/A | Overexpressing the npc48 showed drastic developmental anomalies, including an increase in the rosette diameter, leaf serration, and a delay in the flowering time compared with wild-type plants (Fig. 6A). Overexpression of npc48 led to leaf serration, a phenotype that has been observed in several Arabidopsis mutants such as se or ago1. Quantitative RT-PCR analysis of npc48 accumulation revealed that all transgenic lines exhibiting this phenotype overaccumulated npc48 (Supplemental Fig. 3). | 18997003 | PLNlncRbase | |
EL0999 | npc523 | RT-PCR | flowers | up-regulated | N/A | The majority of siRNAs deriving from these five npcRNAs are 24 nt long and map to both DNA strands of the npcRNA region, suggesting that these npcRNAs correspond to 24-nt-small RNA precursors. Expression analysis in different organs (Fig. 1) revealed that npc351 is enriched in stems and npc34 in aerial parts, whereas npc375 and npc523 show maximal levels in flowers. Specific oligonucleotides for real-time PCR studies could not be obtained for npc520. Whereas the npc375 and npc523 levels appeared unchanged in the rdr2 rdr6 double mutant. | 18997003 | PLNlncRbase | |
EL1000 | npc531 | qRT-PCR | dcl1-9 mutant | up-regulated | N/A | In addition to npcRNAs corresponding to conserved miRNAs, the npc531, which was not previously linked to RNA silencing mechanisms or known to encode a miRNA, also was upregulated in a dcl1-9 mutant, a difference confirmed using quantitative RT-PCR (Fig. 4A, left panel). No known miRNAs map to this gene, suggesting that, alternatively, it could be the target of a miRNA. We identified a putative miR319 target site in npc531 (Fig. 4A, right panel), but 5 RACE-PCR analyses did not reveal any specific cleavage of this transcript in this site (data not shown). | 18997003 | PLNlncRbase | |
EL1001 | npc536 | RT-PCR | phosphate starvation, salt | up-regulated | N/A | npc536 was up-regulated in phosphate starvation. overaccumulate npc536 displayed heightened root growth under salt stress conditions. Transformed plants over-expressing npc536 showed heightened root growth under salt stress conditions, with increased primary root growth and secondary root length; No phenotype could be observed in mutants that carry T-DNA insertions within npc536; In response to certain abiotic stresses such as drought or cold treatment, the root expression of these two genes (AT1G67930 and npc536) tends to be anti-correlated (Pearson correlation coefficient of -0.636 and -0.983, respectively). However, accumulation of the AT1G67930 transcript was not significantly modified in plants over-expressing npc536 or in npc536 mutants. (Ben et al., 2009) npc536 has a large dynamic variation of expression across a wide range of tissue and hormonal, biotic, or abiotic treatment. npc536 exists in the antisense strand of a Golgi-transport complex related protein. 35S::npc536 transformants displayed heigh tened root growth under salt stress conditions. (Matsui et al., 2013) | 18997003, 24252906 | PLNlncRbase | |
EL1002 | npc60 | Northern blot/RT-PCR | salt | up-regulated | N/A | Salt stress resulted in a dramatic 100-fold increase in npc60 accumulation. For npc60, npc82, and npc536, the change in expression observed after 3h of NaCl treatment was maintained after 24h (Fig. 5B), whereas for npc72 the induction was transient. Expression levels of npcRNAs 34 and 60 increased severalfold in phosphate-starved and in 6-benzylaminopurine (BA)-treated roots(Plant Physiol.2006 Apr;140(4):1192-204.). | 18997003 | PLNlncRbase | |
EL1003 | npc78 | RT-PCR | dcl1 mutant | up-regulated | N/A | The npcRNA78 gene contains the miR162 sequence in an alternative intron and corresponds to the MIR162a locus. Although DICER-LIKE 1 (DCL1) mRNA is known to be regulated by miR162-guided cleavage, its level does not change in a mir162a mutant. Alternative splicing of npcRNA78 leads to several transcript isoforms, which all accumulate in a dcl1 mutant. This suggests that npcRNA78 is a genuine substrate of DCL1 and that splicing of this microRNA primary transcript and miR162 processing are competitive nuclear events. | 16500993 | PLNlncRbase | |
EL1004 | npc82 | Northern blot/RT-PCR | NaCl treatment | up-regulated | N/A | For npc60, npc82, and npc536,the change in expression observed after 3 h of NaCl treatment was maintained after 24 h (Fig. 5B), whereas for npc72 the induction was transient (Fig. 5B). | 18997003 | PLNlncRbase | |
EL1005 | npc83 | RT-PCR | N/A | N/A | N/A | Some were already characterized small RNA precursors, such as the tasiRNA precursor TAS3 (npc41) or the MIR162A precursor (npc78) (Hirsch et al. 2006). The npc83 and npc521 corresponded to the miRNA precursors MIR869A and MIR160C, respectively. Among seven known miRNA precursors spotted on the RIBOCHIP, six (MIR160C, MIR162A, MIR164B, MIR166A, MIR166B, and MIR168A) were up-regulated in dcl1 inflorescences, consistent with DCL1-processed conserved miRNAs. In contrast, the nonconserved MIR869A precursor (npc83) did not overaccumulate in dcl1. This miRNA precursor has an unusually stable secondary structure. | 18997003 | PLNlncRbase | |
EL1009 | NR024118 | lncRNAs array, qPCR | Ang II-treated cardiac fibroblasts | down-regulated | expression | Ang II dynamically regulated the expression of lncRNA-NR024118 and Cdkn1c in cardiac fibroblasts, indicating the potential role of NR024118 in cardiac fibroblasts. | 24817929 | ||
EL1009 | NR024118 | N/A | dult rat cardiac fibroblasts | down-regulated | expression | Our current studies showed that the decrease of lncRNA-NR024118 and Cdkn1c induced by Ang II is mediated by AT1 receptor-dependent not AT2 receptor-dependent, which is helpful to understand the molecular mechanism of Ang II receptors in adult rat cardiac fibroblasts. | 25979571 | ||
EL1010 | NRAV | overexpression | human cells or transgenic mice | down-regulated | expression | A lncRNA that we call negative regulator of antiviral response (NRAV) was dramatically downregulated during infection with several viruses, we ectopically expressed NRAV in human cells or transgenic mice and found that it significantly promotes influenza A virus (IAV) replication and virulence. | 25525793 | ||
EL1015 | nta-eTMX27 | N/A | N/A | N/A | interaction | We identified a microRNA (nta-miRX27) and also a lncRNA (nta-eTMX27) as an endogenous target mimicry (eTM) in tobacco targeting the nicotine biosynthesis key gene QPT2 encoding quinolinate phosphoribosyltransferase (QPT) and thereby regulating the nicotine content. | 27172239 | ||
EL1016 | NtENOD40-1 | RT-PCR | nodule initiation | up-regulated | N/A | Whereas Rhizobial Nod-factor signaling sets the process of nodulation in action, the process is further regulated by the phytohormones ethylene, cytokinin and auxin. ENOD40-1 expression is induced by Nod-factors or cytokinin in legumes suggesting that these could be candidate interactors of ENOD40. | 1701140 | PLNlncRbase | |
EL1017 | NUTF2P3 | N/A | N/A | up-regulated | interaction | After downregulating lncRNA-NUTF2P3-001, the proliferation and invasion of pancreatic cancer cell are significantly inhibited both in vitro and vivo, accompanying with decreased KRAS expression. Data from pancreatic cancer patients show a positive correlation between lncRNA-NUTF2P3-001 and KRAS, which is associated with advanced tumor stage and worse prognosis. lncRNA-NUTF2P3-001 and miR-3923 can be applied as novel predictors and therapeutic targets for pancreatic cancer. | 26755660 | ||
EL1018 | ObENOD40 | RT-PCR | Nodule formation | up-regulated | N/A | ENOD40 has been proposed as playing a pivotal role in the organogenesis of legume root nodules. ObENOD40, in which an XbaI fragment (approximately 640 bp) contained a sequence for encoding an oligopeptide that is highly conserved in all legume ENOD40s. | 10363365 | PLNlncRbase | |
EL1020 | OIP5-AS1 | N/A | human cervical carcinoma HeLa cells | N/A | interaction | OIP5-AS1 reduces cell proliferation. OIP5-AS1 serves as a sponge or a competing endogenous (ce)RNA for HuR, restricting its availability to HuR target mRNAs and thereby repressing HuR-elicited proliferative phenotypes. | 26819413 | ||
EL1024 | OsIPS1 | qRT-PCR | roots | down-regulated | N/A | OsIPS1 is a noncoding RNA. IPS1 sequesters miR399 (microRNA 399), which negatively regulates the gene PHO2 at the post-transcriptional level. | 19566645 | PLNlncRbase | |
EL1025 | osk | N/A | Drosophila | N/A | mutation | The Drosophila oskar (osk) mRNA is unusual in having both coding and noncoding functions. The 3' UTR also mediates the noncoding function of osk, which is essential for progression through oogenesis. Mutations which most strongly disrupt the noncoding function are positioned in a short region (the C region) near the 3' end of the mRNA, in close proximity to elements required for activation of translation. | 26433064 | ||
EL1026 | OsPI1 | qRT-PCR | phosphate starvation | up-regulated | N/A | OsPI1 cloned from rice roots. The OsPI1 gene was rapidly induced by phosphate starvation in both shoots and roots. When phosphate was supplied to phosphate-deficient plants, the OsPI1 transcripts rapidly disappeared. suggested that OsPI1 acts as riboregulator, that is, it binds with other molecules under phosphate starvation and regulates their function. | 10.1046/j.1469-8137.2003.00748.x | PLNlncRbase | |
EL1046 | PANDAR | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease | |
EL1048 | Paupar | knockdown | N2A mouse neuroblastoma cells | N/A | N/A | Knockdown of Paupar disrupts the normal cell cycle profile of neuroblastoma cells and induces neural differentiation. Paupar acts in a transcript-dependent manner both locally, to regulate Pax6, as well as distally by binding and regulating genes on multiple chromosomes, in part through physical association with PAX6 protein. Paupar binding sites are enriched near promoters and can function as transcriptional regulatory elements whose activity is Modulated by Paupar transcript levels. | 24488179 | ||
EL1058 | PCGEM1 | N/A | osteoarthritic human synoviocytes | up-regulated | interaction | Exogenous overexpression of PCGEM1 inhibited apoptosis, induced autophagy, and stimulated the proliferation of human synoviocytes. The increased expression of PCGEM1 in human synoviocytes also suppressed the expression of miR-770. Transfection of the miR-770 precursor resulted in reduced proliferation, and induced apoptosis of human synoviocytes. This effect of miR-770 expression was reversed by co-introduction of PCGEM1. PCGEM1 act as sponge lncRNA for miR-770 that regulates proliferation/apoptosis and autophagy, and suggest PCGEM1 as possible target for OA therapy. | 26340084 | ||
EL1064 | pGmENOD40 | RT-PCR | root nodules | up-regulated | N/A | pGmENOD40 RNA is present at a high level in nodules and at a low level in uninoculated roots, stems and flowers. And induced in the nodule primordium and the region of the root pericycle opposite the primordium, and in mature nodules these genes are expressed in the pericycle of the vascular bundle. (Matvienko et al., 1994) In pea roots, ENOD40 is expressed in the region opposite the protoxylem poles, which is also the region where nodules form. This suggests that ethylene provides positional information for nodule primordia to form opposite protoxylem poles. (Vleghels et al., 2003) | 7948896, 14508686 | PLNlncRbase | |
EL1066 | PHO84 antisense transcripts | Western Blotting,Northern Blotting,Epistasis and chromatin immunoprecipitation | Yeast strains | N/A | interaction | knockdown of antisense production prevents PHO84 gene repression, even in the absence of Rrp6. | 18022365 | ||
EL1068 | Pinc | microarray, qRT-PCR | inguinal mammary glands | N/A | mutation | PINC may contribute to the developmentally mediated changes previously observed in the terminal ductal lobular unit-like structures of the parous gland | 16574773 | ||
EL1070 | PINK1-AS | knockdown, qT-PCR | preadipocytes and adipocytes | down-regulated | interaction | PU.1 AS lncRNA promotes adipogenesis through preventing PU.1 mRNA translation via binding to PU.1 mRNA to form mRNA/AS lncRNA duplex in preadipocytes. | 23749759 | ||
EL1072 | Platr14 | weighted gene coexpression network analysis | mouse embryonic stem cells (ESCs) and neural progenitor cells (NPCs) | down-regulated | expression | Among these, we show that acute depletion of Platr14 using antisense oligonucleotides impacts the differentiation- and development-associated gene expression program of ESCs. | 26048247 | ||
EL1075 | pncRNA-D | RNA pull down assay | N/A | N/A | interaction | N/A | 26816614 | ||
EL1080 | pouBW1 | qPCR | different tissues of Gushi chickens and Anka broilers at different development stages | N/A | mutation | A single nucleotide polymorphism (SNP) at the 5'-end of the gene was identified. The SNP was significantly (P < 0.05) associated with leg muscle weight, chest breadth, sternal length and body weight in chickens at 1 day, 4 weeks and 6 weeks of age. | 26643990 | ||
EL1084 | Prep | knockdown; overexpression | primary ovarian granulosa cell and a hepatic cell line | N/A | interaction | this lncRNA could play a role in the POP gene activation in the granulosa cell. | 24369296 | ||
EL1085 | PRINS | N/A | renal tubular cells of wild type mice | up-regulated | interaction | Among HIF-1α dependent LncRNAs, PRINS (Psoriasis susceptibility-related RNA Gene Induced by Stress) was significantly up regulated in hypoxic conditions and had specific interaction with RANTES as confirmed through reporter assay. | 26725683 | ||
EL1086 | Prion-associated RNAs | N/A | N/A | N/A | interaction | These interactions between shsrnas and hrprp suggest possible roles of rnas in the modulation of prp structure and perhaps disease development. | 12946346 | ||
EL1091 | PsiLNCRNA00268512 | N/A | perennial plants | N/A | interaction | PsiLNCRNA00268512 regulates miR396e levels by acting as a target mimic. | 26712827 | ||
EL1093 | psvA antisense RNA | excess transcription, inhibition of RNA synthesis | vegetative cells | N/A | expression | The inhibition of rna synthesis during disaggregation prevents destabilization of the mrna. | 1555240 | ||
EL1099 | Ptgs2os2 | qPCR | dendritic cells, macrophages, splenocytes from Listeria-infected mice | N/A | N/A | mediates both the activation and repression of distinct classes of immune genes.Transcriptional repression of target genes is dependent on interactions of lincRNA-Cox2 with heterogeneous nuclear ribonucleoprotein A/B and A2/B1. | 23907535 | ||
EL1099 | Ptgs2os2 | RNA-seq, qRT-PCR | innate immune cells | N/A | expression | A highly inflammatory inducible lncRNA that is responsible for activation and repression of distinct immune genes. | 26803630 | ||
EL1101 | PU.1 AS | RT-PCR, endogenous ribonuclease protection assay | porcine subcutaneous adipose, heart, liver, spleen, lympha, skeletal muscle and kidney tissues | N/A | expression | PU.1 AS lncRNA (vs. its mRNA translation) promotes adipogenesis through the formation of a sense-antisense RNA duplex with PU.1 mRNA. | 25691151 | ||
EL1109 | RBM5-AS1 | N/A | N/A | N/A | expression | We identified a 326 bp bone marrow cdna fragment (termed je2) that suppresses, upon transfection, cd95-mediated apoptosis in jurkat t cells. | 10949932 | ||
EL1109 | RBM5-AS1 | RNA-seq, qRT-PCR | three different brain regions (cortex, white matter, and cerebellum) of human postmortem tissue | N/A | N/A | Thus, these 5 lncRNAs may be applicable as references for accurate normalisation of lncRNA profiling in multiple brain regions during long PMI, enabling the generation of highly reproducible datasets in lncRNA studies of the human brain. | 25528156 | ||
EL1111 | RD29A | Northern blot/RT-PCR/Microarray | drought | up-regulated | N/A | Fig. 3A shows an fSAT of the drought-inducible gene, RD29A and the novel drought-inducible antisense TUs. The presence of novel drought-inducible TUs on the antisense strand was confirmed by real-time RT-PCR and Northern analyses using strand-specific RNA probes (Figs. 3B, 3C); The RD29A and CYP707A1 lancRNAs that were simultaneously accumulated with sense mRNAs, were accumulated by drought- and ABA treatments(Plant Cell Physiol.2008, 49, 1135–1149.). | 18625610 | PLNlncRbase | |
EL1115 | RHOXF1P1 | LncRHOXF1 knockdown using siRNAs | trophectoderm and primitive endoderm cells of human blastocyst-stage embryos | up-regulated | N/A | regulates the host response to viral infections in human placental progenitor cells | 27066803 | ||
EL1116 | Rian | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Rian was also found to interact with a number of other chromatin binding protein(s)/complexes in mouse embryonic stem cells including PRC1, JARID1B, JARID1C and CBX3, with the general pattern being interaction with repressors of gene expression. | 21874018 | ||
EL1117 | Rmrp | N/A | Rmrp gene mutation in mice | N/A | mutation | A targeted Rmrp gene mutation in mice, corresponding to a gene mutation in cartilage-hair hypoplasia patients, altered lncRNA chromatin occupancy, and reduced the DDX5-RORγt interaction and RORγt target gene transcription | 26675721 | ||
EL1119 | RMST | N/A | anterior neural tube | up-regulated | expression | Rmst expression appears to be restricted to the presumptive dopaminergic neurons of the ventral tegmental area | 20062813 | ||
EL1119 | RMST | tsRMST knockdown cells | human pluripotent stem cells | up-regulated | N/A | disruption of tsRMST expression in hESCs results in the up-regulation of WNT5A, EMT, and lineage-specific genes/markers | 27090862 | ||
EL1120 | RN7SK | Immunoprecipitation,Immunofluorescence microscopy,FISH analysis, | HeLa cell | N/A | interaction | N/A | 17381310 | ||
EL1120 | RN7SK | N/A | N/A | N/A | interaction | The 7sk/p-tefb interaction may serve as a principal control point for the induction of cellular and hiv-1 viral gene expression during stress-related responses. | 11713532 | ||
EL1120 | RN7SK | N/A | N/A | N/A | interaction | The transcription-dependent interaction of p-tefb with 7sk may therefore contribute to an important feedback loop modulating the activity of rna pol ii. | 11713533 | ||
EL1120 | RN7SK | RNA-seq, qRT-PCR | three different brain regions (cortex, white matter, and cerebellum) of human postmortem tissue | N/A | N/A | Thus, these 5 lncRNAs may be applicable as references for accurate normalisation of lncRNA profiling in multiple brain regions during long PMI, enabling the generation of highly reproducible datasets in lncRNA studies of the human brain. | 25528156 | ||
EL1121 | RN7SL1 | a solid phase radioimmune assay | N/A | N/A | expression | Cellular function of 7sl-rna is as a part of srp. | 6196367 | ||
EL1121 | RN7SL1 | N/A | N/A | N/A | expression | The rna is closely identified with the small cytoplasmic 7sl rna and is required for both structural and functional properties of signal recognition protein--which we therefore rename signal recognition particle. | 6181418 | ||
EL1129 | RNY1 | Specific degradation | late-G(1)-phase human cells | down-regulated | mutation | Specific degradation of hY RNAs leads to the inhibition of semiconservative DNA replication in late-G(1)-phase template nuclei. This inhibition is negated by resupplementation of hY RNAs. All four hY RNAs (hY1, hY3, hY4, and hY5) can functionally substitute for each other in this system. Mutagenesis of hY1 RNA showed that the binding site for Ro60 protein, which is required for Ro RNP assembly, is not essential for DNA replication. Degradation of hY1 RNA in asynchronously proliferating HeLa cells by RNA interference reduced the percentages of cells incorporating bromodeoxyuridine in vivo. | 16943439 | ||
EL1130 | roX1 | capture hybridization analysis of RNA targets (CHART) | N/A | N/A | N/A | roX2, a well-studied ncRNA involved in dosage compensation in Drosophila. | 22143764 | ||
EL1130 | roX1 | N/A | N/A | N/A | mutation | Genetic rescue by roX orthologs and engineered synthetic lncRNAs showed that altering the number of focal, repetitive RNA structures determines roX ortholog function. Genomic occupancy maps of roX RNAs in four species revealed conserved targeting of X chromosome neighborhoods but rapid turnover of individual binding sites. Many new roX-binding sites evolved from DNA encoding a pre-existing RNA splicing signal, effectively linking dosage compensation to transcribed genes. Thus, dynamic change in lncRNAs and their genomic targets underlies conserved and essential lncRNA-genome interactions. | 26773003 | ||
EL1131 | roX2 | N/A | N/A | N/A | mutation | Genetic rescue by roX orthologs and engineered synthetic lncRNAs showed that altering the number of focal, repetitive RNA structures determines roX ortholog function. Genomic occupancy maps of roX RNAs in four species revealed conserved targeting of X chromosome neighborhoods but rapid turnover of individual binding sites. Many new roX-binding sites evolved from DNA encoding a pre-existing RNA splicing signal, effectively linking dosage compensation to transcribed genes. Thus, dynamic change in lncRNAs and their genomic targets underlies conserved and essential lncRNA-genome interactions. | 26773003 | ||
EL1138 | AL353732.1 | global lncRNA expression analysis | urine of patients with acute T cell-mediated renal allograft rejection | up-regulated | expression | RP11-354P17.15-001 was associated with higher decline in glomerular filtration rate 1 year after transplantation. | 26506418 | ||
EL1141 | RP11-395P13.3-001 | global lncRNA expression analysis | urine of patients with acute T cell-mediated renal allograft rejection | up-regulated | expression | N/A | 26506418 | ||
EL1146 | RP11-457M11.2 | N/A | N/A | N/A | N/A | N/A | 26325208 | ||
EL1153 | RP11-766N7.3 | LncRNA microarray | Dermal papilla (DP) cells | up-regulated | expression | RP11-766N7.3, H19 and HOTAIR are specific lncRNAs that were aberrantly expressed in DP cells and played an important role in regulating Wnt signaling | 25285630 | ||
EL1172 | Rubie | positional cloning | wildtype SWR/J mice | N/A | N/A | Rubie is the gene mutated in Ecl mice, that it is involved in regulating inner ear expression of Bmp4, and that aberrant Bmp4 expression contributes to the Ecl phenotype. | 22253730 | ||
EL1175 | RZE1 | single molecule fluorescent in situ hybridization (smFISH) | Cryptococcus neoformans | N/A | interaction | A long non-coding RNA (lncRNA) RZE1 functions upstream of ZNF2 in regulating yeast-to-hypha transition. This lncRNA controls Cryptococcus yeast-to-hypha transition through regulating the key morphogenesis regulator Znf2. | 26588844 | ||
EL1176 | SALRNA1 | RNA-Seq, reverse transcription (RT) and real-time,quantitative (q)PCR | human diploid WI-38 fibroblasts, 'old' fibroblasts (PDL 52) | N/A | N/A | delay senescence, reducing SAL-RNA1 levels enhanced the appearance of phenotypic traits of senescence, including an enlarged morphology, positive β-galactosidase activity, and heightened p53 levels. | 23758631 | ||
EL1182 | SENCR | RNA-seq, RT-PCR and rapid amplification of cDNA, Western blotting, Loss-of-function studies | human coronary artery smooth muscle cells | N/A | N/A | SENCR is a new vascular cell-enriched, cytoplasmic lncRNA that seems to stabilize the smooth muscle cell contractile phenotype. | 24578380 | ||
EL1184 | SFTA3 | N/A | lung and foregut endoderm | N/A | interaction | LL18/NANCI acts upstream of Nkx2.1 and downstream from Wnt signaling to regulate lung endoderm gene expression. | 24939938 | ||
EL1186 | Sho | RT-PCR | roots and young leaves | up-regulated | N/A | Sho is a natural antisense transcript. Sho may function in roots and young leaves, involve the production of small RNAs. In addition to cytokinin transport and inactivation, antisense transcription can be activated in a tissue-specific manner to adjust local cytokinin synthesis via degradation of Sho dsRNA. We therefore propose that, in addition to cytokinin transport and inactivation, regulation of local cytokinin synthesis via antisense transcription represents yet another device for the complex control of local cytokinin levels in plants. | 17944812 | PLNlncRbase | |
EL1187 | Si lincRNA113 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1188 | Si lincRNA121 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1189 | Si lincRNA150 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1190 | Si lincRNA18 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1191 | Si lincRNA180 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1192 | Si lincRNA212 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1193 | Si lincRNA248 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1194 | Si lincRNA288 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1195 | Si lincRNA32 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1196 | Si lincRNA373 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1197 | Si lincRNA396 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1198 | Si lincRNA403 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1199 | Si lincRNA416 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1200 | Si lincRNA438 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1201 | Si lincRNA446 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1202 | Si lincRNA489 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1203 | Si lincRNA69 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1204 | Si NAT52 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1205 | Si NAT80 | qRT-PCR | drought | N/A | N/A | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress (Table S12) | 23860794 | PLNlncRbase | |
EL1206 | SIRT1-AS | sequencing and bioinformatic analysis | C2C12 cells | up-regulated | N/A | The expression of both Sirt1 mRNA and Sirt1 AS lncRNA decreased during C2C12 myogenic differentiation, whereas the levels of miR-34a, which targets Sirt1, increased gradually. overexpression of Sirt1 AS lncRNA mutant did not affect the level of Sirt1 protein in C2C12 cells. Moreover, downregulation of Sirt1 mRNA caused by miR-34a was counteracted by Sirt1 AS lncRNA in C2C12 cells. | 24480449 | ||
EL1208 | Six3os1 | RNA-seq, RNA CaptureSeq, and ChIP-seq | adult mouse subventricular zone neural stem cell lineage | N/A | expression | shRNA-mediated knockdown of two such lncRNAs, Six3os and Dlx1as, indicate roles for lncRNAs in the glial-neuronal lineage specification of multipotent adult stem cells. | 23583100 | ||
EL1208 | Six3os1 | SAGE, in situ hybridization | developing retina | N/A | expression | Multiple transcripts that were evolutionarily conserved that did not appear to encode open reading frames of more than 100 amino acids in length ("noncoding rnas") were found to be dynamically and specifically expressed in developing and mature retinal cell types. | 15226823 | ||
EL1217 | sme2 | N/A | N/A | N/A | interaction | Meirna targets mei2 to the nucleus, where it can promote the first meiotic division. | 10021358 | ||
EL1217 | sme2 | N/A | N/A | N/A | interaction | This rna is likely to facilitate the assembly of mei2p into a dot structure and trap the protein as such in the nucleus. | 11423126 | ||
EL1217 | sme2 | N/A | N/A | N/A | interaction | Mei2p dot is a specialized structure, either to foster the assembly of mei2p and meirna or to perform some unidentified function indispensable for meiosis i. | 12808043 | ||
EL1217 | sme2 | N/A | N/A | N/A | expression | Cells without meirna perform premeiotic dna synthesis but cannot undergo meiosis i. | 7520368 | ||
EL1217 | sme2 | N/A | Fission yeast | N/A | interaction | Meirna contributes to the promotion of meiosis i exclusively as a cofactor that assists nuclear transport of mei2p. | 9778252 | ||
EL1221 | SNHG1 | N/A | N/A | N/A | expression | The spliced uhg rna, although it is associated with polysomes, has little potential for protein coding, is short-lived, and is poorly conserved between human and mouse. | 8559254 | ||
EL1221 | SNHG1 | N/A | HeLa cells | N/A | expression | Comparison of the human and mouse u17hg genes has revealed that snorna-encoding intron sequences but not exon sequences are conserved between the two species and that neither human nor mouse spliced u17hg poly(a)+ rnas have the potential to code for proteins. | 9671460 | ||
EL1229 | Snhg3 | knockdown, Screening for pluripotency affects, Lineage expression affects, TF binding and regulation, Chromatin binding and overlap in expression | mouse embryonic stem (ES) cells | N/A | interaction | Involved in maintaining pluripotency in ESCs. | 21874018 | ||
EL1232 | SNHG6 | N/A | N/A | N/A | expression | U87hg rna shows a relatively high degree of conservation suggesting a selective pressure and a possible functional activity of u87hg apart from producing u87 snorna. | 16226852 | ||
EL1236 | SOX2-OT | real-time polymerase chain reaction (RT-PCR) | NT-2 pluripotent cell line | down-regulated | N/A | the down-regulation of SOX2OT and SOX2 genes by an miRNA | 26862518 | ||
EL1236 | SOX2-OT | real-time RT-PCR | five human cancer cell lines | N/A | mutation | SOX2OT-7 is almost the most abundant form of SOX2OT transcript variants in the examined cancer cell lines particularly in NT2 teratocarcinoma cell line where its expression falls upon neuronal-like differentiation similar to SOX2 and OCT4A. | 26703382 | ||
EL1236 | SOX2-OT | real-time RT-PCR | five human cancer cell lines | N/A | mutation | N/A | 26703382 | ||
EL1236 | SOX2-OT | TaqMan gene expression assays, QPCR | human TK6 (p53 positive) and WTK1 (p53 negative) cells | up-regulated | expression | The lncRNA MALAT1 and SOX2OT were induced in both TK6 and WTK1 cells | 23698766 | ||
EL1240 | SPRY4-IT1 | N/A | N/A | down-regulated | interaction | The lncRNA SPRY4-IT1 regulates the intestinal epithelial barrier function by altering expression of tight junction (TJ) proteins. SPRY4-IT1 silencing led to dysfunction of the epithelial barrier in cultured cells by decreasing the stability of mRNAs encoding TJ proteins claudin-1, claudin-3, occludin, and JAM-1 and repressing their translation. In contrast, increasing the levels of SPRY4-IT1 in the intestinal mucosa protected the gut barrier in mice exposed to septic stress by increasing the abundance of TJ proteins. | 26678886 | ||
EL1241 | SRA1 | N/A | N/A | N/A | interaction | SRA is important for maintaining the stem cell state and for reprogramming of human fibroblasts to achieve the pluripotent state. | 26496121 | ||
EL1241 | SRA1 | N/A | N/A | N/A | epigenetics | Mpus1p-dependent pseudouridylation of sra represents an additional type of posttranscriptional modification of a nr-coactivator complex that is important for nr signaling. | 15327771 | ||
EL1241 | SRA1 | overexpression | a transgenic-mouse model, transgenic mammary glands | N/A | expression | Although coactivation of steroid-dependent transcription by sra is accompanied by a proliferative response, overexpression is not in itself sufficient to induce turmorigenesis. | 14517287 | ||
EL1241 | SRA1 | TaqMan gene expression assays, QPCR | human TK6 (p53 positive) and WTK1 (p53 negative) cells | up-regulated | expression | SRA1 was induced in TK6 cells only. | 23698766 | ||
EL1241 | SRA1 | transfected SRA, Biochemical fractionation | N/A | N/A | expression | Sra may act to confer functional specificity upon multiprotein complexes recruited by liganded receptors during transcriptional activation. | 10199399 | ||
EL1242 | SrENOD40-1 | RT-PCR | Nodule formation | down-regulated | N/A | By reverse transcriptase PCR, enhanced SrENOD40-1 expression was observed in the adventitious root primordia between 4 and 8 h after inoculation with Azorhizobium caulinodans. SrENOD40-1 expression with highest levels in middle and inner cortical cells. SrENOD40-1 was expressed in these primordia and in parenchymatous cells surrounding the developing connecting vascular bundles. SrENOD40-1 transcripts were still most prominent around the nodule vascular bundles. In the root, expression was detected around the vascular bundle of lateral root primordia and of the younger parts of the main root. SrENOD40-1 expression was seen, both in longitudinal and in transverse sections. | 9620265 | PLNlncRbase | |
EL1243 | SRG1 | N/A | N/A | N/A | interaction | Expression of the srg1 rna is required for repression of ser3. | 15175754 | ||
EL1243 | SRG1 | N/A | N/A | N/A | interaction | Intergenic transcription allows activators to act indirectly as repressors. | 16291644 | ||
EL1244 | SRP RNA | N/A | N/A | N/A | interaction | Reconstitutions with heterologous components revealed a significant potential of human srp proteins to bind to archaeal srp rnas. m.jannaschii srp rna bound to human srp54m quantitatively in the absence of srp19. | 10684931 | ||
EL1251 | TalIPS1 | qRT–PCR | phosphate balance | up-regulated | N/A | The expression patterns of other members of the TPSI1/Mt4 family in monocots were also investigated. The induced expressions of OsIPS1, HvIPS1, ZmIPS2 and TalIPS2 were stronger than those of OsIPS2, HvIPS2 ZmIPS1 and TalIPS1 in roots after 4 or 10 d of Pi starvation, whereas higher induced expressions of OsIPS2, HvIPS1, ZmIPS1 and TalIPS1 were detected in shoots. | 10.1111/j.1365-3040.2005.01272.x | PLNlncRbase | |
EL1252 | TalncRNA106 | RT-PCR | stripe rust pathogen | up-regulated | N/A | TalncRNA106 were located to wheat chromosome 5B. appeared higher level of expression in resistance genotypes. lncRNA106 could be detected in single-resistance genotype. For TalncRNA18 and TalncRNA106, there appeared higher level of expression in resistance genotypes than that in susceptible genotype at all time points, especially at 2 and 7 days post-infection,That suggests that the fluctuation maybe one primary characterization of long non-protein-coding RNA other than the induction expression. May play a crucial role in assisting the plant defence against pathogen attack in wheat. | 24065539 | PLNlncRbase | |
EL1253 | TalncRNA108 | RT-PCR | stripe rust pathogen | down-regulated | N/A | TalncRNA108 is a homolog to RRNA intron-encoded homing endonuclease(XP003614385.1) and an uncharacterized protein (XP003541241.1) from Medicago truncatula and Glycine max,respectively,the TalncRNA18 consists of 1,393 nt,was located to wheat chromosome 7A and the short arm of chromosome 4B. And played some roles in the proceeding of defense on stripe rust(caused by Puccinia striiformis f.sp.tritici (Pst)) in wheat though RNAi. | 24065539 | PLNlncRbase | |
EL1254 | TalncRNA18 | RT-PCR | stripe rust pathogen | up-regulated | N/A | TalncRNA18 is a partial cDNA of E3 ubiquitin-protein ligase UPL1-like gene. TalncRNA18 contains of six snRNP motifs at the position of 125, 361, 498, 920, 1,107 and 1,331 nt,was located to chromosome 5B. Following inoculation with Pst CYR 32, lncRNA18 transcripts were up-regulated rapidly at 1 dpi in the double-resistance genotype (YrSM139-1B+YrSM139-2D) plant-pathogen incompatible interaction and followed by a stable expression level. Based on statistical analyses, TalncRNA18 expression is significantly higher than that in susceptible line at 0 dpi. Although the expression decreased after 2 dpi, the accumulations of TalncRNA18 are higher than that in single-resistance genotype plant-pathogen incompatible interactions and compatible interactions except 7dpi. And played some roles in the proceeding of defense on stripe rust(caused by Puccinia striiformis f.sp.tritici (Pst)) in wheat though RNAi. | 24065539 | PLNlncRbase | |
EL1255 | TalncRNA73 | RT-PCR | stripe rust pathogen | up-regulated | N/A | TalncRNA73 is an antisense transcript of hypothetical protein,were located to wheat chromosome 7A and the short arm of chromosome 4B. TalncRNA73, a non-proteincoding gene is a natural antisense transcript from a hypothetical protein of S.bicolorand induced by inoculation with stripe rust (caused by Puccinia striiformis f.sp.tritici (Pst)) in wheat. The expression level of TalncRNA73 in double resistance genotype increased rapidly at 1 dpi and reached a peak at 3 dpi, and then decreased to the bottom at 4 dpi, followed by a steeply rise to another peak at 7 dpi and decline again at 10 dpi. The current work suggested that a possible role for TalncRNA73 is to modulate protein-coding gene that trigger a defense response in resistant plants. | 24065539 | PLNlncRbase | |
EL1256 | TapmlnRNA19 | Microarray/qRT-PCR | powdery mildew infection | up-regulated | N/A | TapmlnRNA19 was up-regulated after powdery mildew inoculation, and responsive to powdery mildew infection. TapmlnRNA19 was the precursors of miR2004. TapmlnRNA19 accumulated preferentially in young spike. | 21473757 | PLNlncRbase | |
EL1257 | TapmlnRNA27 | Microarray/qRT-PCR | seeds | N/A | N/A | A total of 48 putative long npcRNAs were only responsive to powdery mildew infection (designated TapmlnRNA), see details in additional file 1. | 21473757 | PLNlncRbase | |
EL1258 | TapmlnRNA30 | Microarray/qRT-PCR | seeds | up-regulated | N/A | TapmlnRNA30 was up-regulated after powdery mildew inoculation. TapmlnRNA30 was only detected in seed. | 21473757 | PLNlncRbase | |
EL1259 | TapmlnRNA5 | Microarray/qRT-PCR | seeds | N/A | N/A | A total of 48 putative long npcRNAs were only responsive to powdery mildew infection (designated TapmlnRNA), see details in additional file 1. | 21473757 | PLNlncRbase | |
EL1260 | TapmlnRNA9 | Microarray/qRT-PCR | young spikes | N/A | N/A | A total of 48 putative long npcRNAs were only responsive to powdery mildew infection (designated TapmlnRNA), see details in additional file 1. | 21473757 | PLNlncRbase | |
EL1261 | TAR-191 | RNA-seq/qRT-PCR | disease development | up-regulated | N/A | TAR-191, a spliced lincRNA located in the intergenic region (c.1.3kb) between At2g25295 and At2g25300, was confirmed by qRT-PCR to be highly induced by Fusarium oxysporum infection. | 24117540 | PLNlncRbase | |
EL1262 | TAR-224 | RNA-seq/qRT-PCR | disease development | down-regulated | N/A | TAR-224 was found c.550-bp downstream of At2g44745. Both TAR-224 and At2g44745 were induced upon Fusarium oxysporum infection but a much higher induction was observed for TAR-224. The expression level of TAR-224 was significantly knocked down in its RNAi plants.but an induction of TAR-224 was not abolished in F6DPI even though the level of induction was c.10-fold lower than that observed in Col-0 Nevertheless, the reduction was enough to enhance disease development. | 24117540 | PLNlncRbase | |
EL1264 | TaS1 | RT-PCR | leaves | up-regulated | N/A | TaS1 was specifically expressed in leaves and hardly detectable in roots. TaS1 could promote host susceptibility which contributed to the pathogen infection. TaS1 were expressed only in susceptible hosts and up-regulated during the phase of the primary fungus infection and haustorial development.the suppression of TaS1 and enhanced wheat resistance susceptibility to powdery mildew. | 10.1007/s10535-014-0404-y | PLNlncRbase | |
EL1265 | TaS2 | RT-PCR | roots | up-regulated | N/A | TaS2 was detected in almost all of the three organs, but preferentially expressed in roots. TaS2 could promote host susceptibility which contributed to the pathogen infection. TaS2 were expressed only in susceptible hosts and up-regulated during the phase of the primary fungus infection and haustorial development.the suppression of TaS2 enhanced wheat resistance susceptibility to powdery mildew. | 10.1007/s10535-014-0404-y | PLNlncRbase | |
EL1272 | TCONS_00000649 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00000649 was obviously up-regulated in stressed leaves, exhibited leaf-specific expression as determined by qRT-PCR. | 24892290 | PLNlncRbase | |
EL1274 | TCONS_00007700 | qRT-PCR/RNA-seq | drought | down-regulated/up-regulated | N/A | TCONS_00007700 was obviously up-regulated in stressed leaves. TCONS_00007700, which was up-regulated in stressed leaves, was down-regulated in stressed roots as determined by qRT-PCR. | 24892290 | PLNlncRbase | |
EL1275 | TCONS_00010027 | RT-PCR/RNA-seq | roots | N/A | N/A | TCONS_00010027 is identified a pre-lncRNA,This pre-lncRNA (TCONS_00010027 ) has se-quence similarity with small RNAs and thus may be chopped into pieces and function as a small RNA. | 24576388 | PLNlncRbase | |
EL1277 | TCONS_00012662 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00012662 is precursor sequences of MIR167j, TCONS_00012662 was intergenic lncRNAs, showed up-regulation in drought-stress leaves in comparison with RNA-seq. | 24892290 | PLNlncRbase | |
EL1278 | TCONS_00012690 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00012690 was obviously up-regulated in stressed leaves as determined by qRT-PCR. | 24892290 | PLNlncRbase | |
EL1279 | TCONS_00012703 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00012703 is homologous to multiple siRNA reads. In addition, the RT-qPCR result of TCONS_00012703 RNA demonstrates that the expression level of the lncRNAs is relatively low in both non-stressed leaves and roots but accumulates to high levels after drought stress in both plant tissues. | 24892290 | PLNlncRbase | |
EL1280 | TCONS_00012768 | qRT-PCR/RNA-seq | drought | down-regulated | N/A | TCONS_00012768 was down-regulated in drought-stressed roots as determined by qRT-PCR. | 24892290 | PLNlncRbase | |
EL1284 | TCONS_00022311 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | In our study, TCONS_00022311 was predicted to target a GA2ox, suggesting that lncRNAs may take part in regulating wood for mation through gibberellin biosynthesis. | 25230698 | PLNlncRbase | |
EL1285 | TCONS_00023843 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | We also checked the sequences for lncRNAs that correspond to miRNA precursors, and found that only three of the 1377 lncRNAs (0.2 %), i.e., TCONS_00061773,TCONS_00023843 and TCONS_00048079, harbor complete precursors, for four miRNAs (Ptc-miR1448, Ptc-miR482a.2, Ptu-172 and Ptu-37) (Table 4; Fig. 7). | 25230698 | PLNlncRbase | |
EL1286 | TCONS_00024309 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00024309 is precursor sequences of MIR399e, TCONS_00024309 was intergenic lncRNAs, exhibited up-regulation in drought-stressed leaves as determined by qRT-PCR but showed down-regulation in comparison with RNA-seq. | 24892290 | PLNlncRbase | |
EL1287 | TCONS_00024310 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00024310 is precursor sequences of MIR399e, TCONS_00024310 was intergenic lncRNAs, exhibited up-regulation in drought-stressed leaves as determined by qRT-PCR but showed down-regulation in comparison with RNA-seq. | 24892290 | PLNlncRbase | |
EL1290 | TCONS_00026694 | RNA-seq/qRT-PCR | wood formation | down-regulated | N/A | The expression of type A and B lncRNAs such as TCONS_00026694 and TCONS_00028236 was NW>TW>OW and NW>OW>TW, and these lncRNAs were similarly suppressed by tension and compression stresses (Supplementary material S6). | 25230698 | PLNlncRbase | |
EL1291 | TCONS_00028236 | RNA-seq/qRT-PCR | wood formation | down-regulated | N/A | The expression of type A and B lncRNAs such as TCONS_00026694 and TCONS_00028236 was NW>TW>OW and NW>OW>TW, and these lncRNAs were similarly suppressed by tension and compression stresses (Supplementary material S6). | 25230698 | PLNlncRbase | |
EL1292 | TCONS_00032782 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | In our study, TCONS_00032782, which was predicted to target Pt-CSLD4, revealed that lncRNA might function in wood formation through regulation of CSLD in Populus. | 25230698 | PLNlncRbase | |
EL1293 | TCONS_00037470 | qRT-PCR/RNA-seq | drought | down-regulated/up-regulated | N/A | TCONS_00037470 was down-regulated in drought-stressed roots as determined by qRT-PCR. And this lncRNA was upregulated in drought-stress leaves(see Table S2 for details). | 24892290 | PLNlncRbase | |
EL1295 | TCONS_00042984 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00042984 is precursor sequences of MIR169h, TCONS_00042984 was intergenic lncRNAs, showed up-regulation in drought-stress leaves in comparison with RNA-seq. | 24892290 | PLNlncRbase | |
EL1296 | TCONS_00044116 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00044116 is precursor sequences of MIR399b, TCONS_00044116 was intergenic lncRNAs, exhibited up-regulation in drought-stressed leaves as determined by qRT-PCR but showed down-regulation in comparison with RNA-seq. | 24892290 | PLNlncRbase | |
EL1297 | TCONS_00044376 | RNA-seq/qRT-PCR | wood formation | down-regulated | N/A | The lncRNAs showing lowest expression in NW belonged to type C (TW>OW>NW) and D (OW>TW>NW), and included TCONS_00044376 and TCONS_00055243 (Supplementary material S6). | 25230698 | PLNlncRbase | |
EL1298 | TCONS_00048079 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | We also checked the sequences for lncRNAs that correspond to miRNA precursors, and found that only three of the 1377 lncRNAs (0.2 %), i.e., TCONS_00061773,TCONS_00023843 and TCONS_00048079, harbor complete precursors, for four miRNAs (Ptc-miR1448, Ptc-miR482a.2, Ptu-172 and Ptu-37) (Table 4; Fig. 7). | 25230698 | PLNlncRbase | |
EL1300 | TCONS_00053930 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | Another target gene( POPTR_0001s07400.1), predicted to be targeted by TCONS_00053930, encodes a protein similar to 4CL, the central enzyme of the plant-specific phenylpropanoid pathway, which has an important role in lignin biosynthesis (Table 3). | 25230698 | PLNlncRbase | |
EL1301 | TCONS_00054544 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00054544 is precursor sequences of MIR827, TCONS_00054544 was an overlapping lncRNAs, exhibited up-regulation in drought-stressed leaves as determined by qRT-PCR but showed down-regulation in comparison with RNA-seq. | 24892290 | PLNlncRbase | |
EL1302 | TCONS_00055243 | RNA-seq/qRT-PCR | wood formation | down-regulated | N/A | The lncRNAs showing lowest expression in NW belonged to type C (TW>OW>NW) and D (OW>TW>NW), and included TCONS_00044376 and TCONS_00055243 (Supplementary material S6). | 25230698 | PLNlncRbase | |
EL1303 | TCONS_00056386 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | Genes encoding glucosyltransferases were predicted as targets of TCONS_00056386 (Table 3; Fig. 3b). Besides the genes related to cellulose, lignin and glucosyltransferase, POPTR_0010s15950.1 (Pt-GA2.3) encodes GA2ox and was predicted as a target of TCONS_00022311 (Fig. 3c). TCONS_00056386) was detected as having its highest expression in OW, then TW and lowest in NW (Supplementary material S5) by RNA-seq and a similar expression pattern was also detected by qRT-PCR. | 25230698 | PLNlncRbase | |
EL1304 | TCONS_00056395 | qRT-PCR/RNA-seq | drought | down-regulated | N/A | A root-specific lncRNA of TCONS_00056395, down regulation in stressed leaves and exhibit maximum expression in leaves stressed for 5h as determined by qRT-PCR. | 24892290 | PLNlncRbase | |
EL1305 | TCONS_00060049 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | Although CCOMTs play important roles in lignin content, little is known about the regulators of CCOMT. TCONS_00060049 was predicted to target CCOMT, suggesting that it may have a potential role in lignin formation by regulation of CCOMT (Table 3). | 25230698 | PLNlncRbase | |
EL1306 | TCONS_00061773 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | TCONS_00061773 harbors precursors for two known miRNAs, Ptc-miR1448 and Ptc-miR482a.2 (Fig. 7). Previous studies supported the idea that Ptc-miR1448 may be involved in the resistance of plants to biotic and abiotic stresses (Lu et al. 2008) and Ptc-miR482a.2 has been reported as a tree-specific miRNA in tension wood (Lu et al. 2005, 2008). The expression measured by qRT-PCR revealed that Ptc-miR1448 is much more abundant than Ptc-miR482a.2, although both miRNAs occur in one cluster in the genome (Lu et al. 2005, 2008). These findings supported the idea that TCONS_00061773 may be associated with abiotic stress tolerance in Populus. | 25230698 | PLNlncRbase | |
EL1307 | TCONS_00082174 | qRT-PCR/RNA-seq | drought | up-regulated | N/A | TCONS_00082174, which was only expressed in leaves, was not detected in roots, which suggests leaf-specific expression as determined by qRT-PCR. | 24892290 | PLNlncRbase | |
EL1308 | TCONS_00089485 | RT-PCR/RNA-seq | embryo sac and ovule tissues | N/A | N/A | TCONS_00089485 is expressed from the Vgt1 regulatory region. This lncRNA is detected in embryo sac and ovule tissues where ZmRap2 is not detected. while ZmRap2 is expressed in other tissues where this HC-lncRNA is not detected, Suggesting the potential for antagonistic expression of this HC-lncRNA and the nearby coding sequence. | 24576388 | PLNlncRbase | |
EL1322 | TER | N/A | Arabidopsis thaliana | N/A | interaction | TER works in concert with the telomerase reverse transcriptase (TERT) to maintain telomeres. | 26442096 | ||
EL1323 | TER1 | RT-PCR | DNA damage | down-regulated | N/A | As the essential RNA subunit of telomerase, TER1 is required for telomere maintenance, while TER2 is assembled in distinct RNP complex (es)to modulate telomerase activity in response to DNA damage. (Wang et al., 2014) TER1 and TER2 copurify with telomerase activity and serve as templates for telomerase in vitro, depletion of TER1, but not TER2, leads to decreased telomerase activity and progressive telomere shortening in vivo. Moreover, mutation of the templating domain in TER1 results in the incorporation of mutant telomere repeats on chromosome ends. Thus, TER1 provides the major template for telomerase in vivo. Both TER1 and TER2 function as templates for TERT in vitro, but only TER1 plays a significant role in telomere maintenance in vivo. Moreover, we show that TER1, but not TER2, specifically binds POT1a in vitro and the two components assemble into an enzymatically active RNP in vivo. These findings underscore the evolution of telomerase and telomere proteins in Arabidopsis and argue that the process is driven by gene duplication. (Cifuentes-Rojas et al., 2011) | 24398630, 21164032 | PLNlncRbase | |
EL1324 | TER2 | RT-PCR | telomere shortening | down-regulated | N/A | We show that TER2 is spliced and its 3' end is truncated in vivo to generate a third TER isoform, TER2S. Plants null for TER2 display increased telomerase enzyme activity, while TER2 overexpression inhibits telomere synthesis from TER1 and leads to telomere shortening. These findings argue that TER2 negatively regulates telomerase by sequestering TERT in a nonproductive RNP complex. Introduction of DNA double-strand breaks by zeocin leads to an immediate and specific spike in TER2 and a concomitant decrease in telomerase enzyme activity. This response is not triggered by replication stress or telomere dysfunction and is abrogated in ter2 mutants. We conclude that Arabidopsis telomerase is modulated by TER2, a novel DNA damage induced noncoding RNA that works in concert with the canonical TER to promote genome integrity. (Cifuentes-Rojas et al., 2012) TER2 (GenBank accession no. HQ401285), was also uncovered. TER2 maps to chromosome 5, in the opposite direction and partially overlapping with the 5′ UTR of another unknown protein coding gene, AT5G24670. TER2 also contains 1.5 copies of the Arabidopsis telomere repeat. RT-PCR confirmed that both TER1 and TER2 RNAs were enriched in purified telomerase fractions, in contrast to a U6 snRNA control. (Cifuentes-Rojas et al., 2011) As the essential RNA subunit of telomerase, TER1 is required for telomere maintenance, while TER2 is assembled in distinct RNP complex (es)to modulate telomerase activity in response to DNA damage. (Wang et al., 2014) | 23109676, 21164032, 24398630 | PLNlncRbase | |
EL1326 | TGFB2-OT1 | microarray, RNA interference, RNA-chiP assay, bioinformatics, luciferase reporter assay | N/A | N/A | interaction | The protein level of MAP1LC3B-II was greatly increased in HUVECs with FLJ11812 overexpression.FLJ11812 could bind with MIR4459 targeting ATG13 (autophagy-related 13), and ATG13 protein level was decreased along with 3BDO-decreased FLJ11812 level. | 25437332 | ||
EL1326 | TGFB2-OT1 | miRNA chip assay, overexpression, 3BDO | vascular endothelial cells (VECs) | N/A | interaction | TGFB2-OT1 regulated the levels of 3 microRNAs, MIR3960, MIR4488 and MIR4459. TGFB2-OT1 acted as a competing endogenous RNA, bound to MIR3960, MIR4488 and MIR4459, then regulated the expression of the miRNA targets CERS1 (ceramide synthase 1), NAT8L (N-acetyltransferase 8-like [GCN5-related, putative]), and LARP1 (La ribonucleoprotein domain family, member 1). TGFB2-OT1 increased the LARP1 level, which promoted SQSTM1 (sequestosome 1) expression, NFKB RELA and CASP1 activation, and then production of IL6, IL8 and IL1B in VECs. | 26565952 | ||
EL1327 | TH2LCRR | N/A | human T-cell cultures | N/A | expression | One lncRNA cluster selectively expressed by the effector TH2 lineage consists of four alternatively spliced transcripts that regulate the expression of TH2 cytokines, IL-4, IL-5 and IL-13.Genes encoding this lncRNA cluster in humans overlap the RAD50 gene and thus are contiguous with the previously described TH2 locus control region (LCR) in the mouse. Given its genomic synteny with the TH2-LCR, we refer to this lncRNA cluster as TH2-LCR lncRNA. | 25903499 | ||
EL1337 | TIP ncRNA | Profiling | murine in vitro neural differentiation system | N/A | N/A | TIP transcription may ensure coordinated regulation of gene networks via dynamic switching and recruitment of PcG proteins both in cis and in trans during lineage commitment. | 22336714 | ||
EL1344 | Tmevp3 | Quantitative RT-PCR, chromatin immunoprecipitation | N/A | up-regulated | interaction | This lncRNA regulates epigenetic marking of IFN-γ-encoding chromatin, expression of IFN-γ, and susceptibility to a viral and a bacterial pathogen. | 23415224 | ||
EL1345 | Tmevpg1 | N/A | N/A | N/A | N/A | The mouse gene and its human orthologue, which are expressed in the immune system at a low level, produce a noncoding mrna. | 11735227 | ||
EL1348 | Tog | qRT-PCR, ChIP on chip | cecal buds | N/A | interaction | N/A | 24075990 | ||
EL1352 | TPS1 | Northern blot/qRT-PCR | roots | up-regulated | N/A | INDUCED BY PHOSPHATE STARVATION1 is a member of the TPS1/Mt4 gene family that acts as a miR399 target mimic in fine tuning of PHO2 (encoding an E2 ubiquintin conjugase-related enzyme)expression and phosphate uptake in Arabidopsis, tomato and Medicago truncatula but does not encode a protein. | 24576388 | PLNlncRbase | |
EL1353 | TPS11 | Northern blot/Southern blot | roots | up-regulated | N/A | This lncRNAs work as a decoy of miRNAs,and exert their functions by binding miRNAs in a target mimicry mechanism to sequestrate the miRNAs’ regulation roles on their target genes, such as lncRNAs IPS1 and at4. | 23726911 | PLNlncRbase | |
EL1354 | TPSI1 | Northern blot/Southern blot | roots | up-regulated | N/A | The TPSI1 transcripts are rapidly induced in roots and leaves during Pi starvation. Induction of the TPSI1 gene appears to be a response specific to Pi starvation since it is not affected by starvation of other nutrients (nitrogen, potassium and iron). The amount of TPSI1 transcript decreased rapidly when Pi-starved tomato plants were resupplied with Pi. These results suggest that TPSI1 gene expression may be a part of the early Pi starvation response mechanism in plants. | 9106510 | PLNlncRbase | |
EL1359 | Trenod40 | Northern blot/Southern blot | nodule development | up-regulated | N/A | Enod40 is one of the genes associated with legume nodule development and has a putative role in general plant organogenesis. In situ hybridization studies revealed that Trenod40 genes were highly expressed in non-symbiotic tissues, particularly in stolon nodes during nodal root and lateral shoot development. High levels of Trenod40 transcripts were also present in the vascular bundles of mature plant organs, mainly at sites of intensive lateral transport, suggesting a role in vascular tissue function. The expression pattern of Trenod40 genes was analyzed further using Trenod40 promoter-gus fusions in transgenic white clover and tobacco (Nicotiana tabacum), indicating that white clover and tobacco share the regulatory mechanisms for Trenod40-1/2 promoters and some aspects of Trenod40-3 regulation. Trenod40 expression occurs in the xylem parenchyma of vascular bundles in white clover nodes that conjoin both young and fully developed leaves provide support for a role in vascular tissue function. | 12114565 | PLNlncRbase | |
EL1360 | Trenod40-1 | Northern blot/Southern blot | nodule development | up-regulated | N/A | Enod40 is one of the genes associated with legume nodule development and has a putative role in general plant organogenesis. We have isolated a small enod40 gene family from white clover (Trifolium repens), with three genes designated Trenod40-1, Trenod40-2, and Trenod40-3, all containing the conserved enod40 regions I and II. Trenod40-1 and Trenod40-2 share over 90% homology in the transcribed regions and high levels of similarity in their upstream regulatory sequences. Trenod40-1 and Trenod40-2 are similar to the enod40 genes of legumes forming indeterminate nodules (group II) and are predominantly expressed in nodules. | 12114565 | PLNlncRbase | |
EL1361 | Trenod40-2 | Northern blot/Southern blot | nodule development | up-regulated | N/A | Enod40 is one of the genes associated with legume nodule development and has a putative role in general plant organogenesis. We have isolated a small enod40 gene family from white clover (Trifolium repens), with three genes designated Trenod40-1, Trenod40-2, and Trenod40-3, all containing the conserved enod40 regions I and II. Trenod40-1 and Trenod40-2 share over 90% homology in the transcribed regions and high levels of similarity in their upstream regulatory sequences. Trenod40-1 and Trenod40-2 are similar to the enod40 genes of legumes forming indeterminate nodules (group II) and are predominantly expressed in nodules. | 12114565 | PLNlncRbase | |
EL1362 | Trenod40-3 | Northern blot/Southern blot | nodule development | up-regulated | N/A | The developing lateral shoot of node N7 also has up-regulation of Trenod40-1/2 expression, which is confined to the vascular tissue at the base of the lateral shoot (Fig. 5E). Trenod40-3 was also expressed in developing lateral shoots, with high levels of expression localized mainly in the vascular tissue but also in other tissues of both the axillary bud of node N6 (Fig. 5F) and more mature lateral shoot of node N8 (Fig. 5G). Trenod40-3 transcript is only present at relatively low levels in nodules, but is abundant in some non-symbiotic tissues. Expression of Trenod40-3 being more prominent and induced both at early and later stages of lateral shoot development. | 12114565 | PLNlncRbase | |
EL1365 | Trp53cor1 | N/A | N/A | N/A | expression | Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms | 23791884 | LncRNADisease | |
EL1369 | Tsix | N/A | mouse embryonic epiblasts, epiblast stem cells, and embryonic stem cells | N/A | mutation | Tsix RNA is believed to orchestrate the initiation of X-inactivation, influencing the choice of which X remains active by preventing expression of the antisense Xist RNA, which is required to silence the inactive-X. | 25981039 | ||
EL1372 | Ttc39aos1 | Inhibition, ectopic expression | mouse erythroid cells | down-regulated | N/A | Long noncoding RNA-mediated anti-apoptotic activity in murine erythroid terminal differentiation . anti-apoptosis and promote erythoid differentiation | 22155924 | ||
EL1373 | tts-1 | N/A | normal strains of Caenorhabditis elegans and those carrying the life-extending daf-2 mutation | N/A | expression | The expression of tts-1 functions in different longevity pathways to reduce ribosome levels in a way that promotes life extension | 25600869 | ||
EL1374 | TU1273 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. | 24932683 | PLNlncRbase | |
EL1375 | TU1378 | RNA-seq, qRT-PCR | mycelia stage | up-regulated | N/A | The expression profiles of 5 lincRNAs were negatively correlated with those of their apcGenes (Figure 5B,r<-0.8). The apcGenes of TU718, TU1378, TU3327, and TU5007 are a putative hydrolase (GL15069), a Barwin-related endoglucanase (GL18494), a putative hydrolase (GL27846), and an alphaamylase (GL24914), respectively, which all belong to CAZy family. | 24932683 | PLNlncRbase | |
EL1376 | TU1403 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. | 24932683 | PLNlncRbase | |
EL1377 | TU1555 | RNA-seq, qRT-PCR | mycelia stage | up-regulated | N/A | The log ratios for the expression levels of lincRNAs to apcGenes were shown in Figure 4. The expression of three lincRNAs (TU1378, TU1555, and TU4508) and an apcGene (GL27157) were detected only in the mycelia stage, whereas the expression of TU3327 was detected in mycelia and primordia stages. | 24932683 | PLNlncRbase | |
EL1378 | TU1567 | RNA-seq, qRT-PCR | mycelia, primordia, stage | up-regulated | N/A | For the other three lincRNAs located at the 5' end of their apcGenes, TU1567 was adjacent to a pheromone B alpha 3 receptor gene. TU1567 was expressed bidirectionally only in the mycelia, consistent with its possible involvement in the mating process. | 24932683 | PLNlncRbase | |
EL1379 | TU1970 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of five lincRNAs/apcGenes pairs exhibited significantly negative correlations (Figure 5B). In this group, four of five lincRNAs located in the 5' region of their apcGenes (Figure 3A and 3B), in which three (TU1970, TU3327, and TU5007) were transcribed in the opposite direction. TU718 was transcribed in the same direction. The other lincRNA (TU1378) located in the 3' region of its apcGenes and was transcribed in the same direction (Figure 3A and 3B). (see in the section "Potential roles of lincRNAs whose expression are significantly correlated with those of apcGenes"for details) | 24932683 | PLNlncRbase | |
EL1380 | TU3327 | RNA-seq, qRT-PCR | mycelia and primordia stages | up-regulated | N/A | The expression profiles of 5 lincRNAs were negatively correlated with those of their apcGenes (Figure 5B,r<-0.8). The apcGenes of TU718, TU1378, TU3327, and TU5007 are a putative hydrolase (GL15069), a Barwin-related endoglucanase (GL18494), a putative hydrolase (GL27846), and an alphaamylase (GL24914), respectively, which all belong to CAZy family. | 24932683 | PLNlncRbase | |
EL1381 | TU3423 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | For the other three lincRNAs located at the 5' end of their apcGenes, TU1567 was adjacent to a pheromone B alpha 3 receptor gene. TU1567 was expressed bidirectionally only in the mycelia, consistent with its possible involvement in the mating process (Figure 3C, Table S4). Two bidirectional lincRNAs (TU532 and TU3423) were adjacent to the CAZy family genes and showed developmentally preferential expression among the three stages (Figure 3C, Table S4). TU532 was expressed bidirectionally in the primordia and expressed in the reverse direction in the mycelia or fruiting bodies (Figure 3C, Table S4). For TU3423, bidirectional transcription was not detected in the fruiting bodies. These two lincRNAs may be involved in carbohydrate metabolism as indicated by their expression profiles. | 24932683 | PLNlncRbase | |
EL1382 | TU4313 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | TU4313 was adjacent to the gene GL24088, encoding a hydrox ymethylglutaryl-CoA reductase (HMGR). HMGR is involved in isopentenyl diphosphate production in the MVA pathway, which is the crucial precursor of triterpenoids. Also showed distinct expression profiles. As HMGR is a rate-limiting enzyme in the MVA pathway, the presence of these three lincRNAs with distinct expression profiles may reflect a novel regulatory mechanism of the MVA pathway. | 24932683 | PLNlncRbase | |
EL1383 | TU4314 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | TU4314 was adjacent to the gene GL24088, encoding a hydroxy methylglutaryl-CoA reductase (HMGR). HMGR is involved in isopentenyl diphosphate production in the MVA pathway, which is the crucial precursor of triterpenoids. Also showed distinct expression profiles. As HMGR is a rate-limiting enzyme in the MVA pathway, the presence of these three lincRNAs with distinct expression profiles may reflect a novel regulatory mechanism of the MVA pathway. | 24932683 | PLNlncRbase | |
EL1384 | TU4508 | RNA-seq, qRT-PCR | mycelia stage | up-regulated | N/A | The log ratios for the expression levels of lincRNAs to apcGenes were shown in Figure 4. The expression of three lincRNAs (TU1378, TU1555, and TU4508) and an apcGene (GL27157) were detected only in the mycelia stage, whereas the expression of TU3327 was detected in mycelia and primordia stages. | 24932683 | PLNlncRbase | |
EL1385 | TU4652 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. The apcGenes of TU4652 and TU781 are a laccase 3 (GL29234) and a glyoxal oxidase precursor (GL20538), respectively, which belong to the lignin degradation pathway. | 24932683 | PLNlncRbase | |
EL1386 | TU4684 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. The apcGenes of TU4652 and TU781 are a laccase 3 (GL29234) and a glyoxal oxidase precursor (GL20538), respectively, which belong to the lignin degradation pathway. In contrast, The apcGenes of TU51, TU4779, and TU4684 are an alpha-glucosidase (GL30020), a putative hydrolase (GL19744), a chitinase 1 (GL24376), respectively, all of which belong to CAZy family. | 24932683 | PLNlncRbase | |
EL1387 | TU4779 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. The apcGenes of TU4652 and TU781 are a laccase 3 (GL29234) and a glyoxal oxidase precursor (GL20538), respectively, which belong to the lignin degradation pathway. In contrast, The apcGenes of TU51, TU4779, and TU4684 are an alpha-glucosidase (GL30020), a putative hydrolase (GL19744), a chitinase 1 (GL24376), respectively, all of which belong to CAZy family. | 24932683 | PLNlncRbase | |
EL1388 | TU5007 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | On the other hand, the expression profiles of 5 lincRNAs were negatively correlated with those of their apcGenes (Figure 5B,r<-0.8). The apcGenes of TU718, TU1378, TU3327, and TU5007 are a putative hydrolase (GL15069), a Barwin-related endoglucanase (GL18494), a putative hydrolase (GL27846), and an alphaamylase (GL24914), respectively, which all belong to CAZy family. | 24932683 | PLNlncRbase | |
EL1389 | TU506 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. | 24932683 | PLNlncRbase | |
EL1390 | TU51 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. The apcGenes of TU4652 and TU781 are a laccase 3 (GL29234) and a glyoxal oxidase precursor (GL20538), respectively, which belong to the lignin degradation pathway. In contrast, The apcGenes of TU51, TU4779, and TU4684 are an alpha-glucosidase (GL30020), a putative hydrolase (GL19744), a chitinase 1 (GL24376), respectively, all of which belong to CAZy family. | 24932683 | PLNlncRbase | |
EL1391 | TU5846 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. | 24932683 | PLNlncRbase | |
EL1392 | TU6607 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. | 24932683 | PLNlncRbase | |
EL1393 | TU6608 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. | 24932683 | PLNlncRbase | |
EL1394 | TU718 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | On the other hand, the expression profiles of 5 lincRNAs were negatively correlated with those of their apcGenes (Figure 5B,r<-0.8). The apcGenes of TU718, TU1378, TU3327, and TU5007 are a putative hydrolase (GL15069), a Barwin-related endoglucanase (GL18494), a putative hydrolase (GL27846), and an alphaamylase (GL24914), respectively, which all belong to CAZy family. | 24932683 | PLNlncRbase | |
EL1395 | TU781 | RNA-seq, qRT-PCR | fruiting bodies, mycelia and primordia stages | up-regulated | N/A | The expression profiles of 11 lincRNAs were positively correlated with their corresponding apcGenes (r>0.8; Figure 5A). The apcGenes of TU5846, TU506, TU6607, TU6608, TU1273, and TU1403 are all CYP450 genes. The apcGenes of TU4652 and TU781 are a laccase 3 (GL29234) and a glyoxal oxidase precursor (GL20538), respectively, which belong to the lignin degradation pathway. | 24932683 | PLNlncRbase | |
EL1400 | Tug1 | Northern blots and in situ hybridization, knockdown, Immunofluorescent staining and microarray analyses | retina | N/A | expression | Tug1 is necessary for the proper formation of photoreceptors in the developing rodent retina. | 15797018 | ||
EL1400 | Tug1 | qRT-PCR, knockdown, MTT, TUNEL and Annexin V-FITC assays and western blot, GSIS, ELISA and immunochemistry | mouse pancreatic β cell | up-regulated | expression | Knockdown of lncRNA TUG1 expression resulted in an increased apoptosis ratio and decreased insulin secretion in β cells both in vitro and in vivo | 25871529 | ||
EL1400 | Tug1 | RNA-seq, overexpression | mouse hepatocytes and liver sinusoidal endothelial cells LSECs | down-regulated | expression | Overexpression of TUG1 attenuated cold-induced apoptosis in mouse hepatocytes and liver sinusoidal endothelial cells LSECs, in part by blocking mitochondrial apoptosis and endoplasmic reticulum (ER) stress pathways. TUG1 attenuated apoptosis, inflammation, and oxidative stress in vivo in livers subjected to cold storage. Overexpression of TUG1 also improved hepatocyte function and prolonged hepatic graft survival rates in mice. These results suggest that the lncRNA TUG1 exerts a protective effect against cold-induced liver damage by inhibiting apoptosis in mice, and suggests a potential role for TUG1 as a target for the prevention of cold-induced liver damage in liver transplantation. | 26785829 | ||
EL1430 | uc022axw.1 | lncRNA microarray | human bone marrow mesenchymal stem cells (MSCs) | up-regulated | expression | The results showed that the two up-regulated lncRNAs are likely to play important roles in osteogenic differentiation process。 | 25634249 | ||
EL1431 | UCA1 | N/A | Human Liver Stem Cell | N/A | interaction | CUDR plays a positive potential role in liver cancer stem cell through the cascade of CUDR-HULC/CUDR-β-catenin signaling. | 26347501 | ||
EL1436 | Uhg1 | N/A | N/A | N/A | expression | We have identified two unusually compact box c/d multi-snorna host genes in d. melanogaster, duhg1 and duhg2, similar in their organization to the corresponding vertebrate non-protein-coding host genes. | 11302516 | ||
EL1437 | Uhg2 | N/A | N/A | N/A | expression | We have identified two unusually compact box c/d multi-snorna host genes in d. melanogaster, duhg1 and duhg2, similar in their organization to the corresponding vertebrate non-protein-coding host genes. | 11302516 | ||
EL1440 | VAI | a peptide phosphorylation assay, U.V. crosslinking experiments and filter binding assay | N/A | N/A | interaction | Eber-1, eber-2 and vai rna exhibit mutually competitive binding to the native or recombinant enzyme | 7901835 | ||
EL1440 | VAI | construct mutants | N/A | N/A | expression | Analysis of the mutant's growth defect indicates that the adenovirus vai rna is required for efficient translation of viral mrnas at late times after infection. | 6297772 | ||
EL1440 | VAI | isothermal titration calorimetry and gel electrophoresis | N/A | N/A | interaction | Autophosphorylation assays confirmed that both EBER(I) and VA(I) are inhibitors of PKR activation, and profiled the kinetics of the inhibition. Binding affinities of dsRNAs to PKR double-stranded RNA-binding domains (dsRBDs) were determined by isothermal titration calorimetry and gel electrophoresis. | 16580685 | ||
EL1440 | VAI | N/A | N/A | N/A | interaction | The virus-associated rnas, va rnai and va rnaii, function as suppressors of rnai by interfering with the activity of dicer. the va rnas bind dicer and function as competitive substrates squelching dicer. | 16014917 | ||
EL1441 | VAII | N/A | N/A | N/A | interaction | The virus-associated rnas, va rnai and va rnaii, function as suppressors of rnai by interfering with the activity of dicer. the va rnas bind dicer and function as competitive substrates squelching dicer. | 16014917 | ||
EL1442 | Vax2os | N/A | photoreceptor progenitors in the mouse retina | N/A | N/A | regulate cell cycle in the mammalian retina during development. the overexpression of Vax2os1 in the developing early postnatal mouse retina causes an impaired cell cycle progression of photoreceptor rogenitors toward their final committed fate and a consequent delay of their differentiation processes. At later developmental stages, this perturbation is accompanied by an increase of apoptotic events in the photoreceptor cell layer, in comparison with control retinas, without affecting the proper cell layering in the adult retina. Similar results are observed in mouse photoreceptor-derived 661W cells in which Vax2os1 overexpression results in an impairment of the cell cycle progression rate and cell differentiation. | 22128341 | ||
EL1442 | Vax2os | RT-PCR and RNA in situ hybridization | retina | N/A | interaction | We found a significant reduction of the expression levels of one of these nats, vax2os (vax2 opposite strand) in a mouse mutant carrying the inactivation of vax2, the corresponding sense gene. | 15703187 | ||
EL1445 | VL30 RNAs | genetic subtraction and microarray analysis, In situ hybridization | neural stem cell (NSC) | N/A | expression | Vl30 is enriched in multiple stem cell populations and may have roles in determining "stemness", or stem cell function. | 14651920 | ||
EL1445 | VL30 RNAs | N/A | N/A | N/A | interaction | Psf also contains two rna-binding domains (rbd) that form a complex with a noncoding vl30 retroelement rna, releasing psf from a gene and reversing repression. | 16079199 | ||
EL1445 | VL30 RNAs | siRNA | mouse steroidogenic adrenal cells | N/A | interaction | Mvl30 rna regulates steroidogenesis, and possibly other physiological processes of mice, by complex formation with psf. | 14704271 | ||
EL1445 | VL30 RNAs | Southern hybridization analyses | an immunodeficient mouse model | N/A | expression | The metastatic effect might be mediated directly by a noncoding mvl30-1 rna or by a peptide or small protein encoded by one of the short orfs in the mvl30-1 rna. | 11959915 | ||
EL1449 | VsENOD40 | RT-PCR | roots | up-regulated | N/A | VsENOD40 expression during Rhizobium-induced nodule formation on Vicia sativa roots. VsENOD40 is expressed at a high level in the pericycle of the nodule vascular bundle . vetch ENOD40 is only expressed in the uninfected cells in this zone. while in pea ENOD40 is expressed in both the uninfected and infected cells of this zone. | 7548828 | PLNlncRbase | |
EL1452 | WFDC21P | knockdown | mouse bone marrow cells | N/A | N/A | The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. | 24744378 | ||
EL1458 | XACT | Gene expression study | human pluripotent cells | N/A | N/A | act a role in the control of human X-chromosome inactivation (XCI) initiation. | 23334669 | ||
EL1459 | XIST | N/A | N/A | N/A | interaction | We describe gene targeting of xist, and provide evidence for its absolute requirement in the process of x chromosome inactivation. | 8538762 | ||
EL1459 | XIST | Targeted Structure-Seq | N/A | N/A | expression | We use this approach to probe the full-length Xist lncRNA to develop new models for functional elements within Xist, including the repeat A element in the 5'-end of Xist. This analysis also identified new structural elements in Xist that are evolutionarily conserved, including a new element proximal to the C repeats that is important for Xist function. | 26646615 | ||
EL1460 | Xist | chemical and enzymatic probes and FRET experiments; combination of RNP affinity chromatography, immunoprecipitation; assays, mass spectrometry, and Western blot analysis | mouse ES cell | N/A | N/A | N/A | 20052282 | ||
EL1460 | Xist | compared between freshly-isolated and cultured dental mesenchymal cells | mouse dental mesenchymal cells | down-regulated in dental mesenchymal cells; up-regulated in odontogenic dental mesenchymal tissue | N/A | loss of odontogenic potential | 26986487 | ||
EL1460 | Xist | mutant | mutant male and female mice | N/A | expression | The xist rna is required for female dosage compensation but plays no role in spermatogenesis. | 9009199 | ||
EL1460 | Xist | mutant | mouse embryonic fibroblasts | N/A | mutation | Loss of xist rna destabilizes the inactive state in somatic cells, leading to an increased reactivation frequency of an x-linked gfp transgene and of the endogenous hypoxanthine phosphoribosyl transferase (hprt) gene in mouse embryonic fibroblasts. | 11352938 | ||
EL1460 | Xist | mutation | mouse embryonic stem cells | N/A | expression | Silencing requires a conserved repeat sequence located at the 5' end of xist. | 11780141 | ||
EL1460 | Xist | N/A | mice embryos, differentiating embryonic stem cells (ESCs) and epiblast stem cells (EpiSCs) | N/A | expression | Ectopic Xist RNA induction and subsequent X-linked gene silencing is sex specific in embryos and in differentiating embryonic stem cells (ESCs) and epiblast stem cells (EpiSCs). A higher frequency of X(ΔTsix)Y male cells displayed ectopic Xist RNA coating compared with X(ΔTsix)X female cells. This increase reflected the inability of X(ΔTsix)Y cells to efficiently silence X-linked genes compared with X(ΔTsix)X cells, despite equivalent Xist RNA induction and coating. Silencing of genes on both Xs resulted in significantly reduced proliferation and increased cell death in X(ΔTsix)X female cells relative to X(ΔTsix)Y male cells. The increased expression of one or more X-inactivation escapees activates Xist and, separately, helps trigger X-linked gene silencing. | 26739568 | ||
EL1460 | Xist | N/A | ES cells | N/A | expression | Xist had to be activated within 48 hr of differentiation to effect silencing, suggesting that reversible repression by xist is a required initiation step that might occur during normal x inactivation in female cells. | 10882105 | ||
EL1460 | Xist | peptide nucleic acid (PNA) interference mapping | N/A | N/A | N/A | A single 19-bp antisense cell-permeating pna targeted against a particular region of xist rna caused the disruption of the xi. | 11481485 | ||
EL1460 | Xist | RT-PCR,RNA and DNA Fluorescence in Situ Hybridization,Immunofluorescence and Antibodies | ES cell | N/A | interaction | It coats and silences 1 of the 2 X chromosomes in female cells and initiates a chromosomewide change in chromatin structure that includes the recruitment of Polycomb proteins | 19164542 | ||
EL1461 | XLOC_000078 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1463 | XLOC_000495 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1465 | XLOC_000629 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1466 | XLOC_000775 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1467 | XLOC_000829 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1468 | XLOC_000869 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1469 | XLOC_000909 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1470 | XLOC_000999 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1471 | XLOC_001095 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1472 | XLOC_001234 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1473 | XLOC_001235 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1476 | XLOC_004026 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1477 | XLOC_004031 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1479 | XLOC_004186 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1480 | XLOC_004275 | qRT-PCR | reproductive stage | N/A | N/A | XLOC_004275 are highly expressed in sperm (Figure 5A, D),and this type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1481 | XLOC_004478 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1482 | XLOC_004507 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1483 | XLOC_004531 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1485 | XLOC_004689 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1486 | XLOC_004714 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1487 | XLOC_004798 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1488 | XLOC_004876 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1489 | XLOC_004881 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1490 | XLOC_004932 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1491 | XLOC_004933 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1492 | XLOC_004944 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1493 | XLOC_005031 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1495 | XLOC_007072 | qRT-PCR | reproductive stage | N/A | N/A | lncRNA (XLOC_0063639 or XLOC_007072) that is highly expressed during the reproductive stage were introduced into rice protoplasts separately. Both XLOC_0063639 and XLOC_007072 dramatically increased the mRNA abundance of corresponding miRNA (OsmiR160 and OsmiR164) targets (LOC_Os02g36880 for miR164 [59]; LOC_Os06G47150 and LOC_Os10g33940 for miR160 [60]) in their transiently expressed protoplasts, suggesting that XLOC_0063639 and XLOC_007072 indeed inhibited the functions of OsmiR160 and miR164, respectively (Figure 6C,E-H). | 25517485 | PLNlncRbase | |
EL1498 | XLOC_009232 | qRT-PCR | reproductive stage | N/A | N/A | XLOC_009232 is specifically expressed in coleoptiles (Figure 5C),and this type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C;Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1504 | XLOC_016182 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1505 | XLOC_018316 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1506 | XLOC_037529 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1507 | XLOC_040350 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1508 | XLOC_057324 | qRT-PCR | panicle development and fertility | N/A | N/A | More importantly, one lncRNA, XLOC_057324, is demonstrated to play a role in panicle development and fertility. lncRNA (XLOC_057324) that is highly expressed in reproductive organs in relation to its physiological function in rice plants. This lncRNA is specifically expressed in young panicles and pistils (expression was restricted to ovules), suggesting that XLOC_057324 might play a role in regulating panicle and/or pistil development (Figure 7A,B). | 25517485 | PLNlncRbase | |
EL1509 | XLOC_057981 | qRT-PCR | reproductive stage | N/A | N/A | This type of lncRNA was expressed during the integrated sexual reproduction process (Figure 3C; Additional file 2), indicating that lncRNAs may function throughout the entire reproductive process in rice. | 25517485 | PLNlncRbase | |
EL1510 | Xlsirts | molecular beacons | N/A | N/A | expression | Destruction of either of these transcripts results in disruption of the cytokeratin cytoskeleton in a transcript-specific manner and interferes with proper formation of the germinal granules and subsequent development of the germline. | 16000384 | ||
EL1512 | XRN1 | RNA-seq, qRT-PCR | yeast | N/A | N/A | The majority of XUTs strongly accumulate in lithium-containing media, indicating that they might have a role in adaptive responses to changes in growth conditions. Notably, RNAPII chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) analysis of Xrn1-deficient strains revealed a significant decrease of RNAPII occupancy over273 genes with antisense XUTs. These genes show an unusual bias for H3K4me3 marks and require the Set1 histone H3 lysine 4 methyl-transferase for silencing. Furthermore, abolishing H3K4me3 triggers the silencing of other genes with antisense XUTs, supporting a model in which H3K4me3 antagonizes antisense ncRNA repessive activity. Our results demonstrate that antisense ncRNA-mediated regulation is a general regulatory pathway for gene expression in S. cerevisiae. | 21697827 | ||
EL1513 | Yam-1 | ChIP-seq | Mouse C2C12 myoblasts (MBs) | down-regulated | N/A | Yam-1 is positively regulated by YY1, Yam-1 is downregulated upon differentiation and acts as an inhibitor of myogenesis.Yam-1 functions through in cis regulation of miR-715, which in turn targets Wnt7b. | 23942234 | ||
EL1519 | Zfhx2os | gene-targeting approach | mouse brain | N/A | interaction | The expression of zfh-5 is additionally regulated by a mechanism depending on this antisense rna. | 16257534 | ||
EL1521 | Zm401 | RT-PCR | flower development | up-regulated | N/A | zm401 likely functions in pollen growth and/or development. RT-PCR amplification demonstrated that the ZM13-driven zm401 gene was spatially expressed in tobacco pollens. It was found that all transgenic tobacco plants expressing zm401 showed various levels of sterility, ranging from abortive flower development to male sterility. Further analyses on anther development of transgenic plants indicated multiple abnormalities in the late stages of anther development. These abnormalities include lagged degradation of the tapetum and connective tissue, failed deposition of fibrous bands in endothecium cells, and aborted pollen grain development. These results strongly suggest that zm401 plays an essential role in anther development. However the exact functions of zm401 is still unclear, and further analysis of zm401 is required to determine the exact mechanism involved in anther development. | 10.1007/s10681-005-5272-2 | PLNlncRbase | |
EL1522 | Zm401 | qRT-PCR | pollens | up-regulated | N/A | Zm401 is involved in the regulation of pollen development. Over expression of Zm401 in maize caused smaller tassels, degenerate or shriveled anthers. Zm401 may be involved in the development of male reproductive organs. Zm401, as a non-coding RNA, plays an essential role in pollen development. Zm401 gene is involved in the late stage of pollen development of maize. Zm401-overexpressed transgenic maize was generated to investigate its function in pollen development. (Dai et al., 2007) Zm401,is expressed specifically in pollens. Forward and reverse genetic studies have shown a function for Zm401 in regulating the expression of critical genes necessary for pollen development including ZmMADS2, MZm3-3 and ZmC5. MZm3-3 was up-regulated in Zm401 mutants while ZmMADS2 and ZmC5 were both down-regulated. Over-expression of Zm401 severely affects pollen development due to abnormal tassels and degenerate anthers. (Au et al., 2011) Zm401 is expressed primarily in the anthers (tapetal cells as well as microspores) in a developmentally regulated manner. That is, it is expressed from floret forming stage, increasing in concentration up to mature pollen. Knockdown of zm401 significantly affected the expression of ZmMADS2, MZm3-3, and ZmC5, critical genes for pollen development. zm401 could be one of the key growth regulators in anther development, the expression of zm401 is associated with the floret development, especially with the development of tapetal cells and microspores. (Ma et al., 2008) ZM401 was specifically or preferentially expressed in mature pollen. ZM401 was transcribed from tetrad stage of microspore development and increased in concentration up to mature pollen, which suggested that ZM401 belongs to lategene in pollen development. (Dai et al., 2004) | 21525783, 18465785, 400866 | PLNlncRbase | |
EL1523 | Zm401p10 | Western blot/RT-PCR | anther development | up-regulated | N/A | Overexpression of Zm401p10 in maize retarded tapetal degeneration and caused microspore abnormalities. The Zm401 gene is one of the major components of the molecular network regulating maize anther development and male fertility, and that Zm401p10 is expressed from the longest ORF of the gene. Zm401p10 plays a major role in pollen development. Overexpression of Zm401p10 in maize resulted in several severe phenotypes, including retardation of tapetum degeneration, accompanied by pollen abortion or pollen grains with low viability. These data suggest that Zm401p10 acts within the tapetum to promote normal pollen development and postmeiotic tapetal degradation.the overexpression of Zm401p10 did not affect ear development or fertilisation. Zm401p10 might play a role in guiding normal early anther development by maintaining the transcription of cysteine proteinases. Zm401p10 overexpression might abolish tapetum flavonoid biosynthesis and lead to male sterility. | 10.1071/FP08187 | PLNlncRbase | |
EL1525 | ZmIPS1 | qRT–PCR | phosphate balance | up-regulated | N/A | The expression patterns of other members of the TPSI1/Mt4 family in monocots were also investigated. The induced expressions of OsIPS1, HvIPS1, ZmIPS2 and TalIPS2 were stronger than those of OsIPS2, HvIPS2 ZmIPS1 and TalIPS1 in roots after 4 or 10 d of Pi starvation, whereas higher induced expressions of OsIPS2, HvIPS1, ZmIPS1 and TalIPS1 were detected in shoots. | 10.1111/j.1365-3040.2005.01272.x | PLNlncRbase | |
EL1528 | ZNF667-AS1 | microarray, qRT-PCR | isogenic normal finite pre-stasis, abnormal finite post-stasis, and immortal human mammary epithelial cells (HMECs) from 4 individuals | down-regulated | epigenetics | The functional importance of DNA hypermethylation in MORT gene silencing is supported by the ability of 5-aza-2'-deoxycytidine to reactivate MORT expression. Analysis of TCGA data revealed deregulation of MORT expression due to DNA hypermethylation in 15 out of the 17 most common human cancers. | 26646903 | ||
EL1530 | ZPR4 | qRT-PCR/RT-PCR | cold, drought and highlight | up-regulated | N/A | We found that 303 lncRNAs (including 245 poly (A)+ and 58 poly(A)- lncRNAs) were differentially expressed under at least one of the stress conditions, lncRNA AT2G36307 is upregulated by cold/drought/highlight stresses.(details are listed in Appendix S2) | 25256571 | PLNlncRbase | |
EL1299 | TCONS_00049512 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | In our study, ptc-miR1445 was predicted to target TCONS_00049512, which has been predicted to function in cleaving the transcripts of development-related or stress responsive genes in Populus (Lu et al. 2008). Besides ptc-miR1445, miRNAs that were specifically expressed in xylem and reportedly participate in formation of tension wood (Lu et al. 2005, 2008; Puzey et al. 2012) were predicted to regulate some of the lncRNAs identified in our study. For example, ptr-miR172, which was only suppressed in compression tissue (Lu et al. 2005), may target TCONS_00012272 and TCONS_00012273, which were detected in our study and showed a type C expression pattern (TW25230698
| PLNlncRbase | | |
EL1276 | TCONS_00012273 | RNA-seq/qRT-PCR | wood formation | up-regulated | N/A | In our study, ptc-miR1445 was predicted to target TCONS_00049512, which has been predicted to function in cleaving the transcripts of development-related or stress responsive genes in Populus (Lu et al. 2008). Besides ptc-miR1445, miRNAs that were specifically expressed in xylem and reportedly participate in formation of tension wood (Lu et al. 2005, 2008; Puzey et al. 2012) were predicted to regulate some of the lncRNAs identified in our study. For example, ptr-miR172, which was only suppressed in compression tissue (Lu et al. 2005), may target TCONS_00012272 and TCONS_00012273, which were detected in our study and showed a type C expression pattern (TW24892290
| PLNlncRbase | | |
EL1294 | TCONS_00039944 | RNA-seq/qRT-PCR | wood formation | down-regulated | N/A | Figure 9a shows that a negative relationship between miRNAs and their potential target lncRNAs were detected; for example, miR2 (Ptc-miR168b-5p) is expressed in OW(OW25230698
| PLNlncRbase | | |
EL1531 | Apela | RNA-Seq, Rescue and overexpression, knockdown, In situ hybridization | N/A | N/A | interaction | Toddler is annotated as a non-coding RNA in zebrafish (ENSDARG00000094729), mouse [Gm10664; also called Ende], and human (LOC100506013) and is present in two lncRNA catalogs; however, it contains a 58–amino acid ORF with a predicted signal sequence and high conservation in vertebrates, including human. Local and ubiquitous production of Toddler promote cell movement, suggesting that Toddler is neither an attractant nor a repellent but acts globally as a motogen. | 24407481 | ||
EL1532 | APELA | RNA-Seq, Rescue and overexpression, knockdown, In situ hybridization | N/A | N/A | interaction | Toddler is annotated as a non-coding RNA in zebrafish (ENSDARG00000094729), mouse [Gm10664; also called Ende], and human (LOC100506013) and is present in two lncRNA catalogs; however, it contains a 58–amino acid ORF with a predicted signal sequence and high conservation in vertebrates, including human. Local and ubiquitous production of Toddler promote cell movement, suggesting that Toddler is neither an attractant nor a repellent but acts globally as a motogen. | 26387754, 25639753, 20153842, 24316148, 24407481 | ||
EL1533 | apela | RNA-Seq, Rescue and overexpression, knockdown, In situ hybridization | early zebrafish embryogenesis | N/A | interaction | Toddler is annotated as a non-coding RNA in zebrafish (ENSDARG00000094729), mouse [Gm10664; also called Ende], and human (LOC100506013) and is present in two lncRNA catalogs; however, it contains a 58–amino acid ORF with a predicted signal sequence and high conservation in vertebrates, including human. Local and ubiquitous production of Toddler promote cell movement, suggesting that Toddler is neither an attractant nor a repellent but acts globally as a motogen. | 24407481 | ||
EL0388 | ENOD40-1 | Western blotting, peptide mass fingerprinting | nodules | N/A | expression | In vitro translation of soybean ENOD40 mRNA in wheat germ extracts revealed that the conserved nucleotide sequence at the 5′ end (region I) encodes two peptides of 12 and 24 aa residues (peptides A and B). ENOD40 peptides are involved in the control of sucrose use in nitrogen-fixing nodules. | 11842184 | ||
EL1534 | Gm34302 | Northern Blot, Western Blot, Co-immunoprecipitations (CoIPs) | Knockout mice, Transgenic mice | N/A | interaction | DWORF is a transmembrane peptide that interacts with SERCA proteins and enhances muscle contractility | 26816378 | ||
EL1535 | DWORF | Northern Blot, Western Blot, Co-immunoprecipitations (CoIPs) | Human Heart Failure Tissue | N/A | interaction | We discovered a putative muscle-specific long noncoding RNA that encodes a peptide of 34 amino acids and that we named dwarf open reading frame (DWORF). | 26816378 | ||
EL1536 | MRLN | Radioisotopic In Situ Hybridization, Co-immunoprecipitations and Western Blot Analysis, Real-time PCR | N/A | N/A | interaction | We discovered a conserved micropeptide, which we named myoregulin (MLN), encoded by a skeletal muscle-specific RNA annotated as a putative long noncoding RNA. MLN as an important regulator of skeletal muscle physiology. | 25640239 | ||
EL1537 | Mrln | Radioisotopic In Situ Hybridization, Co-immunoprecipitations and Western Blot Analysis, Real-time PCR | pseudopregnant female ICR mice | N/A | interaction | We discovered a conserved micropeptide, which we named myoregulin (MLN), encoded by a skeletal muscle-specific RNA annotated as a putative long noncoding RNA. MLN as an important regulator of skeletal muscle physiology. | 25640239 | ||
EL1538 | SclA | RT-PCR, in situ hybridization | Drosophila heart | N/A | interaction | We describe two peptides of less than 30 amino acids regulating calcium transport, and hence influencing regular muscle contraction, in the Drosophila heart. | 23970561 | ||
EL1539 | SclB | RT-PCR, in situ hybridization | Drosophila heart | N/A | interaction | We describe two peptides of less than 30 amino acids regulating calcium transport, and hence influencing regular muscle contraction, in the Drosophila heart. | 23970561 | ||
EL1540 | tal-1A | Immunohistochemistry, In situ hybridisation, sequencing | N/A | N/A | expression | tal function is mediated by several 33-nucleotide–long open reading frames (ORFs), which are translated into 11-amino-acid–long peptides. | 17486114, 17439302 | ||
EL1541 | tal-2A | Immunohistochemistry, In situ hybridisation, sequencing | N/A | N/A | expression | tal function is mediated by several 33-nucleotide–long open reading frames (ORFs), which are translated into 11-amino-acid–long peptides. | 17486114, 17439302 | ||
EL1542 | tal-3A | Immunohistochemistry, In situ hybridisation, sequencing | N/A | N/A | expression | tal function is mediated by several 33-nucleotide–long open reading frames (ORFs), which are translated into 11-amino-acid–long peptides. | 17486114, 17439302 | ||
EL1543 | tal-AA | Immunohistochemistry, In situ hybridisation, sequencing | N/A | N/A | expression | tal function is mediated by several 33-nucleotide–long open reading frames (ORFs), which are translated into 11-amino-acid–long peptides. | 17486114, 17439302 |
INTERACTION | |||||||||
---|---|---|---|---|---|---|---|---|---|
ID | lncRNA Name |
Interaction target |
Level of interaction |
Type of interaction |
Description | PMID | Source | ||
EL0005 | 4930570G19Rik | Negr1 | RNA-DNA | regulation | In vitro knockdown of the long non-coding RNA resulted in significant down-regulation of Negr1 mRNA expression, NEGR1 protein levels and neurite length whereas over-expression enhanced Negr1 mRNA expression, NEGR1 protein levels and increased neurite length. The long non-coding RNA, BC048612, and microRNA-203 were determined to be positive and negative regulators of Negr1 gene expression respectively. | 26723899 | |||
EL0009 | 6430411K18Rik | Rtl1/Peg11 | RNA-RNA | regulation | Several additional mirnas are processed from antipeg11 and that these regulate rtl1/peg11 in trans by guiding risc-mediated cleavage of its mrna. | 15854907 | |||
EL0010 | 9130001E16Rik | Gata6 | RNA-RNA | co-expression | The expression of Gata6bt was negatively correlated with Gata6, being up-regulated during pluripotent EB stages and down-regulated during progressive lineage specification. | 18562676 | LncRNADisease | ||
EL0011 | 9530018H14Rik | p100 and CBP | RNA-Protein | binding | In the limb mesenchyme, LncRNA-HIT was found to be retained in the nucleus, forming a complex with p100 and CBP. | 26633036 | |||
EL0012 | A130040M12Rik | PSF | RNA-Protein | binding | Binding of mouse VL30 (A130040M12Rik) retrotransposon RNA to PSF protein induces genes repressed by PSF: effects on steroidogenesis and oncogenesis. | 14704271 | LncRNADisease | ||
EL0012 | A130040M12Rik | PSF | RNA-Protein | binding | VL30-1 RNA binds and releases PSF from Rab23. | 19805375 | LncRNADisease | ||
EL0014 | AATBC | JNK, NRF2 | RNA-DNA | regulation | The apoptosis following AATBC knockdown was mediated by activation of phosphorylated JNK and suppression of NRF2. | 25473900 | |||
EL0016 | AB073614 | ERK1/2 and AKT-mediated signaling pathway | RNA-Protein | regulation | western blot assays indicated that lncRNA AB073614 may exert its function by targeting ERK1/2 and AKT-mediated signaling pathway. | 26299803 | |||
EL0033 | Adapt15 | TDP-43 | RNA-Protein | binding | UV-induced gadd7 directly binds to TAR DNA-binding protein (TDP-43) and interferes with the interaction between TDP-43 and cyclin-dependent kinase 6 (Cdk6) mRNA, resulting in Cdk6 mRNA degradation. | 23103768 | |||
EL0033 | Adapt15 | Cdk6 | RNA-RNA | regulation | UV-induced gadd7 directly binds to TAR DNA-binding protein (TDP-43) and interferes with the interaction between TDP-43 and cyclin-dependent kinase 6 (Cdk6) mRNA, resulting in Cdk6 mRNA degradation. | 23103768 | |||
EL0033 | Adapt15 | gadd45 and gadd153 | RNA-RNA | co-expression | Near identical responses were also observed for gadd45 and gadd153 rnas, suggesting coordinate regulation of adapt15, gadd45, and gadd153. | 8638945 | |||
EL0039 | AF339813 | NUF2 | RNA-Protein | regulation | Through bioinformatics analysis and knockdown NUF2 in PC cells, we found LncRNA AF339813 was positively regulated by NUF2. We further demonstrated that knockdown of AF339813 by siRNA in PC cells significantly reduced cell proliferation and promoted apoptosis. | 26045769 | |||
EL0040 | AFAP1-AS1 | several small GTPase family members | RNA-Protein | regulation | AFAP1-AS1 knockdown affected the expression levels of several small GTPase family members and molecules in the actin cytokeratin signaling pathway. | 26245991 | |||
EL0040 | AFAP1-AS1 | actin filament associated protein 1 (AFAP1) | RNA-Protein | regulation | AFAP1-AS1 knockdown also increased the expression of its antisense protein coding gene, actin filament associated protein 1 (AFAP1). | 26245991 | |||
EL0040 | AFAP1-AS1 | actin filament associated protein 1 (AFAP1) | RNA-Protein | regulation | AFAP1-AS1 knockdown also increased AFAP1 protein expression. | 26246469 | |||
EL0044 | Airn | G9a | RNA-Protein | binding | Recruits G9a histone methyltransferase to epigenetically silence some target genes. | 11845212 | LncRNADisease | ||
EL0044 | Airn | Igf2r | RNA-DNA | regulation | Controls Igf2r imprinting cluster in mouse | 16874305 | LncRNADisease | ||
EL0044 | Airn | Ig2fr | RNA-RNA | co-expression | Neuron-specific lack of Airn expression results in neuronspecific lack of silencing at the Ig2fr locus. | 18184812 | LncRNADisease | ||
EL0044 | Airn | Slc22a3 | RNA-DNA | regulation | The Airn noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Air accumulates at the Slc22a3 promoter in correlation with localized H3K9 methylation and transcriptional repression. | 18988810 | LncRNADisease | ||
EL0044 | Airn | G9a | RNA-Protein | binding | The Airn noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Airn accumulates at the Slc22a3 promoter in correlation with localized H3K9 methylation and transcriptional repression. | 18988810 | LncRNADisease | ||
EL0044 | Airn | Slc22a3 promoter | RNA-DNA | regulation | Air interacts with the Slc22a3 promoter chromatin and the H3K9 histone methyltransferase G9a in placenta. | 18988810 | |||
EL0044 | Airn | G9a | RNA-Protein | binding | The Airn RNA also binds to G9a and appears to target this enzyme to a silenced gene in the cluster. | 19239885 | LncRNADisease | ||
EL0044 | Airn | G9a | RNA-Protein | binding | The antisense transcript AIRN that is associated with the chromatin-modifying complex G9a. | 19571010 | LncRNADisease | ||
EL0044 | Airn | Igf2r | DNA-DNA | regulation | Deletion of the Airn promoter on the paternal allele results in aberrant activation of paternal Igf2r, Slc22a2, and Slc22a3 genes in cis. | 19727951 | LncRNADisease | ||
EL0044 | Airn | Slc22a2 | DNA-DNA | regulation | Deletion of the Airn promoter on the paternal allele results in aberrant activation of paternal Igf2r, Slc22a2, and Slc22a3 genes in cis. | 19727951 | LncRNADisease | ||
EL0044 | Airn | Slc22a3 | DNA-DNA | regulation | Deletion of the Airn promoter on the paternal allele results in aberrant activation of paternal Igf2r, Slc22a2, and Slc22a3 genes in cis. | 19727951 | LncRNADisease | ||
EL0044 | Airn | Igf2r | RNA-RNA | co-expression | Insertion of a polyadenylation cassette leading to truncation of the Air transcript resulted in the derepression of imprinted genes in the locus, which is suggestive of a direct role for long ncRNAs in imprinting of insulin-like growth factor 2 receptor (Igf2r). | 21831473 | LncRNADisease | ||
EL0044 | Airn | G9a | RNA-Protein | binding | The Airn lncRNA was found to coat its target genes but instead recruits the G9a histone methyltransferase rather than the subunits of PRC2 | 21874119 | LncRNADisease | ||
EL0044 | Airn | G9a | RNA-Protein | binding | Airn transcription unit recruits G9a to its target promoter to bring about gene silencing | 21925379 | LncRNADisease | ||
EL0044 | Airn | Igf2r | DNA-DNA | regulation | A CpG island (CGI) lies at the 5' end of the Airn macro non-protein-coding (nc) RNA that represses the flanking Igf2r promoter in cis on paternally inherited chromosomes. | 22396659 | LncRNADisease | ||
EL0053 | AK081227 | Mecp2 | DNA-Protein | regulation | overexpression of AK081227 mediated by the Mecp2 loss was associated with the downregulation of its host coding protein gene, the gamma-aminobutyric acid receptor subunit Rho 2 (Gabrr2) | 23611944 | |||
EL0061 | AK133808 | Rab11b | RNA-RNA | co-expression | A variety of ncRNAs were broadly upregulated in OLPs, PMOs and MYOs including AK141895 and AK133808, associated with the Slc44a1 and Rab11b genomic loci, respectively. | 20137068 | LncRNADisease | ||
EL0061 | AK133808 | Slc44a1 | RNA-RNA | co-expression | A variety of ncRNAs were broadly upregulated in OLPs, PMOs and MYOs including AK141895 and AK133808, associated with the Slc44a1 and Rab11b genomic loci, respectively. | 20137068 | LncRNADisease | ||
EL0070 | alpha-250 and alpha-280 | S14 | RNA-DNA | regulation | Alpha-250 and alpha-280 stimulate s14 mrna transcription, whereas free ribosomal protein s14 inhibits it. | 7867928 | |||
EL0071 | alpha-280/250 | RPS14 | RNA-DNA | regulation | Regulates RPS14 transcription in humans. | 7867928 | LncRNADisease | ||
EL0073 | Alu lncRNAs | Pol II | RNA-Protein | binding | B2 and Alu RNAs bind directly and tightly to Pol II and co-occupy the promoters of repressed genes along with the polymerase | 19307572 | |||
EL0075 | antisense TGF beta 3 | TGF beta 3 mRNA | RNA-RNA | regulation | The temporally controlled appearance of rna complementary to tgf beta 3 suggests that this molecule may play a role in the regulation of tgf beta 3 production in the heart. | 1511174 | |||
EL0076 | AOC4P | vimentin | RNA-Protein | binding | AOC4P binds to vimentin and promotes its degradation. | 26160837 | |||
EL0076 | AOC4P | UHRF1 | RNA-Protein | regulation | UPAT interacts with and stabilizes the epigenetic factor UHRF1 by interfering with its β-transducin repeat-containing protein (TrCP)-mediated ubiquitination. | 26768845 | |||
EL0080 | APOA1-AS | APOA1 | RNA-Protein | regulation | APOA1-AS can modulate distinct histone methylation patterns that mark active and/or inactive gene expression through the recruitment of histone-modifying enzymes. | 24388749 | |||
EL0081 | APOLO | PID | RNA-DNA | regulation | Altering APOLO expression affects chromatin loop formation, whereas RNA-dependent DNA methylation, active DNA demethylation, and Polycomb complexes control loop dynamics. This dynamic chromatin topology determines PID expression patterns. | 25018019 | PLNlncRbase | ||
EL0088 | ASCO-RNA | At2G33830 | RNA-RNA | binding | By using an in vitro binding assay for an AS target (the auxinregulated protein gene At2g33830), we showed that incubation with nonlabeled At2g33830 mRNA or the ASCO-RNA significantly diminishes the amount of AS target immunoprecipitated | 25073154, 25073153 | PLNlncRbase | ||
EL0093 | ASncmtRNAs | Dicer | RNA-Protein | binding | the ASncmtRNAs are bound to Dicer. | 25100722 | |||
EL0093 | ASncmtRNAs | survivin | RNA-Protein | regulation | knockdown of ASncmtRNAs potentiates apoptotic cell death by inhibiting survivin expression, a member of the inhibitor of apoptosis (IAP) family. | 25100722 | |||
EL0094 | asOct4-pg5 | 41186 | RNA-RNA | regulation | These results indicate that the lncRNA asOct4-pg5 may function to regulate multiple Oct4 related transcripts. | 21151833 | LncRNADisease | ||
EL0095 | AT102202 | mRNA-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) | RNA-Protein | regulation | In particular, the lncRNA AT102202 and its potential targets mRNA-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) were identified. | 25563320 | |||
EL0168 | At4 | PHO2 | RNA-RNA | regulation | In contrast to at4, pho2 accumulates Pi in the shoots under both high- and low-Pi growth conditions and shows higher Pi uptake rates relative to wild type. | 16460506, 21525783, 9880366 | PLNlncRbase | ||
EL0169 | At4-1 | miR399/PHO2 | RNA-RNA | binding | IPS1 and At4 directly inhibits miR-399 activity. | 17643101, 23726911 | PLNlncRbase | ||
EL0170 | At4-2 | miR399/PHO3 | RNA-RNA | binding | IPS1 and At4 directly inhibits miR-399 activity. | 17643101, 23726911 | PLNlncRbase | ||
EL0171 | At4-3 | miR399/PHO4 | RNA-RNA | binding | IPS1 and At4 directly inhibits miR-399 activity. | 17643101, 23726911 | PLNlncRbase | ||
EL0216 | ATXN8OS | GAT4 | RNA-RNA | co-expression | SCA8 CUG(exp) transcripts trigger splicing changes and increased expression of the CUGBP1-MBNL1 regulated CNS target, GABA-A transporter 4 (GAT4/Gabt4). | 19680539 | LncRNADisease | ||
EL0221 | B130024G19Rik | Coup-TfII | RNA-RNA | co-expression | We also have identified a candidate imprinted long antisense ncRNA, AK045070, that encompasses >45 kb and shows expression within the thalamus, pyramidal cells in the ventral hippocampus, and cortical amygdalar area. The adjacent candidate imprinted expressed gene, Coup-TfII, an important nuclear receptor involved in regulating various hormonal and brain functions, also exhibits a similar expression profile within these regions | 18184812 | LncRNADisease | ||
EL0222 | B2 SINE RNA | RNA polymerase II | DNA-DNA | regulation | Transposable B2 SINE elements can provide mobile RNA polymerase II promoters. | 11326281 | LncRNADisease | ||
EL0222 | B2 SINE RNA | CELO | DNA-TF | regulation | CELO protein Gam1 was able to mediate transcriptional activation of these B2 SINE-containing RNAs. | 12729754 | LncRNADisease | ||
EL0222 | B2 SINE RNA | Pol II | RNA-Protein | binding | B2 rna potently inhibits transcription by binding to core pol ii with high affinity and specificity. | 15300239 | |||
EL0222 | B2 SINE RNA | Pol II | RNA-Protein | binding | A small noncoding rna polymerase iii transcript, b2 rna, associates with rna polymerase ii and represses transcription of specific mrna genes. | 15300240 | |||
EL0222 | B2 SINE RNA | RNA polymerase II | RNA-Protein | binding | A 33-nt piece of B2 RNA binds RNA polymerase II, associates with preinitiation complexes, but cannot repress transcription. | 17307818 | LncRNADisease | ||
EL0222 | B2 SINE RNA | RNA polymerase II | RNA-Protein | binding | In vitro B2 RNA assembles into preinitiation complexes on promoter DNA via its interaction with the polymerase, thus rendering the complexes inactive. | 17307818 | |||
EL0222 | B2 SINE RNA | ALAS1 | DNA-DNA | regulation | A B2 SINE can contribute to the regulation of ALAS1 and SINEs in 5'-UTR regions contribute to inter-individual differences in gene expression. | 18929534 | LncRNADisease | ||
EL0222 | B2 SINE RNA | actin | RNA-RNA | co-expression | Upon stress conditions such as heat shock, B2 expression is dramatically enhanced leading to repression of transcription for genes such as actin and hexokinase II. | 19239885 | LncRNADisease | ||
EL0222 | B2 SINE RNA | hexokinase II | RNA-RNA | co-expression | Upon stress conditions such as heat shock, B2 expression is dramatically enhanced leading to repression of transcription for genes such as actin and hexokinase II. | 19239885 | LncRNADisease | ||
EL0222 | B2 SINE RNA | Comt1 | DNA-DNA | regulation | A B2 SINE insertion in the Comt1 gene (Comt1(B2i)) results in an overexpressing, behavior modifying allele present in classical inbred mouse strains.Comt1(B2i) (a B2 SINE insertion) results in a relatively modest difference in Comt1 expression and enzyme activity (comparable to the human Val-Met polymorphism) which has a demonstrable behavioral phenotype across a variety of outbred genetic backgrounds. | 20618449 | LncRNADisease | ||
EL0222 | B2 SINE RNA | Comt1 | DNA-DNA | regulation | Comt1 is differentially expressed among the strains, and this differential expression is cis-regulated. A B2 short interspersed nuclear element (SINE) was inserted in the 3'-untranslated region (3'-UTR) of Comt1 in 14 strains generating a common haplotype that correlates with gene expression. A haplotype, defined by a 3'-UTR B2 SINE element, regulates Comt1 expression and some mouse behaviors. | 20659173 | LncRNADisease | ||
EL0223 | B4GALT1-AS1 | B4GALT1 | RNA-RNA | regulation | B4GALT1 in a divergent manner along with its long non-coding RNA (lncRNA) antisense counterpart B4GALT1-AS1 | 26315939 | |||
EL0224 | BACE1-AS | APP | RNA-Protein | regulation | BACE1-AS is directly implicated in the increased abundance of Aβ 1–42 in Alzheimer’s disease. | 18587408 | LncRNADisease | ||
EL0224 | BACE1-AS | BACE1 | RNA-RNA | regulation | The BACE1-antisense transcript (BACE1-AS) regulates BACE1 mRNA and subsequently BACE1 protein expression in vitro and in vivo.expression of BACE1-AS increases BACE1 mRNA stability. | 18587408 | LncRNADisease | ||
EL0224 | BACE1-AS | BACE1 | RNA-RNA | co-expression | We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p. Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA. | 20507594 | LncRNADisease | ||
EL0224 | BACE1-AS | miR-485-5p | RNA-RNA | regulation | We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p. Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA. | 20507594 | LncRNADisease | ||
EL0224 | BACE1-AS | miR-485-5p | RNA-RNA | binding | masking the binding site for miR-485-5p | 20507594 | |||
EL0224 | BACE1-AS | BACE1 | RNA-DNA | regulation | When expression of lncRNA BACE1-AS was silenced using siRNA, BACE1 expression was downregulated and the antiproliferative and anti-invasive effects of anisomycin were reduced. | 26783004 | |||
EL0226 | BALR-6 | Specificity Protein 1 (SP1) | RNA-Protein | regulation | An enhancement of SP1-mediated transcription in the presence of BALR-6. | 26694754 | |||
EL0227 | BANCR | p21 | RNA-DNA | regulation | our findings suggest that down-regulation of BANCR contributes to the proliferation of colorectal cancer cells, at least in part, through the regulation of p21 protein. | 25928067 | |||
EL0227 | BANCR | BRAF | RNA-DNA | regulation | little is known about the clinical significance of BRAF-activated non-coding RNA (BANCR) in gastric cancer. | 26054683 | |||
EL0227 | BANCR | NF-κB1 | RNA-TF | regulation | Down-regulation of BANCR contributed to a significant decrease of NF-κB1 (P50/105) expression and 3'UTR of NF-κB1 activity. Overexpression of NF-κB1 reversed the effect of BANCR on cancer cell growth and apoptosis. | 26248136 | |||
EL0227 | BANCR | MiroRNA-9 (miR-9) | RNA-RNA | regulation | MiroRNA-9 (miR-9) targeted NF-κB1, and miR-9 inhibitor also reversed the effects of BANCR on gastric cancer cell growth and apoptosis. | 26248136 | |||
EL0227 | BANCR | Ets-1 | DNA-Protein | regulation | Ets-1 negatively regulated BANCR expression via the deacetylation of histones H3 within BANCR promoter. | 26296467 | |||
EL0227 | BANCR | zeste homolog 2 (EZH2) | RNA-Protein | regulation | BANCR was enriched by polycomb enhancer of zeste homolog 2 (EZH2), and silencing BANCR led to decreased chromatin recruitment of EZH2, which resulted significantly reduced expression of TSHR. | 26323637 | |||
EL0227 | BANCR | cyclin D1 | RNA-Protein | regulation | BANCR-knockdown also led to inhibition of cell growth and cell cycle arrest at G0/G1 phase through down-regulation of cyclin D1. | 26323637 | |||
EL0227 | BANCR | thyroid stimulating hormone receptor (TSHR) | RNA-Protein | regulation | BANCR-knockdown in a PTC-derived cell line (IHH-4) resulted in significant suppression of thyroid stimulating hormone receptor (TSHR). | 26323637 | |||
EL0234 | Bc1 | PABP | RNA-Protein | binding | Competition experiments using variants of bc1 and bc200 rnas demonstrated that the central adenosine-rich region of both rnas mediates binding to pabp. | 12162957 | |||
EL0234 | Bc1 | eIF4A | RNA-DNA | regulation | A specific interaction of bc1 rna with eif4a, an rna unwinding factor, and with poly(a)-binding protein. | 12451124 | |||
EL0234 | Bc1 | PABP | RNA-Protein | binding | In vivo, all bc1 rna appears to be complexed with pabp. nevertheless, in the micro-environment of dendritic spines of neuronal cells, bc1 rnps or bc200 rnps might mediate regulatory functions by differential interactions with locally limited pabp and/or directly or indirectly, with other translation initiation factors. | 16154588 | |||
EL0234 | Bc1 | eukaryotic initiation factor 4A and poly(A) binding protein, the fragile X mental retardation protein | RNA-Protein | binding | Interactions of this domain with eukaryotic initiation factor 4A and poly(A) binding protein mediate repression;BC1 RNA modulates translation-dependent processes in neurons and germs cells by directly interacting with translation initiation factors. | 16330711 | |||
EL0237 | BCYRN1 | PABP | RNA-Protein | binding | Competition experiments using variants of bc1 and bc200 rnas demonstrated that the central adenosine-rich region of both rnas mediates binding to pabp. | 12162957 | |||
EL0237 | BCYRN1 | PABP | RNA-Protein | binding | In vivo, all bc1 rna appears to be complexed with pabp. nevertheless, in the micro-environment of dendritic spines of neuronal cells, bc1 rnps or bc200 rnps might mediate regulatory functions by differential interactions with locally limited pabp and/or directly or indirectly, with other translation initiation factors. | 16154588 | |||
EL0237 | BCYRN1 | SRP9/14 heterodimer | RNA-Protein | binding | Inhibits translation. Binds PABP, SRP9/14 heterodimer and eIF4A. | 17175535 | LncRNADisease | ||
EL0237 | BCYRN1 | G22 | RNA-Protein | co-expression | when all upstream regions of the G22 gene were removed, expression was completely abolished, despite the presence of intact internal RNA polymerase III promoter elements | 17175535 | |||
EL0237 | BCYRN1 | eIF4A | RNA-Protein | binding | Inhibits translation. Binds PABP, SRP9/14 heterodimer and eIF4A. | 18316401 | LncRNADisease | ||
EL0237 | BCYRN1 | c-MYC | DNA-Protein | binding | ChIP assay confirmed the binding of c-MYC to the promoter region of BCYRN1 gene. | 25866480 | |||
EL0237 | BCYRN1 | the quadruplex-containing telomerase RNA | RNA-RNA | regulation | An interaction between BC200 and the quadruplex-containing telomerase RNA was confirmed by pull-down assays of the endogenous RNAs. | 26740632 | |||
EL0237 | BCYRN1 | RHAU | RNA-Protein | binding | RHAU binds to an adenosine-rich region near the 3'-end of the RNA. RHAU truncations support binding that is dependent upon a region within the C terminus and is specific to RHAU isoform 1. | 26740632 | |||
EL0237 | BCYRN1 | PABP | RNA-Protein | binding | Inhibits translation. Binds PABP, SRP9/14 heterodimer and eIF4A. | 7684772 | LncRNADisease | ||
EL0237 | BCYRN1 | SRP9 | RNA-Protein | binding | A protein that binds bc200 rna in vivo is immunoreactive with antibodies against srp9. | 9605471 | |||
EL0238 | BCYRN1P2 | FMR1 | RNA-Protein | binding | The neural phenotype of BC1 (BCYRN1P2) is consistent with its known interaction with both FMRP, the product of the fragile X mental retardation gene (FMR1), and with mRNAs regulated by FMRP. | 19239885 | LncRNADisease | ||
EL0239 | BDNF-AS | BDNF | RNA-RNA | binding | BDNF and antiBDNF transcripts form dsRNA duplexes in the brain in vivo, suggesting an important role for antiBDNF in regulating BDNF expression in human. | 17629449 | LncRNADisease | ||
EL0239 | BDNF-AS | BDNF | RNA-RNA | binding | Human BDNF mRNA and BDNFOS (Opposite Strand) lncRNA form in-vivo RNA–RNA duplexes in brain, suggesting the possibility of post-transcriptional cis-regulation, by BDNFOS, of BDNF. | 20951849 | LncRNADisease | ||
EL0246 | BOK-AS1 | WISP1 | RNA-DNA | regulation | LncRNA BOKAS was up-regulated following radiation and promoted WISP1 expression and resultant radioresistance. | 25749038 | |||
EL0247 | Borg | Bone morphogenetic proteins (BMPs) | DNA-Protein | regulation | Borg is a common target gene of bmps | 9642273 | |||
EL0249 | BRCA1 | BRCA1 | RNA-DNA | regulation | In line with a role in regulating HR, DDSR1 interacts with BRCA1 and hnRNPUL1, an RNA-binding protein involved in DNA end resection. | 26411689 | |||
EL0249 | BRCA1 | hnRNPUL1 | RNA-Protein | regulation | In line with a role in regulating HR, DDSR1 interacts with BRCA1 and hnRNPUL1, an RNA-binding protein involved in DNA end resection. | 26411689 | |||
EL0251 | BX647187 | Hec1 | RNA-Protein | regulation | LncRNA BX647187 was positively regulated by Hec1. | 26612002 | |||
EL0253 | bxd | Ubx | RNA-RNA | co-expression | Ubx and several bxd ncRNAs are expressed in nonoverlapping patterns in both embryos and imaginal discs, suggesting that transcription of these ncRNAs is associated with repression, not activation, of Ubx. | 17174895 | LncRNADisease | ||
EL0253 | bxd | Ubx | DNA-DNA | regulation | bxd contains enhancer elements for the nearby Ubx gene. | 19191220 | LncRNADisease | ||
EL0256 | C1orf74 | Notch 1 | RNA-DNA | regulation | Notch 1 can promote the lncRNA AK022798 expression and result in the formation of SGC7901/DDP and BGC823/DDP cells. | 25763542 | |||
EL0257 | C1QTNF9B-AS1 | SET | RNA-Protein | regulation | PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. | 15930275 | LncRNADisease | ||
EL0261 | C5T1lncRNA | C5 | RNA-RNA | co-expression | C5T1lncRNA is expressed predominantly in the nucleus and its expression correlates positively with C5 mRNA in various tissues (P=0.001) and in peripheral blood mononuclear cells (P=0.02) indicating transcriptional co-regulation. Knockdown results in a concurrent decrease in C5 mRNA levels but not of other neighbouring genes. lncRNA C5T1lncRNA is fully located in the associated region and influences transcript levels of C5, a gene previously linked to RA pathogenesis. | 26673966 | |||
EL0262 | C730029A08Rik | EBF2 | RNA-TF | binding | Blnc1 forms a ribonucleoprotein complex with transcription factor EBF2 to stimulate the thermogenic gene program. Further, Blnc1 itself is a target of EBF2, thereby forming a feedforward regulatory loop to drive adipogenesis toward thermogenic phenotype. | 25002143 | |||
EL0263 | C730036E19Rik | TDP-43 | RNA-Protein | binding | LncLSTR forms a molecular complex with TDP-43 to regulate expression of Cyp8b1, a key enzyme in the bile acid synthesis pathway, and engenders an in vivo bile pool that induces apoC2 expression through FXR. | 25738460 | |||
EL0265 | CADM1 | CADM1 mRNA | RNA-RNA | co-expression | CADM1-AS1 expression was positively associated with CADM1 mRNA expression in 786-O cells and ACHN cells. | 25031695 | |||
EL0265 | CADM1 | TSLC1 | RNA-RNA | regulation | A novel lncRNA, TSLC1-AS1, is the antisense transcript of tumor suppressor TSLC1. | 25031725 | |||
EL0269 | CAR Intergenic 10 | ADAM12 | RNA-DNA | regulation | Regulates gene expression of FANK1 and ADAM12 flanking genes through modulating the chromatin structure in cis. | 20404130 | LncRNADisease | ||
EL0269 | CAR Intergenic 10 | FANK1 | RNA-DNA | regulation | Regulates gene expression of FANK1 and ADAM12 flanking genes through modulating the chromatin structure in cis. | 20404130 | LncRNADisease | ||
EL0272 | CASC2 | miR-21 | RNA-RNA | binding | Furthermore,bioinformatics, luciferase reporter assays and pull-down assay confirmed that miR-21 binds to CASC2 in a sequence-specific manner. | 25446261 | |||
EL0274 | CBR3-AS1 | AR | RNA-Protein | regulation | The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. | 22264502 | LncRNADisease | ||
EL0275 | CCAL | AP-2α | RNA-Protein | regulation | CCAL promoted CRC progression by targeting activator protein 2α (AP-2α), which in turn activated Wnt/β-catenin pathway. | 25994219 | |||
EL0276 | CCAT1 | miRNA-218-5p | RNA-RNA | binding | these results suggest that CCAT1 is a driver of malignancy, which acts in part through 'spongeing' miRNA-218-5p. | 25569100 | |||
EL0276 | CCAT1 | E-cadherin and N-cadherin | RNA-Protein | co-expression | The expression of IncRNA-CCAT1 in tumor tissue was significantly higher than that in normal para-carcinoma tissue (P < 0.001), and the expression level of CCAT1was significantly correlated with local infiltration depth (P < 0.001), tumor staging (P < 0.001), vascular invasion (P < 0.001) and CA19-9 level (P < 0.001); but not related with age, gender, location of tumor, tumor differentiation level, size of primary lesion and level of CEA (P > 0.05). The expression of E-cadherin in tumor tissues was significantly lower than in normal para-carcinoma tissues (P < 0.001), and the expression of N-cadherin was significantly higher than that in normal para-carcinoma tissues. The decrease in expression of E-cadherin and increase in expression of N-cadherin were significantly correlated with local infiltration depth (P < 0.001), tumor staging (P < 0.001), vascular invasion (P < 0.001), tumor differentiation level (P < 0.001) and CA19-9 level (P < 0.001), however not related with age, gender, tumor location, size of primary lesion and CEA level (P > 0.05). CONCLUSION: CCAT1 plays an important role in the genesis, development, invasion and metastasis; it mediates the EMT process of colorectal cancer; and it's expected to be a new marker and treatment target in colorectal diagnosis and treatment. | 26064266 | |||
EL0276 | CCAT1 | miR-490 | RNA-RNA | binding | CCAT1 regulates miR-490 in gastric cancer (GC) cells. miR-490 can also repress CCAT1 expression. CCAT1 contains a putative miR-490-binding site, and deletion of this binding site abolishes their miR-490 responsiveness. | 26825578 | |||
EL0278 | CCAT2 | c-Myc | DNA-TF | binding | c-Myc could promote CCAT1 transcription by directly binding to its promoter region | 25185650 | |||
EL0278 | CCAT2 | Wnt signaling pathway | N/A | regulation | The abnormal expression of CCAT2 could influence the Wnt signaling pathway. | 26442763 | |||
EL0282 | CCDC26 | KIT | RNA-DNA | regulation | We suggest that CCDC26 controls growth of myeloid leukemia cells through regulation of KIT expression. A KIT inhibitor might be an effective treatment against the forms of AML in which CCDC26 is altered. | 25928165 | |||
EL0283 | CCEPR | PCNA | RNA-DNA | regulation | RNA pull-down assays confirmed that CCHE1 physically associates with proliferating cell nuclear antigen (PCNA) messenger RNA, consequently enhances the expression of PCNA. The expression of CCHE1 and PCNA is significantly correlated in cervical cancer tissues. | 25921283 | |||
EL0287 | CD99P1 | miR-21, miR-31, miR-101, miR-29, miR-199, and let-7d | RNA-RNA | binding | The sequences of the dysregulated microRNAs in IPF including miR-21, miR-31, miR-101, miR-29, miR-199, and let-7d were used to search NONCODE database containing 33,829 human lncRNAs. A total of 34 lncRNAs with potential binding sites to these microRNAs were identified. Four of them were inversely correlated to the microRNA expression in IPF. | 26269497 | |||
EL0288 | Cdc28 lncRNA | Hog1 and RSC | RNA-Protein | regulation | Cdc28 lncRNA mediates the establishment of gene looping and the relocalization of Hog1 and RSC from the 3' UTR to the +1 nucleosome to induce CDC28 expression. | 24508389 | |||
EL0289 | CDKN2B-AS1 | ARF | RNA-DNA | regulation | Binding to RNA contributes to CBX7 function and disruption of either interaction impacts the ability of CBX7 to repress the INK4b/ARF/INK4a locus and control senescence. | 20541999 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | INK4a | RNA-DNA | regulation | Binding to RNA contributes to CBX7 function and disruption of either interaction impacts the ability of CBX7 to repress the INK4b/ARF/INK4a locus and control senescence. | 20541999 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | INK4b | RNA-DNA | regulation | Binding to RNA contributes to CBX7 function and disruption of either interaction impacts the ability of CBX7 to repress the INK4b/ARF/INK4a locus and control senescence. | 20541999 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | CBX7 | RNA-Protein | binding | Chromobox 7 (CBX7) within the polycomb repressive complex 1 (PRC1) binds to ANRIL. | 20541999 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | CBX7 | RNA-Protein | binding | Here we report that chromobox 7 (CBX7) within the polycomb repressive complex 1 binds to ANRIL, and both CBX7 and ANRIL are found at elevated levels in prostate cancer tissues. | 20541999 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC1 | RNA-Protein | binding | Recruits Polycomb Repressor Complex 1 (PRC1) to epigenetically silence INK4b/ARF/INK4a tumour suppressor locus. | 20541999 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | E2F1 | DNA-TF | regulation | ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. | 20664976 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | CBX7 | RNA-Protein | binding | Chromobox 7 (CBX7) within the polycomb repressive complex 1 (PRC1) has been shown to bind to ANRIL | 20956613 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | p15 | RNA-DNA | regulation | RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15(INK4B) locus. | 21151178 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC2 | RNA-Protein | binding | RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15(INK4B) locus. | 21151178 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | SUZ12 | RNA-Protein | binding | RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15(INK4B) locus. | 21151178 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC1 | RNA-Protein | binding | Although lncRNA-mediated regulation of INK4b-ARF-INK4a gene is not restricted to ANRIL, both polycomb repressive complex-1 (PRC1) and -2 (PRC2) interact with ANRIL to form heterochromatin surrounding the INK4b-ARF-INK4a locus, leading to its repression. | 21828241 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC2 | RNA-Protein | binding | Although lncRNA-mediated regulation of INK4b-ARF-INK4a gene is not restricted to ANRIL, both polycomb repressive complex-1 (PRC1) and -2 (PRC2) interact with ANRIL to form heterochromatin surrounding the INK4b-ARF-INK4a locus, leading to its repression. | 21828241 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC1 | RNA-Protein | binding | Both polycomb repressive complex-1 (PRC1) and -2 (PRC2) interact with ANRIL to form heterochromatin surrounding the INK4b-ARF-INK4a locus, leading to its repression. | 21828241 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC2 | RNA-Protein | binding | Both polycomb repressive complex-1 (PRC1) and -2 (PRC2) interact with ANRIL to form heterochromatin surrounding the INK4b-ARF-INK4a locus, leading to its repression. | 21828241 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PcG | RNA-Protein | binding | PcG repress the expression of INK4b-ARF-INK4a locus by directly binding to the long noncoding RNA (lncRNA) transcript antisense noncoding RNA in the INK4 locus (ANRIL). | 21828241 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PcG | RNA-Protein | binding | The important role of PcG in mediating repression of the INK4b-ARF-INK4a locus, by directly binding to the long noncoding RNA (lncRNA) transcript antisense noncoding RNA in the INK4 locus (ANRIL), was recently shown. | 21828241 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC1 | RNA-Protein | binding | ANRIL (i.e.antisense ncRNA in INK4 locus) has also been linked to transcriptional repression via interaction with both PRC1 and PRC2. | 21831473 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC2 | RNA-Protein | binding | ANRIL (i.e.antisense ncRNA in INK4 locus) has also been linked to transcriptional repression via interaction with both PRC1 and PRC2. | 21831473 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | CBX7 | RNA-Protein | binding | ANRIL was also found to coimmunoprecipitate with CBX7, which is component of the polycomb repressive complex 1 (PRC1). | 21874119 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | Suz12 | RNA-Protein | binding | ANRIL was found to co-immunoprecipitate with Suz12, which is component of PRC2. | 21874119 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | p15INK4B | RNA-RNA | co-expression | full-length ANRIL was shown to repress p15INK4B expression. Induction of p15INK4B and p16INK4A by oncogenic Ras was found to repress ANRIL expression. | 21874119 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | p16INK4A | RNA-RNA | co-expression | induction of p15INK4B and p16INK4A by oncogenic Ras was found to repress ANRIL expression. | 21874119 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC1 | RNA-Protein | binding | Work over the past few years has demonstrated a direct interaction between ANRIL and components from both PRC1 and PRC2 complexes. Binding to ANRIL contributes to the functions of both PRC1 and PRC2 proteins, and disruption of either interaction impacts transcriptional repression of the target INK4b locus. | 21925379 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | PRC2 | RNA-Protein | binding | Work over the past few years has demonstrated a direct interaction between ANRIL and components from both PRC1 and PRC2 complexes. Binding to ANRIL contributes to the functions of both PRC1 and PRC2 proteins, and disruption of either interaction impacts transcriptional repression of the target INK4b locus. | 21925379 | LncRNADisease | ||
EL0289 | CDKN2B-AS1 | Cisplatin and paclitaxel | N/A | regulation | Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | |||
EL0289 | CDKN2B-AS1 | KLF2 and P21 | RNA-DNA | regulation | we uncover that ANRIL could not repress p15 expression in PC9 cells, but through silencing of KLF2 and P21 transcription. | 25504755 | |||
EL0289 | CDKN2B-AS1 | MET and MMP3 | RNA-DNA | regulation | we found that MET and MMP3 are key downstream genes of ANRIL involved in SOC cell migration/invasion. | 25845387 | |||
EL0289 | CDKN2B-AS1 | KLF2 | RNA-DNA | binding | We also found that ANRIL could epigenetically repress Kruppel-like factor 2 (KLF2) transcription in HCC cells by binding with PRC2 and recruiting it to the KLF2 promoter region. | 25966845 | |||
EL0289 | CDKN2B-AS1 | p15 | RNA-DNA | regulation | Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. | 26408699 | |||
EL0289 | CDKN2B-AS1 | Bcl-2, Bax, cytoplasmic cytochrome c and Smac and cleaved caspase-9, caspase-3 and PARP | RNA-Protein | regulation | Knockdown of ANRIL repressed cell proliferation and increased cell apoptosis, along with decreased expression of Bcl-2 and increased expressions of Bax, cytoplasmic cytochrome c and Smac and cleaved caspase-9, caspase-3 and PARP. | 26449463 | |||
EL0289 | CDKN2B-AS1 | p15/CDKN2Bp16/CDKN2A-p14/ARF | RNA-Protein | regulation | These data demonstrate a complex pattern of interactions between lncRNA ANRIL, several miRNAs, PRC2/PRC1 subunits, and p15/CDKN2B-p16/CDKN2A-p14/ARF locus and suggest that their expression should be considered together to evaluate antitumoral drugs, in particular the BET bromodomain inhibitors. | 27102007 | |||
EL0289 | CDKN2B-AS1 | MDR1 and MRP1 | RNA-Protein | co-expression | The expression of ANRIL positively correlated with the expression of MDR1 and MRP1, resprectively | 27121324 | |||
EL0290 | CDR1-AS | miR-7 | RNA-RNA | co-expression | ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner. Although the circRNA is completely resistant to miRNA-mediated target destabilization, it strongly suppresses miR-7 activity, resulting in increased levels of miR-7 targets. In the mouse brain, we observe overlapping co-expression of ciRS-7 and miR-7, particularly in neocortical and hippocampal neurons, suggesting a high degree of endogenous interaction. | 23446346 | |||
EL0293 | ceruloplasmin | STAT1 and RNA polymerase II | RNA-Protein | binding | We identified NRCP as an intermediate binding partner between STAT1 and RNA polymerase II, leading to increased expression of downstream target genes such as glucose-6-phosphate isomerase. | 26686630 | |||
EL0297 | cis-NATPHO1;2 | PHO1;2 | RNA-RNA | regulation | An unexpected role for cis-NATPHO1;2 in promoting PHO1;2 translation and affecting phosphate homeostasis and plant fitness | 24096344 | PLNlncRbase | ||
EL0299 | COLDAIR | PRC2 | RNA-Protein | binding | COLDAIR physically associates with a component of PRC2 and targets PRC2 to FLC. | 21127216 | PLNlncRbase | ||
EL0300 | COOLAIR | AtNDX | DNA-Protein | binding | AtNDX associates with single-stranded DNA rather than double-stranded DNA non-sequence-specifically in vitro, and localizes to a heterochromatic region in the COOLAIR promoter in vivo. Single-stranded DNA was detected in vivo as part of an RNA-DNA hybrid, or R-loop, that covers the COOLAIR promoter. R-loop stabilization mediated by AtNDX inhibits COOLAIR transcription, which in turn modifies FLC expression. | 23641115 | |||
EL0300 | COOLAIR | FLOWERING LOCUS C (FLC) | RNA-DNA | regulation | Alternative polyadenylation of COOLAIR transcripts correlates with different FLC sense expression states. | 24799695 | |||
EL0300 | COOLAIR | cyclin-dependent kinase C (CDKC;2) | RNA-Protein | regulation | In the endogenous gene context, however, the reduction of COOLAIR transcription by cdkc;2 disrupts a COOLAIR-mediated repression mechanism that increases FLC expression. This disruption then feeds back to indirectly increase COOLAIR expression. | 24799695 | |||
EL0301 | CPS1-IT1 | CPS1 | RNA-Protein | co-expression | CPS1 and CPS1‑IT1 were co‑upregulated in ICC tissues compared with non‑cancerous tissues. | 26499888 | |||
EL0304 | CRG | CASK | RNA-DNA | regulation | CRG was required for the recruitment of RNA polymerase II to the CASK promoter regions , which in turn enhanced CASK expression. | 23074190 | |||
EL0306 | Crxos | Crx | RNA-DNA | regulation | We overexpressed another nat, crxos, in mouse adult retina using adeno-associated viral vectors and we observed a significant decrease in the expression levels of the corresponding sense gene, crx. | 15703187 | |||
EL0309 | CTB-89H12.4 | PTEN | RNA-DNA | regulation | The tumour-suppressive function of two lncRNAs (TUG1 and CTB-89H12.4) and their regulation of PTEN expression in prostate cancer. | 26975529 | |||
EL0310 | CTBP1-AS | PSF | RNA-Protein | binding | Binding of mouse VL30 (A130040M12Rik) retrotransposon RNA to PSF protein induces genes repressed by PSF: effects on steroidogenesis and oncogenesis. | 23644382 | |||
EL0311 | CTD-3080P12.3 | miR-1207-5p | RNA-RNA | binding | BC032469 could directly bind to miR-1207-5p and effectively functioned as a sponge for miR-1207-5p to modulate the derepression of hTERT. | 26549025 | |||
EL0319 | CX3CL1 | interferon-gamma receptor gene (IFN-gamma R) | DNA-DNA | co-expression | Their proximity and shared expression pattern suggest a possible functional relationship. | 9027504 | |||
EL0321 | CYP4A22-AS1 | TAL1 | RNA-RNA | co-expression | Depletion of ncRNA-a3 resulted in a specific and potent reduction of TAL1 expression. | 20887892 | LncRNADisease | ||
EL0321 | CYP4A22-AS1 | CYP4A11 | RNA-RNA | co-expression | When ncRNA-a3 was depleted, a significant reduction in CYP4A11 gene on the opposite strand of the DNA was detected. | 20887892 | LncRNADisease | ||
EL0321 | CYP4A22-AS1 | ROCK2 | RNA-RNA | regulation | KLHL12, ROCK2, TAL1, CMPK1, Snai2, and Snai1 are regulated by ncRNA-a2 through ncRNA-a7, respectively. | 21502407 | LncRNADisease | ||
EL0325 | CYTOR | EGFR | RNA-Protein | binding | Linc00152 could directly bind with EGFR which caused an activation of PI3K/AKT signaling. | 26538117 | |||
EL0325 | CYTOR | EpCAM | RNA-DNA | binding | LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-λN/BoxB reporter system. | 26540343 | |||
EL0326 | Dab2 | Dab2 | RNA-RNA | co-expression | The expression profiles of Dab2 and the intronic ncRNA were correlated (R2 = 0.77), suggesting some relationship in their function and/or regulation. | 18562676 | LncRNADisease | ||
EL0327 | DACOR1 | Cystathionine β-synthase | RNA-Protein | regulation | DACOR1 induction resulted in down-regulation of Cystathionine β-synthase, which is known to lead to increased levels of S-adenosyl methionine-the key methyl donor for DNA methylation. | 26307088 | |||
EL0328 | Dalir | DNMT1 DNA methyltransferase i | RNA-Protein | binding | Dali interacts with the DNMT1 DNA methyltransferase in mouse and human and regulates DNA methylation status of CpG island-associated promoters in trans. | 25415054 | |||
EL0329 | DANCR | CTNNB1 | RNA-DNA | regulation | Association of DANCR with CTNNB1 blocked the repressing effect of microRNA (miR)-214, miR-320a, and miR-199a on CTNNB1. | 25964079 | |||
EL0329 | DANCR | Sox4 | DNA-Protein | binding | Sox4 could directly bind to the promoter of long noncoding RNA DANCR and increased its expression. Knockdown of DANCR could reverse the stimulative effect of Sox4 on the proliferation and chondrogenesis of SMSCs. | 26514989 | |||
EL0329 | DANCR | DSPP and DMP-1, p-GSK-3β and β-catenin | RNA-Protein | regulation | lncRNA DANCR overexpression blocked mineralized nodule formation and the expression of DSPP and DMP-1 in hDPCs after 14 days of odontogenic induction. Importantly, the upregulation of DANCR significantly decreased the expression levels of p-GSK-3β and β-catenin expression indicating that lncRNA DANCR can inhibit the activation of the Wnt/β-catenin signal pathway during the odontoblast-like differentiation of hDPCs. | 26646542 | |||
EL0332 | DBET | Ash1L | RNA-Protein | regulation | DBE-T recruits the Trithorax group protein Ash1L to the FSHD locus, driving histone H3 lysine 36 dimethylation, chromatin remodeling, and 4q35 gene transcription. | 22541069 | |||
EL0333 | DBH-AS1 | hepatitis B virus x protein (HBx) | RNA-Protein | regulation | DBH-AS1 could be significantly induced by HBx protein and markedly down-regulated by p53. | 26393879 | |||
EL0333 | DBH-AS1 | p53 | RNA-Protein | regulation | DBH-AS1 could be significantly induced by HBx protein and markedly down-regulated by p53. | 26393879 | |||
EL0333 | DBH-AS1 | MAPK signaling | N/A | regulation | DBH-AS1 was shown to activate MAPK pathway. | 26393879 | |||
EL0333 | DBH-AS1 | CDK6, CCND1, CCNE1 | RNA-Protein | regulation | Overexpression of DBH-AS1 induced cell cycle progression by accelerating G1/S and G2/M transition concomitantly with upregulation of CDK6, CCND1, CCNE1 and downregulation of p16, p21 and p27. | 26393879 | |||
EL0333 | DBH-AS1 | p16, p21 and p27 | RNA-Protein | regulation | Overexpression of DBH-AS1 induced cell cycle progression by accelerating G1/S and G2/M transition concomitantly with upregulation of CDK6, CCND1, CCNE1 and downregulation of p16, p21 and p27. | 26393879 | |||
EL0336 | DGCR5 | REST | DNA-TF | regulation | The DiGeorge syndrome-associated noncoding RNA, DGCR5, is repressed by REST through a proximal upstream binding site. | 19050060 | LncRNADisease | ||
EL0337 | DHFR upstream transcripts | DHFR | RNA-DNA | regulation | Regulates DHFR expression by forming a of triple helix with the DHFR major promoter and interacting with TFIIB. | 21256239 | LncRNADisease | ||
EL0337 | DHFR upstream transcripts | TFIIB | RNA-Protein | binding | Regulates DHFR expression by forming a of triple helix with the DHFR major promoter and interacting with TFIIB. | 21256239 | LncRNADisease | ||
EL0338 | DHRS4-AS1 | H3K9- and H3K27-specific histone methyltransferases G9a and EZH2 | RNA-DNA | regulation | AS1DHRS4 interacts physically in trans with the epigenetic modifiers H3K9- and H3K27-specific histone methyltransferases G9a and EZH2 | 22891334 | |||
EL0343 | DLEU1 | ESR1 | RNA-Protein | co-expression | A statistical analysis revealed that there was a co-expression relationship between ESR1 and lncRNA-DLEU1. | 26416600 | |||
EL0343 | DLEU1 | MiR-19a | RNA-RNA | co-expression | MiR-19a might be co-expressed with lncRNA-DLEU1 to co-regulate the expression of ESR1, which influences the occurrence and development of breast cancer cells with different levels of ER expression. | 26416600 | |||
EL0344 | DLEU2 | trichostatin A (TSA) | RNA-Protein | regulation | TSA and SB increase the expression of Dleu2, miR-15a, and miR-16-1 in lung cancer cells. | 23867991 | |||
EL0344 | DLEU2 | BSAP | DNA-Protein | regulation | transcription factor BSAP (B-cell-specific activator protein) directly interacts with Dleu2, the host gene containing the miR-15a/16-1 loci, and by negative regulation of the Dleu2 promoter, results in repression of miR-15a/16-1 expression. BSAP directly interacts with the Dleu2 promoter. | 23995789 | |||
EL0345 | Dleu2 | Trim13 | RNA-RNA | co-expression | A study found that Dleu2, a previously described ncRNA overlapping but transcribed in the opposite direction of the Trim13 (RFP2/LEU5) gene whose expression is upregulated during early OL maturation and terminal differentiation. | 20137068 | LncRNADisease | ||
EL0347 | Dlx1as | Dlx | RNA-RNA | co-expression | Evf2, Dlx1as, and Dlx4as exhibit similar expression profiles to the associated Dlx genes. | 18562676 | LncRNADisease | ||
EL0347 | Dlx1as | Dlx1 | RNA-RNA | regulation | The reciprocal relationship between Dlx1as and Dlx1 places this sense-antisense pair into a growing class of mammalian lncRNA-mRNA pairs characterized by inverse regulation. | 23415800 | |||
EL0348 | Dlx4os | Dlx | RNA-RNA | co-expression | Evf2, Dlx1as, and Dlx4as exhibit similar expression profiles to the associated Dlx genes. | 18562676 | LncRNADisease | ||
EL0349 | DLX6-AS1 | Dlx-2 | RNA-Protein | regulation | Evf-2 specifically cooperates with Dlx-2 to increase the transcriptional activity of the Dlx-5/6 enhancer in a target and homeodomain-specific manner. A stable complex containing the Evf-2 ncRNA and the Dlx-2 protein forms in vivo, suggesting that the Evf-2 ncRNA activates transcriptional activity by directly influencing Dlx-2 activity. These experiments identify a novel mechanism whereby transcription is controlled by the cooperative actions of an ncRNA and a homeodomain protein. | 16705037 | |||
EL0349 | DLX6-AS1 | Dlx-5 | DNA-DNA | regulation | Evf2 is a long, polyadenylated ncRNA transcribed from an ultraconserved intergenic enhancer region associated with the Dlx-5/6 locus. | 20573714 | LncRNADisease | ||
EL0349 | DLX6-AS1 | Dlx-6 | DNA-DNA | regulation | Evf2 is a long, polyadenylated ncRNA transcribed from an ultraconserved intergenic enhancer region associated with the Dlx-5/6 locus. | 20573714 | LncRNADisease | ||
EL0350 | Dlx6os1 | DLX5 | RNA-DNA | regulation | DLX6-AS1 specifically cooperates with Dlx-2 to increase the transcriptional activity of the Dlx-5/6 enhancer in a target and homeodomain-specific manner. | 16705037 | LncRNADisease | ||
EL0350 | Dlx6os1 | DLX6 | RNA-DNA | regulation | DLX6-AS1 specifically cooperates with Dlx-2 to increase the transcriptional activity of the Dlx-5/6 enhancer in a target and homeodomain-specific manner. | 16705037 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx6 | RNA-DNA | regulation | Evf2 interacts in trans with the homeobox transcription factor Dlx2 to regulate the expression of the Dlx6 gene that it encompasses. | 18184812 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx2 | RNA-Protein | binding | Evf2 interacts in trans with the homeobox transcription factor Dlx2 to regulate the expression of the Dlx6 gene that it encompasses. | 18184812 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx6 | RNA-DNA | regulation | Evf2 interacts in trans with the homeobox transcription factor Dlx2 to regulate the expression of the Dlx6 gene that it encompasses. Consistent with this function, Evf exhibits a coincident expression profile with Dlx2. | 18184812 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx2 | RNA-Protein | binding | Evf2 interacts in trans with the homeobox transcription factor Dlx2 to regulate the expression of the Dlx6 gene that it encompasses. Consistent with this function, Evf exhibits a coincident expression profile with Dlx2. | 18184812 | LncRNADisease | ||
EL0350 | Dlx6os1 | DLX2 | DNA-TF | regulation | Evf2 regulates the binding of the DLX2 transcription factor to its originating enhancer element, which in turn regulates the transcriptional activity of the enhancer. | 18562676 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx2 | RNA-Protein | binding | Single-stranded Evf2 forms a complex with the product of a third homeodomain gene Dlx2 whose sequence lies elsewhere in the mouse genome. | 19239885 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx2 | RNA-Protein | binding | The 3.8-kb Evf-2 ncRNA, which is transcribed from an ultraconserved region, forms a complex with the homeodomain-containing protein Dlx2. | 19571179 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx6 | RNA-DNA | regulation | Evf-2 was previously shown to regulate binding of the Dlx2 transcription factor to the ultraconserved enhancer to activate the expression of the encompassed Dlx6 gene during neurogenesis. | 20137068 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx2 | RNA-Protein | binding | Evf-2 was previously shown to regulate binding of the Dlx2 transcription factor to the ultraconserved enhancer to activate the expression of the encompassed Dlx6 gene during neurogenesis. | 20137068 | LncRNADisease | ||
EL0350 | Dlx6os1 | DLX | DNA-TF | regulation | the lincRNA Evf2 is transcribed from an ultraconserved distal enhancer that recruits positive (i.e., DLX) and negative (i.e., MECP2) transcription factors to the enhancer to modulate the expression of adjacent protein-coding genes | 20380817 | LncRNADisease | ||
EL0350 | Dlx6os1 | MECP2 | DNA-TF | regulation | the lincRNA Evf2 is transcribed from an ultraconserved distal enhancer that recruits positive (i.e., DLX) and negative (i.e., MECP2) transcription factors to the enhancer to modulate the expression of adjacent protein-coding genes | 20380817 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-5 | RNA-DNA | regulation | Evf2 forms a complex with Dlx-2 and recruits Dlx-2 to induce the enhancer activities of ei and eii, resulting in induced expression of both Dlx-5 and -6. | 20573714 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-6 | RNA-DNA | regulation | Evf2 forms a complex with Dlx-2 and recruits Dlx-2 to induce the enhancer activities of ei and eii, resulting in induced expression of both Dlx-5 and -6. | 20573714 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-2 | RNA-Protein | binding | Evf2 forms a complex with Dlx-2 and recruits Dlx-2 to induce the enhancer activities of ei and eii, resulting in induced expression of both Dlx-5 and -6. | 20573714 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-5 | RNA-Protein | regulation | The lncRNA Evf-2 is a putative direct positive regulator of the transcription factor Dlx-2, and is consequently an indirect positive regulator of Dlx-5 and Dlx-6. | 20951849 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-6 | RNA-Protein | regulation | The lncRNA Evf-2 is a putative direct positive regulator of the transcription factor Dlx-2, and is consequently an indirect positive regulator of Dlx-5 and Dlx-6. | 20951849 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-2 | RNA-Protein | regulation | The lncRNA Evf-2 is a putative direct positive regulator of the transcription factor Dlx-2. | 20951849 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-5/6 enhancer | RNA-DNA | regulation | Cooperates with Dlx-2 in vivo to increase the transcriptional activity of the Dlx-5/6 enhancer. | 21256239 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx-5/6 enhancer | RNA-DNA | regulation | Cooperates with Dlx-2 in vivo to increase the transcriptional activity of the Dlx-5/6 enhancer. | 21256239 | LncRNADisease | ||
EL0350 | Dlx6os1 | Dlx6 | RNA-DNA | regulation | Evf-2 modulates transcription of Dlx6 by recruiting DLX2 and MECP2 to the ultraconserved ei enhancer element that is also transcribed as part of Evf-2 itself. | 21936910 | LncRNADisease | ||
EL0350 | Dlx6os1 | DLX2 | RNA-Protein | binding | Evf-2 modulates transcription of Dlx6 by recruiting DLX2 and MECP2 to the ultraconserved ei enhancer element that is also transcribed as part of Evf-2 itself. | 21936910 | LncRNADisease | ||
EL0350 | Dlx6os1 | MECP2 | RNA-Protein | binding | Evf-2 modulates transcription of Dlx6 by recruiting DLX2 and MECP2 to the ultraconserved ei enhancer element that is also transcribed as part of Evf-2 itself. | 21936910 | LncRNADisease | ||
EL0352 | Dmrt2 | TERT | RNA-Protein | binding | TERRA also contacts the telomerase reverse transcriptase (TERT) protein subunit independently of the telomerase template RNA moiety. | 21925379 | LncRNADisease | ||
EL0352 | Dmrt2 | telomerase | RNA-Protein | binding | TERRA has now been demonstrated to physically interact with the telomerase through a repeat sequence complementary to the template sequence of telomerase RNA. | 21925379 | LncRNADisease | ||
EL0354 | DNM3OS | TWIST1 | DNA-TF | regulation | Twist-1 regulates the miR-199a/214 cluster during development. | 19029138 | LncRNADisease | ||
EL0359 | dutA | STAT | RNA-DNA | regulation | Thought to function upstream of Dictyostelium STAT transcription factor Dd-STATa. | 21256239 | LncRNADisease | ||
EL0360 | E130102H24Rik | Cox2 | RNA-RNA | co-expression | AK021368 and Cox2 exhibit overlapping expression profiles in the cerebral cortex, raising the possibility that a similar regulatory mechanism occurs in the brain. | 18184812 | LncRNADisease | ||
EL0361 | EBER | PKR | RNA-Protein | binding | Autophosphorylation assays confirmed that both EBER(I) and VA(I) are inhibitors of PKR activation, and profiled the kinetics of the inhibition. Binding affinities of dsRNAs to PKR double-stranded RNA-binding domains (dsRBDs) were determined by isothermal titration calorimetry and gel electrophoresis. | 16580685 | |||
EL0364 | EGFLAM-AS1 | LIFR | RNA-RNA | regulation | lncRNA-LOWEG is positively correlated with the expression of leukemia inhibitory factor receptor (LIFR) gene at the translational level. LIFR gene is up-regulated by lncRNA-LOWEG. | 26537802 | |||
EL0365 | EGFR-AS1 | GHR | RNA-DNA | regulation | Impeded expression of GHR decreased the expression of EGFR and EGFR-AS1 in vivo and in vitro. | 26271667 | |||
EL0369 | EMX2OS | EMX2 | RNA-RNA | co-expression | Emx2, emx2os, emx2, and emx2os are abundant in the uterine endometrium, with sense and antisense transcripts exhibiting identical expression patterns. | 12573261 | |||
EL0369 | EMX2OS | EMX2 | RNA-RNA | regulation | EMX2OS post-transcriptionally regulates the abundance of the coding transcript, thereby regulating activity of EMX2. | 21128942 | LncRNADisease | ||
EL0370 | Emx2os | Emx2 | RNA-RNA | co-expression | Emx2, emx2os, emx2, and emx2os are abundant in the uterine endometrium, with sense and antisense transcripts exhibiting identical expression patterns. | 12573261 | |||
EL0376 | ENOD40 | MtRBP1 | RNA-Protein | binding | A novel rna binding protein interacting with the enod40 rna, mtrbp1 (for medicago truncatula rna binding protein 1), was identified using a yeast three-hybrid screening. | 15037734 | |||
EL0387 | enod40 | MtRBP1 (Medicago truncatula RNA Binding Protein 1) | RNA-Protein | binding | Direct involvement of the enod40 RNA in MtRBP1 relocalization into cytoplasmic granules was shown using a transient expression assay. | 15037734 | PLNlncRbase | ||
EL0449 | ENST00000414355 | DNA-damage related genes (ATM, ATR and ATRIP) | RNA-DNA | regulation | SiRNA-mediated knockdown of ENST00000414355 inhibited the growth of DNA-damaged cells and decreased the expressions of DNA-damage related genes (ATM, ATR and ATRIP), while increased the expressions of DNA-repair related genes (DDB1, DDB2, OGG1, ERCC1, MSH2, RAD50, XRCC1 and BARD1). | 26464647 | |||
EL0449 | ENST00000414355 | DNA-repair related genes (DDB1, DDB2, OGG1, ERCC1, MSH2, RAD50, XRCC1 and BARD1) | RNA-DNA | regulation | SiRNA-mediated knockdown of ENST00000414355 inhibited the growth of DNA-damaged cells and decreased the expressions of DNA-damage related genes (ATM, ATR and ATRIP), while increased the expressions of DNA-repair related genes (DDB1, DDB2, OGG1, ERCC2, MSH' | 26464647 | |||
EL0479 | ERICD | E2F | DNA-Protein | regulation | expression levels of ERIC were elevated upon activation of exogenous E2F1, E2F3 or endogenous E2Fs. knockdown of either E2F1 or E2F3 reduced ERIC levels and endogenous E2F1 binds ERIC's promoter. Expression of ERIC was cell cycle regulated and peaked in G1 in an E2F1-dependent manner. Inhibition of ERIC expression increased E2F1-mediated apoptosis, suggesting that E2F1 and ERIC constitute a negative feedback loop that modulates E2F1 activity. Furthermore, ERIC levels were increased following DNA damage by the chemotherapeutic drug Etoposide, and inhibition of ERIC expression enhanced Etoposide -induced apoptosis. | 24168400 | |||
EL0484 | EWSAT1 | heterogeneous nuclear ribonucleoprotein (HNRNPK) | RNA-Protein | binding | heterogeneous nuclear ribonucleoprotein (HNRNPK) as an RNA-binding protein that interacts with EWSAT1 | 25401475 | |||
EL0486 | FALEC | ECM1 | RNA-RNA | co-expression | Depletion of ncRNA-a1 (activating long ncRNA 1, LINC00568), results in decreased ECM1 levels, suggesting a direct activating function of ncRNA-a1 on its neighboring gene. | 21502407 | LncRNADisease | ||
EL0486 | FALEC | BMI1 | RNA-DNA | regulation | FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a number of genes including CDKN1A. | 25203321 | |||
EL0486 | FALEC | p21 | RNA-DNA | regulation | The oncogenic activity of FAL1 is partially attributable to its repression of p21. | 25203321 | |||
EL0486 | FALEC | BMI1 | RNA-Protein | regulation | The oncogenic activity of FAL1 was mediated in part by its interaction with BMI1, a component of the chromatin-modifying Polycomb repressive complex 1, which resulted in increased stabilization of BMI1 protein and transcriptional repression of genes involved in processes such as cell proliferation and apoptosis. | 25367941 | |||
EL0487 | FAM30A | β-Catenin | RNA-Protein | regulation | The expression of β-Catenin was increased and the expression of Vimentin was decreased in GBC-SD/M cells after KIAA0125 knockdown. | 26448925 | |||
EL0491 | FAS-AS1 | Fas | RNA-RNA | regulation | Saf might regulate the expression of Fas alternative splice forms through pre-mRNA processing. | 15829500 | LncRNADisease | ||
EL0491 | FAS-AS1 | Fas | RNA-RNA | regulation | Saf might regulate the expression of fas alternative splice forms through pre-mrna processing. | 15829500 | |||
EL0492 | FENDRR | PRC2 | RNA-Protein | binding | Numerous lincRNAs are physically associated with PRC2. | 19571010 | LncRNADisease | ||
EL0492 | FENDRR | FN1 and MMP2/MMP9 | RNA-Protein | regulation | FENDER overexpression suppressed invasion and migration by gastric cancer cells in vitro, by downregulating FN1 and MMP2/MMP9 expression. | 25167886 | |||
EL0494 | FER1L4 | miR-106a-5p | RNA-RNA | regulation | Both FER1L4 and PTEN mRNA were targets of miR-106a-5p. FER1L4 downregulation liberates miR-106a-5p and decreases the abundances of PTEN mRNA and protein. | 26306906 | |||
EL0494 | FER1L4 | PTEN | RNA-RNA | regulation | lncRNA FER1L4 (fer-1-like family member 4, pseudogene) acts as a competing endogenous RNA (ceRNA) to regulate the expression of PTEN (a well-known tumor suppressor gene) by taking up miR-106a-5p in gastric cancer. | 26306906 | |||
EL0503 | FLC | histone H3Lys4 | RNA-Protein | regulation | The degradation of FRI (FRIGIDA) is accompanied by an increase in the levels of the long noncoding RNA ColdAIR, which reduces the level of histone H3Lys4 trimethylation (H3K4me3) in FLOWERING LOCUS C chromatin to promote flowering. | 25538183 | |||
EL0508 | FOXC2-AS1 | ABCB1 | RNA-DNA | regulation | The expression of classical drug resistance-related ATP-binding cassette, subfamily B, member 1 (ABCB1) gene was decreased after the lncRNA ODRUL knockdown. | 26408180 | |||
EL0509 | FOXCUT | FOXC1 | RNA-RNA | regulation | FOXCUT and FOXC1 may function as a lncRNA-RNA gene pair, which may represent a potential prognostic biomarker and therapeutic target for ESCC patients. | 25031703 | |||
EL0509 | FOXCUT | FOXC1 | RNA-DNA | regulation | The results showed that the expression of FOXCUT and FOXC1 were positively correlated | 25516208 | |||
EL0512 | FRLnc1 | FOXM1 | RNA-DNA | co-expression | FRLnc1 expression is positively correlated with FOXM1 level. | 25907137 | |||
EL0514 | FTX | Xist | RNA-RNA | regulation | The Ftx mutation, however, results in widespread alteration of transcript levels within the X-inactivation center (Xic) and particularly important decreases in Xist RNA levels. | 21118898 | |||
EL0514 | FTX | RIG-I | RNA-Protein | regulation | Ectopic expression of RIG-I abrogated the effects of lncRNA Ftx or miR-545 on HCC cells. LncRNA Ftx/miR-545-mediated downregulation of RIG-I led to increased Akt phosphorylation in vitro and in vivo. | 26992218 | |||
EL0514 | FTX | miR-545 , RIG-I | RNA-RNA | co-expression | MiR-545 was positively correlated with lncRNA Ftx expression. | 26992218 | |||
EL0514 | FTX | PI3K/Akt signaling | N/A | regulation | The novel pathway lncRNA Ftx/miR-545/RIG-I promotes HCC development by activating PI3K/Akt signaling. | 26992218 | |||
EL0515 | Ftx | XIST | RNA-DNA | regulation | Ftx has both a global role in the adjustment of the transcription levels of several genes in the Xic and a positive effect on Xist expression that coincides with a role in preventing the methylation of the Xist promoter. | 21329697 | LncRNADisease | ||
EL0515 | Ftx | XIST | RNA-RNA | co-expression | Ftx is upregulated specifically in female cells at the time of Xist upregulation and X inactivation. | 21496640 | LncRNADisease | ||
EL0516 | G22 | PABP | RNA-Protein | binding | Binds PABP and the SRP9/14 heterodimer. | 21256239 | LncRNADisease | ||
EL0516 | G22 | SRP9/14 heterodimer | RNA-Protein | binding | Binds PABP and the SRP9/14 heterodimer. | 21256239 | LncRNADisease | ||
EL0522 | GAL10 | H3 | RNA-Protein | regulation | Cryptic ncRNA transcription can direct H3 K36me3 formation over repressed genes and intergenic regions, which otherwise lack this histone modification. | 19061643 | LncRNADisease | ||
EL0522 | GAL10 | Reb1 | RNA-Protein | regulation | Reb1-driven ncRNA transcription causes reduced acetylation of specific histone residues over the GAL1 and GAL10 coding regions. | 19061643 | LncRNADisease | ||
EL0522 | GAL10 | TRAMP complexes | RNA-Protein | regulation | The GAL10-ncRNA is targeted for degradation by the TRAMP complexes. | 19061643 | LncRNADisease | ||
EL0522 | GAL10 | Reb1 | DNA-TF | regulation | Transcription of GAL10-ncRNA is driven by the DNA-binding protein Reb1. | 19061643 | LncRNADisease | ||
EL0522 | GAL10 | RAT1 | RNA-RNA | co-expression | The importance of RAT1 was reinforced by the finding that GAL10 lncRNA was more functionally compromised by loss of RAT1 than XRN1. | 22325347 | LncRNADisease | ||
EL0524 | GAS1RR | Shh-GLI1 | RNA-Protein | regulation | The Shh-GLI1 pathway associated lncRNA-Hh, transcriptionally regulated by Twist, directly targets GAS1 to stimulate the activation of hedgehog signaling (Hh). | 26418365 | |||
EL0526 | GAS5 | NR3C1 | RNA-Protein | binding | Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Gas5 bound to the DNA-binding domain of the glucocorticoid receptor (GR) by acting as a decoy glucocorticoid response element (GRE), thus competing with DNA GREs for binding to the GR. | 20124551 | LncRNADisease | ||
EL0526 | GAS5 | NR3C1 | RNA-Protein | regulation | The multifunctional GAS5 lncRNA is a negative regulator of the glucocorticoid receptor and other nuclear receptors. | 20951849 | LncRNADisease | ||
EL0526 | GAS5 | miR-21 | RNA-RNA | regulation | miR-21 is capable of suppressing the lncRNA growth arrest-specific 5 (GAS5). GAS5 can also repress miR-21 expression. | 23933812 | |||
EL0526 | GAS5 | Annexin A2 | RNA-Protein | binding | RNA pull-down experiment revealed a direct bind of lncRNA-GAS5 to a Ca2+-dependent RNA-binding protein, Annexin A2. | 25806802 | |||
EL0526 | GAS5 | IGF-1R | RNA-DNA | regulation | GAS5 overexpression was inversely correlated with the expression of the EGFR pathway and IGF-1R proteins. | 25925741 | |||
EL0526 | GAS5 | Y-box binding protein 1 (YBX1) | RNA-Protein | binding | lncRNA GAS5 was shown to interact with Y-box binding protein 1 (YBX1), and lncRNA GAS5 knockdown was shown to accelerate YBX1 protein turnover without affecting YBX1 transcription. | 25959498 | |||
EL0526 | GAS5 | Plexin C1 | RNA-Protein | regulation | The introduction of Gas5 by plasmid transfection increased the expression of tumor suppressor Bcl-2-modifying factor (bmf) and Plexin C1 via directly targeting and reducing the expression of miR-222. | 26364613 | |||
EL0526 | GAS5 | tumor suppressor Bcl-2-modifying factor (bmf) | RNA-Protein | regulation | The introduction of Gas5 by plasmid transfection increased the expression of tumor suppressor Bcl-2-modifying factor (bmf) and Plexin C1 via directly targeting and reducing the expression of miR-222. | 26364613 | |||
EL0526 | GAS5 | miR-21 | RNA-RNA | regulation | Thus, GAS5 acts as a tumor suppressor in HCCs through negative regulation of miR-21 and its targets and proteins about migration and invasion in cancer cells. | 26404135 | |||
EL0526 | GAS5 | miR-222 | RNA-RNA | binding | A pulldown assay further validated that GAS5 could directly bind to miR-222. | 26446789 | |||
EL0526 | GAS5 | BAX, BAK, cleaved-caspase 3 and cleaved-caspase 9 | RNA-Protein | regulation | GAS5 could disrupt mitochondrial membrane potential and promote BAX, BAK, cleaved-caspase 3 and cleaved-caspase 9 expression. | 26503132 | |||
EL0526 | GAS5 | miR-103 | RNA-RNA | regulation | Through inhibiting the expression of miR-103, GAS5 significantly enhanced the expression of PTEN to promote cancer cell apoptosis. | 26511107 | |||
EL0526 | GAS5 | Ki67 | RNA-Protein | regulation | Lower GAS5 levels appeared in the patients with a high Ki67 proliferation index before surgery | 26662314 | |||
EL0526 | GAS5 | vimentin | RNA-Protein | regulation | GAS5 negatively regulates vimentin expression in vitro and in vivo. Notably, vimentin knockdown promoted GAS5‑pcDNA3.1‑inhibition of hepatoma cell proliferation. | 26707238 | |||
EL0526 | GAS5 | MMP2 | RNA-Protein | regulation | Overexpressing lncRNA GAS5 inhibited the migration and invasion ability of melanoma SK-Mel‑110 cells, partially by decreasing the MMP2 expression and its activity. | 26846479 | |||
EL0526 | GAS5 | phosphatase and tensin homologs (PTEN) | RNA-Protein | regulation | GAS5 suppresses cancer proliferation by acting as a molecular sponge for miR-21, leading to the de-repression of phosphatase and tensin homologs (PTEN), the endogenous target of miR-21. | 27034004 | |||
EL0526 | GAS5 | miR-21 | RNA-RNA | binding | GAS5 suppresses cancer proliferation by acting as a molecular sponge for miR-21, leading to the de-repression of phosphatase and tensin homologs (PTEN), the endogenous target of miR-21. | 27034004 | |||
EL0532 | Gfra1 | Gfra1 | RNA-DNA | regulation | LncRNA033862 is an antisense transcript of the GDNF receptor alpha1 (Gfra1) that lacks protein coding potential and regulates Gfra1 expression levels by interacting with Gfra1 chromatin. | 26962690 | |||
EL0535 | Gli3 | Gli3 | RNA-RNA | co-expression | The downregulation of a ncRNA (AK053922) is associated with the Gli3 locus in all progeny of N/OPs, whereas Gli3 was upregulated in N/OPs but downregulated in all progeny of N/Ops. | 20137068 | LncRNADisease | ||
EL0538 | Gm15577 | Negr1, Shh and β-catenin | RNA-DNA | regulation | Gm15577 modulated the RNA expression of Negr1, Shh and β-catenin. Gm15577 may modulate cerebellar granule cell proliferation and differentiation by targeting Negr1, and their dysfunctions or abnormal expression may be related to tumorigenesis of medulloblastoma. | 26705043 | |||
EL0539 | Gm16845 | Ecsit | RNA-RNA | co-expression | A cisantisense ncRNA (GenBank accession no. AK154427) exhibits a negative expression correlation (R2= -0.92) with its sense protein-coding gene Ecsit. | 18562676 | LncRNADisease | ||
EL0541 | Gm30731 | PTBP1 | RNA-Protein | binding | Pnky interacts with the splicing regulator PTBP1, and PTBP1 knockdown also enhances neurogenesis. | 25800779 | |||
EL0552 | GSTT1-AS1 | zeste homolog 2 (EZH2) | RNA-Protein | binding | By recruiting polycomb protein enhancer of zeste homolog 2 (EZH2) to infg/tnfa promoters, lncRNA-CD244 mediates H3K27 trimethylation at infg/tnfa loci toward repressive chromatin states and inhibits IFN-γ/TNF-α expression in CD8(+) T cells | 26150504 | |||
EL0555 | H19 | Igf2 of imprinted gene network (IGN) | RNA-Protein | regulation | We observed postnatal growth reduction in two independent transgenic lines and detected a decrease of Igf2 expression in embryos. An extensive analysis of several other genes from the newly described imprinted gene network (IGN) was performed in both loss- and gain-of-function animals. We found that H19 deletion leads to the upregulation of several genes of the IGN. | 19762426 | |||
EL0555 | H19 | let-7 | RNA-RNA | binding | Acting as a molecular sponge, H19 inhibits microRNA (miRNA) let-7. | 25399420 | |||
EL0555 | H19 | Igf2 (insulin-like growth factor 2) | RNA-DNA | regulation | This is associated with the disruption of igf2 imprinting and the consequent biallelic expression of this gene. | 9203585 | |||
EL0556 | H19 | SERPINE1 | RNA-RNA | co-expression | Half-sbsRNA1 siRNA increased the levels of SERPINE1 and FLJ21870 mRNAs to 2-to-4.5-fold above normal. | 10738131 | |||
EL0556 | H19 | IMP | RNA-Protein | binding | Human h19 rna contains four attachment sites for the oncofetal igf-ii mrna-binding protein (imp) | 10875929 | |||
EL0556 | H19 | IMP-3 | RNA-Protein | regulation | Imp-3 protein associates with igf-ii leader-3 and leader-4 mrnas and h19 rna | 15753088 | |||
EL0556 | H19 | miR-675 | RNA-RNA | co-expression | Recently, it was found that the H19 RNA is host to an exonic microRNA, miR-675, which, as a result, is also imprinted and maternally expressed. | 19239885 | LncRNADisease | ||
EL0556 | H19 | c-myc | DNA-TF | regulation | H19 has been linked to the oncogene, c-myc, which positively regulates its expression in diverse cell types including T98G human glioblastoma cells. | 20380817 | LncRNADisease | ||
EL0556 | H19 | p53 | DNA-TF | regulation | H19 has been linked to the tumor suppressor, p53, which negatively regulates its expression. | 20380817 | LncRNADisease | ||
EL0556 | H19 | GLI1 | DNA-TF | regulation | H19 is a target of the GLI1 transcription factor, which mediates SHH signaling and is amplified more than 50-fold in human gliomas. | 20380817 | LncRNADisease | ||
EL0556 | H19 | SHH | DNA-TF | regulation | H19 is a target of the GLI1 transcription factor, which mediates SHH signaling and is amplified more than 50-fold in human gliomas. | 20380817 | LncRNADisease | ||
EL0556 | H19 | E2F1 | RNA-Protein | regulation | H19 transcription is positively regulated by the cell cycle regulatory factor, E2F1, during the S-phase of growth-stimulated cells. | 20380817 | LncRNADisease | ||
EL0556 | H19 | Igf2 | RNA-RNA | co-expression | Complex functions, influences growth by down-regulating a number of imprinted genes including Igf2, also implicated as both a tumour suppressor and an oncogene. | 21256239 | LncRNADisease | ||
EL0556 | H19 | CTCF1 | RNA-RNA | co-expression | Significant reductions at the H19 CTCF 1 and CTCF 2 binding sites were observed in the offspring of ethanol-treated sires, which was significantly correlated with reduced weight at postnatal days 35-42 (p?0.05). | 22395465 | LncRNADisease | ||
EL0556 | H19 | CTCF2 | RNA-RNA | co-expression | Significant reductions at the H19 CTCF 1 and CTCF 2 binding sites were observed in the offspring of ethanol-treated sires, which was significantly correlated with reduced weight at postnatal days 35-42 (p<=0.05). | 22395465 | LncRNADisease | ||
EL0556 | H19 | CTCF3 | RNA-RNA | co-expression | There is a CTCF-binding site (CTCF3) in the imprinting control region (ICR) upstream of H19. | 22395465 | LncRNADisease | ||
EL0556 | H19 | IGF2 | RNA-Protein | regulation | H19 is an imprinted maternally expressed gene influencing IGF2 expression, whose transcript is a long noncoding (lnc) RNA of unknown biological function harboring the miR-675. | 22527881 | |||
EL0556 | H19 | H19 transcript can counteract 91H-mediated Igf2 activation | RNA-RNA | regulation | A large excess of the H19 transcript can counteract 91H-mediated Igf2 activation. | 22662250 | |||
EL0556 | H19 | Igf2 | RNA-Protein | regulation | Ectopic expression of the mouse 91H RNA can up-regulate Igf2 expression in trans | 22662250 | |||
EL0556 | H19 | let-7 family of microRNAs | RNA-RNA | binding | Vertebrate H19 harbors both canonical and noncanonical binding sites for the let-7 family of microRNAs, which plays important roles in development, cancer, and metabolism. | 24055342 | |||
EL0556 | H19 | H1.3 | RNA-Protein | regulation | H1.3dramatically inhibits H19 expression, which contributes to the suppression of epithelial ovarian carcinogenesis. | 25205099 | |||
EL0556 | H19 | K homology-type splicing regulatory protein (KSRP) | RNA-Protein | binding | KSRP directly binds to H19 in the cytoplasm of undifferentiated multipotent mesenchymal C2C12 cells | 25385579 | |||
EL0556 | H19 | miR-138 and miR-200a | RNA-RNA | regulation | by using bioinformatics study and RNA immunoprecipitation combined with luciferase reporter assays, we demonstrated that H19 functioned as a competing endogenous RNA (ceRNA) for miR-138 and miR-200a, antagonized their functions and led to the de-repression of their endogenous targets Vimentin, ZEB1, and ZEB2, all of which were core marker genes for mesenchymal cells | 26068968 | |||
EL0556 | H19 | MiR-141 | RNA-RNA | binding | MiR-141 binds to H19 in a sequence specific manner, and suppresses H19 expression and functions including proliferation and invasion. MiR-141 could also regulate H19 target genes and miR-141 inhibitor restores H19 siRNA function, while H19 regulates miR-141 target gene ZEB1. | 26160158 | |||
EL0556 | H19 | Yes-associated protein 1 (YAP1) | RNA-Protein | co-expression | H19 expression was found to be significantly associated with YAP1 expression. H19, at least in part, is induced by YAP1 overexpression. | 26163939 | |||
EL0556 | H19 | miR-675 | RNA-RNA | regulation | Ectopic expression of H19 significantly increased bladder cancer cell proliferation and miR-675 expression in vitro. | 26198047 | |||
EL0556 | H19 | histone deacetylase (HDAC) 4/5 | RNA-DNA | regulation | H19/miR-675 downregulated the mRNA and protein levels of histone deacetylase (HDAC) 4/5, and thus increased osteoblast marker gene expression. | 26417995 | |||
EL0556 | H19 | transforming growth factor-β1 (TGF-β1) | RNA-DNA | regulation | H19/miR-675 inhibited mRNA and protein expression of transforming growth factor-β1 (TGF-β1). | 26417995 | |||
EL0556 | H19 | c-Myc | RNA-Protein | regulation | H19 was a direct transcriptional target of c-Myc. | 26482621 | |||
EL0556 | H19 | S-adenosylhomocysteine hydrolase (SAHH) | RNA-Protein | binding | The developmentally regulated H19 lncRNA binds to and inhibits S-adenosylhomocysteine hydrolase (SAHH), the only mammalian enzyme capable of hydrolysing S-adenosylhomocysteine (SAH) | 26687445 | |||
EL0556 | H19 | c-Myc | DNA-DNA | regulation | The activity of the promoter of H19 was strengthened by c-Myc. | 26722426 | |||
EL0556 | H19 | miR-107 | RNA-RNA | regulation | The expression of miR-107 increased or decreased with the overexpression and knockdown of H19, respectively. The number of cells in G2/M stage decreased significantly with the knockdown of H19 and miR-107 compared with the control group. | 26722426 | |||
EL0556 | H19 | heterogeneous nuclear ribonucleoprotein (hnRNP) U and actin | RNA-Protein | regulation | H19 may inhibit the proliferation of fetal liver cells by blocking the interaction between heterogeneous nuclear ribonucleoprotein (hnRNP) U and actin, which results in gene transcriptional repression. | 26801864 | |||
EL0556 | H19 | AKT2 | RNA-RNA | co-expression | The RNA levels of H19 and AKT2 were positively correlated. | 26803515 | |||
EL0556 | H19 | miR-141 and miR-22 | RNA-RNA | binding | H19 functioned as an miRNA sponge for miR-141 and miR-22, both of which were negative regulators of osteogenesis and Wnt/β-catenin pathway. | 26853553 | |||
EL0556 | H19 | HuR | RNA-Protein | regulation | H19 interacts with HuR and regulates the intestinal epithelial barrier function via the H19-encoded miR-675 by altering ZO-1 and E-cadherin expression posttranscriptionally. | 26884465 | |||
EL0556 | H19 | miR-675 | RNA-RNA | regulation | H19 plays an important role in controlling the intestinal epithelial barrier function by serving as a precursor for microRNA 675 (miR-675). H19 overexpression increased the cellular abundance of miR-675, which in turn destabilized and repressed the translation of mRNAs encoding tight junction protein ZO-1 and adherens junction E-cadherin, resulting in the dysfunction of the epithelial barrier. | 26884465 | |||
EL0556 | H19 | RUNX1 | RNA-DNA | regulation | Overexpression of H19 or miR-675 significantly decreased RUNX1 expression in AGS cells, and knockdown of H19 or miR-675 enhanced RUNX1 expression. | 26931432 | |||
EL0556 | H19 | miR-675 | RNA-RNA | regulation | The expression of miR-675 was positively correlated with H19 in patients with gastric cancer. | 26931432 | |||
EL0556 | H19 | eIF4A3 | RNA-Protein | binding | eIF4A3 as an RNA-binding protein that binds to H19. Combining eIF4A3 with H19 obstructed the recruitment of eIF4A3 to the cell-cycle gene mRNA. | 26989025 | |||
EL0556 | H19 | EZH2 | RNA-DNA | regulation | H19 regulated EZH2 expression by suppressing the activity of miR-630, which is a repressor of EZH2 and interacts with H19 in a sequence-specific manner. | 27040767 | |||
EL0556 | H19 | miR-630 | RNA-RNA | regulation | H19 regulated EZH2 expression by suppressing the activity of miR-630, which is a repressor of EZH2 and interacts with H19 in a sequence-specific manner. | 27040767 | |||
EL0556 | H19 | CaMKIIδ | RNA-Protein | regulation | CaMKIIδ was a direct target of miR-675 and partially mediated the effect of H19 on cardiomyocyte hypertrophy. | 27084844 | |||
EL0556 | H19 | miR-675 | RNA-RNA | regulation | H19 encoded miR-675. | 27084844 | |||
EL0560 | Halr1 | Hoxa1 | RNA-DNA | regulation | linc-HOXA1 RNA represses Hoxa1 by recruiting the protein PURB as a transcriptional cofactor. | 23723417 | |||
EL0560 | Halr1 | PURB | RNA-Protein | regulation | linc-HOXA1 RNA represses Hoxa1 by recruiting the protein PURB as a transcriptional cofactor. | 23723417 | |||
EL0561 | HAR1A | RELN | DNA-TF | regulation | The lncRNA HAR1F is transcribed from one of these regions and specifically co-expressed in Cajal-Retzius cells of the human neocortex with the critical neural factor RELN (Pollard et al., 2006), which mediates seminal neural developmental processes and is implicated in the pathophysiology of a broad range of neurological and psychiatric disorders. | 20380817 | LncRNADisease | ||
EL0561 | HAR1A | REST | DNA-TF | regulation | RNA in-situ hybridization showed that HAR1F is expressed in developing neurons of the human embryonic neocortex, and its expression was recently shown to be regulated by the master neural transcriptional repressor, REST. | 20951849 | LncRNADisease | ||
EL0563 | HBB | Dicer | RNA-Protein | regulation | Intergenic transcripts of the beta-globin gene cluster are specifically upregulated in dicer-deficient cells. | 16227618 | |||
EL0565 | HEIH | EZH2 | RNA-Protein | binding | It was shown that lncRNAHEIH associates with EZH2 and that this association is required for the expression of EZH2-regulated target genes. | 21769904 | LncRNADisease | ||
EL0569 | HIF1A-AS1 | HOXD10 | RNA-DNA | regulation | Low expression of HIF1α‑AS1 was sufficient to block the expression of HOXD10. Downregulation of HOXD10 by HIF1α‑AS1 interfered with acetylation, and subsequently resulted in the inhibition of osteoblast differentiation. | 26460121 | |||
EL0571 | HIF2PUT | HIF‑2α | RNA-RNA | regulation | the lncRNA HIF2PUT may be a novel regulatory factor of osteosarcoma stem cells, which may exert its function partly by controlling HIF‑2α expression. | 25434862 | |||
EL0571 | HIF2PUT | HIF-2α | RNA-Protein | regulation | Knockdown of lncRNA-HIF2PUT blocked the HIF-2α expression and inhibited the CSC properties in CRC cell lines DLD-1 and HT29. | 26648739 | |||
EL0574 | Hm629797 | Pc4, hnRNP A/B and hnRNP A2/B1 | RNA-Protein | binding | We also identified interacting proteins of mrhl RNA associated chromatin fraction which included Pc4, a chromatin organizer protein and hnRNP A/B and hnRNP A2/B1 which have been shown to be associated with lincRNA-Cox2 function in gene regulation. | 25584904 | |||
EL0575 | HNF1A-AS1 | cyclin D1, E-cadherin, N-cadherin and β-catenin | RNA-Protein | regulation | HNF1A-AS1 was determined to promote tumor proliferation and metastasis, both in vitro and in vivo, by regulating cyclin D1, E-cadherin, N-cadherin and β-catenin expression. In addition, the binding of HNF1A-AS1 to DNMT1 may explain its regulation of E-cadherin. | 25863539 | |||
EL0575 | HNF1A-AS1 | CEA, CA19-9, RRM1 | RNA-Protein | regulation | Low HNF1A-AS1 expression was associated with tumor size/diameter (p = 0.005, multivariate analysis), levels of serum carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), and RRM1 expression in tissue samples (p = 0.028, p = 0.009, and p = 0.006, respectively). | 26472090 | |||
EL0575 | HNF1A-AS1 | Bcl-2 | RNA-Protein | regulation | HNF1A-AS1 functioned as an oncogene in tumor growth and apoptosis through sponging tumor-suppressive hsa-miR-30b-5p (miR-30b) and de-repressing Bcl-2. | 27084450 | |||
EL0575 | HNF1A-AS1 | miR-30b | RNA-RNA | binding | HNF1A-AS1 functioned as an oncogene in tumor growth and apoptosis through sponging tumor-suppressive hsa-miR-30b-5p (miR-30b) and de-repressing Bcl-2. | 27084450 | |||
EL0576 | Hog | Hoxd | DNA-DNA | binding | The start site of two opposite long noncoding RNAs (lncRNAs), Hotdog and Twin of Hotdog, selectively contacts the expressed Hoxd genes in the framework of a topological domain, coinciding with robust transcription of these genes during cecum budding. | 24075990 | |||
EL0578 | HOTAIR | HOXD | RNA-DNA | regulation | HOTAIR is transcribed at the intersection of opposing chromatin domains in the HOXC locus, but targets Polycomb Repressive Complex 2 (PRC2) to represses transcription in trans across 40 kilobases of the HOXD locus. | 17604720 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | HOTAIR is transcribed at the intersection of opposing chromatin domains in the HOXC locus, but targets Polycomb Repressive Complex 2 (PRC2) to silence 40 kilobases of HOXD. | 17604720 | LncRNADisease | ||
EL0578 | HOTAIR | HOXD | RNA-DNA | regulation | HOTAIR represses transcription in trans across 40 kilobases of the HOXD locus. | 17604720 | LncRNADisease | ||
EL0578 | HOTAIR | HOXD locus,Polycomb Repressive Complex 2 (PRC2) | RNA-Protein | regulation | HOTAIR, which represses transcription in trans across 40 kilobases of the HOXD locus. HOTAIR interacts with Polycomb Repressive Complex 2 (PRC2) and is required for PRC2 occupancy and histone H3 lysine-27 trimethylation of HOXD locus. | 17604720 | |||
EL0578 | HOTAIR | HOXD | RNA-DNA | regulation | HOTAIR represses the expression in trans of genes in the HOXD cluster. Depletion of HOTAIR by siRNA resulted in the activation of HOXD genes in trans. | 19015002 | LncRNADisease | ||
EL0578 | HOTAIR | Ezh2 | RNA-Protein | binding | HOTAIR RNA plays a critical role in establishing H3K27me3 enriched chromosomal domains through interaction with PRC2 complex members such as Suz12 and Ezh2. | 19015002 | LncRNADisease | ||
EL0578 | HOTAIR | Suz12 | RNA-Protein | binding | HOTAIR RNA plays a critical role in establishing H3K27me3 enriched chromosomal domains through interaction with PRC2 complex members such as Suz12 and Ezh2. | 19015002 | LncRNADisease | ||
EL0578 | HOTAIR | HOXD | RNA-RNA | co-expression | HOTAIR showed negative association with HOXD genes. | 19182780 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | HOTAIR coprecipitated with PRC2 in both HeLa and hFFs, but not in hLFs. | 19571010 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | HOTAIR expression may be involved in human cancer by promoting genomic relocalization of Polycomb complex and H3K27 trimethylation. | 20393566 | LncRNADisease | ||
EL0578 | HOTAIR | H3 | RNA-Protein | regulation | HOTAIR expression may be involved in human cancer by promoting genomic relocalization of Polycomb complex and H3K27 trimethylation. | 20393566 | LncRNADisease | ||
EL0578 | HOTAIR | H3 | RNA-Protein | regulation | HOTAIR expression may be involved in human cancer by promoting genomic relocalization of Polycomb complex and H3K27 trimethylation. | 20393566 | LncRNADisease | ||
EL0578 | HOTAIR | LSD1 | RNA-Protein | binding | A 3' domain of HOTAIR binds the LSD1/CoREST/REST complex. | 20616235 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | A 5'domain of HOTAIR binds polycomb repressive complex 2 (PRC2). | 20616235 | LncRNADisease | ||
EL0578 | HOTAIR | LSD1 | RNA-Protein | binding | Immunoprecipitation (IP) of LSD1 retrieved endogenous HOTAIR with comparable enrichment to that of PRC2 IP. It was hypothesized that HOTAIR may also bind the LSD1-CoREST complex. | 20616235 | LncRNADisease | ||
EL0578 | HOTAIR | HOXD | RNA-DNA | regulation | The lincRNA HOTAIR is transcribed from the HOXC locus and targets Polycomb Repressive Complex 2 (PRC2, comprised of H3K27 methylase EZH2, SUZ12, and EED) to silence HOXD and select genes on other chromosomes. | 20616235 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | The lincRNA HOTAIR is transcribed from the HOXC locus and targets Polycomb Repressive Complex 2 (PRC2, comprised of H3K27 methylase EZH2, SUZ12, and EED) to silence HOXD and select genes on other chromosomes. | 20616235 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-DNA | regulation | binding surface assemble select histone modification enzymes thereby specifying the pattern of histone modifications on target genes | 20616235 | |||
EL0578 | HOTAIR | HOXD | RNA-Protein | regulation | The lncRNA HOTAIR is a putative direct positive regulator of the Polycomb repressor complex, and is consequently an indirect negative regulator of homeobox-D transcription factors. | 20951849 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | regulation | The lncRNA HOTAIR is a putative direct positive regulator of the Polycomb repressor complex. | 20951849 | LncRNADisease | ||
EL0578 | HOTAIR | Ezh2 | RNA-Protein | binding | Ezh2 interacts with HOTAIR and Xist. | 21123648 | LncRNADisease | ||
EL0578 | HOTAIR | CoREST | RNA-Protein | binding | Epigenetically silences gene expression at many loci by recruitment of LSD1/CoREST/REST and PRC2 repressive chromatin modifying complexes. Oncogene: promotes tumour metastasis. | 21256239 | LncRNADisease | ||
EL0578 | HOTAIR | LSD1 | RNA-Protein | binding | Epigenetically silences gene expression at many loci by recruitment of LSD1/CoREST/REST and PRC2 repressive chromatin modifying complexes. Oncogene: promotes tumour metastasis. | 21256239 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | Epigenetically silences gene expression at many loci by recruitment of LSD1/CoREST/REST and PRC2 repressive chromatin modifying complexes. Oncogene: promotes tumour metastasis. | 21256239 | LncRNADisease | ||
EL0578 | HOTAIR | REST | RNA-Protein | binding | Epigenetically silences gene expression at many loci by recruitment of LSD1/CoREST/REST and PRC2 repressive chromatin modifying complexes. Oncogene: promotes tumour metastasis. | 21256239 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | CDK1 and CDK2 phosphorylate EZH2 at threonine 350 (T350) and that T350 phosphorylation is important for the binding of EZH2 to PRC2 recruiters, such as noncoding RNAs (ncRNAs) HOTAIR and XIST. | 21278485 | LncRNADisease | ||
EL0578 | HOTAIR | LSD1 | RNA-Protein | binding | Analysis of HOTAIR revealed that a 5' end domain binds PRC2 and a 3' end domain binds an LSD1 (H3K4me2 demethylase) containing complex. | 21496640 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | Analysis of HOTAIR revealed that a 5' end domain binds PRC2 and a 3' end domain binds an LSD1 (H3K4me2 demethylase) containing complex. | 21496640 | LncRNADisease | ||
EL0578 | HOTAIR | HOXD | RNA-DNA | regulation | HOTAIR, a paradigm of this new class of RNAs, is localized within the human HOXC gene cluster and was shown,in human cells, to regulate HOXD genes in trans via the recruitment of Polycomb Repressive Complex 2 (PRC2), followed by the trimethylation of lysine 27 of histone H3. | 21637793 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | HOTAIR, a paradigm of this new class of RNAs, is localized within the human HOXC gene cluster and was shown,in human cells, to regulate HOXD genes in trans via the recruitment of Polycomb Repressive Complex 2 (PRC2), followed by the trimethylation of lysine 27 of histone H3. | 21637793 | LncRNADisease | ||
EL0578 | HOTAIR | PRC2 | RNA-Protein | binding | HOTAIR, a paradigm of this new class of RNAs, is localized within the human HOXC gene cluster and was shown,in human cells, to regulate HOXD genes in trans via the recruitment of Polycomb Repressive Complex 2 (PRC2), followed by the trimethylation of lysine 27 of histone H3. | 21637793 | LncRNADisease | ||
EL0578 | HOTAIR | H3 | RNA-Protein | regulation | HOTAIR, a paradigm of this new class of RNAs, is localized within the human HOXC gene cluster and was shown,in human cells, to regulate HOXD genes in trans via the recruitment of Polycomb Repressive Complex 2 (PRC2), followed by the trimethylation of lysine 27 of histone H3. | 21637793 | LncRNADisease | ||
EL0578 | HOTAIR | Hox | RNA-DNA | regulation | HOTAIR is transcribed from within specific Hox gene clusters but regulates the expression of Hox genes located on different chromosomes. | 21936910 | LncRNADisease | ||
EL0578 | HOTAIR | EZH2 | RNA-Protein | binding | HOTAIR, Kcnq1ot and Xist all mediate their effects by interacting with the Polycomb-repressive complex 2 (PRC2) component Ezh2 (enhancer of zeste homolog 2 (Drosophila)) and modulating histone methylation. | 21936910 | LncRNADisease | ||
EL0578 | HOTAIR | β-catenin | RNA-Protein | regulation | β-catenin is a stretch responsive signaling pathway that represses HOTAIR | 24788418 | |||
EL0578 | HOTAIR | PPARγ and LPL | RNA-DNA | regulation | Ectopic expression of HOTAIR in abdominal preadipocytes produced an increase in differentiation as reflected by a higher percentage of differentiated cells, and increased expression of key adipogenic genes including PPARγ and LPL | 24862299 | |||
EL0578 | HOTAIR | Wnt inhibitory factor 1 | RNA-Protein | regulation | A significant inverse correlation between HOTAIR and WIF-1 expression was demonstrated in Ta/T1 BC tissues. | 25030736 | |||
EL0578 | HOTAIR | Cisplatin and paclitaxel | N/A | regulation | Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | |||
EL0578 | HOTAIR | SiRNA | RNA-RNA | regulation | SiRNA knockdown of HOTAIR in GC cells significantly inhibited cell proliferation | 25280565 | |||
EL0578 | HOTAIR | histone H3 lysine27 | RNA-Protein | binding | MCF-7-TNR cells exhibited reduced suppressive histone H3 lysine27 trimethylation on the HOTAIR promoter. | 25328122 | |||
EL0578 | HOTAIR | endothelial growth factor, matrix metalloproteinase-9 and epithelial-to-mesenchymal transition (EMT)-related genes | RNA-DNA | regulation | HOTAIR regulated the expression of vascular endothelial growth factor, matrix metalloproteinase-9 and epithelial-to-mesenchymal transition (EMT)-related genes | 25405331 | |||
EL0578 | HOTAIR | protein coding gene | RNA-DNA | regulation | GO analyses of most significantly correlated coding genes of HOTAIR and lncRNA-422 showed that these two lncRNAs may participate in carcinogenesis by regulating protein coding genes involved in special biological process relevant to cancer. | 25456707 | |||
EL0578 | HOTAIR | p21 | RNA-DNA | regulation | Knockdown of HOTAIR upregulated p21. | 25547435 | |||
EL0578 | HOTAIR | shHOTAIR | RNA-RNA | regulation | Our findings demonstrated the shHOTAIR-mediated down-regulation of the HOTAIR expression in CD117(+)CD44(+) CSCs can be a promising new opportunity for future clinical trials. | 25792974 | |||
EL0578 | HOTAIR | β-catenin | DNA-Protein | regulation | We show that expression of HOTAIR is regulated by β-catenin through a LEF1/TCF4-binding site. The dual treatment blocks nuclear expression of β-catenin and prevents its recruitment to the HOTAIR promoter. | 25883211 | |||
EL0578 | HOTAIR | c-KIT,miR-193a | RNA-DNA | binding | HOTAIR modulated c-KIT expression by competitively binding miR-193a. | 25979172 | |||
EL0578 | HOTAIR | miR-218 | RNA-RNA | regulation | Hotair negatively regulated miR-218 expression in HCC, which might be mediated through an EZH2-targeting-miR-218-2 promoter regulatory axis. | 26024833 | |||
EL0578 | HOTAIR | HIF-1α | DNA-Protein | binding | The function of the hypoxia-inducible factor-1α (HIF-1α) binding site to hypoxia-responsive elements (HREs) in the HOTAIR promoter region. HOTAIR is a direct target of HIF-1α through interaction with putative HREs in the upstream region of HOTAIR in NSCLC cells. | 26088446 | |||
EL0578 | HOTAIR | E7 | RNA-Protein | co-expression | Expression of HOTAIR and PRC2-complex members (EZH2 and SUZ12), showed significant positive correlation with E7 expression in CaCx cases and E7 transfected C33A cell line, suggestive of interplay between E7 and HOTAIR. | 26152361 | |||
EL0578 | HOTAIR | SETD2 | RNA-DNA | regulation | HOTAIR promotes tumorigenesis via downregulating SETD2 in liver cancer stem cells. | 26172293 | |||
EL0578 | HOTAIR | miR-326 | RNA-RNA | regulation | HOTAIR was confirmed to be the target of miR-326 . knock-down of HOTAIR up-regulated miR-326 expression. | 26183397 | |||
EL0578 | HOTAIR | miR-152 | RNA-RNA | regulation | Long non-coding RNA HOTAIR promotes HLA-G expression via inhibiting miR-152 in gastric cancer cells. | 26187665 | |||
EL0578 | HOTAIR | CaV1.2 | RNA-Protein | regulation | In the present study, we demonstrated that up-regulation of HOTAIR could suppress the expression of CaV1.2 in human cardiomyocytes. | 26255135 | |||
EL0578 | HOTAIR | Wnt/β-catenin pathway | N/A | regulation | HOTAIR promotes the initiation and chemoresistance of ovarian cancer by activating wnt/β-catenin signaling. | 26341496 | |||
EL0578 | HOTAIR | ER | RNA-Protein | regulation | The long non-coding RNA HOTAIR is directly repressed by ER and its upregulation promotes ligand-independent ER activities and contributes to tamoxifen resistance. | 26364613 | |||
EL0578 | HOTAIR | AR | RNA-Protein | binding | HOTAIR binds to the AR protein to block its interaction with the E3 ubiquitin ligase MDM2, thereby preventing AR ubiquitination and protein degradation. | 26411689 | |||
EL0578 | HOTAIR | EZH2 | RNA-Protein | regulation | A significant correlation between EZH2 and HOTAIR expression levels. EZH2 regulates HOTAIR expression. | 26457124 | |||
EL0578 | HOTAIR | microRNA-205 | RNA-RNA | regulation | A long non-coding RNA HOTAIR (HOX transcript antisense RNA) was observed to participate in the silencing of miR-205 in bladder cancer cells by breaking the balance of histone modification between H3K4me3 (histone H3 at lysine 4 methylation) and H3K27me3 on miR-205 promoter. | 26469956 | |||
EL0578 | HOTAIR | cell death pathway | N/A | regulation | Protein expression analysis indicated that mitochondrial related cell death pathway (Bcl-2, BAX, Caspase-3, Cleaved Caspase-3, Cytochrome c) involved in HOTAIR dependent apoptosis process. | 26592246 | |||
EL0578 | HOTAIR | LSH | RNA-Protein | regulation | HOTAIR is associated with LSH, and this association linked with the binding of LSH in the promoter of FOXA1, not FOXA2. | 26658322 | |||
EL0578 | HOTAIR | FOXA1, FOXA2 | RNA-Protein | regulation | HOTAIR regulates the ratio of FOXA1 to FOXA2 and migration and invasion. | 26658322 | |||
EL0578 | HOTAIR | VEGFA and Ang2 | RNA-Protein | regulation | Hotair promoted angiogenesis through directly activating the transcription of angiogenic factor VEGFA as well as through GRP78-mediated upregulation of VEGFA and Ang2 expression. | 26717040 | |||
EL0578 | HOTAIR | c-Myc | RNA-DNA | binding | HBXIP interacted directly with c-Myc through the leucine zippers and recruited the lncRNA Hotair along with the histone demethylase LSD1, for which Hotair serves as a scaffold. | 26719542 | |||
EL0578 | HOTAIR | epithelial-to-mesenchyme transition (EMT) genes | RNA-DNA | regulation | Loss of HOTAIR expression in UBC cell lines alters expression of epithelial-to-mesenchyme transition (EMT) genes including SNAI1, TWIST1, ZEB1, ZO1, MMP1 LAMB3, and LAMC2. | 26800519 | |||
EL0578 | HOTAIR | TNF-α, NF-κB | RNA-Protein | regulation | HOTAIR upregulation in cardiomyocytes of LPS-induced sepsis mice promoted TNF-α production in the circulation by activating NF-κB, involving the phosphorylation of NF-κB p65 subunit. | 26806307 | |||
EL0578 | HOTAIR | miR-125a-5p | RNA-RNA | regulation | microRNA miR-125a-5p decreases and releases caspase 2 to promote cancer cell apoptosis after HOTAIR knockdown. | 26962687 | |||
EL0579 | Hotair | HOXD genes | RNA-DNA | regulation | We show that the cognate mouse Hotair is poorly conserved in sequence; and its absence, along with the deletion of the HoxC cluster, has surprisingly little effect in vivo, neither on the expression pattern or transcription efficiency, nor on the amount of K27me3 coverage of different Hoxd target genes. | 21637793 | |||
EL0579 | Hotair | Polycomb repressive complex 2 and Lsd1 complex | RNA-Protein | binding | Hotair binds to both Polycomb repressive complex 2, which methylates histone H3 at lysine 27 (H3K27), and Lsd1 complex, which demethylates histone H3 at lysine 4 (H3K4) in vivo. Hotair inactivation causes H3K4me3 gain and, to a lesser extent, H3K27me3 loss at target genes. | 24075995 | |||
EL0579 | Hotair | HoxD | RNA-DNA | regulation | RNA sequencing and conditional inactivation reveal an ongoing requirement of Hotair to repress HoxD genes and several imprinted loci such as Dlk1-Meg3 and Igf2-H19 without affecting imprinting choice. | 24075995 | |||
EL0580 | HOTAIRM1 | HOXA1 and HOXA4 | RNA-DNA | regulation | Knockdown of HOTAIRM1 quantitatively blunted RA-induced expression of HOXA1 and HOXA4 during the myeloid differentiation of NB4 cells, and selectively attenuated induction of transcripts for the myeloid differentiation genes CD11b and CD18, but did not noticeably impact the more distal HOXA genes. | 19144990 | |||
EL0580 | HOTAIRM1 | HOXA1 | RNA-RNA | co-expression | HOTAIRM1 knockdown in NB4 cells prevented RA induction of HOXA1 and A4. | 21874119 | LncRNADisease | ||
EL0580 | HOTAIRM1 | HOXA4 | RNA-RNA | co-expression | HOTAIRM1 knockdown in NB4 cells prevented RA induction of HOXA1 and A4. | 21874119 | LncRNADisease | ||
EL0580 | HOTAIRM1 | miR-196b | DNA-RNA | co-expression | HOTAIRM1 expression was associated with a specific 33-microRNA signature that included miR-196b (P < 0.001). | 26433964 | |||
EL0582 | HOTTIP | HOXA | RNA-Protein | binding | HOTTIP RNA binds the adaptor protein WDR5 directly and targets WDR5/MLL complexes across HOXA, driving histone H3 lysine 4 trimethylation and gene transcription. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | HOXA | RNA-Protein | binding | HOTTIP RNA binds the adaptor protein WDR5 directly and targets WDR5/MLL complexes across HOXA, driving histone H3 lysine 4 trimethylation and gene transcription. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | WDR5 | RNA-Protein | binding | HOTTIP RNA binds the adaptor protein WDR5 directly and targets WDR5/MLL complexes across HOXA, driving histone H3 lysine 4 trimethylation and gene transcription. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | WDR5 | RNA-Protein | binding | HOTTIP RNA binds the adaptor protein WDR5 directly and targets WDR5/MLL complexes across HOXA, driving histone H3 lysine 4 trimethylation and gene transcription. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | HOXA | RNA-DNA | regulation | Recently, another trans-acting lincRNA, called HOTTIP, has been described activating the transcription of several HOXA genes in vivo by recruiting the proteins Mll1 and Wdr5 on the transcription start sites of the 5' HOXA genes. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | HOXA | RNA-DNA | regulation | Recently, another trans-acting lincRNA, called HOTTIP, has been described activating the transcription of several HOXA genes in vivo by recruiting the proteins Mll1 and Wdr5 on the transcription start sites of the 5' HOXA genes. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | Mll1 | RNA-Protein | binding | Recently, another trans-acting lincRNA, called HOTTIP, has been described activating the transcription of several HOXA genes in vivo by recruiting the proteins Mll1 and Wdr5 on the transcription start sites of the 5' HOXA genes. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | Mll1 | RNA-Protein | binding | Recently, another trans-acting lincRNA, called HOTTIP, has been described activating the transcription of several HOXA genes in vivo by recruiting the proteins Mll1 and Wdr5 on the transcription start sites of the 5' HOXA genes. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | Wdr5 | RNA-Protein | binding | Recently, another trans-acting lincRNA, called HOTTIP, has been described activating the transcription of several HOXA genes in vivo by recruiting the proteins Mll1 and Wdr5 on the transcription start sites of the 5' HOXA genes. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | Wdr5 | RNA-Protein | binding | Recently, another trans-acting lincRNA, called HOTTIP, has been described activating the transcription of several HOXA genes in vivo by recruiting the proteins Mll1 and Wdr5 on the transcription start sites of the 5' HOXA genes. | 21423168 | LncRNADisease | ||
EL0582 | HOTTIP | WDR5 | RNA-Protein | binding | HOTTIP RNA binds the adaptor protein WDR5 directly and targets WDR5/MLL complexes across HOXA, driving histone H3 lysine 4 trimethylation and gene transcription. | 21423168 | |||
EL0582 | HOTTIP | WDR5 | RNA-Protein | binding | HOTTIP was shown to mediate enhancerlike effects on the adjacent genes through a mechanism involving direct interaction with the adaptor protein WDR5. | 21831473 | LncRNADisease | ||
EL0582 | HOTTIP | HOXA | DNA-DNA | regulation | This study identified HOTTIP in association with the promoter regions of downstream 5'HOXA genes. | 21831473 | LncRNADisease | ||
EL0582 | HOTTIP | HOXA | RNA-RNA | co-expression | Knockdown of HOTTIP in foreskin fibroblasts resulted in lower 5’HOXA gene expression. | 21874119 | LncRNADisease | ||
EL0582 | HOTTIP | WDR5 | RNA-Protein | binding | HOTTIP and Mistral recruit chromatin-activating complexes (WDR5/MLL1) in cis to neighboring genes. | 22190456 | LncRNADisease | ||
EL0582 | HOTTIP | FLJ21870 | RNA-RNA | co-expression | Half-sbsRNA1 siRNA increased the levels of SERPINE1 and FLJ21870 mRNAs to 2-to-4.5-fold above normal. | 23728290 | |||
EL0582 | HOTTIP | HOXA gene cluster,miR-125b | RNA-DNA, RNA-RNA | regulation | Knock-down of HOTTIP significantly suppressed the expression of a number of HOXA genes. Furthermore, we identified miR-125b as a post-transcriptional regulator of HOTTIP. | 25424744 | |||
EL0582 | HOTTIP | HOXA13 | RNA-Protein | regulation | Knockdown of HOXA13 by RNA interference (siHOXA13) revealed that HOTTIP promoted PDAC cell proliferation, invasion, and chemoresistance, at least partly through regulating HOXA13. | 25889214 | |||
EL0582 | HOTTIP | HOX gene | RNA-DNA | regulation | HOTTIP does not regulate HOXA13 but plays a role in regulation of several other HOX genes includingHOXA10, HOXB2, HOXA11, HOXA9 and HOXA1. | 25912306 | |||
EL0582 | HOTTIP | HOXA13 | RNA-Protein | co-expression | LncRNA HOTTIP and HOXA13 were significantly down-regulated in HSCR compared to the controls. SiRNA-mediated knock-down of HOTTIP or HOXA13 correlated with decreased levels of each other and both reduced the cell migration and proliferation without affecting cell apoptosis or cell cycle. | 26043692 | |||
EL0582 | HOTTIP | p21 | RNA-Protein | regulation | HOTTIP potentially contributed to CRC cell growth partially through the silencing of p21 expression. | 26678886 | |||
EL0582 | HOTTIP | miR-192 and miR-204 | DNA-RNA | regulation | miR-192 and miR-204 as two microRNAs (miRNAs) suppressing HOTTIP expression via the Argonaute 2 (AGO2)-mediated RNA interference (RNAi) pathway in HCC. The posttranscriptional silencing of HOTTIP by miR-192, miR-204 or HOTTIP siRNAs could significantly suppress viability of HCC cells. The miR-192/-204-HOTTIP axis may interrupt HCC glutaminolysis through GLS1 inhibition. Besides the known targets (multiple 5' end HOX A genes, i.e. HOXA13), glutaminase (GLS1) was identified as a potential downstream target of the miR-192/-204-HOTTIP axis in HCC. | 26710269 | |||
EL0584 | HOXA11-AS | HOXA11 | RNA-DNA | regulation | Hoxa11 antisense functions by transcriptional interference, repressing hoxa11 expression by competing for transcription of the common gene, rather than by sense/antisense interaction. | 12050232 | |||
EL0584 | HOXA11-AS | Hoxa 11 | RNA-RNA | co-expression | In the developing limbs, the sense and antisense transcripts showed complementary expression patterns | 7789268 | |||
EL0585 | Hoxa11os | Hoxa11 | RNA-DNA | regulation | attempts to block hoxa11 function by transfection of the murine uterus with hoxa11 antisense oligonucleotides failed to interrupt normal uterine function, suggesting that hoxa11 antisense does not regulate hoxa11 mrna by formulation of sense/antisense duplexes. | 12050232 | |||
EL0587 | HOXA-AS | HOXA gene | RNA-DNA | regulation | We have investigated the intergenic, noncoding transcriptomes of mammalian HOX clusters. We show that "opposite strand transcription" from the intergenic spacer regions in the human HOXA cluster correlates with the activity state of adjacent HOXA genes. This noncoding transcription is regulated by the retinoic acid morphogen and follows the colinear activation pattern of the cluster. Opening of the cluster at sites of activation of intergenic transcripts is accompanied by changes in histone modifications and a loss of interaction with Polycomb group (PcG) repressive complexes. | 17185360 | |||
EL0588 | HOXA-AS2 | EZH2 (enhaner of zeste homolog 2) | RNA-Protein | binding | HOXA-AS2 could epigenetically repress the expression of P21, PLK3, and DDIT3 via binding with EZH2 (enhaner of zeste homolog 2), a key component of PRC2 | 26384350 | |||
EL0588 | HOXA-AS2 | P21/PLK3/DDIT3 | RNA-Protein | regulation | HOXA-AS2 could epigenetically repress the expression of P21, PLK3, and DDIT3 via binding with EZH2 (enhaner of zeste homolog 2), a key component of PRC2 | 26384350 | |||
EL0589 | Hoxaas3 | Hoxa3 | RNA-DNA | regulation | 05Rik overexpression suppressed Hoxa3 transcription | 26824344 | |||
EL0592 | HSR1 | HSF-1 | RNA-Protein | regulation | The ncRNAs NRSE and HSR have been shown to regulate the activity of REST and HSF-1, respectively. | 19191220 | LncRNADisease | ||
EL0592 | HSR1 | HSF1 | RNA-Protein | binding | Heat-shock factor 1 (HSF1) A third protein-binding lncRNA is HSR1 (heat shock RNA-1), a 604 nucleotide RNA that, together with eukaryotic translationelongation factor 1A, stimulates trimerization of heat-shock factor 1 (HSF1). | 19239885 | LncRNADisease | ||
EL0592 | HSR1 | HSF1 | RNA-Protein | binding | Heat-shock RNA 1 (HSR1) binds heat-shock transcription factor 1 (HSF1), facilitating its ability to activate genes encoding heat-shock proteins. | 22190456 | LncRNADisease | ||
EL0593 | Hsromega | hnRNPs | RNA-Protein | binding | Immunoprecipitation studies using the hnrnp antibodies further demonstrated a physical association of hnrnps and hsromega transcripts. | 10984439 | |||
EL0593 | Hsromega | hnRNPs | RNA-Protein | regulation | It appears that the p transposon insertion in the promoter region causes a misregulated overexpression of hsromega in cyst cells, which in turn results in excessive sequestration of hnrnps and formation of large clusters of omega speckles in these cell nuclei. | 11910129 | |||
EL0593 | Hsromega | 127Q or MJDtr-Q78 or ataxin1 82Q or httex1p Q93 transgene | RNA-Protein | regulation | Loss of hsromega-n RNA not only suppresses the eye-specific degeneration mediated by GMR-GAL4 driven expression of the 127Q or MJDtr-Q78 or ataxin1 82Q or httex1p Q93 transgene, but also rescues premature death of flies expressing the expanded polyQ proteins pan-neuronally using the elav-GAL4 driver. | 19667761 | |||
EL0594 | HSUR1 | host mRNAs | RNA-RNA | regulation | Hsur 1 and 2 expression correlates with significant increases in a small number of host mrnas, including the t cell-receptor beta and gamma chains, the t cell and natural killer (nk) cell-surface receptors cd52 and dap10, and intracellular proteins--skap55, granulysin, and nkg7--linked to t cell and nk cell activation. | 15916956 | |||
EL0594 | HSUR1 | miR-27 | RNA-RNA | binding | Transient knockdown and ectopic expression of HSUR 1 demonstrate that it directs degradation of mature miR-27 in a sequence-specific and binding-dependent manner. | 20558719 | |||
EL0595 | HSUR2 | host mRNAs | RNA-RNA | regulation | Hsur 1 and 2 expression correlates with significant increases in a small number of host mrnas, including the t cell-receptor beta and gamma chains, the t cell and natural killer (nk) cell-surface receptors cd52 and dap10, and intracellular proteins--skap55, granulysin, and nkg7--linked to t cell and nk cell activation. | 15916956 | |||
EL0600 | HULC | miR-372 | RNA-RNA | binding | Acts as a sponge/target mimic for miR-372 reducing its expression and activity. | 21256239 | LncRNADisease | ||
EL0600 | HULC | miR-372 | RNA-DNA | regulation | highly upregulated in liver cancer (HULC) lncRNA sequesters endogenous miR-372 to modulate its own transcriptional upregulation in HCC. | 21802130 | LncRNADisease | ||
EL0600 | HULC | CLOCK | RNA-Protein | regulation | Our observations showed that HULC was able to heighten the expression levels of CLOCK and its downstream circadian oscillators | 25622901 | |||
EL0600 | HULC | p18 | RNA-Protein | regulation | RIP assay showed that HULC down-regulated the level of p18 directly. | 25952928 | |||
EL0600 | HULC | E2F1 | RNA-TF | regulation | HULC activated the promoter of SPHK1 in hepatoma cells through the transcription factor E2F1. E2F1 was capable of binding to the E2F1 element in the SPHK1 promoter. HULC increased the expression of E2F1 in hepatoma cells and levels of HULC were positively correlated with those of E2F1 in HCC tissues. | 26540633 | |||
EL0600 | HULC | SPHK1 | RNA-Protein | regulation | HULC increased SPHK1 in hepatoma cells. | 26540633 | |||
EL0600 | HULC | miR-107 | RNA-RNA | regulation | HULC sequestered miR-107, which targeted E2F1 mRNA 3'UTR, by complementary base pairing. | 26540633 | |||
EL0600 | HULC | TNF-α | RNA-Protein | regulation | HULC expression was decreased with TNF-α treatment. Restoring HULC expression rescued the apoptosis induced by TNF-α. | 26981838 | |||
EL0600 | HULC | miR-9 | RNA-RNA | regulation | HULC modulated miR-9 expression through association with DNA methyltransferases and suppression of miR-9 expression. | 26981838 | |||
EL0602 | HvCesA6 | Csl genes, and GT8 glycosyl transferase genes | RNA-DNA | regulation | Virus induced gene silencing using unique target sequences derived from HvCesA genes attenuated expression not only of the HvCesA6 gene, but also of numerous nontarget Csls and the distantly related GT8 genes and reduced the incorporation of D-(14)C-Glc into cellulose and into mixed-linkage (1 --> 3),(1 --> 4)-beta-D-glucans of the developing leaves. | 19075248 | PLNlncRbase | ||
EL0603 | HvISP1 | HvPHT1;3, HvPHT1;6 | DNA-DNA | co-expression | Interestingly, the expression of HvPHT1;6 and HvPHT1;3 was correlated with the expression of HvIPS1 (for P starvation inducible; noncoding RNA) | 21606317 | PLNlncRbase | ||
EL0605 | ICR | ICAM-1 | RNA-RNA | regulation | ICR regulated ICAM-1 expression by increasing the stability of its mRNA through RNA duplex formation. | 26667486 | |||
EL0606 | ICR1 | FLO11 | RNA-DNA | regulation | ICR1 could repress FLO11 transcription by occluding its promoter. | 19805129 | LncRNADisease | ||
EL0606 | ICR1 | Sfl1 | DNA-TF | regulation | ICR1 is barely detectable in sfl1 mutants in which Rpd3L function is still intact, indicating that Sfl1 function normally promotes ICR1 transcription. | 19805129 | LncRNADisease | ||
EL0606 | ICR1 | Flo8 | RNA-Protein | regulation | These data implicate Flo8 and Rpd3L as repressors of ICR1. | 19805129 | LncRNADisease | ||
EL0606 | ICR1 | Rpd3L | RNA-Protein | regulation | These data implicate Flo8 and Rpd3L as repressors of ICR1. | 19805129 | LncRNADisease | ||
EL0607 | IFNG-AS1 | IgG | RNA-Protein | regulation | The level of expression of TMEVPG1 was correlated with the level of SSA, ESR and IgG. | 26440590 | |||
EL0607 | IFNG-AS1 | IFNG | RNA-Protein | regulation | IFNG-AS1 regulated the expression of IFNG at both transcriptional and translational level in human CD4(+) T cells. Strong positive correlations between the increased transcript level of IFNG-AS1 and the increased transcript level of T-bet or IFNG were revealed in thyroid tissues from HT patients. | 26634912 | |||
EL0609 | IL7R | H3K27me3 | RNA-Protein | regulation | lnc-IL7R knockdown diminished trimethylation of histone H3 at lysine 27 (H3K27me3), a hallmark of silent transcription, at the proximal promoters of the inflammatory mediators. | 24723426 | |||
EL0610 | ILF3 | NF90 (nuclear factor of activated T-cells, 90 kDa) | RNA-Protein | regulation | SALNR interacts with NF90 (nuclear factor of activated T-cells, 90 kDa), an RNA-binding protein suppressing miRNA biogenesis. NF90 is a SALNR downstream target, whose inhibition led to premature senescence and enhanced expressions of senescence-associated miRNAs. | 26487301 | |||
EL0613 | IPS1 | miR-399 | RNA-RNA | regulation | The IPS1 ncRNA is poorly evolutionarily conserved except for a short motif that is highly complementary to miR-399, a miRNA that is induced in response to phosphate starvation, although the basepairing is interrupted by a mismatched loop at the expected miRNA cleavage site. This interruption in basepairing causes the IPS1 ncRNA to be noncleavable and instead allows IPS1 to sequester miR-399, resulting in increased expression of miR-399 target genes. | 19571179 | LncRNADisease | ||
EL0613 | IPS1 | PHO2 | RNA-RNA | regulation | N/A | 22104407, 17643101, 23429259, 19447594, 24523727 | PLNlncRbase | ||
EL0614 | IPS1 | PHO2 | RNA-RNA | regulation | IPS1 overexpression results in increased accumulation of the miR-399 target PHO2 mRNA and, concomitantly, in reduced shoot Pi content. | 17643101 | PLNlncRbase | ||
EL0615 | IPS1 | PHO2 | RNA-RNA | regulation | IPS1 overexpression results in increased accumulation of the miR-399 target PHO2 mRNA and, concomitantly, in reduced shoot Pi content. | 17643101 | PLNlncRbase | ||
EL0616 | IPS1 | PHO2 | RNA-RNA | regulation | IPS1 overexpression results in increased accumulation of the miR-399 target PHO2 mRNA and, concomitantly, in reduced shoot Pi content. | 17643101 | PLNlncRbase | ||
EL0617 | IPS1 | PHO2 | RNA-RNA | regulation | IPS1 overexpression results in increased accumulation of the miR-399 target PHO2 mRNA and, concomitantly, in reduced shoot Pi content. | 17643101 | PLNlncRbase | ||
EL0619 | IRAIN | chromatin DNA | RNA-DNA | regulation | this lncRNA interacts with chromatin DNA and is involved in the formation of an intrachromosomal enhancer/promoter loop. | 25092925 | |||
EL0622 | Jpx | XIST | RNA-RNA | regulation | For the inactive X, here, Xic-encoded Jpx is an Xist activator. Jpx is trans-acting and functions as ncRNA. | 21029862 | LncRNADisease | ||
EL0622 | Jpx | XIST | RNA-RNA | regulation | Xist is controlled by two parallel RNA switches – Tsix for Xa and Jpx for Xi. Jpx activates Xist on Xi. | 21029862 | LncRNADisease | ||
EL0622 | Jpx | XIST | RNA-RNA | regulation | Regulates X chromosome inactivation in mammals via activation of the Xist lncRNA. | 21256239 | LncRNADisease | ||
EL0622 | Jpx | XIST | RNA-DNA | regulation | Jpx lncRNA acts as a positive regulator of Xist. | 21329697 | LncRNADisease | ||
EL0622 | Jpx | XIST | RNA-DNA | regulation | Xist expression and X inactivation could be rescued by a Jpx transgene located on another chromosome, indicating that Jpx can exert its effects in trans. | 21496640 | LncRNADisease | ||
EL0628 | KCNQ1OT1 | chromatin | RNA-DNA | binding | The bidirectional silencing property of Kcnq1ot1 maps to a highly conserved repeat motif within the silencing domain, which directs transcriptional silencing by interaction with chromatin, resulting in histone H3 lysine 9 trimethylation | 18299392 | |||
EL0628 | KCNQ1OT1 | H3K9- and H3K27-specific histone methyltransferases G9a and the PRC2 complex | RNA-Protein | binding | Kcnq1ot1 interacts with chromatin and with the H3K9- and H3K27-specific histone methyltransferases G9a and the PRC2 complex in a lineage-specific manner. This interaction correlates with the presence of extended regions of chromatin enriched with H3K9me3 and H3K27me3 in the Kcnq1 domain in placenta, whereas fetal liver lacks both chromatin interactions and heterochromatin structures | 18951091 | |||
EL0628 | KCNQ1OT1 | KvDMR1 and the Kcnq1 | RNA-DNA | binding | The 5' region of Kcnq1ot1 RNA orchestrates a long-range intrachromosomal loop between KvDMR1 and the Kcnq1 promoter that is required for maintenance of imprinting.PRC2 (polycomb repressive complex 2), which participates in the allelic repression of Kcnq1, is also recruited by Kcnq1ot1 RNA via EZH2. | 24395636 | |||
EL0628 | KCNQ1OT1 | SLC22A18, PHLDA2 | RNA-DNA | regulation | Knockdown of β-catenin resulted in significant decrease of KCNQ1OT1 lncRNA-coated territory and an increase in the mRNA expression of the SLC22A18 and PHLDA2 genes that are regulated by KCNQ1OT1. | 26868975 | |||
EL0628 | KCNQ1OT1 | β-catenin | DNA-Protein | binding | β-catenin can promote KCNQ1OT1 transcription through direct binding to the KCNQ1OT1 promoter. | 26868975 | |||
EL0629 | Kcnq1ot1 | G9a | RNA-Protein | binding | Kcnq1ot1 interacts with chromatin and with the H3K9- and H3K27-specific histone methyltransferases G9a and the PRC2 complex in a lineage-specific manner. | 18951091 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC2 | RNA-Protein | binding | Kcnq1ot1 interacts with chromatin and with the H3K9- and H3K27-specific histone methyltransferases G9a and the PRC2 complex in a lineage-specific manner. | 18951091 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | H3K9me2 and H3K27me3 | RNA-Protein | regulation | Gene silencing by the Kcnq1ot1 RNA involves repressive histone modifications, including H3K9me2 and H3K27me3, which are partly brought about by the G9a and Ezh2 histone methyltransferases. | 19144718 | |||
EL0629 | Kcnq1ot1 | G9a | RNA-Protein | binding | The Kcnq1ot1 RNA also binds to the histone methyltransferase G9a. | 19239885 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | G9a | RNA-Protein | binding | The Kcnq1ot1 transcript that binds both G9a and PRC2. | 19571010 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC2 | RNA-Protein | binding | The Kcnq1ot1 transcript that binds both G9a and PRC2. | 19571010 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC2 | RNA-Protein | binding | PRC2 recruitment to the domain requires expression of the long ncRNA Kcnq1ot1. | 19760321 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | Dnmt1 | RNA-Protein | binding | Kcnq1ot1 mediates transcriptional gene silencing by interacting with Dnmt1. Kcnq1ot1 recruits Dnmt1 to somatic DMRs by interacting with Dnmt1. | 20573698 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | Dnmt1 | RNA-DNA | binding | Kcnq1ot1 recruits Dnmt1 to somatic DMRs by interacting with Dnmt1 | 20573698 | |||
EL0629 | Kcnq1ot1 | Kcnq1 | RNA-DNA | regulation | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | Kcnq1 | RNA-DNA | regulation | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | Dnmt1 | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | Dnmt1 | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | G9a | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | G9a | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC1 | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC1 | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC2 | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC2 | RNA-Protein | binding | Epigenetically silences the Kcnq1 imprinting control region by recruiting repressive chromatin remodelling complexes such as G9a, PRC1 and PRC2, and the DNA methylase Dnmt1. | 21256239 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | G9a | RNA-Protein | binding | Kcnq1ot1 interacts with the histone methyltransferases G9a and PRC2, effectively forming a repression domain in cis to its transcription site through recruitment of polycomb complexes. | 21925379 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | PRC2 | RNA-Protein | binding | Kcnq1ot1 interacts with the histone methyltransferases G9a and PRC2, effectively forming a repression domain in cis to its transcription site through recruitment of polycomb complexes. | 21925379 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | EZH2 | RNA-Protein | binding | HOTAIR, Kcnq1ot and Xist all mediate their effects by interacting with the Polycomb-repressive complex 2 (PRC2) component Ezh2 (enhancer of zeste homolog 2 (Drosophila)) and modulating histone methylation. | 21936910 | LncRNADisease | ||
EL0629 | Kcnq1ot1 | Kcnq | DNA-DNA | regulation | Kcnq1ot is important for silencing of the Kcnq locus resulting from parental imprinting. | 21936910 | LncRNADisease | ||
EL0630 | Khps1 | SPHK1 | RNA-DNA | binding | Mechanistically, this is achieved by direct association of Khps1 with a homopurine stretch upstream of the transcription start site of SPHK1, which forms a DNA-RNA triplex that anchors the lncRNA and associated effector proteins to the gene promoter. | 26590717 | |||
EL0631 | Khps1a | Sphk1 | RNA-DNA | regulation | Regulates DNA methylation in the tissue-dependent differentially methylated region of Sphk1. | 21256239 | LncRNADisease | ||
EL0632 | KIR antisense lncRNA | MZF-1 | RNA-TF | binding | The antisense promoter contains myeloid zinc finger 1 (MZF-1)-binding sites, a transcription factor found in hematopoietic progenitors and myeloid precursors. | 23863987 | |||
EL0647 | LINC00160 | ERα | DNA-Protein | regulation | LINC01016 and LINC00160 are direct transcriptional targets of ERα, correlate with Erα expression in clinical samples, and show prognostic significance in relation to breast cancer survival. | 26423156 | |||
EL0651 | LINC00261 | FOXA2 | RNA-DNA | regulation | Mechanistically, DEANR1 facilitates FOXA2 activation by facilitating SMAD2/3 recruitment to the FOXA2 promoter. | 25843708 | |||
EL0654 | LINC00312 | ERA | RNA-DNA | regulation | ERR-10 (LINC00312): a new repressor in transcriptional signaling activation of estrogen receptor-alpha. | 15474036 | LncRNADisease | ||
EL0661 | LINC00570 | ROCK2 | RNA-RNA | co-expression | depletion of ncRNA-a5 resulted in a specific reduction in ROCK2 expression levels in HeLa cells, which is located upstream of ncRNA-a5. | 20887892 | LncRNADisease | ||
EL0661 | LINC00570 | CMPK1 | RNA-RNA | regulation | KLHL12, ROCK2, TAL1, CMPK1, Snai2, and Snai1 are regulated by ncRNA-a2 through ncRNA-a7, respectively. | 21502407 | LncRNADisease | ||
EL0663 | LINC00635-001 | Akt | RNA-Protein | regulation | Silencing of LINC00635-001 alone did not remarkably impact HCC827-8-1 cells, but its combination with gefitinib treatment inhibited Akt activation and sensitized HCC827-8-1 cells to gefitinib-induced cytotoxicity. | 26792719 | |||
EL0666 | LINC00668 | E2F1 | RNA-TF | regulation | LINC00668 was a direct transcriptional target of E2F transcription factor 1 (E2F1). | 27036039 | |||
EL0666 | LINC00668 | PRC2 | RNA-Protein | regulation | LINC00668 was associated with PRC2 and that this association was required for epigenetic repression of cyclin-dependent protein kinase inhibitors (CKIs), including p15, p16, p21, p27 and p57, thus contributing to the regulation of the gastric cancer cell cycle. | 27036039 | |||
EL0669 | LINC00853 | CMPK1 | RNA-RNA | co-expression | reduced levels of ncRNA-a4 resulted in a consistent and significant decrease in the level of the gene CMPK1 which is over 150 kb downstream of ncRNA-a4. | 20887892 | LncRNADisease | ||
EL0672 | LINC00951 | rs11752942G allele | DNA-RNA | regulation | rs11752942G allele could markedly attenuate the level of lincRNA-uc003opf.1 both in vivo and in vitro by binding micro-RNA-149*, thereby affecting cell proliferation and tumor growth | 23872665 | |||
EL0674 | LINC00964 | piR-015551 | RNA-DNA | regulation | Furthermore, the authors observed that mRNA expression levels of LNC00964-3 (an lncRNA that included the piR-015551 sequence but not piR-015551) were significantly lower in CRC tissues than in corresponding normal tissues | 25740697 | |||
EL0676 | LINC00974 | KRT19 | RNA-RNA | co-expression | Linc00974 was increased owing to an abnormal hypomethylation promoter, which induced the upregulation of KRT19 via ceRNA interaction, resulting in the activation of the Notch and TGF-β pathways as detected by cDNA microarray. | 25476897 | |||
EL0677 | LINC00982 | P15 and P16 protein | RNA-Protein | regulation | Ectopic expression of LINC00982 inhibited cell proliferation and rendered cell cycle arrest in GC cells partly via regulating P15 and P16 protein expressions. | 26334618 | |||
EL0679 | LINC01016 | ERα | DNA-Protein | regulation | LINC01016 and LINC00160 are direct transcriptional targets of ERα, correlate with Erα expression in clinical samples, and show prognostic significance in relation to breast cancer survival. | 26423156 | |||
EL0681 | LINC01021 | p53 | DNA-DNA | regulation | Up-regulation of the novel direct p53 target genes LINC01021, MDFI, ST14 and miR-486 and showed that ectopic LINC01021 expression inhibits proliferation in SW480 cells. | 26183718 | |||
EL0682 | LINC01024 | Purα | RNA-DNA | regulation | MA-linc1 predominantly functions in cis to repress expression of its neighboring gene, Purα, which is often deleted in human cancers and whose ectopic expression inhibits cell cycle progression. | 26337085 | |||
EL0687 | LINC01158 | TGF-beta | RNA-Protein | regulation | linc-POU3F3 could promote the distribution of Tregs in peripheral blood T cell which caused an enhanced cell proliferation of gastric cancer cells by recruiting TGF-beta as well as activating TGF-beta signal pathway. | 26807174 | |||
EL0688 | LINC01207 | Bad | RNA-DNA | regulation | LINC01207 could bind with EZH2 and mediated trimethylation of histone 3 lysine 27 at the promoter region of Bad, an important pro-apoptotic gene. | 26693067 | |||
EL0688 | LINC01207 | EZH2 | RNA-Protein | binding | LINC01207 could bind with EZH2 and mediated trimethylation of histone 3 lysine 27 at the promoter region of Bad, an important pro-apoptotic gene. | 26693067 | |||
EL0695 | LINC01426 | RUNX1 and alternative splicing (AS) factors | RNA-Protein | regulation | lincRNA-uc002yug.2 promoted a combination of RUNX1 and alternative splicing (AS) factors in the nucleus to produce more RUNX1a, the short isoform and inhibitor of RUNX1, and reduce CEBPα (CCAAT/enhancer-binding protein-α) gene expression | 25486427 | |||
EL0705 | LINC01613 | miR-21, miR-31, miR-101, miR-29, miR-199, and let-7d | RNA-RNA | binding | The sequences of the dysregulated microRNAs in IPF including miR-21, miR-31, miR-101, miR-29, miR-199, and let-7d were used to search NONCODE database containing 33,829 human lncRNAs. A total of 34 lncRNAs with potential binding sites to these microRNAs were identified. Four of them were inversely correlated to the microRNA expression in IPF. | 26269497 | |||
EL0716 | lincDR1 | IgG | RNA-Protein | binding | binding with IgG shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0716 | lincDR1 | PRC2 | RNA-Protein | binding | binding with PRC2 shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0717 | lincGARS | IgG | RNA-Protein | binding | binding with IgG shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0717 | lincGARS | PRC2 | RNA-Protein | binding | binding with PRC2 shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0718 | linc-ITGB1 | N-cadherin, vimentin, E-cadherin, Cdc25C, Cyclin B1 | RNA-Protein | regulation | The linc-ITGB1 knockdown decreased the expression of mesenchymal markers N-cadherin and vimentin while increasing the expression of the epithelial marker E-cadherin. Key cell cycle regulators Cdc25C and Cyclin B1 were also decreased by the linc-ITGB1 knockdown. | 26601916 | |||
EL0720 | lincMLKN1 | IgG | RNA-Protein | binding | binding with IgG shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0720 | lincMLKN1 | PRC2 | RNA-Protein | binding | binding with PRC2 shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0723 | LincR-Ccr2-5'AS | GATA-3 | DNA-Protein | regulation | Many were bound and regulated by the key transcription factors T-bet, GATA-3, STAT4 and STAT6. | 24056746 | |||
EL0747 | LINC-ROR | Nanog | DNA-TF | regulation | lincRNA-RoR, was shown to be directly targeted by the key pluripotency factors Oct4, Sox2, and Nanog through colocalization of the three factors close its promoter region. | 21925379 | LncRNADisease | ||
EL0747 | LINC-ROR | 41186 | DNA-TF | regulation | lincRNA-RoR, was shown to be directly targeted by the key pluripotency factors Oct4, Sox2, and Nanog through colocalization of the three factors close its promoter region. | 21925379 | LncRNADisease | ||
EL0747 | LINC-ROR | Sox2 | DNA-TF | regulation | lincRNA-RoR, was shown to be directly targeted by the key pluripotency factors Oct4, Sox2, and Nanog through colocalization of the three factors close its promoter region. | 21925379 | LncRNADisease | ||
EL0747 | LINC-ROR | p70S6K1 (RPS6KB1), PDK1 and HIF-1α | RNA-Protein | regulation | siRNA to linc-RoR decreased phosphorylation of p70S6K1 (RPS6KB1), PDK1 and HIF-1α protein expression and increased expression of the linc-RoR target microRNA-145 (miR-145). | 24463816 | |||
EL0747 | LINC-ROR | miR-145 | RNA-RNA | regulation | siRNA to linc-RoR decreased phosphorylation of p70S6K1 (RPS6KB1), PDK1 and HIF-1α protein expression and increased expression of the linc-RoR target microRNA-145 (miR-145). | 24463816 | |||
EL0747 | LINC-ROR | NRF2 | RNA-TF | binding | NRF2 binds to two specific NRF2 response elements flanking the ROR promoter and that these two NRF2 response elements are equally important to suppress ROR transcription. In addition, we identified associated H3K27me3 chromatin modification and EZH2 binding at the ROR promoter that was dependent on NRF2 binding. | 25231996 | |||
EL0747 | LINC-ROR | TESC | RNA-DNA | regulation | lncRNA ROR occupies and activates the TESC promoter by repelling the histone G9A methyltransferase and promoting the release of histone H3K9 methylation. | 26169368 | |||
EL0747 | LINC-ROR | miR-145 | RNA-RNA | regulation | ROR may act as a ceRNA, effectively becoming a sink for miR-145, thereby activating the derepression of core transcription factors Nanog. | 26636540 | |||
EL0749 | lincSFPQ | IgG | RNA-Protein | binding | binding with IgG shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0749 | lincSFPQ | PRC2 | RNA-Protein | binding | binding with PRC2 shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL0749 | lincSFPQ | PRC2 | RNA-Protein | binding | Numerous lincRNAs are physically associated with PRC2. | 19571010 | LncRNADisease | ||
EL0750 | LINK-A | BRK | RNA-Protein | regulation | LINK-A facilitates the recruitment of BRK to the EGFR:GPNMB complex and BRK kinase activation. | 26751287 | |||
EL0753 | lnc13 | hnRNPD | RNA-Protein | binding | Lnc13 regulates gene expression by binding to hnRNPD, a member of a family of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs). | 27034373 | |||
EL0758 | Lnc34a | miR-34a | RNA-DNA | regulation | Lnc34a recruits Dnmt3a via PHB2 and HDAC1 to methylate and deacetylate the miR-34a promoter simultaneously, hence epigenetically silencing miR-34a expression independent of its upstream regulator, p53. | 27077950 | |||
EL0763 | lncARSR | AXL and c-MET | RNA-DNA | regulation | lncARSR promoted sunitinib resistance via competitively binding miR-34/miR-449 to facilitate AXL and c-MET expression in RCC cells. | 27117758 | |||
EL0763 | lncARSR | miR-34/miR-449 | RNA-RNA | binding | lncARSR promoted sunitinib resistance via competitively binding miR-34/miR-449 to facilitate AXL and c-MET expression in RCC cells. | 27117758 | |||
EL0764 | lnc-bc060912 | p53,PARP1 and NPM1 | RNA-Protein | regulation | we found that Lnc_bc060912 interacted with the two DNA damage repair proteins PARP1 and NPM1 | 25848691 | |||
EL0768 | lnc-DILC | interleukin-6 (IL-6) promoter | RNA-Protein | regulation | lnc-DILC mediates the crosstalk between TNF-α/NF-κB signaling and autocrine IL-6/STAT3 cascade and connects hepatic inflammation with LCSC expansion | 26812074 | |||
EL0768 | lnc-DILC | TNF-α/NF-κB | RNA-Protein | regulation | lnc-DILC mediates the crosstalk between TNF-α/NF-κB signaling and autocrine IL-6/STAT3 cascade and connects hepatic inflammation with LCSC expansion | 26812074 | |||
EL0768 | lnc-DILC | STAT3 | RNA-Protein | regulation | STAT3 activation and LCSC expansion triggered by lnc-DILC depletion and lnc-DILC overexpression. | 26812074 | |||
EL0775 | lncLGR | GCK | RNA-DNA | regulation | lncLGR facilitates the recruitment of hnRNPL to the GCK promoter and suppresses GCK transcription. | 26904944 | |||
EL0775 | lncLGR | heterogenous nuclear ribonucleoprotein L (hnRNPL) | RNA-DNA | binding | lncLGR specifically binds to heterogenous nuclear ribonucleoprotein L (hnRNPL), which is further confirmed to be a transcriptional repressor of GCK in vivo. | 26904944 | |||
EL0791 | lncRNA-422 | protein coding gene | RNA-DNA | regulation | GO analyses of most significantly correlated coding genes of HOTAIR and lncRNA-422 showed that these two lncRNAs may participate in carcinogenesis by regulating protein coding genes involved in special biological process relevant to cancer. | 25456707 | |||
EL0797 | lncRNA-AK058803 | γ-synuclein gene (SNCG) | RNA-DNA | regulation | Unregulated lncRNA-AK058003 in breast cancer cells promotes cancer cell proliferation, invasion and metastasis via the regulation of SNCG expression. | 26136884 | |||
EL0799 | lncRNA-ATB | SB431542 | RNA-RNA | regulation | Treatment with TGF-β in GC cell lines resulted in morphological EMT changes, upregulation of lncRNA-ATB and ZEB1, and downregulation of miR-200c and CDH1. SB431542 reduced lncRNA-ATB expression | 25986864 | |||
EL0799 | lncRNA-ATB | E-cadherin | RNA-DNA | regulation | Long non-coding RNA-activated by TGF-β may act on colon tumorigenesis by suppressing E-cad expression and promoting EMT process | 26487301 | |||
EL0801 | lncRNA-HSVIII | Prss42/Tessp-2 | RNA-DNA | regulation | The lncRNA-HSVIII locus specifically interacted with the Prss42/Tessp-2 promoter in primary and secondary spermatocytes. | 27111572 | |||
EL0812 | LOC100129973 | miR-4707-5p and miR-4767 | RNA-RNA | binding | Through sponging miR-4707-5p and miR-4767, lncRNA LOC100129973 upregulated the expression of two apoptosis repressors gene, Apoptosis Inhibitor 5 (API5) and BCL2 like 12 (BCL2L12). | 26887505 | |||
EL0822 | LOC105246506 | Nanog | DNA-TF | regulation | AK141205 is repressed by the transcription factor Nanog. | 20026622 | LncRNADisease | ||
EL0822 | LOC105246506 | Oct4 and Nanog | RNA-DNA | binding | AK028326 (Oct4-activated) and AK141205 (Nanog-repressed), are direct targets of Oct4 and Nanog. | 20026622 | |||
EL0822 | LOC105246506 | CXCL13; Nanog | RNA-Protein | regulation | Analysis of CXCL13 expression in SMCs(pcDNA-AK141205) revealed that AK141205 positively promoted CXCL13 expression via acetylation of H4 histone in the promoter region (co-expression); Nanog may directly repress transcription of lncRNA AK141205 (regulation). | 26321662; 20026622 | |||
EL0829 | LOC389641 | E-cadherin | RNA-Protein | co-expression | A significant negative correlation was observed between E-cadherin levels and LOC389641 levels in vivo. Knockdown of LOC389641 upregulated E-cadherin expression, but knockdown of E-cadherin had a limited influence on LOC389641. Importantly, after E-cadherin was inhibited, the enhancement of LOC389641 on cell invasion was hindered. | 26708505 | |||
EL0829 | LOC389641 | TNFRSF10A | DNA-DNA | regulation | The expression of LOC389641 was closely associated with its genomic neighboring gene TNFRSF10A. Lastly, knockdown experiments showed that TNFRSF10A might be a connection between LOC389641and E-cadherin. | 26708505 | |||
EL0831 | LOC401317 | TP53 | RNA-DNA | regulation | Further studies indicated that LOC401317 is directly regulated by p53 and that ectopic expression of LOC401317 inhibits HNE2 cell proliferation in vitro and in vivo by inducing cell cycle arrest and apoptosis. | 25422887 | |||
EL0843 | LSINCT5 | PSPC1 | RNA-RNA | co-expression | Two genes that were significantly downregulated were the lncRNA NEAT-1 and a protein coding gene PSPC1. | 21532345 | LncRNADisease | ||
EL0848 | LUADT1 | p27 | RNA-DNA | regulation | LUADT1 binds to SUZ12, a core component of polycomb repressive complex 2, and mediates the trimethylation of H3K27 at the promoter region of p27. | 26291312 | |||
EL0848 | LUADT1 | SUZ12 | RNA-Protein | binding | LUADT1 binds to SUZ12, a core component of polycomb repressive complex 2, and mediates the trimethylation of H3K27 at the promoter region of p27. | 26291312 | |||
EL0850 | LUNAR1 | IGF1R | RNA-RNA | regulation | one specific Notch-regulated lncRNA, LUNAR1, is required for efficient T-ALL growth in vitro and in vivo due to its ability to enhance IGF1R mRNA expression and sustain IGF1 signaling. | 25083870 | |||
EL0850 | LUNAR1 | E2F1, cyclin D1 and p21 | RNA-Protein | regulation | LUNAR1 knockdown significantly repressed cell proliferation of DLBCL by regulating E2F1, cyclin D1 and p21. | 26796267 | |||
EL0853 | MALAT1 | CREB | DNA-TF | regulation | We identified a shorter transcriptional initiation site and found that CREB binds to the defined proximal promoter of the MALAT1 gene. The expression of the tumor marker MALAT1 ncRNA is sensitive to cell surface receptor activation by oxytocin in a neuroblastoma cell line. | 20149803 | LncRNADisease | ||
EL0853 | MALAT1 | SR | RNA-Protein | binding | MALAT1 interacts with SR proteins and influences the distribution of these and other splicing factors in nuclear speckle domains. | 20797886 | LncRNADisease | ||
EL0853 | MALAT1 | SR proteins | RNA-Protein | binding | MALAT1 interacts with SR proteins and influences the distribution of these and other splicing factors in nuclear speckle domains. | 20797886 | |||
EL0853 | MALAT1 | SR protein family | RNA-Protein | regulation | MALAT1 regulates the expression level, localization, and activity SR proteins. | 20864030 | LncRNADisease | ||
EL0853 | MALAT1 | SRSF1 | RNA-Protein | regulation | Upon MALAT1 depletion, expression of SRSF1 protein is increased. | 20864030 | LncRNADisease | ||
EL0853 | MALAT1 | p54nrb | RNA-Protein | binding | In the current model, NEAT1_2 interacts with core paraspeckle proteins PSF and p54nrb, which recruit PSP1 and NEAT1_1 and other associating molecules to the periphery of paraspeckles. | 21444682 | LncRNADisease | ||
EL0853 | MALAT1 | PSF | RNA-Protein | binding | In the current model, NEAT1_2 interacts with core paraspeckle proteins PSF and p54nrb, which recruit PSP1 and NEAT1_1 and other associating molecules to the periphery of paraspeckles. | 21444682 | LncRNADisease | ||
EL0853 | MALAT1 | Pc2 | DNA-Protein | regulation | methylation/demethylation of Polycomb 2 protein (Pc2) controls relocation of growth-control genes between Polycomb bodies (PcGs) and interchromatin granules (ICGs) in response to growth signals. This movement is the consequence of binding of methylated and unmethylated Pc2 to the ncRNAs TUG1 and MALAT1/NEAT2. | 22078878 | LncRNADisease | ||
EL0853 | MALAT1 | Pc2 | DNA-Protein | regulation | Methylation/demethylation of Polycomb 2 protein (Pc2) controls relocation of growth-control genes between Polycomb bodies (PcGs) and interchromatin granules (ICGs) in response to growth signals. This movement is the consequence of binding of methylated and unmethylated Pc2 to the ncRNAs TUG1 and MALAT1/NEAT2. | 22078878 | LncRNADisease | ||
EL0853 | MALAT1 | RNPS1 | RNA-Protein | regulation | RNAi-mediated repression of the nuclear speckle proteins, RNPS1, SRm160, or IBP160, which are well-known mRNA processing factors, resulted in the diffusion of MALAT-1 to the nucleoplasm. | 22355166 | LncRNADisease | ||
EL0853 | MALAT1 | SRm160 | RNA-Protein | regulation | RNAi-mediated repression of the nuclear speckle proteins, RNPS1, SRm160, or IBP160, which are well-known mRNA processing factors, resulted in the diffusion of MALAT-2 to the nucleoplasm. | 22355166 | LncRNADisease | ||
EL0853 | MALAT1 | IBP160 | RNA-Protein | regulation | RNAi-mediated repression of the nuclear speckle proteins, RNPS1, SRm160, or IBP160, which are well-known mRNA processing factors, resulted in the diffusion of MALAT-3 to the nucleoplasm. | 22355166 | LncRNADisease | ||
EL0853 | MALAT1 | pre-mRNA splicing factors | RNA-Protein | regulation | MALAT1 interacts with pre-mRNA splicing factors and regulates cancer cell migration, synapse formation, cell cycle progression, and responses to serum stimulation. | 23698766 | |||
EL0853 | MALAT1 | Bcl-2 | RNA-DNA | regulation | An interaction of Bcl-2 with MALAT-1 lncRNA expression was revealed. | 25036876 | |||
EL0853 | MALAT1 | Sp1 and LTBP3 promoter | RNA-DNA | binding | lncRNA MALAT1 directly interacted with Sp1 and LTBP3 promoterto increase expression of LTBP3 gene. | 25187517 | |||
EL0853 | MALAT1 | Cisplatin and paclitaxel | N/A | regulation | Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | |||
EL0853 | MALAT1 | SiRNA | RNA-RNA | regulation | SiRNA knockdown of HOTAIR in GC cells significantly inhibited cell proliferation | 25280565 | |||
EL0853 | MALAT1 | PI3K/AKT signaling pathway | RNA-Protein | regulation | MALAT1 might suppress the tumor growth and metastasis via I3K/AKT signaling pathway. | 25431257 | |||
EL0853 | MALAT1 | miR-101 and miR-217 | RNA-RNA | regulation | A significant negative correlation exists between miR-101 or miR-217 and MALAT1 in 42 pairs of ESCC tissue samples and adjacent normal tissues. | 25538231 | |||
EL0853 | MALAT1 | CCL5 | RNA-Protein | regulation | The stimulation of colon cancer progression by TADC-derived CCL5 was associated with the up-regulation of non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), which subsequently increased the expression of Snail. | 25546229 | |||
EL0853 | MALAT1 | ATM-CHK2 pathway | RNA-Protein | regulation | Western-blotting results implicated that the ATM-CHK2 pathway which is associated with G2/M arrest was phosphorylated by MALAT1 knockdown. | 25613496 | |||
EL0853 | MALAT1 | RANKL | RNA-Protein | regulation | We found that RANKL induced the expression of a lncRNA, MALAT1, for the first time. Knockdown of RANK by siRNA blocked the induction of MALAT1 by RANKL. In addition, MALAT1 also regulated OPG expression in hFOB 1.19 cells. | 25817340 | |||
EL0853 | MALAT1 | PI3K-AKT pathway | N/A | regulation | Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. | 26191181 | |||
EL0853 | MALAT1 | miRNA-124 | RNA-RNA | regulation | Knockdown of MALAT1 increased the expression of miRNA-124. MALAT1 can indirectly modulate GRB2 expression via competing miR-124. | 26242259 | |||
EL0853 | MALAT1 | TDP-43 | RNA-Protein | binding | TDP-43 directly bound to MALAT1 RNA. Silencing TDP-43 expression effectively decreased MALAT1 RNA transcript level. In contrast, TDP-43 overexpression markedly increased MALAT1 transcript level. | 26265046 | |||
EL0853 | MALAT1 | hsa-miR-1 | RNA-RNA | regulation | MiR-1 functioned as a tumor suppressor by targeting K-RAS and MALAT1. | 26275461 | |||
EL0853 | MALAT1 | miR-145 | RNA-RNA | regulation | miR-145 and MALAT1 were in the same Ago2 complex and there was a reciprocal repression between them. | 26311052 | |||
EL0853 | MALAT1 | Sp1/3 | DNA-Protein | regulation | Co-silencing of Sp1 and Sp3 synergistically repressed MALAT1 expression. Sp1 binding inhibitor, mithramycin A (MIT), also inhibited MALAT1 expression in HCC cells. | 26352013 | |||
EL0853 | MALAT1 | EZH2 (enhancer of zeste homolog 2) and H3K27me3 | RNA-Protein | regulation | Knockdown of MALAT1 reversed CSE-induced increases of EZH2 (enhancer of zeste homolog 2) and H3K27me3 levels. In addition to the alteration from epithelial to spindle-like mesenchymal morphology, chronic exposure of HBE cells to CSE increased the levels of EZH2, H3K27me3, vimentin, and N-cadherin and decreased E-cadherin levels, effects that were reversed by MALAT1 siRNA or EZH2 siRNA. | 26415832 | |||
EL0853 | MALAT1 | miR-217 | DNA-RNA | regulation | Over-expression of miR-217 with a mimic attenuated the CSE-induced increase of MALAT1 levels, and reduction of miR-217 levels by an inhibitor enhanced expression of MALAT1. MiR-217 regulation of EZH2/H3K27me3 via MALAT1 is involved in CSE-induced EMT and malignant transformation of HBE cells. | 26415832 | |||
EL0853 | MALAT1 | miR-200s | RNA-RNA | binding | MALAT1 promote KIRC proliferation and metastasis through sponging miR-200s in vitro and in vivo. | 26461224 | |||
EL0853 | MALAT1 | miR-1 | RNA-RNA | regulation | There was reciprocal repression between MALAT1 and miR-1, and slug was identified as a downstream target of miR-1. | 26482776 | |||
EL0853 | MALAT1 | EZH2 | RNA-Protein | binding | EZH2 binds to MALAT1.The 3' end of MALAT1 interacts with the N-terminal of EZH2. | 26516927 | |||
EL0853 | MALAT1 | N-cadherin, Vimentin, E-cadherin | RNA-Protein | regulation | MALAT1 knockdown significantly suppressed N-cadherin and Vimentin expression but induced E-cadherin expression in vitro. | 26522444 | |||
EL0853 | MALAT1 | ZO-1, occludin and claudin-5 | RNA-Protein | regulation | Knockdown of MALAT1 resulted in an impairment and increased the permeability of BTB as well as decreased the expression of ZO-1, occludin and claudin-5 in GECs. | 26619802 | |||
EL0853 | MALAT1 | miR-140 | RNA-RNA | regulation | There was reciprocal repression between MALAT1 and miR-140, and miR-140 mediated the effects that MALAT1 knockdown exerted. | 26619802 | |||
EL0853 | MALAT1 | ERK/MAPK signaling | N/A | regulation | Downregulation of MALAT1 could activate ERK/MAPK signaling and promoted proliferation in SHG139 cells. | 26649728 | |||
EL0853 | MALAT1 | Sox2 and Nestin | RNA-Protein | regulation | Downregulation of MALAT1 suppressed the expression of Sox2 and Nestin which are related to stemness. | 26649728 | |||
EL0853 | MALAT1 | Hsa-miR-1 | RNA-RNA | regulation | A reciprocal negative control relationship between MALAT1 and miR-1. | 26676637 | |||
EL0853 | MALAT1 | pro-apoptotic proteins including cleaved caspase-3, cleaved caspase-9 and cleaved poly (ADP-ribose) polymerase-1 (PARP-1). | RNA-Protein | regulation | Reduced expression of MALAT-1 by RNA interference resulted in enhanced apoptosis in JEG-3 cells, accompanied with elevated levels of the pro-apoptotic proteins including cleaved caspase-3, cleaved caspase-9 and cleaved poly (ADP-ribose) polymerase-1 (PARP-1). | 26722461 | |||
EL0853 | MALAT1 | PCDH10 | RNA-DNA | regulation | Long noncoding RNA (lncRNA) MALAT1 binds EZH2, suppresses the tumor suppressor PCDH10, and promotes gastric cellular migration and invasion. | 26871474 | |||
EL0853 | MALAT1 | EZH2 | RNA-Protein | binding | Long noncoding RNA (lncRNA) MALAT1 binds EZH2, suppresses the tumor suppressor PCDH10, and promotes gastric cellular migration and invasion. | 26871474 | |||
EL0853 | MALAT1 | miR-124 | RNA-RNA | binding | MALAT1 acted as an endogenous potent regulator by directly binding to miR-124 and down-regulating miR-124 expression. | 26918449 | |||
EL0853 | MALAT1 | cyclin-dependent kinase 4 (CDK4) | RNA-DNA | regulation | MALAT1 reversed the inhibitory effect of miR-124 on breast cancer proliferation and was involved in the cyclin-dependent kinase 4 (CDK4) expression. | 26918449 | |||
EL0853 | MALAT1 | cdc42 | RNA-DNA | regulation | MALAT1 regulated migration and invasion of breast cancer cells via affecting cdc42 through binding miR-1 competitively. miR-1 bound both MALAT1 and cdc42 3'UTR directly. | 26926567 | |||
EL0853 | MALAT1 | miR-1 | RNA-RNA | binding | MALAT1 regulated migration and invasion of breast cancer cells via affecting cdc42 through binding miR-1 competitively. | 26926567 | |||
EL0859 | MDC1-AS1 | MDC1 | RNA-DNA | regulation | we have identified a novel antisense lncRNA MDC1-AS, which may participate in bladder cancer through up-regulation of its antisense tumor-suppressing gene MDC1. | 25514464 | |||
EL0860 | Mdrl | miR-361 | RNA-RNA | binding | MDRL could directly bind to miR-361 and downregulate its expression levels, which promotes the processing of pri-miR-484. | 25057983 | |||
EL0861 | MEG3 | cAMP | DNA-TF | regulation | Deletion and mutation analysis suggest that a cAMP response element (CRE), located between -69 and -49 of the MEG3 proximal promoter region, is critical for promoter activity. Furthermore, gel shifting, ChIP analysis, and co-transfection experiments show that CREB directly binds to the CRE site and stimulates MEG3 promoter activity. Therefore, MEG3 is a downstream target gene of cAMP. | 16793321 | LncRNADisease | ||
EL0861 | MEG3 | GDF15 | RNA-DNA | regulation | We further found that MEG3 stimulates expression of the growth differentiation factor 15 (GDF15) by enhancing p53 binding to the GDF15 gene promoter. | 17569660 | LncRNADisease | ||
EL0861 | MEG3 | p53 | RNA-Protein | binding | We further found that MEG3 stimulates expression of the growth differentiation factor 15 (GDF15) by enhancing p53 binding to the GDF15 gene promoter. | 17569660 | LncRNADisease | ||
EL0861 | MEG3 | p53 | RNA-RNA | co-expression | MEG3 functions to suppress tumor cell growth, increase protein expression of the tumor suppressor p53, and selectively activate p53 target genes. | 20211686 | LncRNADisease | ||
EL0861 | MEG3 | p53 | RNA-Protein | regulation | The lncRNA MEG3 is a positive regulator of p53. | 20951849 | LncRNADisease | ||
EL0861 | MEG3 | Tp53 | RNA-DNA | regulation | The lncRNA MEG3 activates the expression of Tp53 and enhances its binding affinity to the promoter of its target gene. | 21247874 | LncRNADisease | ||
EL0861 | MEG3 | p53 | RNA-DNA | regulation | Putative tumour suppressor. Regulates p53 expression. Inhibits cell proliferation in the absence of p53. | 21256239 | LncRNADisease | ||
EL0861 | MEG3 | cAMP response element-binding protein | DNA-Protein | binding | We show that menin activates the long noncoding RNA maternally expressed gene 3 (Meg3) by histone-H3 lysine-4 trimethylation and CpG hypomethylation at the Meg3 promoter CRE site, to allow binding of the transcription factor cAMP response element-binding protein. | 25565142 | |||
EL0861 | MEG3 | osterix, osteocalcin, BMP4 | RNA-Protein | regulation | We observed that MEG3 knockdown significantly reduced the expression of key osteogenic markers, including Runt-related transcription factor 2, osterix, and osteocalcin, while overexpression of MEG3 enhanced their expression. Additionally, MEG3 knockdown decreased BMP4 transcription. Here we showed that MEG3 was critical for SOX2 transcriptional repression of the BMP4. | 25753650 | |||
EL0861 | MEG3 | p53 and Bcl-xl | RNA-DNA | co-expression | MEG3 is significantly downregulated in LAD and partially regulates the cisplatin resistance of LAD cells through the control of p53 and Bcl-xl expression. Thus, MEG3 may represent a new marker of poor response to cisplatin and could be a potential therapeutic target for LAD chemotherapy | 25992654 | |||
EL0861 | MEG3 | Rac1 | RNA-DNA | regulation | we also showed that Rac1 was negatively regulated by lncRNA-MEG3 at the posttranscriptional level, via a specific target site within the 3΄UTR by dual luciferase reporter assay. The expression of Rac1 was inversely correlated with lncRNA-MEG3 expression in PTC tissues. Thus, this study suggests that MEG3 acts as novel suppressor of migration and invasion by targeting Rac1 gene. | 25997963 | |||
EL0861 | MEG3 | Bcl-2 | RNA-RNA | regulation | Bcl-2 mRNA level was declined by MEG3 overexpression. | 26223924 | |||
EL0861 | MEG3 | MiR-141 | RNA-RNA | regulation | Mir-141 inhibits gastric cancer proliferation by interacting with long noncoding RNA meg3 and down-regulating e2f3 expression. | 26233544 | |||
EL0861 | MEG3 | Bcl-2 | RNA-Protein | regulation | MEG3 could up-regulated Bcl-2 via its competing endogenous RNA (ceRNA) activity on miR-181a. | 26253106 | |||
EL0861 | MEG3 | miR-181 s | RNA-RNA | regulation | MEG3 sequestering oncogenic miR-181 s in GC cells. | 26253106 | |||
EL0861 | MEG3 | p53 | RNA-Protein | regulation | In addition, inactivation of p53 completely abolished tumor suppression by MEG3, indicating that MEG3 tumor suppression is mediated by p53. | 26284494 | |||
EL0861 | MEG3 | miR-21 | RNA-RNA | regulation | Overexpression of MEG3 reduced the level of miR-21-5p expression. | 26574780 | |||
EL0861 | MEG3 | FoxO1, G6pc, Pepck | RNA-DNA | regulation | MEG3 overexpression significantly increased FoxO1, G6pc, Pepck mRNA expressions and hepatic gluconeogenesis and suppressed insulin-stimulated glycogen synthesis in primary hepatocytes, whereas palmitate-induced increase of FoxO1, G6pc and Pepck protein expressions could be reversed by MEG3 interference. | 26603935 | |||
EL0861 | MEG3 | Bcl-2, Bax, activating caspase 3, Cyclin D1 | RNA-Protein | regulation | MEG3 inhibited intrinsic cell survival pathway in vitro and in vivo by reducing the protein expression of Bcl-2, enhancing Bax and activating caspase 3. MEG3 inhibited the expression of cell cycle regulatory protein Cyclin D1 and induced cell cycle arrest in G0/G1 phase. | 26610246 | |||
EL0861 | MEG3 | p53, caspase-3, MDM2 and cyclin D1, | RNA-Protein | regulation | Ectopic expression of MEG3 increased p53, caspase-3 mRNA and protein levels, decreased MDM2 and cyclin D1 mRNA and protein levels, as well as ILF3 protein expression in HepG2 cells. | 26647875 | |||
EL0861 | MEG3 | ILF3 | RNA-Protein | regulation | ILF3 may participate in the anticancer regulation of MEG3 by interacting with MEG3. | 26647875 | |||
EL0861 | MEG3 | DNMT1 | DNA-Protein | regulation | DNMT1 was involved in MEG3 promoter methylation, and was inversely correlated with MEG3 expression in gliomas. DNMT1-mediated MEG3 hypermethylation caused the loss of MEG3 expression, followed by the inhibition of the p53 pathways in gliomas. | 26676363 | |||
EL0861 | MEG3 | IFN-γ | DNA-Protein | regulation | IFN-γ induced autophagy in infected macrophages resulted in sustained MEG3 down regulation and lack of IFN-γ allowed for counter regulation of MEG3 by viable M. bovis BCG. | 26757825 | |||
EL0861 | MEG3 | miR-140-5p | RNA-RNA | regulation | Pioglitazone up-regulated MEG3 expression to protect EPCs via decreasing miR-140-5p expression and increasing HDAC7 expression in MetS | 26898430 | |||
EL0863 | MEG8 | RBII-36 snoRNA | RNA-RNA | regulation | The novel brain-specific snorna appears to result not only from processing of the debranched lariat but also from endonucleolytic cleavages of unspliced bsr rna | 11346658 | |||
EL0865 | MHM | DMRT1 | RNA-DNA | regulation | Mis-expression of MHM sense and antisense sequences results in overgrowth of tissues in which transcripts are predominantly expressed. This includes altered asymmetric ovarian development in females. In males, MHM mis-expression impairs gonadal expression of the testis gene, DMRT1. Both MHM sense and antisense mis-expression cause brain abnormalities, while MHM sense causes an increase in male-biased embryo mortality. | 22546690 | |||
EL0868 | Mhrt | Brg1 | RNA-Protein | binding | Mhrt prevents Brg1 from recognizing its genomic DNA targets, thus inhibiting chromatin targeting and gene regulation by Brg1. It does so by binding to the helicase domain of Brg1, a domain that is crucial for tethering Brg1 to chromatinized DNA targets. | 25119045 | |||
EL0869 | MIAT | IRES-GFP | DNA-DNA | regulation | fusion of RNCR2 to an IRES-GFP sequence results in mislocalization of this nuclear RNA to the cytoplasm. | 20459797 | LncRNADisease | ||
EL0869 | MIAT | SF1 | RNA-Protein | binding | Celf3 formed novel nuclear bodies (named CS bodies) that colocalized with SF1, another Gomafu-binding protein. | 25145264 | |||
EL0869 | MIAT | Celf3 | RNA-Protein | binding | The RNA-binding protein Celf3 as a novel Gomafu-associating protein. Knockdown of Celf3 led to the down-regulation of Gomafu, and cross-link RNA precipitation analysis confirmed specific binding between Celf3 and Gomafu. | 25145264 | |||
EL0869 | MIAT | Akt | RNA-Protein | regulation | MIAT acted as a ceRNA, and formed a feedback loop with Akt and miR-150-5p to regulate HLEC function. | 26818536 | |||
EL0869 | MIAT | miR-150-5p | RNA-RNA | regulation | MIAT acted as a ceRNA, and formed a feedback loop with Akt and miR-150-5p to regulate HLEC function. | 26818536 | |||
EL0870 | Miat | Oct4 | DNA-TF | regulation | AK028326 is activated by the transcription factor OCT4. | 20026622 | LncRNADisease | ||
EL0870 | Miat | Oct4 and Nanog | RNA-DNA | binding | AK028326 (Oct4-activated) and AK141205 (Nanog-repressed), are direct targets of Oct4 and Nanog | 20026622 | |||
EL0870 | Miat | BMI1 | RNA-Protein | regulation | Our results revealed that Gomafu plays a role in mediating anxiety-like behavior and suggest that this may occur through an interaction with a key member of the polycomb repressive complex 1, BMI1, which regulates the expression of the schizophrenia-related gene beta crystallin(Crybb1). | 25792222 | |||
EL0871 | MIAT | SF1 splicing factor | RNA-Protein | binding | We propose that the Gomafu RNA regulates splicing efficiency by changing the local centration of splicing factors within the nucleus | 21463453 | |||
EL0873 | MINCR | MYC | RNA-DNA | regulation | MINCR acts as a modulator of the MYC transcriptional program. MINCR knockdown was associated with a reduction in MYC binding to the promoters of selected cell cycle genes. | 26351698 | |||
EL0875 | Mir124a-1hg | Ptbp1 | RNA-RNA | co-expression | Ptbp1 and AK044422 exhibit complementary expression profiles. | 20137068 | LncRNADisease | ||
EL0876 | Mir142hg | mir-142-3p | RNA-RNA | co-expression | Two miRNAs, mir-142-5p and mir-142-3p, recently shown to be among the most highly expressed miRNAs in naive, memory, and effector CD8 T cell populations (76), are hosted within the first intron of a long ncRNA (AK020764) that is also strongly expressed in CD8 T cells. | 19494298 | LncRNADisease | ||
EL0876 | Mir142hg | mir-142-5p | RNA-RNA | co-expression | Two miRNAs, mir-142-5p and mir-142-3p, recently shown to be among the most highly expressed miRNAs in naive, memory, and effector CD8 T cell populations (76), are hosted within the first intron of a long ncRNA (AK020764) that is also strongly expressed in CD8 T cells. | 19494298 | LncRNADisease | ||
EL0877 | MIR155HG | MYB | DNA-TF | regulation | MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. | 21296997 | LncRNADisease | ||
EL0878 | MIR17HG | E2F1 | DNA-TF | regulation | Aurora kinase A induces miR-17-92 cluster through regulation of E2F1 transcription factor. | 20300951 | LncRNADisease | ||
EL0880 | MIR31HG | caspase | RNA-Protein | regulation | Loc554202 regulated cell apoptosis partly through the activation of specific caspase cleavage cascades. | 26362196 | |||
EL0880 | MIR31HG | E2F1 and p21 | RNA-Protein | regulation | Knockdown of MIR31HG by small interfering RNA (siRNA) promoted cell proliferation in GC cells partly via regulating E2F1 and p21 expression. | 26692098 | |||
EL0884 | Mira | Hoxa6 | RNA-DNA | regulation | Here, we demonstrate that the long, noncoding RNA (lncRNA) Mistral (Mira) activates transcription of the homeotic genes Hoxa6 and Hoxa7 in mouse embryonic stem cells (mESC) by recruiting MLL1 to chromatin. | 21925392 | LncRNADisease | ||
EL0884 | Mira | Hoxa7 | RNA-DNA | regulation | Here, we demonstrate that the long, noncoding RNA (lncRNA) Mistral (Mira) activates transcription of the homeotic genes Hoxa6 and Hoxa7 in mouse embryonic stem cells (mESC) by recruiting MLL1 to chromatin. | 21925392 | LncRNADisease | ||
EL0884 | Mira | MLL1 | RNA-Protein | binding | Here, we demonstrate that the long, noncoding RNA (lncRNA) Mistral (Mira) activates transcription of the homeotic genes Hoxa6 and Hoxa7 in mouse embryonic stem cells (mESC) by recruiting MLL1 to chromatin. | 21925392 | LncRNADisease | ||
EL0884 | Mira | Hoxa6 and Hoxa7 | RNA-DNA | regulation | Mira-mediated recruitment of MLL1 to the Mira gene triggers dynamic changes in chromosome onformation, culminating in activation of Hoxa6 and Hoxa7 transcription. Hoxa6 and Hoxa7 activate the expression of genes involved in germ layer specification during mESC differentiation in a cooperative and redundant fashion. Our results connect the lncRNA Mira with the recruitment of MLL1 to target genes and implicate lncRNAs in epigenetic activation of gene expression during vertebrate cell-fate determination. | 21925392 | |||
EL0933 | MR1 | TGF-β1; PI3K inhibitor (LY294002); AKT inhibitor (GDC-0068) | DNA-Protein | regulation | the expression of AK056155 can be enhanced by TGF-β1 in a concentration or time depended manner in HUVECs by RT-PCR. Furthermore, the expression of AK056155 was reduced with treatment of PI3K inhibitor (LY294002) or AKT inhibitor (GDC-0068) in combination with TGF-β1. | 26617788 | |||
EL0938 | Msx1 | Msx1 | RNA-RNA | co-expression | In vitro, Msx1 AS RNA decreased endogenous Msx1 S expression and modified Msx1 protein cell distribution.Msx1 AS RNA could also modulate Msx1 function. | 18728357 | LncRNADisease | ||
EL0938 | Msx1 | Dlx5 | RNA-RNA | co-expression | Transient transfection of Msx1 expression vector clearly decreased Dlx5 expression by 40–61% in 705IC5 and 705IH8 cell lines. | 18728357 | LncRNADisease | ||
EL0938 | Msx1 | Bmp4 | RNA-RNA | co-expression | Transient transfection of Msx1 expression vector increased Bmp4 expression by 118% and 48% in 705IC5 and 705IH8 cell lines. | 18728357 | LncRNADisease | ||
EL0939 | Msx1os | Msx1 | RNA-Protein | regulation | The balance between the levels of the two msx1 rnas is related to the expression of msx1 protein. | 11390985 | |||
EL0939 | Msx1os | Msx1 | RNA-RNA | regulation | The balance between antisense and sense msx1 mrnas appeared to control msx1 protein levels. | 12489151 | |||
EL0940 | MT1DP | Rux2 and YAP | RNA-Protein, RNA-TF | regulation | Rux2 and YAP were capable of inhibiting long non-coding RNA (lncRNA) | 25261601 | |||
EL0941 | MT1JP | TIAR | RNA-Protein | binding | By associating with the RNA-binding protein TIAR, MT1JP enhanced the translation of the master transcription factor p53, thereby regulating a series of pathways involving p53, such as the cell cycle, apoptosis and proliferation. | 26909858 | |||
EL0941 | MT1JP | p53 | RNA-Protein | regulation | By associating with the RNA-binding protein TIAR, MT1JP enhanced the translation of the master transcription factor p53, thereby regulating a series of pathways involving p53, such as the cell cycle, apoptosis and proliferation. | 26909858 | |||
EL0942 | Mt4 | miR399 | RNA-RNA | binding | IPS1 and At4 directly inhibits miR-399 activity.IPS1 has many family members in a number of plant species, including At4, At4–1, At4–2 and At4–3 in Arabidopsis thaliana, TPS11 in tomato, Mt4 in Barrel Clover and Alfalfa, Mt4-like in Soybean | 23726911 | PLNlncRbase | ||
EL0947 | MT-ND5 | PTCD2 | RNA-RNA | regulation | PTCD2 decreased the levels of ND5 lncRNA and the lncND6 RNA, which can form the 39 UTR of the ND5 mRNA. | 22028365 | LncRNADisease | ||
EL0948 | MT-ND6 | PTCD2 | RNA-RNA | regulation | PTCD2 decreased the levels of ND5 lncRNA and the lncND6 RNA, which can form the 39 UTR of the ND5 mRNA. | 22028365 | LncRNADisease | ||
EL0950 | MVIH | miR-199a | RNA-RNA | binding | Luciferase reporter assay and RNA immunoprecipitation experiment showed that miR-199a had a direct binding ability to MVIH RNA. MVIH promoted cell growth and inhibited cell apoptosis of HCC via inhibiting miR-199a expression. | 26347410 | |||
EL0950 | MVIH | Ki67 | RNA-Protein | co-expression | High MVIH expression was correlated with Ki67 expression. | 26555546 | |||
EL0959 | NALT1 | NOTCH1 | RNA-Protein | regulation | Up-regulation of NALT associating with NOTCH1 in human samples. A neighbor of NOTCH1, Lnc-RP11-611D20.2 (named NALT) which could regulate the NOTCH1 signal pathway through cis-regulation. | 26330272 | |||
EL0961 | NBAT1 | DKK1 (dickkopf WNT signaling pathway inhibitor 1) | RNA-Protein | regulation | DKK1 (dickkopf WNT signaling pathway inhibitor 1) is found to be regulated by NBAT1 in a PRC2 dependent manner, and is responsible for NBAT1's effects in inhibiting migration and invasion of breast cancer cells. | 26378045 | |||
EL0961 | NBAT1 | EZH2 | RNA-Protein | regulation | NBAT1 is associated with PRC2 member EZH2 and regulates global gene expression profile. | 26378045 | |||
EL0962 | NBR2 | AMP-activated protein kinase (AMPK) | RNA-Protein | regulation | NBR2 in turn interacts with AMPK and promotes AMPK kinase activity | 26999735 | |||
EL0967 | ncRNA-a6 | Snai2 | RNA-RNA | co-expression | Snai2 shows a significant reduction in expression when the adjacent ncRNA-a6 is depleted. | 20887892 | LncRNADisease | ||
EL0967 | ncRNA-a6 | Snai2 | RNA-RNA | regulation | KLHL12, ROCK2, TAL1, CMPK1, Snai2, and Snai1 are regulated by ncRNA-a2 through ncRNA-a7, respectively. | 21502407 | LncRNADisease | ||
EL0968 | ncRNACCND1 | CCND1 | RNA-DNA | regulation | Interacts with CCND1 (cyclin D1) locus and the RNA-binding protein TLS to repress CCND1 expression. | 18509338 | LncRNADisease | ||
EL0968 | ncRNACCND1 | DROSHA | RNA-Protein | binding | We found that knock-down of the miRNA regulator DROSHA, but not DICER, increased the expression level of CCND1ncRNA about four-fold, suggesting that CCND1ncRNA may be processed in a DROSHA-dependent manner. | 20573714 | LncRNADisease | ||
EL0969 | NCRUPAR | PAR-1 | RNA-DNA | regulation | The ncR-uPAR upregulated PAR-1-core promoter-driven luciferase activity and mRNA expression in vitro in a Pol II-dependent manner. This noncoding RNA appears to act in trans, albeit locally at the adjacent PAR-1 promoter. | 12084570 | LncRNADisease | ||
EL0969 | NCRUPAR | PAR-1 | RNA-Protein | regulation | The expression of ncRuPAR was significantly downregulated in CRC compared with paired adjacent nontumor tissues, but the level of PAR-1 mRNA in cancerous tissues was significantly higher than in adjacent normal areas. | 25119598 | |||
EL0971 | Nctc1 | Igf2/H19 shared muscle enhancer | RNA-DNA | regulation | Nctc1 is co-regulated with Igf2 and H19 and physically interacts with the shared muscle enhancer. In fact, all three co-regulated genes have the potential to interact not only with the shared enhancer but also with each other via their enhancer interactions. | 23221643 | |||
EL0973 | NEAT1 | PSP-1 | RNA-Protein | binding | The PSP-1 RNA binding domain is required for its colocalization with NEAT1 RNA in paraspeckles, and biochemical analyses support that NEAT1 RNA binds with paraspeckle proteins. | 19217333 | LncRNADisease | ||
EL0973 | NEAT1 | DBHS | RNA-Protein | binding | DBHS protein expression did not vary between the two cellular contexts, instead, paraspeckle induction and increased RNA nuclear retention correlated with the expression of the paraspeckle-specific structural ncRNA species NEAT1. | 19720872 | LncRNADisease | ||
EL0973 | NEAT1 | P54NRB/NONO | RNA-Protein | binding | NEAT1 associates with DBHS proteins in vivo, as immunoprecipitation of PSF/SFPQ, P54NRB/NONO, and PSPC1 all copurify NEAT1 RNA to varying levels. | 19720872 | LncRNADisease | ||
EL0973 | NEAT1 | PSF/SFPQ | RNA-Protein | binding | NEAT1 associates with DBHS proteins in vivo, as immunoprecipitation of PSF/SFPQ, P54NRB/NONO, and PSPC1 all copurify NEAT1 RNA to varying levels. | 19720872 | LncRNADisease | ||
EL0973 | NEAT1 | PSPC1 | RNA-Protein | binding | NEAT1 associates with DBHS proteins in vivo, as immunoprecipitation of PSF/SFPQ, P54NRB/NONO, and PSPC1 all copurify NEAT1 RNA to varying levels. | 19720872 | LncRNADisease | ||
EL0973 | NEAT1 | P54nrb | RNA-Protein | binding | a novel mechanism which is different from that reported | 20211624 | |||
EL0973 | NEAT1 | PSP1 | RNA-Protein | binding | NEAT1 directly interacts with the paraspeckle protein PSP1. NEAT1 knockdown abolishes paraspeckles and relaxes the constraints on export of Alu-containing RNAs into the cytoplasm. | 20951849 | LncRNADisease | ||
EL0973 | NEAT1 | p54nrb | RNA-Protein | binding | In the current model, NEAT1_2 interacts with core paraspeckle proteins PSF and p54nrb, which recruit PSP1 and NEAT1_1 and other associating molecules to the periphery of paraspeckles. | 21444682 | LncRNADisease | ||
EL0973 | NEAT1 | PSF | RNA-Protein | binding | In the current model, NEAT1_2 interacts with core paraspeckle proteins PSF and p54nrb, which recruit PSP1 and NEAT1_1 and other associating molecules to the periphery of paraspeckles. | 21444682 | LncRNADisease | ||
EL0973 | NEAT1 | Proteins of the Drosophila behavior/human splicing | RNA-Protein | binding | Additionally, mammalian DBHS proteins associate with the architectural long noncoding RNA NEAT1 to form paraspeckles, subnuclear bodies that alter gene expression via the nuclear retention of RNA. | 22416126 | LncRNADisease | ||
EL0973 | NEAT1 | miR-449a | RNA-RNA | regulation | Further study of the interaction between miR-449a and NEAT1 show that NEAT1 was up-regulated when cells were transfected with miR-449a inhibitor, and NEAT1 was down-regulated when cells transfected with miR-449a mimics. | 25818739 | |||
EL0973 | NEAT1 | SWItch/Sucrose NonFermentable (SWI/SNF) chromatin-remodeling complexes | RNA-Protein | binding | Subunits of SWItch/Sucrose NonFermentable (SWI/SNF) chromatin-remodeling complexes were identified as paraspeckle components that interact with PSPs and NEAT1 lncRNA. | 25831520 | |||
EL0973 | NEAT1 | p53 | RNA-Protein | regulation | We used isogenic lymphoma cell line models to prove p53 dependence of NEAT1 and lincRNA-p21. The current work describes the p53-dependent miRNome and identifies lncRNAs NEAT1 and lincRNA-p21 as novel elements of the p53-dependent DNA damage response machinery in CLL and lymphoma. | 25971364 | |||
EL0973 | NEAT1 | MDTH, NM23 and MALAT1 | DNA-DNA | co-expression | high NEAT1 expression levels were significantly associated with the expression level of MDTH, NM23 and MALAT1. | 26191242 | |||
EL0973 | NEAT1 | miR-140 | DNA-RNA | binding | a miR-140 binding site in NEAT1 was identifiedand and mature miR-140 in the nucleus can physically interact with NEAT1, leading to increased NEAT1 expression. | 26457124 | |||
EL0973 | NEAT1 | miR-204/ZEB1 | RNA-RNA | regulation | There was reciprocal repression between NEAT1 and miR-204. | 27020592 | |||
EL0973 | NEAT1 | ZEB1 | RNA-Protein | regulation | ZEB1 was identified as a downstream target of miR-204 and NEAT1 upregulated ZEB1 expression by negatively regulating miR-204 expression. | 27020592 | |||
EL0973 | NEAT1 | HuR | RNA-Protein | binding | NEAT1_1 was stabilized by an RNA-binding protein HuR, but suppressed by miR-124-3p in OC cells. | 27075229 | |||
EL0973 | NEAT1 | miR-124-3p | RNA-RNA | regulation | NEAT1_1 was stabilized by an RNA-binding protein HuR, but suppressed by miR-124-3p in OC cells. | 27075229 | |||
EL0974 | Neat1 | Neat2 | RNA-RNA | co-expression | Neat1 and Neat2 associate with nuclear paraspeckles and adjacent SC35 speckles, respectively;domains where transcription and co-transcriptional premRNA processing occur. | 20137068 | LncRNADisease | ||
EL0974 | Neat1 | SRp40 | RNA-Protein | binding | SRp40 associated with NEAT1, as shown by RNA-IP on days 0 and 8, but decreased on day 4, and concentrations increased over that of IgG control. | 25437750 | |||
EL0975 | Nespas | Nesp | RNA-RNA | co-expression | Transcription of one of its ncRNAs, the Nesp antisense (Nespas) seems important for repression of Nesp on the paternal allele. | 19760321 | LncRNADisease | ||
EL0977 | NKILA | NF-κB/IκB | RNA-Protein | binding | Here, we identify an NF-KappaB Interacting LncRNA (NKILA), which is upregulated by NF-κB, binds to NF-κB/IκB, and directly masks phosphorylation motifs of IκB, thereby inhibiting IKK-induced IκB phosphorylation and NF-κB activation. | 25759022 | |||
EL0978 | Nkx2-2os | Nkx2.2 | RNA-DNA | regulation | Nkx2.2, a transcription factor that is critical for OL lineage specification, is also subject to regulation by a lncRNA, Nkx2.2AS, which is transcribed antisense to the Nkx2.2 gene. | 20380817 | LncRNADisease | ||
EL0984 | NONRATT021972 | ERK1/2 | RNA-Protein | regulation | NONRATT021972 siRNA inhibited the phosphorylation and activation of ERK1/2 in T2DM DRG. | 26742527 | |||
EL0984 | NONRATT021972 | P2X3 | RNA-DNA | regulation | The expression levels of the P2X3 protein and messenger RNA (mRNA) of T2DM rat DRG were higher compared to the control, while those in T2DM rats treated with NONRATT021972 siRNA were significantly lower compared to T2DM rats. | 26742527 | |||
EL0984 | NONRATT021972 | TNF-α | RNA-Protein | regulation | The level of tumor necrosis factor-α (TNF-α) in the serum of T2DM rats treated with NONRATT021972 siRNA was significantly decreased compared with T2DM rats. | 26742527 | |||
EL0985 | NORAD | PUMILIO | RNA-Protein | regulation | NORAD maintains genomic stability by sequestering PUMILIO proteins, which repress the stability and translation of mRNAs to which they bind. In the absence of NORAD, PUMILIO proteins drive chromosomal instability by hyperactively repressing mitotic, DNA repair, and DNA replication factors. | 26724866 | |||
EL0998 | npc48 | miR168/miR164/miR166 | RNA-RNA | regulation | The phenotype of 35S∷npc48 plants resembled that of 35S∷MIR168 plants, which have reduced levels of the miR168 AGO1 target, and of AGO1-sensitive miRNAs such as miR166 (Vaucheret et al. 2006). 35S∷npc48 plants also showed a decrease in miR166 accumulation, but accumulated AGO1 mRNA and miR168 at wild-type levels. In addition, 35S∷npc48 plants, but not 35S∷MIR168 plants, exhibited reduced accumulation of miR164, suggesting that npc48 could regulate a subset of miRNAs. | 18997003 | PLNlncRbase | ||
EL1000 | npc531 | miR319 | RNA-RNA | regulation | We identified a putative miR319 target site in npc531, but 5′ RACE-PCR analyses did not reveal any specific cleavage of this transcript in this site (data not shown) | 18997003 | PLNlncRbase | ||
EL1001 | npc536 | AT1G67930 | RNA-RNA | regulation | npc536 regulates the translation of AT1G67930 mRNA. | 18997003, 24252906 | PLNlncRbase | ||
EL1007 | NPTN-IT1 | EZH2 | DNA-Protein | regulation | lncRNA-LET is transcriptional repressed by EZH2-mediated H3K27 histone methylation on the LET promoter. The expressions of EZH2 and lncRNA-LET are significantly inversely correlated in NPC tissues. | 26243049 | |||
EL1009 | NR024118 | SOCS3 | RNA-DNA | regulation | NR024118 overexpression and interference significantly changed SOCS3 expression and NR024118 interference could reverse regulation of shikonin on SOCS3, proinflammatory cytokines, and MMPs expression level in MH7A cells. | 26640499 | |||
EL1010 | NRAV | interferon-stimulated genes (ISGs) | RNA-DNA | regulation | NRAV negatively regulates the initial transcription of multiple critical interferon-stimulated genes (ISGs), including IFITM3 and MxA, by affecting histone modification of these genes. | 25525793 | |||
EL1013 | NRON | NFAT | RNA-Protein | regulation | By binding to members of the nucleocytoplasmic trafficking machinery, NRON specifically inhibits the nuclear accumulation of NFAT. | 19571179 | LncRNADisease | ||
EL1013 | NRON | NFAT | RNA-Protein | regulation | The conserved lncRNA, named NRON,regulated the nucleocytoplasmic shuttling of the NFAT transcription factor by functioning in a nuclear pore ribonucleoprotein complex. | 20951849 | LncRNADisease | ||
EL1013 | NRON | LRRK2 | RNA-Protein | binding | Mechanistic studies showed that LRRK2 was a potent negative regulator of the transcription factor NFAT and was a component of a complex that included the large noncoding RNA NRON. | 21983832 | LncRNADisease | ||
EL1014 | NRSE | REST | RNA-Protein | regulation | The ncRNAs NRSE and HSR have been shown to regulate the activity of REST and HSF-1, respectively. | 19191220 | LncRNADisease | ||
EL1015 | nta-eTMX27 | QPT2 | RNA-DNA | regulation | We identified a microRNA (nta-miRX27) and also a lncRNA (nta-eTMX27) as an endogenous target mimicry (eTM) in tobacco targeting the nicotine biosynthesis key gene QPT2 encoding quinolinate phosphoribosyltransferase (QPT) and thereby regulating the nicotine content. | 27172239 | |||
EL1017 | NUTF2P3-001 | KRAS | RNA-RNA | co-expression | Microarray co-assay for lncRNAs and mRNAs demonstrates that lncRNA-NUTF2P3-001 is remarkably overexpressed in pancreatic cancer and chronic pancreatitis tissues, which positively correlates with KRAS mRNA expression. | 26755660 | |||
EL1017 | NUTF2P3-001 | miR-3923 | RNA-RNA | binding | The dual-luciferase reporter assay further validates that lncRNA-NUTF2P3-001 and 3'UTR of KRAS mRNA competitively bind with miR-3923. | 26755660 | |||
EL1020 | OIP5-AS1 | miR-424 | RNA-RNA | regulation | miR-424 interacted with OIP5-AS1 and competed with HuR for binding to OIP5-AS1 | 26819413 | |||
EL1020 | OIP5-AS1 | HuR | RNA-Protein | binding | The RNA-binding protein HuR, which enhances cell proliferation, associated with OIP5-AS1 and stabilized it. Tagging OIP5-AS1 with MS2 hairpins to identify associated microRNAs revealed that miR-424 interacted with OIP5-AS1 and competed with HuR for binding to OIP5-AS1. | 26819413 | |||
EL1021 | OR3A4P | PDLIM2, MACC1, NTN4, and GNB2L1 | RNA-DNA | regulation | OR3A4 influenced biologic functions in gastric cancer cells via regulating the activation of PDLIM2, MACC1, NTN4, and GNB2L1. | 26863570 | |||
EL1024 | OsIPS1 | PHO2 | RNA-DNA | regulation | OsSPX3 plays a role in OsIPS1/miR399 mediated long distance regulation on OsPHO2. | 19566645 | PLNlncRbase | ||
EL1025 | osk | BSF | RNA-Protein | binding | Bicoid Stability Factor (BSF) binds specifically to the C region of the mRNA. Although the C region of the osk 3' UTR is required for the noncoding function, BSF binding does not appear to be essential for that function. | 26433064 | |||
EL1034 | P2rx3 | TNF-α | RNA-Protein | regulation | The expression levels of TNF-α in the DRG of DM rats treated with uc.48+ siRNA were significantly decreased compared to those in the DM group. | 26686228 | |||
EL1034 | P2rx3 | P2X3 | RNA-DNA | regulation | The levels of P2X3 protein and mRNA in the DG of DM rats treated with uc.48+ siRNA were significantly decreased compared to those in DM rats. | 26686228 | |||
EL1034 | P2rx3 | ERK1/2 | RNA-Protein | regulation | The phosphorylation and activation of ERK1/2 in the DM DRG were decreased by uc.48+ siRNA treatment. | 26686228 | |||
EL1044 | PACERR | NF-κB complexes | RNA-Protein | regulation | The lncRNA associates with p50, a repressive subunit of NF-κB, and occludes it from the COX-2 promoter, potentially facilitating interaction with activation-competent NF-κB p65/p50 dimers. | 24843008 | |||
EL1045 | PAN | E1B-AP5 | RNA-Protein | binding | E1B-AP5 interacts with the PAN MRE-II motif outside of the 9-nt core in the MRE-II loop. | 22043172 | LncRNADisease | ||
EL1045 | PAN | PABPC1 | RNA-Protein | binding | PABPC1 binds to the 9-nt core of PAN MRE-II. | 22043172 | LncRNADisease | ||
EL1046 | PANDAR | Bcl-2 | RNA-DNA | regulation | PANDAR-mediated growth regulation is in part due to the transcriptional modulation of Bcl-2 by interacting with NF-YA, thus affecting NSCLC cell apoptosis. | 25719249 | |||
EL1047 | PARTICL | MAT2A; G9a and SUZ12 | RNA-DNA, RNA-Protein | binding | Surface plasmon resonance indicates that PARTICLE forms a DNA-lncRNA triplex upstream of a MAT2A promoter CpG island. We show that PARTICLE represses MAT2A via methylation and demonstrate that the radiation-induced PARTICLE interacts with the transcription-repressive complex proteins G9a and SUZ12 (subunit of PRC2). | 25900080 | |||
EL1048 | Paupar | PAX6 | RNA-Protein | binding | Paupar acts in a transcript-dependent manner both locally, to regulate Pax6, as well as distally by binding and regulating genes on multiple chromosomes, in part through physical association with PAX6 protein. Paupar binding sites are enriched near promoters and can function as transcriptional regulatory elements whose activity is Modulated by Paupar transcript levels. | 24488179 | |||
EL1051 | PCA3 | AR cofactors and EMT markers | RNA-DNA | regulation | PCA3 silencing modulates the expression of key cancer-related genes, including those coding for AR cofactors and EMT markers. | 26960690 | |||
EL1052 | PCAT1 | SUZ12 | DNA-TF | regulation | Chromatin immunoprecipitation (ChIP) assays also demonstrated that SUZ12, a core PRC2 protein, directly binds the PCAT-1 promoter approximately 1kb upstream of the TSS. | 21804560 | LncRNADisease | ||
EL1052 | PCAT1 | EZH2 | RNA-RNA | co-expression | Knockdown of EZH2 by shRNA or pharmacologic inhibition of EZH2 with the inhibitor 3-deazaneplanocin A (DZNep) caused a dramatic upregulation in PCAT-1 expression levels. | 21804560 | LncRNADisease | ||
EL1052 | PCAT1 | PRC2 | RNA-Protein | binding | PCAT-1 is a prostate-specific regulator of cell proliferation and show that it is a target of the Polycomb Repressive Complex 2 (PRC2). Patterns of PCAT-1 and PRC2 expression stratified patient tissues into molecular subtypes distinguished by expression signatures of PCAT-1-repressed target genes. | 21804560 | LncRNADisease | ||
EL1052 | PCAT1 | cMyc | RNA-DNA | regulation | The PCAT-1-cMyc relationship is mediated through the post-transcriptional activity of the MYC 3' untranslated region | 25425964 | |||
EL1052 | PCAT1 | p53 | RNA-DNA | regulation | chromatin immunoprecipitation (ChIP) assays confirmed that PANDAR was a direct transcriptional target of p53 in NSCLC cells. | 25731728 | |||
EL1055 | PCAT5 | ERG | RNA-TF | regulation | PCAT5 as a regulatory target for the transcription factor ERG, which is activated in approximately 50% of human prostate cancer. | 26282172 | |||
EL1056 | PCAT6 | KLHL12 | RNA-RNA | co-expression | When ncRNA-a2 was depleted, the KLHL12, a gene known for its negative regulation of the Wnt-beta catenin pathway, on the opposite strand displayed a significant reduction. | 20887892 | LncRNADisease | ||
EL1056 | PCAT6 | KLHL12 | RNA-RNA | regulation | KLHL12, ROCK2, TAL1, CMPK1, Snai2, and Snai1 are regulated by ncRNA-a2 through ncRNA-a7, respectively. | 21502407 | LncRNADisease | ||
EL1058 | PCGEM1 | miR-145 | RNA-RNA | regulation | Downregulation of PCGEM1 expression in LNCaP cells increased expression of miR-145, while overexpression of miR-145 decreased PCGEM1 expression. Transfection of the miR-145 expression vector and siRNA PCGEM1 inhibited tumor cell proliferation, migration, and invasion, and induced early apoptosis both in vitro. In contrast, there was no effect on RWPE-1 cells. | 25200485 | |||
EL1058 | PCGEM1 | miR-770 | RNA-RNA | binding | Target validation showed a direct binding between PCGEM1 and miR-770. PCGEM1 act as sponge lncRNA for miR-770 that regulates proliferation/apoptosis and autophagy, and suggest PCGEM1 as possible target for OA therapy. | 26340084 | |||
EL1059 | PCNA-AS1 | E2F | RNA-Protein | binding | The binding of S phase-specific E2F complexes at the +583 element may help to overcome the negative effect of the antisense transcript, which results in up-regulation of PCNA expression in proliferating cells. | 10488129 | LncRNADisease | ||
EL1065 | PHO84 | PHO84 | RNA-DNA | regulation | Silences PHO84 in aged cells by recruiting histone deacetylases to the locus. | 21256239 | LncRNADisease | ||
EL1065 | PHO84 | histone deacetylases | RNA-Protein | binding | Silences PHO84 in aged cells by recruiting histone deacetylases to the locus. | 21256239 | LncRNADisease | ||
EL1066 | PHO84 antisense transcripts | PHO84 | RNA-DNA | regulation | the knockdown of antisense production prevents PHO84 gene repression, even in the absence of Rrp6. | 18022365 | |||
EL1067 | PICSAR | miR-320a and miR-383 | RNA-DNA | regulation | NLC1-C in the nucleus repressed miR-320a and miR-383 transcript and promoted testicular embryonal carcinoma cell proliferation by binding to Nucleolin. | 26539909 | |||
EL1070 | PINK1-AS | PU.1 mRNA | RNA-RNA | binding | PU.1 AS lncRNA binding to PU.1 mRNA to form mRNA/AS lncRNA duplex in preadipocytes | 23749759 | |||
EL1075 | pncRNA-D | TLS (Translocated in LipoSarcoma, also known as FUsed in Sarcoma) | RNA-Protein | binding | The binding of TLS and pncRNA-D was affected by the presence of GGUG and GGU sequences, and the C terminal domains of TLS function in the interaction with pncRNA-D | 26816614 | |||
EL1079 | POU6F2-AS2 | Ybx1 | RNA-Protein | regulation | POU6F2-AS2 interacts with Ybx1 protein and regulates its chromatin localization. | 27033944 | |||
EL1082 | PRAL | p53 | RNA-Protein | regulation | The three stem-loop motifs at the 5' end of lncRNA-PRAL facilitated the combination of HSP90 and p53 and thus competitively inhibited MDM2-dependent p53 ubiquitination, resulting in enhanced p53 stability. | 26663434 | |||
EL1084 | Prep | Prolyl oligopeptidase (POP) | RNA-Protein | regulation | Knocked down lncPrep+96kb in the primary ovarian granulosa cell and a hepatic cell line, the POP expression was decreased in both cells. In contrast, overexpression of lncPrep+96kb increased the POP expression only in the granulosa cell. | 24369296 | |||
EL1085 | PRINS | G1P3 | RNA-RNA | co-expression | Here, we report that PRINS regulates G1P3, a gene with anti-apoptotic effects in keratinocytes. siRNA-mediated inhibition of PRINS gene resulted in altered cell morphology and gene expression alterations, as demonstrated in a microarray experiment. | 20377629 | LncRNADisease | ||
EL1085 | PRINS | RANTES | RNA-Protein | regulation | Among HIF-1α dependent LncRNAs, PRINS (Psoriasis susceptibility-related RNA Gene Induced by Stress) was significantly up regulated in hypoxic conditions and had specific interaction with RANTES as confirmed through reporter assay. | 26725683 | |||
EL1086 | Prion-associated RNAs | hrPrP | RNA-Protein | binding | Shsrnas that bind to hrprp with high affinity and induce resistance to pk digestion | 12946346 | |||
EL1087 | pRNA | PARP1 | RNA-Protein | binding | We demonstrate that PARP1 associates with TIP5, a subunit of the NoRC complex, via the noncoding pRNA and binds to silent rRNA genes after their replication in mid-late S phase. | 22405650 | LncRNADisease | ||
EL1091 | PsiLNCRNA00268512 | miR396e | RNA-RNA | regulation | PsiLNCRNA00268512 regulates miR396e levels by acting as a target mimic. | 26712827 | |||
EL1093 | psvA antisense RNA | EB4 mRNA | RNA-RNA | regulation | The inhibition of rna synthesis during disaggregation prevents destabilization of the mrna. | 1555240 | |||
EL1096 | PTCSC3 | S100A4 | RNA-DNA | regulation | PTCSC3 downregulates S100A4, leading to a reduction in cell motility and invasiveness. | 26274343 | |||
EL1097 | PTENP1 | PTEN | RNA-RNA | co-expression | We find that PTENP1 is biologically active as it can regulate cellular levels of PTEN and exert a growth-suppressive role. | 20577206 | LncRNADisease | ||
EL1099 | Ptgs2os2 | heterogeneous nuclear ribonucleoprotein A/B and A2/B1 | RNA-Protein | regulation | Transcriptional repression of target genes is dependent on interactions of lincRNA-Cox2 with heterogeneous nuclear ribonucleoprotein A/B and A2/B1. | 23907535 | |||
EL1101 | PU.1 AS | PU.1 mRNA | RNA-RNA | binding | The PU.1 mRNA/PU.1 AS lncRNA duplex was detected by an endogenous ribonuclease protection assay combined with RT-PCR. | 25691151 | |||
EL1102 | PVT1 | c-Myc | DNA-TF | regulation | PVT-1 regulates c-Myc gene transcription over a long distance. PVT-1 is also a downstream target of Myc proteins. | 17503467 | LncRNADisease | ||
EL1102 | PVT1 | c-Myc | RNA-DNA | regulation | PVT-1 regulates c-Myc gene transcription over a long distance. PVT-1 is also a downstream target of Myc proteins. | 17503467 | LncRNADisease | ||
EL1102 | PVT1 | YY1 | RNA-DNA | regulation | The risk allele (G) of rs378854 reduces binding of the transcription factor YY1 in vitro. The region surrounding rs378854 interacts with the MYC and PVT1 promoters.Expression of the PVT1 oncogene in normal prostate tissue increased with the presence of the risk allele of rs378854, while expression of MYC was not affected. | 21814516 | LncRNADisease | ||
EL1102 | PVT1 | P53 | DNA-TF | regulation | The non-protein coding locus PVT1 is a p53-inducible target gene. | 22110125 | LncRNADisease | ||
EL1102 | PVT1 | serum α-fetoprotein | RNA-Protein | regulation | overexpression of PVT1 was associated with a higher serum α-fetoprotein expression level (P=0.011) and a higher recurrence rate (P=0.004). | 25624916 | |||
EL1102 | PVT1 | EZH2 | RNA-Protein | binding | we further confirmed that PVT1 was associated with enhancer of zeste homolog 2 (EZH2) and that this association was required for the repression of p15 and p16 | 25890171 | |||
EL1102 | PVT1 | EZH2 | RNA-Protein | regulation | lncRNA PVT1 could be enriched by EZH2, and silencing PVT1 resulted in the decreased recruitment of EZH2. | 26427660 | |||
EL1102 | PVT1 | cyclin D1 and TSHR | RNA-Protein | regulation | Silenced PVT1significantly decreased cyclin D1 and TSHR expressions. | 26427660 | |||
EL1102 | PVT1 | MYC | DNA-DNA | regulation | Significantly lower MYC and PVT1 expression was observed during all-trans retinoic acid (ATRA)-induced differentiation and cell cycle arrest in the APL cell line. MYC knockdown in NB4 cells led to PVT1 downregulation. Moreover, PVT1 knockdown by RNA interference led to suppression of the MYC protein level, and cell proliferation was inhibited. | 26544536 | |||
EL1102 | PVT1 | LATS2 | RNA-DNA | regulation | PVT1 recruits EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and represses LATS2 transcription. | 26908628 | |||
EL1102 | PVT1 | EZH2 | RNA-Protein | binding | PVT1 recruits EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and represses LATS2 transcription. | 26908628 | |||
EL1103 | PWR1 | FLO11 | RNA-DNA | regulation | PWR1 could promote FLO11 transcription by interfering with ICR1 transcription. | 19805129 | LncRNADisease | ||
EL1103 | PWR1 | Flo8 | DNA-TF | regulation | PWR1 transcription requires Flo8 and is promoted by Rpd3L activity, but is repressed by Sfl1 function. | 19805129 | LncRNADisease | ||
EL1103 | PWR1 | Rpd3L | DNA-TF | regulation | PWR1 transcription requires Flo8 and is promoted by Rpd3L activity, but is repressed by Sfl1 function. | 19805129 | LncRNADisease | ||
EL1103 | PWR1 | Sfl1 | DNA-TF | regulation | PWR1 transcription requires Flo8 and is promoted by Rpd3L activity, but is repressed by Sfl1 function. | 19805129 | LncRNADisease | ||
EL1103 | PWR1 | ICR1 | RNA-DNA | regulation | The fact that low level ICR1 is detected even in sfl1 mutants suggests that ICR1 may be constitutive, supporting a model in which its levels are tuned by PWR1 transcription. | 19805129 | LncRNADisease | ||
EL1107 | RAD51-AS1 | RAD51 | RNA-Protein | regulation | Our results identify TPIP as a novel E2F1 co-activator, suggest a similar role for other TPTEs, and indicate that the TODRA lncRNA affects RAD51 dysregulation and RAD51-dependent DSB repair in malignancy. | 26230935 | |||
EL1108 | RBM4 | FLJ21870 | RNA-RNA | co-expression | Half-sbsRNA1 siRNA increased the levels of SERPINE1 and FLJ21870 mRNAs to 2-to-4.5-fold above normal. | 21307942 | LncRNADisease | ||
EL1108 | RBM4 | SERPINE1 | RNA-RNA | co-expression | Half-sbsRNA1 siRNA increased the levels of SERPINE1 and FLJ21870 mRNAs to 2-to-4.5-fold above normal. | 21307942 | LncRNADisease | ||
EL1109 | RBM5-AS1 | RBM5 | RNA-RNA | co-expression | These results suggest that LUST is a novel, functional, non-coding RNA that plays a role in determining the apoptotic fate of a cell by regulating the expression of RBM5 splice variants. | 19559772 | LncRNADisease | ||
EL1109 | RBM5-AS1 | antisense strand of intron 6 | RNA-DNA | binding | Je2, which mapped to the antisense strand of intron 6 of the putative tumour suppressor gene RBM5/LUCA-15/H37, and functioned as an apoptosis suppressor. | 19559772 | |||
EL1112 | RepA | PRC2 | RNA-Protein | binding | We discovered a 1.6-kilobase ncRNA (RepA) within Xist and identified the Polycomb complex, PRC2, as its direct target. | 18974356 | LncRNADisease | ||
EL1112 | RepA | Ezh2 | RNA-Protein | regulation | Recently, it was shown that a segment of the Xist RNA (called RepA) is important for the targeting of Ezh2 (a component of PRC2) and hence H3K27me3 to the X chromosome. | 19239885 | LncRNADisease | ||
EL1112 | RepA | PRC2 | RNA-Protein | binding | RepA is sufficient to recruit PRC2 to chromatin in vivo. | 19571179 | LncRNADisease | ||
EL1112 | RepA | PRC2 | RNA-Protein | binding | Tsix represses Xist induction by several means, including altering the chromatin state of Xist, deploying Dnmt3a’s DNA methyltransferase activity, recruiting the RNAi machinery, and interfering with the ability of Xist and RepA RNA to engage Polycomb proteins. | 21029862 | LncRNADisease | ||
EL1112 | RepA | XIST | RNA-DNA | regulation | Recruits PRC2 to the inactive X chromosome in mammals. Necessary for initiation of Xist upregulation and X chromosome silencing. | 21256239 | LncRNADisease | ||
EL1112 | RepA | PRC2 | RNA-Protein | binding | Recruits PRC2 to the inactive X chromosome in mammals. Necessary for initiation of Xist upregulation and X chromosome silencing. | 21256239 | LncRNADisease | ||
EL1114 | RGMB-AS1 | RGMB | RNA-Protein | regulation | Studies also indicated that lncRNA RGMB-AS1and RGMB were inversely correlated | 26055877 | |||
EL1117 | Rmrp | DDX5 | RNA-Protein | binding | The ability of DDX5 to interact with RORγt and coactivate its targets depends on intrinsic RNA helicase activity and binding of a conserved nuclear long noncoding RNA (lncRNA), Rmrp, which is mutated in patients with cartilage-hair hypoplasia. | 26675721 | |||
EL1118 | Rmst | miR-135a | RNA-RNA | co-expression | Ncrms serves as a host gene for miR-135a (Rodriguez et al., 2004), an oncogenic miRNA that is dysregulated in medulloblastoma. | 20380817 | LncRNADisease | ||
EL1118 | Rmst | Pax2 | DNA-TF | regulation | The transcription factor, Pax2, plays a role in patterning of the mouse embryonic midbrain and hindbrain, and Ncrms, a lncRNA, is specifically regulated by Pax2 in this region. | 20380817 | LncRNADisease | ||
EL1119 | RMST | WNT5A | RNA-Protein | regulation | tsRMST regulates Wnt and EMT signaling pathways in hESCs by repressing WNT5A, which is a potential EMT inducer for promoting in vitro differentiation of hESCs through PKC activation. | 27090862 | |||
EL1120 | RN7SK | P-TEFb | RNA-Protein | regulation | 7sk inhibits general and hiv-1 tat-specific transcriptional activities of p-tefb in vivo and in vitro by inhibiting the kinase activity of cdk9 and preventing recruitment of p-tefb to the hiv-1 promoter. | 11713532 | |||
EL1120 | RN7SK | P-TEFb | RNA-Protein | binding | The transcription-dependent interaction of p-tefb with 7sk may therefore contribute to an important feedback loop modulating the activity of rna pol ii. | 11713533 | |||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. | 15201869 | LncRNADisease | ||
EL1120 | RN7SK | OCT1 | DNA-TF | regulation | PTF and Oct-1 enhance transcription from the 7SK promoter in an interdependent manner. | 1535687 | LncRNADisease | ||
EL1120 | RN7SK | PTF | DNA-TF | regulation | PTF and Oct-1 enhance transcription from the 7SK promoter in an interdependent manner. | 1535687 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | 7SK RNA binding to a HEXIM1 multimer promotes the simultaneous recruitment and hence inactivation of multiple P-TEFb units. | 15994294 | LncRNADisease | ||
EL1120 | RN7SK | APOBEC3C | RNA-Protein | binding | it is unclear how APOBEC3C's activity is controlled to prevent its mutations of genomic DNA. We show that most of APOBEC3C interact with about half of nuclear 7SK, which suppresses APOBEC3C's deaminase activity and sequesters APOBEC3C in the nucleolus where it could be at a safe distance from most genomic sequences. | 17381310 | |||
EL1120 | RN7SK | BCDIN3 | RNA-Protein | regulation | BCDIN3 is the 7SK snRNA methylphosphate capping enzyme (MePCE) present in an snRNP complex containing both RNA processing and transcription factors, including the elongation factor P-TEFb. | 17643375 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | When associated with 7SK small nuclear RNA, HEXIM1 binds to P-TEFb and inhibits the kinase activity of P-TEFb. | 17671421 | LncRNADisease | ||
EL1120 | RN7SK | LARP7 | RNA-Protein | binding | PIP7S binds and stabilizes nearly all the nuclear 7SK via 3'-UUU-OH, leading to the sequestration and inactivation of P-TEFb. | 18249148 | LncRNADisease | ||
EL1120 | RN7SK | LARP7 | RNA-Protein | binding | LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated. | 18281698 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | HEXIM1 suppresses transcription elongation via sequestration of positive transcription elongation factor b (P-TEFb) using 7SK RNA as a scaffold. | 18407829 | LncRNADisease | ||
EL1120 | RN7SK | PP1a | RNA-Protein | regulation | PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. | 18483222 | LncRNADisease | ||
EL1120 | RN7SK | PP2B | RNA-Protein | regulation | PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. | 18483222 | LncRNADisease | ||
EL1120 | RN7SK | LARP7 | RNA-Protein | binding | The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and affects transcription of cellular and viral polymerase II genes. | 18483487 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | Dissociation of 7SK and HEXIM1 from P-TEFb promotes P-TEFb kinase activity, and thus enhances Pol II elongation | 19239885 | LncRNADisease | ||
EL1120 | RN7SK | P-TEFb | RNA-Protein | regulation | Dissociation of 7SK and HEXIM1 from P-TEFb promotes P-TEFb kinase activity, and thus enhances Pol II elongation. | 19239885 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | The Hexim1 binding site is located in the 24-87 region of 7SK RNA and that the protein residues outside the basic domain of Hexim1 are involved in specific RNA interactions. | 19244621 | LncRNADisease | ||
EL1120 | RN7SK | hLARP7 | RNA-Protein | binding | 7SK snRNP assembly by hLARP7/PIP7S | 20138158 | LncRNADisease | ||
EL1120 | RN7SK | PIP7S | RNA-Protein | binding | 7SK snRNP assembly by hLARP7/PIP7S | 20138158 | LncRNADisease | ||
EL1120 | RN7SK | Tat | RNA-Protein | binding | HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. | 20471949 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | HEXIM1 targets a repeated GAUC motif in the riboregulator of transcription 7SK and promotes base pair rearrangements. | 20675720 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | Although HEXIM1 binds tightly to 7SK RNA in vitro, release of P-TEFb from the 7SK snRNP is accompanied by the loss of HEXIM1. | 20808803 | LncRNADisease | ||
EL1120 | RN7SK | P-TEFb | RNA-Protein | binding | Tat has been shown to bind 7SK directly and recruit P-TEFb to TAR. | 20816986 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNP/HEXIM1 binding. Tax can play a role in regulating the amount of HMW complex present in the cell by decreasing the binding of 7SK snRNP/HEXIM1 to P-TEFb. | 20926576 | LncRNADisease | ||
EL1120 | RN7SK | Tat | RNA-Protein | binding | Tat efficiently replaces HEXIM1 on the 7SK snRNA in vivo and therefore, it promotes the disassembly of the 7SK/HEXIM/P-TEFb negative transcriptional regulatory snRNP to augment the nuclear level of active P-TEFb. | 20976203 | LncRNADisease | ||
EL1120 | RN7SK | HMGA1 | RNA-Protein | binding | The 7SK-HMGA1 interaction not only adds an essential facet to the comprehension of transcriptional plasticity at the coupling of initiation and elongation, but also might provide a molecular link between HIV reprogramming of cellular gene expression-associated oncogenesis. | 21087998 | LncRNADisease | ||
EL1120 | RN7SK | CDK9 | RNA-Protein | regulation | Stable expression of cdNIPP1 increased CDK9 phosphorylation on Thr(186) and the association of CDK9 with 7SK RNA. The stable expression of cdNIPP1 disrupted the interaction of Tat and PP1 and inhibited HIV-1 transcription. Expression of cdNIPP1 as a part of the HIV-1 genome inhibited HIV-1 replication. | 21098020 | LncRNADisease | ||
EL1120 | RN7SK | HMGA1 | RNA-Protein | binding | 7SK snRNA directly interacts through its loop2 (7SK L2) with the first A/T-hook DNA binding motif of HMGA1. | 21282977 | LncRNADisease | ||
EL1120 | RN7SK | P-TEFb | RNA-Protein | binding | TCR signaling led to the rapid dissociation of the large inactive P-TEFb:7SK RNP (small nuclear RNA 7SK ribonucleoprotein) complex and the release of active low-molecular-weight P-TEFb complexes. | 21763495 | LncRNADisease | ||
EL1120 | RN7SK | LARP7 | RNA-Protein | regulation | The Lupus antigen (La)-related protein 7 (LARP7) is a constitutive component, the methylphosphate capping enzyme (MePCE) associates secondarily to phosphorylate the 5' end of 7SK snRNA. | 21853533 | LncRNADisease | ||
EL1120 | RN7SK | HMGA1 | RNA-Protein | binding | We provide evidence for 7SK RNA complexes containing simultaneously HMGA1 and P-TEFb. | 21957495 | LncRNADisease | ||
EL1120 | RN7SK | P-TEFb | RNA-Protein | binding | We provide evidence for 7SK RNA complexes containing simultaneously HMGA1 and P-TEFb. | 21957495 | LncRNADisease | ||
EL1120 | RN7SK | Ars2 | RNA-Protein | regulation | Ars2 contributes to histone mRNA 3'end formation and expression and these functional properties of Ars2 are negatively regulated by interaction with 7SK RNA. | 22244333 | LncRNADisease | ||
EL1120 | RN7SK | P-TEFb | RNA-Protein | regulation | The kinase activity of P-TEFb is reversibly inhibited by formation of a complex with the 334nt 7SK RNA, from which it is released under conditions of stress. | 22303389 | LncRNADisease | ||
EL1120 | RN7SK | P-TEFb | RNA-Protein | binding | Together with the HEXIM proteins, 7SK RNA associates with and sequesters a fraction of cellular P-TEFb into a catalytically inactive complex. | 22377309 | LncRNADisease | ||
EL1120 | RN7SK | P-TEFb | RNA-Protein | regulation | Regulation of P-TEFb by the d7SK snRNP is essential for the growth and differentiation of tissues required during Drosophila development. | 22379134 | LncRNADisease | ||
EL1120 | RN7SK | LARP7 | RNA-Protein | binding | LARP7 negatively regulates positive transcription elongation factor-b (p-TEFb) by binding to and stabilizing 7sk RNA. | 22488152 | LncRNADisease | ||
EL1120 | RN7SK | ABO | RNA-RNA | regulation | Promoters pU6 and p7SK proved to express high levels of siRNA activity and can be used in the experiment of silencing alpha-1,3galactosyltransferase gene. | 22522162 | LncRNADisease | ||
EL1120 | RN7SK | HEXIM1 | RNA-Protein | binding | The activity of P-TEFb is negatively regulated by an RNA-binding protein HEXIM1 in association with 7SK snRNA. | 22609015 | LncRNADisease | ||
EL1121 | RN7SL1 | BRF1 | DNA-TF | regulation | hBRF1 functions at 7SL promoter. | 10921893 | LncRNADisease | ||
EL1121 | RN7SL1 | SRP54 | RNA-Protein | binding | SRP54 may be linked to the rest of SRP through this domain by a direct interaction with 7SL RNA. | 1702385 | LncRNADisease | ||
EL1121 | RN7SL1 | APOBEC3F | RNA-Protein | binding | Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. | 18067920 | LncRNADisease | ||
EL1121 | RN7SL1 | MnSOD | RNA-RNA | binding | The 7SL cytoplasmic non-coding RNA, thought to be related to the common ancestor sequence of Alu repeats, hybridizes to the reverse-Alu-element-containing 3′UTR of the human nuclear-encoded mitochondrial MnSOD gene, repressing MnSOD expression by mechanisms distinct from control of translational initiation. | 20951849 | LncRNADisease | ||
EL1121 | RN7SL1 | SRP19 | RNA-Protein | binding | SRP19 synthesized in a cell-free system specifically bound to 7SL RNA. | 2460823 | LncRNADisease | ||
EL1128 | rncs-1 | RDE-4 | RNA-Protein | binding | rncs-1 can bind RDE-4 in vitro. | 18723671 | LncRNADisease | ||
EL1128 | rncs-1 | Dicer | RNA-Protein | binding | rncs-1 RNA Inhibits Dicer Cleavage,presumably by competing with dsRNA substrate for binding to Dicer or RDE-4. | 18723671 | LncRNADisease | ||
EL1129 | RNY1 | DNA,Ro60 protein | RNA-DNA | binding | Mutagenesis of hY1 RNA showed that the binding site for Ro60 protein, which is required for Ro RNP assembly, is not essential for DNA replication. | 16943439 | |||
EL1130 | roX1 | MSL complex | RNA-Protein | binding | In Drosophila, dosage compensation is controlled by the male-specific lethal (MSL) complex consisting of at least five proteins and two noncoding RNAs, roX1 and roX2. | 15229655 | LncRNADisease | ||
EL1130 | roX1 | MSL1 | RNA-Protein | binding | MSL/MSL2 is recruited by roX. | 20573714 | LncRNADisease | ||
EL1130 | roX1 | MSL2 | RNA-Protein | binding | MSL/MSL2 is recruited by roX. | 20573714 | LncRNADisease | ||
EL1130 | roX1 | specific genomic sites | RNA-DNA | binding | roX2 binds at specific genomic sites that coincide with the binding sites of proteins from the male-specific lethal complex that affects dosage compensation. | 22143764 | |||
EL1131 | roX2 | MSL complex | RNA-Protein | binding | In Drosophila, dosage compensation is controlled by the male-specific lethal (MSL) complex consisting of at least five proteins and two noncoding RNAs, roX1 and roX2. | 15229655 | LncRNADisease | ||
EL1131 | roX2 | MSL complex | RNA-Protein | binding | Comparison of the high-resolution map from roX2 CHART with published data for the MSL complex achieved by using ChIP revealed that roX2 binds at the same sites in chromatin as the MSL complex. | 22143764 | LncRNADisease | ||
EL1154 | RP11-789C1.1 | XLOC_010235 | RNA-RNA | co-expression | Via survival analysis, patients who had high-expressed XLOC_010235 or low-expressed RP11-789C1.1 showed significantly worse survival than patients with inverse-expressed XLOC_010235 or RP11-789C1.1. | 26045391 | |||
EL1162 | RP4-583P15.10 | ZBTB46 gene | RNA-DNA | binding | RP4-583P15.10, an up-regulated lncRNA, was found to be located downstream of the natural antisense of the ZBTB46 gene, which may regulated breast cancer through influence immune system. | 25661361 | |||
EL1170 | Rr18 | 41186 | RNA-Protein | binding | Oct4 directly binds Tsix and Xite, two regulatory noncoding RNA genes of the X-inactivation centre, and also complexes with XCI trans-factors, Ctcf and Yy1. | 19536159 | LncRNADisease | ||
EL1171 | RRP1B | PARP1 | RNA-Protein | binding | However, it is highly unlikely that the RRP1B-PARP1 interaction is an experimental artifact, since there is loss of binding with the ΔC-term sample. | 19710015 | LncRNADisease | ||
EL1171 | RRP1B | CSDA | RNA-Protein | binding | Tandem affinity purification demonstrated that RRP1B physically interacts with many nucleosome binding factors, including histone H1X, poly(ADP-ribose) polymerase 1, TRIM28 (tripartite motif-containing 28), and CSDA (cold shock domain protein A). | 19710015 | LncRNADisease | ||
EL1171 | RRP1B | H1X | RNA-Protein | binding | Tandem affinity purification demonstrated that RRP1B physically interacts with many nucleosome binding factors, including histone H1X, poly(ADP-ribose) polymerase 1, TRIM28 (tripartite motif-containing 28), and CSDA (cold shock domain protein A). | 19710015 | LncRNADisease | ||
EL1171 | RRP1B | TRIM28 | RNA-Protein | binding | Tandem affinity purification demonstrated that RRP1B physically interacts with many nucleosome binding factors, including histone H1X, poly(ADP-ribose) polymerase 1, TRIM28 (tripartite motif-containing 28), and CSDA (cold shock domain protein A). | 19710015 | LncRNADisease | ||
EL1171 | RRP1B | Cisplatin and paclitaxel | N/A | regulation | Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | |||
EL1172 | Rubie | Bmp4 | RNA-Protein | regulation | Rubie lies in the conserved gene desert upstream of Bmp4, within a region previously shown to be important for inner ear expression of Bmp4. the expression patterns of Bmp4 and Rubie are nearly identical in developing inner ears. | 22253730 | |||
EL1175 | RZE1 | Znf2 | RNA-DNA | regulation | Transcriptome analysis indicates that the loss of RZE1 reduces the transcript level of ZNF2 and Znf2's prominent downstream targets. In addition, microscopic examination using single molecule fluorescent in situ hybridization (smFISH) indicates that the loss of RZE1 increases the ratio of ZNF2 transcripts in the nucleus versus those in the cytoplasm. | 26588844 | |||
EL1177 | SAMMSON | p32 | RNA-Protein | regulation | SAMMSON interacts with p32, a master regulator of mitochondrial homeostasis and metabolism, to increase its mitochondrial targeting and pro-oncogenic function. | 27008969 | |||
EL1178 | SARCC | HIF-2α | DNA-Protein | binding | HIF-2α can transcriptionally regulate the LncRNA-SARCC expression via binding to hypoxia-responsive elements on the promoter of LncRNA-SARCC. | 26973243 | |||
EL1178 | SARCC | AR | RNA-Protein | binding | LncRNA-SARCC can post-transcriptionally regulate androgen receptor (AR) by physically binding and destablizing AR protein to suppress AR/HIF-2α/C-MYC signals. | 26973243 | |||
EL1184 | SFTA3 | Nkx2.1 | RNA-TF | regulation | LL18/NANCI acts upstream of Nkx2.1 and downstream from Wnt signaling to regulate lung endoderm gene expression. | 24939938 | |||
EL1188 | Si lincRNA121 | Si031351m, Si024403m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1189 | Si lincRNA150 | Si004757m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1190 | Si lincRNA18 | Si035406m, Si017548m, Si005742m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1191 | Si lincRNA180 | Si020916m, Si040853m, Si040854m, Si040872m, Si040875m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1192 | Si lincRNA212 | Si000320m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1193 | Si lincRNA248 | Si004757m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1194 | Si lincRNA288 | Si005770m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1195 | Si lincRNA32 | Si017867m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1196 | Si lincRNA373 | Si035268m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1197 | Si lincRNA396 | Si001193m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1198 | Si lincRNA403 | Si038221m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1199 | Si lincRNA416 | Si018745m, Si026655m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1200 | Si lincRNA438 | Si017571m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1201 | Si lincRNA446 | Si022090m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1203 | Si lincRNA69 | Si013376m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1204 | Si NAT52 | Si035448m, Si003758m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1205 | Si NAT80 | Si038715m, Si030838m, Si035819m | RNA-DNA | regulation | Differential expression analysis showed that 19 (3.25 %) lncRNAs (17 lincRNAs and 2 NATs) in foxtail millet responded to PEG-induced drought stress | 23860794 | PLNlncRbase | ||
EL1206 | SIRT1-AS | Sirt1 protein | RNA-Protein | regulation | Overexpression of Sirt1 AS lncRNA increased the levels of Sirt1 protein, whereas overexpression of Sirt1 AS lncRNA mutant did not affect the level of Sirt1 protein in C2C12 cells. | 24480449 | |||
EL1206 | SIRT1-AS | SIRT1 | RNA-RNA | binding | SIRT1-AS bound to SIRT1 mRNA at 3'UTR, masked the miR-29c binding site and stabilized SIRT1 mRNA. | 26324025 | |||
EL1208 | Six3os1 | Eya1 | RNA-Protein | binding | Ezh2 and Eya1/3/4 directly bind Six3OS. | 21936910 | LncRNADisease | ||
EL1208 | Six3os1 | Eya3 | RNA-Protein | binding | Ezh2 and Eya1/3/4 directly bind Six3OS. | 21936910 | LncRNADisease | ||
EL1208 | Six3os1 | Eya4 | RNA-Protein | binding | Ezh2 and Eya1/3/4 directly bind Six3OS. | 21936910 | LncRNADisease | ||
EL1208 | Six3os1 | Ezh2 | RNA-Protein | binding | Ezh2 and Eya1/3/4 directly bind Six3OS. | 21936910 | LncRNADisease | ||
EL1208 | Six3os1 | Six3 | RNA-RNA | co-expression | Six3OS was coexpressed with Six3 in retinal progenitors. | 21936910 | LncRNADisease | ||
EL1209 | SKP2 | Skp2 | RNA-RNA | regulation | Meg3 and miR-3163 may coordinate suppression of translation of Skp2 mRNA in NSCLC cells to inhibit NSCLC cell growth. | 26482610 | |||
EL1211 | Slc44a1 | Rab11b | RNA-RNA | co-expression | A variety of ncRNAs were broadly upregulated in OLPs, PMOs and MYOs including AK141895 and AK133808, associated with the Slc44a1 and Rab11b genomic loci, respectively. | 20137068 | LncRNADisease | ||
EL1211 | Slc44a1 | Slc44a1 | RNA-RNA | co-expression | A variety of ncRNAs were broadly upregulated in OLPs, PMOs and MYOs including AK141895 and AK133808, associated with the Slc44a1 and Rab11b genomic loci, respectively. | 20137068 | LncRNADisease | ||
EL1216 | Smad7 | TGF-β | RNA-Protein | regulation | Suppression of lncRNA-Smad7 expression cancelled the anti-apoptotic function of TGF-β. In contrast, forced expression of lncRNA-Smad7 rescued apoptosis induced by a TGF-β type I receptor kinase inhibitor in the mouse breast cancer cell line JygMC(A). | 24863656 | |||
EL1217 | sme2 | Mei2p | RNA-Protein | binding | Meirna targets mei2 to the nucleus, where it can promote the first meiotic division. | 10021358 | |||
EL1217 | sme2 | Mei2p | RNA-Protein | regulation | This rna is likely to facilitate the assembly of mei2p into a dot structure and trap the protein as such in the nucleus. | 11423126 | |||
EL1217 | sme2 | Mei2p | RNA-Protein | binding | The dot may not be a simple reflection of the attachment of mei2p to meirna undergoing transcription. | 12808043 | |||
EL1217 | sme2 | Mei2 | RNA-Protein | binding | A novel, polyadenylated rna species (meirna), which suppresses this temperature-sensitive defect if overexpressed, specifically binds to mei2 both in vivo and in vitro. | 7520368 | |||
EL1217 | sme2 | Mei2p | RNA-Protein | binding | Mei2p binds to a polyadenylated rna molecule, meirna, loss of which blocks meiosis i. | 9778252 | |||
EL1219 | SNCG | SNCG | RNA-DNA | regulation | the SNCG gene CpG island methylation was significantly increased in GC cells depleted of AK058003. Intriguingly, SNCG expression is also increased by hypoxia, and SNCG upregulation by AK058003 mediates hypoxia-induced GC cell metastasis. | 25499222 | |||
EL1220 | SNED1 | Zeb2 | RNA-DNA | regulation | Increased uc.77 led to an enhanced RNA and protein expression of Zeb2 | 26824344 | |||
EL1223 | SNHG12 | AMOT | RNA-DNA | regulation | Upregulation of AMOT mRNA was associated with upregulation of SNHG12. The lncRNA SNHG12 promotes cell proliferation and migration by upregulating AMOT gene expression in osteosarcoma cells in vivo and in vitro. | 26486328 | |||
EL1225 | SNHG15 | MMP2/MMP9 | RNA-Protein | regulation | Ectopic expression of SNHG15 promoted cell proliferation and invasion in GC cells partly via regulating MMP2 and MMP9 protein expression. | 26662309 | |||
EL1235 | Sox2ot | H3 | RNA-Protein | regulation | The expression of Sox2dot and isoforms of Sox2ot with alternative TSSs in the mouse brain is supported by the presence of H3K4me3 histone modifications associated with their promoter regions. | 19767420 | LncRNADisease | ||
EL1235 | Sox2ot | Sox2 | RNA-RNA | co-expression | Sox2 is a key transcription factor that is required for neural induction and maintenance of neural stem and progenitor cells, and a recent study demonstrated that the Sox2OT lncRNA, which contains the Sox2 gene within one of its introns and is transcribed in the same direction (Fantes et al., 2003), is expressed in regions of constitutive adult neurogenesis. | 20380817 | LncRNADisease | ||
EL1236 | SOX2-OT | miR-211 | RNA-RNA | regulation | Overexpression of miR-211 caused a significant down-regulation of both genes (SOX2OT and SOX2 genes). | 26862518 | |||
EL1240 | SPRY4-IT1 | lipin 2 | RNA-Protein | binding | We affinity purified SPRY4-IT1 from melanoma cells and used mass spectrometry to identify the protein lipin 2, an enzyme that converts phosphatidate to diacylglycerol (DAG), as a major binding partner. | 25344859 | |||
EL1240 | SPRY4-IT1 | ZNF703 | RNA-DNA | regulation | ZNF703 was a target of SPRY4-IT1 and was downregulated by SPRY4-IT1 knockdown. | 25742952 | |||
EL1240 | SPRY4-IT1 | tight junction (TJ) mRNAs | RNA-RNA | regulation | SPRY4-IT1 directly interacted with TJ mRNAs, and this process was enhanced through the association with the RNA-binding protein HuR. | 26678886 | |||
EL1241 | SRA1 | mPus1p | RNA-Protein | regulation | Mpus1p-coactivator function required sra, mpus1p-associated mrargamma binding, and pus activities. | 15327771 | |||
EL1241 | SRA1 | MyoD | RNA-Protein | binding | We have found that the RNA helicases p68/p72 are MyoD-associated proteins and that the noncoding RNA SRA also immunoprecipitates with MyoD. | 17011493 | LncRNADisease | ||
EL1241 | SRA1 | p68 | RNA-Protein | binding | One of the RNAs associated with p68/p72 is the noncoding Steroid Receptors RNA Activator (SRA). | 17495528 | LncRNADisease | ||
EL1241 | SRA1 | p72 | RNA-Protein | binding | One of the RNAs associated with p68/p72 is the noncoding Steroid Receptors RNA Activator (SRA). | 17495528 | LncRNADisease | ||
EL1241 | SRA1 | CCL20 | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | DIO2 | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | SLC2A12 | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | SLC2A3 | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | TBL1X | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | TGFB2 | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | TMEM65 | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | TMPRSS2 | RNA-Protein | binding | Eight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2). | 20219889 | LncRNADisease | ||
EL1241 | SRA1 | SHARP | RNA-DNA | regulation | SRA is sequestered by the transcriptionally silent TRa2 to a repressive protein complex containing RNA-binding proteins SHARP and SLIRP. | 20573714 | LncRNADisease | ||
EL1241 | SRA1 | SLIRP | RNA-DNA | regulation | SRA is sequestered by the transcriptionally silent TRa2 to a repressive protein complex containing RNA-binding proteins SHARP and SLIRP. | 20573714 | LncRNADisease | ||
EL1241 | SRA1 | TRa2 | RNA-Protein | binding | SRA is sequestered by the transcriptionally silent TRa2 to a repressive protein complex containing RNA-binding proteins SHARP and SLIRP. | 20573714 | LncRNADisease | ||
EL1241 | SRA1 | SRC1 | RNA-Protein | binding | SRC1 complex is recruited by SRA. | 20573714 | LncRNADisease | ||
EL1241 | SRA1 | MyoD | RNA-RNA | co-expression | SRA ncRNA is known to increase the activity of a range of nuclear receptors as well as the master regulator of muscle differentiation MyoD. | 20855289 | LncRNADisease | ||
EL1241 | SRA1 | CTCF | RNA-Protein | binding | Here we showed that the DEAD-box RNA helicase p68 (DDX5) and its associated noncoding RNA, steroid receptor RNA activator (SRA), form a complex with CTCF that is essential for insulator function. | 20966046 | LncRNADisease | ||
EL1241 | SRA1 | p68 | RNA-Protein | binding | Here we showed that the DEAD-box RNA helicase p68 (DDX5) and its associated noncoding RNA, steroid receptor RNA activator (SRA), form a complex with CTCF that is essential for insulator function. | 20966046 | LncRNADisease | ||
EL1241 | SRA1 | IGF2 | RNA-RNA | co-expression | In vivo depletion of SRA or p68 reduced CTCF-mediated insulator activity at the IGF2/H19 ICR, increased levels of IGF2 expression, and increased interactions between the endodermal enhancer and IGF2 promoter. | 20966046 | LncRNADisease | ||
EL1241 | SRA1 | cohesin complex | RNA-Protein | binding | p68/SRA also interacts with members of the cohesin complex. | 20966046 | LncRNADisease | ||
EL1241 | SRA1 | PPARG | RNA-Protein | binding | We show that the non-coding RNA, Steroid receptor RNA Activator (SRA), associates with PPARgamma and coactivates PPARgamma-dependent reporter gene expression. | 21152033 | LncRNADisease | ||
EL1241 | SRA1 | CTCF | RNA-Protein | binding | DEAD-box RNA helicase p68 (DDX5) and its associated lncRNA, SRA (steroid receptor RNA activator), form a complex with CTCF. CTCF binds to specific genomic binding sequences and plays an important role in transcriptional insulation and long-range physical interaction with other CTCF sites. | 21496640 | LncRNADisease | ||
EL1241 | SRA1 | DDX5 | RNA-Protein | binding | DEAD-box RNA helicase p68 (DDX5) and its associated lncRNA, SRA (steroid receptor RNA activator), form a complex with CTCF. CTCF binds to specific genomic binding sequences and plays an important role in transcriptional insulation and long-range physical interaction with other CTCF sites. | 21496640 | LncRNADisease | ||
EL1241 | SRA1 | Cisplatin and paclitaxel | N/A | regulation | Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | |||
EL1241 | SRA1 | NANOG | RNA-TF | regulation | NANOG was identified as a transcription factor directly interacting with SRA and co-localizing with it genome-wide in NTERA2. | 26496121 | |||
EL1241 | SRA1 | polycomb repressive complex 2 (PRC2) | RNA-Protein | binding | The lncRNA steroid receptor RNA activator (SRA) participates in regulation through complex formation with trithorax group (TrxG) and polycomb repressive complex 2 (PRC2) complexes. Binding of the SRA-associated RNA helicase p68 preferentially stabilizes complex formation between SRA and a TrxG complex but not PRC2. In human pluripotent stem cells NTERA2, SRA binding sites that are also occupied by p68 are significantly enriched for H3K4 trimethylation. | 26496121 | |||
EL1241 | SRA1 | trithorax group (TrxG) | RNA-Protein | binding | The lncRNA steroid receptor RNA activator (SRA) participates in regulation through complex formation with trithorax group (TrxG) and polycomb repressive complex 2 (PRC2) complexes. Binding of the SRA-associated RNA helicase p68 preferentially stabilizes complex formation between SRA and a TrxG complex but not PRC2. In human pluripotent stem cells NTERA2, SRA binding sites that are also occupied by p68 are significantly enriched for H3K4 trimethylation. | 26496121 | |||
EL1243 | SRG1 | SER3 | RNA-DNA | binding | Repression occurs by a transcription-interference mechanism in which srg1 transcription across the ser3 promoter interferes with the binding of activators. | 15175754 | |||
EL1243 | SRG1 | Cha4 | RNA-Protein | binding | This regulation requires Cha4, a serine-dependent activator that binds to the SRG1 promoter and is required for SRG1 induction in the presence of serine. | 16291644 | LncRNADisease | ||
EL1243 | SRG1 | Cha4 | DNA-Protein | binding | Srg1 transcription is regulated by serine. this regulation requires cha4, a serine-dependent activator that binds to the srg1 promoter and is required for srg1 induction in the presence of serine. | 16291644 | |||
EL1243 | SRG1 | SER3 | RNA-DNA | regulation | Some cases, such as the SRG1 transcript in yeast that blocks activation of the SER3 gene, involve transcriptional regulation of a protein coding gene by an ncRNA. | 19191220 | LncRNADisease | ||
EL1243 | SRG1 | SER3 | RNA-DNA | regulation | The 3' end of SRG1 contains regulatory elements within the SER3 promoter, and premature termination of SRG1 transcription prevents repression of SER3. | 19239885 | LncRNADisease | ||
EL1243 | SRG1 | Spt6 | RNA-Protein | regulation | Repression by SRG1 transcription is dependent on the Spt6 and Spt16 transcription elongation factors. | 21156811 | LncRNADisease | ||
EL1243 | SRG1 | Spt2 | RNA-Protein | regulation | We find that Spt2 and Spt6 are required for the repression of SER3 by SRG1 transcription. | 21220514 | LncRNADisease | ||
EL1243 | SRG1 | Spt6 | RNA-Protein | regulation | We find that Spt2 and Spt6 are required for the repression of SER3 by SRG1 transcription. | 21220514 | LncRNADisease | ||
EL1243 | SRG1 | SER3 | RNA-DNA | regulation | SRG1 transcription deposits nucleosomes over the SER3 promoter to prevent transcription factors from binding and activating SER3. | 21873510 | LncRNADisease | ||
EL1244 | SRP RNA | SRP54M | RNA-Protein | binding | M.jannaschii srp rna bound to human srp54m quantitatively in the absence of srp19. | 10684931 | |||
EL1276 | TCONS_00012273 | ptr-miR172 | RNA-RNA | regulation | ptr-miR172, which was only suppressed in compression tissue (Lu et al. 2005), may target TCONS_00012272 and TCONS_00012273 | 25230698 | PLNlncRbase | ||
EL1284 | TCONS_00022311 | GA2ox | RNA-Protein | regulation | TCONS_00022311 was predicted to target a GA2ox | 25230698 | PLNlncRbase | ||
EL1285 | TCONS_00023843 | Ptc-miR1448/Ptc-miR482a.2/Ptu-172/Ptu-37 | RNA-RNA | regulation | only three of the 1377 lncRNAs (0.2 %), i.e., TCONS_00061773, TCONS_00023843 and TCONS_00048079, harbor complete precursors, for four miRNAs (Ptc-miR1448, PtcmiR482a.2, Ptu-172 and Ptu-37) | 25230698 | PLNlncRbase | ||
EL1290 | TCONS_00026694 | POPTR_0002s09860.1 | RNA-DNA | regulation | Similar to probable UDP-glucuronosyltransferase (EC 2.4.1.–) | 25230698 | PLNlncRbase | ||
EL1292 | TCONS_00032782 | Pt-CSLD4 | RNA-DNA | regulation | The lncRNA TCONS_00032782 was predicted to regulate POPTR_0013s07900.1 (Pt-CSLD4), which encodes a protein similar to cellulase synthase 3. | 25230698 | PLNlncRbase | ||
EL1294 | TCONS_00039944 | Ptc-miR168b-5p | RNA-RNA | regulation | miR2 (Ptc-miR168b-5p) is expressed in OW (OW [ TW[ NW), while its potential target lncRNA lmR2 (TCONS_00039944) showed its lowest expression in OW (NW [ TW [ OW). | 25230698 | PLNlncRbase | ||
EL1298 | TCONS_00048079 | Ptc-miR1448/Ptc-miR482a.2/Ptu-172/Ptu-37 | RNA-RNA | regulation | only three of the 1377 lncRNAs (0.2 %), i.e., TCONS_00061773, TCONS_00023843 and TCONS_00048079, harbor complete precursors, for four miRNAs (Ptc-miR1448, PtcmiR482a.2, Ptu-172 and Ptu-37) | 25230698 | PLNlncRbase | ||
EL1299 | TCONS_00049512 | ptc-miR1445 | RNA-RNA | regulation | ptc-miR1445 was predicted to target TCONS_00049512, which has been predicted to function in cleaving the transcripts of development-related or stressresponsive genes in Populus | 25230698 | PLNlncRbase | ||
EL1300 | TCONS_00053930 | POPTR_0001s07400.1 | RNA-DNA | regulation | Another target gene, predicted to be targeted by TCONS_00053930, encodes a protein similar to 4CL | 25230698 | PLNlncRbase | ||
EL1303 | TCONS_00056386 | Pt-GA2.3 | RNA-DNA | regulation | Genes encoding glucosyltransferases were predicted as targets of TCONS_00056386 | 25230698 | PLNlncRbase | ||
EL1305 | TCONS_00060049 | CCOMT | RNA-DNA | regulation | TCONS_00060049 was predicted to target CCOMT, suggesting that it may have a potential role in lignin formation by regulation of CCOMT | 25230698 | PLNlncRbase | ||
EL1306 | TCONS_00061773 | Ptc-miR1448/Ptc-miR482a.2 | RNA-RNA | regulation | only three of the 1377 lncRNAs (0.2 %), i.e., TCONS_00061773, TCONS_00023843 and TCONS_00048079, harbor complete precursors, for four miRNAs (Ptc-miR1448, PtcmiR482a.2, Ptu-172 and Ptu-37) | 25230698 | PLNlncRbase | ||
EL1321 | TDRG1 | FGF1 | DNA-Protein | regulation | The increase of acetyl‑histones, H3 and H4 was diminished in the TDRG1 promoter of BMSCs that were infected with Ad‑FGF1, which indicated that the process of acetylation was promoted when the BMSCs were infected with Ad-FGF1. FGF1 induces the proliferation of BMSCs in patients with AA via promoting acetylation in lncRNA of the TDRG1 gene promoter. | 26460236 | |||
EL1322 | TER | TERT | RNA-Protein | regulation | Two TERs in A. thaliana. One is a conventional telomerase template. The other lncRNA negatively regulates telomerase activity in response to DNA damage, a function mediated by co-option of a transposable element. | 26442096 | |||
EL1326 | TGFB2-OT1 | MIR4459 | RNA-RNA | binding | FLJ11812 could bind with MIR4459 targeting ATG13 (autophagy-related 13), and ATG13 protein level was decreased along with 3BDO-decreased FLJ11812 level. | 25437332 | |||
EL1326 | TGFB2-OT1 | MIR3960, MIR4488 and MIR4459 | RNA-RNA | binding | TGFB2-OT1 acted as a competing endogenous RNA, bound to MIR3960, MIR4488 and MIR4459 | 26565952 | |||
EL1335 | tie-1as | TIE1 | RNA-RNA | co-expression | The tie-1AS lncRNA selectively binds tie-1 mRNA in vivo and regulates tie-1 transcript levels, resulting in specific defects in endothelial cell contact junctions in vivo and in vitro. | 19880500 | LncRNADisease | ||
EL1336 | TINCR | staufen1 (STAU1) protein | RNA-Protein | binding | A high-throughput screen to analyse TINCR binding capacity to approximately 9,400 human recombinant proteins revealed direct binding of TINCR RNA to the staufen1 (STAU1) protein. | 23201690 | |||
EL1337 | TIP ncRNA | Polycomb (PcG) proteins | RNA-Protein | regulation | The relationship between TIP transcription and PcG recruitment switches dynamically during differentiation between different states, in which transcription and PcG recruitment exclude each other, or in which both are present. Reporter assays show that transcribed TIP sites can repress a flanking gene. Knockdown experiments demonstrate that TIP ncRNAs are themselves required for repression of target genes both in cis and in trans. | 22336714 | |||
EL1338 | TK105282 | Bai3 | RNA-RNA | co-expression | TK105282 were both co-expressed with their host gene Bai3,a brain specific inhibitor of angiogenesis. | 21247874 | LncRNADisease | ||
EL1339 | TK111271 | Lck | RNA-RNA | co-expression | the lncRNA TK111271 is co-expressed and co-located with Lck, a key signal gene in T-cell development. | 21247874 | LncRNADisease | ||
EL1340 | TK99129 | Bai3 | RNA-RNA | co-expression | TK99129 and TK105282 were both co-expressed with their host gene Bai3,a brain specific inhibitor of angiogenesis. | 21247874 | LncRNADisease | ||
EL1344 | Tmevp3 | WDR5 | RNA-Protein | binding | NeST RNA was found to bind WDR5, a component of the histone H3 lysine 4 methyltransferase complex, and to alter histone 3 methylation at the IFN-γ locus. | 23415224 | |||
EL1344 | Tmevp3 | interferon-γ | RNA-DNA | regulation | this lncRNA regulates epigenetic marking of IFN-γ-encoding chromatin, expression of IFN-γ, and susceptibility to a viral and a bacterial pathogen. | 23415224 | |||
EL1348 | Tog | Hoxd | DNA-DNA | binding | The start site of two opposite long noncoding RNAs (lncRNAs), Hotdog and Twin of Hotdog, selectively contacts the expressed Hoxd genes in the framework of a topological domain, coinciding with robust transcription of these genes during cecum budding. | 24075990 | |||
EL1349 | TP53COR1 | cyclin D1, CDK4 and p21 | RNA-Protein | regulation | Ectopic expression of lincRNA-p21 inhibited cell proliferation, arrested cycle progression and modulated cyclin D1, CDK4 and p21 expression in DLBCL cell lines. | 26475621 | |||
EL1349 | TP53COR1 | miR-451 | RNA-RNA | regulation | Integration of miR-451 MREs into the adenovirus efficiently delivered lincRNA-p21 into CSCs that contained low levels of miR-451. | 26497997 | |||
EL1349 | TP53COR1 | β-catenin | RNA-Protein | regulation | lincRNA-p21 inhibited the activity of β-catenin signaling, thereby attenuating the viability,self-renewal, and glycolysis of CSCs in vitro. | 26497997 | |||
EL1350 | TP53TG1 | TP53 | DNA-TF | regulation | TP53 target gene 1 | 9713990 | LncRNADisease | ||
EL1351 | TP73-AS1 | BDH2 | RNA-Protein | regulation | LncRNA TP73-AS1 knockdown inhibited BDH2 expression in EC9706 and KYSE30 cells. | 26799587 | |||
EL1352 | TPS1 | miR399 | RNA-RNA | binding | INDUCED BY PHOSPHATE STARVATION1 is a member of the TPS1/Mt4 gene family that acts as a miR399 target mimic in fine tuning of PHO2 (encoding an E2 ubiquintin conjugase-related enzyme) expression and phosphate uptake in Arabidopsis, tomato and Medicago truncatula but does not encode a protein | 24576388 | PLNlncRbase | ||
EL1353 | TPS11 | miR399 | RNA-RNA | binding | IPS1 and At4 directly inhibits miR-399 activity.IPS1 has many family members in a number of plant species, including At4, At4–1, At4–2 and At4–3 in Arabidopsis thaliana, TPS11 in tomato, Mt4 in Barrel Clover and Alfalfa, Mt4-like in Soybean | 23726911 | PLNlncRbase | ||
EL1355 | TRAF3IP2-AS1 | TRAF3IP2 | RNA-DNA | regulation | TRAF3IP2-AS1 may regulate TRAF3IP2 gene expression, perhaps through local chromatin changes at this locus (right). | 26222413 | |||
EL1356 | TRE1 | Ash1 | RNA-Protein | binding | Ash1 is recruited by TRE1-3. | 20573714 | LncRNADisease | ||
EL1357 | TRE2 | Ash1 | RNA-Protein | binding | Ash1 is recruited by TRE1-3. | 20573714 | LncRNADisease | ||
EL1358 | TRE3 | Ash1 | RNA-Protein | binding | Ash1 is recruited by TRE1-3. | 20573714 | LncRNADisease | ||
EL1363 | TRERNA1 | Snai1 | RNA-RNA | regulation | KLHL12, ROCK2, TAL1, CMPK1, Snai2, and Snai1 are regulated by ncRNA-a2 through ncRNA-a7, respectively. Knockdown of ncRNA-a7 in A549 cells represses the expression of Snai1 specifically and diminishes cell migration to levels similar to that seen when knocking down Snai1. NcRNA-a7 serves as a transcriptional enhancer of Snai1. | 21502407 | LncRNADisease | ||
EL1363 | TRERNA1 | miR-190a | RNA-RNA | regulation | miR-190a can silence treRNA post-transcriptionally. Suppression of treRNA by miR-190a led to significant changes of mesenchymal-epithelial transition markers and impaired migration and invasion capability of hepatoma cells. | 26608035 | |||
EL1365 | Trp53cor1 | p53 | DNA-TF | regulation | lincRNA-p21 is induced by p53 in different cell systems. lincRNA-p21 as a repressor in the p53 pathway.lincRNA-p21 is a direct p53 transcriptional target in response to DNA damage. | 20673990 | LncRNADisease | ||
EL1365 | Trp53cor1 | hnRNP-K | RNA-DNA | regulation | The depletion of lincRNA-p21 causes a significant reduction in the association of hnRNP-K at the promoter regions of genes that are normally repressed in a lincRNA-p21 and p53-dependent fashion. | 20673990 | LncRNADisease | ||
EL1365 | Trp53cor1 | p53 | DNA-TF | regulation | Induced by p53 and mediates p53 repression of many genes in association with hnRNP-k. | 21256239 | LncRNADisease | ||
EL1365 | Trp53cor1 | hnRNP-k | RNA-Protein | binding | Induced by p53 and mediates p53 repression of many genes in association with hnRNP-k. | 21256239 | LncRNADisease | ||
EL1365 | Trp53cor1 | hnRNP-K | RNA-Protein | binding | hnRNP-K interacted with a 50 domain of lincRNA-p21 that was necessary but not sufficient to induce apoptosis, suggesting that other regions of the RNA are required to recruit other factors or target the complex to chromatin or both. | 21496640 | LncRNADisease | ||
EL1365 | Trp53cor1 | p53 | RNA-DNA | regulation | lincRNA-p21 acts as a transcriptional repressor turning off multiple genes during the p53 response. | 21496640 | LncRNADisease | ||
EL1365 | Trp53cor1 | p53 | DNA-TF | regulation | p53 regulates lincRNA-p21 by directly inducing its expression, likely through direct binding to the lincRNA-p21 promoter, while reduction of large intergenic ncRNA (lincRNA)-p21 increases expression of numerous p53-repressed transcripts. lincRNA-p21 repressed p53-regulated genes through its binding to and modulation of heterogeneous nuclear ribonucleoprotein K (hnRNP-K) localization. | 21925379 | LncRNADisease | ||
EL1365 | Trp53cor1 | hnRNP-K | RNA-Protein | binding | p53 regulates lincRNA-p21 by directly inducing its expression, likely through direct binding to the lincRNA-p21 promoter, while reduction of large intergenic ncRNA (lincRNA)-p21 increases expression of numerous p53-repressed transcripts. lincRNA-p21 repressed p53-regulated genes through its binding to and modulation of heterogeneous nuclear ribonucleoprotein K (hnRNP-K) localization. | 21925379 | LncRNADisease | ||
EL1365 | Trp53cor1 | Cdkn1a | DNA-DNA | co-expression | LincRNA-p21 is an antisense transcript that is 15kb downstream from Cdkn1a locus and appears to be cotranscribed with the protein coding gene Cdkn1a at 8.0mg/kg furan. | 23853263 | |||
EL1368 | TSIX | TGF-β | RNA-Protein | regulation | The upregulation of TSIX seen in SSc fibroblasts may result from activated endogenous TGF-β signalling and may play a role in the constitutive upregulation of collagen in these cells. | 26566700 | |||
EL1368 | TSIX | collagen | RNA-RNA | regulation | TSIX is a new regulator of collagen expression which stabilizes the collagen mRNA. | 26566700 | |||
EL1369 | Tsix | XIST | RNA-DNA | regulation | Tsix directly regulates its transcription. | 16507360 | LncRNADisease | ||
EL1369 | Tsix | 41186 | RNA-Protein | binding | Oct4 directly binds Tsix and Xite, two regulatory noncoding RNA genes of the X-inactivation centre, and also complexes with XCI trans-factors, Ctcf and Yy1. | 19536159 | LncRNADisease | ||
EL1369 | Tsix | XIST | RNA-RNA | regulation | For the active X, the antisense Tsix RNA is an established Xist repressor. | 21029862 | LncRNADisease | ||
EL1369 | Tsix | XIST | RNA-DNA | regulation | Tsix represses Xist induction by several means, including altering the chromatin state of Xist, deploying Dnmt3a’s DNA methyltransferase activity, recruiting the RNAi machinery, and interfering with the ability of Xist and RepA RNA to engage Polycomb proteins. | 21029862 | LncRNADisease | ||
EL1369 | Tsix | XIST | RNA-RNA | regulation | Xist is controlled by two parallel RNA switches – Tsix for Xa and Jpx for Xi. Tsix represses Xist on Xa. | 21029862 | LncRNADisease | ||
EL1369 | Tsix | XIST | RNA-DNA | regulation | Epigenetically silences Xist expression by inhibiting RepA recruitment of polycomb complexes to maintain the active X chromosome in females. | 21256239 | LncRNADisease | ||
EL1369 | Tsix | RepA | RNA-RNA | regulation | Epigenetically silences Xist expression by inhibiting RepA recruitment of polycomb complexes to maintain the active X chromosome in females. | 21256239 | LncRNADisease | ||
EL1369 | Tsix | XIST | RNA-DNA | regulation | Tsix is associated with both enrichment of the H3K4me3 active mark and prevention of the deposition of the repressive mark H3K27me3 within the body of the Xist gene. Tsix, for instance, may be subject to Xist silencing at the onset of XCI. | 21329697 | LncRNADisease | ||
EL1369 | Tsix | XIST | RNA-RNA | regulation | The noncoding Tsix RNA is an antisense repressor of Xist and regulates X inactivation in mice. | 21852535 | LncRNADisease | ||
EL1369 | Tsix | Xist RNA | RNA-RNA | regulation | Tsix is instead required to silence Xist on the active-X as epiblast cells differentiate in both males and females. | 25981039 | |||
EL1372 | Ttc39aos1 | Pycard | RNA-DNA | regulation | This lncRNA represses expression of Pycard, a proapoptotic gene, explaining in part the inhibition of programmed cell death. | 22155924 | |||
EL1374 | TU1273 | CYP450 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1375 | TU1378 | GL18494 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1376 | TU1403 | CYP450 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1378 | TU1567 | pheromone B alpha 3 receptor gene | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1380 | TU3327 | GL27846 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1385 | TU4652 | GL29234 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1386 | TU4684 | GL24376 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1387 | TU4779 | GL19744 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1388 | TU5007 | GL24914 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1389 | TU506 | CYP450 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1390 | TU51 | GL30020 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1391 | TU5846 | CYP450 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1392 | TU6607 | CYP450 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1393 | TU6608 | CYP450 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1394 | TU718 | GL15069 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1395 | TU781 | GL20538 | RNA-DNA | regulation | In the 16 lincRNA/apcGene pairs that showed significantly positive or negative correlation, 9 apcGenes are involved in wood degradation and 6 apcGenes belong to the CYP450 families, suggesting genes involved in these biological processes be potentially regulated by lincRNAs. | 24932683 | PLNlncRbase | ||
EL1399 | TUG1 | IgG | RNA-Protein | binding | binding with IgG shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL1399 | TUG1 | PRC2 | RNA-Protein | binding | binding with PRC2 shown by RIP-Chip data. | 19571010 | LncRNADisease | ||
EL1399 | TUG1 | p53 | DNA-TF | regulation | TUG1 is induced by p53, binds to PRC2, and has a role in repressing specific genes involved in cell-cycle regulation. | 19571010 | LncRNADisease | ||
EL1399 | TUG1 | PRC2 | RNA-Protein | binding | TUG1 is induced by p53, binds to PRC2, and has a role in repressing specific genes involved in cell-cycle regulation. | 19571010 | LncRNADisease | ||
EL1399 | TUG1 | PRC2 | RNA-Protein | binding | Required for the proper formation of photoreceptors in the developing retina. Tug1 associates with PRC2 and represses a number of cell cycle genes. | 21256239 | LncRNADisease | ||
EL1399 | TUG1 | Pc2 | DNA-Protein | regulation | methylation/demethylation of Polycomb 2 protein (Pc2) controls relocation of growth-control genes between Polycomb bodies (PcGs) and interchromatin granules (ICGs) in response to growth signals. This movement is the consequence of binding of methylated and unmethylated Pc2 to the ncRNAs TUG1 and MALAT1/NEAT2. | 22078878 | LncRNADisease | ||
EL1399 | TUG1 | polycomb repressive complex 2 (PRC2) | RNA-Protein | binding | binding to polycomb repressive complex 2 (PRC2), | 25366138 | |||
EL1399 | TUG1 | miR-145 | RNA-RNA | regulation | TUG1 decreased the expression of miR-145 and there was a reciprocal repression between TUG1 and miR-145 in an Argonaute2-dependent manner. | 26318860 | |||
EL1399 | TUG1 | PRC2 | RNA-Protein | binding | TUG1 could epigeneticly repress Kruppel-like factor 2 (KLF2) transcription in HCC cells by binding with PRC2 and recruiting it to KLF2 promoter region. | 26336870 | |||
EL1399 | TUG1 | Kruppel-like factor 2 (KLF2) | RNA-Protein | regulation | TUG1 could epigeneticly repress Kruppel-like factor 2 (KLF2) transcription in HCC cells by binding with PRC2 and recruiting it to KLF2 promoter region. | 26336870 | |||
EL1399 | TUG1 | Bcl-2 | RNA-Protein | regulation | Taurine upregulated gene 1 promoted cell apoptosis of glioma cells by activating caspase-3 and -9-mediated intrinsic pathways and inhibiting Bcl-2-mediated anti-apoptotic pathways, acting as a tumor suppressor in human glioma. | 26748401 | |||
EL1399 | TUG1 | caspase-3 and -9 | RNA-Protein | regulation | Taurine upregulated gene 1 promoted cell apoptosis of glioma cells by activating caspase-3 and -9-mediated intrinsic pathways and inhibiting Bcl-2-mediated anti-apoptotic pathways, acting as a tumor suppressor in human glioma. | 26748401 | |||
EL1399 | TUG1 | PTEN | RNA-DNA | regulation | The tumour-suppressive function of two lncRNAs (TUG1 and CTB-89H12.4) and their regulation of PTEN expression in prostate cancer. | 26975529 | |||
EL1400 | Tug1 | PRC2 | RNA-Protein | binding | Numerous lincRNAs are physically associated with PRC2. | 19571010 | LncRNADisease | ||
EL1401 | TUNAR | Sox2 | RNA-DNA | regulation | Linc00617 functions as an important regulator of EMT and promotes breast cancer progression and metastasis via activating the transcription of Sox2. | 26207516 | |||
EL1402 | TUSC7 | P53 | RNA-DNA | regulation | loc285194 is a p53 transcription target. | 23558749 | |||
EL1402 | TUSC7 | Bcl2 | RNA-Protein | regulation | After silence of TUSC7, the proapoptotic Bcl2 expression was downregulated. | 26781978 | |||
EL1402 | TUSC7 | Eph tyrosine kinase receptor A4 (EphA4) | RNA-Protein | regulation | TUSC7 could decrease the expression of Eph tyrosine kinase receptor A4 (EphA4), a downstream target of miR-10a as well as an EMT suppressor, through TUSC7-miR-10a-EphA4 axis. | 27002617 | |||
EL1402 | TUSC7 | miR-10a | RNA-RNA | binding | TUSC7 inhibited cell metastasis, invasion, and epithelial-to-mesenchymal transformation (EMT) through competitively binding miR-10a. | 27002617 | |||
EL1407 | uc.173 | miR-291a-3p | RNA-RNA | regulation | Uc.173 might inter-regulate with miR-291a-3p in lead-induced apoptosis and regulate apoptosis-associated genes. | 26683706 | |||
EL1431 | UCA1 | 171. C/EBPα-p30 | RNA-Protein | regulation | we identified the oncogenic urothelial carcinoma associated 1 (UCA1) lncRNA as a novel target of the C/EBPα-p30. | 26053097 | |||
EL1431 | UCA1 | Hyaluronoglucosaminidase 1 (HYAL1) | RNA-Protein | co-expression | There was a significant positive correlation between HYAL1 and the selected epigenetic biomarkers. | 26138586 | |||
EL1431 | UCA1 | AKT/mTOR pathway | N/A | regulation | UCA1 may induce non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway and EMT. | 26160838 | |||
EL1431 | UCA1 | Ets-2 | DNA-Protein | binding | Ets-2 bound to the UCA1 core promoter using luciferase assays. | 26238511 | |||
EL1431 | UCA1 | β-catenin | RNA-Protein | regulation | CUDR causes highly upregulated in liver cancer (HULC) and β-catenin abnormal expression by inhibiting HULC promoter methylation and promoting β-catenin promoter-enhancer chromatin looping formation mediated by CUDR-ccctc-binding factor (CTCF) complex, which recruits more RNA polII and P300. | 26347501 | |||
EL1431 | UCA1 | histone H3 twenty-seventh lysine (H3K27me3) | RNA-Protein | regulation | CUDR could enhance the human embryonic stem cells (ESC) differentiation into hepatocyte-like cells by reducing trimethylation on histone H3 twenty-seventh lysine (H3K27me3). | 26347501 | |||
EL1431 | UCA1 | miR-16 | RNA-RNA | regulation | Urothelial carcinoma-associated 1 regulated the expression of GLS2 through interfering with miR-16, and repressed ROS formation in bladder cancer cells. | 26373319 | |||
EL1431 | UCA1 | miR-143 | RNA-RNA | binding | There are direct interactions between miR-143 and the miRNA recognition sites of UCA1. UCA1 is present in Ago2-containing RNA-induced silencing complex (RISC), through association with miR-143. | 26439035 | |||
EL1431 | UCA1 | H19 | RNA-DNA | binding | CUDR-CyclinD1 complex loads onto the long noncoding RNA H19 promoter region that may lead to reduce the DNA methylation on H19 promoter region and then to enhance the H19 expression. | 26513297 | |||
EL1431 | UCA1 | C-myc | RNA-DNA | binding | Insulator CTCF recruits the CUDR-CyclinD1 complx to form the composite CUDR-CyclinD1-insulator CTCF complex which occupancied on the C-myc gene promoter region, increasing the outcome of oncogene C-myc. | 26513297 | |||
EL1431 | UCA1 | CyclinD1 | RNA-Protein | binding | The decrease of PTEN in cells may lead to increase binding capacity of CUDR to CyclinD1. | 26513297 | |||
EL1431 | UCA1 | ZEB1 and ZEB2 | RNA-Protein | regulation | lncRNA-UCA1 induced EMT of bladder cancer cells by upregulating the expression levels of zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2) | 26544536 | |||
EL1431 | UCA1 | hsa-miR-145 | RNA-RNA | binding | The binding site for hsa-miR-145 within exons 2 and 3 of lncRNA-UCA1 contributed to the reciprocal negative regulation of lncRNA-UCA1 and hsa-miR-145. | 26544536 | |||
EL1431 | UCA1 | KLF4 | RNA-Protein | regulation | UCA1 loss-of-function could decrease KLF4 expression, subsequently, the downregulation of KRT6 and KRT13. | 26550172 | |||
EL1431 | UCA1 | SET1A | RNA-Protein | regulation | SET1A cooperates with CUDR to play a positive potential role during hepatocarcinogenesis and hepatocyte-like stem cells' malignant transformation epigenetically | 26581161 | |||
EL1431 | UCA1 | miR-193a-3p | RNA-RNA | binding | UCA1 upregulated the expression of miR-193a-3p target gene ERBB4 through competitively 'spongeing' miR-193a-3p. | 26655272 | |||
EL1431 | UCA1 | MMP14 | RNA-Protein | regulation | Depletion of UCA1 was involved in the downregulation of matrix metallopeptidase 14 (MMP14) expression, a target gene of miR-485-5p. | 26867765 | |||
EL1431 | UCA1 | miR-485-5p | RNA-RNA | binding | UCA1 could function as an endogenous sponge by directly binding to miR-485-5p. | 26867765 | |||
EL1431 | UCA1 | CREB1 | RNA-Protein | regulation | CREB1 as a new target of miR-204-5p. The protein levels of CREB1 were significantly up-regulated in CRCs, negatively associated with survival time and positively correlated with the UCA1 expression. | 27046651 | |||
EL1431 | UCA1 | miR-204-5p | RNA-RNA | binding | UCA1 could sponge endogenous miR-204-5p and inhibit its activity. | 27046651 | |||
EL1434 | UCHL1-AS1 | UCHL1 | RNA-Protein | regulation | In Parkinson's Disease the lncRNA UCHL1-AS1 acts by directly promoting translation of UCHL1 protein leading to perturbation of the ubiquitin-proteasome system. | 27338628 | |||
EL1435 | UFC1 | microRNA 34a | RNA-RNA | regulation | The lincRNA-UFC1, a target of microRNA 34a, promotes proliferation and reduces apoptosis in HCC cells to promote growth of xenograft tumors in mice. | 25449213 | |||
EL1438 | ULK4P2 | enhancer of zeste homolog 2 | RNA-DNA | binding | The upregulated large intergenic noncoding RNA ULK4P2 was physically combined with enhancer of zeste homolog 2. | 26109807 | |||
EL1440 | VAI | RISC | RNA-Protein | binding | Whereas both strands of the va rnai-specific sirna are incorporated into risc, the 3' strand of the va rnaii-specific sirna is selectively incorporated during a lytic infection. | 16014917 | |||
EL1440 | VAI | PKR | RNA-Protein | binding | The binding sites on inhibitor RNAs and the dsRBDs of PKR have been mapped by NMR chemical shift perturbation experiments, which indicate that inhibitors of PKR employ similar surfaces of interaction as activators. | 16580685 | |||
EL1440 | VAI | PKR | RNA-Protein | binding | Eber-1, eber-2 and vai rna exhibit mutually competitive binding to the native or recombinant enzyme | 7901835 | |||
EL1441 | VAII | Dicer | RNA-Protein | binding | The va rnas bind dicer and function as competitive substrates squelching dicer. | 16014917 | |||
EL1442 | Vax2os | Vax2 | RNA-DNA | regulation | We found a significant reduction of the expression levels of one of these nats, vax2os (vax2 opposite strand) in a mouse mutant carrying the inactivation of vax2, the corresponding sense gene. | 15703187 | |||
EL1442 | Vax2os | Crx | DNA-TF | regulation | Vax2OS was independently identified as a transcriptional target of both Crx and Nrl in a recent microarray-based screen. | 19191220 | LncRNADisease | ||
EL1442 | Vax2os | Nrl | DNA-TF | regulation | Vax2OS was independently identified as a transcriptional target of both Crx and Nrl in a recent microarray-based screen. | 19191220 | LncRNADisease | ||
EL1443 | VIM2P | MMP13 and ADAMTS5 | RNA-Protein | regulation | Silencing of lncRNA-CIR by small interfering RNA promoted the formation of collagen and aggrecan and reduced the expression of matrix-degrading enzymes, such as MMP13 and ADAMTS5. | 24757148 | |||
EL1445 | VL30 RNAs | PSF | RNA-Protein | binding | Mvl30 rna regulates steroidogenesis, and possibly other physiological processes of mice, by complex formation with psf. | 14704271 | |||
EL1445 | VL30 RNAs | PSF | RNA-Protein | binding | Psf also contains two rna-binding domains (rbd) that form a complex with a noncoding vl30 retroelement rna, releasing psf from a gene and reversing repression. | 16079199 | |||
EL1451 | Wbp1l | Casp6 and Adrb2 | RNA-DNA | regulation | Coding non-coding co-expression network analysis showed that the BC088414 lncRNA expression was correlated with apoptosis-related genes, including Casp6 and Adrb2. Silencing of lncRNA BC088414 in PC12 cells caused reduced mRNA level of Casp6 and Adrb2, decreased cell apoptosis and increased cell proliferation. | 26349411 | |||
EL1452 | WFDC21P | STAT3 | RNA-Protein | binding | lnc-DC bound directly to STAT3 in the cytoplasm, which promoted STAT3 phosphorylation on tyrosine-705 by preventing STAT3 binding to and dephosphorylation by SHP1. | 24744378 | |||
EL1454 | WRAP53 | TP53 | RNA-RNA | regulation | Wrap53 regulates p53 via Wrap53/p53 RNA interaction. | 19250907 | LncRNADisease | ||
EL1454 | WRAP53 | TP53 | RNA-RNA | regulation | Wrap53 is a natural antisense transcript of p53 that regulates endogenous p53 mRNA levels and is furthermore required for induction of p53 protein by targeting the 5'untranslated region of p53 mRNA. | 19571673 | LncRNADisease | ||
EL1455 | WSPAR | SWI/SNF complex | RNA-Protein | binding | lncTCF7 recruits the SWI/SNF complex to the promoter of TCF7 to regulate its expression | 25842979 | |||
EL1455 | WSPAR | STAT3 | RNA-Protein | regulation | IL-6 transcriptionally activated the expression of lncTCF7 in HCC cells by activating STAT3. | 26452542 | |||
EL1455 | WSPAR | STAT3 | RNA-Protein | binding | STAT3, a transcription activator which binds to promoter regions of lncTCF7. | 26452542 | |||
EL1456 | WT1-AS | WT1 | RNA-DNA | binding | WT1-AS downregulates WT1 by binding to the TATA region of the WT1 promotor. | 26462627 | |||
EL1459 | XIST | H3 | RNA-Protein | regulation | The concentration of PRC2 at the 59 end of Xist is intriguing because recruitment of PRC2 and H3-K27me3 are two of the earliest changes to occur on the X following Xist up-regulation. | 19684108 | LncRNADisease | ||
EL1459 | XIST | PRC2 | RNA-Protein | binding | During female development, Xist RNA is expressed from the inactive X and coats the X chromosome from which it is transcribed, leading to recruitment of Polycomb repressive complex 2 (PRC2), which trimethylates histone H3 at lysine 27 to silence transcription. | 21496640 | LncRNADisease | ||
EL1459 | XIST | miR-152 | RNA-RNA | regulation | miR-152 mediated the tumor-suppressive effects that knockdown of XIST exerted. | 25578780 | |||
EL1460 | Xist | Hprt | RNA-DNA | regulation | Loss of xist rna destabilizes the inactive state in somatic cells, leading to an increased reactivation frequency of an x-linked gfp transgene and of the endogenous hypoxanthine phosphoribosyl transferase (hprt) gene in mouse embryonic fibroblasts. | 11352938 | |||
EL1460 | Xist | H2A | RNA-Protein | binding | The association of the xi with macro-histone h2a is also disturbed by pna interference mapping. | 11481485 | |||
EL1460 | Xist | TAP/NXF1 | RNA-Protein | binding | The export factor TAP/NXF1 binds poorly to XIST RNA in comparison to exported mRNAs, suggesting that reduced TAP/NFX1 binding may contribute to nuclear retention of XIST RNA. | 17333237 | LncRNADisease | ||
EL1460 | Xist | Dicer | RNA-DNA | binding | In the absence of Dicer, coating by Xist RNA, initiation of silencing, and recruitment of Polycomb proteins occur normally | 19164542 | |||
EL1460 | Xist | PRC2 | RNA-Protein | binding | A large noncoding RNA encoded within the 5 of XIST that can target PRC2 to the inactive X chromosome. | 19571010 | LncRNADisease | ||
EL1460 | Xist | PRC2 | RNA-Protein | binding | The concentration of PRC2 at the 59 end of Xist is intriguing because recruitment of PRC2 and H3-K27me3 are two of the earliest changes to occur on the X following Xist up-regulation. | 19684108 | LncRNADisease | ||
EL1460 | Xist | HNRNPU | RNA-Protein | binding | Xist RNA and hnRNP U interact and upon depletion of hnRNP U, Xist RNA is detached from the Xi and diffusely localized into the nucleoplasm. | 20833368 | LncRNADisease | ||
EL1460 | Xist | SAF-A | RNA-Protein | binding | SAF-A is a plausible candidate for an anchor point of the Xist nrRNA to inactive X-chromosomes. | 20940252 | LncRNADisease | ||
EL1460 | Xist | Rnf12 | RNA-RNA | co-expression | Overexpression of Rnf12 ectopically induces Xist expression in XY cells. | 21029862 | LncRNADisease | ||
EL1460 | Xist | PRC2 | RNA-Protein | binding | Tsix represses Xist induction by several means, including altering the chromatin state of Xist, deploying Dnmt3a’s DNA methyltransferase activity, recruiting the RNAi machinery, and interfering with the ability of Xist and RepA RNA to engage Polycomb proteins. | 21029862 | LncRNADisease | ||
EL1460 | Xist | PRC2 | RNA-Protein | binding | X chromosome inactivation requires Xist, an ncRNA that coats the X and recruits Polycomb proteins. | 21029862 | LncRNADisease | ||
EL1460 | Xist | Ezh2 | RNA-Protein | binding | Ezh2 interacts with HOTAIR and Xist. | 21123648 | LncRNADisease | ||
EL1460 | Xist | PRC2 | RNA-Protein | binding | CDK1 and CDK2 phosphorylate EZH2 at threonine 350 (T350) and that T350 phosphorylation is important for the binding of EZH2 to PRC2 recruiters, such as noncoding RNAs (ncRNAs) HOTAIR and XIST. | 21278485 | LncRNADisease | ||
EL1460 | Xist | YY1 | RNA-Protein | binding | Here, we define the nucleation center for Xist RNA and show that YY1 docks Xist particles onto the X chromosome. | 21729784 | LncRNADisease | ||
EL1460 | Xist | HNRNPU | RNA-Protein | binding | Xist RNA and hnRNP U interact, and depletion of hnRNP U causes Xist to detach from the Xi and to localize diffusely in the nucleoplasm. | 21925379 | LncRNADisease | ||
EL1460 | Xist | EZH2 | RNA-Protein | binding | HOTAIR, Kcnq1ot and Xist all mediate their effects by interacting with the Polycomb-repressive complex 2 (PRC2) component Ezh2 (enhancer of zeste homolog 2 (Drosophila)) and modulating histone methylation. | 21936910 | LncRNADisease | ||
EL1495 | XLOC_007072 | miR164 | RNA-RNA | binding | identify several lncRNAs as competing endogenous RNAs (ceRNAs), which sequester miR160 or miR164 in a type of target mimicry | 25517485 | PLNlncRbase | ||
EL1500 | XLOC_010235 | RP11-789C1.1 | RNA-RNA | co-expression | Via survival analysis, patients who had high-expressed XLOC_010235 or low-expressed RP11-789C1.1 showed significantly worse survival than patients with inverse-expressed XLOC_010235 or RP11-789C1.1. | 26045391 | |||
EL1513 | Yam-1 | YY1,miR-715 | RNA-Protein, RNA-RNA | regulation | Yam-1 is positively regulated by YY1, Yam-1 is downregulated upon differentiation and acts as an inhibitor of myogenesis.Yam-1 functions through in cis regulation of miR-715, which in turn targets Wnt7b. | 23942234 | |||
EL1515 | ZEB1-AS1 | ZEB1 | RNA-DNA | regulation | The ZEB1-AS1 gene is located in physical contiguity with ZEB1 and positively regulates the ZEB1 expression. | 26073087 | |||
EL1516 | ZEB2-AS1 | TGFβ1 | RNA-RNA | co-expression | TGFβ1 mRNA expression is positively correlated with ZEB2NAT transcript and ZEB2 protein levels in human bladder cancer specimens. | 26152796 | |||
EL1517 | ZFAS1 | ZEB1, MMP14, and MMP16 | RNA-DNA | regulation | ZFAS1 activated ZEB1, MMP14, and MMP16 expression, inhibiting these effects of miR-150. | 26069248 | |||
EL1517 | ZFAS1 | miR-150 | RNA-RNA | binding | ZFAS1 functions as an oncogene in HCC progression by binding miR-150 and abrogating its tumor-suppressive function in this setting. | 26069248 | |||
EL1517 | ZFAS1 | p53 | RNA-Protein | regulation | destabilization of p53 | 26506418 | |||
EL1517 | ZFAS1 | CDK1 | RNA-Protein | regulation | Interaction with CDK1/cyclin B1 complex leading to cell cycle progression and inhibition of apoptosis. | 26506418 | |||
EL1519 | Zfhx2os | zfh-5 | RNA-RNA | regulation | This antisense rna has a negative regulatory role on the expression of zfh-5 mrna. | 16257534 | |||
EL1522 | Zm401 | ZmMADS2, MZm3-3 and ZmC5 | RNA-DNA | regulation | Knockdown of zm401 significantly affected the expression of ZmMADS2, MZm3-3, and ZmC5, critical genes for pollen development | 21525783, 18465785, 400866 | PLNlncRbase | ||
EL1531 | Apela | APJ/Apelin receptors | Peptide-Protein | regulation | Toddler drives internalization of G protein–coupled APJ/Apelin receptors, and activation of APJ/Apelin signaling rescues toddler mutants. | 24407481 | |||
EL1532 | APELA | APJ/Apelin receptors | Peptide-Protein | regulation | Toddler drives internalization of G protein–coupled APJ/Apelin receptors, and activation of APJ/Apelin signaling rescues toddler mutants. | 26387754, 25639753, 20153842, 24316148, 24407481 | |||
EL1533 | apela | APJ/Apelin receptors | Peptide-Protein | regulation | Toddler drives internalization of G protein–coupled APJ/Apelin receptors, and activation of APJ/Apelin signaling rescues toddler mutants. | 24407481 | |||
EL0388 | ENOD40-1 | nodulin 100 | Peptide-Protein | binding | Both peptides specifically bind to the same 93-kDa protein, which was affinity purified from soybean nodules. | 11842184 | |||
EL1534 | Gm34302 | SERCA | Peptide-Protein | binding | Although DWORF peptides bind to the SERCA protein, they do not intrinsically activate the SERCA. Instead, DWORF displaces the binding of MLN, PLN, or SLN peptides, relieving their inhibitory activity. The DWORF peptide thus appears as an antagonist of negative regulators, competing for binding to the SERCA. | 26816378 | |||
EL1535 | DWORF | SERCA | Peptide-Protein | binding | DWORF localizes to the SR membrane, where it enhances SERCA activity by displacing the SERCA inhibitors, phospholamban, sarcolipin, and myoregulin. | 26816378 | |||
EL1536 | MRLN | SERCA | Peptide-Protein | regulation | MLN interacts directly with SERCA and impedes Ca(2+) uptake into the SR. | 25640239 | |||
EL1537 | Mrln | SERCA | Peptide-Protein | regulation | MLN interacts directly with SERCA and impedes Ca(2+) uptake into the SR. | 25640239 | |||
EL1538 | SclA | SERCA | Peptide-Protein | binding | Scl similarly to Sln and Pln binding to SERCA. | 23970561 | |||
EL1539 | SclB | SERCA | Peptide-Protein | binding | Scl similarly to Sln and Pln binding to SERCA. | 23970561 |